<SEC-DOCUMENT>0001140361-18-016477.txt : 20180402
<SEC-HEADER>0001140361-18-016477.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402171839
ACCESSION NUMBER:		0001140361-18-016477
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OncoCyte Corp
		CENTRAL INDEX KEY:			0001642380
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				271041563
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37648
		FILM NUMBER:		18730178

	BUSINESS ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
		BUSINESS PHONE:		510-775-0515

	MAIL ADDRESS:	
		STREET 1:		1010 ATLANTIC AVENUE
		STREET 2:		SUITE 102
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94501
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>10-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Washington, D.C. 20549</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-K</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OF THE SECURITIES EXCHANGE ACT OF 1934</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For the fiscal year ended December 31, 2017</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OR</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OF THE SECURITIES EXCHANGE ACT OF 1934</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For the transition period from___________ to __________</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Commission file number 1-37648</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 24pt; FONT-WEIGHT: bold">OncoCyte Corporation</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;(Exact name of registrant as specified in its charter)</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0fb9ab8550ce4fdd9e43cd8b5924422b" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 48.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">California</div>
</td>
<td style="WIDTH: 2.01%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">27-1041563</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation or organization)</div>
</td>
<td style="WIDTH: 2.01%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(I.R.S. Employer Identification No.)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1010 Atlantic Avenue, Suite 102</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Alameda, California 94501</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(Address of principal executive offices) (Zip Code)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Registrant's telephone number, including area code <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(510) 775-0515</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities registered pursuant to Section 12(b) of the Act:</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z4d8ccc9d28834e37b8a664cc0306d810" border="0" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 13px">
<td style="WIDTH: 48.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of each class</div>
</td>
<td style="WIDTH: 2.01%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name of exchange on which registered</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48.99%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Common Stock, no par value</div>
</td>
<td style="WIDTH: 2.01%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">NYSE American</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(g) of the Act:</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">None</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160; &#160;&#160; Yes&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font>&#160; No&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160; &#160;&#160; Yes&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font>&#160; No&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160;&#160; Yes&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font>&#160; No&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; &#160;&#160; Yes&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font>&#160; No&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div>
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%2%%%-->
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z51aeeb1982d548e395afe09434399ca9" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 60%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Large accelerated filer <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>
</td>
<td style="WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accelerated filer <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 60%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Non-accelerated filer&#160;&#9746; (Do not check if a smaller reporting company)</div>
</td>
<td style="WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Smaller reporting company <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744;</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 60%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Emerging growth company <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#9746;</font></div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. </font><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9744; </font>No&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#9746;</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The approximate aggregate market value of shares of voting common stock held by non-affiliates computed by reference to the price at which shares of common stock were last sold as of June 30, 2017 was $41.4 million. Shares held by each executive officer and director and by each person who beneficially owns more than 5% of the outstanding common stock have been excluded in that such persons may under certain circumstances be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of March 20, 2018, there were outstanding 31,468,558 shares of common stock, no par value.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">DOCUMENTS INCORPORATED BY REFERENCE</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Portions of the registrant's Proxy Statement for its 2018 Annual Meeting of Shareholders are incorporated by reference in Part III</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%2%%%-->
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OncoCyte Corporation</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="TableofContents"><!--Anchor--></a>Table of Contents</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zade1047dba684514a8fa105c50962762" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 7.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Part I.</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Information</div>
</td>
<td style="WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item1.">Business</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1A -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item1A.">Risk Factors</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">32</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1B -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item1B.">Unresolved Staff Comments</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">46</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item2.">Properties</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">46</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item3.">Legal Proceedings</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">46</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item4.">Mine Safety Disclosures</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">46</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Part II.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Information</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 5 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item5.">Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">46</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item6.">Selected Financial Data</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">48</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item7.">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">49</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7A -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item7A.">Quantitative and Qualitative Disclosures about Market Risk</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">56</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 8 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item8.">Financial Statements and Supplementary Data</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">59</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item9.">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">82</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9A -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#ControlsandProcedures">Controls and Procedures</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">82</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9B -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#OtherInformation">Other Information</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">82</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Part III.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 10 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#Item10.">Directors, Executive Officers, and Corporate Governance</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">83</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 11 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#ExecutiveCompensation">Executive Compensation</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">83</div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 12 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#SecurityOwnershipofCertai">Security Ownership of Certain Beneficial Owners and Management, and Related Stockholder Matters</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">83</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 13 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#CertainRelationshipsandRe">Certain Relationships and Related Transactions, and Director Independence</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">83</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 14 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#PrincipalAccountingFeesan">Principal Accounting Fees and Services</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">83</div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Part IV</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 15 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#ExhibitsFinancialStatemen">Exhibits, Financial Statement Schedules</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">84</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 16 -</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 77%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#SIGNATURES">Summary</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">86</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 77%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: top" colspan="3">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a href="#SIGNATURES">Signatures</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 7.98%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">87</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">2</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Certain statements contained herein are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of OncoCyte, particularly those mentioned in the cautionary statements found in OncoCyte's filings with the Securities and Exchange Commission. OncoCyte disclaims any intent or obligation to update these forward-looking statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">References to "OncoCyte," "our" or "us" mean OncoCyte Corporation.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The description or discussion, in this Form 10-K, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INDUSTRY AND MARKET DATA</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This Annual Report (&#8220;Report&#8221;) on Form 10-K contains market data and industry forecasts that were obtained from industry publications, third party market research and publicly available information. These publications generally state that the information contained therein has been obtained from sources believed to be reliable. While we believe that the information from these publications is reliable, we have not independently verified such information.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this Report from our own research as well as from industry and general publications, surveys and studies conducted by third parties, some of which may not be publicly available. Such data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRELIMINARY NOTE ABOUT OWNERSHIP OF OUR COMMON STOCK</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of March 20, 2018, we had 249 shareholders of record and there were 31,468,558 shares of our common stock outstanding, of which 14,674,244 shares were held by our parent BioTime, Inc. ("BioTime"). Beginning on February 17, 2017, the shares held by BioTime account for less than 50% of our total common stock outstanding. Accordingly, effective February 17, 2017, we are a no longer a consolidated subsidiary of BioTime. See Note 1 of our financial statements included elsewhere in this Report.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REVERSE STOCK SPLIT</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On November 18, 2015, OncoCyte effected a 1-for-2 reverse stock split of its common stock. All references to common stock, warrants, and options to purchase common stock, and all per share data and related information, including the price at which shares of common stock have been sold or may be issued, have been retroactively adjusted, where applicable, to reflect the reverse stock split of OncoCyte common stock as if it had occurred at the beginning of the earliest period presented.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbd98e2a5fc9a4cb496906fc581693c40" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item1."><!--Anchor--></a>Item 1.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our mission is to develop highly accurate, easy to administer, non-invasive molecular diagnostic tests to improve the standard of care for cancer diagnosis to better meet the needs of patients, physicians and payers.&#160; Our initial focus will be confirmatory diagnostics, utilizing novel liquid biopsy technology, for use in conjunction with imaging to confirm initial suspicious imaging results such as lung nodules and breast lesions within certain oncology indications. Our lead product is DetermaVu&#8482;, which we are developing as a confirmatory diagnostic test for lung cancer.</div>

<div>&#160;</div>

<div>
<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">3</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our initial liquid biopsy diagnostic tests, such as DetermaVu&#8482;, will be confirmatory diagnostics and are being developed to reduce false positive results associated with current diagnostic protocols. These new diagnostic tests are intended to:</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z46aa6861e87a4491997c205272e7cd54" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reduce unnecessary and sometimes risky procedures, as well as lower the cost of care through the avoidance of more expensive diagnostic procedures, including invasive biopsies;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zba0df44b37cc401985c95dc942d18fc1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Improve the quality of life for cancer patients by reducing the anxiety associated with non-definitive diagnoses; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zcb66b04cc4364a218580eab8a05a86d3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Improve health outcomes through avoidance of unnecessary invasive procedures</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our strategic focus is to develop diagnostic tests in areas of high unmet need and our initial work has been devoted to developing tests to detect lung cancer, breast cancer, and bladder cancer. We have prioritized our efforts on DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;FONT-VARIANT: small-caps">TM</sup> because we believe that lung cancer has one of the greatest unmet needs and because timing is opportune due to the focus on lung cancer screening awareness.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition, we may develop screening diagnostics as potential replacements for screening imaging protocols that do not meet the needs of patients, health care providers or payers. For some indications, we may also pursue the probability of recurrence of a specific cancer through the development of prognostics; or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We were incorporated in 2009 in the state of California. Our principal executive offices are located at 1010 Atlantic Avenue, Suite 102, Alameda, California 94501. Our telephone number is (510) 775-0515.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Strategy</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our strategy is to identify medical indications where current diagnostic technology is not meeting the needs of patients, physicians, or payers due to poor early detection and/or a large number of false positives.&#160; Those indications are characterized by a current standard of care requiring patients to endure unnecessary, costly and risky additional confirmatory procedures. By focusing on what we believe to be the biggest unmet needs with manageable technological hurdles and potentially rapid times to market, we believe our strategy is an efficient and risk-balanced use of capital and human resources.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Unmet need for confirmatory diagnostics, as we see it, can be defined from the physician and payer perspective as low five year survival rates and as low specificity or high numbers of false positive test results.&#160; Oncology indications that fit these parameters include lung and breast cancer, as can be seen in the following graphic.&#160; Additionally, our strategy is to focus on indications where competition is low, a specialty sales force can be leveraged rather than those that require a large primary care sales force.&#160; See Graphic 1.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6c4596daceef407e824c6bd87cc954bb" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 1</div>
</td>
<td style="WIDTH: 20%">
<div style="TEXT-ALIGN: center"><img src="image00021.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In order to address this unmet need, we are developing blood and urine based liquid biopsy molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in specific types of cancer. The diagnostic markers we have discovered thus far may address unmet needs in cancer diagnostic indications that have a strong potential to generate short- to mid-term revenues. Our approach is based on focusing on unmet medical needs, large market sizes and ease of use of the product.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">4</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our current development strategy for cancer diagnostic tests is to develop, evaluate and validate specific diagnostics using methods of detecting proteins, messenger RNA ("mRNA") or micro RNA ("miRNA"). We believe that this approach, which is often referred to as a biomarker or analyte agnostic approach, allows us to have a broader look into the genetic markers that differentially express in cancer. Differential expression means that we are looking for proteins, mRNA or miRNA that are present in bodily fluids more often or less often when the patient has a specific type of cancer present in their body as compared to patients with no cancer. These elements in the bodily fluids are referred to as biomarkers. Our development strategy will be matched to our market planning strategy to determine which:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3eb70499c38e4c2a985206cea1852d04" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Diagnostic tests to prioritize in our development program;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc58a7d1a3a7649cab7c989a753022c1f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Diagnostic tests we should market ourselves;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze418927c61b5450da2ac068e13ff2be1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Diagnostic tests we should co-market through an alliance with one or more other companies; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z030792f91b5c4a8a9b2221bbb848eed3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Diagnostic tests we should out-license to third parties for development and/or commercialization.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional Information</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an "emerging growth company" until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.0 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act"); (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the "JOBS Act," and references herein to "emerging growth company" shall have the meaning associated with it in the JOBS Act.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies. These provisions include:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z74c1ccac532b49fdb3ae1c8b6beaec00" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reduced disclosure about our executive compensation arrangements;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc74d908b2ae64823aeab9e3ea3ae5e9a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">No non-binding shareholder advisory votes on executive compensation or golden parachute arrangements; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z121c101a6bfe48c287f020894fa1e98b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DetermaVu&#8482; Lung Cancer Diagnostic Test</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Clinical Trials</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">To develop DetermaVu&#8482; we tested blood samples from patients who were at risk for lung cancer, based on having positive or suspicious results from Low Dose Computed Tomography or LDCT screening, and who had undergone biopsies to determine the pathology results or who had undergone a series of imaging procedures (LDCT or PETscans) to determine if the nodule is continuing to grow. We then assessed gene expression patterns in those blood samples to determine whether gene expression can distinguish between patients who likely have lung cancer and those who likely do not.&#160; Additionally, we will test blood samples from patients who used alternative screening procedures such as chest x-rays and who were referred for biopsies in order to validate our test on both screened patients with nodules and patients who had their nodules incidentally detected.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our clinical trials began through work we sponsored at The Wistar Institute of Anatomy and Biology (&#8220;Wistar&#8221;).&#160; Wistar investigators and OncoCyte have assessed gene expression patterns in blood cells of patients with imaging detected nodules to differentiate malignant lung nodules from patients with non-malignant lung nodules. Initial analysis of patient data from this study was completed during the first quarter of 2015.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">5</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Wistar study results presented in 2015 included both nodules and non-nodules and is the first proof of concept for both our confirmatory and screening lung cancer diagnostic.&#160; A larger proof of concept study conducted by Wistar validated Wistar&#8217;s earlier results with comparable findings. This larger analysis of 610 patients showed that the biomarkers alone had an AUC or ROC score of 0.82, resulting in a sensitivity of 90% and a specificity of 62%. These results suggest that a diagnostic comprised of biomarkers and a classifier could help clinicians manage treatment of patients with intermediate size nodules in way that would both improve health outcomes by potentially avoiding morbidity and mortality associated with lung biopsies as well as decreasing the overall costs of lung cancer detection.&#160; See Graphic 2 and Graphic 3.</div>

<div><br>
</div>

<div style="WIDTH: 48%; FLOAT: left" id="EFPFTCL">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z38f9bb047478480986b4f0f1ba9b0738" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 2</div>
</td>
<td style="WIDTH: 20%">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">Wistar 2015 Study</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><img style="WIDTH: 249px; HEIGHT: 237px" src="image1.jpg"></div>
</div>
</td>
<td style="WIDTH: 40%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#160;</div>
</div>

<div style="WIDTH: 48%; FLOAT: right" id="EFPFTCR">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z412fa615be444338a3ed68b7cf932274" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 40%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 3</div>
</td>
<td style="WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">Wistar 2016 Study</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><img style="WIDTH: 248px; HEIGHT: 216px" src="image2.jpg"></div>
</td>
<td style="WIDTH: 40%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#160;</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; CLEAR: both; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">DetermaVu&#8482; R&amp;D Validation Study</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As an independent validation of Wistar's work, we developed our own algorithm using a subset of the biomarkers identified at Wistar, and combining data from the top mRNA biomarkers with clinical data such as nodule size. We used this new algorithm in an R&amp;D validation study of DetermaVu&#8482; in which we tested 299 blood samples collected from patients at 26 sites across the United States. The samples were collected from patients with nodules ranging in size from five to thirty millimeters, the size range presenting the greatest diagnostic challenge to clinicians. For patients with these size nodules physicians must weigh the risk of cancer against the risks posted by invasive biopsies to confirm whether the nodules are malignant or benign.&#160;&#160; Our R&amp;D validation study was able to surpass the results of the Wistar study with consistent findings of sensitivity of 97% (confidence interval of 90-98%) and specificity of 73% (confidence interval of 65-79%) compared to Wistar&#8217;s 2015 results that showed a sensitivity of 76% and a specificity of 88%.&#160; See Graphic 2.&#160; Sensitivity refers to the probability of detecting the presence of the disease accurately; while specificity refers to the probability of accurately predicting not having the disease. The OncoCyte and Wistar preliminary lung cancer test had a false positive rate of only 12%. In comparison, National Lung Screening Test results reported in the New England Journal of Medicine (August 2011) showed that LDCTs have a very high false positive rate of approximately 96%. Under Lung RADS, most nodules over 10 mms are sent to biopsy even through the probability of malignancy is less than 12%.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Using a methodology referred to as violin plots, Dr. Anil Vachani a pulmonologist at the University of Pennsylvania demonstrated that DetermaVu&#8482; was more accurate in calling a benign versus malignant sample than nodule size, which is used in the standard of care Lung RADS and the Veterans Administration model, a probability model used by some clinicians to estimate the probability of malignancy.&#160; See Graphic 5 violin plot is a graphic tool that allows the viewer to see the clustering effect of the test.&#160; In the case of a binary call of malignant versus benign, clustering can be desirable.&#160; Clustering for our lung cancer test, which is designated as the &#8220;classifier&#8221; in Graphic 4, shows low scores for most of the benign samples suggesting high specificity, and high scores for the malignant samples suggesting high sensitivity; while the scores for nodule size and the VA model are more spread out suggesting that nodule size and the model are less accurate than our test.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">6</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z08d7b6c92ccd49f9860484b11cb8d28d" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 4</div>
</td>
<td style="WIDTH: 20%">
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OncoCyte 2017 Results</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><img src="image00022.jpg"></div>
</div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1645cd96f82c49a0b5f241a07658d46b" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 5</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%"><img style="WIDTH: 432px; HEIGHT: 246px" src="image4.jpg"></td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Clinical Validation Study</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">After completing our R&amp;D validation study, we proceeded with work to commence a clinical validation study of DetermaVu&#8482;.&#160; We collected our own patient blood samples to conduct the clinical validation study to assure that the samples were geographically diverse, from different types of care centers, and represented a cross-section of the high-risk patient population with nodules. The patients selected for sample collection have lung nodules of 5 to 30 millimeters in size, which is the size range of nodules in patients for which the DetermaVu&#8482; is intended.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the process of running initial samples for our clinical validation study in November 2017, inconsistent analytic results were observed by our technical team. We determined that this was caused by a variance in the lots of consumables used in the analytic system that analyzes blood samples for the genetic markers that may indicate whether lung nodules found in patients are benign or suspicious. We engaged with the system manufacturer to more completely understand the issues that have delayed the </font>DetermaVu&#8482;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> clinical validation study.</font></div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Over the past few months, we reviewed a number of diagnostic testing&#160;platforms and during that analysis, we conducted studies that enabled us to discover new, not previously identified biomarkers, for which we have&#160;filed patent applications. <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</font>Many of the new biomarkers were detected on multiple molecular diagnostic testing platforms, providing confidence in the results. In addition, many of the new biomarkers have fold changes greater than what&#160;we had&#160;seen in&#160;our earlier&#160;biomarkers. Fold change is a measure describing how much a biomarker changes between the average benign sample level and the average malignant sample level. For example, an average benign sample biomarker level of 100 and an average malignant biomarker level of 300 corresponds to a fold change of 3 or in common terms, a three-fold increase. The larger fold changes of these new biomarkers could make the biomarker more detectable using DetermaVu&#8482; with standard molecular diagnostic laboratory testing platforms and therefore more operationally efficient and consistent.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">7</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">These new biomarkers also </font>potentially may enhance the lung cancer signal identified by DetermaVu&#8482; and as such we have incorporated certain of these biomarkers into a revised algorithm. This revised algorithm was tested on approximately 60 patient blood samples and resulted in accuracy as measured by AUC data equivalent or superior to our previously reported results, although the error bar or potential range of results from this small sample set is wide and the results must be confirmed in a larger sample set.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are continuing to evaluate alternative diagnostic testing platforms by doing a follow-on study utilizing a larger set of clinical samples. We expect to complete the process of choosing the commercial diagnostic testing platform during the second quarter of 2018. After concluding this process, data will be available to determine which platform delivers the most accurate, consistent and robust test results while maintaining a reasonable cost of goods. If the results indicate that the chosen platform can produce consistent result in our CLIA lab, we plan to complete product development on the selected platform by carrying out an R&amp;D validation study followed by an analytical validation study, and if those studies are successfully completed, we plan to conduct a clinical validation study. Clinical validation is the final step prior to commercial launch of a diagnostic test, and we are targeting completion of a clinical validation study by the latter part of 2018. We have collected all the samples necessary for carrying out these studies.&#160; If these studies are completed successfully, we plan to commercialize DetermaVu&#8482;.&#160; Until we perform these studies, we will not know whether we can successfully complete the development of DetermaVu&#8482; and commence commercialization of the test.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Current Standard of Care</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The current standard of care for diagnosing lung cancer in high risk patients is LDCT scanning. The United States Preventive Services Task force ("USPSTF") guidelines recommend annual LDCTs for patients at high risk for lung cancer. The USPSTF was created in 1984 as an independent, volunteer panel of national experts in prevention and evidence-based medicine. The USPSTF works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services, and preventive medications.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The guidelines, released in December of 2013, recommend annual LDCT scans for all Americans aged 55 to 80 years old who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. A 30 pack-year smoking history is defined as the number of cigarette packs smoked per day times the number of years smoked. A 30 pack-year patient would include the following types of patients:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z12a7f624022f464cbbc9b94bb23c58d1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Person who has smoked a pack a day (20 cigarettes) for 30 years;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z50dfe6e0261f46a19f30eb6d3ffcbf63" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Person who has smoked 15 cigarettes a day for 40 years; or</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z29305e91764a45f8aa37ae2428357f5b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Person who has smoked 40 cigarettes a day for 15 years.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">These guidelines were driven by a need to improve the standard of care for diagnosing lung cancer. Currently, the survival rate for lung cancer is very low &#8211; only 17% of people are still alive five years after a lung cancer diagnosis. These low survival rates result in one of the highest mortality rates for lung cancer, which is projected to kill 154,050 Americans in 2018 (American Cancer Society).&#160; See Graphic 6.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5e19c1d505cc4fc8b1a954d12209821f" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 6</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 Year Survival Rates by Indication</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1975 to 2007</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00023.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt">&#160;</div>
</div>

<div>
<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">8</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Moreover, the lung cancer survival rate, unlike many other types of cancer, has not increased significantly in the last 30 years. The low probability of surviving lung cancer is significantly affected by the late diagnosis &#8211; with more than half of all patients diagnosed after the point that the cancer has spread. Poor survival rates for lung cancer was one of the drivers for the development of the USPSTF guidelines. Annual screening with LDCTs is projected to increase the probability of detecting lung cancer in earlier stages such as Stage I where it is treatable and where survival rates could be significantly improved. The number of Stage I patients has been projected to almost double as LDCT becomes part of the high risk patients&#8217; annual check-ups.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">However, the earlier detection of lung cancer will not come without risks.&#160; LDCTs are highly sensitive imaging procedures and they result in many false positives.&#160; About one out of every four high risk patients have been shown to have a nodule detected by LDCT as was seen in the National Lung Study Trial. However, the vast majority of these patients (96%) do not have cancer; only 4% of these patients are actually found to have cancer. This results in patients being referred for risky downstream procedures including bronchoscopies, needle biopsies and surgery. These invasive procedures have been shown to result in morbidity and mortality including:</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z42f80ae8495a4a60a6b45d0ca707c491" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">0.5 to 1% mortality and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zafb0756c0774426781a49db704c1138a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4-20% major complications.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Source: Evaluation of Individuals with Pulmonary Nodules: When is it Lung Cancer? Chest 2013 May: 143 (Suppl):e83-e120.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In order to provide better guidance for physicians in managing lung nodules, the American College of Radiology developed the Lung CT Screening Reporting and Data System (LungRADS).&#160; LungRADS was developed to be a quality assurance tool designed to: standardize lung cancer screening reporting and management recommendations; reduce confusion in lung cancer screening interpretation; and facilitate outcome monitoring.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At a high level, LungRADS divides nodules for clinical management into three categories.&#160; For patients with nodules less than 5 mm, no follow-up procedures are necessary; while patients with nodules greater than 5 mm have follow-up procedures.&#160; In the case of nodules that are 5 to 7 mm, watchful waiting or serial imaging is recommended. Watchful waiting is the process where an individual is monitored through a series of follow-up scans to see if a nodule grows over time.&#160; A patient can be brought back quarterly or semi-annually to monitor if the nodule is growing. Typically, when a nodule has not grown for one to two years, the nodule is considered to be benign. Patients in the third category, with nodules over 8 mms, are often recommended for more invasive procedures, such as bronchoscopic biopsy, needle biopsy, open biopsy or video assisted thoracoscopic surgery.&#160; See Graphic 7.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zadf094594b48451d8cd5a1dc46323ed7" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 7</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LungRADs Guidelines</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00024.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Need and Market for DetermaVu</font>&#8482;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Lung cancer is a primary cause of cancer-related death, in part because there is no effective diagnostic test to screen patients for lung cancer at an early stage. USPSTF guidelines, which recommend LDCT scans for patients at high risk for lung cancer, may impact up to 10 million Americans who fit the criteria of 30 pack-year smokers. Research has shown that although nodule size is a strong predictor of malignancy, it is not always accurate.&#160; Even the largest nodules, those that are greater than three centimeters, have a low malignancy rate of only 41%.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Overall, nodules that are sent to biopsy have a malignancy of between 1.7% for nodules 7 to 10 mm to 41.3% for nodules greater than 30 mm, meaning that for every cancer that is found in a biopsy, there are many false positives.&#160; In the case of smaller nodules from 7 to 10 mm, 98% of the nodules are benign; while in the case of larger nodules from 30 mms or larger 59% are benign.&#160; This would suggest that the number of biopsies performed each year could be significantly reduced by a molecular diagnostic that could help clinicians triage patients with intermediate size nodules from 8 mm to 30 mm.&#160; See Graphic 8.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">9</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9ebcfd79e851450ba8535982386b23db" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 8</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nodule Size by Prevalence</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00025.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte is initially focusing on patients with indeterminate diagnoses of larger nodules over 8 millimeters, which is shown as "Initial Focus" in the graph below.&#160; See Graphic 9. These nodules are most likely to be sent for biopsies. This potential market is estimated to include between 400,000 to 600,000 patients annually based on the estimates of patients eligible for USPSTF guidelines (7 to 10 million based on USPSTF and NCI estimates) as well as the approximately 5 million patients with incidentally detected nodules (Gould MK, et al. Am J Resp Critical Care Med 2015 Nov). We intend to expand the use of our lung cancer diagnostic into smaller nodules shown as "Expanded Use" in the graph below, which targets patients with smaller nodules, who currently are put into a wait and hold pattern and can be scheduled for repeated LDCTs, raising the risk of increased radiation exposure and incurring incremental costs to determine whether the nodule is growing. This will increase the potential patient population to approximately 1.4 million patients. Finally, we may pursue work on a diagnostic that could be used as a screening diagnostic and potentially replace LDCTs for the 7-10 million patients who meet the USPSTF guidelines for high risk, which is represented as the overall lung nodule market in the following graph.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z62c134744c0f4e9eb9c891b121133ea7" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 9</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Opportunity for Lung Diagnostics</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00026.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">TAM Numbers based on company estimates and secondary data: 7-10 Million screening patients (USPSTF, NCI);</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4.9 Million patients with incidental nodules (Gould MK, et al. <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Am J Respir Crit Care Med </font>2015 Nov 15; 192 (10):1208-1214).</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">10</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte estimates the revenue opportunity associated with this test is between $2.1B and $4.7B yearly with the initial use targeting the larger nodules (greater than 8 mms) and the expanded use targeting nodules greater than 5 mms. See Graphic 10.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8a3da18b88c54a3490d19308beca7563" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 10</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%"><img src="image00027.jpg"></td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfa54e363bd14480cb81c3fd94760f20d" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 11</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Lung Nodule Standard of Care</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00028.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div>
<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">11</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte&#8217;s DetermaVu&#8482; test could eventually fit in the lung cancer screening standard of care, by being used as a way to triage patients with suspicious nodules. See Graphic 11. The test would be run and patients who receive a benign or suspicious result would either be:</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z20672c33094e4b78a9b59f15c2cd1f2e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cleared with a benign result and sent home and told to come back for annual scans like a mammogram</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z61dfd3b46c944c8b9bbeeca0c71cdde3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">monitored and sent home and told to return for a follow-up scan in three to six months.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Breast Cancer Diagnostic Tests</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Breast Cancer Diagnostic Clinical Trials</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have completed proof of concept study for a confirmatory test for breast cancer. Our study looked at serum samples from 100 women who had a mammogram with a result of BIRADs 3 or 4. These samples were collected over approximately two years during 2014 and 2016 and by March of 2016, we had collected over 900 patient blood samples. The 100 women whose samples were used in the analysis were all sent for biopsies and half of the patients had a pathology confirmed benign and half of them had a pathology confirmed malignant. The analysis looked at proteins that were differentially expressing in women with malignances from a large screen of 1,310 proteins.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The results of this analysis were quite promising with a 15 marker model producing a sensitivity of 90% and a specificity of 76%. The analysis was a strong proof of concept that a non-invasive blood test could help differentiate women with indeterminate mammograms into two groups &#8211; those needing to be biopsied and those for whom the finding was highly likely to be benign.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We subsequently conducted a larger follow-on liquid biopsy breast cancer diagnostic test study that showed that a blood based assay may have the ability to differentiate women who have breast cancer from those who do not.&#160; A nineteen marker model resulted in an AUC of 0.935 with a sensitivity of 90% and a specificity of 82%.&#160; This data was consistent with the data from our previous study.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are encouraged by the results of the studies that have been done to date. However, since 2017 we have devoted substantially all of our time and resources to the development of DetermaVu&#8482;, and we plan to continue to devote our resources to lung cancer tests at least for the near term.&#160; If our financial and other resources permit, we may continue to pursue the development effort of our breast cancer test.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Current Standard of Care</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The early detection of cancer is typically associated with improved outcomes for patients. Mammography has been widely used since the 1970s for breast cancer screening in asymptomatic women; in 2017, over 39 million screening mammograms were performed in the US alone. Current US National Cancer Institute ("NCI") guidelines recommend screening mammograms every one to two years in women 40 years and older, while the American Cancer Society and the National Comprehensive Cancer Network both recommend screening mammography every year starting at age 40. However, in November of 2009, USPSTF revised their screening recommendations increasing the age to 50 and length of time between screenings from annual to biennial. This was partially driven by the concerns around false positives. Approximately 10% of women are recalled from screening mammography for further testing and approximately 95% of those women's test results end up as false positives. Over the course of 10 years of screening, one out of every two women will experience a false positive with 7% to 17% of those women having unnecessary biopsies. (Rosenberg RD et al. Radiology 2006. Elmore JG et al. N Engl J Med 1998, Hubbard RA et al. Ann Intern Med 2011, Rosenberg RD et al. Radiology 1998, Kerlikowske K et al. JAMA 1996, Porter PL et al. J Natl Cancer Inst 1999)</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At the same time, mammography screening in women aged 40 to 74 has been associated with the relative reduction in breast cancer mortality of 15% to 20%. However, the NCI estimates that approximately 20% of all breast cancers are not detected by mammography during screening. In the case of women with dense breast tissue, mammography has been shown to have poor sensitivity with only 62-69% of all cancers detected (Carney et al 2003, Pisano et al 2006) This has resulted in 27 state legislatures dictating that radiologists notify women about the difficulties of detecting breast cancer in dense breast tissue and alert them that supplemental screening may be appropriate in their case. These false negatives or missed diagnoses, together with the false positives or over diagnoses, indicate a strong unmet need for a breast cancer screening test with superior specificity and sensitivity when compared to standard screening mammography.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Additionally, guidelines recommend MRI screening for approximately 6 million women who either have a family history, a BRCA gene mutation or dense breast tissue, since mammograms have been shown to miss cases of cancer in patients that meet these profiles.&#160; See Graphic 12.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">12</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9592b5cc40404fa381856aad25650332" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 12</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Breast Cancer Screening Protocol</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt"><img src="image00029.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte&#8217;s goal has been to develop a confirmatory diagnostic test that could be used with women who have an indeterminate mammogram result (BI-RADS 3 or 4). In the case of a mammogram BI-RADS 3 score, repeat imaging is recommended, which means that women may have to schedule another mammogram or they may be referred to a more costly MRI procedure. In the case of a mammogram BI-RADS 4 score, women are often referred for a biopsy. Our breast confirmatory diagnostic could be incorporated into breast screening protocols to confirm whether women with BI-RADS 3 or 4 scores need to undergo additional costly imaging or an invasive biopsy.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Need and Market for a Breast Cancer Liquid Biopsy</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Each year approximately 5% of women have mammograms that are suspicious and many of these women are sent on to biopsies (Geller et al Radiology 222:2 2002). Currently it is estimated that about 16% or 250,000 of these biopsies will be cancerous. This is the focus of our initial research for our breast cancer confirmatory diagnostic as shown in Graphic 13. We could also expand our research efforts to include the second intended use &#8211; women who meet the guidelines for MRIs. There are over 6 million women in the U.S. for whom the guidelines recommend both a mammogram and a MRI yearly.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Additionally, we may elect to expand the use of our diagnostic in the future to meet the needs for a better breast cancer screening diagnostic, which could impact up to 38 million women each year. Research over the last 25 years has shown that large numbers of women are having unnecessary biopsies resulting in estimates of $4 billion a year being spent on false positives (Health Affairs, 34, no.4 (2015):576-583).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z872a4b8a1fff40d086c9fd8529ecbd58" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 13</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Opportunity for Breast Cancer Diagnostic Tests</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center"><img style="WIDTH: 482px; HEIGHT: 264px" src="image12.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">13</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bladder Cancer Diagnostic Tests</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Bladder Cancer Diagnostic Test Clinical Trials</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As part of our clinical development of a urine-based bladder cancer diagnostic test, we initiated a clinical trial in January 2014 that was expanded to a multi-site trial.&#160; Preliminary findings from that trial showed a sensitivity of 90% and a specificity of 83%. Sensitivity is the probability of detecting the presence of the disease accurately. A sensitivity of 90% means that 9 out of 10 cancers were detected. Specificity is the probability of accurately predicting not having the disease.&#160; Due to marketing considerations and the limits of our resources, we have not proceeded further with our bladder cancer test development in order to focus our clinical operations on the development of our lung cancer test.&#160; See &#8220;Need and Market for a Bladder Cancer Liquid Biopsy.&#8221;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Current Standard of Care</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The current standard of care for bladder cancer diagnosis is cytology and cystoscopies. Urine cytology is a test to look for abnormal cells in a patient's urine. Urine cytology is used along with other tests and procedures to diagnose urinary tract cancers. Cystoscopy is a procedure that allows a doctor to examine the lining of the bladder and the urethra, tube that carries urine out of the body. A hollow tube called a cystoscope, equipped with a lens, is inserted into the patient's urethra and slowly advanced into the bladder. Increasingly over the years, cystoscopies have been used in conjunction with cytology which has resulted in increasing costs for the detection and surveillance of bladder cancer.&#160; See Graphic 14.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z4ce951839b4c432ba1543ea8b7302c90" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 14</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Bladder Diagnostic Protocol</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00030.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Need and Market for a Bladder Cancer Liquid Biopsy</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Bladder cancer has the highest lifetime treatment costs per patient of all cancers. High prevalence, high recurrence rates and ongoing invasive monitoring requirements are the key contributors to the economic and human toll of this disease.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Urothelial carcinoma constitutes more than 90% of bladder cancers in the Americas, Europe and Asia. Although most patients with bladder cancer can be treated with organ-sparing chemotherapy, UC has a relapse rate of nearly 70% and can progress to invasive, metastatic, and lethal disease. The regular surveillance and treatment of recurrent disease from the time of diagnosis for the remainder of a patient's life makes urothelial Carcinoma the most costly malignancy on a per patient basis. The problem is amplified because the two standard methods for surveillance - microscopic assessment of urinary cytology specimens and bladder cystoscopy &#8211; possess significant limitations with respect to both performance and cost. Although urine cytology does have a very high positive predictive value and low false positive rate, it has a low negative predictive value and a high indeterminate rate. Patients who have indeterminate urine cytology results commonly undergo cystoscopy, which is painful, time consuming, costly, and unnecessary in many cases since a neoplasm is often not present. In urothelial carcinoma, as in virtually all other cancers, earlier and more accurate diagnosis, including diagnosis of disease recurrence, is generally associated with better outcomes and lower cost.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">14</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbcaf8a833e7e4061a7e576fdde18da50" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 15</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bladder Diagnostic Market Opportunity</div>

<div>
<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00031.jpg"></div>
</div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><br>
 &#160;</div>
</div>

<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">TAM numbers based on company estimates and secondary data</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Overall markets for bladder cancer diagnostics are large and growing. Based on National Cancer Institute SEER statistics it was estimated that in 2017 there were 79,030 new cases of bladder cancer in the United States.&#160; The same source estimates that as of </font>2014, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">there were 696,440 patients with bladder cancer in the United States.&#160; Many of these patients would be monitored for recurrence using cystoscopy or urine cytology. Additionally, another 3 million patients present yearly with hematuria (blood in urine), an early symptom of bladder cancer and 500,000 patients have indeterminate cytology findings. These three patient profiles: indeterminate cytology, hematuria and surveillance, could result in a potential market opportunity of approximately 4.5 million tests yearly. See Graphic 15.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte believes that in order to obtain coverage by insurance companies, the target market for this test will need to be primary care physicians. To market this test successfully will require a large sales force, which is not part of OncoCyte&#8217;s business model.&#160; Due to this need and our limited financial and marketing resources, we are seeking to enter into an agreement with a larger company that has greater marketing resources for the marketing of our bladder cancer test. We have elected to co-develop or license out this test to another company, retaining rights to receive a royalty on sales and possibly some sales related milestone payments, or we may complete the development of the test and seek to license the test to another company. There is no assurance that we will be successful in entering into a licensing or co-marketing arrangement or that a licensee or co-marketing partner will succeed in marketing our bladder cancer diagnostic test. If we enter into a license or co-marketing agreement, our revenues from the sale of our bladder cancer diagnostic test may be substantially less than the amount of revenues and gross profits that we might receive if we were to market that diagnostic test ourselves.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Future Diagnostic Development Milestones</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Over the next two years, we will continue to work to achieve the following milestones relating to the development and commercialization of our lung cancer diagnostic test:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd1e5de2585d947cb9f74b8b7527cca39" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Complete R&amp;D studies to the extent necessary to ready DetermaVu&#8482; for clinical validation.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0038aedf9e8048bca5b8e48cd8a5ba01" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 13px">
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Finish Clinical validation of DetermaVu&#8482;;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfa9282629d1e4bf4a2199542e8a852d8" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Launch DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup></div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3b4d9bdbc5594a8db83c7a5511655b5d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 13px">
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Start clinical utility studies of DetermaVu&#8482;;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za2a43cc93a6e457c8a1cdbe94ccec235" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Submit dossier to CMS for draft Medicare Local Coverage Decision for DetermaVu&#8482;; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z530ab2e0803d45788756e394fd089da6" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Obtain a certificate of registration, a certificate of compliance and inspection for our CLIA laboratory for all 50 states by completing requirements for State of Florida, Maryland, New York, and Rhode Island.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">15</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Achieving the commercialization and reimbursement milestones will require expanding our commercial team to include sales, marketing, market access, customer support and medical affairs.&#160; In September of 2017, we started the process of building our sales team by hiring a Vice President of Sales.&#160; We will need to build a sales force along with marketing, market access, customer support and medical affairs teams to market DetermaVu&#8482;, gain reimbursement coverage, and support the ordering of DetermaVu&#8482; tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Diagnostic Tests</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Based on substantial unmet needs, large markets, and data generated thus far from patient serum (blood) or urine screening, we have focused our efforts on biomarkers associated with lung, breast and bladder cancers. The DetermaVu&#8482; lung cancer development program is our highest priority.&#160; Our approach is based on utilizing detectable amounts of cancer-associated biomarkers in patients with early-stage disease. Our identification of certain combinations of biomarkers in lung, breast and bladder cancer as well as clinician and payer feedback on unmet need has led us to identify promising initial indications and target analytes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The relative ease of administering a liquid biopsy diagnostic and cost savings due to the elimination of unnecessary costlier and invasive surgical biopsy procedures, we believe, will make liquid biopsy diagnostic tests useful as routine tests that could be performed in men and women of any age and at any desired frequency in conjunctions with normal screening procedures to detect lung, breast or bladder cancer. If successful, our tests will initially reduce diagnosis uncertainty and eliminate unnecessary down-stream procedures resulting from indeterminate low dose computed tomography ("LDCT"), mammography, or cytology results.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We intend to initially develop and market a lung cancer diagnostic test in the United States before seeking regulatory approvals required to market the diagnostic test in other countries. DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> is being developed as a blood confirmatory test for cancer biomarkers, which will be used in conjunction with LDCT for patients with indeterminate pulmonary nodules to help clinicians triage patients for follow-up procedures.&#160; DetermaVu&#8482; will be regulated under the Clinical Laboratory Improvements Amendment ("CLIA") as a laboratory diagnostic test or "LDT". We may also develop <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in vitro</font> diagnostic tests ("IVDs") that will be subject to approval by the United States Food and Drug Administration (the "FDA") and through the European Directive on <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in vitro</font> diagnostics in the European Union.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have established a CLIA certified, California state licensed, clinical laboratory in Alameda, California. The laboratory is fully operational with state of the art equipment and staffed with experienced and highly skilled licensed clinical laboratory scientists. We have implemented a quality assurance program designed to ensure regulatory compliance and accurate, timely test results.&#160; The CLIA certification and California state license are accepted by forty four other states as proof of quality and good standing in order to do accept diagnostic test samples from patients in states outside of California.&#160; Five other states, Florida, Maryland, Rhode Island, Pennsylvania and New York, require out-of-state diagnostic laboratories to obtain their individual state clinical laboratory licenses or permits in order to perform diagnostic tests for patients residing in those states. We have already obtained the Pennsylvania state clinical laboratory permit and plans on obtaining the balance of the other state licenses or permits by year end.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Types of Diagnostic Use</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cancer diagnostics may have as many as five different types of intended uses depending on whether the cancer has been diagnosed and the stage of the cancer. These intended uses include:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf4a0dbbcadfb4b43a59590db21d20bfa" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Screening diagnostics could replace or be used as an alternative to existing screening procedures. Lung cancer screening is currently being done through the use of Low Dose Computed Tomography (LDCT) for high risk patients who meet the guideline requirements.&#160; A diagnostic could be developed that could be used as an alternative to the annual LDCTs.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z65f56c9afc454f8ba512845f00442b3a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Confirmatory diagnostics could be used in conjunction with a current standard of care screening procedure. For example, our lung confirmatory diagnostic would be used in conjunction with LDCT to confirm a suspicious nodule by yielding a secondary or confirming suspicious versus benign result. In the case of a benign result, the patient would not need additional invasive procedures to determine the presence of cancer. In the case of a suspicious result, additional procedures would be highly warranted.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0cc694e0f42647eb8888e6b442002aa8" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Prognostic or risk predictors could be used by physicians to determine if a patient is at high risk of a cancer recurrence and may be a candidate for closer monitoring or for adjuvant therapies;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zce7c7d32e53f419a90d6e68fa6ddeff4" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Companion diagnostics could be used by physicians to help determine an optimal therapy for a specific patient. An example of this would be PDL-1 and Keytruda;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z83cc18e2226b45758315b180c6195883" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Recurrence diagnostics could be used for patients who had previously been diagnosed with cancer but are currently in remission.&#160; These diagnostics could potentially catch recurrence before cancer growth appears on follow-up imaging.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">16</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Currently we are focused on diagnostics to detect early stage cancer due to the market opportunity associated with these types of diagnostics. Piper Jaffrey estimated that the domestic revenue opportunity for initial diagnosis tests is $15 billion.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are presently focused on confirmatory diagnostics, which we feel will have the largest market opportunity with the greatest barriers to entry.&#160; We believe that the confirmatory diagnostic market, like the recurrence risk predictor market, have both high barriers to entry and a first entrant advantage.&#160; The barriers to entry include:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd512ef7ada014237b640b470439f9152" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expertise:&#160; development of a confirmatory diagnostic necessitates developing a scoring algorithm and the detection of multiple analytes to differentiate those patients who have the disease from those who do not.&#160; In the case of our confirmatory diagnostics, the tests distinguish a benign nodule or mass from a suspicious nodule or mass.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2289dec039544ba4be914bb7ea4473e7" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Clinical relationships:&#160; relationships with larger cancer centers are required to produce the thousands of samples needed for the full continuum of trials from proof of concept to clinical validation of the diagnostic test.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z39bc883ad9b14abfa22a5ee51e2cfde0" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medical community input: Key Opinion Leaders&#8217; feedback from nationally recognized cancer clinicians is needed to determine whether the intended test is likely to be accepted and used by physicians in the applicable field of oncology.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z04f8c15385be4fd99664e4ccf028a289" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 16</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Types of Oncology Diagnostics</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="image00032.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We believe that competitors that launch a &#8220;me too&#8221; product, a product that is comparable in predictive abilities with a product already on the market, will not be able to significantly erode the market share of the established product. Industry analogues of this are Genomic Health&#8217;s Oncotype Dx and Veractye&#8217;s Afirma diagnostic tests.&#160; Genomic Health continues to maintain 90% share for its Oncotype Dx breast test, with three competitors in the market; while Afirma appears to have about an 80% market share for its thyroid test. See Graphic 16.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Technology for Diagnostic Tests</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For our liquid biopsy tests for lung, breast and bladder cancer, we used the same general strategy for the identification of mRNA, miRNA or protein biomarkers, and the development of an algorithm or gene expression classifier to interpret the differential marker expression.&#160; Our goal is to develop tests that yield a highly accurate benign call to allow clinicians to triage patients for follow-up procedures.&#160;&#160; Ultimately our research may rely on only one type of biomarker in a specific indication. In the case of lung cancer, DetermaVu&#8482; is being developed on mRNA biomarkers only. In the case of breast cancer, our study has evolved from the use of RNA markers to an immunoassay directed to proteins only.&#160; See Graphic 17.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">17</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3e509c56971f4414bcbe99955295aa11" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 17</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%"><img src="image00033.jpg"></td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the case of our lung cancer test, blood samples were collected by venipuncture into tubes and total RNA was isolated. mRNA biomarkers were identified for screening. The best performing mRNA biomarkers will be transferred to the commercial diagnostic testing platform we will use in our CLIA laboratory. The optimal combination and final panel of mRNA or miRNA biomarkers together with potential protein-based tests will be determined using bioinformatics and algorithm development strategies. The optimal algorithm will be selected that yields the best discrimination between malignant and benign. The performance of the final biomarker panel and classifier will be tested in a clinical validation study using an independent set of samples to determine performance characteristics of the test.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Biomarkers are important to the diagnosis of cancer in that their presence or absence in a specific patient sample drives the sensitivity and specificity scores of a molecular diagnostic. For example, if a specific mRNA is only seen expressed in patients with cancer, it can be used to help make a malignant call on that sample. The use of biomarkers with an algorithm can help ensure that the sensitivity score, which is a measure of correcting identifying the disease is sufficiently high to reduce false negative, ensuring that patients with the disease are correctly diagnosed. At the same time, biomarkers can be used to hone the specificity measure, which is a measure of correctly identifying patients without the disease, which reduces the number of patients who are unnecessarily referred to biopsy.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Development Pathway</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our diagnostic tests for cancer will, in general, each go through four stages of development prior to commercialization: Research, Assay Development, R&amp;D Validation Studies, and Clinical Validation Studies. The following graph illustrates the development pathway.&#160; Although the pathway diagram shows the development process as linear, in practice certain stages of the process may be conducted concurrently rather than sequentially or portions of certain stages may overlap. This general development flow may be customized for each specific product, depending on the circumstances and requirements for that individual test system. A fifth stage, Clinical Utility Studies will also be conducted after commencement of the marketing of a diagnostic test.&#160; See Graphic 18.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze09dc163d8054022ad2e48f33cfdab31" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 18</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Diagnostic Development Stag</font>e<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">s</font></div>

<div style="TEXT-ALIGN: center"><br>
</div>

<div style="TEXT-ALIGN: center"><img src="image00034.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">18</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb0732cd489b744beab6f72d7b71a8286" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research</font>: The first stage of the development of a CLIA LDT is the research stage. In the research stage of a molecular diagnostic, biological markers are analyzed to determine if specific markers are differentially expressed in certain diseases. We are developing blood and urine tests that differentiate malignant patient samples from benign patient samples by looking at differences in the amount of specific analytes expressed in whole blood or urine from cancer patients compared to patients who are cancer free. For our lung and bladder cancer tests the analytes we are looking at are specific mRNA and/or miRNA expressed in whole blood or urine; while for our breast cancer test we are looking at differentially expressing proteins. The objective of this phase of the development process is to delineate promising biomarkers, for further development and verification, before proceeding to validation work.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd5b09dd07c6d42f09075478c7495b31d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">2)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assay Development</font>: The second stage is Assay Development. In this stage the best performing analytes (mRNA, miRNA, or protein biomarkers) are combined with all of the processes needed to create an assay system. The assay system includes the sample collection methods, sample processing and extractions, biomarker assay methods, and the mathematical "algorithm" required to provide a clinical test result for a sample. The optimal combination and weighting of biomarkers in an algorithm to be used in the final diagnostic are determined through bioinformatics which may be combined with machine learning software strategies that also reflect the biomarker contributions to and reliability within the algorithm. The end result of assay development is an assay system, including a "defined" algorithm, the performance of which has been verified on clinical samples from the targeted 'intended use' population. The test system, including the algorithm, can be further optimized during the R&amp;D Validation phase.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z74fb03526b8d40169e725eb4a11ca990" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">3)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">R&amp;D Validation:</font> The third stage is R&amp;D Validation. There are three areas of studies that are undertaken during R&amp;D Validation. These studies are carried out in our R&amp;D laboratories.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za61415125ba84d5da2e058b57c97b821" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Assay System Reproducibility: During Assay System Reproducibility various critical aspects of diagnostic laboratory procedures are studied and tested to assure that the laboratory can produce consistent, reliable results. Multiple lots of reagents used in the laboratory are tested to determine whether lot to lot differences lead to differences in test results. Procedures for the collection of blood or urine samples from patients, the handling and storage of those samples, and the manner in which the samples are shipped to OncoCyte's diagnostic testing laboratory, are studied to assure that acceptable procedures are followed and that any variations in the procedures that can occur do not affect the diagnostic test results. Samples are studied for the stability of the biomarkers when the samples are subjected to various conditions that could be encountered throughout the total process of handling and shipping the samples, in order to define the conditions under which the clinical results for the sample will not change, at which point the results will change and lead to a different and erroneous result being reported by the lab.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z43b61e1ebfbe4f5287685abc59c78ad2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Algorithm Optimization and Lock: The Algorithm Optimization work that leads to an algorithm lock is usually customized to the needs of the specific product. In the case of the lung cancer test, we are employing a statistical method referred to as cross-validation where the algorithm is optimized on a subset of the clinical samples and then tested on the remaining untested samples. This process of optimizing the algorithm on a subset of samples and then testing on the remaining samples is repeated multiple times. Cross-validation is one of the methods for verifying the algorithm performance that leads to a 'lock' on the algorithm.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zedb13941b2c9432a8631766dcf92013e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Analytical Validation Studies. The last area of study in R&amp;D Validation is Analytical Validation. The studies required for Analytical Validation have been established in the CLSI (Clinical Lab Standards Institute) Guidelines. These guidelines cover the testing for such matters as limits of quantitation, precision, reproducibility, and interfering substances. When completed, these Analytical Validation studies establish the performance characteristics of the assay system for subsequent clinical validation in the CLIA laboratory.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z643bd356ffce42c6af182303ad77a197" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">4)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical Validation:</font> The fourth stage is Clinical Validation. This stage has two distinct sets of studies within it, that are carried out in our CLIA laboratory.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3c5e0678eed24fcf98f0438f98f013c6" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CLIA Lab Validation: In the CLIA Lab Validation Study, the CLIA lab will assay patient samples previously tested during the R&amp;D Validation stage. This study is to demonstrate that the full assay system utilized in the CLIA lab, run by CLIA staff and on certified instrumentation, provides the same results on clinical samples as those obtained in the R&amp;D lab.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb8a3fbe6ae484791b154b4ae67676e45" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CLIA Lab Clinical Validation. The second kind of study performed in Clinical Validation is the CLIA Lab Clinical Validation. In this study, in general, additional new clinical samples will be collected and sent blinded to the CLIA lab. The CLIA lab will perform assays on these blinded samples and the performance of the full assay system will be assessed against clinical diagnosis.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">19</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7f27486685484b80992d930c6499a9ef" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">5)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical Utility:</font> The final phase of the diagnostic pathway occurs after the diagnostic test has been launched and consists of carrying out one or more<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Clinical Utility Studies.</font> These studies are important for driving adoption and obtaining coverage and reimbursement from payers such as Medicare, Medicaid, third party commercial insurers, health maintenance organizations ("HMOs"), and large corporations that self-insure. Clinical Utility Studies analyze the improvement in patient health outcomes associated with a diagnostic test. The outcomes of these studies can also be used to understand the health economics, including the cost effectiveness, of the new diagnostic. Clinical utility studies compare the treatment choices and outcomes of patients who received the test results versus those who did not receive the test results.&#160; The results of this phase may be published in peer review journals and are generally compiled in dossiers to share with managed care groups, including both public and commercial payers.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Licensed Technology from Wistar</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have entered into a License Agreement with Wistar that entitles us to use certain patents, know-how and data belonging to Wistar.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Licenses Granted</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under the License Agreement, we have obtained an exclusive, worldwide license under certain patents, and under certain know-how and data ("Technical Information") belonging to Wistar, for use in the field of molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples (the &#8220;Licensed Field&#8221;). We have the right to grant sublicenses of the licensed patents and Technical Information subject to certain conditions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Royalties, License Fees and Other Payment Obligations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have paid Wistar an initial license fee and will pay Wistar royalties on &#8220;net sales&#8221; of licensed products,&#8221; as those terms are defined in the License Agreement. The royalty rates will range from 3% to 5% depending upon the amount of cumulative net sales. The amount of royalties payable to Wistar will be reduced by the amount of any royalties that we must pay to any third parties on the sale of the licensed products, but subject to a maximum reduction of 50%. Our obligation to pay royalties to Wistar will terminate on a licensed product by-licensed product and country-by-country basis until the later of (i) the date a valid claim of a licensed patent covering the licensed product no longer exists, or (ii) the tenth (10th) anniversary of the first commercial sale of the licensed product in each country.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will pay Wistar a minimum annual royalty each year, which in each case will be credited against total royalties due on net sales of licensed products during the year in which the minimum royalty is paid. We will also be obligated to pay Wistar an annual license maintenance fee in the mid-five figures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will pay Wistar a portion of any non-royalty sublicensing income that we may receive from the sub-licensee. Non-royalty sublicensing income will include any consideration received from a sub-licensee for granting the sublicense, but excluding royalties, the fair market value of any equity or debt securities sold to a sub-licensee, and any payments received from a sub-licensee for any related research we conduct for the sub-licensee.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We also will pay Wistar (a) milestone payments upon the occurrence of certain milestone events in the development and commercialization of a licensed product, and (b) all past or ongoing costs incurred or to be incurred by Wistar, including government fees and attorneys' fees, in the course of prosecuting the licensed patents.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other Obligations</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have agreed to use commercially reasonable diligent efforts, directly or through sub-licensees, to develop and commercialize licensed products. We have agreed that we or a sub-licensee will commence commercial sale of a licensed product by a specified date. If sales of a licensed product do not commence by the specified date, we may purchase up to three one-year extensions of the deadline by paying Wistar a designated fee for the applicable extension.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have agreed to indemnify Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel and staff, from and against certain claims and liabilities related to the License Agreement and the development, manufacture and sale of licensed products, excluding liabilities that result from or arise out of an indemnified party's gross negligence or willful misconduct.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Termination of the License Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Wistar has the right to terminate the License Agreement, subject to certain notice and cure periods and <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">force majeure</font> delays in certain cases, if any of the following occur:&#160; (a) we fail to pay any amount payable to Wistar; (b) we materially breach any covenant or agreement or any continuing representation or warranty contained in the License Agreement; (c) we become subject to certain bankruptcy or insolvency events, (d) we dissolve or cease operations, (e) we or any of our affiliates or sub-licensees or affiliates of any our sub-licensees challenges the validity, patentability, scope, construction, enforceability, non-infringement, or Wistar's ownership of any issued patent comprising the licensed patents, or assists any third party in any such challenge; or (f) we fail to fulfill our product development and commercialization diligence obligations and related performance milestones.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have the right to terminate the License Agreement with or without cause, upon the passage of a specified period of time after giving Wistar written notice of termination.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Wistar's Retained Rights to Certain Proposed Products</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Wistar has reserved the right to (i) make, use, practice and further develop the licensed patents and Technical Information for educational, research, and other internal purposes; (ii) grant to any academic, government, research or non-profit institution or organization the right to make, use and practice the licensed patents or Technical Information for non-commercial research and educational purposes; and (iii) grant licenses under the Licensed Patents or Technical Information to any party for any field, product, service or territory other than the licensed products in the Licensed Field.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition, if Wistar determines to develop or have developed an actual or potential licensed product that is for an application, product, sub-field or indication in the Licensed Field, but for which Wistar reasonably believes a licensed product is not being actively developed or commercialized by us or by our affiliates or sub-licensees, Wistar may give us notice of the proposed product. If we timely inform Wistar of our election to develop the proposed product, and if we successfully negotiate a development plan and milestones for the proposed product, we will be entitled to develop the proposed product as a licensed product under the License Agreement. If we do not elect to develop the proposed product or do not reach agreement with Wistar for a development plan and milestones for the proposed product, Wistar may exclude the proposed product from our license under the License Agreement and may develop the proposed product itself or grant licenses to third parties under the licensed patents and Technical Information for the development and commercialization of the proposed product.</div>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">20</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<!--PROfilePageNumberReset%Num%22%%%-->
<div style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Facilities Required</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under a Shared Facilities and Services Agreement (the "Shared Facilities Agreement") with BioTime, we have use of laboratory and office space at BioTime's facility in Alameda, California. BioTime has leased approximately 30,795 square feet of office and laboratory space in two buildings located in Alameda, and is providing OncoCyte use of space for a CLIA diagnostic laboratory.</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Raw Materials</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The processing of our diagnostics will use commercially available reagents that are sourced by one or more manufacturers of molecular diagnostic analyzers, prep stations and reagents. An interruption in supply or quality control issues with supplies such as reagents could require us to find a different source of supply of both the reagents and the analytic equipment that we will be using in our CLIA laboratory. An interruption in supply of reagents could cause us to suspend or limit laboratory operations, and a change in analytic equipment could require us to re-establish various testing procedures, which also could disrupt our operations. We have encountered issues with reagents used in the diagnostic testing platform that we acquired for the development of our diagnostic tests, and we are evaluating alternative diagnostic testing platforms, pending a resolution of the reagent issues with the analytic platform that we initially used.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Marketing</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Following clinical validation of a diagnostic test, we intend to market our diagnostic test directly to health care providers working in the areas of lung cancer and in other areas of cancer where we will be developing molecular diagnostics. These health care providers will collect blood samples or send patients to laboratories to have blood or urine samples collected. These samples, also referred to as liquid biopsies, will be sent to our CLIA laboratory in California, either by the health care provider or the laboratory who drew the specimen. The sample will be run through an assay and a gene expression classifier at our Alameda California laboratory to determine a binary result, either benign or suspicious. That result will be presented to the physician ordering the procedure in a standardized report.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will ramp up sales and marketing teams over the next two to three years for our first product. Over time, we will continue to grow our sales, market access and marketing organizations to increase the awareness and utilization of our diagnostic tests and to prepare for additional diagnostic test launches.&#160; The focus of our marketing organization will be to position and promote our planned lung cancer confirmatory diagnostic to the three key stakeholders:&#160; physician, patients and payers.&#160; See Graphic 19.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z97720c79ee444efc9fad7fd4f63e9f83" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 19</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commercialization Strategy</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="image00035.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will market DetermaVu&#8482;, primarily to pulmonologists, and secondarily to radiologists and thoracic surgeons who either do the screening for lung cancer or conduct the biopsies or serial imaging procedures.&#160; See Graphic 20.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">21</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf02a08c22a264217ac135d08ecc18afd" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 20</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Target Markets for DetermaVu&#8482;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt"><img src="image00036.jpg"></div>
</td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The focus of our physician marketing efforts will be outreach through:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3ab2e14c660a4173aafe3401f9737330" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">medical conferences and symposia, for which the primary conferences are Chest, American Thoracic Society and the World Conference on Lung Cancer;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z480ec00e06804b7390bae45fd4e127ee" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">speakers bureaus; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zea242f8a59c7416382527e87f818f151" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">peer review journal articles</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have presented data from our clinical studies at the CHEST and the American Thoracic Society (ATS) medical conferences.&#160; At ATS in May of 2017, we had a booth, clinical symposiums focused on nodule management and the role of biomarkers, and a poster presentation of our R&amp;D validation study.&#160;&#160; In October 2017, we presented our data at the CHEST conference, where we had a booth, a clinical symposium on nodule management and the role of biomarkers, and a presentation on additional data associated with our R&amp;D validation study.&#160; &#160; We plan to continue to present our study data in 2018 at the ATS conference and at the Chest International Conference in San Antonio, Texas.&#160; Additionally, we may elect to present data at the World Congress on Lung Cancer in Toronto, Canada.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we are successful in developing DetermaVu&#8482;, our marketing efforts to patients will be focused on increasing the awareness of lung cancer screening through work with advocacy groups and patient outreach. Additionally, we may develop a patient assistance program to help reduce the financial burden to patients of out of pocket expenses due to lack of insurance coverage, high co-insurance payments or high deductibles.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Access &#8211; Reimbursement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">One of the more critical functions in a diagnostic company is market access. We have a Market Access Team that develops and implements our strategy to obtain coverage and reimbursement from public and private payers. For an oncology diagnostic, one of the most critical payers is Medicare or CMS, because oncology is a cancer that typically presents in older populations. For our lung test, Medicare may cover up to 55% of the patients for whom the test is ordered. We started the Market Access Team in mid-2016 with a team leader who has over 10 years of molecular diagnostics market access and commercial operations experience.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Obtaining medical coverage generally takes twelve to sixteen months from the time that sufficient evidence is published establishing clinical utility. Medicare, both at the local and national coverage determination levels occasionally establishes coverage prior to the completion and publication of a diagnostic&#8217;s clinical utility study. As a consequence, it may be possible to obtain Medicare coverage prior to the publication of our clinical utility study.&#160; A recent example of this was CMS&#8217;s national coverage determination (NDC) for NGS cancer panels for off-label use. In 2017, Noridian, the Medicare administrative contractor (MAC) for the JE jurisdiction that includes California, issued Local Coverage Decisions or LCDs for a number of diagnostics, while evidence was still under development. Private payors, on the other hand, require clinical utility studies to be published before providing favorable coverage decisions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Until a new cancer diagnostic test is accepted by third party payers for reimbursement, we will have to market the test to physicians on a patient pay basis, meaning that the patient will need to pay the full cost of the test. In the absence of reimbursement by a health insurance plan or Medicare, patients who would be candidates for the use of our diagnostic tests may decline to use our tests, and physicians may be reluctant to prescribe our tests, due to the cost of the test to the patients.&#160; Because of this patient cost factor, revenues from any new cancer test that we market will experience slow growth until the test is approved for reimbursement in an amount commensurate with the cost to the patient.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">22</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our market access strategy is based on three components:&#160; coding, coverage and reimbursement.&#160; For product coding we will launch our diagnostic with an unlisted code and seek to get a unique CPT code later. We believe that our lung cancer confirmatory diagnostic will meet the requirements of a Multi Analyte Algorithm Assay (MAAA) in that the diagnostic that we are developing will be comprised of multiple mRNA biomarkers with a gene expression classifier.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The second focus of our reimbursement strategy will be to obtain coverage by both public and commercial payors. We will first focus on receiving a Medicare coverage decision and then focus on obtaining coverage decisions for larger commercial payors, including private health insurance plans. Medicare through the MolDX program has developed clear guidelines for the level of evidence of efficacy required to be obtained through clinical trials. Our strategy is to achieve the highest level of evidence (IA) by conducting studies for clinical utility that are randomized and prospective. Additionally, our plan is to run two clinical validation studies. We took the approach of sharing our clinical protocol designs with payors, much like many therapeutic companies share their clinical utility designs with the FDA, for feedback. See Graphic 21.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 90%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za0b5591697e949c0ba07f91f2c6cb108" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="TEXT-ALIGN: center; WIDTH: 35%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Graphic 21</div>
</td>
<td style="TEXT-ALIGN: center; WIDTH: 20%"><img src="image00037.jpg"></td>
<td style="WIDTH: 35%">
<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 36pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We previewed our clinical protocol designs with ten payers that represent over 77 million covered lives late last year and received favorable feedback on the design of our studies, the number of our studies, and the primary and secondary endpoints.&#160; From this interaction, we believe that if we are successful in meeting the endpoints of our clinical utility studies, we will receive favorable coverage decisions by some large payers.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Patents and Trade Secrets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We rely primarily on patents and contractual obligations with employees and third parties to protect our proprietary rights. We have sought, and intend to continue to seek, appropriate patent protection for important and strategic components of our proprietary technologies by filing patent applications in the U.S. and certain foreign countries. There can be no assurance that any of our patents will guarantee protection or market exclusivity for our diagnostic tests and diagnostic test candidates. We may also use license agreements both to access technologies developed by other companies and universities and to convey certain intellectual property rights to others. Our financial success will be dependent in part on our ability to obtain commercially valuable patent claims and to protect our intellectual property rights and to operate without infringing upon the proprietary rights of others.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our diagnostic patent portfolio includes 13 patent families owned by us with claims directed to compositions of matter and methods useful for detection of breast, bladder, colon, pancreatic, ovarian, and thyroid cancers using specific biomarkers or a panel of specific biomarkers. Patents are pending in various jurisdictions, including the United States, Europe, Australia, Canada, China, Hong Kong, Japan and Republic of Korea, with projected expiration dates ranging from 2032 to 2036. Additionally, we have one issued patent in Australia, with claims directed to a method of detecting bladder cancer; and one accepted patent application in Australia, with claims directed to a method of detecting breast cancer. The issued patent will expire in 2032.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">23</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have also obtained an exclusive license from Wistar to certain pending patent applications in the field of molecular diagnostics for lung cancer. The pending claims are directed to compositions of matter and methods useful for detection of lung cancer using specific biomarkers or a panel of specific biomarkers, with projected expiration dates in 2036. Additionally, we have obtained from Wistar an exclusive option under which we may obtain licenses to additional issued and pending patents in the field of molecular diagnostics for lung cancer. Patents covered by the exclusive option have issued in the United States and Europe and are pending in the United States, Canada and India. Those patents are projected to expire in 2028 - 2030.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to relying on patents, we will rely on trade secrets, know-how, and continuing technological advancement to maintain our competitive position. We have entered into intellectual property, invention, and non-disclosure agreements with our employees, and it is our practice to enter into confidentiality agreements with our consultants. There can be no assurance, however, that these measures will prevent the unauthorized disclosure or use of our trade secrets and know-how, or that others may not independently develop similar trade secrets and know-how or obtain access to our trade secrets, know-how, or proprietary technology.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General Risks Related to Obtaining and Enforcing Patent Protection</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our patents and patent applications are directed to compositions of matter, formulations, methods of use and/or methods of manufacturing. The patent positions of pharmaceutical and biotechnology companies, including ours, are generally uncertain and involve complex legal and factual questions. Our business could be negatively impacted by any of the following:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc00a0f7f1132454bb728730153d499b3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The claims of any patents that are issued may not provide meaningful protection, may not provide a basis for commercially viable diagnostic tests or may not provide us with any competitive advantages;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc9e79976103b43d48012d930f34fed9c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our patents may be challenged by third parties;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z071ecac24bcc4ab287f9040b8d535390" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Others may have patents that relate to our technology or business that may prevent us from marketing our diagnostic test candidates unless we are able to obtain a license to those patents;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze11f4cf983cb4df1913ad2d0d4f47986" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Patent applications to which we have rights may not result in issued patents; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8ab8920cc1954f658b8c3bbec6777002" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may not be successful in developing additional proprietary technologies that are patentable.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition, others may independently develop similar or alternative technologies, duplicate any of our technologies and, if patents are licensed or issued to us, design around the patented technologies licensed to or developed by us. Moreover, we could incur substantial costs in litigation if we have to defend ourselves in patent lawsuits brought by third parties or if we initiate such lawsuits</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The United States Supreme Court's decisions in<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font> and<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Association for Molecular Pathology v. Myriad Genetics</font> may limit our ability to obtain patent protection on diagnostic methods that merely recite a correlation between a naturally occurring event and a diagnostic outcome associated with that event. Our cancer diagnostic tests are based on the presence of certain genetic markers for a variety of cancers. In<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font>, the Supreme Court ruled that patent protection is not available for the use of a mathematical correlation of the presence of a well-known naturally occurring metabolite as a means of determining proper drug dosage. The claims in the contested patents that were the subject of that decision were directed to measuring the serum level of a drug metabolite and adjusting the dosing regimen of the drug based on the metabolite level. The Supreme Court said that a patent claim that merely claimed a correlation between the blood levels of a drug metabolite and the best dosage of the drug was not patentable subject matter because it did no more than recite a correlation that occurs in nature.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Association for Molecular Pathology v. Myriad Genetics,</font> the Supreme Court ruled that the discovery of the precise location and sequence of certain genes, mutations of which can dramatically increase the risk of breast and ovarian cancer, was not patentable. Knowledge of the gene location and sequences was used to determine the genes' typical nucleotide sequence, which, in turn, enabled the development of medical tests useful for detecting mutations in these genes in a particular patient to assess the patient's cancer risk. But the mere discovery of an important and useful gene did not render the genes patentable as a new composition of matter.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Also, in <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ariosa Diagnostics, Inc. v. Sequenom, Inc.</font>, the Federal Circuit ruled that a method for detecting a paternally inherited nucleic acid of fetal origin performed on a maternal serum or plasma sample from a pregnant female was not patent eligible subject matter under the framework set forth in <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Mayo Collaborative Services v. Prometheus Laboratories, Inc</font>. The court examined the elements of the claim to determine whether the claim contained an inventive concept sufficient to transform the claimed naturally occurring phenomenon into a patent eligible application and found that the method steps did not support patentability because they used conventional amplification and detection techniques. Although the claims can be distinguished from the claims at issue in <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Mayo Collaborative Services v. Prometheus Laboratories, Inc</font>., the court was bound by the language of the Supreme Court decision to hold Sequenom's claims unpatentable.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">24</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">While the cases discussed above are instructive, the United States Patent and Trademark Office (the "USPTO") has issued interim guidelines in light of the Supreme Court decisions indicating that process claims having a natural principle as a limiting step will be evaluated to determine if the claim includes additional steps that practically apply the natural principle such that the claim amounts to significantly more than the natural principle itself. Because the diagnostic tests that we are developing combine an innovative methodology with newly discovered compositions of matter, we are hopeful that this Supreme Court decision will not preclude the availability of patent protection for our diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The USPTO has also issued a Subject Matter Eligibility Update to provide further guidance in determining subject matter eligibility.&#160; The Subject Matter Eligibility Update includes new Subject Matter Eligibility Examples for the Life Sciences. These examples provide favorable exemplary subject matter eligibility analysis of hypothetical claims covering diagnostic tests and claims drawn from case law. This update from the USPTO does not change our opinion on our ability to obtain meaningful patent protection.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There is a risk that any patent applications that we file and any patents that we hold or later obtain could be challenged by third parties and declared invalid or infringing of third party claims. A patent interference proceeding may be instituted with the USPTO when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent filed before March 16, 2013. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO's decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us. In addition to interference proceedings, the USPTO can reexamine issued patents at the request of a third party seeking to have the patent invalidated. After March 16, 2013 an inter partes review proceeding will allow third parties to challenge the validity of an issued patent where there is a reasonable likelihood of invalidity. This means that patents owned or licensed by us may be subject to re-examination and may be lost if the outcome of the re-examination is unfavorable to us.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Post Grant Review under the America Invents Act makes available opposition-like proceedings in the United States. As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application. Also, a derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries. As with the USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The enforcement of patent rights often requires litigation against third party infringers, and such litigation can be costly to pursue. Even if we succeed in having new patents issued or in defending any challenge to issued patents, there is no assurance that our patents will be comprehensive enough to provide us with meaningful patent protection against our competitors.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to patents, we rely on trade secrets, know-how, and continuing technological advancement to maintain our competitive position. The molecular diagnostics that we are developing use gene expression classifiers or algorithms, which are mathematical models that weight the biomarkers to produce a score.&#160; We will treat the mathematical models as trade secrets. We have entered into intellectual property, invention, and non-disclosure agreements with our employees, and it is our practice to enter into confidentiality agreements with our consultants. There can be no assurance, however, that these measures will prevent the unauthorized disclosure or use of our trade secrets and know-how, or that others may not independently develop similar trade secrets and know-how or obtain access to our trade secrets, know-how, or proprietary technology.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Third-Party Payer Reimbursement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Billing, Coverage, and Reimbursement for Diagnostic tests</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Revenues from our clinical laboratory testing will be derived from several different sources. Depending on the billing arrangement, the instruction of the ordering physician, and applicable law, parties that may reimburse us for our services include:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfb2ac99af76745b2a5f4907b8faf33e8" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Third-party payers that provide coverage to the patient, such as an insurance company, a managed care organization, or a governmental payer program;</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">25</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z57fa071e3ab744d1802a1e8f5e33a80b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Physicians or other authorized parties, such as hospitals or independent laboratories, that order the testing service or otherwise refer the testing services to us; or</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8b19046e68ee4222856329bad416a86d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Patients in cases where the patient has no insurance, has insurance that partially covers the testing, or owes a co-payment, co-insurance, or deductible amount.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We expect that a substantial portion of the patients for whom we will perform diagnostic tests will have Medicare as their primary medical insurance. We cannot assure that, without Medicare reimbursement our planned tests will produce sufficient revenues to enable us to reach profitability and achieve its other commercial objectives.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Clinical diagnostic laboratory tests are generally reimbursed under the Medicare Clinical Laboratory Fee Schedule ("CLFS") and reimbursement under the Medicare program for the diagnostic tests that we will offer is based on the CLFS.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare has coverage policies that can be national or regional in scope. Coverage means that the test is approved as a benefit for Medicare beneficiaries. If there is no coverage, neither we nor any other party, such as a reference laboratory, may receive reimbursement from Medicare for the service.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">From time to time, Congress has revised the Medicare statute and the formulas it establishes for the clinical laboratory fee schedules or CLFS. The payment amounts under the Medicare fee schedules are important because they will determine the amount of reimbursement for a diagnostic under Medicare, and those payment amounts are also often used as a basis for payment amounts set by other governmental and private third-party payers. For example, state Medicaid programs are prohibited from paying more than the Medicare fee schedule limit for clinical laboratory services furnished to Medicaid recipients.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Protecting Access to Medicare Act of 2014 ("PAMA"), enacted April 1, 2014 establishes a market-based pricing methodology for laboratory test. Two categories of tests are established under PAMA: clinical diagnostic lab tests (&#8220;CDLT&#8221;) and advanced diagnostic lab tests (&#8220;ADLT&#8221;). ADLTs are CDLTs furnished by a single laboratory, not sold for use by other entities, and meeting at least one of the following criteria:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfea8ed72cda343cc8d66edb1db3ecac0" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Analysis of multiple biomarkers of DNA, RNA or proteins combined with a unique algorithm to yield a single patient-specific result;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z25c1fb3ac8454e56bee5b9bd523c7493" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cleared or approved by the FDA; or</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8b27593f2b2843eb946a0a02bcfac59a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Meets other similar criteria established by the Secretary of Health and Human Services.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Prices for both CDLTs and ADLTs are established using the same methodology: the law establishes that CLFS prices will be equal to the weighted median rates paid by private payors. However, CDLT prices are adjusted every three years whereas ADLT prices are adjusted annually. The other difference between the two types of tests is the establishment of the initial price. For CDLTs, the price paid for the first three years is established by CMS through a gap-fill methodology. For ADLTs, the price paid for the first 9 months is the test&#8217;s list price (if the list price is greater than 130% of the weighted median private payor price, CMS will recoup the difference from the laboratory through a payment claw back). It is not known at this point if the tests we are developing will be classified as CDLTs or ADLTs. The gap-fill pricing methodology for CDLTs represents a significant short-term risk because pricing under the gap-fill methodology can vary significantly.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On January 1, 2018 the new PAMA-based CLFS went into effect for the first time. PAMA-based prices did not impact all lab tests equally. Some tests had price reductions while others saw price increases.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Congress has proposed on several occasions to impose a 20% coinsurance charge on patients for CDLTs reimbursed under CLFS, which would require us to bill patients for these amounts. Because of the relatively low reimbursement for many CDLTs, in the event that Congress enacts such legislation, the cost of billing and collecting for these services would often exceed the amount receivable from the patient.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Some Medicare claims may be subject to policies issued by the Medicare Administrative Contractor ("MAC") for California. CMS relies on a network of MACs to process Medicare claims, and MACs serve as the primary operational contact between the Medicare Fee-For-Service program and approximately 1.5 million health care providers enrolled in the program. The predecessor to the current California MAC, acting on behalf of many MACs, issued a Local Coverage Determination that affects coverage, coding and billing of many molecular diagnostic tests. Under this Local Coverage Determination, the MAC took the position that it would not cover any molecular diagnostic test unless the test is expressly included in a National Coverage Determination issued by CMS, or a Local Coverage Determination, or coverage article issued by the MAC. Denial of coverage for our diagnostic tests by the current California MAC, Noridian Healthcare Solutions, or reimbursement at inadequate levels, would have a material adverse impact on our business and on market acceptance of our planned diagnostic tests.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">26</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Private and Governmental Third Party Payers</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Where there is a private or governmental third-party payer coverage policy in place, we will bill the payer and the patient in accordance with the established policy. Where there is no coverage policy in place, we will pursue reimbursement on a case-by-case basis. Our efforts in obtaining reimbursement based on individual claims, including pursuing appeals or reconsiderations of claims denials, could take a substantial amount of time, and bills may not be paid for many months, if at all. Furthermore, if a third-party payer denies coverage after final appeal, payment may not be received at all.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reimbursement rates paid by private third-party payers can vary based on whether the provider is considered to be an "in-network" provider, a participating provider, a covered provider, an "out-of-network" provider or a non-participating provider. These definitions can vary among payers. An in-network provider usually has a contract with the payor or benefits provider. This contract governs, among other things, service-level agreements and reimbursement rates. In certain instances, an insurance company may negotiate an in-network rate for our testing. An in-network provider may have rates that are lower per test than those that are out-of-network, and that rate can vary widely. Rates vary based on the payer, the testing type and often the specifics of the patient's insurance plan. If a laboratory agrees to contract as an in-network provider, it generally expects to receive quicker payment and access to additional covered patients. However, it is likely that we will initially be considered an "out-of-network" or non-participating provider by payers who cover the vast majority of patients until we can negotiate contracts with the payers.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We cannot predict whether, or under what circumstances, payers will reimburse for patients for our tests. Full or partial denial of coverage by payers, or reimbursement at inadequate levels, would have a material adverse impact on our business and on market acceptance of our tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Direct Billing Laws and Other State Law Restrictions on Billing for Laboratory Services</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In some cases, if not prohibited by law or regulation, we may bill physicians, hospitals and other laboratories directly for the services that they order. However, laws and regulations in certain states prohibit laboratories from billing physicians or other purchasers for testing that they order. Some states may allow laboratories to bill physicians directly but may prohibit the physician and, in some cases, other purchasers from charging more than the purchase price for the services, or may allow only for the recovery of acquisition costs, or may require disclosure of certain information on the invoice. An increase in the number of states that impose similar restrictions could adversely affect us by encouraging physicians to perform laboratory services in-house or by causing physicians to refer services to other laboratories that are not subject to the same restrictions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Government Regulation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CLIA--Clinical Laboratory Improvement Amendments of 1988 and State Regulation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As a provider of laboratory testing on human specimens for the purpose of disease diagnosis, prevention, or treatment, we are required to hold certain federal, state, and local licenses, certifications and permits to conduct our business. In 1988, Congress enacted CLIA, which established quality standards for all laboratories that provide testing services to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test is performed.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under CLIA, a laboratory is defined as any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of, or assessment of health of human beings. CLIA requires that we hold a certificate applicable to the complexity of the categories of testing we perform and that we comply with certain standards. Laboratories performing high complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. CLIA regulations require clinical laboratories like our laboratory to comply with various operational, personnel, facilities administration, quality, and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is a prerequisite for reimbursement eligibility for services provided to state and federal health care program beneficiaries. CLIA is user-fee funded. Therefore, all costs of administering the program must be covered by the regulated facilities, including certification and survey costs.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">27</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our laboratory has obtained a CLIA certificate of accreditation and is also currently licensed in California and Pennsylvania. </font>We will be required to meet laboratory licensing and other requirements under laws of Florida, Maryland, Rhode Island, and New York if we wish to receive blood or urine samples for testing from patients in those states<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. To maintain our current licensing, we will be subject to regular surveys and inspections that will continue to assess our compliance with program standards.</font></div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">FDA Regulation of Diagnostic Tests</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our diagnostic tests will likely be classified as LDTs and consequently be governed under the CLIA regulations, as administered by CMS, as well as by applicable state laws. Historically, the FDA has exercised enforcement restraint with respect to most LDTs and has not required laboratories that offer LDTs to comply with FDA requirements for medical devices, such as registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls. In recent years, however, the FDA has stated it intends to end its policy of enforcement restraint and begin regulating certain LDTs as medical devices. On October 3, 2014, the FDA issued two draft guidance documents, entitled "Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)" and "FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)", respectively, that set forth a proposed risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. The FDA has indicated that it does not intend to modify its policy of enforcement restraint until the draft guidance documents are finalized.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On January 13, 2017, the FDA issued a Discussion Paper on LDTs ("Discussion Paper"), which follows the FDAs late 2016 announcement that contrary to its earlier reports, it would not issue a final guidance on its proposed oversight of LDTs and allow for further public discussion on appropriate oversight. As it did in its 2014 guidance documents, the FDA continues to advocate a risk based approach to LDT oversight and proposes focusing on new and significantly modified high and moderate risk LDTs; however, new and significantly modified LDTs in certain categories would not be expected to comply with premarket review, quality systems, and registration and listing requirements unless necessary to protect public health. These exempt categories include low risk LDTs, LDTs for rare diseases, traditional LDTs, LDTs intended solely for public health surveillance, certain LDTs used in CLIA certified labs, and LDTs intended solely for forensic use. Based on the FDA's guidance in the Discussion Paper, our DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> products will likely not require FDA filing before launch. With respect to the postmarket surveillance of LDTs, the FDA's Discussion Paper recommends that laboratories initially report serious adverse events for all tests except the exempted categories of tests, which include LDTs intended for public health surveillance, some stem cell/tissue/organ transplantation LDTs, and LDTs intended solely for forensic use. The Discussion Paper notes that while the report neither represents the formal position of the FDA and nor is it a final version of the LDT guidance documents published in 2014, it is hoped that its publication will continue to advance further public disclosure.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Based on guidance set forth in the Discussion Paper, FDA premarket review of new and significantly modified LDTs could be phased-in over four years, however, to date no firm time commitments have been set. Nonetheless, the FDA may decide to regulate certain LDTs on a case-by-case basis at any time.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Failure to comply with applicable FDA regulatory requirements may trigger a range of enforcement actions by the FDA, including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations, and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity. We cannot predict the ultimate form or impact of any such FDA guidance and the potential effect on our diagnostic test services.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We cannot provide any assurance that FDA regulation, including premarket review, will not be required in the future for our diagnostic tests, whether through additional guidance or regulations issued by the FDA, new enforcement policies adopted by the FDA or new legislation enacted by Congress. It is possible that proposed legislation discussed above or other new legislation could be enacted into law, or new regulations or guidance could be issued by the FDA. Such new legislation may result in new or increased regulatory requirements for us to continue to offer our diagnostic tests or to develop and introduce new tests or services.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If premarket review, including approval, is required, our business could be negatively affected until such review is completed and clearance to market or approval is obtained. If we are selling any of our diagnostic tests when new FDA approval requirements are implemented, we may be required to suspend sales until we obtain premarket clearance or approval. If our diagnostic tests are allowed to remain on the market but there is uncertainty about the legal status of those tests, if we are required by the FDA to label them investigational, or if labeling claims the FDA allows us to make are limited, order levels for the use of our tests may decline and reimbursement may be adversely affected.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">FDA regulations could also require, among other things, additional clinical studies and submission of a premarket notification or filing a Premarket Approval ("PMA") application with the FDA. For example, LDTs with the same intended use as a cleared or approved companion diagnostic are defined in FDA's draft guidance as "high-risk LDTs (Class III medical devices)" for which premarket review would be required. This may include the use of our LDTs for screening patients for cancer. See the discussion of FDA regulation of medical devices below under<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> In Vitro Diagnostics.</font> If premarket review is required by the FDA, there can be no assurance that our diagnostic tests will be cleared or approved on a timely basis, if at all, nor can there any be assurance that labeling claims allowed by the FDA will be consistent with our intended claims or will be adequate to support continued adoption of and reimbursement for our tests. Compliance with FDA regulations would increase the cost of conducting our business, and subject us to heightened requirements of the FDA and penalties for failure to comply with these requirements. We may also decide voluntarily to pursue FDA premarket review of our diagnostic tests if we determine that doing so would be appropriate.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">28</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Legislative proposals addressing oversight of genetic testing and LDTs have been introduced in previous Congresses and we expect that new legislative proposals will be introduced from time to time in the future. We cannot provide any assurance that FDA regulation, including premarket review, will not be required in the future for our tests, whether through finalization of guidance issued by the FDA, new enforcement issued by the FDA, new enforcement policies adopted by the FDA or new legislation enacted by Congress.&#160; It is possible that legislation will be enacted into law or guidance could be issue by the FDA, which may result in increased regulatory burdens for us to continue to offer our tests or to develop and introduce new tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We cannot predict the ultimate form of any statutes, regulations or guidance and the potential impact on our existing tests, our tests in development or materials used to perform our tests. If pre&#8209;market review is required, our business could be negatively impacted until such review is completed and clearance or approval is obtained, and the FDA could require that we stop selling our tests pending pre&#8209;market clearance or approval. If our tests are allowed to remain on the market but there is uncertainty about the regulatory status of our tests, if they are labeled investigational by the FDA, or if labeling claims the FDA allows us to make are more limited than the claims we currently make, orders or reimbursement may decline. The regulatory review process may involve, among other things, successfully completing additional clinical trials and submitting a pre&#8209;market clearance notice or filing a pre-market application with the FDA.&#160; If pre-market review is required by the FDA, there can be assurance that our tests will be cleared or approved on a timely basis, if at all, nor can there be assurance that the labeling claims cleared or approved by the FDA will be consistent with our current claims or adequate to support continued adoption of and reimbursement for out tests.&#160; Ongoing compliance with FDA regulations would increase the costs of conduction our business and could subject us to FDA inspection and regulator requirements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">California State Laboratory Licensing</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to federal certification requirements of laboratories under CLIA, we are required to maintain licensure under California law for our San Francisco Bay Area based laboratory. Such laws include standards for the day-to-day operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory.&#160; Our diagnostic laboratory was certified by the state of California during 2017.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will not be permitted to perform diagnostic tests at our California CLIA laboratory if our laboratory fails to comply with California standards. If we do not meet the requirements of California laws, the California Department of Health Services ("DHS") may suspend, restrict or revoke our license to operate our laboratory, assess substantial civil money penalties, or impose specific corrective action plans. Any such actions could materially affect our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other State Laboratory Licensing</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Some states require licensure of out-of-state laboratories that accept specimens from those states. Our laboratories will need to pass various state inspections in order to get licensed to provide LDTs in each of state that requires licensure. All states except five states accept federal CLIA certification and state of residence licensure as proof of quality and good standing in order to perform diagnostic tests.&#160; The five exceptions are Florida, Maryland, Rhode Island, Pennsylvania and New York.&#160; These states require out-of-state labs to obtain their individual state clinical laboratory licenses or permits in order to perform tests for patients residing in those states. We have already obtained the Pennsylvania state clinical laboratory permit and we plan on obtaining the licenses required by Florida, Maryland, Rhode Island, and New York by the end of 2018.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In Vitro Diagnostics</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the future, we may elect to develop IVDs, which are regulated by the FDA as medical devices. Medical devices marketed in the United States are subject to the regulatory controls under CLIA, the Federal Food, Drug, and Cosmetic Act, and regulations adopted by the FDA. Some requirements, known as premarket requirements, apply to medical devices before they are marketed, and other requirements, known as post-market requirements, apply to medical devices after they are marketed.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The particular premarket requirements that must be met to market a medical device in the United States will depend on the classification of the device under FDA regulations. Medical devices are categorized into one of three classes, based on the degree of risk they present. Devices that pose the lowest risk are designated as Class I devices; devices that pose moderate risk are designated as Class II devices and are subject to general controls and special controls; and the devices that pose the highest risk are designated as Class III devices and are subject to general controls and premarket approval.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A premarket submission to the FDA will be required for some Class I devices, most Class II devices; and all Class III devices. Most Class I and some Class II devices are exempt from premarket submission requirements. Some Class I and most Class II devices may be marketed after a 510(k) premarket notification, while a more extensive PMA is required to market Class III devices.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Until all regulatory requirements are phased in, our initial confirmatory diagnostics will not require FDA filing before launch. Since the tests are being developed as LDTs, the regulatory pathway that we will be following is the CLIA certification and inspection pathway.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">29</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If the new requirements are phased in or if we elect to develop IVDs, our future screenings diagnostics may require a 510(k) submission or a PMA. In a 510(k) submission, the device sponsor must demonstrate that the new device is "substantially equivalent" to a predicate device in terms of intended use, technological characteristics, and performance testing. A 510(k) requires demonstration of substantial equivalence to another device that is legally marketed in the United States. Substantial equivalence means that the new device is at least as safe and effective as the predicate. A device is substantially equivalent if, in comparison to a predicate it (a) has the same intended use as the predicate and has the same technological characteristics as the predicate; or (b) has the same intended use as the predicate, has different technological characteristics, and the information submitted to FDA does not raise new questions of safety and effectiveness, and is demonstrated to be at least as safe and effective as the legally marketed predicate device.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A claim of substantial equivalence does not mean the new and predicate devices must be identical. Substantial equivalence is established with respect to intended use, design, energy used or delivered, materials, chemical composition, manufacturing process, performance, safety, effectiveness, labeling, biocompatibility, standards, and other characteristics. A device may not be marketed in the United States until the submitter receives a letter declaring the device substantially equivalent. If the FDA determines that a device is not substantially equivalent, the applicant may resubmit another 510(k) with new data, or request a Class I or II designation through the FDA's<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> de novo</font> process that allows a new device without a valid predicate to be classified into Class I or II if it meets certain criteria, or file a reclassification petition, or submit a PMA.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A new 510(k) submission is required for changes or modifications to an existing approved device, where the modifications could significantly affect the safety or effectiveness of the device or the device is to be marketed for a new or different indication for use.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A PMA for Class III devices is the most stringent type of premarket submission. Before the FDA approves a PMA, the sponsor must provide valid scientific evidence demonstrating reasonable assurance of safety and effectiveness for the device's intended use.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Submission of an application is no guarantee that the CMS or FDA will find it complete and accept it for filing. If an application is accepted for filing or licensing, following the CMS or FDA's review, the CMS or FDA may grant marketing approval, request additional information or deny the application if it determines that the application does not provide an adequate basis for approval.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Health Insurance Portability and Accountability Act</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under the Health Insurance Portability and Accountability Act ("HIPAA"), the Department of Health and Human Services ("HHS") has issued regulations to protect the privacy and security of protected health information. HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include civil and criminal penalties.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CMS and the Office of Civil Rights issued a final rule in February 2014 to amend both the HIPAA and CLIA regulations. The final rule amended the HIPAA privacy rule to remove the CLIA laboratory exceptions, and as a result, HIPAA-covered laboratories are now required to provide individuals, upon request, with access to their completed test reports. Under the 2014 rule, CLIA laboratories and CLIA-exempt laboratories may provide copies of a patient's completed test reports that, using the laboratory's authentication process, can be identified as belonging to that patient. These changes to the CLIA regulations and the HIPAA Privacy Rule provide individuals with a greater ability to access their health information, empowering them to take a more active role in managing their health and health care. CLIA laboratories must create and maintain policies, procedures, and other documentation necessary to inform patients of the right to access laboratory test reports and how to exercise that right.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">New laws governing privacy may also be adopted in the future. We will take steps to comply with all current health information privacy requirements of which we are aware and with which we must comply. However, we can provide no assurance that we will remain in compliance with diverse privacy requirements in all of the jurisdictions in which we do business. The current requirements may periodically change and could have an effect on our business operations if compliance becomes substantially more costly than under current requirements. Failure to comply with privacy requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">30</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Physician Referral Prohibitions</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under a federal law directed at "self-referral," commonly known as the Stark Law, there are prohibitions, with certain exceptions, on Medicare and Medicaid payments for laboratory tests referred by physicians who personally, or through a family member, have a "financial relationship"&#8212;including an investment or ownership interest or a compensation arrangement&#8212;with the clinical laboratory performing the tests. Several Stark Law exceptions are relevant to arrangements involving clinical laboratories, including: (1) fair market value compensation for the provision of items or services; (2) payments by physicians to a laboratory for clinical laboratory services; (3) certain space and equipment rental arrangements that satisfy certain requirements, and (4) personal services arrangements that satisfy certain requirements. The laboratory cannot submit claims to the Medicare Part B program for services furnished in violation of the Stark Law, and Medicaid reimbursements may be at risk as well. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from the federal health care programs. Many states have comparable laws that are not limited to Medicare and Medicaid referrals.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Corporate Practice of Medicine</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A number of states, including California, do not allow business corporations to employ physicians to provide professional services. This prohibition against the "corporate practice of medicine" is aimed at preventing corporations such as us from exercising control over the medical judgments or decisions of physicians. The state licensure statutes and regulations and agency and court decisions that enumerate the specific corporate practice rules vary considerably from state to state and are enforced by both the courts and regulatory authorities, each with broad discretion. If regulatory authorities or other parties in any jurisdiction successfully assert that we are engaged in the unauthorized corporate practice of medicine, we could be required to restructure our contractual and other arrangements. In addition, violation of these laws may result in sanctions imposed against us and/or the professional through licensure proceedings, and we could be subject to civil and criminal penalties that could result in exclusion from state and federal health care programs.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Federal and State Fraud and Abuse Laws</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A variety of federal and state laws prohibit fraud and abuse. These laws are interpreted broadly and enforced aggressively by various state and federal agencies, including CMS, the Department of Justice, the Office of Inspector General for HHS, and various state agencies. In addition, the Medicare and Medicaid programs increasingly use a variety of contractors to review claims data and to identify improper payments as well as fraud and abuse. These contractors include Recovery Audit Contractors, Medicaid Integrity Contractors and Zone Program Integrity Contractors. In addition, CMS conducts Comprehensive Error Rate Testing audits, the purpose of which is to detect improper Medicare payments. Any overpayments identified must be repaid unless a favorable decision is obtained on appeal. In some cases, these overpayments can be used as the basis for an extrapolation, by which the error rate is applied to a larger universe of claims, and which can result in even higher repayments.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, to induce or in return for either the referral of an individual, or the furnishing, recommending, or arranging for the purchase, lease or order of any health care item or service reimbursable, in whole or in part, under a federal health care program. The definition of "remuneration" has been broadly interpreted to include anything of value, including gifts, discounts, credit arrangements, payments of cash, ownership interests and providing anything at less than its fair market value. Recognizing that the Anti- Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements within the health care industry, the Office of Inspector General for HHS has issued a series of regulatory "safe harbors." These safe harbor regulations set forth certain requirements that, if met, will assure immunity from prosecution under the federal Anti-Kickback Statute. Although full compliance with these provisions ensures against prosecution under the federal Anti-Kickback Statute, the failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback Statute will be pursued. For further discussion of the impact of federal and state health care fraud and abuse laws and regulations on our business, see the section entitled "Risk Factors."</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">HIPAA also created new federal crimes, including health care fraud and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private third-party payers. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from federal health care programs, such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from federal health care programs.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Many states have laws similar to the federal laws described above, and state laws may be broader in scope and may apply regardless of payor.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">31</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 35.9pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Additionally, the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other Regulatory Requirements</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our laboratory will be subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood samples and other human tissue. Typically, we will use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors will be licensed or otherwise qualified to handle and dispose of such waste.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Occupational Safety and Health Administration has established extensive requirements relating to workplace safety for health care employers, including requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, we employed 16 persons on a full-time basis. Four of our full-time employees hold Ph.D. degrees in one or more fields of science.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z43fb96a40b74445d8a6e8721fa8f01c2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item1A."><!--Anchor--></a>Item1A.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risk Factors</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our business is subject to various risks, including those described below. You should consider the following risk factors, together with all of the other information included in this Report, which could materially adversely affect our proposed operations, our business prospects, and financial condition, and the value of an investment in our business. There may be other factors that are not mentioned here or of which we are not presently aware that could also affect our business operations and prospects.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Business Operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have incurred operating losses since inception and we do not know if we will attain profitability.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Since our inception in September 2009, we have incurred operating losses and negative cash flow and we expect to continue to incur losses and negative cash flows in the future. Our net losses for the years ended December 31, 2017 and 2016 were approximately $19.4 million and $11.2 million and we had an accumulated deficit of approximately $54.7 million and $35.3 million as of December 31, 2017 and 2016, respectively. Since inception, we have financed our operations through sales of our common stock and warrants, loans from BioTime and BioTime affiliates, warrant exercises, a bank loan, and sale of BioTime common shares that we hold as available-for-sale securities. Although BioTime may continue to provide administrative support to us on a reimbursable basis, there is no assurance that BioTime will provide future financing. There is no assurance that we will be able to obtain any additional financing that we may need, or that any such financing that may become available will be on terms that are favorable to us and our shareholders. Ultimately, our ability to generate sufficient operating revenue to earn a profit depends upon our success in developing and marketing or licensing our diagnostic tests and technology.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are experiencing a delay in conducting our clinical validation study of DetermaVu&#8482;.</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the process of running initial samples for the clinical validation study of DetermaVu&#8482;, inconsistent analytic results were observed by our technical team. We have determined that the inconsistent results were caused by a variance in the lots of consumables used in the diagnostic testing platform&#160;that analyzes blood samples for the genetic biomarkers that may indicate whether lung nodules found in patients are benign or suspicious. We have been engaged with the system manufacturer to more completely understand the issues that have delayed the DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> validation study.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Due to the issues with the diagnostic testing platform, we are evaluating alternative diagnostic testing platforms for DetermaVu&#8482;.&#160; While further testing is needed, our initial results on a small set of blood samples indicate that two market-leading diagnostic testing platforms could be suitable for the further clinical development studies that are necessary for the commercialization of DetermaVu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup>. We are continuing to evaluate alternative diagnostic testing platforms by doing a follow-on study utilizing a larger set of clinical samples. We expect to complete the process during the second quarter of 2018. After concluding this process, data will be available to determine which platform delivers the most accurate, consistent and robust test results while maintaining a reasonable cost of goods. If the results indicate that the chosen platform can produce consistent result in a commercial lab, we plan to complete product development on the selected platform by carrying out an R&amp;D validation study followed by an analytical validation study, and if those studies are successfully completed, we plan to conduct a clinical validation study. Clinical validation is the final step prior to commercial launch of a diagnostic test, and we are targeting completion of a clinical validation study by the latter part of 2018. We have collected all the samples necessary for carrying out these studies.&#160; If these studies are completed successfully, we plan to commercialize the test.&#160; Until we perform these studies, we will not know whether we can successfully complete the development of DetermaVu&#8482; and commence commercialization of the test</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">32</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We do not yet know the extent to which a resolution of the issue that has caused the delay in the clinical validation study will result in additional costs to us.&#160; In addition to a loss of productivity during the period of the delay, we could incur additional quality control costs and the cost of acquiring new diagnostic testing platform equipment and reagents and training our staff in the use of the new platform. Delays in the successful completion of the clinical validation study and commercialization of DetermaVu&#8482; could prevent us from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&#8482; or the other cancer diagnostic tests that we are developing.</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we were to determine to change diagnostic testing platforms and abandon the use of our current platform for research and development purposes and for clinical testing in our CLIA laboratory, our current diagnostic testing platform equipment could be considered an impaired asset for financial reporting purposes and we would write down the value of that equipment on our balance sheet and take a charge to earnings for the impaired value. We acquired the equipment through a lease and we would remain obligated to continue to make payments under the lease even if we discontinue use of the equipment.</div>

<br>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will spend a substantial amount of our capital on research and development but we might not succeed in developing diagnostic tests and technologies that are useful in medicine.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbb60f627c5454c7a9725420415c60e80" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are attempting to develop new medical diagnostic tests and technologies. The main focus of our business is on diagnostic tests for cancer. Our diagnostic tests are being developed through the use of blood and urine samples obtained in prospective and retrospective clinical trials involving humans, but none of our diagnostic tests have been used in medicine to diagnose cancer. Our technologies many not prove to be sufficiently efficacious to use in the diagnosis of cancer.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3335aa19b4564f4a8f96d1b8f2ca7f7f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Some of our research could also have applications in new cancer therapeutics. None of our experimental therapeutic technologies have been applied in human medicine and have only been used in laboratory studies<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> in vitro</font>.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1cc72fc5be984e259443073de2a890d7" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The experimentation we are doing is costly, time consuming, and uncertain as to its results. We incurred research and development expenses amounting to approximately $7.2 million and $5.7 million during years ended December 31, 2017 and 2016, respectively. Since 2011, most of our research has been devoted to the development of our lead diagnostic tests to detect lung cancer, breast cancer, and bladder cancer.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z59047f247cd24fe5bab98f7b05944837" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we are successful in developing a new technology or diagnostic test, refinement of the new technology or diagnostic test and definition of the practical applications and limitations of the technology or diagnostic test may take years and require the expenditure of large sums of money.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not currently have any diagnostic tests on the market and have not yet generated any revenues from operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2e0545ee195b480e9c0b9d9aa9ef53ba" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We need to successfully develop and market or license the diagnostic tests that we are developing in order to earn revenues in sufficient amounts to meet our operating expenses.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7ba48b188f33416f9d5e052983cfff1f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Without diagnostic test sales or licensing fee revenues, we will not be able to operate at a profit, and we will not be able to cover our operating expenses without raising additional capital.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf05f37faca574733b8bcd5fa9b4a6e11" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Should we be able to successfully develop and market our diagnostic tests we may not be able to receive reimbursement for them from payers, such as health insurance companies, health maintenance organizations and Medicare, or any reimbursement that we receive may be lower than we anticipate.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sales of any diagnostic tests that we may develop could be adversely impacted by the reluctance of physicians to adopt the use of our tests and by the availability of competing diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7a6b2f10d8084301b626d125ad144165" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Physicians and hospitals may be reluctant to try a new diagnostic test due to the high degree of risk associated with the application of new technologies and diagnostic test in the field of human medicine, especially if the new test differs from the current standard of care for detecting cancer in patients.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z52fa729f03714e7584579cb4c9ce7381" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Competing tests for the initial diagnosis, reoccurrence diagnosis and optimal treatment of cancer are being manufactured and marketed by established companies and by other smaller biotechnology companies.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za4ce88aff5354f1eb6c8434a094ddcbf" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Currently there are two diagnostic tests for lung cancer and multiple diagnostic tests for bladder cancer on the market. There is one diagnostic product for breast cancer that has been approved in Europe. In order to compete with other diagnostic tests, particularly any that sell at lower prices, our diagnostic tests will have to provide medically significant advantages or be more cost effective.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6825d27ddd194337a4da84928282a80b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There also is a risk that our competitors may succeed in developing safer, more accurate or more cost effective diagnostic tests that could render our diagnostic tests and technologies obsolete or noncompetitive.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">33</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be able to produce a high enough sensitivity to offset the availability of minimally invasive biopsies for breast cancer and this could result in an impediment to the commercialization of our planned breast cancer confirmatory test.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Very high sensitivity may be needed for our breast confirmatory test because unlike lung cancer biopsies that involve an invasive surgical procedure, breast cancer biopsies often can be performed using minimally invasive procedures that result in significantly less risk, discomfort, and cost to the patient while providing a diagnostic result that is as accurate or more accurate than our diagnostic test.&#160; As a result, physicians and patients may prefer to rely on a biopsy of a breast lesion, which may have a higher sensitivity to confirm the presence of breast cancer rather than use the blood tests that we are developing.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will need to issue additional equity or debt securities in order to raise additional capital needed to pay our operating expenses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf47e25c8b1d24ee3a088d76448dba7ce" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We plan to continue to incur substantial research and development expenses and we anticipate that we will be incurring significant sales and marketing costs as we develop and commercialize our diagnostic test candidates. We will need to raise additional capital to pay operating expenses until we are able to generate sufficient revenues from diagnostic test sales, royalties, and license fees, and we will need to sell additional equity or debt securities to meet those capital needs.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5f1c975723b44682bf4c353861f2f477" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our ability to raise additional equity or debt capital will depend not only on progress made in developing our diagnostic tests, but also will depend on access to capital and conditions in the capital markets. There is no assurance that we will be able to raise capital at times and in amounts needed to finance the development and commercialization of our diagnostic tests and general operations. Even if capital is available, it may not be available on terms that we or our shareholders would consider favorable.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z47f1694d3e3845c688e40e45aeae0748" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales of additional equity securities by us could result in the dilution of the interests of our shareholders.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our business will depend on several critical technologies that have licensed from Wistar for our lung cancer diagnostic test. The license agreement imposes obligations on us, including payment obligations and obligations to pursue development and commercialization of diagnostic tests under the licensed patents and technology. If Wistar believes that we have failed to meet our obligations under a license agreement, Wistar could seek to limit or terminate our license rights, which could lead to costly and time-consuming litigation and, potentially, a loss of the licensed rights. During the period of any such litigation our ability to carry out the development and commercialization of potential diagnostic tests, and our ability to raise any capital that we might then need, could be significantly and negatively affected. If our license rights were restricted or ultimately lost, we would not be able to continue to use the licensed patents and technology in our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have limited marketing and sales resources and no distribution resources for the commercialization of any diagnostic tests that we might successfully develop.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we are successful in developing marketable diagnostic tests, we will need to build our own marketing and sales capability, which will require the investment of significant financial and management resources to recruit, train, and manage a sales force.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to adequately protect, or disputes relating to, trademarks, could harm our business.</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We cannot be certain that the legal steps we are taking are sufficient to protect our trademark rights or that, notwithstanding legal protection, others do not or will not infringe or misappropriate our intellectual property rights. In addition, we could come into conflict with third parties over trademark rights, which could result in disruptive and expensive litigation. Challenges to our trademarks could result in significant costs related to the prosecution or defense of the registrations of our trademarks or rebranding if we need to abandon or modify a trademark.</div>

<div>
<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">34</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business could be adversely affected if we lose the services of the key personnel upon whom we depend.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We presently rely on a small senior management team to direct our diagnostics program and our commercial activities, including marketing, market access, and sales. Accordingly, the loss of the services of one or more of the members of that management team could have a material adverse effect on our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have granted a security interest in substantially all of our assets to secure our obligations under a bank loan agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have entered into a Loan and Security Agreement with Silicon Valley Bank for a loan that will be secured by substantially all of our assets, other than our patents and trade secrets, as collateral for the loan. If a default were to arise under the Loan and Security Agreement, the bank could foreclose on its security interest and we could lose our collateral, which could force us to discontinue our operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business and operations could suffer in the event of system failures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of data for our diagnostic test candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. To the extent that any disruption or security breach was to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our diagnostic test candidates could be delayed.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure of our internal control over financial reporting could harm our business and financial results.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting for external purposes in accordance with accounting principles generally accepted in the U.S. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. Our growth and entry into new diagnostic tests, technologies and markets will place significant additional pressure on our system of internal control over financial reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our ability to report our financial results accurately and timely or to detect and prevent fraud.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are presently relying in part on financial systems maintained by BioTime and upon services provided by BioTime personnel. BioTime allocates certain expenses among itself, us, and BioTime's other subsidiaries, which creates a risk that the allocations may not accurately reflect the benefit of an expenditure or use of financial or other resources by us, BioTime as our parent company, and the BioTime subsidiaries among which the allocations are made.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Industry</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We face certain risks arising from regulatory, legal, and economic factors that affect our business and the business of other companies engaged in the development and marketing of diagnostic tests for human diseases. Because we are a small company without revenues and with limited capital resources, we may be less able to bear the financial impact of these risks than larger companies that have substantial income and available capital.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may need to obtain regulatory approval of our diagnostic test candidates and laboratory facilities.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will need to maintain certification for our diagnostic laboratory under CLIA, and under the laws and regulations of California, and in certain other states that require their own certification if we wish to receive blood or urine samples for testing from patients in those states. If we do not meet the CLIA or specific state requirements and regulations our laboratory certification may be suspended, restricted, or revoked, and we may incur substantial civil money penalties or be subject to specific corrective action plans. Any such actions could materially affect our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will also need to obtain FDA and other regulatory approvals for any<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</font>IVDs that we may develop, in order to market those IVD tests. The need to obtain regulatory approval to market a new diagnostic test means that:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7ac6577b05bb418e8309e63677970b59" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The diagnostic tests that we may develop cannot be sold until the CMS or the FDA, and corresponding foreign regulatory authorities approve the laboratory tests or the IVDs for medical use.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">35</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdcb10fec50f04a3d90ca9be198e79c8e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will have to obtain a CLIA certificate of registration license for our laboratory for the manufacture and use of diagnostic tests and as part of the submission, our laboratory will be inspected.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze54d2507308a48c19458e0e53897472a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to meeting federal regulatory requirements, each state has its own laboratory certification and inspection requirements for a CLIA laboratory that must be met in order to sell diagnostic tests in the state.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfff431897e8e419c86d6099ea76e2239" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We will have to conduct expensive and time consuming clinical trials of new diagnostic tests. The full cost of conducting and completing clinical trials necessary to obtain FDA approval of IVD tests or CLIA certification of a new laboratory diagnostic test or for gaining reimbursement from health insurance companies, health maintenance organizations, Medicare, and other third party payers cannot be presently determined but could exceed our current financial resources.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0b0f4d3a500540139e92b84aec4a7b05" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Data obtained from preclinical and clinical studies is susceptible to varying interpretations that could delay, limit or prevent regulatory agency approvals. Delays or denials of the regulatory approvals may be encountered as a result of changes in regulatory agency policy, regulations, or laws.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2464bccba966471bb05b47f4223cdb1a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A diagnostic test that is approved may be subject to restrictions on use.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z586334a6685b4b38acf4b93b367ea425" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The FDA can withdraw approval of an FDA regulated product if problems arise.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb39237d9f3104c6db91f24eb9f88d413" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CLIA licensed laboratories can lose their licenses if problems arise during a periodic inspection.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The FDA may impose additional regulations for laboratory developed tests such as the ones we are developing.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The FDA issued two draft guidance documents and a discussion paper that set forth a proposed risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs such as those we are developing. If the FDA implements the regulatory measures set forth in these documents:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z07cf7f604079475d85751e24cfd08817" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may be required to obtain pre-market clearance or approval before selling our diagnostic tests;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zab34bf2c6c934a8d9a12b8d9baae7850" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As a result of required FDA pre-market review, our tests may not be cleared or approved on a timely basis, if at all;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc47de54c299a44f4bd50c701c30a0e48" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">FDA labeling requirements may limit our claims about our diagnostic tests, which may have a negative effect on orders from physicians;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfa551540207d41f289a19a09d1c42819" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The regulatory approval process may involve, among other things, successfully completing additional clinical trials and making a 510(k) submission, or filing a pre-market approval application with the FDA; and,</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd03fe99d9ff04159b27ba153ef62b360" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If regulatory actions affect any of the reagents we obtain from suppliers and use in conducting our tests, our business could be adversely affected in the form of increased costs of testing or delays, limits or prohibitions on the purchase of reagents necessary to perform our testing.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If the FDA regulates LDTs such as the ones we are developing and requires that we seek pre-market approval, there is no assurance that we will be able to comply with FDA requirements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">It may take two years or more to conduct the clinical studies and trials necessary to obtain pre-market approval from the FDA. Even if our clinical trials are completed as planned, we cannot be certain that the results will support our test claims or that the FDA will agree with our conclusions regarding our test results. Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior clinical trials and studies. If we are required to conduct pre-market clinical trials, delays in the commencement or completion of clinical testing could significantly increase our test development costs and delay commercialization. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The clinical trial process may fail to demonstrate that our tests are effective for the proposed indicated uses, which could cause us to abandon a test candidate and may delay development of other tests.</div>

<div>
<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">36</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If the FDA regulates LDTs such as the ones we are developing, we may be subject to a medical device manufacturer&#8217;s tax</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Affordable Care Act (&#8220;ACA&#8221;) requires that medical device manufacturers pay a 2.3% excise tax on U.S. sales of certain devices. The medical device excise tax moratorium expired on December 31, 2017, but Congress extended the moratorium for an additional two years and as a result the medical device excise tax will not apply to the sale of taxable medical devices by the manufacturer, producer, or importer of the device during the period beginning on Jan. 1, 2016 and ending on Dec. 31, 2019.&#160; The extension of the moratorium was retroactive to Jan. 1, 2018. None of our LDTs are anticipated to be listed with the FDA and therefore to be subject to this tax, however, if in the future our tests were to be regulated by the FDA we could become subject to the excise tax.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">In 2019, when certain provisions of the Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;) are scheduled to take effect, the demand and payment for our services may be impacted</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;), which was signed into law on April 16, 2015, makes substantial changes to the payment structure for physicians. This legislation, beginning in 2019, encourages physicians to enroll in alternative payment methods which incentivize physicians differently than how they are currently. We do not currently know how or if this will impact the future demand or payments for our services.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical trial failures can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Clinical trial failures or delays can occur at any stage of the trials, and may be directly or indirectly caused by a variety of factors, including but not limited to:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zab3d36383a634f6c9ca8938f6c1c3d34" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Delays in securing clinical investigators or trial sites for our clinical trials;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z508f8e3720744cc1a80e32b373fed529" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Delays in obtaining Institutional Review Board and other regulatory approvals to commence a clinical trial;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z23a6eff922d94e5b86df53372e8575aa" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Slower than anticipated rates of patient recruitment and enrollment, or failing to reach the targeted number of patients due to competition for patients from other trials;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zba7215338af042d8bf5772cc591cc8b1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Limited or no availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payers for the use of our diagnostic test candidates in our clinical trials;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zba6948f45e114ac1b96a955c8ff0f165" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Negative or inconclusive results from clinical trials;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z790065d0f82f42148dd3551c7d939290" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Approval and introduction of new diagnostic or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications obsolete;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z67007eabc1da4c35bd2b04f9f6040aed" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z90944533ac6544608598f89aa8dbabae" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbe3e017c230f495b858af6a056f3308f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Inability or unwillingness of medical investigators to follow our clinical protocols.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will depend on Medicare and a limited number of private payers for a significant portion of our revenues, and our revenues could decline if these payers fail to provide timely and adequate payment for our diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We expect that a substantial portion of the patients for whom we will perform diagnostic tests will have Medicare as their primary medical insurance. Even if our planned tests are otherwise successful, without Medicare reimbursement we might not be able to generate sufficient revenues to enable us to reach profitability and achieve our other commercial objectives. It generally takes two to three years to obtain Medicare coverage and other third party reimbursement approvals for a new LDT and there can be no assurance we will obtain such approvals for any of the cancer diagnostics that we are developing. Until a new cancer diagnostic test is accepted by third party payers for reimbursement, we will have to market the test to physicians on a patient pay basis. In the absence of reimbursement by Medicare, patients who would be candidates for the use of our diagnostic tests and who rely on Medicare coverage may decline to use our tests, and physicians may be reluctant to prescribe our tests, due to the cost of the test to the patients. Because of this patient cost factor, revenues from any new cancer test that we market will experience slow growth until the test is approved for reimbursement in an amount commensurate with the cost to the patient.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">37</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare and other third-party payers may change their coverage policies or cancel future contracts with us at any time; review and adjust the rate of reimbursement; or stop paying for our tests altogether, which would reduce our total revenues. Payers have increased their efforts to control the cost, utilization, and delivery of health care services, and have undertaken measures to reduce payment rates for and decrease utilization of clinical laboratory testing. Because of the cost-trimming trends, any third-party payers that will cover and provide reimbursement for our diagnostic tests may suspend, revoke or discontinue coverage at any time, or may reduce the reimbursement rates payable to us. Any such action could have a negative impact on our revenues, which may have a material adverse effect on our financial condition, results of operations and cash flows.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in healthcare laws and policies may have a material adverse effect on our financial condition, results of operations and cash flows.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The ACA substantially changed the way health care is financed by both governmental and private insurers, and Congressional leaders and the President have voiced their intent to amend the ACA or to repeal and replace it with new legislation, the provisions of which are not yet known. Among the ACA's key changes, the ACA reduced payment rates under the Medicare Clinical Laboratory Fee Schedule and established an Independent Payment Advisory Board to reduce the per capita rate of growth in Medicare spending if spending exceeds a target growth rate. If retained, such provisions may negatively impact payment rates for our diagnostic tests.</font>&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Furthermore, effective January 1, 2013, the ACA included a 2.3% excise tax on the sale of certain medical devices sold outside of the retail setting. Although a moratorium has been imposed on this excise tax for 2016 through 2019, the excise tax is scheduled to be restored in 2020.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">PAMA significantly altered the payment methodology under the Clinical Laboratory Fee Schedule that determines Medicare coverage for laboratory tests. Under PAMA, clinical laboratories are required to report test payment data for each Medicare-covered clinical diagnostic laboratory test and beginning in 2017, the Medicare payment rate for each clinical diagnostic laboratory test will be equal to the weighted median amount for the test from the most recent data collection period.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Congress has proposed on several occasions to impose a 20% coinsurance payment requirement on patients for clinical laboratory tests reimbursed under the Medicare Clinical Laboratory Fee Schedule, which would require us to bill patients for these amounts. In the event that Congress were to ever enact such legislation, the cost of billing and collecting for our tests could often exceed the amount actually received from the patient.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare payments for new ADLTs are now based on the list price or charge. After the test is commercially available for three quarters, the laboratory will be required to report payment and volume information and that data will be used to set payment for the test for the following year.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z356c0f2b1e774a308508d7f0db5097dc" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If data shows that the list price was greater than 130% of the payment using established methodology (a weighted median), CMS will recoup the difference from the laboratory through a payment claw back.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf635d5cef5a74cf7a2bb2b212c18add2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Payment will be updated annually based on the weighted median of commercial payer reimbursement.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On January 1, 2018 the new PAMA-based Medicare Clinical Laboratory Fee Schedule went into effect for the first time. PAMA-based prices did not impact all lab tests equally. Some tests had price reductions while others saw price increases.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We cannot predict whether future health care initiatives will be implemented at the federal or state level, or how any future legislation or regulation may affect us. The expansion of government's role in the U.S. health care industry as a result of the ACA or the repeal or amendment of the ACA, and changes to the reimbursement amounts paid by Medicare and other payers for diagnostic tests may have a materially adverse effect on our business, financial condition, results of operations and cash flows.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because of certain Medicare billing policies, we may not receive complete reimbursement for tests provided to Medicare patients.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare has coverage policies that can be national or regional in scope. Coverage means that the test or assay is approved as a benefit for Medicare beneficiaries. If there is no coverage, neither the supplier nor any other party, such as a diagnostic laboratory, may receive reimbursement from Medicare for the service. Regional policies are directed by Medicare's regional MACs. Reimbursement for our diagnostic testing may be negatively impacted by California MAC policies.</div>

<div>
<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">38</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long payment cycles of Medicare, Medicaid and/or other third-party payors, or other payment delays, could hurt our cash flows and increase our need for working capital.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Medicare and Medicaid have complex billing and documentation requirements that we will have to satisfy in order to receive payment. Failure to comply with these requirements and other laws applicable to billing may result in, among other things, non-payment, refunds, exclusion from government healthcare programs, and civil or criminal liabilities, any of which may have a material adverse effect on our revenues and earnings. Similarly, the failure of private health insurers or other private third-party payers to properly process our payment claims in a timely manner could delay our receipt of payment for our diagnostic tests and services, which may have a material adverse effect on our cash flows.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Private health insurance company policies may deny coverage or limit the amount they will reimburse us for the performance of our diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Patients who are not covered by Medicare will generally rely on health insurance provided by private health insurance companies. If we are considered a "non-contracted provider" by a third-party payer, that payer may not reimburse patients for diagnostic tests performed by us, or doctors within the payer's network of covered physicians may not use our services to perform diagnostic tests for their patients. As a result, we may need to enter into contracts with health insurance companies or other private payers to provide diagnostic tests to their insured patients at specified rates of reimbursement which may be lower than the rates we might otherwise collect.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will be required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The HIPAA sets forth security regulations that establish administrative, physical and technical standards for maintaining the confidentiality, integrity and availability of Protected Health Information in electronic form. We also may be required to comply with state laws that are more stringent than HIPAA or that provide individuals with greater rights with respect to the privacy or security of, and access to, their health care records. The Health Information Technology for Economic and Clinical Health Act ("HITECH") established certain health information security breach notification obligations that require covered entities to notify each individual whose "protected health information" is breached.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may incur significant compliance costs related to HIPAA and HITECH privacy regulations and varying state privacy regulations and varying state privacy and security laws. Given the complexity of HIPAA and HITECH and their overlap with state privacy and security laws, and the fact that these laws are rapidly evolving and are subject to changing and potentially conflicting interpretation, our ability to comply with the HIPAA, HITECH and state privacy requirements is uncertain and the costs of compliance are significant. The costs of complying with any changes to the HIPAA, HITECH and state privacy restrictions may have a negative impact on our operations. Noncompliance could subject us to criminal penalties, civil sanctions and significant monetary penalties as well as reputational damage.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to federal and state healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are subject to health care fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These health care laws and regulations include the following:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z47405fc6833846b5ad281f16868c26e1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The federal Anti-Kickback Statute;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9c7c97f196654d4f85fc79017ff8dd6f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The federal physician self-referral prohibition, commonly known as the Stark Law;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z294d3b0c48a7416385088d683e324eac" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The federal false claims and civil monetary penalties laws;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdf2d6a6b34e0423b901f3a4136a58cf2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The federal Physician Payment Sunshine Act requirements under the ACA; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc340b12985d64976a400daf9e98b75e8" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">State law equivalents of each of the federal laws enumerated above.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any action brought against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including, among others, administrative, civil and criminal penalties, damages and fines, and/or exclusion from participation in Medicare, Medicaid programs, including the California Medical Assistance Program (Medi-Cal&#8212;the California Medicaid program) or other state or federal health care programs. Additionally, we could be required to refund payments received by us, and we could be required to curtail or cease our operations.</div>

<div>
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">39</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Intellectual Property</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we are unable to obtain and enforce patents and to protect our trade secrets, others could use our technology to compete with us, which could limit opportunities for us to generate revenues by licensing our technology and selling diagnostic tests.</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5c42f48132af46f4992766a7dcaa0d1f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our success will depend in part on our ability to obtain and enforce patents and maintain trade secrets in the United States and in other countries. If we are unsuccessful in obtaining and enforcing patents, our competitors could use our technology and create diagnostic tests that compete with our diagnostic tests, without paying license fees or royalties to us.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze2b5d3b0bfc9444cb31a28c4ead2f76c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The preparation, filing, and prosecution of patent applications can be costly and time consuming. Our limited financial resources may not permit us to pursue patent protection of all of our technology and diagnostic tests throughout the world.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze6372bcc85be41c587b42a2d4b54502e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Even if we are able to obtain issued patents covering our technology or diagnostic tests, we may have to incur substantial legal fees and other expenses to enforce our patent rights in order to protect our technology and diagnostic tests from infringing uses. We may not have the financial resources to finance the litigation required to preserve our patent and trade secret rights.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8d3cbbb4a02244e4a1bfb4286fcd4ac0" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Supreme Court decisions in<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font> and<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Association for Molecular Pathology v. Myriad Genetics</font> may adversely impact our ability to obtain patent protection for some or all of our diagnostic tests, which use certain gene markers to indicate the presence of certain cancers. The claims in the contested patents that were the subject of the Supreme Court decision in<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font> were directed to measuring the serum level of a drug metabolite and adjusting the dosing regimen of the drug based on the metabolite level. The Supreme Court said that a patent claim that merely claimed a mathematical correlation between the blood levels of a drug metabolite and the best dosage of the drug was not patentable subject matter because it did no more than recite a correlation that occurs in nature. In<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Association for Molecular Pathology v. Myriad Genetics,</font> the Supreme Court ruled that the discovery of the precise location and sequence of certain genes, mutations of which can dramatically increase the risk of breast and ovarian cancer, was not patentable. Knowledge of the gene location and sequences was used to determine the genes&#8217; typical nucleotide sequence, which, in turn, enabled the development of medical tests useful for detecting mutations in these genes in a particular patient to assess the patient&#8217;s cancer risk. But the mere discovery of an important and useful gene did not render the genes patentable as a new composition of matter. The holdings in<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font> and<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Association for Molecular Pathology v. Myriad Genetics</font> may limit our ability to obtain patent protection on diagnostic methods that merely recite a correlation between a naturally occurring event and a diagnostic outcome associated with that event.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is no certainty that our pending or future patent applications will result in the issuance of patents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have filed patent applications for technology that we have developed, and we may obtain licenses for patent applications covering genes that we or our partners have discovered, that we believe will be useful in producing new diagnostic tests. We may also file additional new patent applications in the future seeking patent protection for new technology or diagnostics tests or products that we develop ourselves or jointly with others. However, there is no assurance that any of our licensed patent applications, or any patent applications that we have filed or that we may file in the future in the United States or abroad, will result in the issuance of patents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The process of applying for and obtaining patents can be expensive and slow.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze92e87c1dd294d8c8b3a1c0d3666b61a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The preparation and filing of patent applications, and the maintenance of patents that are issued, may require substantial time and money.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za2158ad46ca84cf8a6a358f4034cf515" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A patent interference proceeding may be instituted with the USPTO when more than one person files a patent application covering the same technology, or if someone wishes to challenge the validity of an issued patent. At the completion of the interference proceeding, the USPTO will determine which competing applicant is entitled to the patent, or whether an issued patent is valid. Patent interference proceedings are complex, highly contested legal proceedings, and the USPTO's decision is subject to appeal. This means that if an interference proceeding arises with respect to any of our patent applications, we may experience significant expenses and delay in obtaining a patent, and if the outcome of the proceeding is unfavorable to us, the patent could be issued to a competitor rather than to us.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z30f8c13f86474ad2a63aaca1e82d9d1b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A derivation proceeding may be instituted by the USPTO or an inventor alleging that a patent or application was derived from the work of another inventor.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z11278ee85f114fdfa434370fa150896e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Post Grant Review under the America Invents Act enables opposition-like proceedings in the United States. As with the USPTO interference proceedings, Post Grant Review proceedings will be very expensive to contest and can result in significant delays in obtaining patent protection or can result in a denial of a patent application.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">40</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zccc44ea350a94211a8aa1f65dbb9d23a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Oppositions to the issuance of patents may be filed under European patent law and the patent laws of certain other countries. As with USPTO interference proceedings, these foreign proceedings can be very expensive to contest and can result in significant delays in obtaining a patent or can result in a denial of a patent application.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our patents may not protect our diagnostic tests from competition.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z60e08817d7214c1fbab4ea8bee852063" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We might not be able to obtain any patents beyond the bladder cancer marker patent and lung cancer marker patents that have been issued by the USPTO, and any patents that we do obtain might not be comprehensive enough to provide us with meaningful patent protection.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdefd64d05a6c4e91b371f4817a5c457b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There will always be a risk that our competitors might be able to successfully challenge the validity or enforceability of any patent issued or licensed or licensed to us.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfa544e54fd054b158c5f3e7b9e0378e6" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to interference proceedings, the USPTO can reexamine issued patents at the request of a third party. Our patents may be subject to inter partes review (replacing the reexamination proceeding), a proceeding in which a third party can challenge the validity of one of our patents to have the patent invalidated. This means that patents owned or licensed by us may be subject to reexamination and may be lost if the outcome of the reexamination is unfavorable to us.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be subject to patent infringement claims that could be costly to defend, which may limit our ability to use disputed technologies, and which could prevent us from pursuing research and development or commercialization of some of our diagnostic tests, require us to pay licensing fees to have freedom to operate and/or result in monetary damages or other liability for us.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The success of our business depends significantly on our ability to operate without infringing patents and other proprietary rights of others. If the technology that we use infringes a patent held by others, we could be sued for monetary damages by the patent holder or its licensee, or we could be prevented from continuing research, development, and commercialization of diagnostic tests that rely on that technology, unless we are able to obtain a license to use the patent. The cost and availability of a license to a patent cannot be predicted, and the likelihood of obtaining a license at an acceptable cost would be lower if the patent holder or any of its licensees is using the patent to develop or market a diagnostic test with which our diagnostic test would compete. If we were unable to obtain a necessary license, we would need to develop or obtain rights to alternative technologies, which could prove costly and could cause delays in diagnostic test development, or we could be forced to discontinue the development or marketing of any diagnostic tests that were developed using the technology covered by the patent.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Relationship with BioTime</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Until recently we were a subsidiary of BioTime, and BioTime retains a substantial stock ownership position that may allow it to assert significant influence over us.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Although BioTime now owns less than 50% (approximately 47%) of our issued and outstanding shares of common stock, it still holds a sufficient number of shares to elect at least a minority, and potentially a majority, depending on how other shareholders vote, of the members of our Board of Directors and to influence our management. Two of the seven members of our Board of Directors are also officers or directors of BioTime and one of our directors is our Chief Executive Officer. This commonality of directors means that representatives of BioTime and our management are participating in making business decisions on our behalf.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime's voting power may allow BioTime to cause corporate actions to be taken even if the interests of BioTime conflict with the interests of our other shareholders. This concentration of voting power could have the effect of deterring or preventing a change in control that might be beneficial to our other shareholders.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">With the support of only a small number of other shareholders BioTime could have the voting power to approve or disapprove any matter or corporate transaction presented to our shareholders for approval, including but not limited to:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z538c7e751b864f94864b5c7dc5675989" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any amendment of our articles of incorporation or bylaws;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z153bd23f41214b82a5b3bc69ec5df639" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any merger or consolidation of us with another company;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8fdd788203e14c1ea581c7e8a7485a63" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any recapitalization or reorganization of our capital stock;</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">41</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z636a8aff83334e789dd76371beddf47c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any sale of assets or purchase of assets; or</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfe93a83fd26b464c84154bed105cd08e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A corporate dissolution or a plan of liquidation of our business.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We presently rely on BioTime for certain services and resources.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Although we have our own CLIA certified diagnostic laboratory, our own scientific personnel, and many critical management personnel, we presently rely on BioTime to provide certain management and administrative services, including patent prosecution, certain legal services, accounting, financial management, and controls over financial accounting and reporting. We have entered into the Shared Facilities Agreement with BioTime under which we have agreed to bear costs allocated to us by BioTime for the use of BioTime office and research facilities, human resources, services, and materials provided for our benefit by BioTime. We will pay BioTime 105% of its costs of providing personnel and services to us, and for any use of its facilities by us, including an allocation of general overhead based on that use. We may also share the services of some research personnel with BioTime.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If BioTime's human resources and facilities are not sufficient to serve both BioTime's needs and ours, we will have to hire additional personnel of our own, either on a full-time or part-time basis, as employees or as consultants, and the cost of doing so could be greater than the costs that would be allocated to us by BioTime. Also, any new personnel that we may need to hire may not be as familiar with our business or operations as BioTime's personnel, which means that we would incur the expense and inefficiencies related to training new employees or consultants.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conflicts of interest may arise from our relationship with BioTime.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our relationship with BioTime could give rise to certain conflicts of interest that could have an impact on our research and development programs, business opportunities, and operations generally.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z751e9cfca50f4a4cb4e0a57ff02aa3bf" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Even if we utilize different technologies than BioTime or its subsidiaries, we could find ourselves in competition with them for research scientists, financing and other resources, licensing, manufacturing, and distribution arrangements, and for customers if we and BioTime or a BioTime subsidiary both bring diagnostic tests to market.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zbf672b9f2ce5475e9756dad6b6b159de" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime may retain sufficient influence through its share ownership to deter us from engaging in research and development programs, investments, business ventures, or agreements to develop, license, or acquire diagnostic tests or technologies that would or might compete with those owned, licensed, or under development by BioTime or any of its other subsidiaries.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zcb672b5a825342c8b51ba82c6ab29413" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime and its subsidiaries will engage for their own accounts in research and product development programs, investments, and business ventures, and we will not be entitled to participate or to receive an interest in those programs, investments, or business ventures. BioTime and its subsidiaries will not be obligated to present any particular research and development, investment, or business opportunity to us, even if the opportunity would be within the scope of our research and development plans or programs, business objectives, or investment policies. These opportunities may include, for example, opportunities to acquire businesses or assets, including but not limited to patents and other intellectual property that could be used by us or by BioTime or by any of BioTime's subsidiaries. Our respective boards of directors will have to determine which company should pursue those opportunities, taking into account relevant facts and circumstances at the time, such as the financial and other resources of the companies available to acquire and utilize the opportunity, and the best "fit" between the opportunity and the business and research and development programs of the companies. However, to the extent that BioTime has sufficient voting power to elect the members of our Board of Directors, BioTime may have the ultimate say in decision making with respect to the allocation of opportunities.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze8a9ed2344fb4548a0eb7f2046e62fa0" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we enter into any patent or technology license or sublicense, or any other agreement with BioTime or with a BioTime subsidiary, a conflict of interest could arise in determining how and when a party should enforce its rights under the agreement if the other BioTime company that is a party were to default or otherwise fail to perform any of its obligations under the agreement.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z819b1a4598704eb68afccb1af2ae6d8d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">One of our significant assets is 353,264 BioTime common shares that we acquired from BioTime in exchange for shares of our common stock. We may sell the BioTime shares from time to time, or pledge the shares as collateral for loans, to raise capital to finance our operations. Because a sale of those shares could have a depressing effect on the market value of BioTime common shares, BioTime will have a continuing interest in the number of shares we sell, the prices at which we sell the shares, and the time and manner in which the shares are sold. Further, we may need or find it desirable to sell BioTime common shares at the same time as BioTime, or BioTime subsidiaries that hold BioTime common shares, also desire to sell some of their BioTime common shares. Concurrent sales of BioTime common shares by us, BioTime, or BioTime subsidiaries cold have a depressing effect on the market price of the BioTime common shares, lower the price at which we and they are able to sell BioTime common shares, and result in lower net proceeds from the sales. We plan to coordinate any future sales of our BioTime common shares with BioTime and its subsidiaries in order to provide an orderly and controlled process for raising capital through the sale of BioTime shares. This will include an agreement as to the number of shares to be sold, the time period or "market window" for selling shares, the use of a common securities broker-dealer, and a fair allocation of net sales based on average sales prices during any trading day on which we and they sell BioTime shares.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">42</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6353735c680b48929a9769cfe0a25c8a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Each conflict of interest will be resolved by our respective boards of directors in keeping with their fiduciary duties and such policies as they may implement from time to time. However, the terms and conditions of patent and technology licenses and other agreements between us and BioTime or BioTime subsidiaries will not be negotiated on an arm's-length basis due to BioTime's ownership interest in us and due to the commonality of certain directors serving on our respective boards of directors.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Dependence on Third Parties</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">There is a limited number of manufacturers of molecular diagnostic testing equipment and related chemical reagents necessary for the provision of our diagnostic tests.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have been developing our lung cancer diagnostic test using diagnostic testing equipment and reagents from one manufacturer.&#160; However, we have encountered inconsistent results using that equipment, which we believe was caused by issues with the chemical reagents that are required for use with that particular manufacturer's equipment. The chemical reagents are available only from that equipment manufacturer. We are evaluating alternative analytic platforms from other manufacturers to determine which, if any, could replace the initial diagnostic testing platform that we have been using.&#160; If we need to acquire different diagnostic testing equipment, we will need to conduct additional R&amp;D validation, and analytic studies to determine whether our previous test results can be reproduced using the new equipment. As a result, we are experiencing delays in developing our diagnostic tests.&#160; If similar issues were to arise after commercialization of a diagnostic test, we could experience a disruption for a period of time in providing the diagnostic tests to patients and we would lose revenues and potentially market share as a result.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In order to facilitate the development, manufacture and commercialization of our diagnostic tests we may enter into strategic alliances with diagnostic, pharmaceutical, or medical device companies to advance our programs and enable us to maintain our financial and operational capacity. We will face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all. If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our product development or research programs, or we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If we are able to enter into development and marketing arrangements with diagnostic, pharmaceutical or medical device companies for our diagnostic tests, we may license product development, manufacturing, and marketing rights to the pharmaceutical or medical device company or to a joint venture company formed with the pharmaceutical or medical device company. Under such arrangements we might receive only a royalty on sales of the diagnostic tests developed or an equity interest in a joint venture company that develops the diagnostic test. As a result, our revenues from the sale of those diagnostic tests may be substantially less than the amount of revenues and gross profits that we might receive if we were to develop, manufacture, and market the diagnostic tests ourselves.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may become dependent on possible future collaborations to develop and commercialize many of our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may enter into various kinds of collaborative research and development, manufacturing, and diagnostic test marketing agreements to develop and commercialize our diagnostic tests. Any future milestone payments and cost reimbursements from collaboration agreements could provide an important source of financing for our research and development programs, thereby facilitating the application of our technology to the development and commercialization of our diagnostic tests, but there are risks associated with entering into collaboration arrangements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There is a risk that we could become dependent upon one or more collaborative arrangements for diagnostic test development or manufacturing or as a source of revenues from the sale of any diagnostic tests that may be developed by us alone or through one of the collaborative arrangements. A collaborative arrangement upon which we might depend might be terminated by our collaboration partner or they might determine not to actively pursue the development or commercialization of our diagnostic tests. A collaboration partner also may not be precluded from independently pursuing competing diagnostic tests or technologies.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">43</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There is a risk that a collaboration partner might fail to perform its obligations under the collaborative arrangements or may be slow in performing its obligations. In addition, a collaboration partner may experience financial difficulties at any time that could prevent it from having available funds to contribute to the collaboration. If a collaboration partner fails to conduct its diagnostic test development, manufacturing, commercialization, regulatory compliance, sales and marketing or distribution activities successfully and in a timely manner, or if it terminates or materially modifies its agreements with us, the development and commercialization of one or more diagnostic test candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue diagnostic test development, manufacturing, and commercialization on our own.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Pertaining to Our Common Stock</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ownership of our common stock will entail certain risks associated with the limited history of the trading of our common stock, volatility of prices for our shares, and the fact that we do not pay dividends.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we are engaged in the development of medical diagnostic tests, the price of our stock may rise and fall rapidly.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The market price of our common stock, like that of the shares of many biotechnology companies, may be highly volatile. The price of our common stock may rise or fall rapidly as a result of a number of factors, including:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7357c0eabd2544e9a7df9655474c6afc" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales or potential sales of substantial amounts of our common stock;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z763ff75feb8744a7bb37b7d16803e78e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Results of or delays in preclinical testing or clinical trials of our diagnostic test candidates;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z37aff62838c0465390b2598e2dc9b6fa" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Announcements about us or about our competitors, including clinical trial results, regulatory approvals, new diagnostic test introductions and commercial results;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z68ef9f21c25b4160b3b6464cd3bb972a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The cost of our development programs;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8f05594b258143faa28232903b4f818b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The success of competitive diagnostic tests or technologies;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z15a7bac2ccd44003b98e45ddf3b740db" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Litigation and other developments relating to our issued patents or patent applications or other proprietary rights or those of our competitors;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z752dda74bdf5492cb2c0d15aa7d4f630" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Conditions in the diagnostic, pharmaceutical or biotechnology industries;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za7275ec0da774a48a4e38c4514bca920" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfdbd02da3e554ef1a2a4b6d667077757" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Variations in our financial results or those of companies that are perceived to be similar to us, including the failure of our earnings to meet analysts' expectations;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zae8b2e09c0d24630afdffb5119116a62" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General economic, industry and market conditions; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1e39acb3afc74abcac4d8925f5bccc8a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Changes in payer coverage and or reimbursement.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnological companies in particular, have been experiencing extreme price and volume fluctuations which have affected the market price of the equity securities without regard to the operating performance of the issuing companies. Broad market fluctuations, as well as industry factors and general economic and political conditions, may adversely affect the market price of our common stock.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">44</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>
</div>

<div>
<div style="FONT-WEIGHT: bold">The implementation of a new FASB accounting standard could increase the risk that our future financial statements could be qualified by going concern uncertainty.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern." ASU No. 2014-15 defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures. ASU No. 2014-15 is effective for us for the year ended December 31, 2016, and all annual and interim periods thereafter. In connection with preparing financial statements for each annual and interim reporting period, ASU No. 2014-15 requires that an entity's management evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). As a result of the implementation of ASU No. 2014-15, we will be required to have more cash, cash equivalents, and liquid investments on hand on the date we issue or file our financial statements than had been the case during prior years in order to avoid going a concern qualification in our auditor's report and in the footnotes to our financial statements. If our financial statements were to become subject to a going concern qualification or uncertainty or if we are unable to alleviate substantial doubt as part of our going concern assessment, or both, the market price of our common stock could decline.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime will also be impacted by ASU No. 2014-15 in much the same manner us. If the consolidated financial statements BioTime were to become subject to a going concern qualification or uncertainty, the market price of their common stock could decline, resulting in a loss or decline in value of the BioTime shares we own as available for sale securities.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we do not pay dividends, our stock may not be a suitable investment for anyone who needs to earn dividend income.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We do not pay cash dividends on our common stock. For the foreseeable future we anticipate that any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to our shareholders. Under a Loan and Security Agreement with Silicon Valley Bank, we have agreed not to pay dividends or to make any distributions or to redeem to repurchase any capital stock without Silicon Valley Bank's prior written consent while the Loan and Security Agreement remains in effect. This means that our stock may not be a suitable investment for anyone who needs to earn income from their investments.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities analysts may not initiate coverage or continue to cover our common stock, and this may have a negative impact on the market price of our shares.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The market for our common stock will depend, in part, on the research and reports that securities analysts publish about our business and our common stock. We do not have any control over these analysts. Four securities analysts cover our shares and they could issue reports or recommendations that are unfavorable to the price of our shares, and they could downgrade a previously favorable report or recommendation, and in either case our share price could decline as a result of the report. If one or more of these analysts ceases to cover our shares or fails to publish regular reports on our business, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present shareholders. We are currently authorized to issue an aggregate of 55,000,000 shares of capital stock consisting of 50,000,000 shares of common stock and 5,000,000 "blank check" shares of preferred stock. At March 20, 2018, there were 31,468,558 shares of common stock outstanding, 2,779,221 shares of common stock reserved for exercise of warrants and 3,373,287 shares of common stock reserved for issuance upon the exercise of options under our employee stock option plan. No shares of preferred stock are presently outstanding.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may issue additional common stock or other securities that are convertible into or exercisable for common stock in order to raise additional capital, or in connection with hiring or retaining employees or consultants, or in connection with future acquisitions of licenses to technology or rights to acquire diagnostic tests in connection with future business acquisitions, or for other business purposes. The future issuance of any such additional common stock or other securities may create downward pressure on the trading price of our common stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We may also issue preferred stock having rights, preferences, and privileges senior to the rights of our common stock with respect to dividends, rights to share in distributions of our assets if we liquidate our company, or voting rights. Any preferred stock may also be convertible into common stock on terms that would be dilutive to holders of common stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are an "emerging growth company," and may elect to comply with reduced public company reporting requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are an "emerging growth company," as defined in the JOBS Act, and we may to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an "emerging growth company." We will remain an "emerging growth company" until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.0 billion or more; (ii) the fifth anniversary of the completion of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">45</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will incur costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As a public reporting company, we will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC, have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will entail significant legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept low policy limits and coverage.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z16b3f81783e54b22b38a75ed225d1d26" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item1B."><!--Anchor--></a>Item 1B.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unresolved Staff Comments</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">None</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zcbb116fbfd4a4c0f9c180419fc8c7277" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item2."><!--Anchor--></a>Item 2.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Properties</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under a Shared Facilities Agreement with BioTime, we have use of laboratory and office space at BioTime's facility in Alameda, California. BioTime has leased approximately 30,795 square feet of office and laboratory space in two buildings located in Alameda, and will provide OncoCyte use of space sufficient for a CLIA compliant diagnostic laboratory.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zddf03fb72320494488c92290773de373" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item3."><!--Anchor--></a>Item 3.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Proceedings</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">From time to time, we may be involved in routine litigation incidental to the conduct of our business. We are not presently involved in any material litigation or proceedings, and to our knowledge no such litigation or proceedings are contemplated.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd4ad73250359407394d65de9e445a8b2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item4."><!--Anchor--></a>Item 4.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Mine Safety Disclosures</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Not applicable</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf318cd98d6b24449b2b21dbf9ff47a41" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item5."><!--Anchor--></a>Item 5.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our common stock has been traded on the NYSE American under the symbol "OCX" since January 4, 2016. The following table sets forth the range of high and low closing prices for our common shares for the fiscal year ended December 31, 2017, as reported by the NYSE American:</div>

<div><br>
</div>

<table style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3895fdcddd2c4206b52c9219dfe409fb" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quarter Ended</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">High</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Low</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">March 31, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10.11</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.62</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">June 30, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">6.07</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.37</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">September 30, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5.32</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.25</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">December 31, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7.70</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.95</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">March 31, 2017</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7.00</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4.70</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">June 30, 2017</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7.35</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4.95</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">September 30, 2017</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7.55</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.60</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 26%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">December 31, 2017</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7.40</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.90</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of March 20, 2018, we had 249 holders of record of our common stock. This number does not include shareholders whose shares of OncoCyte common stock are held in "street name" in accounts with securities broker-dealers or other financial institutions or fiduciaries.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">46</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following table shows certain information concerning the options outstanding and available for issuance under all of our compensation plans and agreements as of December 31, 2017 (in thousands, except weighted average exercise price):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5308cadf98dc413085f37f12dc7e8c0a" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 58%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plan Category</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of Shares</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">to be Issued</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">upon Exercise of</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding Options,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants, and Rights</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted Average</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise Price of</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">the Outstanding</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options, Warrants,</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Rights</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of Shares</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Remaining Available</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">for Future Issuance</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">under Equity</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation Plans</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 58%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OncoCyte Stock Option Plans Approved by Shareholders</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,390</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$3.25</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,384</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Additional information concerning our Employee Stock Option Plan and the stock options may be found in Note 7 to the Financial Statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividend Policy</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have never paid cash dividends on our capital stock and we do not anticipate paying cash dividends in the foreseeable future, but intend to retain our capital resources for reinvestment in our business. Under a Loan and Security Agreement with Silicon Valley Bank, we have agreed not to pay dividends or to make any distributions or to redeem to repurchase any capital stock without Silicon Valley Bank's prior written consent. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon the repayment of the loans from Silicon Valley Bank, our financial condition, results of operations, capital requirements and other factors as our Board of Directors deems relevant.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Performance Measurement Comparison <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(1)</sup></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following graph compares total stockholder returns of OncoCyte for the last twelve months beginning December 31, 2015 to two indices: the NYSE Amex Market Value &#8211; U.S. Companies ("Amex Market Value") and the NYSE Arca Biotechnology Index. The total return for our common shares and for each index assumes the reinvestment of dividends, although we have never declared dividends on OncoCyte common shares, and is based on the returns of the component companies weighted according to their capitalizations as of the end of each quarterly period. The Amex Market Value tracks the aggregate price performance of equity securities of U.S. companies listed therein. The NYSE Arca Biotechnology Index represents biotechnology companies, trading on NYSE American under the Standard Industrial Classification ("SIC") Code Nos. 283 (Drugs) and 382 (Laboratory Apparatus and Analytical, Optical) main categories (2834: Pharmaceutical Preparations; 2835: Diagnostic Substances; 2836: Biological Products; 3826: Laboratory Analytical Instruments; and 3829: Measuring &amp; Controlling Devices). OncoCyte common stock trades on the NYSE American and is a component of the NYSE Amex Market Value &#8211; US Companies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comparison of Twenty-Four Month Cumulative Total Return on Investment</div>

<div><br>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z182873e91ad34c448a925f94d82bee17" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">12/31/2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3/31/2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">6/30/2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9/30/2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">12/31/2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3/31/2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">6/30/2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9/30/2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">12/31/2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OncoCyte Corporation</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Return %</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-26.24</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-22.78</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">41.57</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">39.88</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-15.60</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-12.61</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">45.19</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-38.41</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cum $</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">100.00</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">73.76</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">56.96</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">80.64</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">112.80</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">95.20</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">83.20</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">120.80</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">74.40</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">AMEX Market Value Index (US Companies)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Return %</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-0.87</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5.86</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5.81</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1.27</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.92</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.18</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">0.10</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.48</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cum $</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">100.00</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">99.13</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">104.94</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">111.04</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">112.45</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">116.85</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">119.40</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">119.53</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">123.68</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NYSE Arca Biotechnology Index</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Return %</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-22.37</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.31</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11.50</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-8.70</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">16.03</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8.32</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8.96</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">0.53</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cum $</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">100.00</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">77.63</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">79.42</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">88.55</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">80.85</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">93.81</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.62</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">110.73</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">111.33</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">47</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OncoCyte Corporation, the Amex Market Value and NYSE Arca Biotechnology Index <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(2)</sup></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: center"><img src="image00003.jpg"></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z431fdc7bafc846ee81ec1f409bce2023" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This Section is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference in any filing of OncoCyte under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z759fded2856647b2bd8f04dff6bd650b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Shows the cumulative total return on investment assuming an investment of $100 in each of OncoCyte, the Amex Market Value and the NYSE Arca Biotechnology Index on December 31, 2015. The cumulative total return on OncoCyte common shares has been computed based on a price of $9.00 per share, the price at which OncoCyte's common shares closed on January 4, 2016, OncoCyte's first day of "regular way" trading on NYSE American.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb22591bc7d374d969188a9024b834f80" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item6."><!--Anchor--></a>Item 6.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selected Financial Data (in thousands, except per share data)</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z45e8631a2da94bfeb3e339e52784062a" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OPERATING EXPENSES</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,174</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,677</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,527</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,232</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,265</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,867</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sales and marketing</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,443</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,198</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">324</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total operating expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">18,849</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,140</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8,718</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loss from operations</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(18,849</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,140</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,718</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER EXPENSES, NET</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loss on sale of available-for-sale securities and other expenses, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(309</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Interest expense, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(217</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(28</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other income, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total other expenses, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(526</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(28</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(17</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Basic and diluted net loss per share</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.64</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Weighted average shares outstanding: basic and diluted</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">30,195</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">26,529</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">21,009</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">48</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6c7575b3efd44c48b75829b5710af32d" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance Sheet Data (in thousands):</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,600</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,174</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BioTime shares held as available-for-sale securities, at fair value</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">760</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,237</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">746</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">988</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,216</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">14,447</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,813</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,585</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total stockholders' equity</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,403</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,862</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z077e49eccadc47e5921d853ec0de07c9" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item7."><!--Anchor--></a>Item 7.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management's Discussion and Analysis of Financial Condition and Results of Operations</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our audited financial statements for the years ended December 31, 2017, 2016 and 2015, and highlight certain other information which, in the opinion of management, will enhance a reader's understanding of our financial condition, changes in financial condition and results of operations. These historical financial statements may not be indicative of our future performance. This Management's Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks described throughout this filing, particularly in "Risk Factors."</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Emerging Growth Company Status</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Jumpstart our Business Startups Act of 2012 ("JOBS Act") permits an "emerging growth company" such as OncoCyte to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. However, we elected to comply with newly adopted or revised accounting standards when they become applicable to public companies because our financial statements were consolidated with those of BioTime, which is not an emerging growth company under the JOBS Act and is therefore not permitted to delay the adoption of new or revised accounting standards that become applicable to public companies. This election under the JOBS Act to not delay the adoption of new or revised accounting standards is irrevocable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management's Discussion and Analysis of Financial Condition and Results of Operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We were incorporated during September 2009. Our operations have included planning and launching research and diagnostic test development programs in house and with partners, pursuing patents, and conducting clinical trials.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The inherent uncertainties of developing new diagnostic tests for medical use make it impossible to predict the amount of time and expense that will be required to complete the development and commence commercialization of new diagnostic tests. There is no assurance that we will be successful in developing new technology or diagnostic tests, or that any technology or diagnostic tests that we may develop will be proven safe and effective in diagnosis of cancer in humans, or will be successfully commercialized.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We believe we have sufficient cash, cash equivalents, and working capital to carry out our current operations through at least twelve months from the issuance date of our financial statements included elsewhere in this Report. We will need to obtain additional financing in order to commercialize any diagnostic tests that we develop and to continue our operations, including additional capital equipment purchases for our diagnostic laboratory and adding personnel required in 2018 and beyond to perform any laboratory diagnostic tests that we develop. Our determination as to when we will seek new financing and the amount of financing that we will need will be based on our evaluation of the progress we make in our research and development programs, any changes to or the expansion of the scope and focus of our research, progress and results of commercializing our diagnostic tests after completion of development, and our projection of future costs. See "Liquidity and Capital Resources" for a discussion of our available capital resources, our need for future financing, and possible sources of capital.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States ("GAAP"), requires management to make estimates and assumptions that affect the reported amounts in our financial statements and related notes. Our significant accounting policies are described in Note 2 to our financial statements included elsewhere in this Report. We have identified below our critical accounting policies and estimates that we believe require the greatest amount of judgment. On an ongoing basis, we evaluate estimates which are subject to significant judgment, including those related to the&#160;going concern assessments of our financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates. On an ongoing basis, we evaluate our estimates compared to historical experience and trends, which form the basis for making judgments about the carrying value of assets and liabilities. To the extent that there are material differences between our estimates and our actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">49</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We believe the assumptions and estimates associated with the following have the greatest potential impact on our financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Going concern assessment</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">With the implementation of FASB's new standard on going concern, ASU No. 2014-15, beginning with the year ended December 31, 2016 and all annual and interim periods thereafter, we assess going concern uncertainty in our financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital, including available loans or lines of credit, if any, to operate for a period of at least one year from the date our financial statements are issued or are available to be issued, which is referred to as the "look-forward period" as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections, and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Related party transactions - Shared Facilities and Services Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As more fully described in Note 4 to our financial statements, to the extent we do not employ our own human resources for operations, BioTime, or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for our benefit, under the Shared Facilities Agreement. Accordingly, BioTime allocates expenses such as personnel costs and related benefits incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to our affairs. Other expenses such as legal, accounting, marketing, travel, and entertainment expenses are allocated to us to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities, utilities, leasing, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to our operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for warrants</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We determine the accounting classification of warrants we issue, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font>, then in accordance with ASC 815-40, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock</font>.&#160; Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate us to settle the warrants or the underlying shares by paying cash or other assets, and warrants that must or may require settlement by issuing variable number of shares.&#160; If warrants do not meet the liability classification under ASC 480-10, we assess the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature.&#160; If the warrants do not require liability classification under ASC 815-40, in order to conclude equity classification, we also assess whether the warrants are indexed to our common stock and whether the warrants are classified as equity under ASC 815-40 or other GAAP. After all such assessments, we conclude whether the warrants are classified as liability or equity.&#160; Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the statements of operations.&#160; Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. We do not have any liability classified warrants as of any period presented. See Note 6 to our financial statements.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">50</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stock-based compensation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have adopted accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values. We utilize the Black-Scholes-Merton option pricing model. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. Because our common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, we estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to us, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, we estimated the expected volatility using our own stock price volatility to the extent applicable or a combination of our stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options. The expected term of options granted is based upon the "simplified method" provided under<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14, including, in part, based on our own experience. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with FASB guidance, the key inputs and assumptions may change as we develop our own company estimates, experience and key inputs including our expected term, and stock price volatility based on the trading history of our stock on the NYSE American. Changes in these subjective assumptions can materially affect the estimated value of equity grants and the stock-based compensation that we record in our financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for BioTime Shares</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We account for the BioTime shares we hold as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Investments &#8211; Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 2 to our financial statements included elsewhere in this Report, on February 17, 2017, BioTime deconsolidated our financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses we generate from the sale of BioTime shares after February 17, 2017 are included in our statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Business Combinations</font> ("ASC 805"), transactions between entities under common control. See Note 2 under the section <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Recent Accounting Pronouncements</font> for additional disclosures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Long-lived intangible assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Impairment of long-lived assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We assess the impairment of long-lived assets, which consist primarily of long-lived intangible assets, equipment and furniture, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset's carrying value over its fair value is recorded. To date, there have been no such impairment losses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income taxes</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have filed a standalone U.S. federal income tax return since our inception. For California purposes, our activity for 2015, 2016 and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of our outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning February 17, 2017 and thereafter, we will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, our effective tax rate in future years could vary from our historical effective tax rates depending on our future legal structure and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by us, will remain with us. We account for income taxes in accordance with ASC 740, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. Our judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If our assumptions and consequently our estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on our statements of operations.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">51</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. We will recognize accrued interest and penalties, if any, related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of the financial statements periods presented herein. We are not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the periods presented herein. We are currently unaware of any tax issues under review.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&#8220;2017 Tax Act&#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&#8220;NOLs&#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &#8220;deemed repatriation&#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8 to our financial statements included elsewhere in this Report).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated to us by BioTime that benefit or support our research and development functions of OncoCyte. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated to us by BioTime under the Shared Facilities Agreement (see Note 4 </font>to our financial statements included elsewhere in this Report<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">), are primarily based on our headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated to us by BioTime that benefit or support our general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated to us by BioTime under the Shared Facilities Agreement (<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">see Note 4 </font>to our financial statements included elsewhere in this Report) are primarily based on our headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, and expenses incurred for trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on our headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Comparison of the Years Ended December 31, 2017 and 2016</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following tables show our operating expenses for the years ended December 31, 2017 and 2016 (in thousands).</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdcd1aa371ec649f9bb7075430f7ef849" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">% </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,174</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,677</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,497</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">26.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,232</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,265</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,967</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">116.5</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,443</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,198</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">1,245</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">103.9</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">52</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="FONT-STYLE: italic">Research and development expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses for the year ended December 31, 2017 increased to $7.2 million from $5.7 million during 2016. This $1.5 million increase in research and development expenses is primarily due to the certification and maintenance costs related to the CLIA laboratory and the cost of&#160;DetermaVu&#8482; program. The increase includes $0.8 million in outside laboratory and clinical trial expenses, $0.7 million in personnel and benefits costs, which includes $0.4 million in stock-based compensation expense, and $0.4 million in research and development allocated amounts charged to us by BioTime for facilities and other services <font style="TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">provided to us</font>.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We expect to continue to incur a significant amount of research and development expenses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses for the year ended December 31, 2017 increased to $9.2 million from $4.3 million during 2016. The $5.0 million increase in general and administrative expenses during 2017 is primarily attributable to $4.1 million in noncash expense for the issuance of additional warrants to certain investors who exercised stock purchase warrants that we issued during 2016, $0.4 million in legal-patent related expenses, $0.3 million in personnel cost and related benefits, including stock-based compensation expense, and $0.2 million in insurance expense.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses for the year ended December 31, 2017 increased to $2.4 million from $1.2 million during 2016, as we prepared for the commercial launch of our lung cancer diagnostic test, DetermaVu&#8482;. The increase in sales and marketing expenses during 2017 is attributable to increases of $0.6 million in salaries and payroll related expenses, $0.2 million in sales and marketing expenses amounts charged to us by BioTime for facilities and services provided to us, $0.2 million in consulting expenses and $0.1 million in stock-based compensation expenses.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We expect that our sales and marketing expenses will continue to increase significantly as we build a sales force for the commercialization of any cancer diagnostic tests that we successfully develop. Our sales and marketing efforts, and the amount of related expenses that we will incur, in the near term will largely depend upon the outcome of our clinical validation study of DetermaVu&#8482;, and the amount of capital, if any, that we are able to raise to finance development and commercialization of that test. Our current cash resources will require us to limit our initial sales and marketing efforts unless and until we are able to raise additional capital. Our future expenditures on sales and marketing will also depend on the amount of revenue that those efforts are likely to generate. Because physicians are more likely to prescribe a test for their patients if the cost is covered by Medicare or health insurance, demand for our diagnostic tests and our expenditures on sales and marketing are likely to increase if our diagnostic tests qualify for reimbursement by Medicare and private health insurance companies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Comparison of the Years Ended December 31, 2016 and 2015</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following tables show our operating expenses for the years ended December 31, 2016 and 2015 (in thousands).</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdffd4e9f405a45d7b58221ffffb0b779" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">%</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Increase</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" rowspan="2" nowrap="nowrap"></td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">2015</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,677</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,527</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+1,150</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+ 25.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,265</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,867</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+398</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+10.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sales and marketing expenses</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,198</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">324</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+874</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">+269.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">53</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div>
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following table shows the approximate amounts and percentages of our total research and development expenses of $5.7 million and $4.5 million allocated to our primary research and development projects during the years ended December 31, 2016 and 2015, respectively (in thousands).</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf04d08716c9d43acaa811a1b8b101791" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount </font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(1)</sup></div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percent</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Program</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,649</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,687</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">29.1</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">37.3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Lung Cancer Confirmatory Diagnostic</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,940</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">763</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">51.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">16.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Bladder Cancer Confirmatory Diagnostic</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">376</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">895</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">6.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">19.8</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Breast Cancer Confirmatory Diagnostic</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,105</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">6.6</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">24.4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CLIA Lab</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">337</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">77</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5.9</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1.7</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,677</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,527</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">100&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">100</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div>
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; WIDTH: 90%; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za33776e4bded4d318332a2e7337d3708" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Amount also includes certain general research and development expenses, such as laboratory supplies, laboratory expenses, rent allocated, and insurance allocated to research and development expenses, incurred directly by BioTime on behalf of OncoCyte and allocated to OncoCyte under the Shared Facilities Agreement.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses for the year ended December 31, 2016 increased to $5.7 million from $4.5 million during 2015. Overall the increase in research and development expenses is due to increased staffing and costs of clinical trials as part of the development of our cancer diagnostic tests. The increases in research and development expenses during 2016 are primarily attributable to increases of $0.4 million in laboratory expenses, $0.3 million in salaries and payroll related expenses, $0.2 million in business development expenses, and $0.2 million in clinical trials expenses, principally focused on the lung cancer confirmatory diagnostic test.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We expect to continue to incur a significant amount of research and development expenses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative and sales and marketing expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative and sales and marketing expenses for the year ended December 31, 2016 increased to $5.5 million from $4.2 million during 2015. The increase in general and administrative expenses during 2016 is primarily attributable to increases of $0.6 million in general consulting expenses, $0.5 million in salaries and payroll related expenses, $0.2 million in marketing research expenses, $0.2 million in general and administrative expenses allocated to us by BioTime, and $0.4 million in other general administrative costs including legal fees and SEC filing fees. These increases were in part offset by a decrease in stock-based compensation expense of $0.8 million due to fewer stock option grants made in 2016 as compared to 2015 and certain modifications of stock option grants to an executive in 2015 that resulted in higher expense in 2015. Stock-based compensation was also lower in 2016 due to OncoCyte not granting stock options to employees of BioTime in 2016, whereas options were granted during 2015 and prior years to certain BioTime employees who provided services to us 2015 and prior years, which are treated as nonemployee grants and generally result in higher stock-based compensation expense in OncoCyte's financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income taxes</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, we had net operating loss carryforwards of approximately $47.8 million for U.S. federal income tax purposes and $15.6 million for state income tax purposes, which expire generally between 2029 and 2037. In addition, as of December 31, 2017, we had research and development credit carryforwards for federal and state tax purposes of $1.0 million and $1.1 million, respectively. The federal credits expire between 2030 and 2037, while the state credits have no expiration. Due to our losses incurred for all periods presented, we did not record any provision or benefit for income taxes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During 2017, we sold 266,442 BioTime common shares in at-the-market transactions which resulted in a taxable&#160;loss of approximately $301,000. No BioTime common shares were sold in 2016. During 2015, we sold 259,712 BioTime common shares in at-the-market transactions which resulted in a taxable&#160;loss of approximately $397,000. </div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017, we had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Since inception, we have financed our operations through the sale of our common stock and warrants to our shareholders, loans from BioTime and BioTime affiliated entities, the sale of BioTime common shares, a bank loan, and exercises of our warrants.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On March 28, 2018, we entered into a securities purchase agreement with two accredited investors. The agreement provides for the private placement of 7,936,508 shares of our common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, we have received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common stock, and one of the investors irrevocably committed in the agreement to pay to us an additional $2.0 million on or prior to April 30, 2018 for the purchase of an additional 1,587,302 shares of common stock (see Note 10 to our financial statements included elsewhere in this Report).</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to us on or prior to April 30, 2018 (see Note 10 to our financial statements included elsewhere in this Report), we believe we have sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out our current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if we determine to devote more resources to the development or initial commercialization efforts for our lung cancer test during that time frame.</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">54</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank (the "Bank") pursuant to which OncoCyte borrowed $2.0 million on March 23, 2017. Payments of interest only on the principal balance were due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal of approximately $67,000 plus interest are due and payable. The outstanding principal balance of the loan bears interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of December 31, 2017, the latest published prime rate plus 0.75% was 5.25% per annum.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The outstanding principal amount plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. OncoCyte accrued the $116,000 final payment fee included in the loan payable as a deferred financing cost on March 23, 2017.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to&#160; 2.0% of the outstanding principal balance if prepaid after February 21, 2018 but not later than February 21, 2019, or 1.0% of the outstanding principal balance if prepaid after February 21, 2019. Any amounts borrowed and repaid may not be reborrowed.&#160; As of December 31, 2017, no amounts are available to be borrowed under this Loan Agreement.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an "Event of Default" as defined in the Loan Agreement occurs and is not cured within any applicable cure period. Upon the occurrence and during the continuance of an Event of Default, all obligations due to the Bank will bear interest at a rate per annum which is 5% above the then applicable interest rate. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte's business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and copies of filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE American. OncoCyte's obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns. Accordingly, if an Event of Default were to occur and not be cured, the Bank could foreclose on its security interest in the collateral. OncoCyte was in compliance with the Loan Agreement as of the filing date of this report.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">55</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cash used in operations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the years ended December 31, 2017 and 2016, our research and development expenses were $7.2 million and $5.7 million, our general and administrative expenses were $9.2 million and $4.3 million, and our sales and marketing expenses were $2.4 million and $1.2 million, respectively. Net loss for the years ended December 31, 2017 and 2016 amounted to $19.4 million and $11.2 million, respectively. Net cash used in operating activities during these periods amounted to $13.4 million and $7.5 million, respectively. The amount by which our net loss exceeded net cash used in our operations during 2017 is primarily due to the following noncash items: a $4.1 million noncash charge related to warrants issued to certain investors as an inducement to exercise previously issued warrants; $1.6 million of stock-based compensation; $580,000 in depreciation and amortization expenses; and a $309,000 loss on sales of BioTime shares held as available-for-sale securities. Changes in working capital amounted to an approximate $686,000 of additional use of cash.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cash used in investing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the years ended December 31, 2017 and 2016, $91,000 and $106,000 in cash payments were made for purchase of machinery and equipment, respectively, and $934,000 in net cash proceeds were received from the sale of 266,442 shares of BioTime common stock we held as available-for-sale securities. We used these proceeds to pay down amounts owed to BioTime and affiliates. Under the provisions of the Loan Agreement discussed in Note&#160;5 of the notes to financial statements, after October 26, 2017, we can use any proceeds from sale of BioTime shares to pay amounts owed to BioTime and its affiliates or for working capital purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cash provided by financing activities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the year ended December 31, 2017, cash provided by financing activities was $10.0 million. During this period, certain investors exercised 2,392,000 warrants at an exercise price of $3.25 per warrant, providing us with total exercise proceeds of $7.8 million. We also received $610,000 in proceeds from exercise of stock options and we borrowed $2.0 million from a bank. These cash inflows were offset by $265,000 used to pay down capital lease obligations and $133,000 in payments due on the bank loan.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Contractual obligations</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, our contractual obligations for the next five years and thereafter were as follows (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9b36dd3a7fa34284adc69904c3854cc8" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 40.05%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="18" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Principal Payments Due by Period</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.05%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Obligations <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(1)</sup></div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Less Than</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1 Year</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1-3 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4-5 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">After</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 Years</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40.05%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Shared Facilities Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(2)</sup></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,099</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,099</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40.05%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Capital lease <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(3)</sup></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">690</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">383</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">307</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40.05%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loan payable <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(4)</sup></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,097</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">876</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,221</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.04%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.04%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6034d7ccf58441ac9a44d75fb9c4b445" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This table does not include payments to key employees that could arise if their employment is involuntary terminated or if their employment terminated following a change in control of OncoCyte.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zabe4886f7dbc418c8d0cc017d38c18b5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under the Shared Facilities Agreement, we reimburse BioTime for a portion of the rent and other expenses of leasing our office and laboratory facility, and for BioTime's cost of providing us with the use of laboratory and office equipment and supplies, utilities, and personnel. Salaries and related expenses for accounting services and building maintenance are allocated based on a fixed percentage evaluated by BioTime management and us on a periodic basis and adjusted based on the level of activity, if warranted.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfe7fc947e5524bb4a037c6eaf0bd5078" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Includes certain capital leases for lab equipment.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7262e8e5fbf44ead944ea4fea34f8deb" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(4)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Loan payable amounts include principal and interest.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2344f00495dd40ef92ca28ff2e768349" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item7A."><!--Anchor--></a>Item 7A.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quantitative and Qualitative Disclosures about Market Risk</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Foreign Currency Exchange Risk</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We are not presently exposed in a significant degree to foreign exchange currency risks because we are not conducting international business at this time, and we do not engage in foreign currency hedging activities. If we engage in international transactions, we will need to translate foreign currencies into U.S. dollars for reporting purposes, and currency fluctuations could have an impact on our financial results.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">56</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Credit Risk</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under our Loan Agreement with Silicon Valley Bank, we are required to hold our cash in (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any state thereof having maturities of not more than one year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &amp; Poor's Ratings Group or Moody's Investors Service, Inc.; (c) certificates of deposit issued by the Bank and maturing no more than one (1) year after issue, or deposit accounts with other banks. Deposits with banks may temporarily exceed the amount of insurance provided on such deposits. We will monitor the cash balances in the accounts and adjust the cash balances as appropriate, and as permitted by the Loan Agreement, but if the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Interest Rate Risk</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We hold our funds in investments permitted by the Loan Agreement.&#160; The primary objective of our investments will be to preserve principal and liquidity while earning a return on our invested capital, without incurring significant risks. Our future investment income is not guaranteed and may fall short of expectations due to changes in prevailing interest rates.&#160; If we sell any investment security prior to its maturity date, we may suffer a loss in principal if the market value of the security declines below our acquisition cost.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Available for sale securities at fair value</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We hold 353,264 BioTime common shares at fair value as available-for-sale securities. Those shares are subject to changes in market value. BioTime common shares trade on the NYSE American under the ticker "BTX". As of December 31, 2017, the 52-week high/low stock price per share range for BioTime was $3.73 to $2.15.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">57</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stockholders and </font>Board of Directors</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte Corporation</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Alameda, California</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Opinion on the Financial Statements</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have audited the accompanying balance sheets of OncoCyte Corporation (the &#8220;Company&#8221;) as of December 31, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2017 and </font>2016<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">,</font> the related statements of operations, comprehensive loss, stockholders&#8217; equity (deficit), and cash flows for each of the three years in the period ended December 31, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2017, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">,</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basis for Opinion</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">These financial statements are the re<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sponsibility of the Company&#8217;s management. Our responsibility is to express an opinion on </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We conducted our audits in accordance with the standards of the <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">PCAOB.</font> Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, whether due to error or fraud.</font>&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Company is not required to have, nor were we engaged to perform, </font>an audit of its internal control over financial reporting. As part of our audits <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">we are required to obtain an understanding</font> of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordin<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">gly, we</font> express no such opinion.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included</font> examining, on a test basis, evidence <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">regarding</font> the amounts and disclosures in the financial statements<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. Our audits also included evaluating</font> the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> of the financial statements</font>. We believe that our audits provide a reasonable basis for our opinion.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ OUM &amp; CO. LLP</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">San Francisco, California</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2018</font></div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have served as the Company's auditor since 2015.</div>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">58</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z02557a003caf430e8915d226ca9d0e06" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item8."><!--Anchor--></a>Item 8.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Statements and Supplementary Data</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BALANCE SHEETS</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In thousands</font>)</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf8bf1e960ea741ef8f3c06fad767ca0e" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,600</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,174</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">BioTime shares held as available-for-sale securities, at fair value</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">760</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,237</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">168</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">285</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total current assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8,528</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">12,696</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NONCURRENT ASSETS</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">746</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">988</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Equipment and furniture, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">822</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">688</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Deposits</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">120</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">75</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL ASSETS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,216</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">14,447</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CURRENT LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amount due to BioTime and affiliates</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,099</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,854</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accounts payable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">175</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">422</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accrued expenses and other current liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,042</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">797</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loan payable, current</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">800</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Capital lease liability, current</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">338</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">202</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total current liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,454</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,275</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">LONG-TERM LIABILITIES</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loan payable, net of deferred financing costs, noncurrent</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,070</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Capital lease liability, noncurrent</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">289</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">310</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL LIABILITIES</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,813</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,585</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Commitments and contingencies (see Note 9)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">STOCKHOLDERS&#8217; EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">59,968</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">45,818</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accumulated other comprehensive loss on available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(888</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(654</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accumulated deficit</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(54,677</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(35,302</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Total stockholders&#8217; equity</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,403</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,862</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,216</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">14,447</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The accompanying notes are an integral part of these financial statements.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">59</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF OPERATIONS</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(In thousands, except per share data)</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2adde6d909ce45fa9ff4f108a02f78eb" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OPERATING EXPENSES</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Research and development</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,174</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5,677</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,527</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">General and administrative</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,232</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,265</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,867</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Sales and marketing</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,443</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,198</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">324</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Total operating expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">18,849</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,140</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8,718</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Loss from operations</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(18,849</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,140</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,718</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OTHER EXPENSES, NET</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loss on sale of available-for-sale securities and other expenses, net</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(309</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Interest expense, net</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(217</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(28</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Other income, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Total other expenses, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(526</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(28</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(17</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Basic and diluted net loss per share</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.64</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Weighted average shares outstanding: basic and diluted</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">30,195</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">26,529</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">21,009</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The accompanying notes are an integral part of these financial statements.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">60</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF COMPREHENSIVE LOSS</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(In thousands)</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z114f2013ba5d4f6ea7978143aada105b" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NET LOSS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other comprehensive loss, net of tax:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Realized loss on sale of available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">293</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">397</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Unrealized gain (loss) on available-for-sale securities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(527</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(304</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">75</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPREHENSIVE LOSS</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,609</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,472</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,263</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The accompanying notes are an integral part of these financial statements.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">61</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(In thousands)</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5ced22ea9f9e428e92abe56c905b7ed1" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="6" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Common Stock</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other </div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comprehensive</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accumulated</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shareholders&#8217;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Shares</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Amount</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Loss</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Deficit</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Equity (Deficit)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BALANCE AT DECEMBER 31, 2014</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">18,200</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">15,147</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(822</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(15,399</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(1,074</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Unrealized gain on BioTime shares held as available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">75</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">75</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,815</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,815</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common stock issued to BioTime for extinguishment of debt</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common stock issued to investors for cash</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,508</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,318</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,318</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Common stock issued to BioTime for cash</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,711</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8,349</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">8,349</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Exercise of stock options</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Fair value of contingently issuable warrant</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">65</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">65</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">OncoCyte common stock received as a dividend in kind from BioTime</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(31</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 35px">
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Transfer of realized loss into equity from sale of BioTime shares</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(397</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">397</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BALANCE AT DECEMBER 31, 2015</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">25,391</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">34,901</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(350</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(24,134</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,417</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Unrealized loss on BioTime shares held as available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(304</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(304</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">922</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">922</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Proceeds from issuance of common stock and warrants, net of discounts and financing costs</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,246</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,777</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,777</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Exercise of stock options</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">100</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">218</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">218</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BALANCE AT DECEMBER 31, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">28,737</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">45,818</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(654</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(35,302</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,862</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Unrealized loss on BioTime shares held as available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(527</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(527</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,630</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,630</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">Issuance of common stock upon exercise of 2016 warrants</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,392</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,774</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,774</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Exercise of stock options</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">323</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">610</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">610</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Issuance of warrants for inducement to exercise&#160;2016 warrants</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,074</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,074</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Issuance of warrants to Silicon Valley Bank</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">62</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">62</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 40%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Transfer of realized loss on sale of BioTime shares</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">293</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">293</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 40%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">BALANCE AT DECEMBER 31, 2017</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">31,452</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">59,968</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(888</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(54,677</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,403</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The accompanying notes are an integral part of these financial statements.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">62</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">STATEMENTS OF CASH FLOWS</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(In thousands)</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z239f91cf16954e3bb1be9b35a3d7d9f4" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Depreciation expense</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">338</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">145</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">41</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">242</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">242</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">242</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Stock-based compensation</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,630</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">922</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,815</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Loss on sale of available-for-sale securities, including selling commissions</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">309</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Warrants issued to certain shareholders as inducement to exercise of warrants</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4,074</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Contingently issuable warrant expense to investors</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">65</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amortization of debt issuance costs and interest expense</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">83</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">18</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Amount due to BioTime and affiliates</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(753</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,007</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,557</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Prepaid expenses and other current assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">115</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(274</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(48</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">229</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,042</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net cash used in operating activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(13,385</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(7,522</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(4,229</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Net proceeds from sale of available-for-sale securities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">934</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">815</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Purchase of equipment</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(91</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(106</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(500</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Security deposit</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(75</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net cash provided by (used in) investing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">843</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(181</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">315</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from exercise of options</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">610</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">218</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from exercise of warrants</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,774</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from sale of common stock</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,649</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from sale of common stock and warrants</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,550</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Financing costs related to sale of common stock and warrants</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(773</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Proceeds from issuance of loan payable, net of financing costs</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,982</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Repayment of loan payable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(133</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Repayment of capital lease obligation</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(265</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(114</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net cash provided by financing activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,968</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">9,881</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,653</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(2,574</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,178</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,739</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">CASH AND CASH EQUIVALENTS:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">At beginning of the year</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,174</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,996</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">257</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">At end of the year</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,600</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">10,174</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">7,996</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Cash paid for interest</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">130</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">29</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Equipment purchased under capital leases</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">381</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">626</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Debt issuance costs</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">196</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Common stock issued to BioTime for extinguishment of debt</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Common stock issued to BioTime upon conversion of convertible note payable and accrued interest</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,318</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Realized loss on sale of BioTime shares</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">397</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The accompanying notes are an integral part of these financial statements.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">63</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE CORPORATION</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1. Organization, Description of the Business and Liquidity</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte Corporation ("OncoCyte") is a developer of novel, non-invasive blood-based tests for the early detection of cancer. It is focused on developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers that are differentially expressed in certain types of cancers. OncoCyte efforts have focused on developing diagnostic tests for use in detecting lung, bladder, and breast cancers. During 2017, OncoCyte devoted substantially all of its efforts on developing its lung cancer diagnostic test DetermaVu&#8482;.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte was incorporated in 2009 in the state of California and at December 31, 2016 was a majority-owned subsidiary of BioTime, Inc. ("BioTime"), a publicly traded, clinical-stage, biotechnology company targeting degenerative diseases primarily in the fields of ophthalmology, aesthetics and cell/drug delivery. Beginning on February 17, 2017, OncoCyte ceased to be a subsidiary of BioTime for financial reporting purposes when BioTime's percentage ownership of outstanding OncoCyte common stock declined below 50% as a result of the issuance of additional OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants (see Note 6).</div>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Liquidity</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For all periods presented, OncoCyte generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants, warrant exercises, a bank loan (see Note 5), and sales of BioTime common shares that OncoCyte holds as available-for-sale securities. BioTime has also provided OncoCyte with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4</font>. OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $54.7 million and $35.3 million as December 31, 2017 and 2016, respectively.</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017, OncoCyte had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to OncoCyte on or prior to April 30, 2018 (see Note 10), OncoCyte believes it has sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if it determines to devote more resources to the development or initial commercialization efforts for its lung cancer test during that time frame.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2. Summary of Significant Accounting Policies</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Basis of presentation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Prior to February 17, 2017, BioTime consolidated the results of OncoCyte into BioTime's consolidated results based on BioTime's ability to control OncoCyte's operating and financial decisions and policies through its majority ownership of OncoCyte common stock. BioTime owned 51.1% of the outstanding common stock of OncoCyte at December 31, 2016. Beginning on February 17, 2017, BioTime's percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of "control" of OncoCyte under GAAP and, as a result, BioTime deconsolidated OncoCyte's financial statements from BioTime's consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP with effect from February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime's retained share ownership in OncoCyte, which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">64</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte&#8217;s operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reverse stock split</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Use of estimates</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to the going concern assessments of OncoCyte financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Going concern assessment</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">With the implementation of FASB&#8217;s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Fair value measurements</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Fair Value Measurements</font> (&#8220;ASC 820&#8221;). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">65</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zddd9a600d51643ed9a9444bfbc969c33" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Level 1</font> &#8211; Quoted prices in active markets for identical assets and liabilities.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z05e1cc417e534aef84f54dd902d2b400" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Level 2</font> &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z4fc4e3bfb77c445482cf0ca44947cea5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Level 3</font> &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating market rate (see Note 5).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cash and cash equivalents</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2017 and 2016, OncoCyte's cash balances totaled $7.6 million and $10.2 million, respectively.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for BioTime shares</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Investments &#8211; Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte&#8217;s financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Business Combinations</font> ("ASC 805"), transactions between entities under common control. See section <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Recent Accounting Pronouncements</font> included herein.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In 2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes. The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of $0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates or for working capital purposes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Long-lived intangible assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">66</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Equipment and furniture</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte&#8217;s results of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Impairment of long-lived assets</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset&#8217;s carrying value over its fair value is recorded. Through 2017, there have been no such impairment losses.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for warrants</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font>, then in accordance with ASC 815-40, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</font>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income taxes</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte activity for 2015, 2016, and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of OncoCyte outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning on February 17, 2017 and thereafter, OncoCyte will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte&#8217;s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte&#8217;s statements of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2017 and 2016. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2017, 2016 and 2015. OncoCyte is currently unaware of any tax issues under review.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">67</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&#8220;2017 Tax Act&#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&#8220;NOLs&#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &#8220;deemed repatriation&#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 8).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance</font>. Research and development costs are expensed as incurred.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">see Note 4</font>) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on OncoCyte&#8217;s headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stock-based compensation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Compensation &#8211; Stock Compensation</font> (&#8220;ASC 718&#8221;).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;&#160; OncoCyte adopted ASU 2016-09 beginning on January 1, 2017.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">68</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In connection with the adoption of ASU 2016-09, OncoCyte changed its accounting policies including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable.&#160; All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations.&#160; Prior to the adoption of ASU 2016-09, OncoCyte recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized either as an offset to accumulated excess tax benefits, if any, on OncoCyte&#8217;s statements of operations.&#160; An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.&#160; Because OncoCyte has a full valuation allowance for all periods presented (see Note 8) and an insignificant number of stock option exercises during the current quarter, there was no impact to OncoCyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest.&#160; Based on the nature and timing of OncoCyte&#8217;s grants, straight line expense attribution of stock based compensation for the entire award and the relatively low forfeiture rate on OncoCyte&#8217;s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not significant to OncoCyte&#8217;s financial statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. OncoCyte uses the Black-Scholes-Merton option pricing model for estimating the fair value of options granted under OncoCyte&#8217;s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Equity-Based Payments to Non-Employees</font>. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee&#8217;s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Valuation of Privately Held Company Equity Securities Issued As Compensation</font>.&#160; OncoCyte common stock began to trade publicly on the NYSE American on December 31, 2015, and since that date the fair value of OncoCyte common stock underlying stock options has been determined with reference to closing prices reported on the NYSE American.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the &#8220;simplified method&#8221; provided under<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14, including, in part, based on its own experience.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Because OncoCyte&#8217;s common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte&#8217;s stock options.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">69</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The dividend yield assumption is based on OncoCyte&#8217;s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Net loss per common share</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb2299d64b34944caaffcb22b026e452e" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(19,375</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(11,168</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(8,735</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Weighted average common shares outstanding &#8211; basic and diluted</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">30,195</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">26,529</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">21,009</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net loss per common share &#8211; basic and diluted</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.64</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9.17%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(0.42</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1.17%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1c39b7245a0947d3988b8ab2672a2884" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Stock options</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,390</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,017</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,240</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Warrants</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,779</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,246</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Segments</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte&#8217;s executive management team, as a group, represents the entity&#8217;s chief operating decision makers. To date, OncoCyte&#8217;s executive management team has viewed OncoCyte&#8217;s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte&#8217;s sole operating segment.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reclassifications</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Certain reclassifications from general and administrative expenses have been made to present sales and marketing expenses shown on the statements of operations for the years ended December 31, 2016 and 2015 to conform and be comparable to the year ended December 31, 2017 presentation. These reclassifications have been made as OncoCyte's sales and marketing expenses have increased in 2017, thus making separate presentation of those category of expenses more meaningful to the readers of this report. The reclassifications had no impact to loss from operations or net loss as reported in the statements of operations and had no impact to the statements of cash flows or to the balance sheets for any period presented.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Recent accounting pronouncements</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">70</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, <font style="FONT-STYLE: italic">Financial Instruments&#8211;Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font> (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte&#8217;s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, <font style="FONT-STYLE: italic">Leases (Topic 842)</font>, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU 2017-09, </font><font style="BACKGROUND-COLOR: #ffffff; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope of Modification Accounting</font><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. OncoCyte currently applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. OncoCyte believes the adoption of ASU 2017-09 will not have a material impact on its financial statements.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3. Selected Balance Sheet Components</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Accrued expenses and other current liabilities</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za51a05efa17c43709c278c9b132095e3" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accrued bonuses and payroll related expenses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">636</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">549</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other accrued expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">406</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">248</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accrued expenses and other current liabilities</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,042</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">797</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Intangible assets, net</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za384fc838e824906ad9add9333b02451" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,419</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,419</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated amortization</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(1,673</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(1,431</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Intangible assets, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">746</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">988</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Amortization expense amounted to approximately $242,000 annually.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">71</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Equipment and furniture, net</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z6c56e28cb41a4651be310228b93517b9" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment and furniture</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,479</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,007</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Accumulated depreciation</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(657</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(319</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Equipment and furniture, net</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">822</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">688</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Depreciation expense amounted to approximately $338,000, $145,000 and $41,000 for the years ended December 31, 2017, 2016 and 2015, respectively. During the year ended December 31, 2017 and 2016, OncoCyte entered into capital leases for laboratory equipment totaling $381,000 and $626,000, respectively (see Note 9).</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4. Related Party Transactions</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Shared Facilities and Service Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On October 8, 2009, OncoCyte and BioTime executed a Shared Facilities and Services Agreement (&#8220;Shared Facilities Agreement&#8221;). Under the terms of the Shared Facilities Agreement, BioTime will allow OncoCyte to use its premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime will also provide OncoCyte with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime charges OncoCyte a Use Fee for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates costs incurred, as applicable, to OncoCyte, such costs include services of Bio Time employees, equipment, insurance, lease, professional, software, supplies and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime (collectively &#8220;Use Fees&#8221;). BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime has not elected to charge this markup since the inception of the Shared Facilities Agreement and through the end of 2015. Beginning in 2016, BioTime commenced charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2017 BioTime has not charged OncoCyte any interest.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers thereof to invoice OncoCyte directly.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement otherwise is terminated under another provision of the agreement.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">72</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the aggregate, BioTime allocated and charged such Use Fees to OncoCyte&#160;of $268,000, $790,000 and $595,000 included in general and administrative expenses and&#160;Use Fees of $1.1 million, $691,000 and $565,000 included in research and development expenses,&#160;during the years ended December 31, 2017, 2016 and 2015, respectively.&#160;Use Fees of $213,000 in sales and marketing expenses are included in OncoCyte&#8217;s statements of operations during the year ended December 31, 2017. There were no Use Fees allocated to sales and marketing expenses during 2016 and 2015.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017 and 2016, OncoCyte had $2.1 million and $2.9 million outstanding and payable to BioTime and affiliates included in current liabilities in connection with the costs incurred under the Shared Facilities Agreement. Since these amounts are due and payable in 30 days of being invoiced, the payables are classified as current liabilities for all periods presented.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The minimum fixed payments due under the Shared Facilities Agreement are approximately $131,000 per month.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5. <font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Loan Payable to Silicon Valley Bank</font></div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank (the "Bank") pursuant to which OncoCyte borrowed $2.0 million on March 23, 2017. Payments of interest only on the principal balance were due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal of approximately $67,000 plus interest are due and payable. The outstanding principal balance of the loan bears interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of December 31, 2017, the latest published prime rate plus 0.75% was 5.25% per annum.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The outstanding principal amount plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. OncoCyte accrued the $116,000 final payment fee included in the loan payable as a deferred financing cost on March 23, 2017 draw date.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to&#160; 2.0% of the outstanding principal balance if prepaid after February 21, 2018 but not later than February 21, 2019, or 1.0% of the outstanding principal balance if prepaid after February 21, 2019. Any amounts borrowed and repaid may not be reborrowed.&#160; There are no amounts available to be borrowed on the Loan Agreement.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an "Event of Default" as defined in the Loan Agreement occurs and is not cured within any applicable cure period. Upon the occurrence and during the continuance of an Event of Default, all obligations due to the Bank will bear interest at a rate per annum which is 5% above the then applicable interest rate. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte's business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and copies of filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE American. OncoCyte's obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns. Accordingly, if an Event of Default were to occur and not be cured, the Bank could foreclose on its security interest in the collateral. OncoCyte was in compliance with the Loan Agreement as of the filing date of this Report.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under the provisions of the Loan Agreement, as consented by the Bank on October 26, 2017, any proceeds received by OncoCyte from sales of BioTime shares may be used by OncoCyte to fund its operations.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Bank Warrants</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On February 21, 2017 and in conjunction with the $2.0 million becoming available under the Loan Agreement, OncoCyte issued common stock purchase warrants to the Bank (the "Bank Warrants") entitling the Bank to purchase shares of OncoCyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase 8,247 shares of OncoCyte common stock at an exercise price of $4.85 per share, through February 21, 2027. On March 23, 2017, in conjunction with borrowing $2 million, the Bank was issued warrants to purchase an additional 7,321 shares at an exercise price of $5.46 per share, through March 23, 2027. The Bank may elect to exercise the Bank Warrants on a "cashless exercise" basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">73</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Bank Warrants are classified as equity since, among other factors, they are not mandatorily redeemable, cannot be settled in cash or other assets and require settlement by issuing a fixed number of shares of common stock of OncoCyte. OncoCyte determined the fair value of the Bank Warrants using the Black-Scholes option pricing model to be approximately $62,000, which was recorded as a deferred financing cost against the loan payable balance. Aggregate deferred financing costs of $196,000, recorded against the loan payable balance, are amortized to interest expense over the term of the loan using the effective interest method. As of December 31, 2017, unamortized deferred financing costs were $113,000.</div>

<div><br>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Future Cash Payments of Loan Payable</div>

<div><br>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, principal and interest payments due on the loan payable in each of the next three years are as follows (in thousands):</div>

<div>&#160;</div>

<div>
<table style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z85ce081266b54f2fad54faf50d446006" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ending</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loan</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Payments</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2018</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">876</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2019</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">835</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2020</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">386</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total payments of principal and interest</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,097</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Less: amounts representing interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(114</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total payments of principal before deferred financing costs</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,983</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Less: deferred financing costs</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(113</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total loan payable, net of deferred financing costs</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,870</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div><br>
 &#160;</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6. Shareholders&#8217; Equity</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Preferred Stock</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte is authorized to issue up to 5,000,000 shares of no par value preferred stock. As of December 31, 2017, no preferred shares were issued or outstanding.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Common Stock</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has up to 50,000,000 shares of no par value common stock authorized. The holders of OncoCyte&#8217;s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of OncoCyte common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of OncoCyte outstanding preferred shares, if any.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of OncoCyte stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.</div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Issuance of Common Stock and Warrants</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the &#8220;2016 Warrants&#8221;), at a price of $3.25 per unit (the &#8220;Offering&#8221;). The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime. At the close of the Offering, <font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">BioTime&#8217;s percentage ownership of the outstanding common stock of OncoCyte declined to 51.2% through which BioTime retained a controlling interest in OncoCyte</font>. OncoCyte received $9.8 million in net proceeds after discounts, commissions and expenses from the Offering. OncoCyte will use the proceeds from the Offering for funding its operations or for working capital or other general corporate purposes.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">74</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to the terms of the Purchase Agreements, OncoCyte agreed (i) to file a resale registration statement with the Securities and Exchange Commission, or SEC, to register for sale under the Securities Act of 1933, as amended, or the Securities Act, the shares of OncoCyte common stock sold in the Offering and the shares of OncoCyte common stock, or Warrant Shares, that may be issued if the Warrants are exercised, and (ii) to use commercially reasonable efforts to maintain the effectiveness of the resale registration statement under the Securities Act until the earlier of (a) the date that all shares of its common stock covered by the Resale Registration Statement have been sold or can be sold publicly without restriction or limitation under Rule 144 (including, without limitation, the requirement to be in compliance with Rule 144(c)(1)), or (b) August 29, 2018.<br>
 &#160;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2016 Warrants and New Warrants</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The 2016 Warrants have an exercise price of $3.25 per Warrant Share, and may be exercised for five years from October 17, 2016, the date the 2016 Warrants became exercisable. The 2016 Warrants may be exercised on a net &#8220;cashless exercise&#8221; basis, meaning that the value of a portion of Warrant Shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if the Resale Registration Statement is not effective when and as required by the Purchase Agreements. The exercise price and the number of Warrant Shares will be adjusted to account for certain transactions, including stock splits, dividends paid in common stock, combinations or reverse splits of common stock, or reclassifications of common stock.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Under certain provisions of the 2016 Warrants, in the event of a Fundamental Transaction, as defined in the 2016 Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the 2016 Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of 2016 Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the 2016 Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration as the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte is not required to net cash settle the 2016 Warrants under any circumstance. </font>OncoCyte considered the guidance in ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. Since solely an acquirer, and not OncoCyte itself, may be required to net cash settle the 2016 Warrants in the event of a Fundamental Transaction, the 2016 Warrants are classified as equity.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On February 17, 2017, certain OncoCyte investors exercised 2016 Warrants to acquire 625,000 shares of common stock at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the "Warrant exercise"). In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the "New Warrants"). Certain investors received New Warrants to purchase 200,000 shares of common stock at an exercise price of $5.50 per share and one investor received New Warrants to purchase 212,500 shares of common stock at an exercise of $3.25 per share. The New Warrants are exercisable at any time for five years from February 17, 2017.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The New Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the New Warrants was treated as an inducement offer to certain shareholders to exercise their 2016 Warrants. Accordingly, the fair value of the New Warrants, determined using the </font>Black-Scholes option pricing model,<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> approximating $1.1 million was recognized by OncoCyte as a noncash charge to shareholder expense included in general and administrative expenses and a corresponding increase to equity on February 17, 2017, the issuance date.</font></div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On July 21, 2017, OncoCyte entered into three forms of Warrant Exercise Agreements (each, an "Exercise Agreement") with certain holders of the 2016 Warrants providing for the cash exercise of their 2016 Warrants and the issuance of new warrants (the "July 2017 Warrants") to them.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to one form of Exercise Agreement, two investors exercised 2016 Warrants to purchase 226,923 shares of OncoCyte's common stock at the exercise price of $3.25 per share, and OncoCyte issued to them July 2017 Warrants expiring five years from the date of issue, to purchase 226,923 shares of common stock at an exercise price of $5.50 per share.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to a second form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 540,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor a July 2017 Warrant, expiring five years from the date of issue, to purchase 270,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> commercially reasonable efforts to </font>file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">75</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to a third form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 1,000,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor (i) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $5.50 per share, and (ii) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use commercially reasonable efforts to file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><br>
 &#160;</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the aggregate, upon the exercise of 2016 Warrants under the Exercise Agreements, OncoCyte received gross proceeds of approximately $5.74 million and issued July 2017 Warrants to purchase 1,496,923 shares of common stock at a weighted average price of $4.34 per share.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The July 2017 Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the July 2017 Warrants is treated as an inducement offer to certain investors to exercise their 2016 Warrants. Accordingly, the fair value of the July 2017 Warrants, determined to be approximately $3.0 million using the </font>Black-Scholes option pricing model, <font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">was recorded as a noncash charge to shareholder expense included in general and administrative expenses, and a corresponding increase was recorded to equity on July 21, 2017, the issuance date.</font></div>

<div><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, OncoCyte has an aggregate of 2,779,221 warrants issued and outstanding at exercise prices ranging from $3.25 and $5.50 per warrant.</div>

<div><br>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stock Option Exercises</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During the years ended December 31, 2017 and 2016, 323,019 and 99,496 shares of common stock were issued upon the exercise of stock options, from which OncoCyte received $610,000 and $218,000 in cash proceeds, respectively.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7. Stock-based Compensation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stock Option Plan</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has adopted a 2010 Stock Option Plan (the &#8220;Plan&#8221;) under which 5,200,000 shares of common stock were made available for the grant of stock options or the sale of restricted stock. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As discussed in Note 4, OncoCyte may grant stock options to employees of BioTime, or employees of other BioTime subsidiaries, who perform services for OncoCyte. OncoCyte records stock-based compensation expense in the accompanying statements of operations for those services performed in the periods presented.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Stock Options</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Options granted under the Plan may be either &#8220;incentive stock options&#8221; within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">76</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The options&#8217; exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant&#8217;s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Options Granted</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, 1,384,198 shares were available for future grants under the Plan.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z345915789f6e43ba8a87a9bde79cbfd1" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">for Grant</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise Price</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total at January 1, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,757</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,240</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.03</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options granted</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(962</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">962</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.58</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options exercised</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(100</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.19</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options forfeited, cancelled or expired</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">85</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(85</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.00</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total at December 31, 2016</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">880</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,017</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.52</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Increase in pool</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,200</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options granted</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(896</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">896</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">5.17</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options exercised</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(323</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1.89</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Options forfeited, cancelled or expired</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">200</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(200</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.11</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total at December 31, 2017</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,384</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3,390</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.25</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Exercisable at December 31, 2017</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,835</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.48</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">At December 31, 2017 and 2016, OncoCyte had approximately $1.6 million and $2.7 million, respectively, of total unrecognized compensation expense related to the Plan that will be recognized over a weighted-average period of approximately 2.5 and 2.4 years, respectively.</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1e5be6636bc54e0d9126372fd0bf4629" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="10" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">668</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">312</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">456</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">General and administrative</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">841</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">610</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,359</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Sales and marketing</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">121</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 64%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total stock-based compensation expense</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,630</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">922</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,815</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">77</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The assumptions that were used to calculate the grant date fair value of OncoCyte&#8217;s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zba1e45ac5bc741e283af35179949dfeb" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="13" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Expected life (in years)</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">6.15</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">6.21</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">6.83</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom"></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Risk-free interest rates</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">2.03</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">1.46</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">1.87</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Volatility</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">66.01</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">64.64</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">74.15</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="BACKGROUND-COLOR: #ffffff"></font>

<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Dividend yield</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">-</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">-</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom"><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</font></td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">-</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: normal">&#160;</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">With the adoption of ASU 2016-09, effectively January 1, 2017, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2017, 2016 and 2015, may have been significantly different.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8. Income Taxes</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">U.S. Federal Income Tax Reform</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On December 22, 2017, in response to the enactment of the 2017 Tax Act (see Note 2), the SEC staff issued SAB 118 that allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. OncoCyte is currently analyzing the 2017 Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures, including and changes to OncoCyte&#8217;s existing deferred tax balances, for the year ended December 31, 2017.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte remeasured certain deferred tax assets and liabilities based on the enacted tax rate at which they are expected to reverse in the future. The estimated tax affected amount related to the remeasurement of these balances was a reduction of OncoCyte&#8217;s net deferred tax assets by $6.8 million with a corresponding decrease in the valuation allowance by the same amount, recognized as of December 31, 2017, as discussed below.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2017, the federal portion of the deferred tax assets and liabilities for 2017 were re-rated from 34 percent to 21 percent pursuant to the 2017 Tax Act.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has filed standalone U.S. federal income tax returns since its inception. For California purposes, OncoCyte&#8217;s activity for 2015 and 2016 was included in BioTime&#8217;s California Combined tax return. As a result of OncoCyte&#8217;s deconsolidation from BioTime on February 17, 2017, (see Note 1), OncoCyte will file a separate California return for tax year 2017.&#160; The provision for state income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The deferred tax assets, including the operating loss and credit carryforwards, generated by OncoCyte, will remain with OncoCyte.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands):</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z041819a0680341d4b83810d7f083e9bb" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Deferred liabilities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Available-for-sale securities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(761</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total deferred tax liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(761</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Deferred tax assets:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net operating loss carryforwards</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,414</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">11,730</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development credit carryforwards</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2,141</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,765</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Patents and fixed assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">268</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">179</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Stock-based compensation and accrued payroll</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,260</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1,041</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Valuation Allowance</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(15,083</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(13,954</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total deferred tax assets</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">761</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Net deferred tax asset (liability)</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">78</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Due to losses incurred for all periods presented, OncoCyte did not record any provision or benefit for income taxes.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z337fce724c5a4c1a98d6f393a63a3fa9" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="13" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ended December 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2017</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Computed tax benefit at federal statutory rate</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">34</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">34</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">34</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Re-rate of federal net deferred tax assets</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(35</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">0</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">0</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Permanent differences</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(8</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(1</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(9</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">State tax benefit</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">3</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">2</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">15</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Research and development credits</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">1</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">2</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">2</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Other</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">0</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">7</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">3</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">Adjust basis for available-for-sale-securities</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">11</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">%</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;0</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">%&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: 9pt; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">0</td>
<td style="BORDER-BOTTOM-COLOR: ; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">%&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Change in valuation allowance</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(6</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(44</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">(45</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)%</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 61%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">-</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">-</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 6%; VERTICAL-ALIGN: bottom" valign="bottom">-</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">%</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As of December 31, 2017, OncoCyte has net operating loss carryforwards of approximately $<font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">47.8 million </font>for U.S. federal income tax purposes and <font style="BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$15.6 million </font>for state income tax purposes. Federal net operating loss carryforwards expire in varying amounts from 2030 and 2037, and state carryforwards expire from 2029 and 2037. In addition, as of December 31, 2017, OncoCyte has research and development credit carryforwards for federal and state purposes of $1.0 million and $1.1 million, respectively. The federal credits will expire between 2030 and 2037, while the state credits have no expiration.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">During 2017, OncoCyte sold 266,442 BioTime common shares, in at-the-market transactions which resulted in a taxable loss of approximately $301,000.&#160; No BioTime common shares were sold in 2016. During 2015, OncoCyte sold 259,712 BioTime common shares in at-the-market transactions which resulted in a taxable loss of approximately $397,000.</div>

<br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $1.1 million and $5.1 million for the years ended December 31, 2017 and 2016, respectively.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Other Income Tax Matters</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Internal Revenue Code Section 382 places a limitation (&#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these &#8220;change in ownership&#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. In general, OncoCyte is no longer subject to tax examination by major taxing authorities for years before 2013. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9. Commitments and Contingencies</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has certain commitments other than those under the Shared Facilities and Services Agreement described in Note 4.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">79</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Master Lease Line Agreement</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On April 7, 2016, OncoCyte entered into a Master Lease Line Agreement ("Lease Agreement&#8221;) with an unrelated financing company for the purchase and financing of certain equipment. OncoCyte may use up to $881,000, as amended, for purchases of equipment financed under the Lease Agreement through April 2017. Each lease schedule OncoCyte enters into under Lease Agreement must be in minimum increments of $50,000 each with a 36-month lease term, collateralized by the equipment financed under the lease schedule. Each lease schedule requires a deposit for the first and last payment under that schedule. Monthly payments will be determined using a lease factor approximating an interest rate of 10% per annum. At the end of each lease schedule under Lease Agreement, assuming no default has occurred, OncoCyte may either return the equipment financed under the schedule for a restocking fee of 7.5% of the original cost of the equipment or purchase the equipment from the financing company at a fair value not less than 12.5% of the original cost of the equipment.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On April 7, 2016, OncoCyte entered into a lease schedule under the Lease Agreement (&#8220;Lease Schedule No. 1&#8221;) for certain equipment costing approximately $435,000 applied against the lease line, requiring payments of $14,442 per month over 36 months. In December 2016, OncoCyte entered into another lease schedule (&#8220;Lease Schedule No. 2&#8221;) for certain equipment costing approximately $161,000, requiring payments of $5,342 per month over 36 months. In April 2017, OncoCyte entered into a third and final lease schedule (&#8220;Lease Schedule No. 3&#8221;) for certain equipment costing approximately $285,000, requiring payments of $9,462 per month over 36 months. After this last tranche, the Lease Agreement was closed and has no remaining financing available.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has accounted for these leases as a capital lease in accordance with ASC 840,<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> Leases</font>, due to the net present value of the payments under the lease approximating the fair value of the equipment at inception of the lease. The payments under the lease schedules will be amortized to capital lease obligations and interest expense using the interest method at an imputed rate of approximately 10% per annum.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On May 11, 2017, OncoCyte entered into another Master Lease Line Agreement ("Lease Agreement No. 2") with the same finance company above and similar terms. OncoCyte may use up to $900,000 for purchases of equipment financed under Lease Agreement No. 2 through October 28, 2018. As of December 31, 2017, $820,000 under Lease Agreement No. 2 was available to OncoCyte.</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Future minimum annual lease payments under </font>Lease Schedule No.&#8217;s 1, 2, and 3 above <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for the years ending after December 31, 2017 are as follows (in thousands):</font></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8c254dc3c3da44c4957df84db6bf6df2" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year Ending</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2" nowrap="nowrap">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital Lease</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Payments</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2018</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">383</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2019</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">248</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">2020</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">59</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Total minimum lease payments</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">690</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 16.2pt; FONT-SIZE: 10pt">Less amounts representing interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(63</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 5%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 33%; VERTICAL-ALIGN: middle">
<div style="TEXT-INDENT: -7.2pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 7.2pt; FONT-SIZE: 10pt">Present value of net minimum lease payments</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">627</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Wistar License Agreement</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte has entered into a License Agreement with The Wistar Institute of Anatomy and Biology (&#8220;Wistar&#8221;) that entitles OncoCyte to use certain patents, know-how and data belonging to Wistar.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Under the License Agreement, OncoCyte has obtained an exclusive, worldwide license under certain patents, and under certain know-how and data ("Technical Information") belonging to Wistar, for use in the field of molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.&#160;OncoCyte has the right to grant sublicenses of the licensed patents and Technical Information subject to certain conditions.</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte paid Wistar an initial license fee and will pay Wistar royalties on &#8220;net sales&#8221; of &#8220;licensed products,&#8221; as such terms are defined in the License Agreement. The royalty rates will range from 3% to 5% depending upon the amount of cumulative net sales. The amount of royalties payable to Wistar will be reduced by the amount of any royalties that OncoCyte must pay to any third parties on the sale of the licensed products, but subject to a maximum reduction of 50%. The obligation to pay royalties to Wistar will terminate on a licensed product by-licensed product and country-by-country basis until the later of (i) the date a valid claim of a licensed patent covering the licensed product no longer exists, or (ii) the tenth (10th) anniversary of the first commercial sale of the licensed product in each country.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte will pay Wistar a minimum annual royalty each year, which in each case will be credited against total royalties due during the year in which the minimum royalty is paid. OncoCyte will also be obligated to pay Wistar an annual license maintenance fee in the mid-five figures.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte will also pay Wistar a portion of any non-royalty sublicensing income that OncoCyte may receive from any sub-licensee. Non-royalty sublicensing income will include any consideration received from a sub-licensee for granting the sublicense, but excluding royalties, the fair market value of any equity or debt securities sold to a sub-licensee, and any payments received from a sub-licensee for any related research conducted by OncoCyte for the sub-licensee.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte also will pay Wistar (a) milestone payments upon the occurrence of certain milestone events in the development and commercialization of a licensed product, and (b) all past or ongoing costs incurred or to be incurred by Wistar, including government fees and attorneys' fees, in the course of prosecuting the licensed patents.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte has agreed to use commercially reasonable diligent efforts, directly or through sub-licensees, to develop and commercialize licensed products. OncoCyte has agreed that it or a sub-licensee will commence commercial sale of a licensed product by a specified date. If sales of a licensed product do not commence by the specified date, OncoCyte may purchase up to three one-year extensions of the deadline by paying Wistar a designated fee for the applicable extension.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte has agreed to indemnify Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel and staff from and against certain claims and liabilities related to the License Agreement and development, manufacture and sale of licensed products, excluding liabilities that result from or arise out of an indemnified party's gross negligence or willful misconduct.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">Wistar has the right to terminate the License Agreement, subject to certain notice and cure periods and <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">force majeure</font> delays in certain cases, if any of the following occur:&#160; (a) OncoCyte fails to pay any amount payable to Wistar; (b) OncoCyte materially breaches any covenant or agreement or any continuing representation or warranty contained in the License Agreement; (c) OncoCyte becomes subject to certain bankruptcy or insolvency events, (d) OncoCyte dissolves or ceases operations, (e) OncoCyte or any of its affiliates or sub-licensees or affiliates of any our sub-licensees challenges the validity, patentability, scope, construction, enforceability, non-infringement, or Wistar's ownership of any issued patent comprising the licensed patents, or assists any third party in any such challenge; or (f) OncoCyte fails to fulfill its product development and commercialization diligence obligations and related performance milestones.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 0.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 0.1pt">OncoCyte may terminate the License Agreement, with or without cause, upon the passage of a specified period of time after giving Wistar written notice of termination.</div>

<div>&#160;</div>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Litigation &#8211; General</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When OncoCyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, OncoCyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, OncoCyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. OncoCyte is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Tax Filings</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes OncoCyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the financial statements.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">80</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Contracts</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte has entered into employment contracts with certain executive officers. Under the provisions of the contracts, OncoCyte may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indemnification</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In the normal course of business, OncoCyte may provide indemnification of varying scope under OncoCyte&#8217;s agreements with other companies or consultants, typically OncoCyte&#8217;s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, OncoCyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of OncoCyte&#8217;s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to OncoCyte&#8217;s diagnostic tests. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments OncoCyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, OncoCyte has not been subject to any claims or demands for indemnification. OncoCyte also maintains various liability insurance policies that limit OncoCyte&#8217;s financial exposure. As a result, OncoCyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, OncoCyte has not recorded any liabilities for these agreements as of December 31, 2017 and 2016.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10. Subsequent Events</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">On March 28, 2018, OncoCyte entered into a securities purchase agreement with two accredited investors. The agreement provides for the private placement of 7,936,508 shares of OncoCyte's common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, OncoCyte has received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common stock, and one of the investors irrevocably committed in the agreement to pay to OncoCyte an additional $2.0 million on or prior to April 30, 2018 for the purchase of an additional 1,587,302 shares of common stock. The agreement contains certain registration rights. The investors are existing security holders of OncoCyte, including Broadwood Partners, L.P., which beneficially owns more than 5% of OncoCyte's outstanding common stock.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">81</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf448c04306fd439485fdb61de65450d7" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item9."><!--Anchor--></a>Item 9.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ChangesinandDisagreements"><!--Anchor--></a>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Not applicable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdb714d1c90334a4d9b883bfdf3d8395a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item9A."><!--Anchor--></a>Item 9A.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ControlsandProcedures"><!--Anchor--></a>Controls and Procedures</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Evaluation of Disclosure Controls and Procedures</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">It is management&#8217;s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule 13a-15 under the Exchange Act. Our management, including our principal executive officer and our principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end of our fourth quarter. Following this review and evaluation<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">,</font> management collectively determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) is accumulated and communicated to management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Changes in Internal Control over Financial Reporting</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting that occurred during the period covered by this Annual Report on Form 10-K that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Management&#8217;s Report on Internal Control over Financial Reporting</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f), is a process designed by, or under the supervision of, our principal executive officer, our principal operations officer, and our principal financial officer, and effected by our Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zea9d18fdccd14b8f9c13037766f9d239" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1c772f62b9f449d0a00a257ab4c93263" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze045eab15db341aa828769907925ec8a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 18pt; FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#183;</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. </div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2017, based on criteria established in the 2013 Internal Control - Integrated Framework issued by COSO. Based on this assessment, management believes that, as of that date, our internal control over financial reporting was effective.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z509e27e9239b487c8d996c0f75bc8f56" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item9B."><!--Anchor--></a>Item 9B.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="OtherInformation"><!--Anchor--></a>Other Information</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">82</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART III</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb00f4eb17221459b83c30f8905f0faa3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item10."><!--Anchor--></a>Item 10.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="DirectorsExecutiveOfficer"><!--Anchor--></a>Directors, Executive Officers, and Corporate Governance</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The name, age, and background of each of our directors are contained under the caption &#8220;Election of Directors&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and are incorporated herein by reference. Information about our executive officers, committees of the Board of Directors, and compensation of directors is reported under the caption &#8220;Corporate Governance&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">We have a written Code of Ethics that applies to our principal executive officer, our principal financial officer and accounting officer, our other executive officers, and our directors. The purpose of the Code of Ethics is to promote (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with or submit to the Securities and Exchange Commission and in our other public communications; (iii) compliance with applicable governmental rules and regulations; (iv) prompt internal reporting of violations of the Code of Ethics to an appropriate person or persons identified in the Code; and (v) accountability for adherence to the Code. A copy of our Code of Ethics has been posted on our internet website and can be found at<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><u> www.oncocyte.com</u></font>. If we amend or waive a provision of our Code of Ethics that applies to our chief executive officer or chief financial officer, we will post the amended Code of Ethics or information about the waiver on our internet website.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information about our compliance with Section 16(a) of the Securities Exchange Act of 1934 is reported under the caption &#8220;Compliance with Section 16(a) of the Securities Exchange Act of 1934&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z07902364c3db43dfb02df1ff8a4505c7" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item11."><!--Anchor--></a>Item 11.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ExecutiveCompensation"><!--Anchor--></a>Executive Compensation</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information on compensation of our executive officers is reported under the caption &#8220;Executive Compensation&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z8c410d1a6af74c08a8334933c7f12af5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item12."><!--Anchor--></a>Item 12.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SecurityOwnershipofCertai"><!--Anchor--></a>Security Ownership of Certain Beneficial Owners and Management, and Related Stockholder Matters</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information on the number of common shares of OncoCyte beneficially owned by each shareholder known by us to be the beneficial owner of 5% or more of our common shares, and by each director and named executive officer, and by all directors and named executive officers as a group, is contained under the caption &#8220;Principal Shareholders&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z65dec16cd74e49d78b47427d427afc2a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item13."><!--Anchor--></a>Item 13.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="CertainRelationshipsandRe"><!--Anchor--></a>Certain Relationships and Related Transactions, and Director Independence</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information about transactions with related persons; review, and approval or ratification of transactions with related persons; and director independence is reported under the caption &#8220;Election of Directors&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9512a158825946f8834f43615f44db47" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item14."><!--Anchor--></a>Item 14.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="PrincipalAccountingFeesan"><!--Anchor--></a>Principal Accounting Fees and Services</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information about our Audit Committee&#8217;s pre-approval policy for audit services, and information on our principal accounting fees and services is reported under the caption &#8220;Ratification of the Selection of Our Independent Auditors&#8221; in our Proxy Statement for our 2018 Annual Meeting of Shareholders, and is incorporated herein by reference.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">83</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART IV</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd1471a234f0048f6ba08f27952a3db17" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item15."><!--Anchor--></a>Item 15.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="ExhibitsFinancialStatemen"><!--Anchor--></a>Exhibits, Financial Statement Schedules</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb5596ea114034c7c98a91f9b3c257f67" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(a-1)</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Financial Statements.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">The following financial statements of OncoCyte Corporation are filed in the Form 10-K:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Balance Sheets</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Statements of Operations</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Statements of Comprehensive Loss</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Statements of Shareholders' Equity (Deficit)</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Statements of Cash Flows</div>

<div><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc13ac2f923554085af60d178368815f6" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 8.49%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Numbers</div>
</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 90%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit Description</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex3_1.htm">3.1</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Articles of Incorporation with all amendments<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex3_2.htm">3.2</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top"></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">By-Laws, as amended<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115045227/ex4_1.htm">4.1</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Specimen of Common Stock Certificate <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116078067/ex4_1.htm">4.2</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of August 2016 Warrant <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(5)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009369/ex4_3.htm">4.3</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of 2017 Warrant, Exercise Price $3.25 <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(7)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009369/ex4_4.htm">4.4</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of 2017 Warrant, Exercise Price $5.50 <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(7)</sup></div>
</td>
</tr>

<tr style="HEIGHT: 13px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009369/ex4_5.htm">4.5</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Silicon Valley Bank Warrant <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(7)</sup></div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex4-1.htm">4.6</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant, Exercise Price $5.50; five-year term <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex4-2.htm">4.7</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant, Exercise Price $3.25, five-year term <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; FONT-FAMILY: 'Times New Roman'; VERTICAL-ALIGN: top">
<div><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex4-3.htm">4.8</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant, Exercise Price $3.25, two-year term <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex4-4.htm">4.9</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant, Exercise Price $5.50, two-year term <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_1.htm">10.1</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Shared Facilities Agreement, dated October 8, 2009 between OncoCyte Corporation and BioTime, Inc. <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_4.htm">10.2</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of Director/Consultant Option Agreement</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_3.htm">10.3</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of Employee Incentive Stock Option Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_6.htm">10.4</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Agreement, dated June 15, 2015, between OncoCyte Corporation and William Annett<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_7.htm">10.5</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Agreement, dated August 1, 2015, between OncoCyte Corporation and Kristine Mechem<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_8.htm">10.6</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Registration Rights Agreement dated October 15, 2009<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_9.htm">10.7</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Amendment of Registration Rights Agreement, dated August 23, 2011<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 90%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115042557/ex10_10.htm">10.8</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 2%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 90%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Second Amendment of Registration Rights Agreement, dated May 8, 2015<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top"> (1)</sup></div>
</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">84</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5d286d2768a9499a9961abd1b580fea1" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036115045227/ex10_20.htm">10.9</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Third Amendment to Registration Rights Agreement, dated November 16, 2015 <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(2)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116059543/ex10_21.htm">10.10</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment) <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(3)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0e4c833e8f1649bda8bdc9811be1aaba" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116059543/ex10_22.htm">10.11</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">First Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(3)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116075892/ex10_1.htm">10.12</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Second Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(4)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116078067/ex10_1.htm">10.13</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of OncoCyte Corporation Securities Purchase Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(5)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036116078067/ex10_2.htm">10.14</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Alternate Form of OncoCyte Corporation Securities Purchase Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(5)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009369/ex10_26.htm">10.15</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Agreement, dated November 1, 2016, between OncoCyte Corporation and Lyndal Hesterberg <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(7)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009201/ex10_1.htm">10.16</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of Warrant Exercise Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(6)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009201/ex10_2.htm">10.17</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of Alternate Warrant Exercise Agreement <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(6)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117009369/ex10_29.htm">10.18</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Loan and Security Agreement, dated February 21, 2017, between OncoCyte Corporation and Silicon Valley Bank <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(7)</sup></div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000114036117017245/ex10_4.htm">10.19</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Termination and Release Agreement, dated February 27, 2017, between OncoCyte Corporation and Karen Chapman <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(8)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217007389/ex4-2.htm">10.20</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2017 Amendment to 2010 Stock Option Plan <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(9)</sup></div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex10-1.htm">10.21</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant Exercise Agreement (July 2017 Warrant for 100% of shares received on exercise of Original Warrant, at $5.50 exercise price with five-year term) <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex10-2.htm">10.22</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant Exercise Agreement (July 2017 Warrant for 50% of shares received on exercise of Original Warrant, at $3.25 exercise price with five-year term) <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1642380/000149315217008171/ex10-3.htm">10.23</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Form of July 2017 Warrant Exercise Agreement (July 2017 Warrant for 50% of shares received on exercise of Original Warrant, at $3.25 exercise price with two-year term, and July 2017 Warrant for 50% of shares received on exercise of Original Warrant, at $5.50 exercise price with two-year term) <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">(10)</sup></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top"><a href="ex10_24.htm">10.24</a></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Agreement, dated November 15, 2017, between OncoCyte Corporation and Mitchell Levine*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top"><a href="ex10_25.htm">10.25</a></td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employment Agreement, dated August 31, 2017, between OncoCyte Corporation and Michael Vicari*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="ex23_1.htm">23.1</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Consent of OUM &amp; Co. LLP*</font></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="ex31.htm">31</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Rule 13a-14(a)/15d-14(a) Certification<font style="BACKGROUND-COLOR: #cceeff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">*</font></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><a href="ex32.htm">32</a></div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Section 1350 Certification *</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Interactive Data Files</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.INS</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Instance Document*</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.SCH</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Taxonomy Extension Schema*</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">85</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za8135ef9ba62462ea46fe531f30340aa" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.CAL</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Taxonomy Extension Calculation Linkbase*</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.DEF</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Taxonomy Extension Definition Document*</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.LAB</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Taxonomy Extension Label Linkbase*</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.49%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 89%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 8.49%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">101.PRE</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.02%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">XBRL Taxonomy Extension Presentation Linkbase*</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0f74ad65018a4b94a38d671fe94dc361" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Form 10 12(b) filed with the Securities and Exchange Commission on November 23, 2015.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zba5c331940534bbcaf07ae26dcb9392a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(2)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Form 10 12(b) A-1 filed with the Securities and Exchange Commission on December 29, 2015.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z83474ccebcc54bc9b76b05616723b78b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(3)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z2e2a2ca215474103baf1e7d4a7ba19b3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(4)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9bb43c9bfaa94a88974ced16a796e6b5" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(5)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 29, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zaa885cb6d7b74b1ba08ce881a47b2324" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(6)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation's Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2017.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3d413c4442184d96b5c7fda18b070bc3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(7)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 27, 2017.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z9d1113fd20aa4c1ba2bf0568b98c5cce" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(8)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 28, 2017.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z847393beae7849a19cffc4925ce5ed1f" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(9)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to Registration Statement on Form S-8, File Number 333-219109 filed with the Securities and Exchange Commission on June 30, 2017.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3b22bcef2ce2413aa485626af7cd9079" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">(10)</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Incorporated by reference to OncoCyte Corporation's Current Report on Form 8-K filed with the Securities and Exchange Commission on July 26, 2017.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="TEXT-ALIGN: justify">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z1227d3e8c5bf4b22a4eed4fb62004698" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 27pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">*</td>
<td style="TEXT-ALIGN: justify; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Filed herewith.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">&#160;</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zacbac2f97fdb49019c09e9e80206f56a" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 63pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right"><a name="Item16."><!--Anchor--></a>Item 16.</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 27pt; FONT-SIZE: 10pt">None.</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">86</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div style="WIDTH: 100%" id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal"><a href="#TableofContents">Table of Contents</a></div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;LINE-HEIGHT: 1; FONT-SIZE: smaller; VERTICAL-ALIGN: text-top">nd</sup> day of April 2018.</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z120fda3f34b541f6a13ecb6b29cc9d5b" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 49.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ONCOCYTE CORPORATION</div>
</td>
<td style="WIDTH: 22%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 49.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="VERTICAL-ALIGN: top" colspan="2">&#160;</td>
<td style="WIDTH: 22%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 49.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">By:</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">William Annett</font></div>
</td>
<td style="WIDTH: 22%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 49.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">William Annett</div>
</td>
<td style="WIDTH: 22%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 49.94%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 3%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">President and Chief Executive Officer</div>
</td>
<td style="WIDTH: 22%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left"><br>
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z0855c97f789e4e6eb72f834376598750" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Signature</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Title</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Date</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">William Annett</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">President and Chief Executive Officer and Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">WILLIAM ANNETT</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(Principal Executive Officer)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Mitchell Levine</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Chief Financial Officer</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">MITCHELL LEVINE</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(Principal Financial and Accounting Officer)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Andrew Arno</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ANDREW ARNO</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Alfred D. Kingsley</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ALFRED D. KINGSLEY</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Andrew Last</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ANDREW LAST</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Aditya Mohanty</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ADITYA MOHANTY</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">/s/ <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cavan Redmond</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">April 2, 2018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">CAVAN REDMOND</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 23%; VERTICAL-ALIGN: bottom">&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">87</font></div>

<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>ex10_24.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: right">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; HEIGHT: 4px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
<font style="FONT-WEIGHT: bold">Exhibit 10.24</font><br>
</div>

<div style="TEXT-ALIGN: left">
<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">EMPLOYMENT AGREEMENT</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 45pt; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">THIS </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">EMPLO</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">YM</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ENT&#160; AGREEMENT </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">("Agreement</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">) </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">mad</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e as of&#160;Nove</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">mber 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2017 </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by and between OncoCyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Corpora</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tion </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Onco</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cyte"), </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a California </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">corpora</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tion</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Mitchell </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Le</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">("Executive").</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 45pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">E</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ngagement</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">; </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">Position and Duties</font>.</font></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; MARGIN-RIGHT: 2.15pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Onco</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cyte agrees </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">emplo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">position described on </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">E</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">xhibit A (which </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exh</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">bit </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A is </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a part of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Agreeme</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt) </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">effective </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the d</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ate of this Agreeme</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hall perform </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e dut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">fun</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tion</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">de</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sc</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ribed on Exhibit </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A and s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uch </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">other </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">dut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tive(</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s) </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hom </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">reports</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">he Boar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ma</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">determ</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">devote </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">effo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rt</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ski</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nd </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">biliti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es to the bus</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ine</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ss of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subs</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">idi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">pur</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uant </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to, and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">accorda</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nc</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">with, bu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ess </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">polici</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and procedures, as fixed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by the Board of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Director</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Policie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s"). Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">covenant</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">agrees </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">will faithfully adhere to and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">fulfill </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Po</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">li</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cies, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">includin</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g any c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ang</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Policies that may </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">b</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">made in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">future. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">may </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">pro</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">id</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d with a copy </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">emp</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">oyee </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">manual </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Ma</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nual</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">") </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">contain</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the Policies. OncoCyte may chan</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ge </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ts </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Po</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">li</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tim</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to time</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">case Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ill </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be notified of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">change</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">wr</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">itin</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">b</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">memorandum, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tter, or an update </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">revision </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employee </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">m</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; MARGIN-RIGHT: 2.6pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Performance of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Services </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ie</font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">s.</font> </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve acknow</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">edges and agrees </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">although OncoCyte does not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ave </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any subsidiaries </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Effec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve Date, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">it i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">possibl</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">O</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">coCyte wi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">organ</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ze </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">acquire one or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">more </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ub</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">idiar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">companies in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e future, which </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">m</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ay </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">-</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">owned or pa</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">owned by OncoCyte (eac</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Su</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">b</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">idi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">). </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ddition to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> performance </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rvice</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">E</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">xecut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">extent so </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">req</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uir</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte, a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">so perform </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">serv</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ices </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">fo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">on</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">mor</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subs</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">diar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">provid</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ice</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e consistent </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">with </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the kind </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">vices </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">p</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">erfo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rm</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">may </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be requ</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ir</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">perform for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">und</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r thi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ag</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ee</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">m</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">en</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t.&#160; </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">If </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive perform</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">an</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y serv</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ices for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y S</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ub</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">diary, Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hall </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">en</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">titl</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">receive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any comp</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sat</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ion </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">remun</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">eration in ad</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">di</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tio</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in li</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">eu </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">compensat</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ion </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">emuneratio</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">pro</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">id</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d und</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">this </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Agreement on account of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">such services </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">The Policie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">will gove</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rn </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's emp</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">lo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">m</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d any Subsidiar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">whic</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s aske</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">p</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ov</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">id</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e Serv</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ces. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">add</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ition</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cove</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ants and agrees </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ill </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">faithfully </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">adhere to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">fulfill </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">add</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ition</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">pol</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cies gove</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rnin</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">officers </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">mployees </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">genera</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">may </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">establi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">bo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rd </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">dir</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ectors of a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y S</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ub</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">idi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ary </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for which </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">perform</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ces, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ex</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ent </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">such pol</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">es and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">proc</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">dures differ </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">are </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ddi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tion to the Po</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">li</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">c</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s adopted </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">b</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyt</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.4pt; MARGIN-RIGHT: 17.9pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">No Conflicting </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Obligations</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">repr</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">esen</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nd </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">warra</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte that Execut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">is </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">under no </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">obligations or comm</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">it</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ments</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">whethe</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">con</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ractual or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">otherwis</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that are </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">co</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ste</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s ob</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">iga</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nde</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">this </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Agreemen</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">at wou</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">d </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">prohibit </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">co</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ntr</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">actua</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ot</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rwi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">from </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">p</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">erfo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rmin</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">duties </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">und</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">er </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">thi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Agree</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">m</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and the Policie</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">.</font></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt; MARGIN-RIGHT: 11.7pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">No Unauthorized Use </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Third Party </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Intellectual </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Property. </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ep</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ese</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s and warran</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Onco</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">at </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve w</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ill </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">di</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">clo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">co</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nn</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ection with </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uti</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ve's e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">mployment by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">an</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary, any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">patent</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tr</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ade sec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rets</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">confidential </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nformation</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ot</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">er </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">propriet</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ry information or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">int</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ll</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tual property </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">whic</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">h </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any other&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">person</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"> has </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ri</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ht</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">i</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tle </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">o</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">r int</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">re</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">st, except </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ex</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tent that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte or a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Sub</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sid</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">iar</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hold</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">va</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">lid li</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ce</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">n</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font></font>other written permission for such use from the owner(s) thereof. Executive represents and warrants to OncoCyte that Executive has returned all property and confidential information belonging to any prior employer, other than his current consulting clients.</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%2%%%-->
<div style="TEXT-ALIGN: left; MARGIN-LEFT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.7pt; MARGIN-RIGHT: 4.6pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Salary. </font>During the term of this Agreement, OncoCyte shall pay to the Executive the salary shown on Exhibit <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A. </font>Executive's salary shall be paid in equal semi-monthly installments, consistent with OncoCyte's regular salary payment practices. Executive's salary may be increased from time-to-time by OncoCyte, in OncoCyte's sole and absolute discretion, without affecting this Agreement.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.35pt; MARGIN-RIGHT: 4.95pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bonus. </font>Executive may be eligible for an annual bonus, as may be approved by the Board of Directors in its discretion, based on Executive's performance and achievement of goals or, milestones set by the Board of Directors from time to time. Executive agrees that the Board of </font>Directors of OncoCyte may follow the recommendations of the Compensation Committee of the Board of Directors of OncoCyte in determining whether to award a bonus or to establish performance goals or milestones. Executive also agrees that the Board of Directors and OncoCyte are not obligated to adopt any bonus plan, to maintain in effect any bonus plan that may now be in effect or that may be adopted during the term of Executive's employment, or to pay Executive a bonus unless a bonus is earned under the terms and conditions of any bonus plan adopted by OncoCyte or Executive attaining the bonus performance goals for Executive established by the Board of Directors or its Compensation Committee; provided, that unless otherwise provided in a bonus plan or award, a bonus shall not be earned until paid and shall not be paid unless Executive remains an employee of OncoCyte on the date of payment.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.35pt; MARGIN-RIGHT: 8.4pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Expense Reimbursements. </font>OncoCyte or a Subsidiary shall reimburse Executive for reasonable travel and other business expenses (but not expenses of commuting to his primary workplace) incurred by Executive in the performance of Executive's duties under this Agreement, subject to the Policies and procedures in effect from time to time, and provided that Executive submits supporting vouchers.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.35pt; MARGIN-RIGHT: 5.5pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Benefit Plans. </font>Executive may be eligible (to the extent Executive qualifies) to participate in certain retirement, pension, life, health, accident and disability insurance, stock option plan or other similar employee benefit plans which may be adopted by OncoCyte (or a Subsidiary) for its executive officers or other employees. OncoCyte and the Subsidiaries have the right, at any time and without any amendment of this Agreement, and without prior notice to or consent from Executive, to adopt, amend, change, or terminate any such benefit plans that may now be in effect or that may be adopted in the future, in each case without any further financial obligation to Executive; provided that </font>such unilateral change does apply to Executive in a manner different than other OncoCyte executives or employees of a comparable executive level, except for changes required by applicable federal, state, or local law, or implemented in response to any change of federal, state or local law or regulation. Any benefits to which Executive may be entitled under any benefit plan shall be governed by the terms and conditions of the applicable benefit plan, and any related plan documents, as in effect from time to time. If Executive receives any grant of stock options or stock or stock related equity awards ("Awards") under any stock option plan, stock purchase plan, or other equity incentive plan of OncoCyte or any Subsidiary (an "Equity Plan"), the terms and conditions of the Award, and Executive's rights with respect to the Award, shall be governed by (i) the terms of the Equity Plan, as the same may be amended from time to time, and (ii) the terms and conditions of any stock option agreement. stock <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">purchase agreement, or other agreement that Executive may sign or be required to sign with respect to any Award.</font></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">2</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.2pt; MARGIN-RIGHT: 2.45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Vacation; Sick Leave. </font>Executive shall be entitled&#160; to the number of days of vacation and sick leave (without reduction in compensation) during each calendar year shown on Exhibit A or as may be provided by the Policies. Executive's vacation shall be taken at such time as is consistent with the needs and Policies of OncoCyte and its Subsidiaries. All vacation days and sick leave days shall accrue annually based upon days of service. Executive's right to leave from work due to illness is subject to the Policies and the provisions of this Agreement governing termination due to disability, sickness or illness.&#160; The Policies governing the disposition of unused vacation days and sick leave days remaining at the end of OncoCyte's fiscal year shall govern whether unused vacation days or sick leave days will be paid, lost, or carried over into subsequent fiscal years.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45.65pt; MARGIN-RIGHT: 3.5pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Competitive Activities. </font>During the term of Executive's employment, and for one year thereafter, Executive shall not, for Executive or any third party, directly&#160; or indirectly employ, solicit for employment or recommend for employment any person employed by OncoCyte or any Subsidiary. During the term of Executive's employment, Executive shall not, directly or indirectly as an employee, contractor, officer, director, member, partner, agent, or equity owner, engage in any activity&#160; or business that to the best of Executive's knowledge competes with the business of OncoCyte or any Subsidiary. Executive acknowledges that there is a substantial likelihood that the activities described in this Section would (a) involve the unauthorized use or disclosure of OncoCyte's or a Subsidiary's Confidential Information and that use or disclosure would be extremely difficult to detect, and (b) result in substantial competitive harm to the business of OncoCyte or a Subsidiary. Executive has accepted the limitations of this Section as a reasonably practicable and unrestrictive means of preventing such use or disclosure of Confidential Information and preventing such competitive harm.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventions/Intellectual Property/Confidential Information</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">As used in this Agreement, "Intellectual Property" means&#160; any and all inventions, discoveries, formulas, improvements, writings, designs, or other intellectual property. Any and all Intellectual Property relating to or in any way pertaining to or connected with the systems, products, apparatus, or methods employed, manufactured, constructed, or researched by OncoCyte, or any Subsidiary, which Executive may conceive or make while performing services for OncoCyte or a Subsidiary shall be the sole and exclusive property of OncoCyte or the applicable Subsidiary and is referred to in this Agreement as OncoCyte Intellectual Property. Executive hereby irrevocably assigns and transfers to OncoCyte, or a Subsidiary, all rights, title and interest in and to all OncoCyte Intellectual Property that Executive may now or in the future have under patent, copyright, trade secret, trademark or other law, in perpetuity or for the longest period otherwise permitted by law, without the necessity of further consideration. OncoCyte and the Subsidiaries will be entitled to obtain and hold in their own name all copyrights, patents, trade secrets, trademarks and other similar registrations with respect to such OncoCyte Intellectual Property.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.2pt; MARGIN-RIGHT: 2.2pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Moral Rights. </font>To the extent allowed by law, the rights to OncoCyte Intellectual Property assigned by Executive to OncoCyte or any Subsidiary includes all rights of paternity, integrity, disclosure and withdrawal, and any other rights that may be known as or referred to as "moral rights," "artist's rights," "droit moral," or the like (collectively "Moral Rights"). To the extent Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">retains any such Moral Rights under applicable law, Executive hereby ratifies and consents to any action that may be taken with respect to such Moral Rights by or authorized by OncoCyte or a Subsidiary and agrees not to assert any Moral Rights with respect thereto. Executive shall confirm in </font>writing any such ratifications, consents, and agreements from time to time as requested by OncoCyte or Subsidiary.</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">3</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 71.85pt; MARGIN-RIGHT: 4.4pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Execution of Documents; Power of Attorney. </font>Executive agrees to execute and sign any and all applications, assignments, or other instruments which OncoCyte or a Subsidiary may deem necessary in order to enable OncoCyte or a Subsidiary, at its expense, to apply for, prosecute, and obtain patents of the United States or foreign countries for the OncoCyte Intellectual Property, or in order to assign or convey to, perfect, maintain or vest in OncoCyte or a Subsidiary the sole and exclusive right, title, and interest in and to the OncoCyte Intellectual Property. If OncoCyte or a Subsidiary is unable after reasonable efforts to secure Executive's signature, cooperation or assistance </font>in accordance with the preceding sentence, whether because of Executive's incapacity or any other reason whatsoever, Executive hereby designates and appoints OncoCyte or any Subsidiary or its designee as Executive's agent and attorney-in-fact, to act on Executive's behalf, to execute and file documents and to do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect OncoCyte's or a Subsidiary's rights in the OncoCyte Intellectual Property": Executive acknowledges and agrees that such appointment is coupled with an interest and is irrevocable.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 71.85pt; MARGIN-RIGHT: 11.8pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Disclosure of Intellectual Property. </font>Executive agrees to disclose promptly to OncoCyte or a Subsidiary all OncoCyte Intellectual Property which Executive may create or conceive solely, jointly, or commonly with others.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.55pt; MARGIN-RIGHT: 5.45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Limitations. </font>The obligations provided for by this Section 4 do not apply to any rights Executive may have acquired in connection with Intellectual Property for which no equipment, supplies, facility, or trade secret information of OncoCyte or a Subsidiary was used and which was developed entirely on the Executive's own time and (i) which at the time of conception or reduction to practice does not relate directly or indirectly to the business of OncoCyte or a Subsidiary, or to the actual or demonstrable anticipated research or development activities or plans of OncoCyte or a Subsidiary, or (ii) which does not result from any work performed by Executive for OncoCyte or a Subsidiary. All Intellectual Property that (l) results from the use of equipment, supplies, facilities, or trade secret information of OncoCyte or a Subsidiary; (2) relates, at the time of conception or reduction to practice of the invention, to the business of OncoCyte or a Subsidiary, or actual or demonstrably anticipated research or development of OncoCyte or a Subsidiary; or (3) results from any work performed by Executive for OncoCyte or a Subsidiary shall be deemed OncoCyte Intellectual Property and shall be assigned and is hereby assigned to OncoCyte or the applicable Subsidiary. The parties understand and agree that this limitation is intended to be consistent with California Labor Code, Section 2870, a copy of which is attached as Exhibit <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">A. </font>If Executive wishes to clarify that something created by Executive prior to Executive's employment by OncoCyte that relates to the actual or proposed business of OncoCyte is not within the scope of this Agreement, Executive has listed it on Exhibit B in a manner that does not violate any third party rights.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">4</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Confidential and Proprietary Information. </font>During Executive's employment, Executive will have access to trade secrets and confidential information of OncoCyte and one or more Subsidiaries. Confidential Information means all information and ideas, in any form, relating in any manner to matters such as: products; formulas; technology and know-how; inventions; clinical trial plans and data; business plans; marketing plans; the identity, expenses, and compensation of employees and contractors; systems, procedures, and manuals; customers; suppliers; joint venture partners; </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">research collaborators; licensees; and financial information. Confidential Information also shall include any information of any kind, whether belonging to OncoCyte, a Subsidiary, or any third party, that OncoCyte or a Subsidiary has agreed to keep secret or confidential under the terms of any agreement </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">with any third party. Confidential Information does not include: (i) information that is or becomes publicly known through lawful means other than unauthorized </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">di</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sclosure </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive; </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(ii) information that was rightfully in Executive's possession prior to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment with OncoCyte and was not assigned to OncoCyte or a Subsidiary or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">was </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">not disclosed to Executive in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">capacity as a director </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">other fiduciary of OncoCyte or a Subsidiary; or (iii) information disclosed to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">after the termination of Executive's employment by OncoCyte, without a confidential restriction by a third party who rightfully </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">possesses </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the information and did not obtain </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">it</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, either directly </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">indirectly, from OncoCyte or a Subsidiary, and who is not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sub</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">j</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ect </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to an obligation </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">keep such </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">information </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">confidential for the benefit of OncoCyte, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary, or any third </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">party </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">with whom OncoCyte or a Subsidiary </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">has </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">contractual </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">relationship</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive understands and agrees that all Confidential Information shall be kept confidential by Executive both during </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and after Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment by OncoCyte or&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">further agrees that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">will not, without </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">prior written </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">app</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">roval </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by OncoCyte or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary, disclose any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Confidential </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">se </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Confident</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ial </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Information </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any way, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">either during the term of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's emp</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">lo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">yme</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or at any time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ther</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">eafter, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">except as required by OncoCyte or a Subsidiary in the course of Executive's employment.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Termination of Employment. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">understands and agrees that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's employment </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">has no specific </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">term. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This Agreement, and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment relationship, are </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">"at will" </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and may be terminated&#160;by Executive or by OncoCyte (and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by any Subsidiary by be terminated </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">b</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary) with or without cause at any time by notice given </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ora</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">lly </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">writing. Except as otherwise agreed in writing </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as otherwise </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">pro</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">v</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ided in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">this Agreement, upon termination of Executive's employment, OncoCyte and the Subsidiaries shall have no further obligation to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by way of compensation </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">otherwise as expressly provided in this Agreement or in any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">separate </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment agreement </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">that </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">might </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">then </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">exist between Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Subsidiary.</font></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.55pt; MARGIN-RIGHT: 24.4pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Payments Due </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Upon Termination </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font></font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">Employment.</font> </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Upon termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment with OncoCyte </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">all Subsidiaries at any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">for any reason, in the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">event of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the termination of Executive</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment by OncoCyte for </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cause, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or termination of Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">em</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">plo</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">y</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ment </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">as a result of death, Disability, or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">res</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ignation, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">will be entitled to receive only the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">seve</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rance </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">benefits </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">set forth </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">below, but Executive will not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">entitled to any other compensation, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">awa</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">rd</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">dam</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ages </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">with respect to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ive</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">'s </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment or te1mination of employment.</font></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Termination/or </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cause, </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Death, Disability, or Resignation</font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the event </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the termination of Executive's employment by OncoCyte for Cause, or termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment as a result of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">death, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Disability, or resignation, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">will be entitled to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">receive </font></font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">payment for all accrued </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">but </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">unpaid salary actually </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">earned </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">prior to or as of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">date of termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execu</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tiv</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment, and vacation or paid </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">time </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">off accrued as of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">th</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">e </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">date </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment. Executive will not be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">entitled </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cash </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">severance benefits or additional </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">vesting </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">of any </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">tock </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">options or other equity or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">cash </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">awards.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Termination Without </font><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cause. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">event of termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ut</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ive's employme</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">nt </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by OncoCyte without </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Cause </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">on or </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">after </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Au</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">g</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">t 1</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, 2</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">018</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">, Executive will be </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ent</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">itled </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to (A) the benefits </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">set </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">forth in paragraph (a)(i) of this Section, and (B) payment </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">in </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">an amount eq</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">u</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">l </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">six </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">months' base </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">salary, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">which may be paid in a lump </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">sum </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">or, at the election of OncoCyte, in installments consistent with the payment of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive's salary </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">while employed by OncoCyte, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">subject </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">s</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">uch </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">payroll deductions and withholdings as are required by </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">law. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">This paragraph shall not </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">apply </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">to (x) termination of Executive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">emp</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">loyment </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by a Subsidiary if </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">remains </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">by OncoCyte, or (y) termination of </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Exec</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">utive's </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">employment by OncoCyte if Executive remains employed by a Subsidiary.</font></font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">5</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Change of Control. </font>If, on or after August 1, 2018, OncoCyte (or any successor in interest to OncoCyte that has assumed OncoCyte's obligation under this Agreement) terminates Executive's employment without Cause " or Executive resigns for "Good Reason" within twelve (12) months following a Change in Control, Executive will be entitled to (A) the benefits set forth in paragraph (a)(i) and (a)(ii) of this Section, and (B)) payment in an amount equal to twelve months' base salary. This paragraph shall not apply to (x) termination of Executive's employment by a Subsidiary if Executive remains employed by OncoCyte or a successor in interest, or (y) termination of Executive's employment by OncoCyte or a successor in interest if Executive remains employed by a Subsidiary.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Release. </font>Any other provision of this Agreement notwithstanding, paragraphs (a)(ii) and (a)(iii) of this Section shall not apply unless the Executive (i) has executed a general release of all claims against OncoCyte or its successor in interest and the Subsidiaries (in a form prescribed by OncoCyte or its successor in interest), (ii) has returned all property in the Executive's possession </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">belonging OncoCyte or its successor in interest and any Subsidiaries, and (iii) if serving as </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">a </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">director of </font>OncoCyte or any Subsidiary, has tendered his written resignation as a director as provided in Section 7.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Definitions. </font>For purposes of this Section, the following definitions shall apply:</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Affiliated Group" means (A) a Person and one or more other Persons in control of, controlled by, or under common control with such Person; and (B) two or more Persons who, by written agreement among them, act in concert to acquire Voting securities entitling them to elect a majority of the directors of OncoCyte.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Cause" means: (A) the failure to properly perform Executive's job responsibilities, as determined reasonably and in good faith by the Board of Directors; (B) commission of any act of fraud, gross misconduct or dishonesty with respect to OncoCyte or any Subsidiary; (C) conviction of, or plea of guilty or "no contest" to, any felony, or a crime involving moral turpitude; (D) breach of any provision of this Agreement or any provision of any proprietary information and inventions agreement with OncoCyte or any Subsidiary; (E) failure to follow the lawful directions of </font>the Board of Directors of OncoCyte or any Subsidiary; (F) chronic alcohol or drug abuse; (G) obtaining, in connection with any transaction in which OncoCyte, any Subsidiary, or any of OncoCyte's affiliates is a party, a material undisclosed financial benefit for Executive or for any member of Executive's immediate family or for any corporation, partnership, limited liability company, or trust in which Executive or any member of Executive's immediate family owns a material financial interest; or (H) harassing or discriminating against, or participating or assisting in the harassment of or discrimination against, any employee of OncoCyte (or a Subsidiary or an affiliate of OncoCyte) based upon gender, race, religion, ethnicity, or nationality.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Change of Control" means (A) the acquisition of Voting Securities of OncoCyte by a Person or an Affiliated Group entitling the holder thereof to elect a majority of the directors of OncoCyte; provided, that an increase in the amount of Voting Securities held by a Person or Affiliated Group who on the date of this Agreement owned beneficially owned (as deemed in Section l3(d) of the Securities Exchange Act of 1934, as amended, and the regulations thereunder) more than </font>10% of the Voting Securities shall not constitute a Change of Control; and provided, further, that an acquisition of Voting Securities by one or more Persons acting as an underwriter in connection with a sale or distribution of such Voting Securities shall not constitute a Change of Control under this clause (A); (B) the sale of all or substantially all of the assets of OncoCyte; or (C) a merger or consolidation of OncoCyte with or into another corporation or entity in which the stockholders of OncoCyte <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">immediately before such merger or consolidation do not own, in the aggregate, Voting Securities of the surviving corporation or entity (or the ultimate parent of the surviving corporation or entity) entitling them, in the aggregate (and without regard to whether they constitute an Affiliated Group) to elect a majority of the directors or persons holding similar powers of the surviving corporation or entity (or the ultimate parent of the surviving corporation or entity); provided, however, that in no event shall any transaction described in clauses (A), (B) or (C) be a Change of Control if all of the Persons acquiring Voting Securities or assets of OncoCyte or merging or consolidating with OncoCyte are one or more Subsidiaries.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">6</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">(iv)&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Disability" shall mean Executive's inability to perform the essential functions of Executive's job responsibilities for a period of one hundred eighty&#160; (180) days in the aggregate in any twelve (12) month period.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(v)</font>&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Good Reason" means (A) a diminution in Executive's base salary; (B) a material change in geographic location at which Executive must perform services (a change in location of the OncoCyte office at which Executive will primarily work will be considered material only if it increases Executive's current one-way commute by more than fifty (50) miles); (C) any material failure of the successors to OncoCyte after a Change of Control to perform, or causing OncoCyte not to perform, OncoCyte' obligations under this Agreement; (D) any action or inaction of OncoCyte that constitutes a material breach of the terms of this Agreement; or (E) any other material adverse change in Executive's duties, authorities, responsibilities, or reporting structure (for example, if Executive is required to report to anyone other than a Chief Executive Officer or the Board of Directors of OncoCyte or its successor).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Person" means any natural person or any corporation, partnership, limited liability company, trust, unincorporated business association, or other entity.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(vii)</font>&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Voting&#160; Securities" means shares of capital stock or other equity securities entitling the holder thereof to regularly vote for the election of directors (or for person performing a similar function if the issuer is not a corporation), but does not include the power to vote upon the happening of some condition or event which has not yet occurred.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Turnover of Property and Documents on Termination. </font>Executive agrees that on or before termination of Executive's employment, Executive will return to OncoCyte and all Subsidiaries all equipment and other property belonging to OncoCyte and the Subsidiaries, and all originals and copies&#160; of Confidential Information (in any and all media and formats, and including any document or other item containing Confidential Information) in Executive's possession or control, and all of the following (in any and all media and formats, and whether or not constituting or containing Confidential Information) in Executive's possession or control:&#160; (a) lists and sources of customers; (b) proposals or drafts of proposals for any research grant, research or development project or program, marketing plan, licensing arrangement, or other arrangement with any third party; (c) reports, job or laboratory notes, specifications, and drawings pertaining to the research, development, products, patents, and technology of OncoCyte and any Subsidiaries; (d) any and all Intellectual Property developed by Executive during the course of employment; and (e) the Manual and memoranda related to the Policies.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Resignation </font><font style="FONT-WEIGHT: bold">as a</font> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director on Termination of Employment. </font>If Executive's employment by OncoCyte is terminated for any reason or for no reason, whether by way of resignation, Disability, or termination by OncoCyte with or without Cause, and if Executive is then a member of the Board of Directors of OncoCyte or any Subsidiary, Executive shall within two business days after such <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">termination of employment resign from the Board of Directors of OncoCyte and from the board of directors of each and every Subsidiary, by delivering to OncoCyte (and each Subsidiary, as applicable) a letter or other written communication addressed to the Board of Directors of OncoCyte (and each Subsidiary, as applicable) stating that Executive is resigning from the Board of Directors of OncoCyte (and each Subsidiary, as applicable) effective immediately. A business day shall be any day other than a Saturday, Sunday, or federal holiday on which federal offices are closed.</font></font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">7</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Arbitration. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">It </font>is the intention of Executive and OncoCyte that the Federal Arbitration Act and the California Arbitration Act shall apply with respect to the arbitration of disputes, claims, and controversies pursuant to, arising under, or in connection with this Agreement. Except for injunctive proceedings against unauthorized disclosure of Confidential Information, any and all claims or controversies between OncoCyte or any Subsidiary and Executive, including but not limited to (a) those involving the construction or application of any of the terms, provisions, or conditions of this </font>Agreement (including but not limited to the applicability and enforceability of provisions of this Section 8 with respect to any dispute, claim, or controversy) or the Policies; (b) all contract or tort claims of any kind; and (c) any .claim based on any federal, state, or local law, statute, regulation, or ordinance, including claims for unlawful discrimination or harassment, shall be settled by arbitration in accordance with the then current Employment Dispute Resolution Rules of the American Arbitration Association or the Employment Arbitration Rules <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&amp; </font>Procedures of the Judicial Arbitration and Mediation Service ("JAMS"), as selected by OncoCyte or a Subsidiary. Judgment on the award rendered by the arbitrator(s) may be entered by any court having jurisdiction over OncoCyte and Executive. The location of the arbitration shall be San Francisco, California. Unless OncoCyte or a subsidiary and Executive mutually agree otherwise, the arbitrator shall be a retired judge selected from a panel provided by the American Arbitration Association, or JAMS. OncoCyte, or a Subsidiary if the Subsidiary is a party to the arbitration proceeding, shall pay the arbitrator's fees and costs. Executive shall pay for Executive's own costs and attorneys' fees, if any. OncoCyte and any Subsidiary that is a party to an arbitration proceeding shall pay for its own costs and attorneys' fees, if any. However, if any party prevails on a statutory claim which affords the prevailing party attorneys' fees, the arbitrator may award reasonable attorneys' fees and costs to the prevailing party.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">EMPLOYEE UNDERSTANDS AND AGREES THAT THIS AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF EMPLOYEE'S RIGHT TO A TRIAL BY JURY OF ANY MATTERS COVERED BY THIS AGREEMENT TO ARBITRATE.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Severability. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In </font>the event that any of the provisions of this Agreement or the Policies shall be held to be invalid or unenforceable in whole or in part, those provisions to the extent enforceable and all other provisions shall nevertheless continue to be valid and enforceable as though the invalid or unenforceable&#160;parts had not been included in this Agreement or the Policies. In the event that any provision relating to a time period of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period such court deems reasonable and enforceable, then the time period of restriction deemed reasonable and enforceable by the court shall become and shall thereafter be the maximum time period.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement Read and Understood. </font>Executive acknowledges that Executive has carefully read the terms of this Agreement, that Executive has had an opportunity to consult with an attorney or other representative of Executive's own choosing regarding this Agreement, that Executive understands the terms of this Agreement, and that Executive is entering this agreement of Executive's own free will.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">8</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Complete Agreement, Modification.&#160; </font>This Agreement is the complete agreement between Executive and OncoCyte on the subjects contained in this Agreement. This Agreement supersedes and replaces all previous correspondence, promises, representations, and agreements, if any, either written or oral with respect to Executive's employment by OncoCyte or any Subsidiary and any matter covered by this Agreement. No provision of this Agreement may be modified, amended, or waived except by a written document signed both by OncoCyte and Executive.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Governing Law. </font>This Agreement shall be construed and enforced according to the laws of the State of California.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assignability. </font>This Agreement, and the rights and obligations of Executive and OncoCyte under this Agreement, may not be assigned by Executive. OncoCyte may assign any of its rights and obligations under this Agreement to any successor or surviving corporation, limited liability company, or other entity resulting from a merger, consolidation, sale of assets, sale of stock, sale of membership interests, or other reorganization, upon condition that the assignee shall assume, either expressly or by operation of law, all of OncoCyte's obligations under this Agreement.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Survival. </font>This Section 14 and the covenants and agreements contained in Sections 4 and 6 of this Agreement shall survive termination of this Agreement and Executive's employment.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">15.</font>&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notices. </font>Any notices or other communication required or permitted to be given under this Agreement shall be in writing and shall be mailed by certified mail, return receipt requested, or sent by next business day air courier service, or personally delivered to the party to whom it is to be given at the address of such party set forth on the signature page of this Agreement (or to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 15).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 45pt; FONT-SIZE: 10pt">IN WITNESS WHEREOF, Executive and OncoCyte have executed this Agreement on the day and year first above written.</div>

<div><br>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7c01c596f93c45ada83eff6c607de933" border="0" cellspacing="0" cellpadding="0">
<tr>
<td>
<div>EMPLOYEE</div>
</td>
<td style="WIDTH: 30%">
<div>&#160;</div>
</td>
<td style="WIDTH: 40%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td>
<div>&#160;</div>
</td>
<td style="WIDTH: 30%">
<div>&#160;</div>
</td>
<td style="WIDTH: 40%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid">/s/ Mitch Levine</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 30%">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 40%">&#160;</td>
</tr>

<tr>
<td>
<div>Signature</div>
</td>
<td style="WIDTH: 30%">
<div>&#160;</div>
</td>
<td style="WIDTH: 40%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td></td>
<td style="WIDTH: 30%">&#160;</td>
<td style="WIDTH: 40%">&#160;</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: normal">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Mitch Levine</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 30%">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 40%">&#160;</td>
</tr>

<tr>
<td>(Please Print Name)</td>
<td style="WIDTH: 30%">&#160;</td>
<td style="WIDTH: 40%">&#160;</td>
</tr>
</table>

<div>&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">9</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ONCOCYTE:</div>

<div>&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z4a858d5cb1e14499b75ebfed70ec8c44" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte Corporation</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 45%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">By:</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 45%; VERTICAL-ALIGN: top">/s/&#160;William Annett</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top"></td>
<td style="WIDTH: 45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">William Annett</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Title:</div>
</td>
<td style="WIDTH: 45%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Chief Executive Officer</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">10</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT A</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Job Title:</font>&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Chief Financial Officer</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Job and Duties:</font>&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte agrees to employ Executive in the position of Chief Financial Officer. Executive shall perform the duties and functions as are normally carried out by a Chief Financial Officer of a developer of cancer diagnostic tests and products of a size comparable to OncoCyte that has a class equity securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, and as the Board of Directors of OncoCyte (the "Board of Directors") shall from time to time reasonably determine. Without limiting the generality of the immediately preceding sentence, Executive shall</font></div>

<div>&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z34fdbe0fdfe14bff87b9cca4c6f28fb6" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 24.4pt"></td>
<td style="WIDTH: 17.6pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#8226;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Reports to Chief Executive Officer ("CEO")</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb207a69eb95a488383c52767fb97560d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.4pt"></td>
<td style="WIDTH: 17.6pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Job Duties: </font>As the senior financial executive in the Company, the incumbent will provide technical expertise, business strategy and leadership in key financial areas, including advising the Board of Directors, and actively participating in the planning, decision- making and execution of the Company's strategic plans. This individual will have responsibility for compliance with all reporting obligations of a public corporation, and will help the Company maintain the highest level of ethics, profitability, financial strength and operating efficiency. He will also possess business leadership expertise along with the demonstrated ability to manage and lead a team and optimize the financial organization. Additional representative responsibilities will include, but not necessarily be limited to, the following:</div>
</td>
</tr>
</table>
</div>

<div>&#160;<br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z4f3a5cd40bec41b2a2bbcb6928cfbbc6" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 16.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Provide overall leadership, financial strategy and proactive direction to the Company's financial organization, and recruit and develop financial talent as required.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zf6f0b98475b74a4689b77d8fc4f3849c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 17.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Provide advice and counsel on all financial matters to the Chief Executive Officer and the Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5104a10a0c7144aa91b36ce0fd1c521c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 17.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Contribute to the strategic direction of the Company and collaborate with other senior management and the Board of Directors to refine and implement the Company's strategic plan.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z7fb3bffa251645c7a48e22e19d58a5f4" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 17.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">In collaboration with the Chief Executive Officer be responsible for ensuring that the Company has adequate capital to execute its strategic and business plans, creating financing plans, and executing equity and debt transactions as approved by the Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z954040327181423d9bae10a17a261d06" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 17.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Work closely with Senior Management to assess and execute potential partnering opportunities and collaborations.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z5b1468cbe4b84024966d91ebc9399a64" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 16.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ensure an effective investor relations function and, with the Chief Executive Officer serve as a primary point of contact with institutional investors, analysts and shareholders.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z78db80ce5b8d4e15aa3a209d46615be1" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 16.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Participate actively in Board of Directors and Audit Committee meetings; provide advice and counsel on matters pertaining to governance and corporate compliance.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="ze1e734b73ae34889b5824c630c92bc51" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 16.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Manage key relationships and serve as the Company's principal contact with external auditors and tax advisors.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc8394fa0f300441fb147febc08a19a50" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.05pt"></td>
<td style="WIDTH: 16.95pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Ensure the Finance Department maintains a high level of performance, productivity and integrity.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">11</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Annual Salary:&#160;&#160;&#160;&#160;</font>$330,000</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Target Bonus:&#160;&#160;&#160;&#160; &#160;</font>Subject to the discretion of the Board of Directors, and as provided in Section 2(b) of this Agreement, the target annual bonus amount for Executive shall be 40% of his base salary.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Options:&#160;&#160;&#160;&#160; </font>Options to purchase 200,000&#160; shares of OncoCyte common stock under OncoCyte's Employee Stock Option Plan (the "Plan"). The exercise price of the options shall be the fair market value of OncoCyte's common shares on the date of grant determined in accordance with the Plan. The date of grant of the options shall be the date on which Executive's employment by OncoCyte commended.&#160; Executive shall execute a stock option agreement consistent with the terms of the option grant and the Plan.&#160; The options shall vest and thereby become exercisable as follows: twenty-five percent of the options shall vest upon Executive's completion of one year of continuous service as an employee of OncoCyte or of a Subsidiary, and the balance of the options shall vest in 36 equal monthly installments, commencing on the first anniversary date of the grant, based upon Executive's continued service as an employee of OncoCyte or of a Subsidiary. Except to the extent that provisions of the Plan relating to termination of service as an employee apply, to the extent not exercised, the options shall expire ten years from the effective date of grant. The options shall be incentive stock options to the extent permitted by Section 422 of the Internal Revenue Code.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 18pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Executive may also receive a grant of an additional 50,000 stock options during the first quarter of 2018, subject to approval by the Board of Directors and the terms and conditions of the Plan and such vesting and other provisions as the Board of Directors may determine.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Paid Time Off:&#160;&#160;&#160;&#160; &#160;</font>Executive shall be entitled to a total of twenty business days per year as "paid time off," accrued on a biweekly pay period basis, for sick leave and vacation, plus an additional 24 hours of sick time per calendar year.</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0.35pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 5.1pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 23.4pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">12</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT B</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">California Labor Code Section 2870.</div>

<div><br>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: -0.35pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 6.5pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 51.3pt">Application of provision providing that employee shall assign or offer to assign rights in invention to employer.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer's equipment, supplies, facilities, or trade secret information except for those inventions that either:</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72.35pt; MARGIN-LEFT: 6.15pt; MARGIN-RIGHT: 2.9pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Relate at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development of the employer; or</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Result from any work performed by the employee for his employer.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber"></font>&#160;</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal">13</div>
</div>

<div>
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.XI
<SEQUENCE>3
<FILENAME>ex10_25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div style="TEXT-ALIGN: right">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; HEIGHT: 4px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
<font style="FONT-WEIGHT: bold">Exhibit 10.25</font><br>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EMPLOYMENT AGREEMENT</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 45pt; FONT-SIZE: 10pt">THIS EMPLOYMENT AGREEMENT ("Agreement") is made as of August 31, 2017 by and between OncoCyte Corporation ("OncoCyte"), a California corporation, and Michael Vicari ("Employee").</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Engagement; Position and Duties.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte agrees to employ Employee in the position described on Exhibit A (which Exhibit A is a part of this Agreement) effective as of the date of this Agreement. Employee shall perform the duties and functions described on Exhibit A and such other duties as the executive(s) to whom Employee reports or the Board of Directors of OncoCyte may from time to time determine. Employee shall devote Employee's best efforts, skills, and abilities, on a full-time basis, exclusively to the business of OncoCyte and its Related Companies pursuant to, and in accordance with, business policies and procedures, as fixed from time to time by the Board of Directors (the "Policies"). </font>Employee covenants and agrees that Employee will faithfully adhere to and fulfill the Policies, including any changes to the Policies that may be made in the future. Employee may be provided with a copy of OncoCyte's employee manual (the "Manual") which contains the Policies. OncoCyte may change its Policies from time to time, in which case Employee will be notified of the changes in writing by a memorandum, a letter, or an update or revision of OncoCyte's employee manual.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Performance of Services for Related Companies. </font>In addition to the performance of services for OncoCyte, Employee shall, to the extent so required by OncoCyte, also perform services for one or more members of a consolidated group of which OncoCyte is a part ("Related Company"), provided that such services are consistent with the kind of services Employee performs or may be required to perform for OncoCyte under this Agreement. If Employee performs any services for any Related Company, Employee shall not be entitled to receive any compensation or remuneration in addition to or in lieu of the compensation and remuneration provided under this </font>Agreement on account of such services for the Related Company. The Policies will govern Employee's employment by OncoCyte and any Related Companies for which Employee is asked to provide Services. In addition, Employee covenants and agrees that Employee will faithfully adhere to and fulfill such additional policies as may be established from time to time by the board of directors of any Related Company for which Employee performs services, to the extent that such policies and procedures differ from or are in addition to the Policies adopted by OncoCyte.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">No Conflicting Obligations. </font>Employee represents and warrants to OncoCyte </font>and each Related Company that Employee is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with Employee's obligations under this Agreement or that would prohibit Employee, contractually or otherwise, further performing Employee's duties as under this Agreement and the Policies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">No Unauthorized Use of Third Party Intellectual Property. </font>Employee represents and warrants to OncoCyte and each Related Company that Employee will not use or disclose, in connection with Employee's employment by OncoCyte or any Related Company, any patents, trade secrets, confidential information, or other proprietary information or intellectual property as to which any other person has any right, title or interest, except to the extent that OncoCyte to a Related Company holds a valid license or other written permission for such use from the owner(s) </font>thereof. Employee represents and warrants to OncoCyte and each Related Company that Employee has returned all property and confidential information belonging to any prior employer.</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%2%%%-->
<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Compensation</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Salary. </font>During the term of this Agreement, OncoCyte shall pay to the Employee the salary shown on Exhibit A. Employee's salary shall be paid in equal biweekly installments, consistent with OncoCyte's regular salary payment practices. Employee's salary may be increased </font>from time-to-time by OncoCyte, in OncoCyte's sole and absolute discretion, without affecting this Agreement.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Bonus. </font>Employee may be eligible for an annual bonus, as may be approved by the Board of Directors in its discretion, based on Employee's performance and achievement of goals or milestones set by the Board of Directors from time to time. Employee agrees that the Board of Directors of OncoCyte may follow the recommendations of its Compensation Committee in determining whether to award a&#160;bonus or to establish performance goals or milestones. Employee also agrees that the Board of Directors and OncoCyte are not obligated to adopt any bonus plan, to maintain in effect any bonus plan that may now be in effect or that may be adopted during the term of Employee's employment, or to pay Employee a bonus unless a bonus is earned under the terms and conditions of any bonus plan adopted by OncoCyte or Employee attaining the bonus performance goals for Employee established by the Board of Directors or its Compensation Committee; provided, that unless otherwise provided in a bonus plan or award, a bonus shall not be earned until paid and shall not be paid unless Employee remains an employee of the Company on the date of payment.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Expense Reimbursements. </font>OncoCyte or a Related Company shall reimburse Employee for reasonable travel and other business expenses (but not expenses of commuting to work) incurred by Employee in the performance of Employee's duties under this Agreement, subject to the Policies and procedures in effect from time to time, and provided that Employee submits supporting vouchers.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Benefit Plans. </font>Employee may be eligible (to the extent Employee qualifies) to participate in certain retirement, pension, life, health, accident and disability insurance, stock option plan or other similar employee benefit plans which may be adopted by OncoCyte (or a Related Company) for its employees. OncoCyte and the Related Companies have the right, at any time and without any amendment of this Agreement, and without prior notice to or consent from Employee, to adopt, amend, change, to&#183; terminate any such benefit plans that may now be in effect or that may be adopted in the future, in each case without any further financial obligation to Employee. Any benefits to which Employee may be entitled under any benefit plan shall be governed by the terms and </font>conditions of the applicable benefit plan, and any related plan documents, as in effect from time to time. If Employee receives any grant of stock options or restricted under any stock option plan or stock purchase plan of OncoCyte or any Related Company, the terms and conditions of the stock options or restricted stock, and Employee's rights with respect to the stock options or restricted stock, shall be governed by (i) the terms of the applicable stock option or stock purchase plan, as the same may be amended from time to time, and (ii) the terms and conditions of any stock option agreement or stock purchase agreement and related agreements that Employee may sign or be required to sign with respect to the stock options or restricted stock.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Vacation; Sick Leave. </font>Employee shall be entitled to the number of days of vacation and sick leave (without reduction in compensation) during each calendar year shown on Exhibit A or as may be provided by the Policies. Employee's vacation shall be taken at such time as is consistent with the needs and Policies of OncoCyte and its Related Companies. All vacation days and sick leave days shall accrue annually based upon days of service. Employee's right to leave from work due to illness is subject to the Policies and the provisions of this Agreement governing termination due to disability, sickness or illness. The Policies governing the disposition of unused vacation days and sick leave days remaining at the end of OncoCyte's fiscal year shall govern whether unused vacation days or sick leave days will be paid, lost, or carried over into subsequent fiscal years.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">2</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">Competitive Activities.</font> During the term of Employee's employment, and for one year thereafter, Employee shall not, for Employee or any third party, directly or indirectly employ, solicit for employment or recommend for employment any person employed by OncoCyte or any Related Company. during the term of Employee's employment, Employee shall not, directly or indirectly as an employee, contractor, officer, director, member, partner, agent, or equity owner, engage in any activity or business that competes or could reasonably be expected to compete with the business of OncoCyte or any Related Company. Employee acknowledges that there is a substantial likelihood that the activities described in this Section would (a) involve the unauthorized use or disclosure of OncoCyte's or a Related Company's Confidential Information and that use or disclosure would be extremely difficult to detect, and (b) result in substantial competitive harm to the business of OncoCyte or a Related Company.&#160; Employee has accepted the limitations of this Section as a reasonably practicable and unrestrictive means of preventing such use or disclosure of Confidential Information and preventing such competitive harm.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Inventions/Intellectual Property/Confidential Information</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employee acknowledges the execution and delivery to OncoCyte of an Confidentiality, Intellectual Property and Non-Competition Agreement (the "Confidentiality and IP Agreement").</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(b)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Execution of Documents; Power of Attorney. </font>Employee agrees to execute and sign any and all applications, assignments, or other instruments which OncoCyte or a Related Company may deem necessary in order to enable OncoCyte or a Related Company, at its expense, to apply for, prosecute, and obtain patents of the United States or foreign countries for the Intellectual Property, or in order to assign or convey to, perfect, maintain or vest in OncoCyte or a Related Company the sole and exclusive right, title, and interest in and to the Intellectual Property. If OncoCyte or a Related Company is unable after reasonable efforts to secure Employee's signature, cooperation or assistance in </font>accordance with the preceding sentence, whether because of Employee's incapacity or any other reason whatsoever, Employee hereby designates and appoints OncoCyte or any Related Company or its designee as Employee's agent and attorney-in-fact, to act on Employee's behalf, to execute and file documents and to do all other lawfully permitted acts necessary or desirable to perfect, maintain or otherwise protect OncoCyte's or a Related Company's rights in the Intellectual Property. Employee acknowledges and agrees that such appointment is coupled with an interest and is irrevocable.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 6.2pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 6.5pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">3</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Confidential and Proprietary Information. </font>During Employee's employment, Employee will have access to trade secrets and confidential information of OncoCyte and one or more Related Companies. Confidential Information means all information and ideas, in any form, relating in any manner to matters such as: products; formulas; technology and know-how; inventions; clinical trial plans and data; business plans; marketing plans; the identity, expertise, and compensation of employees and contractors; systems, procedures, and manuals; customers; suppliers; joint venture partners; </font>research collaborators; licensees; and financial information. Confidential Information also shall include any information of any kind, whether belonging to OncoCyte, a Related Company, or any third party, that OncoCyte or a Related Company has agreed to keep secret or confidential under the terms of any agreement with any third party. Confidential Information does not include: (i) information that is or becomes publicly known through lawful means other than unauthorized disclosure by Employee; (ii) information that was rightfully in Employee's possession prior to Employee's employment with OncoCyte and was not assigned to OncoCyte or a Related Company or was not disclosed to Employee in Employee's capacity as a director or other fiduciary of OncoCyte or a Related Company; or (iii) information disclosed to Employee, after the termination of Employee's employment by OncoCyte, without a confidential restriction by a third party who rightfully possesses the information and did not obtain it, either directly or indirectly, from OncoCyte or a Related Company, and who is not subject to an obligation to keep such information confidential for the benefit of OncoCyte, a Related Company, or any third party with whom OncoCyte or a Related Company has a contractual relationship. Employee understands and agrees that all Confidential Information shall be kept confidential by Employee both during and after Employee's employment by OncoCyte or any Related Company. Employee further agrees that Employee will not, without the prior written approval by OncoCyte or a Related Company, disclose any Confidential Information, or use any Confidential Information in any way, either during the term of Employee's employment or at any time thereafter, except as required by OncoCyte or a Related Company in the course of Employee's employment. To the extent any terms between this Agreement and the Confidentiality and IP Agreement conflict, the Confidentiality and IP Agreement's terms control.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Termination of Employment. </font>Employee understands and agrees that Employee's employment has no specific term. This Agreement, and the employment relationship, are "<font style="FONT-WEIGHT: bold">at</font> <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">will" </font>and may be terminated by Employee or by OncoCyte (and the employment of Employee by any Related Company by be terminated by the Related Company) with or without cause at any time by notice given orally or in writing. Except as otherwise agreed in writing or as otherwise provided in this Agreement, upon termination of Employee's employment, OncoCyte and the Related Companies shall have no further obligation to Employee by way of compensation or otherwise as expressly provided in this Agreement or in any separate employment agreement that might then exist between Employee and a Related Company.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Payments Due Upon Termination of Employment. </font>Upon termination of Employee's employment with OncoCyte and all Related Companies at any time and for any reason, Employee will be entitled to receive only the severance benefits set forth below, but Employee will not be entitled to any other compensation, award, or damages with respect to Employee's employment or termination of employment.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Termination for Cause, Death, Disability, or Resignation. </font>In the event of the termination of Employee's employment by OncoCyte for Cause, or termination of Employee's employment as a result of death, Disability, or resignation, Employee will be entitled to receive </font>payment for all accrued but unpaid salary actually earned prior to or as of the date of termination of Employee's employment, and vacation or paid time off accrued as of the date of termination of Employee's employment. Employee will not be entitled to any cash severance benefits or additional vesting of any stock options or other equity or cash awards.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Termination Without Cause. </font>In the event of termination of Employee's employment by OncoCyte without Cause, Employee will be entitled to (A) the benefits set forth in paragraph (a)(i) of this Section, and (B) payment in an amount equal to: <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(1) </font>three months' base salary if terminated within the first 12 months of employment, or (2) six months' base salary if terminated after </font>12 months of employment, either of which may be paid in a lump sum or, at the election of OncoCyte, in installments consistent with the payment of Employee's salary while employed by OncoCyte, subject to such payroll deductions and withholdings as are required by law. This paragraph shall not apply to (x) termination of Employee's employment by a Related Company if Employee remains employed by OncoCyte, or (y) termination of Employee's employment by OncoCyte if Employee remains employed by a Related Company.</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">4</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Change of Control. </font>In the event OncoCyte (or any successor in interest to OncoCyte that has assumed OncoCyte's obligation under this Agreement) terminates Employee's employment without Cause or Employee resigns for "Good Reason" within twelve (12) months following a Change in Control, Employee will be entitled to (A) the benefits set forth in paragraph (a)(i) and (a)(ii) of this Section, and (B) accelerated vesting of one hundred percent (100%) of any then unvested stock options as may have been granted to Employee by OncoCyte of termination of employment occurs by OncoCyte. This paragraph shall not apply to (x) termination of Employee's employment by a Related Company if Employee remains employed by OncoCyte or a successor in interest, or (y) termination of Employee's employment by OncoCyte or a successor in interest if Employee remains employed by a Related Company.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Release. </font>Any other provision of this Agreement notwithstanding, paragraphs (a)(ii) and (a)(iii) of this Section shall not apply unless the Employee (i) has executed a general release of all claims against OncoCyte or its successor in interest and the Related Companies (in a form prescribed by OncoCyte or its successor in interest), (ii) has returned all property in the Employee's possession belonging OncoCyte or its successor in interest and any Related Companies, and (iii) if serving as a director of OncoCyte or any Related Company, has tendered her written resignation as a director as provided in Section 7.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 72pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Definitions. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For purposes of this Section, the following definitions shall apply:</font></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Affiliated Group" means (A) a Person and one or more other Persons in control of, controlled by, or under common control with such Person; and (B) two or more Persons who, by written agreement among them, act in concert to acquire Voting Securities entitling them to elect a majority of the directors of OncoCyte.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Cause" means: (A) the failure to properly perform Employee's job responsibilities, as determined reasonably and in good faith by the Board of Directors; (B) commission of any act of fraud, gross misconduct or dishonesty with respect to OncoCyte or any Related Company; (C) conviction of, or plea of guilty or "no contest" to, any felony, or a crime involving moral turpitude; (D) breach of any provision of this Agreement or any provision of any proprietary information and inventions agreement with OncoCyte or any Related Company; (E) failure to follow the lawful directions of the Board of Directors of OncoCyte or any Related Company; (F) chronic alcohol or drug abuse; (G) obtaining, in connection with any transaction in which OncoCyte, any Related Company, or any of OncoCyte's affiliates is a party, a material undisclosed financial benefit for Employee or for any member of Employee's immediate family or for any corporation, partnership, limited liability company, or trust in which Employee or any member of Employee's immediate family owns a material financial interest; or (H) harassing or discriminating against, or participating or assisting in the harassment of or discrimination against, any employee of OncoCyte (or a Related Company or an affiliate of OncoCyte) based upon gender, race, religion, ethnicity, or nationality.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">5</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Change of Control" means (A) the acquisition of Voting Securities of OncoCyte by a Person or an Affiliated Group entitling the holder thereof to elect a majority of the directors of OncoCyte; provided, that an increase in the amount of Voting Securities held by a Person or Affiliated Group who on the date of this Agreement beneficially owned (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended, and the regulations thereunder) more than 10% of the Voting Securities shall not constitute a Change of Control; and provided, further, that an acquisition of Voting Securities by one or more Persons acting as an underwriter in connection with a sale or distribution of such Voting Securities shall not constitute a Change of Control under this clause (A); (B) the sale of all or substantially all of the assets of OncoCyte; or (C) a merger or consolidation of OncoCyte with or into another corporation or entity in which the stockholders of OncoCyte </font>immediately before such merger or consolidation do not own, in the aggregate, Voting Securities of the surviving corporation or entity (or the ultimate parent of the surviving corporation or entity) entitling them, in the aggregate (and without regard to whether they constitute an Affiliated Group) to elect a majority of the directors or persons holding similar powers of the surviving corporation or entity (or the ultimate parent of the surviving corporation or entity); provided, however, that in no event shall any transaction described in clauses (A), (B) or (C) be a Change of Control if all of the Persons acquiring Voting Securities or assets of OncoCyte or merging or consolidating with OncoCyte are one or more Related Companies.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Disability" shall mean Employee's inability to perform the essential functions of Employee's job responsibilities for a period of one hundred eighty (180) days in the aggregate in any twelve (12) month period.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Good Reason" means (A) a diminution in Employee's base salary; (B) a material change in geographic location at which Employee must perform services (a change in location of the OncoCyte office at which Employee will primarily work will be considered material only if it increases Employee's current one-way commute by more than fifty (50) miles); (C) any material failure of the successors to OncoCyte after a Change of Control to perform, or causing OncoCyte not to perform, OncoCyte's&#160;obligations under this Agreement; (D) any action or inaction of OncoCyte that constitutes a material breach of the terms of this Agreement; or (E) any other material adverse change in Employee's duties, authorities, responsibilities, or reporting structure (for example, if Employee is required to report to anyone other than a Chief Executive Officer or the Board of Directors of OncoCyte or its successor).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Person" means any natural person or any corporation, partnership, limited liability company, trust, unincorporated business association, or other entity.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 99pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">"Voting Securities" means shares of capital stock or other equity securities entitling the holder thereof to regularly vote for the election of directors (or for person performing a similar function if the issuer is not a corporation), but does not include the power to vote upon the happening of some condition or event which has not yet occurred.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Turnover of Property and Documents on Termination. </font>Employee agrees that on or before termination of Employee's employment, Employee will return to OncoCyte and all Related Companies all equipment and other property belonging to OncoCyte and the Related Companies, and all originals and copies of Confidential Information (in any and all media and formats, and including any document or other item containing Confidential Information) in Employee's possession or control, </font>and all of the following (in any and all media and formats, and whether or not constituting or containing Confidential Information) in Employee's possession or control: (a) lists and sources of customers; (b) proposals or drafts of proposals for any research grant, research or development project or program, marketing plan, licensing arrangement, or other arrangement with any third party; (c) reports, job or laboratory notes, specifications, and drawings pertaining to the research, development, products, patents, and technology of OncoCyte and any Related Companies; (d) any and all Intellectual Property developed by Employee during the course of employment; and (e) the Manual and memoranda related to the Policies.</div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">6</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Arbitration. </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">It </font>is the intention of Employee and OncoCyte that the Federal Arbitration Act and the California Arbitration Act shall apply with respect to the arbitration of disputes, claims, and controversies pursuant to, arising under, or in connection with this Agreement. Except for injunctive proceedings against unauthorized disclosure of Confidential Information, any and all disputes, claims, </font>or controversies between OncoCyte or any Related Company and Employee, including but not limited to (a) those involving the construction, application, or enforceability of any of the terms, provisions, or conditions of this Agreement (including but not limited to the applicability and enforceability of provisions of this Section 7 with respect to any dispute, claim, or controversy) or the Policies; (b) all contract or tort claims of any kind; and (c) any claim based on any federal, state, or local law, statute, regulation, or ordinance, including claims for unlawful discrimination or harassment, shall be settled by arbitration in accordance with the then current Employment Dispute Resolution Rules of the American Arbitration Association. Judgment on the award rendered by the arbitrator(s) may be entered by any court having jurisdiction over the Company and Employee. The location of the arbitration shall be San Francisco, California. Unless OncoCyte or a Related Company and Employee mutually agree otherwise, the arbitrator shall be a retired judge selected from a panel provided by the American Arbitration Association, or the Judicial Arbitration and Mediation Service (JAMS). OncoCyte, or a Related Company if the Related Company is a party to the arbitration proceeding, shall pay the arbitrator's fees and costs. Employee shall pay for Employee's own costs and attorneys' fees, if any. OncoCyte and any Related Company that is a party to an arbitration proceeding shall pay for its own costs and attorneys' fees, if any. However, if any party prevails on a statutory claim which affords the prevailing party attorneys' fees, the arbitrator may award reasonable attorneys' fees and costs to the prevailing party.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0.35pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 6.25pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 33.8pt">EMPLOYEE UNDERSTANDS AND AGREES THAT THIS AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF EMPLOYEE'S RIGHT TO A TRIAL BY JURY OF ANY MATTERS COVERED BY THIS AGREEMENT TO ARBITRATE.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Severability. </font>In the event that any of the provisions of this Agreement or the Policies shall be held to be invalid or unenforceable in whole or in part, those provisions to the extent enforceable and all other provisions shall nevertheless continue to be valid and enforceable as though the invalid or unenforceable parts had not been included in this Agreement or the Policies. In the event that any provision relating to a time period of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period such court deems reasonable and enforceable, then the time period of restriction deemed reasonable and enforceable by the court shall become and shall thereafter be the maximum time period.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Agreement Read and Understood. </font>Employee acknowledges that Employee has carefully read the terms of this Agreement, that Employee has had an opportunity to consult with an attorney or other representative of Employee's own choosing regarding this Agreement, that Employee understands the terms of this Agreement, and that Employee is entering this agreement of Employee's own free will.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Complete Agreement, Modification. </font>This Agreement is the complete agreement between Employee and OncoCyte on the subjects contained in this Agreement. This Agreement supersedes and replaces all previous correspondence, promises, representations, and agreements, if any, either written or oral with respect to Employee's employment by OncoCyte or any Related Company and any matter covered by this Agreement. No provision of this Agreement may be modified, amended, or waived except by a written document signed both by OncoCyte and Employee.</font></div>

<div style="TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">7</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Governing Law. </font>This Agreement shall be construed and enforced according to the laws of the State of California.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Assignability. </font>This Agreement, and the rights and obligations of Employee and OncoCyte under this Agreement, may not be assigned by Employee. OncoCyte may assign any of its rights and obligations under this Agreement to any successor or surviving corporation, limited liability company, or other entity resulting from a merger, consolidation, sale of assets, sale of stock, sale of membership interests, or other reorganization, upon condition that the assignee shall assume, either expressly or by operation of law, all of OncoCyte's obligations under this Agreement.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">13.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Survival. </font>This Section 13 and the covenants and agreements contained in Sections 4 and 6 of this Agreement shall survive termination of this Agreement and Employee's employment.</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 45pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">14.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notices. </font>Any notices or other communication required or permitted to be given under this Agreement shall be in writing and shall be mailed by certified mail, return receipt requested, or sent by next business day air courier service, or personally delivered to the party to whom it is to be given at the address of such party set f01th on the signature page of this Agreement (or to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 14).</font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(SIGNATURE PAGE TO THE EMPLOYMENT AGREEMENT FOLLOWS)</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">8</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 45pt; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">IN </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">WITNESS </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">WHEREOF, </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Employee and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">OncoCyte have </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">executed </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">this Agreement </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">on the </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">day and </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">year </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">first </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">above written.</font></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb5c57ff6d7e4474fab796b9f1992320a" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33.33%">
<div>EMPLOYEE</div>
</td>
<td style="WIDTH: 33.33%">
<div>&#160;</div>
</td>
<td style="WIDTH: 33.33%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 33.33%">
<div>&#160;</div>
</td>
<td style="WIDTH: 33.33%">
<div>&#160;</div>
</td>
<td style="WIDTH: 33.33%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 33.33%">
<div>/s/ Michael Vicari</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 33.33%">
<div>&#160;</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 33.33%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 33.33%">Signature, Michael Vicari</td>
<td style="WIDTH: 33.33%">&#160;</td>
<td style="WIDTH: 33.33%">&#160;</td>
</tr>
</table>

<div>&#160;</div>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z3d1df24968944e41a58f8bd96f215328" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ONCOCYTE:</div>
</td>
<td style="WIDTH: 50%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%">
<div>&#160;</div>
</td>
<td style="WIDTH: 50%">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%">
<div>OncoCyte C01&#183;por</div>
</td>
<td style="WIDTH: 50%">
<div>&#160;</div>
</td>
</tr>
</table>

<div>&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc3d31d8accd64b879453f26ffb12c039" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 5%">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 5%">By:</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40%">/s/ William Annett</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 50%">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%">&#160;</td>
<td style="WIDTH: 5%">&#160;</td>
<td style="WIDTH: 40%">Signature, William Annett</td>
<td style="WIDTH: 50%">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%">&#160;</td>
<td style="WIDTH: 5%">&#160;</td>
<td style="WIDTH: 40%">&#160;</td>
<td style="WIDTH: 50%">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 5%">&#160;</td>
<td style="WIDTH: 5%">Title:</td>
<td style="WIDTH: 40%">C<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">hi</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">ef Executive </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Officer</font></td>
<td style="WIDTH: 50%">&#160;</td>
</tr>
</table>

<div>&#160;</div>
</div>

<div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">[</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">S</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">I</font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">GNATURE </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">PAGE TO THE </font><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">EMPLOYMENT AGREEMENT]</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">9</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 207.9pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 206.15pt">EXHIBIT A</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Job Title: Vice President, Sales, OncoCyte Corporation</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Job and Duties:</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zb355c337845b4aa6a666ec5249e9284d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.45pt"></td>
<td style="WIDTH: 16.55pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Inspire the US Sales organization to meet and exceed defined sales and revenue targets and other business objectives when selling a suite of breakthrough products that fulfill significant unmet clinical needs, to maximize the huge commercial potential for OncoCyte products in the US market.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z30c70b1535f345eea32cf007b94f982b" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.8pt"></td>
<td style="WIDTH: 16.2pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Manage resources for and provide leadership and development of the US Sales organization that encompasses Physician Sales, Sales Management, Sales Operations, and Sales Training.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za44a1ff394894314a6e12c7d9db0ac6e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.8pt"></td>
<td style="WIDTH: 15.2pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Lead and coach the sales management team, drive change management when needed, and be a visible example of leadership through presence, influence, and negotiation.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za9067388fe2843f4a8026ebd6cf53ce3" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.8pt"></td>
<td style="WIDTH: 16.2pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Partner with sales management, human resources, and other cross functional partners to recruit, train, and develop the US sales organization, implementing retention and succession plans to maximize and sustain effectiveness as the company grows.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zc8bbbf5cbc1c40f7923818c22e522416" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Lead all sales business planning efforts, including development of field sales strategies, setting of sales objectives by territory with input from Marketing, sales reporting and business opportunity identification, and alignment with marketing plans and tactics.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zafd91379607f45f2a1d2bb2912f328ec" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Provide leadership, guidance, and direction to sales management regarding sales strategy, call planning/frequency, sales productivity, POA execution, etc.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zfac37e7070984cdd9ab562c1fa27227c" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Build and foster strategic partnerships with key customers and KOLs to maintain effective local, regional, and national relationships that can be leveraged as the company grows.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd303b2106eb54e42a7e770fa5c225cab" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Oversee all sales meetings and associated operations for national meetings and sales training, coordinating with marketing and other key cross functional partners on planning and content.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="z477bc407a49d4a0d867f626d7f3d7544" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Collaborate with Marketing and Market Access teams to develop strategic business plans and tactics for near and long-term planning cycles as the company grows.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zd99ab04c31654971be6621e00955fc6d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; align: right">&#8226;</td>
<td style="TEXT-ALIGN: left; WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Regularly monitor, track, and report sales performance/progress including use of budget and resources across all US sales regions and territories.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="zdcd28dc23c9f429aa29f8d7cc30a9b1d" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#8226;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Be a key part of, and contributor to, the senior management team at OncoCyte.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt" id="za34c40cf14bf481698f6147e48942425" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 57.15pt"></td>
<td style="WIDTH: 15.85pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#8226;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; align: left">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Comply with laws, regulations and policies that govern our commercial activities.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Annual Salary: </font>$280,000</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bonus: </font>Target set at 40% of base salary subject to the discretion of the Company's Board of Directors or its Compensation Committee. 50% of total bonus amount will be based on the achievement of a revenue goal. This portion of the bonus will be paid quarterly with potential acceleration of bonus payment as measured against targets as determined by the Board of Directors or its Compensation Committee. The other 50% of the total bonus amount will be based on the attainment of Company performance goals and milestones as the Board of Directors or its Compensation Committee may set.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">10</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock Options: </font>Employee shall be entitled to receive such number of options to purchase Company common shares under the Company's&#160; Equity Incentive Plan (the "Plan") as the Company's&#160; Board of Directors or Compensation Committee may determine. The exercise price of the options shall be the fair market value of the Company's common shares on the effective date of grant determined in accordance with the Plan. The date of grant of the options shall be the date on which Employee's employment has commenced under this Agreement. Employee shall execute a stock option agreement consistent with the terms of the option grant and the Plan. The options shall vest and thereby become exercisable, and the options shall expire, as provided in the Plan and the terms of the option grant.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Paid Time Off: </font>Employee shall be entitled to a total of twenty (20) paid time off days per annum (accrued on a biweekly pay period basis) as "paid time off' for vacation, three (3) days sick leave, and all company observed holidays.</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber"></font>&#160;</div>

<div style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 8pt; FONT-WEIGHT: normal">11</div>
</div>

<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">
<hr style="BORDER-BOTTOM: medium none; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; BORDER-TOP: medium none; MARGIN-RIGHT: auto; BORDER-RIGHT: medium none" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 4px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">EXHIBIT 23.1</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt">We hereby consent to the incorporation by reference in Amendment No. 2 to Registration Statements on Form S-1 (No. 333-213810), on Form S-3 (No. 333-220769) and in Registration Statement on Form S-8 (Nos. 333-219109 and 333-208935) of OncoCyte Corporation of our report dated April 2, 2018 relating to the financial statements of OncoCyte Corporation, which appears in this Annual Report on Form 10-K.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff"><br>
 &#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">/s/ OUM &amp; Co. LLP</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">San Francisco, California</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">April 2, 2018</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>ex31.htm
<DESCRIPTION>EXHIBIT 31
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 4px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right">Exhibit 31</div>

<div><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">CERTIFICATIONS</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">I, William Annett, certify that:</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">1. I have reviewed this annual report on Form 10-K of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">OncoCyte Corporation</font>;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Date: April 2, 2018</div>

<div><br>
</div>
</div>

<table id="z761b40e44abd4295b551bc60c5c92df0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">/s/ <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">William Annett</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">William Annett</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">Exhibit 31</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">CERTIFICATIONS</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">I, Mitchell Levine, certify that:</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">1. I have reviewed this annual report on Form 10-K of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">OncoCyte Corporation</font>;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this periodic report is being prepared;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Date: April 2, 2018</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<table id="za84ea07d168e40ad95e44ebc8ad127e8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">/s/ <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">Mitchell Levine</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Mitchell Levine</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">Chief Financial Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 80%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>
</table>

<div style="BACKGROUND-COLOR: #ffffff">&#160;</div>

<div style="BACKGROUND-COLOR: #ffffff">&#160;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ex32.htm
<DESCRIPTION>EXHIBIT 32
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Broadridge Financial Solutions, Inc.
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 4px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">Exhibit 32</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">AS ADOPTED PURSUANT TO</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">In connection with the Annual Report on Form 10-K of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">OncoCyte Corporation</font> (the &#8220;Company&#8221;) for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BACKGROUND-COLOR: #ffffff">William Annett</font>, Chief Executive Officer, and Mitchell Levine, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>

<div><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify; BACKGROUND-COLOR: #ffffff">Date: April 2, 2018</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<table id="z2c112b806c874ff0be46ef8ba457bae9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">/s/ <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">William Annett</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">William Annett</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: left">/s/ <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-STYLE: italic">Mitchell Levine</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Mitchell Levine</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.38%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; TEXT-ALIGN: justify">Chief Financial Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 77%; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>
</table>

<div>&#160;</div>

<div>&#160;</div>

<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>ocx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:ocx="http://oncocyte.com/20171231" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ocx-20171231.xsd" />
  <xbrli:context id="c20170101to20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180320">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20141231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ocx:InvestorTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-28</xbrli:startDate>
      <xbrli:endDate>2018-03-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-28</xbrli:startDate>
      <xbrli:endDate>2018-03-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151118to20151118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-18</xbrli:startDate>
      <xbrli:endDate>2015-11-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocx:EquipmentAndFurnitureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ocx:EquipmentAndFurnitureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180101to20181231_StatementScenarioAxis_ScenarioPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_BalanceSheetLocationAxis_CurrentLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ocx:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_BalanceSheetLocationAxis_CurrentLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ocx:CurrentLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170323_DebtInstrumentAxis_LoanAndSecurityAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-21</xbrli:startDate>
      <xbrli:endDate>2017-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember_VariableRateAxis_PrimeRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-21</xbrli:startDate>
      <xbrli:endDate>2017-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_DebtInstrumentAxis_LoanAndSecurityAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170221_ClassOfWarrantOrRightAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170323_ClassOfWarrantOrRightAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_ClassOfWarrantOrRightAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160829">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-08-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160829to20160829">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-29</xbrli:startDate>
      <xbrli:endDate>2016-08-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721to20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:FirstFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-21</xbrli:startDate>
      <xbrli:endDate>2017-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721to20170721_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-21</xbrli:startDate>
      <xbrli:endDate>2017-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721to20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:SecondFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-21</xbrli:startDate>
      <xbrli:endDate>2017-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217to20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:NewWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-17</xbrli:startDate>
      <xbrli:endDate>2017-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:SecondFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart2WarrantExerciseAgreementJuly212017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormPart2WarrantExerciseAgreementJuly212017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorsGroupOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">ocx:InvestorsGroupOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:NewWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:FirstFormWarrantExerciseAgreementJuly2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:July2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217_ClassOfWarrantOrRightAxis_Warrants2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:Warrants2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart1WarrantExerciseAgreementJuly212017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormPart1WarrantExerciseAgreementJuly212017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:SecondFormWarrantExerciseAgreementJuly2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:NewWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:FirstFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:FirstFormWarrantExerciseAgreementJuly2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormPart1WarrantExerciseAgreementJuly212017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormPart1WarrantExerciseAgreementJuly212017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_July2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:July2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:SecondFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:SecondFormWarrantExerciseAgreementJuly2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_NewWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:NewWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormPart2WarrantExerciseAgreementJuly212017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormPart2WarrantExerciseAgreementJuly212017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_Warrants2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:Warrants2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:FirstFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:ThirdFormWarrantExerciseAgreement2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721to20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:July2017WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-21</xbrli:startDate>
      <xbrli:endDate>2017-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217to20170217_ClassOfWarrantOrRightAxis_Warrants2016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:Warrants2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-17</xbrli:startDate>
      <xbrli:endDate>2017-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170217to20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocx:NewWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-17</xbrli:startDate>
      <xbrli:endDate>2017-02-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170721to20170721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-21</xbrli:startDate>
      <xbrli:endDate>2017-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_StatementClassOfStockAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_IncomeTaxAuthorityAxis_DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_TaxCreditCarryforwardAxis_ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_RangeAxis_MaximumMember_TaxCreditCarryforwardAxis_ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_RangeAxis_MinimumMember_TaxCreditCarryforwardAxis_ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20151231_ConsolidatedEntitiesAxis_ParentCompanyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170430_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170511_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-05-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-07</xbrli:startDate>
      <xbrli:endDate>2016-04-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170401to20170430_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2017-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-07</xbrli:startDate>
      <xbrli:endDate>2016-04-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">ocx:MasterLeaseLineAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_RangeAxis_MaximumMember_TypeOfArrangementAxis_WistarLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocx:WistarLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_RangeAxis_MinimumMember_TypeOfArrangementAxis_WistarLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocx:WistarLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20171231_TypeOfArrangementAxis_WistarLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocx:WistarLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20170101to20171231_TypeOfArrangementAxis_WistarLicenseAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocx:WistarLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180328_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-28</xbrli:startDate>
      <xbrli:endDate>2018-03-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20180328_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BroadwoodPartnersLPMember_SubsequentEventTypeAxis_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ocx:BroadwoodPartnersLPMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U005">
    <xbrli:measure>ocx:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U006">
    <xbrli:measure>ocx:Vote</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U007">
    <xbrli:measure>ocx:Investor</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U008">
    <xbrli:measure>ocx:Form</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U009">
    <xbrli:measure>ocx:Extension</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20170101to20171231">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20170101to20171231">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20170101to20171231">2017-12-31</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20170101to20171231">No</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20170101to20171231">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20170101to20171231">Yes</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20170101to20171231">Non-accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Public Float-->
  <dei:EntityPublicFloat contextRef="c20170630" unitRef="U001" decimals="-5">41400000</dei:EntityPublicFloat>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20170101to20171231">OncoCyte Corp</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20170101to20171231">0001642380</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20180320" unitRef="U002" decimals="INF">31468558</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20170101to20171231">2017</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20170101to20171231">FY</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20170101to20171231">10-K</dei:DocumentType>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-527000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-304000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">75000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231" unitRef="U001" decimals="-3">75000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-304000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Accumulated Deficit [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-527000</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Unrealized gain (loss) on BioTime shares held as available-for-sale securities-Common Stock [Member]-->
  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">1042000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">797000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <!--Other accrued expenses-->
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">248000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <!--Other accrued expenses-->
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">406000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20161231" unitRef="U001" decimals="-3">422000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20171231" unitRef="U001" decimals="-3">175000</us-gaap:AccountsPayableCurrent>
  <!--Accrued Liabilities, Current-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">549000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued Liabilities, Current-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">636000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accumulated other comprehensive loss on available-for-sale securities-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20171231" unitRef="U001" decimals="-3">-888000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss on available-for-sale securities-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20161231" unitRef="U001" decimals="-3">-654000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20171231" unitRef="U001" decimals="-3">657000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment-->
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20161231" unitRef="U001" decimals="-3">319000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">1815000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">922000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">1630000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-General and Administrative Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">1359000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Sales and Marketing [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">121000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Research and Development [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">456000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3">922000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-General and Administrative Expense [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">610000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Sales and Marketing [Member]-Employee Stock Option [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3">1815000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-General and Administrative Expense [Member]-Employee Stock Option [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">841000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Research and Development [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">668000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Sales and Marketing [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-3">1630000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Allocated Share-based Compensation Expense-Employee Stock Option [Member]-Research and Development [Member]-->
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">312000</us-gaap:AllocatedShareBasedCompensationExpense>
  <!--Amortization of Debt Issuance Costs-Loan and Security Agreement [Member]-->
  <us-gaap:AmortizationOfFinancingCosts contextRef="c20170101to20171231_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U001" decimals="-3">116000</us-gaap:AmortizationOfFinancingCosts>
  <!--Amortization of Debt Issuance Costs and Discounts-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20170101to20171231" unitRef="U001" decimals="-3">83000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Amortization of Debt Issuance Costs and Discounts-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20150101to20151231" unitRef="U001" decimals="-3">18000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Amortization of Debt Issuance Costs and Discounts-->
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20160101to20161231" unitRef="U001" decimals="-3">242000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20170101to20171231" unitRef="U001" decimals="-3">242000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Amortization of intangible assets-->
  <us-gaap:AmortizationOfIntangibleAssets contextRef="c20150101to20151231" unitRef="U001" decimals="-3">242000</us-gaap:AmortizationOfIntangibleAssets>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">3017000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20170101to20171231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3">2779000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20170101to20171231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">3390000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Employee Stock Option [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20150101to20151231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">2240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive securities excluded from computation of earnings per share (in shares)-Warrant [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20160101to20161231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="-3">3246000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Asset Impairment Charges-->
  <us-gaap:AssetImpairmentCharges contextRef="c20170101to20171231" unitRef="U001" decimals="-6">0</us-gaap:AssetImpairmentCharges>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20161231" unitRef="U001" decimals="-3">14447000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20171231" unitRef="U001" decimals="-3">10216000</us-gaap:Assets>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20171231" unitRef="U001" decimals="-3">8528000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20161231" unitRef="U001" decimals="-3">12696000</us-gaap:AssetsCurrent>
  <!--Available-for-sale Securities, Gross Realized Gain (Loss)-->
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <!--Available-for-sale Securities, Gross Realized Gain (Loss)-->
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-309000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <!--Available-for-sale Securities, Gross Realized Gain (Loss)-->
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <!--Shares held as available-for-sale securities, at fair value-->
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">760000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <!--Shares held as available-for-sale securities, at fair value-->
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">2237000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <!--Shares held as available-for-sale securities, at fair value-BioTime, Inc. [Member]-->
  <us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent contextRef="c20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-5">800000</us-gaap:AvailableForSaleSecuritiesEquitySecuritiesCurrent>
  <!--Basis of presentation-->
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Basis of presentation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;). Prior to February 17, 2017, BioTime consolidated the results of OncoCyte into BioTime's consolidated results based on BioTime's ability to control OncoCyte's operating and financial decisions and policies through its majority ownership of OncoCyte common stock. BioTime owned 51.1% of the outstanding common stock of OncoCyte at December 31, 2016. Beginning on February 17, 2017, BioTime's percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of "control" of OncoCyte under GAAP and, as a result, BioTime deconsolidated OncoCyte's financial statements from BioTime's consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP with effect from February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime's retained share ownership in OncoCyte, which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte&amp;#8217;s operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <!--Increment value of lease agreement-Master Lease Line Agreement [Member]-Minimum [Member]-->
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember" unitRef="U001" decimals="-3">50000</us-gaap:CapitalLeaseObligationsIncurred>
  <!--2020-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c20171231" unitRef="U001" decimals="-3">59000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
  <!--Lease agreement value-->
  <us-gaap:CapitalLeaseObligations contextRef="c20171231" unitRef="U001" decimals="-3">381000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-->
  <us-gaap:CapitalLeaseObligations contextRef="c20161231" unitRef="U001" decimals="-3">626000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeaseObligations contextRef="c20170430_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3">285000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-Maximum [Member]-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeaseObligations contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MaximumMember" unitRef="U001" decimals="-3">881000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeaseObligations contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3">161000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeaseObligations contextRef="c20170511_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3">900000</us-gaap:CapitalLeaseObligations>
  <!--Lease agreement value-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeaseObligations contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3">435000</us-gaap:CapitalLeaseObligations>
  <!--Capital Leases, Future Minimum Payments Due-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="c20171231" unitRef="U001" decimals="-3">690000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
  <!--2018-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="c20171231" unitRef="U001" decimals="-3">383000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
  <!--Capital Lease Obligations, Current-->
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="c20171231" unitRef="U001" decimals="-3">338000</us-gaap:CapitalLeaseObligationsCurrent>
  <!--Capital Lease Obligations, Current-->
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="c20161231" unitRef="U001" decimals="-3">202000</us-gaap:CapitalLeaseObligationsCurrent>
  <!--2019-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c20171231" unitRef="U001" decimals="-3">248000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
  <!--Capital lease liability, noncurrent-->
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c20171231" unitRef="U001" decimals="-3">289000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <!--Capital lease liability, noncurrent-->
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="c20161231" unitRef="U001" decimals="-3">310000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <!--Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="c20171231" unitRef="U001" decimals="-3">627000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
  <!--Monthly payment under capital lease-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20170430_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="0">9462</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <!--Monthly payment under capital lease-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20161231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="0">5342</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <!--Monthly payment under capital lease-Master Lease Line Agreement [Member]-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="0">14442</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <!--Monthly payment under capital lease-->
  <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="c20171231" unitRef="U001" decimals="-3">63000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
  <!--Cash-->
  <us-gaap:Cash contextRef="c20171231" unitRef="U001" decimals="-5">7600000</us-gaap:Cash>
  <!--Cash-->
  <us-gaap:Cash contextRef="c20161231" unitRef="U001" decimals="-5">10200000</us-gaap:Cash>
  <!--Cash and Cash Equivalents, Policy [Policy Text Block]-->
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2017 and 2016, OncoCyte's cash balances totaled $7.6 million and $10.2 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20161231" unitRef="U001" decimals="-3">10174000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20171231" unitRef="U001" decimals="-3">7600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20141231" unitRef="U001" decimals="-3">257000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20151231" unitRef="U001" decimals="-3">7996000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20160101to20161231" unitRef="U001" decimals="-3">2178000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-2574000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20150101to20151231" unitRef="U001" decimals="-3">7739000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Warrants outstanding (in shares)-->
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c20171231" unitRef="U002" decimals="INF">2779221</us-gaap:ClassOfWarrantOrRightOutstanding>
  <!--Warrants issued (in shares)-Warrant [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170221_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="INF">8247</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Warrant [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170323_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="INF">7321</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Second Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U002" decimals="INF">540000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Third Form Part2 Warrant Exercise Agreement July21 2017 [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" unitRef="U002" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Investors Group One [Member]-New Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorsGroupOneMember" unitRef="U002" decimals="INF">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-First Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" unitRef="U002" decimals="INF">226923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-July 2017 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember" unitRef="U002" decimals="INF">1496923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Warrants 2016 [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170217_ClassOfWarrantOrRightAxis_Warrants2016Member" unitRef="U002" decimals="INF">625000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Third Form Part1 Warrant Exercise Agreement July21 2017 [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" unitRef="U002" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Second Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" unitRef="U002" decimals="INF">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Investor One [Member]-New Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorMember" unitRef="U002" decimals="INF">212500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-First Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U002" decimals="INF">226923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants issued (in shares)-Third Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U002" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <!--Warrants exercise price (in dollars per share)-Warrant [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170323_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2">5.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Warrant [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170221_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2">4.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Warrants 2016 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_ClassOfWarrantOrRightAxis_Warrants2016Member" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Second Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Third Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-New Warrants [Member]-Investors Group One [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorsGroupOneMember" unitRef="U003" decimals="2">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Third Form Part1 Warrant Exercise Agreement July21 2017 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" unitRef="U003" decimals="2">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Investor One [Member]-New Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorMember" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-First Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" unitRef="U003" decimals="2">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Second Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-Third Form Part2 Warrant Exercise Agreement July21 2017 [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Warrants exercise price (in dollars per share)-First Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U003" decimals="2">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <!--Class of Warrant or Right, Unissued-->
  <us-gaap:ClassOfWarrantOrRightUnissued contextRef="c20171231" unitRef="U002" decimals="INF">2779221</us-gaap:ClassOfWarrantOrRightUnissued>
  <!--Class of Warrant or Right, Number of Securities Called by Each Warrant or Right-->
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c20160829" unitRef="U002" decimals="INF">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <!--Commitments and Contingencies Disclosure [Text Block]-->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;9. Commitments and Contingencies&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has certain commitments other than those under the Shared Facilities and Services Agreement described in Note 4.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;"&gt;Master Lease Line Agreement&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On April 7, 2016, OncoCyte entered into a Master Lease Line Agreement ("Lease Agreement&amp;#8221;) with an unrelated financing company for the purchase and financing of certain equipment. OncoCyte may use up to $881,000, as amended, for purchases of equipment financed under the Lease Agreement through April 2017. Each lease schedule OncoCyte enters into under Lease Agreement must be in minimum increments of $50,000 each with a 36-month lease term, collateralized by the equipment financed under the lease schedule. Each lease schedule requires a deposit for the first and last payment under that schedule. Monthly payments will be determined using a lease factor approximating an interest rate of 10% per annum. At the end of each lease schedule under Lease Agreement, assuming no default has occurred, OncoCyte may either return the equipment financed under the schedule for a restocking fee of 7.5% of the original cost of the equipment or purchase the equipment from the financing company at a fair value not less than 12.5% of the original cost of the equipment.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On April 7, 2016, OncoCyte entered into a lease schedule under the Lease Agreement (&amp;#8220;Lease Schedule No. 1&amp;#8221;) for certain equipment costing approximately $435,000 applied against the lease line, requiring payments of $14,442 per month over 36 months. In December 2016, OncoCyte entered into another lease schedule (&amp;#8220;Lease Schedule No. 2&amp;#8221;) for certain equipment costing approximately $161,000, requiring payments of $5,342 per month over 36 months. In April 2017, OncoCyte entered into a third and final lease schedule (&amp;#8220;Lease Schedule No. 3&amp;#8221;) for certain equipment costing approximately $285,000, requiring payments of $9,462 per month over 36 months. After this last tranche, the Lease Agreement was closed and has no remaining financing available.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;OncoCyte has accounted for these leases as a capital lease in accordance with ASC 840,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Leases&lt;/font&gt;, due to the net present value of the payments under the lease approximating the fair value of the equipment at inception of the lease. The payments under the lease schedules will be amortized to capital lease obligations and interest expense using the interest method at an imputed rate of approximately 10% per annum.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On May 11, 2017, OncoCyte entered into another Master Lease Line Agreement ("Lease Agreement No. 2") with the same finance company above and similar terms. OncoCyte may use up to $900,000 for purchases of equipment financed under Lease Agreement No. 2 through October 28, 2018. As of December 31, 2017, $820,000 under Lease Agreement No. 2 was available to OncoCyte.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Future minimum annual lease payments under &lt;/font&gt;Lease Schedule No.&amp;#8217;s 1, 2, and 3 above &lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;for the years ending after December 31, 2017 are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;br class="Apple-interchange-newline" /&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Year Ending&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Capital Lease&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Payments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;59&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;690&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less amounts representing interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(63&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Present value of net minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;627&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Wistar License Agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte has entered into a License Agreement with The Wistar Institute of Anatomy and Biology (&amp;#8220;Wistar&amp;#8221;) that entitles OncoCyte to use certain patents, know-how and data belonging to Wistar.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;Under the License Agreement, OncoCyte has obtained an exclusive, worldwide license under certain patents, and under certain know-how and data ("Technical Information") belonging to Wistar, for use in the field of molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.&amp;#160; OncoCyte has the right to grant sublicenses of the licensed patents and Technical Information subject to certain conditions.&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte paid Wistar an initial license fee and will pay Wistar royalties on &amp;#8220;net sales&amp;#8221; of &amp;#8220;licensed products,&amp;#8221; as such terms are defined in the License Agreement. The royalty rates will range from 3% to 5% depending upon the amount of cumulative net sales. The amount of royalties payable to Wistar will be reduced by the amount of any royalties that OncoCyte must pay to any third parties on the sale of the licensed products, but subject to a maximum reduction of 50%. The obligation to pay royalties to Wistar will terminate on a licensed product by-licensed product and country-by-country basis until the later of (i) the date a valid claim of a licensed patent covering the licensed product no longer exists, or (ii) the tenth (10th) anniversary of the first commercial sale of the licensed product in each country.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte will pay Wistar a minimum annual royalty each year, which in each case will be credited against total royalties due during the year in which the minimum royalty is paid. OncoCyte will also be obligated to pay Wistar an annual license maintenance fee in the mid-five figures.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte will also pay Wistar a portion of any non-royalty sublicensing income that OncoCyte may receive from any sub-licensee. Non-royalty sublicensing income will include any consideration received from a sub-licensee for granting the sublicense, but excluding royalties, the fair market value of any equity or debt securities sold to a sub-licensee, and any payments received from a sub-licensee for any related research conducted by OncoCyte for the sublicensee.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte also will pay Wistar (a) milestone payments upon the occurrence of certain milestone events in the development and commercialization of a licensed product, and (b) all past or ongoing costs incurred or to be incurred by Wistar, including government fees and attorneys' fees, in the course of prosecuting the licensed patents.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte has agreed to use commercially reasonable diligent efforts, directly or through sub-licensees, to develop and commercialize licensed products. OncoCyte has agreed that it or a sub-licensee will commence commercial sale of a licensed product by a specified date. If sales of a licensed product do not commence by the specified date, OncoCyte may purchase up to three one-year extensions of the deadline by paying Wistar a designated fee for the applicable extension.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte has agreed to indemnify Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel and staff from and against certain claims and liabilities related to the License Agreement and development, manufacture and sale of licensed products, excluding liabilities that result from or arise out of an indemnified party's gross negligence or willful misconduct.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;Wistar has the right to terminate the License Agreement, subject to certain notice and cure periods and &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;force majeure&lt;/font&gt; delays in certain cases, if any of the following occur:&amp;#160; (a) OncoCyte fails to pay any amount payable to Wistar; (b) OncoCyte materially breaches any covenant or agreement or any continuing representation or warranty contained in the License Agreement; (c) OncoCyte becomes subject to certain bankruptcy or insolvency events, (d) OncoCyte dissolves or ceases operations, (e) OncoCyte or any of its affiliates or sub-licensees or affiliates of any our sub-licensees challenges the validity, patentability, scope, construction, enforceability, non-infringement, or Wistar's ownership of any issued patent comprising the licensed patents, or assists any third party in any such challenge; or (f) OncoCyte fails to fulfill its product development and commercialization diligence obligations and related performance milestones.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;"&gt;OncoCyte may terminate the License Agreement, with or without cause, upon the passage of a specified period of time after giving Wistar written notice of termination.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Litigation &amp;#8211; General&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When OncoCyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, OncoCyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, OncoCyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. OncoCyte is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Tax Filings&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;"&gt;OncoCyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes OncoCyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the financial statements.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Employment Contracts&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has entered into employment contracts with certain executive officers. Under the provisions of the contracts, OncoCyte may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Indemnification&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In the normal course of business, OncoCyte may provide indemnification of varying scope under OncoCyte&amp;#8217;s agreements with other companies or consultants, typically OncoCyte&amp;#8217;s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, OncoCyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of OncoCyte&amp;#8217;s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to OncoCyte&amp;#8217;s diagnostic tests. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments OncoCyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, OncoCyte has not been subject to any claims or demands for indemnification. OncoCyte also maintains various liability insurance policies that limit OncoCyte&amp;#8217;s financial exposure. As a result, OncoCyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, OncoCyte has not recorded any liabilities for these agreements as of December 31, 2017 and 2016.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!--Commitments and contingencies (Note 9)-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20171231" unitRef="U001" xsi:nil="true" />
  <!--Commitments and contingencies (Note 9)-->
  <us-gaap:CommitmentsAndContingencies contextRef="c20161231" unitRef="U001" xsi:nil="true" />
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20171231" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common shares, par value (in dollars per share)-->
  <us-gaap:CommonStockNoParValue contextRef="c20161231" unitRef="U003" decimals="INF">0</us-gaap:CommonStockNoParValue>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20171231" unitRef="U002" decimals="-3">50000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20161231" unitRef="U002" decimals="-3">50000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20161231" unitRef="U002" decimals="-3">28737000</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20171231" unitRef="U002" decimals="-3">31452000</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-BioTime, Inc. [Member]-->
  <us-gaap:CommonStockSharesIssued contextRef="c20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">266442</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-BioTime, Inc. [Member]-->
  <us-gaap:CommonStockSharesIssued contextRef="c20151231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">259712</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-BioTime, Inc. [Member]-->
  <us-gaap:CommonStockSharesIssued contextRef="c20161231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">0</us-gaap:CommonStockSharesIssued>
  <!--Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively-->
  <us-gaap:CommonStockValue contextRef="c20171231" unitRef="U001" decimals="-3">59968000</us-gaap:CommonStockValue>
  <!--Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively-->
  <us-gaap:CommonStockValue contextRef="c20161231" unitRef="U001" decimals="-3">45818000</us-gaap:CommonStockValue>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20161231" unitRef="U002" decimals="-3">28737000</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231" unitRef="U002" decimals="-3">31452000</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">18200000</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">25391000</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">28737000</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-Common Stock [Member]-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">31452000</us-gaap:CommonStockSharesOutstanding>
  <!--Comprehensive Income (Loss), Net of Tax, Attributable to Parent-->
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-11472000</us-gaap:ComprehensiveIncomeNetOfTax>
  <!--Comprehensive Income (Loss), Net of Tax, Attributable to Parent-->
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-19609000</us-gaap:ComprehensiveIncomeNetOfTax>
  <!--Comprehensive Income (Loss), Net of Tax, Attributable to Parent-->
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-8263000</us-gaap:ComprehensiveIncomeNetOfTax>
  <!--Equipment purchased under capital leases-->
  <us-gaap:ContributionOfProperty contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:ContributionOfProperty>
  <!--Equipment purchased under capital leases-->
  <us-gaap:ContributionOfProperty contextRef="c20170101to20171231" unitRef="U001" decimals="-3">381000</us-gaap:ContributionOfProperty>
  <!--Equipment purchased under capital leases-->
  <us-gaap:ContributionOfProperty contextRef="c20160101to20161231" unitRef="U001" decimals="-3">626000</us-gaap:ContributionOfProperty>
  <!--Basis spread variable rate-Loan and Security Agreement [Member]-Prime Rate [Member]-->
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember_VariableRateAxis_PrimeRateMember" unitRef="U004" decimals="INF">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <!--Debt Conversion, Converted Instrument, Amount-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Amount-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231" unitRef="U001" decimals="-3">3300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Amount-Common Stock [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">3300000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Amount-Accumulated Deficit [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Amount-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Amount-->
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <!--Debt Conversion, Converted Instrument, Shares Issued-Common Stock [Member]-->
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">1500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <!--Long-term Debt, Gross-->
  <us-gaap:DebtInstrumentCarryingAmount contextRef="c20171231" unitRef="U001" decimals="-3">2097000</us-gaap:DebtInstrumentCarryingAmount>
  <!--Prime rate plus variable spread per annum-Loan and Security Agreement [Member]-->
  <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c20170101to20171231_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.0525</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <!--Base rate-Loan and Security Agreement [Member]-->
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <!--Debt Instrument, Face Amount-Loan and Security Agreement [Member]-->
  <us-gaap:DebtInstrumentFaceAmount contextRef="c20170323_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U001" decimals="-5">2000000</us-gaap:DebtInstrumentFaceAmount>
  <!--Periodic payment term-Loan and Security Agreement [Member]-->
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember">Monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <!--Debt issuance costs-->
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <!--Debt issuance costs-->
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c20170101to20171231" unitRef="U001" decimals="-3">196000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <!--Debt issuance costs-->
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <!--Periodic payments of principal and interest-Loan and Security Agreement [Member]-->
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U001" decimals="-3">67000</us-gaap:DebtInstrumentPeriodicPayment>
  <!--Deferred Tax Liabilities, Investments-->
  <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c20171231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxLiabilitiesInvestments>
  <!--Deferred Tax Liabilities, Investments-->
  <us-gaap:DeferredTaxLiabilitiesInvestments contextRef="c20161231" unitRef="U001" decimals="-3">761000</us-gaap:DeferredTaxLiabilitiesInvestments>
  <!--Deferred financing costs-Warrant [Member]-->
  <us-gaap:DeferredFinanceCostsNet contextRef="c20171231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="-3">62000</us-gaap:DeferredFinanceCostsNet>
  <!--Deferred Tax Liabilities, Gross-->
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="c20171231" unitRef="U001" decimals="-3">0</us-gaap:DeferredIncomeTaxLiabilities>
  <!--Deferred Tax Liabilities, Gross-->
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="c20161231" unitRef="U001" decimals="-3">761000</us-gaap:DeferredIncomeTaxLiabilities>
  <!--Net operating loss carryforwards-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20171231" unitRef="U001" decimals="-3">11414000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Net operating loss carryforwards-->
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c20161231" unitRef="U001" decimals="-3">11730000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <!--Deferred Tax Assets, Net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20161231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Deferred Tax Assets, Net-->
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c20171231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <!--Deferred Tax Assets, Net of Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsNet contextRef="c20161231" unitRef="U001" decimals="-3">761000</us-gaap:DeferredTaxAssetsNet>
  <!--Deferred Tax Assets, Net of Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsNet contextRef="c20171231" unitRef="U001" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20171231" unitRef="U001" decimals="-3">15083000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Assets, Valuation Allowance-->
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c20161231" unitRef="U001" decimals="-3">13954000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <!--Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20171231" unitRef="U001" decimals="-3">1260000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost-->
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c20161231" unitRef="U001" decimals="-3">1041000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <!--Research and development credit carryforwards-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20171231" unitRef="U001" decimals="-3">2141000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <!--Research and development credit carryforwards-->
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c20161231" unitRef="U001" decimals="-3">1765000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <!--Deposits-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20171231" unitRef="U001" decimals="-3">120000</us-gaap:DepositsAssetsNoncurrent>
  <!--Deposits-->
  <us-gaap:DepositsAssetsNoncurrent contextRef="c20161231" unitRef="U001" decimals="-3">75000</us-gaap:DepositsAssetsNoncurrent>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20170101to20171231" unitRef="U001" decimals="-3">338000</us-gaap:Depreciation>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20150101to20151231" unitRef="U001" decimals="-3">41000</us-gaap:Depreciation>
  <!--Depreciation expense-->
  <us-gaap:Depreciation contextRef="c20160101to20161231" unitRef="U001" decimals="-3">145000</us-gaap:Depreciation>
  <!--Disclosure of Compensation Related Costs, Share-based Payments [Text Block]-->
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;7. Stock-based Compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Stock Option Plan&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has adopted a 2010 Stock Option Plan (the &amp;#8220;Plan&amp;#8221;) under which 5,200,000 shares of common stock were made available for the grant of stock options or the sale of restricted stock. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As discussed in Note 4, OncoCyte may grant stock options to employees of BioTime, or employees of other BioTime subsidiaries, who perform services for OncoCyte. OncoCyte records stock-based compensation expense in the accompanying statements of operations for those services performed in the periods presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Stock Options&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Options granted under the Plan may be either &amp;#8220;incentive stock options&amp;#8221; within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the &amp;#8220;Code&amp;#8221;), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The options&amp;#8217; exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant&amp;#8217;s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Options Granted&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, 1,384,198 shares were available for future grants under the Plan.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Shares&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Available&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;for Grant&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Number of&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Options&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Outstanding&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Weighted&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Average&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at January 1, 2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,757&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.03&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(962&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;962&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.19&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options forfeited, cancelled or expired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.00&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at December 31, 2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;880&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.52&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Increase in pool&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(896&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;896&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;5.17&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1.89&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options forfeited, cancelled or expired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.11&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,390&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.25&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Exercisable at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,835&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.48&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, OncoCyte had approximately $1.6 million and $2.7 million, respectively, of total unrecognized compensation expense related to the Plan that will be recognized over a weighted-average period of approximately 2.5 and 2.4 years, respectively.&lt;/div&gt;&lt;div style="text-align: justify;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;668&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;312&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;456&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;841&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;610&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,359&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Sales and marketing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,630&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,815&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The assumptions that were used to calculate the grant date fair value of OncoCyte&amp;#8217;s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Expected life (in years)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.15&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.21&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.83&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Risk-free interest rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;2.03&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;1.46&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;1.87&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;66.01&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;64.64&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;74.15&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="background-color: #ffffff;"&gt;&lt;/font&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;With the adoption of ASU 2016-09, effectively January 1, 2017, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2017, 2016 and 2015, may have been significantly different.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <!--OncoCyte common stock received as a dividend in kind from BioTime-Common Stock [Member]-->
  <us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:DividendsCommonStockPaidinkind>
  <!--OncoCyte common stock received as a dividend in kind from BioTime-Accumulated Deficit [Member]-->
  <us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:DividendsCommonStockPaidinkind>
  <!--OncoCyte common stock received as a dividend in kind from BioTime-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:DividendsCommonStockPaidinkind>
  <!--OncoCyte common stock received as a dividend in kind from BioTime-->
  <us-gaap:DividendsCommonStockPaidinkind contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:DividendsCommonStockPaidinkind>
  <!--Amount due to BioTime and affiliates-->
  <us-gaap:DueToRelatedPartiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">2099000</us-gaap:DueToRelatedPartiesCurrent>
  <!--Amount due to BioTime and affiliates-->
  <us-gaap:DueToRelatedPartiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">2854000</us-gaap:DueToRelatedPartiesCurrent>
  <!--Basic and diluted net loss per share (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20160101to20161231" unitRef="U003" decimals="2">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Basic and diluted net loss per share (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20150101to20151231" unitRef="U003" decimals="2">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Basic and diluted net loss per share (in dollars per share)-->
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c20170101to20171231" unitRef="U003" decimals="2">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
  <!--Earnings Per Share, Policy [Policy Text Block]-->
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Net loss per common share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(19,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(11,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(8,735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Weighted average common shares outstanding &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;30,195&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;26,529&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;21,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.64&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,390&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Warrants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,779&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,246&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <!--State tax benefit-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20170101to20171231" unitRef="U004" decimals="2">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <!--State tax benefit-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20160101to20161231" unitRef="U004" decimals="2">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <!--State tax benefit-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c20150101to20151231" unitRef="U004" decimals="2">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <!--Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c20170101to20171231" unitRef="U004" decimals="2">-0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <!--Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c20160101to20161231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <!--Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c20150101to20151231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <!--Computed tax benefit at federal statutory rate-Plan [Member]-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20180101to20181231_StatementScenarioAxis_ScenarioPlanMember" unitRef="U004" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Computed tax benefit at federal statutory rate-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20160101to20161231" unitRef="U004" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Computed tax benefit at federal statutory rate-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20170101to20171231" unitRef="U004" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Computed tax benefit at federal statutory rate-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c20150101to20151231" unitRef="U004" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <!--Research and development credits-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20160101to20161231" unitRef="U004" decimals="2">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <!--Research and development credits-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20170101to20171231" unitRef="U004" decimals="2">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <!--Research and development credits-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c20150101to20151231" unitRef="U004" decimals="2">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <!--Change in valuation allowance-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20150101to20151231" unitRef="U004" decimals="2">-0.45</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Change in valuation allowance-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20160101to20161231" unitRef="U004" decimals="2">-0.44</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Change in valuation allowance-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c20170101to20171231" unitRef="U004" decimals="2">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <!--Other-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20160101to20161231" unitRef="U004" decimals="2">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <!--Other-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20150101to20151231" unitRef="U004" decimals="2">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <!--Other-->
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c20170101to20171231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <!--Effective Income Tax Rate Reconciliation, Percent-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20170101to20171231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Effective Income Tax Rate Reconciliation, Percent-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20150101to20151231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Effective Income Tax Rate Reconciliation, Percent-->
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c20160101to20161231" unitRef="U004" decimals="0">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <!--Total unrecognized compensation costs-Employee Stock Option [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <!--Total unrecognized compensation costs-Employee Stock Option [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="-5">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <!--Weighted average recognition period-Employee Stock Option [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <!--Weighted average recognition period-Employee Stock Option [Member]-->
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <!--Equity Method Investment, Ownership Percentage-BioTime, Inc. [Member]-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20170217_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U004" decimals="INF">0.5</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Equity Method Investment, Ownership Percentage-BioTime, Inc. [Member]-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20161231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U004" decimals="INF">0.511</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Equity Method Investment, Ownership Percentage-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20160829" unitRef="U004" decimals="INF">0.512</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Equity Method Investment, Ownership Percentage-Employee Stock Option [Member]-Minimum [Member]-->
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF">0.1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <!--Fair value of contingently issuable warrant-Common Stock [Member]-->
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">65000</us-gaap:FairValueAdjustmentOfWarrants>
  <!--Fair value of contingently issuable warrant-->
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231" unitRef="U001" decimals="-3">65000</us-gaap:FairValueAdjustmentOfWarrants>
  <!--Fair value of contingently issuable warrant-Accumulated Deficit [Member]-->
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>
  <!--Fair value of contingently issuable warrant-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:FairValueAdjustmentOfWarrants>
  <!--Fair value measurements-->
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Fair value measurements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 820,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Fair Value Measurements&lt;/font&gt; (&amp;#8220;ASC 820&amp;#8221;). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 1&lt;/font&gt; &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 2&lt;/font&gt; &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 3&lt;/font&gt; &amp;#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating market rate (see Note 5).&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <!--Intangible assets, net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20161231" unitRef="U001" decimals="-3">988000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Intangible assets, net-->
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c20171231" unitRef="U001" decimals="-3">746000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20171231" unitRef="U001" decimals="-3">1673000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Finite-Lived Intangible Assets, Accumulated Amortization-->
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c20161231" unitRef="U001" decimals="-3">1431000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <!--Intangible assets, useful life-Long-lived Intangible Assets [Member]-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20170101to20171231_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Intangible assets, useful life-->
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c20170101to20171231">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20161231" unitRef="U001" decimals="-3">2419000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Finite-Lived Intangible Assets, Gross-->
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c20171231" unitRef="U001" decimals="-3">2419000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <!--Gain (Loss) on Sale of Equity Investments-->
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:GainLossOnSaleOfEquityInvestments>
  <!--Gain (Loss) on Sale of Equity Investments-->
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:GainLossOnSaleOfEquityInvestments>
  <!--Gain (Loss) on Sale of Equity Investments-->
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20150101to20151231" unitRef="U001" decimals="-3">397000</us-gaap:GainLossOnSaleOfEquityInvestments>
  <!--Gain (Loss) on Sale of Equity Investments-BioTime, Inc. [Member]-->
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20150101to20151231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">-397000</us-gaap:GainLossOnSaleOfEquityInvestments>
  <!--Gain (Loss) on Sale of Equity Investments-BioTime, Inc. [Member]-->
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">-309000</us-gaap:GainLossOnSaleOfEquityInvestments>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">3867000</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">4265000</us-gaap:GeneralAndAdministrativeExpense>
  <!--General and Administrative Expense-->
  <us-gaap:GeneralAndAdministrativeExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">9232000</us-gaap:GeneralAndAdministrativeExpense>
  <!--Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]-->
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset&amp;#8217;s carrying value over its fair value is recorded. Through 2017, there have been no such impairment losses.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <!--Income Taxes-->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;8. Income Taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;U.S. Federal Income Tax Reform&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On December 22, 2017, in response to the enactment of the 2017 Tax Act (see Note 2), the SEC staff issued SAB 118 that allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. OncoCyte is currently analyzing the 2017 Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures, including and changes to OncoCyte&amp;#8217;s existing deferred tax balances, for the year ended December 31, 2017.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte remeasured certain deferred tax assets and liabilities based on the enacted tax rate at which they are expected to reverse in the future. The estimated tax affected amount related to the remeasurement of these balances was a reduction of OncoCyte&amp;#8217;s net deferred tax assets by $6.8 million with a corresponding decrease in the valuation allowance by the same amount, recognized as of December 31, 2017, as discussed below.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2017, the federal portion of the deferred tax assets and liabilities for 2017 were re-rated from 34 percent to 21 percent pursuant to the 2017 Tax Act.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has filed standalone U.S. federal income tax returns since its inception. For California purposes, OncoCyte&amp;#8217;s activity for 2015 and 2016 was included in BioTime&amp;#8217;s California Combined tax return. As a result of OncoCyte&amp;#8217;s deconsolidation from BioTime on February 17, 2017, (see Note 1), OncoCyte will file a separate California return for tax year 2017.&amp;#160; The provision for state income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The deferred tax assets, including the operating loss and credit carryforwards, generated by OncoCyte, will remain with OncoCyte.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Deferred liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Available-for-sale securities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;11,414&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;11,730&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development credit carryforwards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,141&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,765&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Patents and fixed assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;268&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;179&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Stock-based compensation and accrued payroll&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,260&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,041&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Valuation Allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(15,083&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net deferred tax asset (liability)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Due to losses incurred for all periods presented, OncoCyte did not record any provision or benefit for income taxes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Computed tax benefit at federal statutory rate&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Re-rate of federal net deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;(35)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(8)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(1)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(9)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;State tax benefit&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;3&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;15&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development credits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;1&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;7&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;3&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;Adjusted basis for available-for-sale-securities&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;11&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;0&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;0&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(6)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(44)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(45)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;"&gt;As of December 31, 2017, OncoCyte has net operating loss carryforwards of approximately $47&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;.8 million &lt;/font&gt;for U.S. federal income tax purposes and &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;$15.6 million &lt;/font&gt;for state income tax purposes. Federal net operating loss carryforwards expire in varying amounts from 2030 and 2037, and state carryforwards expire from 2029 and 2037. In addition, as of December 31, 2017, OncoCyte has research and development credit carryforwards for federal and state purposes of $1.0 million and $1.1 million, respectively. The federal credits will expire between 2030 and 2037, while the state credits have no expiration.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;During 2017, OncoCyte sold 266,442 BioTime common shares, in at-the-market transactions which resulted in taxable&amp;#160;loss of approximately $301,000.&amp;#160; &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;No BioTime common shares were sold in 2016. &lt;/font&gt;During 2015, OncoCyte sold 259,712 BioTime common shares in at-the-market transactions which resulted in taxable loss of approximately $397,000.&amp;#160;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $1.1 million&amp;#160;and $5.1 million for the years ended December 31, 2017 and 2016, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Other Income Tax Matters&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Internal Revenue Code Section 382 places a limitation (&amp;#8220;Section 382 Limitation&amp;#8221;) on the amount of taxable income that can be offset by net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these &amp;#8220;change in ownership&amp;#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.&amp;#160;&amp;#160; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. In general, OncoCyte is no longer subject to tax examination by major taxing authorities for years before 2013. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <!--Income Tax, Policy [Policy Text Block]-->
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte activity for 2015, 2016, and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of OncoCyte outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning on February 17, 2017 and thereafter, OncoCyte will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Income Taxes&lt;/font&gt;, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte&amp;#8217;s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte&amp;#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte&amp;#8217;s statements of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2017 and 2016. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2017, 2016&amp;#160;and 2015. OncoCyte is currently unaware of any tax issues under review.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&amp;#8220;2017 Tax Act&amp;#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&amp;#8220;AMT&amp;#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&amp;#8220;NOLs&amp;#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&amp;#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &amp;#8220;deemed repatriation&amp;#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8).&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 8).&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20150101to20151231" unitRef="U001" decimals="-3">1042000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-48000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Accounts payable and accrued liabilities-->
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c20160101to20161231" unitRef="U001" decimals="-3">229000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <!--Increase (Decrease) in Due to Related Parties-->
  <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20150101to20151231" unitRef="U001" decimals="-3">1557000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <!--Increase (Decrease) in Due to Related Parties-->
  <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-753000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <!--Increase (Decrease) in Due to Related Parties-->
  <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c20160101to20161231" unitRef="U001" decimals="-3">2007000</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20150101to20151231" unitRef="U001" decimals="-3">274000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-101000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-115000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Long-lived intangible assets-->
  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Long-lived intangible assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <!--Interest Income (Expense), Nonoperating, Net-->
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-19000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <!--Interest Income (Expense), Nonoperating, Net-->
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-217000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <!--Interest Income (Expense), Nonoperating, Net-->
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-28000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c20170101to20171231" unitRef="U001" decimals="-3">130000</us-gaap:InterestPaidNet>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:InterestPaidNet>
  <!--Cash paid for interest-->
  <us-gaap:InterestPaidNet contextRef="c20160101to20161231" unitRef="U001" decimals="-3">29000</us-gaap:InterestPaidNet>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20161231" unitRef="U001" decimals="-3">14447000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20171231" unitRef="U001" decimals="-3">10216000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20171231" unitRef="U001" decimals="-3">5813000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20161231" unitRef="U001" decimals="-3">4585000</us-gaap:Liabilities>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20171231" unitRef="U001" decimals="-3">4454000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20161231" unitRef="U001" decimals="-3">4275000</us-gaap:LiabilitiesCurrent>
  <!--Loan payable, current-->
  <us-gaap:LoansPayableCurrent contextRef="c20171231" unitRef="U001" decimals="-3">800000</us-gaap:LoansPayableCurrent>
  <!--Loan payable, current-->
  <us-gaap:LoansPayableCurrent contextRef="c20161231" unitRef="U001" decimals="-3">0</us-gaap:LoansPayableCurrent>
  <!--Long-term Debt-->
  <us-gaap:LongTermDebt contextRef="c20171231" unitRef="U001" decimals="-3">1870000</us-gaap:LongTermDebt>
  <!--Loan Payable to Silicon Valley Bank-->
  <us-gaap:LongTermDebtTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;5. &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;Loan Payable to Silicon Valley Bank&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank (the "Bank") pursuant to which OncoCyte borrowed $2.0 million on March 23, 2017. Payments of interest only on the principal balance were due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal of approximately $67,000 plus interest are due and payable. The outstanding principal balance of the loan bears interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of December 31, 2017, the latest published prime rate plus 0.75% was 5.25% per annum.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;The outstanding principal amount plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. OncoCyte accrued the $116,000 final payment fee included in the loan payable as a deferred financing cost on March 23, 2017 draw date.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to&amp;#160; 2.0% of the outstanding principal balance if prepaid after February 21, 2018 but not later than February 21, 2019, or 1.0% of the outstanding principal balance if prepaid after February 21, 2019. Any amounts borrowed and repaid may not be reborrowed.&amp;#160; There are no amounts available to be borrowed on the Loan Agreement.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an "Event of Default" as defined in the Loan Agreement occurs and is not cured within any applicable cure period. Upon the occurrence and during the continuance of an Event of Default, all obligations due to the Bank will bear interest at a rate per annum which is 5% above the then applicable interest rate. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte's business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and copies of filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE American. OncoCyte's obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns. Accordingly, if an Event of Default were to occur and not be cured, the Bank could foreclose on its security interest in the collateral. OncoCyte was in compliance with the Loan Agreement as of the filing&amp;#160;date of this Report.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Under the provisions of the Loan Agreement, as consented by the Bank on October 26, 2017, any proceeds received by OncoCyte from sales of BioTime shares may be used by OncoCyte to fund its operations.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Bank Warrants&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On February 21, 2017 and in conjunction with the $2.0 million becoming available under the Loan Agreement, OncoCyte issued common stock purchase warrants to the Bank (the "Bank Warrants") entitling the Bank to purchase shares of OncoCyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase 8,247 shares of OncoCyte common stock at an exercise price of $4.85 per share, through February 21, 2027. On March 23, 2017, in conjunction with borrowing $2 million, the Bank was issued warrants to purchase an additional 7,321 shares at an exercise price of $5.46 per share, through March 23, 2027. The Bank may elect to exercise the Bank Warrants on a "cashless exercise" basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The Bank Warrants are classified as equity since, among other factors, they are not mandatorily redeemable, cannot be settled in cash or other assets and require settlement by issuing a fixed number of shares of common stock of OncoCyte. OncoCyte determined the fair value of the Bank Warrants using the Black-Scholes option pricing model to be approximately $62,000, which was recorded as a deferred financing cost against the loan payable balance. Aggregate deferred financing costs of $196,000, recorded against the loan payable balance, are amortized to interest expense over the term of the loan using the effective interest method. As of December 31, 2017, unamortized deferred financing costs were $113,000.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Future Cash Payments of Loan Payable&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, principal and interest payments due on the loan payable in each of the next three years are as follows (in thousands):&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160; &lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Year Ending&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Loan&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Payments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;876&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;835&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;386&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total payments of principal and interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,097&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less: amounts representing interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total payments of principal before deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,983&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less: deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(113&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total loan payable, net of deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <!--Interest rate on obligations due to bank-Loan and Security Agreement [Member]-->
  <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.050</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
  <!--Long-term Debt, Maturities, Repayments of Principal in Year Three-->
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c20171231" unitRef="U001" decimals="-3">386000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <!--Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months-->
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c20171231" unitRef="U001" decimals="-3">876000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
  <!--Loan payable, net of deferred financing costs, noncurrent-->
  <us-gaap:LongTermLoansPayable contextRef="c20171231" unitRef="U001" decimals="-3">1070000</us-gaap:LongTermLoansPayable>
  <!--Loan payable, net of deferred financing costs, noncurrent-->
  <us-gaap:LongTermLoansPayable contextRef="c20161231" unitRef="U001" decimals="-3">0</us-gaap:LongTermLoansPayable>
  <!--Long-term Debt, Maturities, Repayments of Principal in Year Two-->
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c20171231" unitRef="U001" decimals="-3">835000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <!--Accounting for BioTime shares-->
  <us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Accounting for BioTime shares&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Investments &amp;#8211; Debt and Equity Securities&lt;/font&gt;, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte&amp;#8217;s financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Business Combinations&lt;/font&gt; ("ASC 805"), transactions between entities under common control. See section &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt; included herein.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;In 2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes. The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of $0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates or for working capital purposes.&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesAvailableForSaleSecuritiesPolicy>
  <!--Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners-Minimum [Member]-Subsequent Event [Member]-Broadwood Partners LP [Member]-->
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c20180328_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_BroadwoodPartnersLPMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="INF">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20160101to20161231" unitRef="U001" decimals="-3">9881000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20150101to20151231" unitRef="U001" decimals="-3">11653000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20170101to20171231" unitRef="U001" decimals="-3">9968000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20170101to20171231" unitRef="U001" decimals="-3">843000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-181000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20150101to20151231" unitRef="U001" decimals="-3">315000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-13385000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-4229000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-7522000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-19375000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-8735000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-11168000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-8735000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Common Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Common Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Common Stock [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-11168000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-19375000</us-gaap:NetIncomeLoss>
  <!--New Accounting Pronouncements, Policy [Policy Text Block]-->
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Recent accounting pronouncements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, &lt;font style="font-style: italic;"&gt;Financial Instruments&amp;#8211;Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt; (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte&amp;#8217;s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;font style="font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718) &amp;#8211; Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. OncoCyte currently applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. OncoCyte believes the adoption of ASU 2017-09 will not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-17000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-526000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-28000</us-gaap:NonoperatingIncomeExpense>
  <!--Number of Operating Segments-->
  <us-gaap:NumberOfOperatingSegments contextRef="c20170101to20171231" unitRef="U005" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <!--Operating loss carryforwards, expiration date-Minimum [Member]-State [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20170101to20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MinimumMember">2029-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--Operating loss carryforwards, expiration date-Federal [Member]-Maximum [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20170101to20171231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MaximumMember">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--Operating loss carryforwards, expiration date-Minimum [Member]-Federal [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20170101to20171231_IncomeTaxAuthorityAxis_DomesticCountryMember_RangeAxis_MinimumMember">2030-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--Operating loss carryforwards, expiration date-State [Member]-Maximum [Member]-->
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="c20170101to20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_RangeAxis_MaximumMember">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-11140000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20150101to20151231" unitRef="U001" decimals="-3">-8718000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-18849000</us-gaap:OperatingIncomeLoss>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20160101to20161231" unitRef="U001" decimals="-3">11140000</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20170101to20171231" unitRef="U001" decimals="-3">18849000</us-gaap:OperatingExpenses>
  <!--Operating Expenses-->
  <us-gaap:OperatingExpenses contextRef="c20150101to20151231" unitRef="U001" decimals="-3">8718000</us-gaap:OperatingExpenses>
  <!--Operating Loss Carryforwards-Federal [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20171231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="-5">47800000</us-gaap:OperatingLossCarryforwards>
  <!--Operating Loss Carryforwards-State [Member]-->
  <us-gaap:OperatingLossCarryforwards contextRef="c20171231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="-5">15600000</us-gaap:OperatingLossCarryforwards>
  <!--Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;1. Organization, Description of the Business and Liquidity&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte Corporation ("OncoCyte") is a developer of novel, non-invasive blood-based tests for the early detection of cancer. It is focused on developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers that are differentially expressed in certain types of cancers. OncoCyte efforts have focused on developing diagnostic tests for use in detecting lung, bladder, and breast cancers. During 2017, OncoCyte devoted substantially all of its efforts on developing its lung cancer diagnostic test DetermaVu&amp;#8482;.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte was incorporated in 2009 in the state of California and at December 31, 2016 was a majority-owned subsidiary of BioTime, Inc. ("BioTime"), a publicly traded, clinical-stage, biotechnology company targeting degenerative diseases primarily in the fields of ophthalmology, aesthetics and cell/drug delivery. Beginning on February 17, 2017, OncoCyte ceased to be a subsidiary of BioTime for financial reporting purposes when BioTime's percentage ownership of outstanding OncoCyte common stock declined below 50% as a result of the issuance of additional OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants (see Note 6).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Liquidity&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;For all periods presented, OncoCyte generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants, warrant exercises, a bank loan (see Note 5), and sales of BioTime common shares that OncoCyte holds as available-for-sale securities. BioTime has also provided OncoCyte with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4&lt;/font&gt;. OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $54.7 million and $35.3 million as December 31, 2017 and 2016, respectively.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017, OncoCyte had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to OncoCyte on or prior to April 30, 2018 (see Note 10), OncoCyte believes it has sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if it determines to devote more resources to the development or initial commercialization efforts for its lung cancer test during that time frame.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&amp;#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&amp;#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&amp;#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&amp;#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <!--Realized loss on sale of available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <!--Realized loss on sale of available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3">397000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <!--Realized loss on sale of available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c20170101to20171231" unitRef="U001" decimals="-3">293000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <!--Unrealized gain (loss) on available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20150101to20151231" unitRef="U001" decimals="-3">75000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Unrealized gain (loss) on available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20160101to20161231" unitRef="U001" decimals="-3">-304000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Unrealized gain (loss) on available-for-sale securities-->
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c20170101to20171231" unitRef="U001" decimals="-3">-527000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <!--Other Nonoperating Income (Expense)-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">2000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other Nonoperating Income (Expense)-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other Nonoperating Income (Expense)-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Payments for Deposits-->
  <us-gaap:PaymentsForDeposits contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:PaymentsForDeposits>
  <!--Payments for Deposits-->
  <us-gaap:PaymentsForDeposits contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:PaymentsForDeposits>
  <!--Payments for Deposits-->
  <us-gaap:PaymentsForDeposits contextRef="c20160101to20161231" unitRef="U001" decimals="-3">75000</us-gaap:PaymentsForDeposits>
  <!--Payments of Debt Issuance Costs-Warrant [Member]-->
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="-3">196000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <!--Payments of Stock Issuance Costs-->
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <!--Payments of Stock Issuance Costs-->
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <!--Payments of Stock Issuance Costs-->
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c20160101to20161231" unitRef="U001" decimals="-3">773000</us-gaap:PaymentsOfStockIssuanceCosts>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20150101to20151231" unitRef="U001" decimals="-3">500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20170101to20171231" unitRef="U001" decimals="-3">91000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20160101to20161231" unitRef="U001" decimals="-3">106000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20161231" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockNoParValue contextRef="c20171231" unitRef="U003" decimals="INF">0</us-gaap:PreferredStockNoParValue>
  <!--Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding-->
  <us-gaap:PreferredStockValue contextRef="c20171231" unitRef="U001" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding-->
  <us-gaap:PreferredStockValue contextRef="c20161231" unitRef="U001" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20171231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20161231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20171231" unitRef="U002" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20161231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20171231" unitRef="U002" decimals="-3">5000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20161231" unitRef="U002" decimals="-3">5000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20161231" unitRef="U001" decimals="-3">285000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20171231" unitRef="U001" decimals="-3">168000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Reclassifications-->
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Reclassifications&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Certain reclassifications from general and administrative expenses have been made to present sales and marketing expenses shown on the statements of operations for the years ended December 31, 2016 and 2015 to conform and be comparable to the year ended December 31, 2017 presentation. These reclassifications have been made as OncoCyte's sales and marketing expenses have increased in 2017, thus making separate presentation of those category of expenses more meaningful to the readers of this report. The reclassifications had no impact to loss from operations or net loss as reported in the statements of operations and had no impact to the statements of cash flows or to the balance sheets for any period presented.&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <!--Proceeds from issuance of loan payable, net of financing costs-->
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c20170101to20171231" unitRef="U001" decimals="-3">1982000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <!--Proceeds from issuance of loan payable, net of financing costs-->
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <!--Proceeds from issuance of loan payable, net of financing costs-->
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <!--Proceeds from exercise of warrants-->
  <us-gaap:ProceedsFromWarrantExercises contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromWarrantExercises>
  <!--Proceeds from exercise of warrants-->
  <us-gaap:ProceedsFromWarrantExercises contextRef="c20170101to20171231" unitRef="U001" decimals="-3">7774000</us-gaap:ProceedsFromWarrantExercises>
  <!--Proceeds from exercise of warrants-->
  <us-gaap:ProceedsFromWarrantExercises contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromWarrantExercises>
  <!--Proceeds from Issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150101to20151231" unitRef="U001" decimals="-3">11649000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Issuance of Common Stock-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Issuance of Common Stock-BioTime, Inc. [Member]-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20150101to20151231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">815000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Issuance of Common Stock-BioTime, Inc. [Member]-->
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">934000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <!--Proceeds from Issuance of Private Placement-Subsequent Event [Member]-Investor Two [Member]-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorTwoMember" unitRef="U001" decimals="-5">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from Issuance of Private Placement-Subsequent Event [Member]-Investor One [Member]-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorMember" unitRef="U001" decimals="-5">8000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Proceeds from Issuance of Private Placement-Subsequent Event [Member]-->
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5">10000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <!--Net proceeds from sale of available-for-sale securities-->
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
  <!--Net proceeds from sale of available-for-sale securities-->
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20150101to20151231" unitRef="U001" decimals="-3">815000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
  <!--Net proceeds from sale of available-for-sale securities-->
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="c20170101to20171231" unitRef="U001" decimals="-3">934000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
  <!--Proceeds from Issuance of Warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c20170101to20171231" unitRef="U001" decimals="-3">4074000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds from Issuance of Warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds from Issuance of Warrants-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds from Issuance of Warrants-July 2017 Warrants [Member]-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c20170721to20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember" unitRef="U001" decimals="-4">5740000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds from Issuance of Warrants-Warrants 2016 [Member]-->
  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c20170217to20170217_ClassOfWarrantOrRightAxis_Warrants2016Member" unitRef="U001" decimals="-5">2000000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <!--Proceeds from exercise of options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20170101to20171231" unitRef="U001" decimals="-3">610000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from exercise of options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20150101to20151231" unitRef="U001" decimals="-3">4000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from exercise of options-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20160101to20161231" unitRef="U001" decimals="-3">218000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from exercise of options-Common Stock [Member]-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20160101to20161231_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-3">218000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from exercise of options-Common Stock [Member]-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-3">610000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Property, Plant and Equipment, Policy [Policy Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Equipment and furniture&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte&amp;#8217;s results of operations&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <!--Property, Plant and Equipment [Table Text Block]-->
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment and furniture&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,479&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,007&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(319&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment and furniture, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;822&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;688&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <!--Equipment and furniture, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20161231" unitRef="U001" decimals="-3">688000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Equipment and furniture, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20171231" unitRef="U001" decimals="-3">822000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20171231" unitRef="U001" decimals="-3">1479000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Property, Plant and Equipment, Gross-->
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20161231" unitRef="U001" decimals="-3">1007000</us-gaap:PropertyPlantAndEquipmentGross>
  <!--Equipment and furniture, useful life-Equipment [Member]-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Equipment and furniture, useful life-Maximum [Member]-Equipment and Furniture [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Equipment and furniture, useful life-Equipment [Member]-Maximum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Equipment and furniture, useful life-Equipment and Furniture [Member]-Minimum [Member]-->
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c20170101to20171231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <!--Related Party Transactions Disclosure [Text Block]-->
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;4. Related Party Transactions&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Shared Facilities and Service Agreement&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On October 8, 2009, OncoCyte and BioTime executed a Shared Facilities and Services Agreement (&amp;#8220;Shared Facilities Agreement&amp;#8221;). Under the terms of the Shared Facilities Agreement, BioTime will allow OncoCyte to use its premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime will also provide OncoCyte with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;BioTime charges OncoCyte a Use Fee for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates costs incurred, as applicable, to OncoCyte, such costs include services of Bio Time employees, equipment, insurance, lease, professional, software, supplies and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime (collectively &amp;#8220;Use Fees&amp;#8221;). BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime has not elected to charge this markup since the inception of the Shared Facilities Agreement and through the end of 2015. Beginning in 2016, BioTime commenced charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2017 BioTime has not charged OncoCyte any interest.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers thereof to invoice OncoCyte directly.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement otherwise is terminated under another provision of the agreement.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In the aggregate, BioTime allocated and charged such Use Fees to OncoCyte $268,000, $790,000 and $595,000 included in general and administrative expenses, and&amp;#160;Use Fees of $1.1 million, $691,000 and $565,000 included in research and development expenses, during the years ended December 31, 2017, 2016 and 2015 respectively.&amp;#160;Use Fees of $213,000 in sales and marketing expenses are included in OncoCyte&amp;#8217;s statements of operations during the year ended December 31, 2017. There were no Use Fees allocated to sales and marketing expenses during 2016 and 2015.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017 and 2016, OncoCyte had $2.1 million and $2.9 million outstanding and payable to BioTime and affiliates included in current liabilities in connection with the costs incurred under the Shared Facilities Agreement. Since these amounts are due and payable in 30 days of being invoiced, the payables are classified as current liabilities for all periods presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The minimum fixed payments due under the Shared Facilities Agreement are approximately $131,000 per month.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <!--Repayments of Long-term Capital Lease Obligations-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20170101to20171231" unitRef="U001" decimals="-3">265000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Repayments of Long-term Capital Lease Obligations-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20160101to20161231" unitRef="U001" decimals="-3">114000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Repayments of Long-term Capital Lease Obligations-->
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <!--Repayments of Debt-->
  <us-gaap:RepaymentsOfDebt contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</us-gaap:RepaymentsOfDebt>
  <!--Repayments of Debt-->
  <us-gaap:RepaymentsOfDebt contextRef="c20170101to20171231" unitRef="U001" decimals="-3">133000</us-gaap:RepaymentsOfDebt>
  <!--Repayments of Debt-->
  <us-gaap:RepaymentsOfDebt contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</us-gaap:RepaymentsOfDebt>
  <!--Research and Development Expense, Policy [Policy Text Block]-->
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Research and development expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&amp;#8217;s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance&lt;/font&gt;. Research and development costs are expensed as incurred.&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <!--Research and Development Expense-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">4527000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">7174000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and Development Expense-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">5677000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20171231" unitRef="U001" decimals="-3">-54677000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Accumulated deficit-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20161231" unitRef="U001" decimals="-3">-35302000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Expected life-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember">P6Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Expected life-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember">P6Y2M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Expected life-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">85000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">2.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value-Maximum [Member]-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U001" decimals="0">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">1757000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">880000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares-Employee Stock Option [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">1384000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <!--Sale of Stock, Consideration Received on Transaction-->
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c20160829to20160829" unitRef="U001" decimals="-5">9800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <!--Sale of Stock, Number of Shares Issued in Transaction-BioTime, Inc. [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20160101to20161231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Sale of Stock, Number of Shares Issued in Transaction-BioTime, Inc. [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">266442</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Sale of Stock, Number of Shares Issued in Transaction-BioTime, Inc. [Member]-->
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c20150101to20151231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">259712</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <!--Share-based Compensation, Stock Options, Activity [Table Text Block]-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Shares&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Available&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;for Grant&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Number of&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Options&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Outstanding&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Weighted&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Average&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Exercise Price&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at January 1, 2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,757&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.03&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(962&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;962&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.58&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(100&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.19&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options forfeited, cancelled or expired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(85&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.00&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at December 31, 2016&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;880&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.52&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Increase in pool&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options granted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(896&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;896&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;5.17&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options exercised&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1.89&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Options forfeited, cancelled or expired&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(200&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.11&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,384&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,390&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;$&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3.25&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Exercisable at December 31, 2017&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,835&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2.48&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Components of Deferred Tax Assets and Liabilities-->
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Deferred liabilities:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Available-for-sale securities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;11,414&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;11,730&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development credit carryforwards&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,141&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,765&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Patents and fixed assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;268&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;179&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Stock-based compensation and accrued payroll&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,260&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,041&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Valuation Allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(15,083&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(13,954&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;761&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net deferred tax asset (liability)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <!--Computations of Basic and Diluted Net Loss Per Share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(19,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(11,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(8,735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Weighted average common shares outstanding &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;30,195&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;26,529&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;21,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.64&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Income Tax Reconciliation-->
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Computed tax benefit at federal statutory rate&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;34&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Re-rate of federal net deferred tax assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;(35)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(8)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(1)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;(9)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;State tax benefit&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;3&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;15&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development credits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;1&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;2&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;0&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;7&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;3&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;Adjusted basis for available-for-sale-securities&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;11&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;0&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&amp;#160;0&lt;/td&gt;&lt;td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;%&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(6)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(44)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;(45)&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;-&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <!--Schedule of Finite-Lived Intangible Assets [Table Text Block]-->
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(1,673&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(1,431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;746&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;988&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <!--Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]-->
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The assumptions that were used to calculate the grant date fair value of OncoCyte&amp;#8217;s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Expected life (in years)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.15&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.21&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;6.83&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Risk-free interest rates&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;2.03&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;1.46&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;1.87&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;66.01&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;64.64&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;74.15&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;font style="background-color: #ffffff;"&gt;&lt;/font&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <!--Future Minimum Annual Lease Payments-->
  <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Future minimum annual lease payments under &lt;/font&gt;Lease Schedule No.&amp;#8217;s 1, 2, and 3 above &lt;font style="font-size: 10pt; font-family: 'Times New Roman';"&gt;for the years ending after December 31, 2017 are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;br class="Apple-interchange-newline" /&gt;&lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Year Ending&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Capital Lease&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Payments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;383&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;59&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;690&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less amounts representing interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(63&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Present value of net minimum lease payments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;627&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
  <!--Principal and interest payments due on loan payable-->
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, principal and interest payments due on the loan payable in each of the next three years are as follows (in thousands):&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160; &lt;table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Year Ending&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Loan&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Payments&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2018&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;876&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;835&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;386&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total payments of principal and interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,097&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less: amounts representing interest&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total payments of principal before deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,983&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;"&gt;Less: deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(113&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 94px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total loan payable, net of deferred financing costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,870&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <!--Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock-->
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,390&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Warrants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,779&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,246&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <!--Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]-->
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;668&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;312&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;456&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;841&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;610&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,359&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Sales and marketing&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;121&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,630&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;922&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,815&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <!--Segments-->
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Segments&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte&amp;#8217;s executive management team, as a group, represents the entity&amp;#8217;s chief operating decision makers. To date, OncoCyte&amp;#8217;s executive management team has viewed OncoCyte&amp;#8217;s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte&amp;#8217;s sole operating segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <!--Sales and marketing-->
  <us-gaap:SellingAndMarketingExpense contextRef="c20150101to20151231" unitRef="U001" decimals="-3">324000</us-gaap:SellingAndMarketingExpense>
  <!--Sales and marketing-->
  <us-gaap:SellingAndMarketingExpense contextRef="c20170101to20171231" unitRef="U001" decimals="-3">2443000</us-gaap:SellingAndMarketingExpense>
  <!--Sales and marketing-->
  <us-gaap:SellingAndMarketingExpense contextRef="c20160101to20161231" unitRef="U001" decimals="-3">1198000</us-gaap:SellingAndMarketingExpense>
  <!--General and administrative expenses-->
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;General and administrative expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&amp;#8217;s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;see Note 4&lt;/font&gt;) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <!--Share price (in dollars per share)-Subsequent Event [Member]-->
  <us-gaap:SharePrice contextRef="c20180328_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2">1.26</us-gaap:SharePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">2.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">1.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period-Maximum [Member]-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">3.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">5.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">962000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">896000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.6601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.7415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.6464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.0203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c20150101to20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF">5200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20151231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">2240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">3390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">3017000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options-Employee Stock Option [Member]-->
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">1835000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <!--Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]-->
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Stock-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Compensation &amp;#8211; Stock Compensation&lt;/font&gt; (&amp;#8220;ASC 718&amp;#8221;).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160;&amp;#160; OncoCyte adopted ASU 2016-09 beginning on January 1, 2017.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In connection with the adoption of ASU 2016-09, OncoCyte changed its accounting policies including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable.&amp;#160; All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations.&amp;#160; Prior to the adoption of ASU 2016-09, OncoCyte recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized either as an offset to accumulated excess tax benefits, if any, on OncoCyte&amp;#8217;s statements of operations.&amp;#160; An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.&amp;#160; Because OncoCyte has a full valuation allowance for all periods presented (see Note 8) and an insignificant number of stock option exercises during the current quarter, there was no impact to OncoCyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest.&amp;#160; Based on the nature and timing of OncoCyte&amp;#8217;s grants, straight line expense attribution of stock based compensation for the entire award and the relatively low forfeiture rate on OncoCyte&amp;#8217;s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not significant to OncoCyte&amp;#8217;s financial statements.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. OncoCyte uses the Black-Scholes-Merton option pricing model for estimating the fair value of options granted under OncoCyte&amp;#8217;s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Equity-Based Payments to Non-Employees&lt;/font&gt;. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee&amp;#8217;s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Valuation of Privately Held Company Equity Securities Issued As Compensation&lt;/font&gt;.&amp;#160; OncoCyte common stock began to trade publicly on the NYSE American on December 31, 2015, and since that date the fair value of OncoCyte common stock underlying stock options has been determined with reference to closing prices reported on the NYSE American.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the &amp;#8220;simplified method&amp;#8221; provided under&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Staff Accounting Bulletin, Topic 14&lt;/font&gt;, or SAB Topic 14, including, in part, based on its own experience.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Because OncoCyte&amp;#8217;s common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte&amp;#8217;s stock options.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The dividend yield assumption is based on OncoCyte&amp;#8217;s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;2. Summary of Significant Accounting Policies&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Basis of presentation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;). Prior to February 17, 2017, BioTime consolidated the results of OncoCyte into BioTime's consolidated results based on BioTime's ability to control OncoCyte's operating and financial decisions and policies through its majority ownership of OncoCyte common stock. BioTime owned 51.1% of the outstanding common stock of OncoCyte at December 31, 2016. Beginning on February 17, 2017, BioTime's percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of "control" of OncoCyte under GAAP and, as a result, BioTime deconsolidated OncoCyte's financial statements from BioTime's consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP with effect from February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime's retained share ownership in OncoCyte, which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte&amp;#8217;s operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Reverse stock split&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Use of estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to the&amp;#160;going concern assessments of OncoCyte financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Going concern assessment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;With the implementation of FASB&amp;#8217;s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &amp;#8220;look-forward period&amp;#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Fair value measurements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 820,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Fair Value Measurements&lt;/font&gt; (&amp;#8220;ASC 820&amp;#8221;). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 1&lt;/font&gt; &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 2&lt;/font&gt; &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: left;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td style="width: 36pt;"&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;"&gt;&amp;#183;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Level 3&lt;/font&gt; &amp;#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating market rate (see Note 5).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2017 and 2016, OncoCyte's cash balances totaled $7.6 million and $10.2 million, respectively.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Accounting for BioTime shares&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Investments &amp;#8211; Debt and Equity Securities&lt;/font&gt;, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte&amp;#8217;s financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Business Combinations&lt;/font&gt; ("ASC 805"), transactions between entities under common control. See section &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/font&gt; included herein.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;In 2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes. The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of $0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates or for working capital purposes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Long-lived intangible assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Equipment and furniture&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte&amp;#8217;s results of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset&amp;#8217;s carrying value over its fair value is recorded. Through 2017, there have been no such impairment losses.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Accounting for warrants&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/font&gt;, then in accordance with ASC 815-40, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&amp;#8217;s Own Stock&lt;/font&gt;. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Income taxes&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte activity for 2015, 2016, and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of OncoCyte outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning on February 17, 2017 and thereafter, OncoCyte will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Income Taxes&lt;/font&gt;, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte&amp;#8217;s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte&amp;#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte&amp;#8217;s statements of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2017 and 2016. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2017, 2016&amp;#160;and 2015. OncoCyte is currently unaware of any tax issues under review.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&amp;#8220;2017 Tax Act&amp;#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&amp;#8220;AMT&amp;#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&amp;#8220;NOLs&amp;#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&amp;#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &amp;#8220;deemed repatriation&amp;#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8).&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 8).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Research and development expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&amp;#8217;s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance&lt;/font&gt;. Research and development costs are expensed as incurred.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;General and administrative expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&amp;#8217;s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;see Note 4&lt;/font&gt;) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Sales and marketing expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on OncoCyte&amp;#8217;s headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Stock-based compensation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Compensation &amp;#8211; Stock Compensation&lt;/font&gt; (&amp;#8220;ASC 718&amp;#8221;).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&amp;#160;&amp;#160; OncoCyte adopted ASU 2016-09 beginning on January 1, 2017.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In connection with the adoption of ASU 2016-09, OncoCyte changed its accounting policies including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable.&amp;#160; All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations.&amp;#160; Prior to the adoption of ASU 2016-09, OncoCyte recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized either as an offset to accumulated excess tax benefits, if any, on OncoCyte&amp;#8217;s statements of operations.&amp;#160; An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.&amp;#160; Because OncoCyte has a full valuation allowance for all periods presented (see Note 8) and an insignificant number of stock option exercises during the current quarter, there was no impact to OncoCyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest.&amp;#160; Based on the nature and timing of OncoCyte&amp;#8217;s grants, straight line expense attribution of stock based compensation for the entire award and the relatively low forfeiture rate on OncoCyte&amp;#8217;s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not significant to OncoCyte&amp;#8217;s financial statements.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. OncoCyte uses the Black-Scholes-Merton option pricing model for estimating the fair value of options granted under OncoCyte&amp;#8217;s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Equity-Based Payments to Non-Employees&lt;/font&gt;. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee&amp;#8217;s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Valuation of Privately Held Company Equity Securities Issued As Compensation&lt;/font&gt;.&amp;#160; OncoCyte common stock began to trade publicly on the NYSE American on December 31, 2015, and since that date the fair value of OncoCyte common stock underlying stock options has been determined with reference to closing prices reported on the NYSE American.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the &amp;#8220;simplified method&amp;#8221; provided under&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt; Staff Accounting Bulletin, Topic 14&lt;/font&gt;, or SAB Topic 14, including, in part, based on its own experience.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Because OncoCyte&amp;#8217;s common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte&amp;#8217;s stock options.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The dividend yield assumption is based on OncoCyte&amp;#8217;s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Net loss per common share&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(19,375&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(11,168&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(8,735&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Weighted average common shares outstanding &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;30,195&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;26,529&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;21,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Net loss per common share &amp;#8211; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.64&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(0.42&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2015&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Stock options&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,390&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,240&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Warrants&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,779&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;3,246&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Segments&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte&amp;#8217;s executive management team, as a group, represents the entity&amp;#8217;s chief operating decision makers. To date, OncoCyte&amp;#8217;s executive management team has viewed OncoCyte&amp;#8217;s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte&amp;#8217;s sole operating segment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Reclassifications&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Certain reclassifications from general and administrative expenses have been made to present sales and marketing expenses shown on the statements of operations for the years ended December 31, 2016 and 2015 to conform and be comparable to the year ended December 31, 2017 presentation. These reclassifications have been made as OncoCyte's sales and marketing expenses have increased in 2017, thus making separate presentation of those category of expenses more meaningful to the readers of this report. The reclassifications had no impact to loss from operations or net loss as reported in the statements of operations and had no impact to the statements of cash flows or to the balance sheets for any period presented.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Recent accounting pronouncements&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, &lt;font style="font-style: italic;"&gt;Financial Instruments&amp;#8211;Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt; (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte&amp;#8217;s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;font style="font-style: italic;"&gt;Leases (Topic 842)&lt;/font&gt;, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;In May 2017, the FASB issued ASU 2017-09, &lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718) &amp;#8211; Scope of Modification Accounting&lt;/font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. OncoCyte currently applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. OncoCyte believes the adoption of ASU 2017-09 will not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Exercise of stock options-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20170101to20171231" unitRef="U001" decimals="-3">610000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Deficit [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231" unitRef="U001" decimals="-3">218000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">218000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Deficit [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Deficit [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231" unitRef="U001" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">610000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">323000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="INF">323019</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Common Stock [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20160101to20161231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="INF">99496</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Employee Stock Option [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Exercise of stock options (in shares)-Employee Stock Option [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">323000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Stock-based compensation-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231" unitRef="U001" decimals="-3">922000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Accumulated Deficit [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20170101to20171231" unitRef="U001" decimals="-3">1630000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231" unitRef="U001" decimals="-3">1815000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Accumulated Deficit [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Common Stock [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">1630000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Accumulated Deficit [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Common Stock [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">1815000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Common Stock [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">922000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stock-based compensation-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20171231" unitRef="U001" decimals="-3">4403000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20161231" unitRef="U001" decimals="-3">9862000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-15399000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20141231" unitRef="U001" decimals="-3">-1074000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-822000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20141231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">15147000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20151231" unitRef="U001" decimals="-3">10417000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-888000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-350000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">34901000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-54677000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-35302000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Deficit [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">-24134000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">45818000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Accumulated Other Comprehensive Loss [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">-654000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-Common Stock [Member]-->
  <us-gaap:StockholdersEquity contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">59968000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Note Disclosure [Text Block]-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;6. Shareholders&amp;#8217; Equity&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Preferred Stock&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte is authorized to issue up to 5,000,000 shares of no par value preferred stock. As of December 31, 2017, no preferred shares were issued or outstanding.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Common Stock&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte has up to 50,000,000 shares of no par value common stock authorized. The holders of OncoCyte&amp;#8217;s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of OncoCyte common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of OncoCyte outstanding preferred shares, if any.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of OncoCyte stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Issuance of Common Stock and Warrants&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the &amp;#8220;2016 Warrants&amp;#8221;), at a price of $3.25 per unit (the &amp;#8220;Offering&amp;#8221;). The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime. At the close of the Offering, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;BioTime&amp;#8217;s percentage ownership of the outstanding common stock of OncoCyte declined to 51.2% through which BioTime retained a controlling interest in OncoCyte&lt;/font&gt;. OncoCyte received $9.8 million in net proceeds after discounts, commissions and expenses from the Offering. OncoCyte will use the proceeds from the Offering for funding its operations or for working capital or other general corporate purposes.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Pursuant to the terms of the Purchase Agreements, OncoCyte agreed (i) to file a resale registration statement with the Securities and Exchange Commission, or SEC, to register for sale under the Securities Act of 1933, as amended, or the Securities Act, the shares of OncoCyte common stock sold in the Offering and the shares of OncoCyte common stock, or Warrant Shares, that may be issued if the Warrants are exercised, and (ii) to use commercially reasonable efforts to maintain the effectiveness of the resale registration statement under the Securities Act until the earlier of (a) the date that all shares of its common stock covered by the Resale Registration Statement have been sold or can be sold publicly without restriction or limitation under Rule 144 (including, without limitation, the requirement to be in compliance with Rule 144(c)(1)), or (b) August 29, 2018.&lt;br /&gt; &amp;#160;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;2016 Warrants and New Warrants&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;The 2016 Warrants have an exercise price of $3.25 per Warrant Share, and may be exercised for five years from October 17, 2016, the date the 2016 Warrants became exercisable. The 2016 Warrants may be exercised on a net &amp;#8220;cashless exercise&amp;#8221; basis, meaning that the value of a portion of Warrant Shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if the Resale Registration Statement is not effective when and as required by the Purchase Agreements. The exercise price and the number of Warrant Shares will be adjusted to account for certain transactions, including stock splits, dividends paid in common stock, combinations or reverse splits of common stock, or reclassifications of common stock.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Under certain provisions of the 2016 Warrants, in the event of a Fundamental Transaction, as defined in the 2016 Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the 2016 Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of 2016 Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the 2016 Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration as the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;OncoCyte is not required to net cash settle the 2016 Warrants under any circumstance. &lt;/font&gt;OncoCyte considered the guidance in ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. Since solely an acquirer, and not OncoCyte itself, may be required to net cash settle the 2016 Warrants in the event of a Fundamental Transaction, the 2016 Warrants are classified as equity.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On February 17, 2017, certain OncoCyte investors exercised 2016 Warrants to acquire 625,000 shares of common stock at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the "Warrant exercise"). In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the "New Warrants"). Certain investors received New Warrants to purchase 200,000 shares of common stock at an exercise price of $5.50 per share and one investor received New Warrants to purchase 212,500 shares of common stock at an exercise of $3.25 per share. The New Warrants are exercisable at any time for five years from February 17, 2017.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;The New Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the New Warrants was treated as an inducement offer to certain shareholders to exercise their 2016 Warrants. Accordingly, the fair value of the New Warrants, determined using the &lt;/font&gt;Black-Scholes option pricing model,&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt; approximating $1.1 million was recognized by OncoCyte as a noncash charge to shareholder expense included in general and administrative expenses and a corresponding increase to equity on February 17, 2017, the issuance date.&lt;/font&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;On July 21, 2017, OncoCyte entered into three forms of Warrant Exercise Agreements (each, an "Exercise Agreement") with certain holders of the 2016 Warrants providing for the cash exercise of their 2016 Warrants and the issuance of new warrants (the "July 2017 Warrants") to them.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Pursuant to one form of Exercise Agreement, two investors exercised 2016 Warrants to purchase 226,923 shares of OncoCyte's common stock at the exercise price of $3.25 per share, and OncoCyte issued to them July 2017 Warrants expiring five years from the date of issue, to purchase 226,923 shares of common stock at an exercise price of $5.50 per share.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Pursuant to a second form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 540,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor a July 2017 Warrant, expiring five years from the date of issue, to purchase 270,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt; commercially reasonable efforts to &lt;/font&gt;file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Pursuant to a third form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 1,000,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor (i) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $5.50 per share, and (ii) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use commercially reasonable efforts to file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"&gt;&lt;br /&gt; &amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;In the aggregate, upon the exercise of 2016 Warrants under the Exercise Agreements, OncoCyte received gross proceeds of approximately $5.74 million and issued July 2017 Warrants to purchase 1,496,923 shares of common stock at a weighted average price of $4.34 per share.&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;The July 2017 Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the July 2017 Warrants is treated as an inducement offer to certain investors to exercise their 2016 Warrants. Accordingly, the fair value of the July 2017 Warrants, determined to be approximately $3.0 million using the &lt;/font&gt;Black-Scholes option pricing model, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;was recorded as a noncash charge to shareholder expense included in general and administrative expenses, and a corresponding increase was recorded to equity on July 21, 2017, the issuance date.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2017, OncoCyte has an aggregate of 2,779,221 warrants issued and outstanding at exercise prices ranging from $3.25 and $5.50 per warrant.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Stock Option Exercises&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;During the years ended December 31, 2017 and 2016, 323,019 and 99,496 shares of common stock were issued upon the exercise of stock options, from which OncoCyte received $610,000 and $218,000 in cash proceeds, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Stockholders' Equity Note, Stock Split, Conversion Ratio-->
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c20151118to20151118" unitRef="U004" decimals="1">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <!--Subsequent Events [Text Block]-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;10. Subsequent Events&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On March 28, 2018, OncoCyte entered into a securities purchase agreement with two accredited investors. The agreement provides for the private placement of 7,936,508 shares of OncoCyte's common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, OncoCyte has received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common stock, and one of the investors irrevocably committed in the agreement to pay to OncoCyte an additional $2.0 million on or prior to April 30, 2018 for the purchase of an additional 1,587,302 shares of common stock. The agreement contains certain registration rights. The investors are existing security holders of OncoCyte, including Broadwood Partners, L.P., which beneficially owns more than 5% of OncoCyte's outstanding common stock.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Selected Balance Sheet Components-->
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"&gt;3. Selected Balance Sheet Components&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued bonuses and payroll related expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;636&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,042&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;797&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Intangible assets, net&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;2,419&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated amortization&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(1,673&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(1,431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Intangible assets, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;746&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;988&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;Amortization expense amounted to approximately $242,000 annually.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Equipment and furniture, net&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment and furniture&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,479&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,007&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accumulated depreciation&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(657&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;(319&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Equipment and furniture, net&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;822&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;688&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Depreciation expense amounted to approximately $338,000, $145,000 and $41,000 for the years ended December 31, 2017, 2016 and 2015, respectively. During the year ended December 31, 2017 and 2016, OncoCyte entered into capital leases for laboratory equipment totaling $381,000 and $626,000, respectively (see Note 9).&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <!--Unamortized Debt Issuance Expense-->
  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c20171231" unitRef="U001" decimals="-3">113000</us-gaap:UnamortizedDebtIssuanceExpense>
  <!--Accrued interest and penalties-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20171231" unitRef="U001" decimals="-6">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Accrued interest and penalties-->
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c20161231" unitRef="U001" decimals="-6">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <!--Use of estimates-->
  <us-gaap:UseOfEstimates contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Use of estimates&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to the&amp;#160;going concern assessments of OncoCyte financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <!--Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount-->
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c20160101to20161231" unitRef="U001" decimals="-5">5100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <!--Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount-->
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c20170101to20171231" unitRef="U001" decimals="-5">1100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <!--Weighted average shares outstanding - basic and diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20160101to20161231" unitRef="U002" decimals="-3">26529000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding - basic and diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20170101to20171231" unitRef="U002" decimals="-3">30195000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Weighted average shares outstanding - basic and diluted (in shares)-->
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c20150101to20151231" unitRef="U002" decimals="-3">21009000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]-->
  <ocx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2017&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"&gt;2016&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued bonuses and payroll related expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;636&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;549&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;406&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;248&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;"&gt;Accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;1,042&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman';"&gt;797&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ocx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
  <!--Contingently issuable warrant expense to investors-->
  <ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</ocx:ContingentlyIssuableWarrantExpenseToInvestors>
  <!--Contingently issuable warrant expense to investors-->
  <ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20150101to20151231" unitRef="U001" decimals="-3">65000</ocx:ContingentlyIssuableWarrantExpenseToInvestors>
  <!--Contingently issuable warrant expense to investors-->
  <ocx:ContingentlyIssuableWarrantExpenseToInvestors contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</ocx:ContingentlyIssuableWarrantExpenseToInvestors>
  <!--Common stock issued conversion of convertible note payable and accrued interest-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231" unitRef="U001" decimals="-3">3318000</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Common stock issued conversion of convertible note payable and accrued interest-Common Stock [Member]-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">3318000</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Common stock issued conversion of convertible note payable and accrued interest-Accumulated Deficit [Member]-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Common stock issued conversion of convertible note payable and accrued interest-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Common stock issued conversion of convertible note payable and accrued interest-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Common stock issued conversion of convertible note payable and accrued interest-->
  <ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20160101to20161231" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Proceeds From Issuance Of Common Shares And Warrants-->
  <ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20160101to20161231" unitRef="U001" decimals="-3">10550000</ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
  <!--Proceeds From Issuance Of Common Shares And Warrants-->
  <ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
  <!--Proceeds From Issuance Of Common Shares And Warrants-->
  <ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants contextRef="c20170101to20171231" unitRef="U001" decimals="-3">0</ocx:ProceedsFromIssuanceOfCommonSharesAndWarrants>
  <!--Common Stock, Shares Held as Available for Sale Securities-BioTime, Inc. [Member]-->
  <ocx:CommonStockSharesHeldAsAvailableForSaleSecurities contextRef="c20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U002" decimals="INF">353264</ocx:CommonStockSharesHeldAsAvailableForSaleSecurities>
  <!--Reverse Stock Split [Policy Text Block]-->
  <ocx:ReverseStockSplitPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Reverse stock split&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.&lt;/div&gt;&lt;/div&gt;</ocx:ReverseStockSplitPolicyTextBlock>
  <!--Going concern assessment [Policy Text Block]-->
  <ocx:GoingConcernAssessmentPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Going concern assessment&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;With the implementation of FASB&amp;#8217;s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &amp;#8220;look-forward period&amp;#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.&lt;/div&gt;&lt;/div&gt;</ocx:GoingConcernAssessmentPolicyTextBlock>
  <!--Accounting for warrants [Policy Text Block]-->
  <ocx:AccountingForWarrantsPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;"&gt;Accounting for warrants&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity&lt;/font&gt;, then in accordance with ASC 815-40, &lt;font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&amp;#8217;s Own Stock&lt;/font&gt;. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.&lt;/div&gt;&lt;/div&gt;</ocx:AccountingForWarrantsPolicyTextBlock>
  <!--Sales and Marketing Costs, Policy [Text Block]-->
  <ocx:SalesAndMarketingCostsPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="background-color: #ffffff;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Sales and marketing expenses&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"&gt;Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on OncoCyte&amp;#8217;s headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.&lt;/div&gt;&lt;/div&gt;</ocx:SalesAndMarketingCostsPolicyTextBlock>
  <!--Transfer of realized loss into equity from sale of shares-Accumulated Deficit [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231" unitRef="U001" decimals="-3">0</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20170101to20171231" unitRef="U001" decimals="-3">293000</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">397000</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-Common Stock [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">0</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-Accumulated Deficit [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">293000</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Transfer of realized loss into equity from sale of shares-Common Stock [Member]-->
  <ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">-397000</ocx:TransferOfRealizedLossIntoEquityFromSaleOfShares>
  <!--Common Stock Shares Issued to Investors for Cash-Common Stock [Member]-->
  <ocx:CommonStockSharesIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">1500000</ocx:CommonStockSharesIssuedToInvestorsForCash>
  <!--Common Stock Issued to Investors for Cash-->
  <ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231" unitRef="U001" decimals="-3">3300000</ocx:CommonStockIssuedToInvestorsForCash>
  <!--Common Stock Issued to Investors for Cash-Common Stock [Member]-->
  <ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">3300000</ocx:CommonStockIssuedToInvestorsForCash>
  <!--Common Stock Issued to Investors for Cash-Accumulated Deficit [Member]-->
  <ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedToInvestorsForCash>
  <!--Common Stock Issued to Investors for Cash-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:CommonStockIssuedToInvestorsForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedToInvestorsForCash>
  <!--Common Stock Shares Issued Conversion Of Convertible Note Payable And Accrued Interest-Common Stock [Member]-->
  <ocx:CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">1508000</ocx:CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest>
  <!--Warrants Issued to Banks-Common Stock [Member]-->
  <ocx:WarrantsIssuedToBanks contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">62000</ocx:WarrantsIssuedToBanks>
  <!--Warrants Issued to Banks-Accumulated Deficit [Member]-->
  <ocx:WarrantsIssuedToBanks contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:WarrantsIssuedToBanks>
  <!--Warrants Issued to Banks-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:WarrantsIssuedToBanks contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:WarrantsIssuedToBanks>
  <!--Warrants Issued to Banks-->
  <ocx:WarrantsIssuedToBanks contextRef="c20170101to20171231" unitRef="U001" decimals="-3">62000</ocx:WarrantsIssuedToBanks>
  <!--Warrants issued to certain shareholders as inducement of exercise of warrants-Common Stock [Member]-->
  <ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">4074000</ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants>
  <!--Warrants issued to certain shareholders as inducement of exercise of warrants-->
  <ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants contextRef="c20170101to20171231" unitRef="U001" decimals="-3">4074000</ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants>
  <!--Warrants issued to certain shareholders as inducement of exercise of warrants-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants>
  <!--Warrants issued to certain shareholders as inducement of exercise of warrants-Accumulated Deficit [Member]-->
  <ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants>
  <!--Common Stock Issued for Cash-Accumulated Deficit [Member]-->
  <ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedForCash>
  <!--Common Stock Issued for Cash-Common Stock [Member]-->
  <ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">8349000</ocx:CommonStockIssuedForCash>
  <!--Common Stock Issued for Cash-->
  <ocx:CommonStockIssuedForCash contextRef="c20150101to20151231" unitRef="U001" decimals="-3">8349000</ocx:CommonStockIssuedForCash>
  <!--Common Stock Issued for Cash-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:CommonStockIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:CommonStockIssuedForCash>
  <!--Common Stock Shares Issued for Cash-Common Stock [Member]-->
  <ocx:CommonStockSharesIssuedForCash contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">2711000</ocx:CommonStockSharesIssuedForCash>
  <!--Common Stock Dividends Shares Received-Common Stock [Member]-->
  <ocx:CommonStockDividendsSharesReceived contextRef="c20150101to20151231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">31000</ocx:CommonStockDividendsSharesReceived>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231" unitRef="U001" decimals="-3">9777000</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-Common Stock [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">7774000</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-Accumulated Deficit [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3">0</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20170101to20171231" unitRef="U001" decimals="-3">7774000</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-Common Stock [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3">9777000</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs-Accumulated Other Comprehensive Loss [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3">0</ocx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance Of Common Stock Shares And Warrants Net Of Discounts And Financing Costs-Common Stock [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20160101to20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">3246000</ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Proceeds From Issuance Of Common Stock Shares And Warrants Net Of Discounts And Financing Costs-Common Stock [Member]-->
  <ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3">2392000</ocx:ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts>
  <!--Minimum Fixed Payment Due Shared Facility Agreement-->
  <ocx:MinimumFixedPaymentDueSharedFacilityAgreement contextRef="c20170101to20171231" unitRef="U001" decimals="-3">131000</ocx:MinimumFixedPaymentDueSharedFacilityAgreement>
  <!--Percentage of Markup Fee Allocated But Not Charged-BioTime, Inc. [Member]-->
  <ocx:PercentageOfMarkupFeeAllocatedButNotCharged contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U004" decimals="INF">0.05</ocx:PercentageOfMarkupFeeAllocatedButNotCharged>
  <!--Allocated Services and Facility Use Fee Payable-Current Liabilities [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeePayable contextRef="c20171231_BalanceSheetLocationAxis_CurrentLiabilitiesMember" unitRef="U001" decimals="-5">2100000</ocx:AllocatedServicesAndFacilityUseFeePayable>
  <!--Allocated Services and Facility Use Fee Payable-Current Liabilities [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeePayable contextRef="c20161231_BalanceSheetLocationAxis_CurrentLiabilitiesMember" unitRef="U001" decimals="-5">2900000</ocx:AllocatedServicesAndFacilityUseFeePayable>
  <!--Term Of Payment-BioTime, Inc. [Member]-->
  <ocx:TermOfPayment contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember">P30D</ocx:TermOfPayment>
  <!--Interest on Unpaid Overdue Invoice-BioTime, Inc. [Member]-->
  <ocx:InterestOnUnpaidOverdueInvoice contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U004" decimals="INF">0.15</ocx:InterestOnUnpaidOverdueInvoice>
  <!--Allocated Services and Facility Use Fee, Expense-Research and Development [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20160101to20161231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">691000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20170101to20171231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">268000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20160101to20161231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">790000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-Sales and Marketing [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20170101to20171231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">213000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-Research and Development [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20170101to20171231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-5">1100000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-Sales and Marketing [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20160101to20161231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">0</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-General and Administrative Expense [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3">595000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-Research and Development [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3">565000</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Allocated Services and Facility Use Fee, Expense-Sales and Marketing [Member]-->
  <ocx:AllocatedServicesAndFacilityUseFeeExpense contextRef="c20150101to20151231_IncomeStatementLocationAxis_SellingAndMarketingExpenseMember" unitRef="U001" decimals="-3">0</ocx:AllocatedServicesAndFacilityUseFeeExpense>
  <!--Percentage of Fair Market Value of Common Stock-Employee Stock Option [Member]-Minimum [Member]-->
  <ocx:PercentageOfFairMarketValueOfCommonStock contextRef="c20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF">1.1</ocx:PercentageOfFairMarketValueOfCommonStock>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period Maximum Term-Employee Stock Option [Member]-->
  <ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">P10Y</ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm>
  <!--Period of nontransferable for stock option grants-Maximum [Member]-Employee Stock Option [Member]-->
  <ocx:PeriodOfNontransferableForStockOptionGrants contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P3M</ocx:PeriodOfNontransferableForStockOptionGrants>
  <!--Share Based Compensation Arrangement By Share Based Payment Award Exercises In Period Maximum Term-Employee Stock Option [Member]-->
  <ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">P10Y</ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm>
  <!--Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross-Employee Stock Option [Member]-->
  <ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross contextRef="c20160101to20161231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">962000</ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross>
  <!--Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross-Employee Stock Option [Member]-->
  <ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3">896000</ocx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross>
  <!--Period for exercising vested option-Employee Stock Option [Member]-->
  <ocx:PeriodForExercisingVestedOption contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">P12M</ocx:PeriodForExercisingVestedOption>
  <!--Prepayment Fee if Prepaid Two Years or More-Loan and Security Agreement [Member]-->
  <ocx:PrepaymentFeeIfPrepaidTwoYearsOrMore contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.010</ocx:PrepaymentFeeIfPrepaidTwoYearsOrMore>
  <!--Prepayment Fee if Prepaid More than One Year but Less than Two Years-Loan and Security Agreement [Member]-->
  <ocx:PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.020</ocx:PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears>
  <!--Debt Instrument, Interest-->
  <ocx:DebtInstrumentInterest contextRef="c20171231" unitRef="U001" decimals="-3">114000</ocx:DebtInstrumentInterest>
  <!--Debt Instrument, Carrying Amount After Interest but Before Financing Costs-->
  <ocx:DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts contextRef="c20171231" unitRef="U001" decimals="-3">1983000</ocx:DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts>
  <!--Additional Final Payment Fee Percentage-Loan and Security Agreement [Member]-->
  <ocx:AdditionalFinalPaymentFeePercentage contextRef="c20170221to20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember" unitRef="U004" decimals="INF">0.058</ocx:AdditionalFinalPaymentFeePercentage>
  <!--Debt Default, Legal Action Amount-Minimum [Member]-Loan and Security Agreement [Member]-->
  <ocx:DebtDefaultLegalActionAmount contextRef="c20170221_DebtInstrumentAxis_LoanAndSecurityAgreementMember_RangeAxis_MinimumMember" unitRef="U001" decimals="-3">50000</ocx:DebtDefaultLegalActionAmount>
  <!--Amount Available under Capital Lease Agreement-Master Lease Line Agreement [Member]-->
  <ocx:AmountAvailableUnderCapitalLeaseAgreement contextRef="c20171231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U001" decimals="-3">820000</ocx:AmountAvailableUnderCapitalLeaseAgreement>
  <!--Percentage of Restocking Fee Paid on Original Cost of Equipment-Master Lease Line Agreement [Member]-->
  <ocx:PercentageOfRestockingFeePaidOnOriginalCostOfEquipment contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U004" decimals="INF">0.075</ocx:PercentageOfRestockingFeePaidOnOriginalCostOfEquipment>
  <!--Capital Lease Agreement Imputed Annual Interest Rate-Master Lease Line Agreement [Member]-->
  <ocx:CapitalLeaseAgreementImputedAnnualInterestRate contextRef="c20170401to20170430_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U004" decimals="INF">0.1</ocx:CapitalLeaseAgreementImputedAnnualInterestRate>
  <!--Capital Lease Agreement Imputed Annual Interest Rate-Master Lease Line Agreement [Member]-->
  <ocx:CapitalLeaseAgreementImputedAnnualInterestRate contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember" unitRef="U004" decimals="INF">0.1</ocx:CapitalLeaseAgreementImputedAnnualInterestRate>
  <!--Capital Lease Payment Term-Master Lease Line Agreement [Member]-->
  <ocx:CapitalLeasePaymentTerm contextRef="c20170101to20171231_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember">P36M</ocx:CapitalLeasePaymentTerm>
  <!--Percentage of Fair Value on Original Cost to Purchase an Equipment-Master Lease Line Agreement [Member]-Minimum [Member]-->
  <ocx:PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment contextRef="c20160407to20160407_LeaseArrangementTypeAxis_MasterLeaseLineAgreementMember_RangeAxis_MinimumMember" unitRef="U004" decimals="INF">0.125</ocx:PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment>
  <!--Period in which change of ownership for a specified percentage should occur-->
  <ocx:PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur contextRef="c20170101to20171231">P3Y</ocx:PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur>
  <!--Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)-->
  <ocx:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit contextRef="c20170101to20171231" unitRef="U001" decimals="-5">6800000</ocx:TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit>
  <!--Effective Income Tax Rate Reconciliation, Permanent differences-->
  <ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20160101to20161231" unitRef="U004" decimals="2">-0.01</ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <!--Effective Income Tax Rate Reconciliation, Permanent differences-->
  <ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20150101to20151231" unitRef="U004" decimals="2">-0.09</ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <!--Effective Income Tax Rate Reconciliation, Permanent differences-->
  <ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c20170101to20171231" unitRef="U004" decimals="2">-0.08</ocx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <!--Investors Taxable Gain (Loss)-BioTime, Inc. [Member]-->
  <ocx:InvestorsTaxableGainLoss contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">-301000</ocx:InvestorsTaxableGainLoss>
  <!--Investors Taxable Gain (Loss)-BioTime, Inc. [Member]-->
  <ocx:InvestorsTaxableGainLoss contextRef="c20150101to20151231_ConsolidatedEntitiesAxis_ParentCompanyMember" unitRef="U001" decimals="-3">-397000</ocx:InvestorsTaxableGainLoss>
  <!--Percentage of change in ownership-->
  <ocx:PercentageOfChangeInOwnership contextRef="c20170101to20171231" unitRef="U004" decimals="1">0.5</ocx:PercentageOfChangeInOwnership>
  <!--Deferred tax Assets, Patents and Fixed Assets-->
  <ocx:DeferredTaxAssetsPatentsAndFixedAssets contextRef="c20161231" unitRef="U001" decimals="-3">179000</ocx:DeferredTaxAssetsPatentsAndFixedAssets>
  <!--Deferred tax Assets, Patents and Fixed Assets-->
  <ocx:DeferredTaxAssetsPatentsAndFixedAssets contextRef="c20171231" unitRef="U001" decimals="-3">268000</ocx:DeferredTaxAssetsPatentsAndFixedAssets>
  <!--Tax Credit Carryforward, Expiration Date, Federal-Maximum [Member]-Research Tax Credit Carryforward [Member]-->
  <ocx:TaxCreditCarryforwardExpirationDateFederal contextRef="c20170101to20171231_RangeAxis_MaximumMember_TaxCreditCarryforwardAxis_ResearchMember">2037-12-31</ocx:TaxCreditCarryforwardExpirationDateFederal>
  <!--Tax Credit Carryforward, Expiration Date, Federal-Research Tax Credit Carryforward [Member]-Minimum [Member]-->
  <ocx:TaxCreditCarryforwardExpirationDateFederal contextRef="c20170101to20171231_RangeAxis_MinimumMember_TaxCreditCarryforwardAxis_ResearchMember">2030-12-31</ocx:TaxCreditCarryforwardExpirationDateFederal>
  <!--Tax Credit Carryforward, Amount, State-Research Tax Credit Carryforward [Member]-->
  <ocx:TaxCreditCarryforwardAmountState contextRef="c20171231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-5">1100000</ocx:TaxCreditCarryforwardAmountState>
  <!--Tax Credit Carryforward, Amount, Federal-Research Tax Credit Carryforward [Member]-->
  <ocx:TaxCreditCarryforwardAmountFederal contextRef="c20171231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-6">1000000</ocx:TaxCreditCarryforwardAmountFederal>
  <!--Effective Income Tax Rate Reconciliation, Change in Basis for Available-for-sale Securities, Percent-->
  <ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent contextRef="c20170101to20171231" unitRef="U004" decimals="2">0.11</ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent>
  <!--Effective Income Tax Rate Reconciliation, Change in Basis for Available-for-sale Securities, Percent-->
  <ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent contextRef="c20160101to20161231" unitRef="U004" decimals="0">0</ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent>
  <!--Effective Income Tax Rate Reconciliation, Change in Basis for Available-for-sale Securities, Percent-->
  <ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent contextRef="c20150101to20151231" unitRef="U004" decimals="0">0</ocx:EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent>
  <!--Liquidity [Policy Text Block]-->
  <ocx:LiquidityPolicyTextBlock contextRef="c20170101to20171231">&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;"&gt;Liquidity&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"&gt;For all periods presented, OncoCyte generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants, warrant exercises, a bank loan (see Note 5), and sales of BioTime common shares that OncoCyte holds as available-for-sale securities. BioTime has also provided OncoCyte with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4&lt;/font&gt;. OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $54.7 million and $35.3 million as December 31, 2017 and 2016, respectively.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;At December 31, 2017, OncoCyte had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to OncoCyte on or prior to April 30, 2018 (see Note 10), OncoCyte believes it has sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if it determines to devote more resources to the development or initial commercialization efforts for its lung cancer test during that time frame.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"&gt;OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&amp;#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&amp;#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&amp;#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&amp;#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</ocx:LiquidityPolicyTextBlock>
  <!--Stock Issued During Period, Shares, Private Placement-Subsequent Event [Member]-->
  <ocx:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF">7936508</ocx:StockIssuedDuringPeriodSharesPrivatePlacement>
  <!--Stock Issued During Period, Shares, Private Placement-Subsequent Event [Member]-Investor One [Member]-->
  <ocx:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorMember" unitRef="U002" decimals="INF">6349206</ocx:StockIssuedDuringPeriodSharesPrivatePlacement>
  <!--Stock Issued During Period, Shares, Private Placement-Subsequent Event [Member]-Investor Two [Member]-->
  <ocx:StockIssuedDuringPeriodSharesPrivatePlacement contextRef="c20180328to20180328_SubsequentEventTypeAxis_SubsequentEventMember_TitleOfIndividualAxis_InvestorTwoMember" unitRef="U002" decimals="INF">1587302</ocx:StockIssuedDuringPeriodSharesPrivatePlacement>
  <!--Number of Accredited Investors-Subsequent Event [Member]-->
  <ocx:NumberOfAccreditedInvestors contextRef="c20180328_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="INF">2</ocx:NumberOfAccreditedInvestors>
  <!--Number of Common Stock Shares Available in each Separable Unit-->
  <ocx:NumberOfCommonStockSharesAvailableInEachSeparableUnit contextRef="c20160829" unitRef="U002" decimals="INF">1</ocx:NumberOfCommonStockSharesAvailableInEachSeparableUnit>
  <!--Issuance of Separable Units-->
  <ocx:IssuanceOfSeparableUnits contextRef="c20160829" unitRef="U002" decimals="INF">3246153</ocx:IssuanceOfSeparableUnits>
  <!--Number of warrants available in each separable unit-->
  <ocx:NumberOfWarrantsAvailableInEachSeparableUnit contextRef="c20160829" unitRef="U002" decimals="INF">1</ocx:NumberOfWarrantsAvailableInEachSeparableUnit>
  <!--Separable Units, Exercise Price-->
  <ocx:SeparableUnitsExercisePrice contextRef="c20160829" unitRef="U003" decimals="INF">3.25</ocx:SeparableUnitsExercisePrice>
  <!--Common Stock Votes Per Share-->
  <ocx:CommonStockVotesPerShare contextRef="c20171231" unitRef="U006" decimals="INF">1</ocx:CommonStockVotesPerShare>
  <!--Number Of Warrant Holders-First Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:NumberOfWarrantHolders contextRef="c20170721to20170721_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U007" decimals="INF">2</ocx:NumberOfWarrantHolders>
  <!--Number Of Warrant Holders-Third Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:NumberOfWarrantHolders contextRef="c20170721to20170721_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U007" decimals="INF">1</ocx:NumberOfWarrantHolders>
  <!--Number Of Warrant Holders-Second Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:NumberOfWarrantHolders contextRef="c20170721to20170721_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember" unitRef="U007" decimals="INF">1</ocx:NumberOfWarrantHolders>
  <!--Number Of Warrant Holders-New Warrants [Member]-Investor One [Member]-->
  <ocx:NumberOfWarrantHolders contextRef="c20170217to20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember_TitleOfIndividualAxis_InvestorMember" unitRef="U007" decimals="INF">1</ocx:NumberOfWarrantHolders>
  <!--Number Of Forms In Warrant Exercise Agreement-->
  <ocx:NumberOfFormsInWarrantExerciseAgreement contextRef="c20170721to20170721" unitRef="U008" decimals="INF">3</ocx:NumberOfFormsInWarrantExerciseAgreement>
  <!--Class of Warrant or Right, Weighted Average Price of Warrants or Rights-July 2017 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights contextRef="c20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember" unitRef="U003" decimals="2">4.34</ocx:ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights>
  <!--Noncash Charge To Shareholder Expense Included In General And Administrative Expenses-New Warrants [Member]-->
  <ocx:NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses contextRef="c20170217to20170217_ClassOfWarrantOrRightAxis_NewWarrantsMember" unitRef="U001" decimals="-5">1100000</ocx:NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses>
  <!--Noncash Charge To Shareholder Expense Included In General And Administrative Expenses-July 2017 Warrants [Member]-->
  <ocx:NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses contextRef="c20170721to20170721_ClassOfWarrantOrRightAxis_July2017WarrantsMember" unitRef="U001" decimals="-5">3000000</ocx:NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses>
  <!--Class of Warrant or Right, Exercised Period-First Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Third Form Part1 Warrant Exercise Agreement July21 2017 [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormPart1WarrantExerciseAgreementJuly212017Member">P2Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-July 2017 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_July2017WarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Second Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreement2016WarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Second Form, Warrant Exercise Agreement, July 2017 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-New Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_NewWarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Third Form Part2 Warrant Exercise Agreement July21 2017 [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormPart2WarrantExerciseAgreementJuly212017Member">P2Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Warrants 2016 [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_Warrants2016Member">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-First Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_FirstFormWarrantExerciseAgreement2016WarrantsMember">P5Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Class of Warrant or Right, Exercised Period-Third Form, Warrant Exercise Agreement, 2016 Warrants [Member]-->
  <ocx:ClassOfWarrantOrRightExercisedPeriod contextRef="c20170101to20171231_ClassOfWarrantOrRightAxis_ThirdFormWarrantExerciseAgreement2016WarrantsMember">P2Y</ocx:ClassOfWarrantOrRightExercisedPeriod>
  <!--Royalty, Percentage-Wistar License Agreement [Member]-Maximum [Member]-->
  <ocx:RoyaltyPercentage contextRef="c20170101to20171231_RangeAxis_MaximumMember_TypeOfArrangementAxis_WistarLicenseAgreementMember" unitRef="U004" decimals="INF">0.05</ocx:RoyaltyPercentage>
  <!--Royalty, Percentage-Wistar License Agreement [Member]-Minimum [Member]-->
  <ocx:RoyaltyPercentage contextRef="c20170101to20171231_RangeAxis_MinimumMember_TypeOfArrangementAxis_WistarLicenseAgreementMember" unitRef="U004" decimals="INF">0.03</ocx:RoyaltyPercentage>
  <!--Maximum reduction in royalty payments-Wistar License Agreement [Member]-->
  <ocx:MaximumReductionInRoyaltyPayments contextRef="c20171231_TypeOfArrangementAxis_WistarLicenseAgreementMember" unitRef="U004" decimals="INF">0.5</ocx:MaximumReductionInRoyaltyPayments>
  <!--Commencement of Commercial Sale Deadline, Number of One Year Extensions-Wistar License Agreement [Member]-->
  <ocx:CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions contextRef="c20170101to20171231_TypeOfArrangementAxis_WistarLicenseAgreementMember" unitRef="U009" decimals="INF">3</ocx:CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ocx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<xs:schema targetNamespace="http://oncocyte.com/20171231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ocx="http://oncocyte.com/20171231" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://oncocyte.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>010000 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <!--Parent Role: BALANCE SHEETS-->
        <link:definition>010100 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>020000 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
        <link:definition>030000 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
        <link:definition>040000 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>050000 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" id="OrganizationDescriptionOfBusinessAndLiquidity">
        <link:definition>060100 - Disclosure - Organization, Description of the Business and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponents" id="SelectedBalanceSheetComponents">
        <link:definition>060300 - Disclosure - Selected Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060400 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" id="LoanPayableToSiliconValleyBank">
        <link:definition>060500 - Disclosure - Loan Payable to Silicon Valley Bank</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquity" id="ShareholdersEquity">
        <link:definition>060600 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060700 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060800 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060900 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061000 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies" id="OrganizationDescriptionOfBusinessAndLiquidityPolicies">
        <!--Parent Role: Organization, Description of the Business and Liquidity-->
        <link:definition>070100 - Disclosure - Organization, Description of the Business and Liquidity (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsTables" id="SelectedBalanceSheetComponentsTables">
        <!--Parent Role: Selected Balance Sheet Components-->
        <link:definition>080300 - Disclosure - Selected Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables" id="LoanPayableToSiliconValleyBankTables">
        <!--Parent Role: Loan Payable to Silicon Valley Bank-->
        <link:definition>080500 - Disclosure - Loan Payable to Silicon Valley Bank (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>080700 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income Taxes-->
        <link:definition>080800 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>080900 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails" id="OrganizationDescriptionOfBusinessAndLiquidityDetails">
        <!--Parent Role: Organization, Description of the Business and Liquidity-->
        <link:definition>090100 - Disclosure - Organization, Description of the Business and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails" id="SelectedBalanceSheetComponentsDetails">
        <!--Parent Role: Selected Balance Sheet Components-->
        <link:definition>090300 - Disclosure - Selected Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: Related Party Transactions-->
        <link:definition>090400 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails" id="LoanPayableToSiliconValleyBankDetails">
        <!--Parent Role: Loan Payable to Silicon Valley Bank-->
        <link:definition>090500 - Disclosure - Loan Payable to Silicon Valley Bank (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquityDetails" id="ShareholdersEquityDetails">
        <!--Parent Role: Shareholders' Equity-->
        <link:definition>090600 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails" id="ShareholdersEquity2016WarrantsAndNewWarrantsDetails">
        <!--Parent Role: Shareholders' Equity-->
        <link:definition>090602 - Disclosure - Shareholders' Equity, 2016 Warrants and New Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails" id="ShareholdersEquityStockOptionExercisesDetails">
        <!--Parent Role: Shareholders' Equity-->
        <link:definition>090604 - Disclosure - Shareholders' Equity, Stock Option Exercises (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/StockbasedCompensationDetails" id="StockbasedCompensationDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090700 - Disclosure - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090800 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090900 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails" id="CommitmentsAndContingenciesWistarLicenseAgreementDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090902 - Disclosure - Commitments and Contingencies, Wistar License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oncocyte.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091000 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:element name="SelectedBalanceSheetComponentsAbstract" id="ocx_SelectedBalanceSheetComponentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ContingentlyIssuableWarrantExpenseToInvestors" id="ocx_ContingentlyIssuableWarrantExpenseToInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" id="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ProceedsFromIssuanceOfCommonSharesAndWarrants" id="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ReverseStockSplitAbstract" id="ocx_ReverseStockSplitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockSharesHeldAsAvailableForSaleSecurities" id="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IncomeTaxDisclosureTable" id="ocx_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncomeTaxDisclosureLineItems" id="ocx_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquipmentAndFurnitureMember" id="ocx_EquipmentAndFurnitureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReverseStockSplitPolicyTextBlock" id="ocx_ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="GoingConcernAssessmentPolicyTextBlock" id="ocx_GoingConcernAssessmentPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccountingForWarrantsPolicyTextBlock" id="ocx_AccountingForWarrantsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SalesAndMarketingCostsPolicyTextBlock" id="ocx_SalesAndMarketingCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TransferOfRealizedLossIntoEquityFromSaleOfShares" id="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommonStockSharesIssuedToInvestorsForCash" id="ocx_CommonStockSharesIssuedToInvestorsForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommonStockIssuedToInvestorsForCash" id="ocx_CommonStockIssuedToInvestorsForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" id="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WarrantsIssuedToBanks" id="ocx_WarrantsIssuedToBanks" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" id="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommonStockIssuedForCash" id="ocx_CommonStockIssuedForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommonStockSharesIssuedForCash" id="ocx_CommonStockSharesIssuedForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CommonStockDividendsSharesReceived" id="ocx_CommonStockDividendsSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" id="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" id="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SharedFacilitiesAndServiceAgreementAbstract" id="ocx_SharedFacilitiesAndServiceAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MinimumFixedPaymentDueSharedFacilityAgreement" id="ocx_MinimumFixedPaymentDueSharedFacilityAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PercentageOfMarkupFeeAllocatedButNotCharged" id="ocx_PercentageOfMarkupFeeAllocatedButNotCharged" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AllocatedServicesAndFacilityUseFeePayable" id="ocx_AllocatedServicesAndFacilityUseFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="TermOfPayment" id="ocx_TermOfPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InterestOnUnpaidOverdueInvoice" id="ocx_InterestOnUnpaidOverdueInvoice" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AllocatedServicesAndFacilityUseFeeExpense" id="ocx_AllocatedServicesAndFacilityUseFeeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CurrentLiabilitiesMember" id="ocx_CurrentLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfFairMarketValueOfCommonStock" id="ocx_PercentageOfFairMarketValueOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodOfNontransferableForStockOptionGrants" id="ocx_PeriodOfNontransferableForStockOptionGrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodForExercisingVestedOption" id="ocx_PeriodForExercisingVestedOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DocumentAndEntityInformationAbstract" id="ocx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionExercisesAbstract" id="ocx_StockOptionExercisesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightBankWarrantsAbstract" id="ocx_ClassOfWarrantOrRightBankWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanAndSecurityAgreementAbstract" id="ocx_LoanAndSecurityAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaymentFeeIfPrepaidTwoYearsOrMore" id="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" id="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FutureCashPaymentsOfLoanPayableAbstract" id="ocx_FutureCashPaymentsOfLoanPayableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentInterest" id="ocx_DebtInstrumentInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LoanAndSecurityAgreementMember" id="ocx_LoanAndSecurityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" id="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AdditionalFinalPaymentFeePercentage" id="ocx_AdditionalFinalPaymentFeePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtDefaultLegalActionAmount" id="ocx_DebtDefaultLegalActionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AmountAvailableUnderCapitalLeaseAgreement" id="ocx_AmountAvailableUnderCapitalLeaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" id="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CapitalLeaseAgreementImputedAnnualInterestRate" id="ocx_CapitalLeaseAgreementImputedAnnualInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CapitalLeasePaymentTerm" id="ocx_CapitalLeasePaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" id="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MasterLeaseLineAgreementMember" id="ocx_MasterLeaseLineAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" id="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" id="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InvestorsTaxableGainLoss" id="ocx_InvestorsTaxableGainLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PercentageOfChangeInOwnership" id="ocx_PercentageOfChangeInOwnership" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredTaxAssetsPatentsAndFixedAssets" id="ocx_DeferredTaxAssetsPatentsAndFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TaxCreditCarryforwardExpirationDateFederal" id="ocx_TaxCreditCarryforwardExpirationDateFederal" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TaxCreditCarryforwardAmountState" id="ocx_TaxCreditCarryforwardAmountState" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TaxCreditCarryforwardAmountFederal" id="ocx_TaxCreditCarryforwardAmountFederal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" id="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LiquidityPolicyTextBlock" id="ocx_LiquidityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InvestorTwoMember" id="ocx_InvestorTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesPrivatePlacement" id="ocx_StockIssuedDuringPeriodSharesPrivatePlacement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfAccreditedInvestors" id="ocx_NumberOfAccreditedInvestors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="BroadwoodPartnersLPMember" id="ocx_BroadwoodPartnersLPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IssuanceOfCommonStockAndWarrantsAbstract" id="ocx_IssuanceOfCommonStockAndWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfCommonStockSharesAvailableInEachSeparableUnit" id="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IssuanceOfSeparableUnits" id="ocx_IssuanceOfSeparableUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfWarrantsAvailableInEachSeparableUnit" id="ocx_NumberOfWarrantsAvailableInEachSeparableUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="SeparableUnitsExercisePrice" id="ocx_SeparableUnitsExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CommonStockVotesPerShare" id="ocx_CommonStockVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="Warrants2016Member" id="ocx_Warrants2016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="July2017WarrantsMember" id="ocx_July2017WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecondFormWarrantExerciseAgreement2016WarrantsMember" id="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" id="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" id="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" id="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" id="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ThirdFormWarrantExerciseAgreement2016WarrantsMember" id="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstFormWarrantExerciseAgreement2016WarrantsMember" id="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NewWarrantsMember" id="ocx_NewWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="Warrants2016AndNewWarrantsAbstract" id="ocx_Warrants2016AndNewWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfWarrantHolders" id="ocx_NumberOfWarrantHolders" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFormsInWarrantExerciseAgreement" id="ocx_NumberOfFormsInWarrantExerciseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" id="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" id="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ClassOfWarrantOrRightExercisedPeriod" id="ocx_ClassOfWarrantOrRightExercisedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InvestorsGroupOneMember" id="ocx_InvestorsGroupOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WistarLicenseAgreementMember" id="ocx_WistarLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WistarLicenseAgreementAbstract" id="ocx_WistarLicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoyaltyPercentage" id="ocx_RoyaltyPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumReductionInRoyaltyPayments" id="ocx_MaximumReductionInRoyaltyPayments" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" id="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ocx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBankDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponentsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfComprehensiveLoss" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfOperations" />
  <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocx-20171231.xsd#BalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAssetsNoncurrent" xlink:title="calculation: Assets to DepositsAssetsNoncurrent" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="calculation: AssetsCurrent to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="calculation: Assets to FiniteLivedIntangibleAssetsNet" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LoansPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to LoansPayableCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="CapitalLeaseObligationsCurrent" xlink:title="calculation: LiabilitiesCurrent to CapitalLeaseObligationsCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="DueToRelatedPartiesCurrent" xlink:title="DueToRelatedPartiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="DueToRelatedPartiesCurrent" xlink:title="calculation: LiabilitiesCurrent to DueToRelatedPartiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableAndAccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="CapitalLeaseObligationsNoncurrent" xlink:title="CapitalLeaseObligationsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="CapitalLeaseObligationsNoncurrent" xlink:title="calculation: Liabilities to CapitalLeaseObligationsNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermLoansPayable" xlink:title="calculation: Liabilities to LongTermLoansPayable" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingAndMarketingExpense" xlink:title="calculation: OperatingExpenses to SellingAndMarketingExpense" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: NetIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="calculation: NonoperatingIncomeExpense to InterestIncomeExpenseNonoperatingNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="calculation: NonoperatingIncomeExpense to AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="NetIncomeLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTax to NetIncomeLoss" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfLongTermCapitalLeaseObligations" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfStockIssuanceCosts" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:label="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:title="ProceedsFromIssuanceOfCommonSharesAndWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonSharesAndWarrants" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfDebt" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromDebtNetOfIssuanceCosts" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromWarrantExercises" order="8.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInFinancingActivities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="IncreaseDecreaseInDueToRelatedParties" xlink:title="IncreaseDecreaseInDueToRelatedParties" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDueToRelatedParties" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDueToRelatedParties" order="37.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ContingentlyIssuableWarrantExpenseToInvestors" xlink:label="ContingentlyIssuableWarrantExpenseToInvestors" xlink:title="ContingentlyIssuableWarrantExpenseToInvestors" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ContingentlyIssuableWarrantExpenseToInvestors" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ContingentlyIssuableWarrantExpenseToInvestors" order="35.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfFinancingCostsAndDiscounts" order="36.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="39.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfIntangibleAssets" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="33.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AllocatedShareBasedCompensationExpense" order="20.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ProceedsFromIssuanceOfWarrants" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInOperatingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="PaymentsForDeposits" xlink:title="PaymentsForDeposits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsForDeposits" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsForDeposits" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashAndCashEquivalentsPeriodIncreaseDecrease to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccountsPayableAndAccruedLiabilitiesCurrent to AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsGross" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="calculation: FiniteLivedIntangibleAssetsNet to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:label="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentCarryingAmount" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="calculation: DebtInstrumentCarryingAmount to LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentCarryingAmount" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="calculation: DebtInstrumentCarryingAmount to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentCarryingAmount" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="calculation: DebtInstrumentCarryingAmount to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:to="DebtInstrumentCarryingAmount" xlink:title="calculation: DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts to DebtInstrumentCarryingAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentInterest" xlink:label="DebtInstrumentInterest" xlink:title="DebtInstrumentInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:to="DebtInstrumentInterest" xlink:title="calculation: DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts to DebtInstrumentInterest" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="calculation: LongTermDebt to DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="UnamortizedDebtIssuanceExpense" xlink:title="calculation: LongTermDebt to UnamortizedDebtIssuanceExpense" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="DeferredTaxLiabilitiesInvestments" xlink:title="DeferredTaxLiabilitiesInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="DeferredTaxLiabilitiesInvestments" xlink:title="calculation: DeferredIncomeTaxLiabilities to DeferredTaxLiabilitiesInvestments" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredIncomeTaxLiabilities" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DeferredTaxAssetsPatentsAndFixedAssets" xlink:label="DeferredTaxAssetsPatentsAndFixedAssets" xlink:title="DeferredTaxAssetsPatentsAndFixedAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsPatentsAndFixedAssets" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsPatentsAndFixedAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsNet" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="CapitalLeasesFutureMinimumPaymentsDue" xlink:title="CapitalLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CapitalLeasesFutureMinimumPaymentsDue" xlink:to="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="calculation: CapitalLeasesFutureMinimumPaymentsDue to CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:title="CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CapitalLeasesFutureMinimumPaymentsDue" xlink:to="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:title="calculation: CapitalLeasesFutureMinimumPaymentsDue to CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CapitalLeasesFutureMinimumPaymentsDue" xlink:to="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="calculation: CapitalLeasesFutureMinimumPaymentsDue to CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="CapitalLeasesFutureMinimumPaymentsDue" xlink:title="calculation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments to CapitalLeasesFutureMinimumPaymentsDue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="calculation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments to CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="1.0" weight="-1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ocx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesWistarLicenseAgreementDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensationDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensationDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquityStockOptionExercisesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquity2016WarrantsAndNewWarrantsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBankDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponentsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBankTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponentsTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidityPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocx-20171231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBank" />
  <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ocx-20171231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponents" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponents" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfComprehensiveLoss" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfOperations" />
  <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ocx-20171231.xsd#BalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocx-20171231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://oncocyte.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ocx-20171231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:title="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:title="definition: StatementLineItems to AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="definition: StatementLineItems to StockGrantedDuringPeriodValueSharebasedCompensation" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="definition: StatementLineItems to DebtConversionConvertedInstrumentSharesIssued1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="definition: StatementLineItems to DebtConversionConvertedInstrumentAmount1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedToInvestorsForCash" xlink:label="CommonStockSharesIssuedToInvestorsForCash" xlink:title="CommonStockSharesIssuedToInvestorsForCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssuedToInvestorsForCash" xlink:title="definition: StatementLineItems to CommonStockSharesIssuedToInvestorsForCash" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedToInvestorsForCash" xlink:label="CommonStockIssuedToInvestorsForCash" xlink:title="CommonStockIssuedToInvestorsForCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockIssuedToInvestorsForCash" xlink:title="definition: StatementLineItems to CommonStockIssuedToInvestorsForCash" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="definition: StatementLineItems to CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="definition: StatementLineItems to CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedForCash" xlink:label="CommonStockSharesIssuedForCash" xlink:title="CommonStockSharesIssuedForCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssuedForCash" xlink:title="definition: StatementLineItems to CommonStockSharesIssuedForCash" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedForCash" xlink:label="CommonStockIssuedForCash" xlink:title="CommonStockIssuedForCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockIssuedForCash" xlink:title="definition: StatementLineItems to CommonStockIssuedForCash" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: StatementLineItems to FairValueAdjustmentOfWarrants" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockDividendsSharesReceived" xlink:label="CommonStockDividendsSharesReceived" xlink:title="CommonStockDividendsSharesReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockDividendsSharesReceived" xlink:title="definition: StatementLineItems to CommonStockDividendsSharesReceived" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockPaidinkind" xlink:label="DividendsCommonStockPaidinkind" xlink:title="DividendsCommonStockPaidinkind" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsCommonStockPaidinkind" xlink:title="definition: StatementLineItems to DividendsCommonStockPaidinkind" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:label="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:title="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:title="definition: StatementLineItems to WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToBanks" xlink:label="WarrantsIssuedToBanks" xlink:title="WarrantsIssuedToBanks" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WarrantsIssuedToBanks" xlink:title="definition: StatementLineItems to WarrantsIssuedToBanks" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:label="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:title="TransferOfRealizedLossIntoEquityFromSaleOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:title="definition: StatementLineItems to TransferOfRealizedLossIntoEquityFromSaleOfShares" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="25.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to RetainedEarningsAccumulatedDeficit" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to CashAndCashEquivalentsAtCarryingValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ScheduleOfEquityMethodInvestmentsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="definition: ConsolidatedEntitiesDomain to ParentCompanyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to SubsequentEventTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorTwoMember" xlink:label="InvestorTwoMember" xlink:title="InvestorTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorTwoMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorTwoMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureLineItems" xlink:label="IncomeTaxDisclosureLineItems" xlink:title="IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="definition: IncomeTaxDisclosureLineItems to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureTable" xlink:label="IncomeTaxDisclosureTable" xlink:title="IncomeTaxDisclosureTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="IncomeTaxDisclosureTable" xlink:title="definition: IncomeTaxDisclosureLineItems to IncomeTaxDisclosureTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeTaxDisclosureTable" xlink:to="StatementScenarioAxis" xlink:title="definition: IncomeTaxDisclosureTable to StatementScenarioAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="ScenarioPlanMember" xlink:title="ScenarioPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioPlanMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioPlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EquipmentAndFurnitureMember" xlink:label="EquipmentAndFurnitureMember" xlink:title="EquipmentAndFurnitureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentAndFurnitureMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentAndFurnitureMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FairValueByAssetClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FairValueByAssetClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="FiniteLivedIntangibleAssetsMember" xlink:title="FiniteLivedIntangibleAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="FiniteLivedIntangibleAssetsMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to FiniteLivedIntangibleAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: SubsidiarySaleOfStockLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="GainLossOnSaleOfEquityInvestments" xlink:title="GainLossOnSaleOfEquityInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="GainLossOnSaleOfEquityInvestments" xlink:title="definition: SubsidiarySaleOfStockLineItems to GainLossOnSaleOfEquityInvestments" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:title="CommonStockSharesHeldAsAvailableForSaleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:title="definition: SubsidiarySaleOfStockLineItems to CommonStockSharesHeldAsAvailableForSaleSecurities" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="definition: SubsidiarySaleOfStockLineItems to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="definition: SubsidiarySaleOfStockLineItems to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="definition: ConsolidatedEntitiesDomain to ParentCompanyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="definition: ScheduleOfEquityMethodInvestmentsLineItems to ScheduleOfEquityMethodInvestmentsTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfEquityMethodInvestmentsTable to ConsolidatedEntitiesAxis" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="definition: ConsolidatedEntitiesDomain to ParentCompanyMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SharedFacilitiesAndServiceAgreementAbstract" xlink:label="SharedFacilitiesAndServiceAgreementAbstract" xlink:title="SharedFacilitiesAndServiceAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharedFacilitiesAndServiceAgreementAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to SharedFacilitiesAndServiceAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfMarkupFeeAllocatedButNotCharged" xlink:label="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:title="PercentageOfMarkupFeeAllocatedButNotCharged" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:title="definition: RelatedPartyTransactionLineItems to PercentageOfMarkupFeeAllocatedButNotCharged" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TermOfPayment" xlink:label="TermOfPayment" xlink:title="TermOfPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="TermOfPayment" xlink:title="definition: RelatedPartyTransactionLineItems to TermOfPayment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InterestOnUnpaidOverdueInvoice" xlink:label="InterestOnUnpaidOverdueInvoice" xlink:title="InterestOnUnpaidOverdueInvoice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="InterestOnUnpaidOverdueInvoice" xlink:title="definition: RelatedPartyTransactionLineItems to InterestOnUnpaidOverdueInvoice" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeeExpense" xlink:label="AllocatedServicesAndFacilityUseFeeExpense" xlink:title="AllocatedServicesAndFacilityUseFeeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AllocatedServicesAndFacilityUseFeeExpense" xlink:title="definition: RelatedPartyTransactionLineItems to AllocatedServicesAndFacilityUseFeeExpense" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeePayable" xlink:label="AllocatedServicesAndFacilityUseFeePayable" xlink:title="AllocatedServicesAndFacilityUseFeePayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AllocatedServicesAndFacilityUseFeePayable" xlink:title="definition: RelatedPartyTransactionLineItems to AllocatedServicesAndFacilityUseFeePayable" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MinimumFixedPaymentDueSharedFacilityAgreement" xlink:label="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:title="MinimumFixedPaymentDueSharedFacilityAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:title="definition: RelatedPartyTransactionLineItems to MinimumFixedPaymentDueSharedFacilityAgreement" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="definition: ConsolidatedEntitiesDomain to ParentCompanyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to IncomeStatementLocationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="SellingAndMarketingExpenseMember" xlink:title="SellingAndMarketingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingAndMarketingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to SellingAndMarketingExpenseMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="BalanceSheetLocationAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to BalanceSheetLocationAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain_2" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain_2" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CurrentLiabilitiesMember" xlink:label="CurrentLiabilitiesMember" xlink:title="CurrentLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BalanceSheetLocationDomain" xlink:to="CurrentLiabilitiesMember" xlink:title="definition: BalanceSheetLocationDomain to CurrentLiabilitiesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementAbstract" xlink:label="LoanAndSecurityAgreementAbstract" xlink:title="LoanAndSecurityAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LoanAndSecurityAgreementAbstract" xlink:title="definition: DebtInstrumentLineItems to LoanAndSecurityAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightBankWarrantsAbstract" xlink:label="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:title="ClassOfWarrantOrRightBankWarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightBankWarrantsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FutureCashPaymentsOfLoanPayableAbstract" xlink:label="FutureCashPaymentsOfLoanPayableAbstract" xlink:title="FutureCashPaymentsOfLoanPayableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FutureCashPaymentsOfLoanPayableAbstract" xlink:title="definition: DebtInstrumentLineItems to FutureCashPaymentsOfLoanPayableAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentInterest" xlink:label="DebtInstrumentInterest" xlink:title="DebtInstrumentInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterest" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterest" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:label="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="UnamortizedDebtIssuanceExpense" xlink:title="definition: DebtInstrumentLineItems to UnamortizedDebtIssuanceExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="definition: DebtInstrumentLineItems to LongTermDebt" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DeferredFinanceCostsNet" xlink:title="definition: DebtInstrumentLineItems to DeferredFinanceCostsNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: DebtInstrumentLineItems to PaymentsOfDebtIssuanceCosts" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFrequencyOfPeriodicPayment" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPayment" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateDuringPeriod" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AdditionalFinalPaymentFeePercentage" xlink:label="AdditionalFinalPaymentFeePercentage" xlink:title="AdditionalFinalPaymentFeePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AdditionalFinalPaymentFeePercentage" xlink:title="definition: DebtInstrumentLineItems to AdditionalFinalPaymentFeePercentage" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfFinancingCosts" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfFinancingCosts" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:label="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:title="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:title="definition: DebtInstrumentLineItems to PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:label="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:title="PrepaymentFeeIfPrepaidTwoYearsOrMore" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:title="definition: DebtInstrumentLineItems to PrepaymentFeeIfPrepaidTwoYearsOrMore" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="LongTermDebtPercentageBearingFixedInterestRate" xlink:title="LongTermDebtPercentageBearingFixedInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtPercentageBearingFixedInterestRate" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtPercentageBearingFixedInterestRate" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtDefaultLegalActionAmount" xlink:label="DebtDefaultLegalActionAmount" xlink:title="DebtDefaultLegalActionAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtDefaultLegalActionAmount" xlink:title="definition: DebtInstrumentLineItems to DebtDefaultLegalActionAmount" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="28.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementMember" xlink:label="LoanAndSecurityAgreementMember" xlink:title="LoanAndSecurityAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="LoanAndSecurityAgreementMember" xlink:title="definition: DebtInstrumentNameDomain to LoanAndSecurityAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="definition: VariableRateDomain to PrimeRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: DebtInstrumentTable to ClassOfWarrantOrRightAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016AndNewWarrantsAbstract" xlink:label="Warrants2016AndNewWarrantsAbstract" xlink:title="Warrants2016AndNewWarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="Warrants2016AndNewWarrantsAbstract" xlink:title="definition: ClassOfStockLineItems to Warrants2016AndNewWarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfWarrantHolders" xlink:label="NumberOfWarrantHolders" xlink:title="NumberOfWarrantHolders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NumberOfWarrantHolders" xlink:title="definition: ClassOfStockLineItems to NumberOfWarrantHolders" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightExercisedPeriod" xlink:label="ClassOfWarrantOrRightExercisedPeriod" xlink:title="ClassOfWarrantOrRightExercisedPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightExercisedPeriod" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightExercisedPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfWarrants" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:label="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:title="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:title="definition: ClassOfStockLineItems to NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfFormsInWarrantExerciseAgreement" xlink:label="NumberOfFormsInWarrantExerciseAgreement" xlink:title="NumberOfFormsInWarrantExerciseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="NumberOfFormsInWarrantExerciseAgreement" xlink:title="definition: ClassOfStockLineItems to NumberOfFormsInWarrantExerciseAgreement" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="ClassOfWarrantOrRightUnissued" xlink:title="ClassOfWarrantOrRightUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightUnissued" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightUnissued" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfStockByClassTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016Member" xlink:label="Warrants2016Member" xlink:title="Warrants2016Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="Warrants2016Member" xlink:title="definition: ClassOfWarrantOrRightDomain to Warrants2016Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NewWarrantsMember" xlink:label="NewWarrantsMember" xlink:title="NewWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="NewWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to NewWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to FirstFormWarrantExerciseAgreement2016WarrantsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SecondFormWarrantExerciseAgreement2016WarrantsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="ThirdFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to ThirdFormWarrantExerciseAgreement2016WarrantsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:title="definition: ClassOfWarrantOrRightDomain to ThirdFormPart1WarrantExerciseAgreementJuly212017Member" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:title="definition: ClassOfWarrantOrRightDomain to ThirdFormPart2WarrantExerciseAgreementJuly212017Member" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_July2017WarrantsMember" xlink:label="July2017WarrantsMember" xlink:title="July2017WarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="July2017WarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to July2017WarrantsMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsGroupOneMember" xlink:label="InvestorsGroupOneMember" xlink:title="InvestorsGroupOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorsGroupOneMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorsGroupOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockOptionExercisesAbstract" xlink:label="StockOptionExercisesAbstract" xlink:title="StockOptionExercisesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockOptionExercisesAbstract" xlink:title="definition: ClassOfStockLineItems to StockOptionExercisesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ClassOfStockLineItems to ProceedsFromStockOptionsExercised" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EquityMethodInvestmentOwnershipPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairMarketValueOfCommonStock" xlink:label="PercentageOfFairMarketValueOfCommonStock" xlink:title="PercentageOfFairMarketValueOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfFairMarketValueOfCommonStock" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfFairMarketValueOfCommonStock" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodOfNontransferableForStockOptionGrants" xlink:label="PeriodOfNontransferableForStockOptionGrants" xlink:title="PeriodOfNontransferableForStockOptionGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodOfNontransferableForStockOptionGrants" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodOfNontransferableForStockOptionGrants" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodForExercisingVestedOption" xlink:label="PeriodForExercisingVestedOption" xlink:title="PeriodForExercisingVestedOption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodForExercisingVestedOption" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodForExercisingVestedOption" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="37.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="SellingAndMarketingExpenseMember" xlink:title="SellingAndMarketingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingAndMarketingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to SellingAndMarketingExpenseMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesIssued" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsTaxableGainLoss" xlink:label="InvestorsTaxableGainLoss" xlink:title="InvestorsTaxableGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="InvestorsTaxableGainLoss" xlink:title="definition: ClassOfStockLineItems to InvestorsTaxableGainLoss" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfStockByClassTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="definition: ConsolidatedEntitiesDomain to ParentCompanyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountFederal" xlink:label="TaxCreditCarryforwardAmountFederal" xlink:title="TaxCreditCarryforwardAmountFederal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmountFederal" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmountFederal" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountState" xlink:label="TaxCreditCarryforwardAmountState" xlink:title="TaxCreditCarryforwardAmountState" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmountState" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmountState" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardExpirationDateFederal" xlink:label="TaxCreditCarryforwardExpirationDateFederal" xlink:title="TaxCreditCarryforwardExpirationDateFederal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardExpirationDateFederal" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardExpirationDateFederal" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardTable" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="definition: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain_2" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain_2" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to ResearchMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="RangeAxis" xlink:title="definition: TaxCreditCarryforwardTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsExpirationDate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="definition: IncomeTaxAuthorityDomain to DomesticCountryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="definition: OperatingLossCarryforwardsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureLineItems" xlink:label="IncomeTaxDisclosureLineItems" xlink:title="IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="definition: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateContinuingOperations" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureTable" xlink:label="IncomeTaxDisclosureTable" xlink:title="IncomeTaxDisclosureTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="IncomeTaxDisclosureTable" xlink:title="definition: IncomeTaxDisclosureLineItems to IncomeTaxDisclosureTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeTaxDisclosureTable" xlink:to="StatementScenarioAxis" xlink:title="definition: IncomeTaxDisclosureTable to StatementScenarioAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="ScenarioPlanMember" xlink:title="ScenarioPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioPlanMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioPlanMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="CapitalLeaseObligations" xlink:title="definition: OtherCommitmentsLineItems to CapitalLeaseObligations" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="CapitalLeaseObligationsIncurred" xlink:title="definition: OtherCommitmentsLineItems to CapitalLeaseObligationsIncurred" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeasePaymentTerm" xlink:label="CapitalLeasePaymentTerm" xlink:title="CapitalLeasePaymentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="CapitalLeasePaymentTerm" xlink:title="definition: OtherCommitmentsLineItems to CapitalLeasePaymentTerm" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:title="CapitalLeaseAgreementImputedAnnualInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:title="definition: OtherCommitmentsLineItems to CapitalLeaseAgreementImputedAnnualInterestRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:label="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:title="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:title="definition: OtherCommitmentsLineItems to PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:label="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:title="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:title="definition: OtherCommitmentsLineItems to PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="definition: OtherCommitmentsLineItems to CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AmountAvailableUnderCapitalLeaseAgreement" xlink:label="AmountAvailableUnderCapitalLeaseAgreement" xlink:title="AmountAvailableUnderCapitalLeaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="AmountAvailableUnderCapitalLeaseAgreement" xlink:title="definition: OtherCommitmentsLineItems to AmountAvailableUnderCapitalLeaseAgreement" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsTable" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="definition: OtherCommitmentsTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="LeaseArrangementTypeAxis" xlink:title="LeaseArrangementTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="LeaseArrangementTypeAxis" xlink:title="definition: OtherCommitmentsTable to LeaseArrangementTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="LeaseArrangementTypeDomain" xlink:title="LeaseArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LeaseArrangementTypeAxis" xlink:to="LeaseArrangementTypeDomain" xlink:title="definition: LeaseArrangementTypeAxis to LeaseArrangementTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="LeaseArrangementTypeDomain_2" xlink:title="LeaseArrangementTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LeaseArrangementTypeAxis" xlink:to="LeaseArrangementTypeDomain_2" xlink:title="definition: LeaseArrangementTypeAxis to LeaseArrangementTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MasterLeaseLineAgreementMember" xlink:label="MasterLeaseLineAgreementMember" xlink:title="MasterLeaseLineAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LeaseArrangementTypeDomain" xlink:to="MasterLeaseLineAgreementMember" xlink:title="definition: LeaseArrangementTypeDomain to MasterLeaseLineAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementAbstract" xlink:label="WistarLicenseAgreementAbstract" xlink:title="WistarLicenseAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="WistarLicenseAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to WistarLicenseAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentage" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MaximumReductionInRoyaltyPayments" xlink:label="MaximumReductionInRoyaltyPayments" xlink:title="MaximumReductionInRoyaltyPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumReductionInRoyaltyPayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumReductionInRoyaltyPayments" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:label="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:title="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementMember" xlink:label="WistarLicenseAgreementMember" xlink:title="WistarLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="WistarLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to WistarLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfAccreditedInvestors" xlink:title="definition: SubsequentEventLineItems to NumberOfAccreditedInvestors" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="definition: SubsequentEventLineItems to StockIssuedDuringPeriodSharesPrivatePlacement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SharePrice" xlink:title="definition: SubsequentEventLineItems to SharePrice" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: SubsequentEventLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:title="MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:title="definition: SubsequentEventLineItems to MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: SubsequentEventTable to TitleOfIndividualAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorTwoMember" xlink:label="InvestorTwoMember" xlink:title="InvestorTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorTwoMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to InvestorTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_BroadwoodPartnersLPMember" xlink:label="BroadwoodPartnersLPMember" xlink:title="BroadwoodPartnersLPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="BroadwoodPartnersLPMember" xlink:title="definition: RelatedPartyDomain to BroadwoodPartnersLPMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="definition: SubsequentEventTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ocx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:title="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_lbl" xml:lang="en-US" id="us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_lbl">Unrealized gain (loss) on BioTime shares held as available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_lbl" xlink:title="label: AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 to us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl">Accrued expenses and other current liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl1">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: AccountsPayableAndOtherAccruedLiabilitiesCurrent to us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued bonuses and payroll related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl">Accumulated other comprehensive loss on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl2">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl">Amortization of deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCosts_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl1">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl1" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl">Amortization of debt issuance costs and interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl">Impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentCharges_lbl1" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl1">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl1" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract_lbl">Impairment of long-lived assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="AssetsNoncurrentAbstract" xlink:title="AssetsNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsNoncurrentAbstract_lbl">NONCURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:title="label: AssetsNoncurrentAbstract to us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl">Loss on sale of available-for-sale securities and other expenses, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:title="label: AvailableForSaleSecuritiesGrossRealizedGainLossNet to us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl1">Loss on sale of available-for-sale securities, including selling commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl1" xlink:title="label: AvailableForSaleSecuritiesGrossRealizedGainLossNet to us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl2" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl2">Available-for-sale Securities, Gross Realized Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl2" xlink:title="label: AvailableForSaleSecuritiesGrossRealizedGainLossNet to us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl">Shares held as available-for-sale securities, at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" xlink:title="label: AvailableForSaleSecuritiesEquitySecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl1">BioTime shares held as available-for-sale securities, at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl1" xlink:title="label: AvailableForSaleSecuritiesEquitySecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="us-gaap_BalanceSheetLocationDomain_lbl">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xlink:title="label: BalanceSheetLocationDomain to us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="us-gaap_BalanceSheetLocationAxis_lbl">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:title="label: BalanceSheetLocationAxis to us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsIncurred_lbl">Increment value of lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:title="label: CapitalLeaseObligationsIncurred to us-gaap_CapitalLeaseObligationsIncurred_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsDueInThreeYears to us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligations_lbl">Laboratory equipment value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl" xlink:title="label: CapitalLeaseObligations to us-gaap_CapitalLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligations_lbl1" xml:lang="en-US" id="us-gaap_CapitalLeaseObligations_lbl1">Lease agreement value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl1" xlink:title="label: CapitalLeaseObligations to us-gaap_CapitalLeaseObligations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="CapitalLeasesFutureMinimumPaymentsDue" xlink:title="CapitalLeasesFutureMinimumPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsDue to us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl1">Capital Leases, Future Minimum Payments Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl1" xlink:title="label: CapitalLeasesFutureMinimumPaymentsDue to us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:title="CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsDueCurrent to us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsCurrent_lbl">Capital lease liability, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:title="label: CapitalLeaseObligationsCurrent to us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsCurrent_lbl1" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsCurrent_lbl1">Capital Lease Obligations, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl1" xlink:title="label: CapitalLeaseObligationsCurrent to us-gaap_CapitalLeaseObligationsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsDueInTwoYears to us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="CapitalLeaseObligationsNoncurrent" xlink:title="CapitalLeaseObligationsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_CapitalLeaseObligationsNoncurrent_lbl">Capital lease liability, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:title="label: CapitalLeaseObligationsNoncurrent to us-gaap_CapitalLeaseObligationsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:label="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:title="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract_lbl">Future Minimum Annual Lease Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl">Present value of net minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments to us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl1" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl1">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl1" xlink:title="label: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments to us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl">Monthly payment under capital lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:title="label: CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments to us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl1" xml:lang="en-US" id="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl1">Less amounts representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl1" xlink:title="label: CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments to us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Cash_lbl" xml:lang="en-US" id="us-gaap_Cash_lbl">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl" xlink:title="label: Cash to us-gaap_Cash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash_lbl1" xml:lang="en-US" id="us-gaap_Cash_lbl1">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl1" xlink:title="label: Cash to us-gaap_Cash_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">At end of the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">At beginning of the year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" xlink:title="label: CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAbstract_lbl">Cash and Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:title="label: CashAndCashEquivalentsAbstract to us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAbstract_lbl1">CASH AND CASH EQUIVALENTS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl1" xlink:title="label: CashAndCashEquivalentsAbstract to us-gaap_CashAndCashEquivalentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfStockLineItems_lbl1" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl1">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl1" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Number of common stock shares called by warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Warrant exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Warrants exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="ClassOfWarrantOrRightUnissued" xlink:title="ClassOfWarrantOrRightUnissued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightUnissued_lbl">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xlink:title="label: ClassOfWarrantOrRightUnissued to us-gaap_ClassOfWarrantOrRightUnissued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightUnissued_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightUnissued_lbl1">Class of Warrant or Right, Unissued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl1" xlink:title="label: ClassOfWarrantOrRightUnissued to us-gaap_ClassOfWarrantOrRightUnissued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl">Number of common shares callable by each warrant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockNoParValue_lbl">Common shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:title="label: CommonStockNoParValue to us-gaap_CommonStockNoParValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockMember_lbl1" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Company share in market transactions (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">BALANCE (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">BALANCE (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl2">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" id="us-gaap_ConsolidatedEntitiesDomain_lbl">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesDomain" xlink:to="us-gaap_ConsolidatedEntitiesDomain_lbl" xlink:title="label: ConsolidatedEntitiesDomain to us-gaap_ConsolidatedEntitiesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" id="us-gaap_ConsolidatedEntitiesAxis_lbl">Consolidated Entities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesAxis_lbl" xlink:title="label: ConsolidatedEntitiesAxis to us-gaap_ConsolidatedEntitiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="ContributionOfProperty" xlink:title="ContributionOfProperty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContributionOfProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US" id="us-gaap_ContributionOfProperty_lbl">Equipment purchased under capital leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl" xlink:title="label: ContributionOfProperty to us-gaap_ContributionOfProperty_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl">Basis spread variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl">Common stock issued to BioTime for extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:title="label: DebtConversionConvertedInstrumentAmount1 to us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xlink:title="label: DebtConversionConvertedInstrumentAmount1 to us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">Loan Payable to Silicon Valley Bank [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl">Common stock issued to BioTime for extinguishment of debt (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:title="label: DebtConversionConvertedInstrumentSharesIssued1 to us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl1" xml:lang="en-US" id="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl1">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl1" xlink:title="label: DebtConversionConvertedInstrumentSharesIssued1 to us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl">Total payments of principal and interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl1">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl">Prime rate plus variable spread per annum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:title="label: DebtInstrumentInterestRateDuringPeriod to us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Base rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Amount borrowed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl">Periodic payment term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:title="label: DebtInstrumentFrequencyOfPeriodicPayment to us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" id="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl">Debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:title="label: DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction to us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPayment_lbl">Periodic payments of principal and interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:title="label: DebtInstrumentPeriodicPayment to us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="DeferredTaxLiabilitiesInvestments" xlink:title="DeferredTaxLiabilitiesInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesInvestments_lbl">Available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:title="label: DeferredTaxLiabilitiesInvestments to us-gaap_DeferredTaxLiabilitiesInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesInvestments_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesInvestments_lbl1">Deferred Tax Liabilities, Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl1" xlink:title="label: DeferredTaxLiabilitiesInvestments to us-gaap_DeferredTaxLiabilitiesInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredFinanceCostsNet_lbl">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:title="label: DeferredFinanceCostsNet to us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities_lbl">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities_lbl1">Deferred Tax Liabilities, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGrossAbstract_lbl">Deferred tax assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:title="label: DeferredTaxAssetsGrossAbstract to us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl">Net deferred tax asset (liability)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl">Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl">Stock-based compensation and accrued payroll</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearch to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesAbstract_lbl">Deferred liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:title="label: DeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DepositsAssetsNoncurrent_lbl">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:title="label: DepositsAssetsNoncurrent to us-gaap_DepositsAssetsNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockPaidinkind" xlink:label="DividendsCommonStockPaidinkind" xlink:title="DividendsCommonStockPaidinkind" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockPaidinkind_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsCommonStockPaidinkind_lbl" xml:lang="en-US" id="us-gaap_DividendsCommonStockPaidinkind_lbl">OncoCyte common stock received as a dividend in kind from BioTime</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsCommonStockPaidinkind" xlink:to="us-gaap_DividendsCommonStockPaidinkind_lbl" xlink:title="label: DividendsCommonStockPaidinkind to us-gaap_DividendsCommonStockPaidinkind_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="us-gaap_DomesticCountryMember_lbl">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:title="label: DomesticCountryMember to us-gaap_DomesticCountryMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="DueToRelatedPartiesCurrent" xlink:title="DueToRelatedPartiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="us-gaap_DueToRelatedPartiesCurrent_lbl">Amount due to BioTime and affiliates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:title="label: DueToRelatedPartiesCurrent to us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl">Computations of Basic and Diluted Net Loss Per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:title="label: EarningsPerShareBasicAndDilutedAbstract to us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAndDiluted_lbl1">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl1" xlink:title="label: EarningsPerShareBasicAndDiluted to us-gaap_EarningsPerShareBasicAndDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Net loss per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl">State tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl">Re-rate of federal net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl">Federal corporate tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1">Computed tax benefit at federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditsResearch to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl">Income Tax Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Total unrecognized compensation costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Stock Option Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl2">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Weighted average recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Shareholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Equity ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1">Percentage of ownership interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2">Equity Method Investment, Ownership Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl">Fair value of contingently issuable warrant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl">Fair value measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByAssetClassAxis_lbl">Asset Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:title="label: FairValueByAssetClassAxis to us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl">Asset Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="FiniteLivedIntangibleAssetsMember" xlink:title="FiniteLivedIntangibleAssetsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMember_lbl">Long-lived Intangible Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMember" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMember_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMember to us-gaap_FiniteLivedIntangibleAssetsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Intangible assets, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Intangible assets useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1">Intangible assets, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="GainLossOnSaleOfEquityInvestments" xlink:title="GainLossOnSaleOfEquityInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xml:lang="en-US" id="us-gaap_GainLossOnSaleOfEquityInvestments_lbl">Realized loss on sale of BioTime shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xlink:title="label: GainLossOnSaleOfEquityInvestments to us-gaap_GainLossOnSaleOfEquityInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnSaleOfEquityInvestments_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnSaleOfEquityInvestments_lbl1">Gain (Loss) on Sale of Equity Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl1" xlink:title="label: GainLossOnSaleOfEquityInvestments to us-gaap_GainLossOnSaleOfEquityInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1">General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl1">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl1" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis_lbl">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain_lbl">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="IncreaseDecreaseInDueToRelatedParties" xlink:title="IncreaseDecreaseInDueToRelatedParties" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl">Amount due to BioTime and affiliates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:title="label: IncreaseDecreaseInDueToRelatedParties to us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1">Increase (Decrease) in Due to Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1" xlink:title="label: IncreaseDecreaseInDueToRelatedParties to us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="IntangibleAssetsFiniteLivedPolicy" xlink:title="IntangibleAssetsFiniteLivedPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl">Long-lived intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:title="label: IntangibleAssetsFiniteLivedPolicy to us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestorMember_lbl" xml:lang="en-US" id="us-gaap_InvestorMember_lbl">Investor One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:title="label: InvestorMember to us-gaap_InvestorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestorMember_lbl1" xml:lang="en-US" id="us-gaap_InvestorMember_lbl1">Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="us-gaap_InvestorMember_lbl1" xlink:title="label: InvestorMember to us-gaap_InvestorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="LeaseArrangementTypeAxis" xlink:title="LeaseArrangementTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" id="us-gaap_LeaseArrangementTypeAxis_lbl">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:title="label: LeaseArrangementTypeAxis to us-gaap_LeaseArrangementTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="LeaseArrangementTypeDomain" xlink:title="LeaseArrangementTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" id="us-gaap_LeaseArrangementTypeDomain_lbl">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:title="label: LeaseArrangementTypeDomain to us-gaap_LeaseArrangementTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl">LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_LoansPayableCurrent_lbl">Loan payable, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:title="label: LoansPayableCurrent to us-gaap_LoansPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl">Total loan payable, net of deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl1">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl1" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">Loan Payable to Silicon Valley Bank</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="LongTermDebtPercentageBearingFixedInterestRate" xlink:title="LongTermDebtPercentageBearingFixedInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl">Interest rate on obligations due to bank</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:title="label: LongTermDebtPercentageBearingFixedInterestRate to us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl1">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl">2018</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl1">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="us-gaap_LongTermLoansPayable_lbl">Loan payable, net of deferred financing costs, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:title="label: LongTermLoansPayable to us-gaap_LongTermLoansPayable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl">2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl1">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl1" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:label="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:title="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" xml:lang="en-US" id="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl">Accounting for BioTime shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" xlink:title="label: MarketableSecuritiesAvailableForSaleSecuritiesPolicy to us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="us-gaap_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:title="label: MaximumMember to us-gaap_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="us-gaap_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:title="label: MinimumMember to us-gaap_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:title="MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl">Beneficial ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByNoncontrollingOwners to us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" xlink:title="label: MinorityInterestOwnershipPercentageByNoncontrollingOwners to us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl3">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent accounting pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other expenses, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">OTHER EXPENSES, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl1">Number of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl1" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">OPERATING EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl">Operating loss carryforwards, expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:title="label: OperatingLossCarryforwardsExpirationDate to us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl1" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable_lbl">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems_lbl">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Organization, Description of the Business and Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">Organization, Description of the Business and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsLineItems_lbl">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:title="label: OtherCommitmentsLineItems to us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl1">Other Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsTable_lbl">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:title="label: OtherCommitmentsTable to us-gaap_OtherCommitmentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl">Realized loss on sale of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax to us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl">Other comprehensive loss, net of tax:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" id="us-gaap_PrimeRateMember_lbl">Prime Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:title="label: PrimeRateMember to us-gaap_PrimeRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ParentCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ParentCompanyMember_lbl" xml:lang="en-US" id="us-gaap_ParentCompanyMember_lbl">BioTime, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentCompanyMember" xlink:to="us-gaap_ParentCompanyMember_lbl" xlink:title="label: ParentCompanyMember to us-gaap_ParentCompanyMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ParentCompanyMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ParentCompanyMember_lbl1" xml:lang="en-US" id="us-gaap_ParentCompanyMember_lbl1">BioTime, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentCompanyMember" xlink:to="us-gaap_ParentCompanyMember_lbl1" xlink:title="label: ParentCompanyMember to us-gaap_ParentCompanyMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="PaymentsForDeposits" xlink:title="PaymentsForDeposits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForDeposits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsForDeposits_lbl" xml:lang="en-US" id="us-gaap_PaymentsForDeposits_lbl">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForDeposits" xlink:to="us-gaap_PaymentsForDeposits_lbl" xlink:title="label: PaymentsForDeposits to us-gaap_PaymentsForDeposits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForDeposits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForDeposits_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForDeposits_lbl1">Payments for Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForDeposits" xlink:to="us-gaap_PaymentsForDeposits_lbl1" xlink:title="label: PaymentsForDeposits to us-gaap_PaymentsForDeposits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl">Aggregate deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl">Financing costs related to sale of common stock and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl1">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNoParValue_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:title="label: PreferredStockNoParValue to us-gaap_PreferredStockNoParValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNoParValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockNoParValue_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockNoParValue_lbl1">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl1" xlink:title="label: PreferredStockNoParValue to us-gaap_PreferredStockNoParValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:title="label: PriorPeriodReclassificationAdjustmentDescription to us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl">Proceeds from issuance of loan payable, net of financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:title="label: ProceedsFromDebtNetOfIssuanceCosts to us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromWarrantExercises_lbl">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:title="label: ProceedsFromWarrantExercises to us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl">Gross proceeds from private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl">Net proceeds from sale of available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xlink:title="label: ProceedsFromSaleOfAvailableForSaleSecuritiesEquity to us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl">Warrants issued to certain shareholders as inducement to exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Equipment and furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Equipment and Furniture, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Equipment and furniture, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Equipment and furniture, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Equipment and furniture, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Equipment and furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Equipment and furniture, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeMember_lbl" xml:lang="en-US" id="us-gaap_RangeMember_lbl">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="us-gaap_RangeMember_lbl" xlink:title="label: RangeMember to us-gaap_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="us-gaap_RangeAxis_lbl">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:title="label: RangeAxis to us-gaap_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl">Repayment of capital lease obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl1">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl1" xlink:title="label: RepaymentsOfLongTermCapitalLeaseObligations to us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt_lbl">Repayment of loan payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfDebt_lbl1">Repayments of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl1" xlink:title="label: RepaymentsOfDebt to us-gaap_RepaymentsOfDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchMember_lbl" xml:lang="en-US" id="us-gaap_ResearchMember_lbl">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:title="label: ResearchMember to us-gaap_ResearchMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl">Options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl">Increase in pool (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl">Options forfeited, cancelled or expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl">Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Aggregate fair value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl">End of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1">Beginning of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl">Proceeds from sale of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:title="label: SaleOfStockConsiderationReceivedOnTransaction to us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xlink:title="label: SaleOfStockConsiderationReceivedOnTransaction to us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl">Number of shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="us-gaap_ScenarioUnspecifiedDomain_lbl">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="ScenarioPlanMember" xlink:title="ScenarioPlanMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScenarioPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" id="us-gaap_ScenarioPlanMember_lbl">Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" xlink:title="label: ScenarioPlanMember to us-gaap_ScenarioPlanMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl">Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl">Computations of Basic and Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl">Income Tax Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl">Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Assumptions used to Calculate Fair Value of Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:title="label: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl">Future Minimum Annual Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:title="label: ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock to us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl">Principal and interest payments due on loan payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl">Schedule of Equity Method Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentsTable to us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentsLineItems to us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Categories of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="SellingAndMarketingExpenseMember" xlink:title="SellingAndMarketingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" id="us-gaap_SellingAndMarketingExpenseMember_lbl">Sales and Marketing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:title="label: SellingAndMarketingExpenseMember to us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingAndMarketingExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_SellingAndMarketingExpenseMember_lbl1">Sales and Marketing Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl1" xlink:title="label: SellingAndMarketingExpenseMember to us-gaap_SellingAndMarketingExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US" id="us-gaap_SellingAndMarketingExpense_lbl">Sales and marketing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:title="label: SellingAndMarketingExpense to us-gaap_SellingAndMarketingExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharePrice_lbl" xml:lang="en-US" id="us-gaap_SharePrice_lbl">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:title="label: SharePrice to us-gaap_SharePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Share-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Options exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Term of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Option granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Option granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weighted-average assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Beginning of the period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">End of the period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl">Options forfeited, cancelled or expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl">Options forfeited, cancelled or expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">End of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Beginning of the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Number of Options Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember_lbl">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl">STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:title="label: StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="us-gaap_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to us-gaap_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US" id="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:title="label: StockGrantedDuringPeriodValueSharebasedCompensation to us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">BALANCE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">BALANCE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl">Reverse stock split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockLineItems_lbl">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:title="label: SubsidiarySaleOfStockLineItems to us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:title="label: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl">Selected Balance Sheet Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:title="label: SupplementalBalanceSheetDisclosuresTextBlock to us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardNameDomain_lbl">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:title="label: TaxCreditCarryforwardNameDomain to us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardTable_lbl">Tax Credit Carryforward [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:title="label: TaxCreditCarryforwardTable to us-gaap_TaxCreditCarryforwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAxis_lbl">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:title="label: TaxCreditCarryforwardAxis to us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardLineItems_lbl">Tax Credit Carryforward [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:title="label: TaxCreditCarryforwardLineItems to us-gaap_TaxCreditCarryforwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="us-gaap_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to us-gaap_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US" id="us-gaap_UnamortizedDebtIssuanceExpense_lbl">Less: deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:title="label: UnamortizedDebtIssuanceExpense to us-gaap_UnamortizedDebtIssuanceExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnamortizedDebtIssuanceExpense_lbl1" xml:lang="en-US" id="us-gaap_UnamortizedDebtIssuanceExpense_lbl1">Unamortized Debt Issuance Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl1" xlink:title="label: UnamortizedDebtIssuanceExpense to us-gaap_UnamortizedDebtIssuanceExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl">Accrued interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="us-gaap_VariableRateDomain_lbl">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xlink:title="label: VariableRateDomain to us-gaap_VariableRateDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="us-gaap_VariableRateAxis_lbl">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:title="label: VariableRateAxis to us-gaap_VariableRateAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Bank Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl2" xml:lang="en-US" id="us-gaap_WarrantMember_lbl2">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl2" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl">Weighted average shares outstanding: basic and diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" xlink:title="label: WeightedAverageNumberOfShareOutstandingBasicAndDiluted to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SelectedBalanceSheetComponentsAbstract" xlink:label="SelectedBalanceSheetComponentsAbstract" xlink:title="SelectedBalanceSheetComponentsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_SelectedBalanceSheetComponentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SelectedBalanceSheetComponentsAbstract_lbl1" xml:lang="en-US" id="ocx_SelectedBalanceSheetComponentsAbstract_lbl1">Selected Balance Sheet Components [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="ocx_SelectedBalanceSheetComponentsAbstract_lbl1" xlink:title="label: SelectedBalanceSheetComponentsAbstract to ocx_SelectedBalanceSheetComponentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl">Tabular disclosure of the carrying amounts of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock to ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock to ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl2" xml:lang="en-US" id="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl2">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl2" xlink:title="label: ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock to ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ContingentlyIssuableWarrantExpenseToInvestors" xlink:label="ContingentlyIssuableWarrantExpenseToInvestors" xlink:title="ContingentlyIssuableWarrantExpenseToInvestors" />
    <link:label xlink:type="resource" xlink:label="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl" xml:lang="en-US" id="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl">Amount of contingently issuable warrants expense to investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentlyIssuableWarrantExpenseToInvestors" xlink:to="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl" xlink:title="label: ContingentlyIssuableWarrantExpenseToInvestors to ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl1" xml:lang="en-US" id="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl1">Contingently issuable warrant expense to investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentlyIssuableWarrantExpenseToInvestors" xlink:to="ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl1" xlink:title="label: ContingentlyIssuableWarrantExpenseToInvestors to ocx_ContingentlyIssuableWarrantExpenseToInvestors_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xml:lang="en-US" id="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl">The fair value of common shares issued for conversion of convertible note payable and accrued interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xlink:title="label: CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xml:lang="en-US" id="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1">Common stock issued conversion of convertible note payable and accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xlink:title="label: CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xml:lang="en-US" id="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xlink:title="label: CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl3" xml:lang="en-US" id="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl3">Common stock issued to BioTime upon conversion of convertible note payable and accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl3" xlink:title="label: CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:label="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:title="ProceedsFromIssuanceOfCommonSharesAndWarrants" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl">The cash inflow from the additional capital contribution including the issuance of warrant rights to purchase common shares at predetermined price (usually issued together with corporate debt) to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:to="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonSharesAndWarrants to ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl1" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl1">Proceeds From Issuance Of Common Shares And Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:to="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonSharesAndWarrants to ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl2" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl2">Proceeds from sale of common stock and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:to="ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonSharesAndWarrants to ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_ReverseStockSplitAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ReverseStockSplitAbstract_lbl1" xml:lang="en-US" id="ocx_ReverseStockSplitAbstract_lbl1">Reverse Stock Split [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitAbstract" xlink:to="ocx_ReverseStockSplitAbstract_lbl1" xlink:title="label: ReverseStockSplitAbstract to ocx_ReverseStockSplitAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:title="CommonStockSharesHeldAsAvailableForSaleSecurities" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" xml:lang="en-US" id="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl">Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:to="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" xlink:title="label: CommonStockSharesHeldAsAvailableForSaleSecurities to ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl1" xml:lang="en-US" id="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl1">Common Stock, Shares Held as Available for Sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:to="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl1" xlink:title="label: CommonStockSharesHeldAsAvailableForSaleSecurities to ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl2" xml:lang="en-US" id="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl2">Shares held as available-for-sale securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:to="ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl2" xlink:title="label: CommonStockSharesHeldAsAvailableForSaleSecurities to ocx_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureTable" xlink:label="IncomeTaxDisclosureTable" xlink:title="IncomeTaxDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="ocx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" id="ocx_IncomeTaxDisclosureTable_lbl">Disclosure of information about income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTable" xlink:to="ocx_IncomeTaxDisclosureTable_lbl" xlink:title="label: IncomeTaxDisclosureTable to ocx_IncomeTaxDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_IncomeTaxDisclosureTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_IncomeTaxDisclosureTable_lbl1" xml:lang="en-US" id="ocx_IncomeTaxDisclosureTable_lbl1">Income Tax Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTable" xlink:to="ocx_IncomeTaxDisclosureTable_lbl1" xlink:title="label: IncomeTaxDisclosureTable to ocx_IncomeTaxDisclosureTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureLineItems" xlink:label="IncomeTaxDisclosureLineItems" xlink:title="IncomeTaxDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="ocx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" id="ocx_IncomeTaxDisclosureLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="ocx_IncomeTaxDisclosureLineItems_lbl" xlink:title="label: IncomeTaxDisclosureLineItems to ocx_IncomeTaxDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_IncomeTaxDisclosureLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_IncomeTaxDisclosureLineItems_lbl1" xml:lang="en-US" id="ocx_IncomeTaxDisclosureLineItems_lbl1">Income Tax Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="ocx_IncomeTaxDisclosureLineItems_lbl1" xlink:title="label: IncomeTaxDisclosureLineItems to ocx_IncomeTaxDisclosureLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EquipmentAndFurnitureMember" xlink:label="EquipmentAndFurnitureMember" xlink:title="EquipmentAndFurnitureMember" />
    <link:label xlink:type="resource" xlink:label="ocx_EquipmentAndFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_EquipmentAndFurnitureMember_lbl" xml:lang="en-US" id="ocx_EquipmentAndFurnitureMember_lbl">Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndFurnitureMember" xlink:to="ocx_EquipmentAndFurnitureMember_lbl" xlink:title="label: EquipmentAndFurnitureMember to ocx_EquipmentAndFurnitureMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_EquipmentAndFurnitureMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_EquipmentAndFurnitureMember_lbl1" xml:lang="en-US" id="ocx_EquipmentAndFurnitureMember_lbl1">Equipment and Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndFurnitureMember" xlink:to="ocx_EquipmentAndFurnitureMember_lbl1" xlink:title="label: EquipmentAndFurnitureMember to ocx_EquipmentAndFurnitureMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_EquipmentAndFurnitureMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_EquipmentAndFurnitureMember_lbl2" xml:lang="en-US" id="ocx_EquipmentAndFurnitureMember_lbl2">Equipment and Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndFurnitureMember" xlink:to="ocx_EquipmentAndFurnitureMember_lbl2" xlink:title="label: EquipmentAndFurnitureMember to ocx_EquipmentAndFurnitureMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ReverseStockSplitPolicyTextBlock" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:title="ReverseStockSplitPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="ocx_ReverseStockSplitPolicyTextBlock_lbl">Disclosure of accounting policy of reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="ocx_ReverseStockSplitPolicyTextBlock_lbl" xlink:title="label: ReverseStockSplitPolicyTextBlock to ocx_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ReverseStockSplitPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ReverseStockSplitPolicyTextBlock_lbl1" xml:lang="en-US" id="ocx_ReverseStockSplitPolicyTextBlock_lbl1">Reverse Stock Split [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="ocx_ReverseStockSplitPolicyTextBlock_lbl1" xlink:title="label: ReverseStockSplitPolicyTextBlock to ocx_ReverseStockSplitPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ReverseStockSplitPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ReverseStockSplitPolicyTextBlock_lbl2" xml:lang="en-US" id="ocx_ReverseStockSplitPolicyTextBlock_lbl2">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitPolicyTextBlock" xlink:to="ocx_ReverseStockSplitPolicyTextBlock_lbl2" xlink:title="label: ReverseStockSplitPolicyTextBlock to ocx_ReverseStockSplitPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_GoingConcernAssessmentPolicyTextBlock" xlink:label="GoingConcernAssessmentPolicyTextBlock" xlink:title="GoingConcernAssessmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_GoingConcernAssessmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_GoingConcernAssessmentPolicyTextBlock_lbl" xml:lang="en-US" id="ocx_GoingConcernAssessmentPolicyTextBlock_lbl">Disclosure of accounting policy for going concern assessment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoingConcernAssessmentPolicyTextBlock" xlink:to="ocx_GoingConcernAssessmentPolicyTextBlock_lbl" xlink:title="label: GoingConcernAssessmentPolicyTextBlock to ocx_GoingConcernAssessmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_GoingConcernAssessmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_GoingConcernAssessmentPolicyTextBlock_lbl1" xml:lang="en-US" id="ocx_GoingConcernAssessmentPolicyTextBlock_lbl1">Going concern assessment [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoingConcernAssessmentPolicyTextBlock" xlink:to="ocx_GoingConcernAssessmentPolicyTextBlock_lbl1" xlink:title="label: GoingConcernAssessmentPolicyTextBlock to ocx_GoingConcernAssessmentPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_GoingConcernAssessmentPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_GoingConcernAssessmentPolicyTextBlock_lbl2" xml:lang="en-US" id="ocx_GoingConcernAssessmentPolicyTextBlock_lbl2">Going concern assessment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoingConcernAssessmentPolicyTextBlock" xlink:to="ocx_GoingConcernAssessmentPolicyTextBlock_lbl2" xlink:title="label: GoingConcernAssessmentPolicyTextBlock to ocx_GoingConcernAssessmentPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AccountingForWarrantsPolicyTextBlock" xlink:label="AccountingForWarrantsPolicyTextBlock" xlink:title="AccountingForWarrantsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_AccountingForWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_AccountingForWarrantsPolicyTextBlock_lbl" xml:lang="en-US" id="ocx_AccountingForWarrantsPolicyTextBlock_lbl">Disclosure of accounting policy for accounting for warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingForWarrantsPolicyTextBlock" xlink:to="ocx_AccountingForWarrantsPolicyTextBlock_lbl" xlink:title="label: AccountingForWarrantsPolicyTextBlock to ocx_AccountingForWarrantsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_AccountingForWarrantsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_AccountingForWarrantsPolicyTextBlock_lbl1" xml:lang="en-US" id="ocx_AccountingForWarrantsPolicyTextBlock_lbl1">Accounting for warrants [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingForWarrantsPolicyTextBlock" xlink:to="ocx_AccountingForWarrantsPolicyTextBlock_lbl1" xlink:title="label: AccountingForWarrantsPolicyTextBlock to ocx_AccountingForWarrantsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_AccountingForWarrantsPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_AccountingForWarrantsPolicyTextBlock_lbl2" xml:lang="en-US" id="ocx_AccountingForWarrantsPolicyTextBlock_lbl2">Accounting for warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingForWarrantsPolicyTextBlock" xlink:to="ocx_AccountingForWarrantsPolicyTextBlock_lbl2" xlink:title="label: AccountingForWarrantsPolicyTextBlock to ocx_AccountingForWarrantsPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SalesAndMarketingCostsPolicyTextBlock" xlink:label="SalesAndMarketingCostsPolicyTextBlock" xlink:title="SalesAndMarketingCostsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl" xml:lang="en-US" id="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl">Disclosure of accounting policy for the recognition of sales and marketing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAndMarketingCostsPolicyTextBlock" xlink:to="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl" xlink:title="label: SalesAndMarketingCostsPolicyTextBlock to ocx_SalesAndMarketingCostsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl1" xml:lang="en-US" id="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl1">Sales and Marketing Costs, Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAndMarketingCostsPolicyTextBlock" xlink:to="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl1" xlink:title="label: SalesAndMarketingCostsPolicyTextBlock to ocx_SalesAndMarketingCostsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl2" xml:lang="en-US" id="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl2">Sales and marketing expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAndMarketingCostsPolicyTextBlock" xlink:to="ocx_SalesAndMarketingCostsPolicyTextBlock_lbl2" xlink:title="label: SalesAndMarketingCostsPolicyTextBlock to ocx_SalesAndMarketingCostsPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:label="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:title="TransferOfRealizedLossIntoEquityFromSaleOfShares" />
    <link:label xlink:type="resource" xlink:label="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl" xml:lang="en-US" id="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl">This line item represents the amount transfer of realized loss into equity from sale of shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:to="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl" xlink:title="label: TransferOfRealizedLossIntoEquityFromSaleOfShares to ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl1" xml:lang="en-US" id="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl1">Transfer of realized loss into equity from sale of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:to="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl1" xlink:title="label: TransferOfRealizedLossIntoEquityFromSaleOfShares to ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl2" xml:lang="en-US" id="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl2">Transfer of realized loss into equity from sale of BioTime shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:to="ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl2" xlink:title="label: TransferOfRealizedLossIntoEquityFromSaleOfShares to ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedToInvestorsForCash" xlink:label="CommonStockSharesIssuedToInvestorsForCash" xlink:title="CommonStockSharesIssuedToInvestorsForCash" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl" xml:lang="en-US" id="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl">Number of shares of stock issued during the period for investors for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedToInvestorsForCash" xlink:to="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl" xlink:title="label: CommonStockSharesIssuedToInvestorsForCash to ocx_CommonStockSharesIssuedToInvestorsForCash_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl1" xml:lang="en-US" id="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl1">Common Stock Shares Issued to Investors for Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedToInvestorsForCash" xlink:to="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl1" xlink:title="label: CommonStockSharesIssuedToInvestorsForCash to ocx_CommonStockSharesIssuedToInvestorsForCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl2" xml:lang="en-US" id="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl2">Common stock issued to investors for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedToInvestorsForCash" xlink:to="ocx_CommonStockSharesIssuedToInvestorsForCash_lbl2" xlink:title="label: CommonStockSharesIssuedToInvestorsForCash to ocx_CommonStockSharesIssuedToInvestorsForCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedToInvestorsForCash" xlink:label="CommonStockIssuedToInvestorsForCash" xlink:title="CommonStockIssuedToInvestorsForCash" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedToInvestorsForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockIssuedToInvestorsForCash_lbl" xml:lang="en-US" id="ocx_CommonStockIssuedToInvestorsForCash_lbl">The amount of common stock issued to investors for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToInvestorsForCash" xlink:to="ocx_CommonStockIssuedToInvestorsForCash_lbl" xlink:title="label: CommonStockIssuedToInvestorsForCash to ocx_CommonStockIssuedToInvestorsForCash_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedToInvestorsForCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockIssuedToInvestorsForCash_lbl1" xml:lang="en-US" id="ocx_CommonStockIssuedToInvestorsForCash_lbl1">Common Stock Issued to Investors for Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToInvestorsForCash" xlink:to="ocx_CommonStockIssuedToInvestorsForCash_lbl1" xlink:title="label: CommonStockIssuedToInvestorsForCash to ocx_CommonStockIssuedToInvestorsForCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedToInvestorsForCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockIssuedToInvestorsForCash_lbl2" xml:lang="en-US" id="ocx_CommonStockIssuedToInvestorsForCash_lbl2">Common stock issued to investors for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedToInvestorsForCash" xlink:to="ocx_CommonStockIssuedToInvestorsForCash_lbl2" xlink:title="label: CommonStockIssuedToInvestorsForCash to ocx_CommonStockIssuedToInvestorsForCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xml:lang="en-US" id="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl">Number of shares Issued common stock for conversion of convertible note payable and accrued interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" xlink:title="label: CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xml:lang="en-US" id="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1">Common Stock Shares Issued Conversion Of Convertible Note Payable And Accrued Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" xlink:title="label: CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xml:lang="en-US" id="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:to="ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" xlink:title="label: CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest to ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToBanks" xlink:label="WarrantsIssuedToBanks" xlink:title="WarrantsIssuedToBanks" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_WarrantsIssuedToBanks_lbl" xml:lang="en-US" id="ocx_WarrantsIssuedToBanks_lbl">Value of warrants issued during the period to banks related to financing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToBanks" xlink:to="ocx_WarrantsIssuedToBanks_lbl" xlink:title="label: WarrantsIssuedToBanks to ocx_WarrantsIssuedToBanks_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToBanks_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_WarrantsIssuedToBanks_lbl1" xml:lang="en-US" id="ocx_WarrantsIssuedToBanks_lbl1">Warrants Issued to Banks</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToBanks" xlink:to="ocx_WarrantsIssuedToBanks_lbl1" xlink:title="label: WarrantsIssuedToBanks to ocx_WarrantsIssuedToBanks_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToBanks_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_WarrantsIssuedToBanks_lbl2" xml:lang="en-US" id="ocx_WarrantsIssuedToBanks_lbl2">Issuance of warrants to Silicon Valley Bank</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToBanks" xlink:to="ocx_WarrantsIssuedToBanks_lbl2" xlink:title="label: WarrantsIssuedToBanks to ocx_WarrantsIssuedToBanks_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:label="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:title="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl" xml:lang="en-US" id="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl">Refers to warrants issued to certain shareholders as inducement of exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:to="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl" xlink:title="label: WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants to ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl1" xml:lang="en-US" id="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl1">Warrants issued to certain shareholders as inducement of exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:to="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl1" xlink:title="label: WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants to ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl2" xml:lang="en-US" id="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl2">Issuance of warrants for inducement to exercise 2016 warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:to="ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl2" xlink:title="label: WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants to ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedForCash" xlink:label="CommonStockIssuedForCash" xlink:title="CommonStockIssuedForCash" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockIssuedForCash_lbl" xml:lang="en-US" id="ocx_CommonStockIssuedForCash_lbl">The value of common stock issued for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedForCash" xlink:to="ocx_CommonStockIssuedForCash_lbl" xlink:title="label: CommonStockIssuedForCash to ocx_CommonStockIssuedForCash_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedForCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockIssuedForCash_lbl1" xml:lang="en-US" id="ocx_CommonStockIssuedForCash_lbl1">Common Stock Issued for Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedForCash" xlink:to="ocx_CommonStockIssuedForCash_lbl1" xlink:title="label: CommonStockIssuedForCash to ocx_CommonStockIssuedForCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockIssuedForCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockIssuedForCash_lbl2" xml:lang="en-US" id="ocx_CommonStockIssuedForCash_lbl2">Common stock issued to BioTime for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedForCash" xlink:to="ocx_CommonStockIssuedForCash_lbl2" xlink:title="label: CommonStockIssuedForCash to ocx_CommonStockIssuedForCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedForCash" xlink:label="CommonStockSharesIssuedForCash" xlink:title="CommonStockSharesIssuedForCash" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedForCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockSharesIssuedForCash_lbl" xml:lang="en-US" id="ocx_CommonStockSharesIssuedForCash_lbl">Number of shares issued for common stock for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedForCash" xlink:to="ocx_CommonStockSharesIssuedForCash_lbl" xlink:title="label: CommonStockSharesIssuedForCash to ocx_CommonStockSharesIssuedForCash_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedForCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockSharesIssuedForCash_lbl1" xml:lang="en-US" id="ocx_CommonStockSharesIssuedForCash_lbl1">Common Stock Shares Issued for Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedForCash" xlink:to="ocx_CommonStockSharesIssuedForCash_lbl1" xlink:title="label: CommonStockSharesIssuedForCash to ocx_CommonStockSharesIssuedForCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockSharesIssuedForCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockSharesIssuedForCash_lbl2" xml:lang="en-US" id="ocx_CommonStockSharesIssuedForCash_lbl2">Common stock issued to BioTime for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssuedForCash" xlink:to="ocx_CommonStockSharesIssuedForCash_lbl2" xlink:title="label: CommonStockSharesIssuedForCash to ocx_CommonStockSharesIssuedForCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockDividendsSharesReceived" xlink:label="CommonStockDividendsSharesReceived" xlink:title="CommonStockDividendsSharesReceived" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockDividendsSharesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockDividendsSharesReceived_lbl" xml:lang="en-US" id="ocx_CommonStockDividendsSharesReceived_lbl">Number of shares of common stock issued as dividends received during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsSharesReceived" xlink:to="ocx_CommonStockDividendsSharesReceived_lbl" xlink:title="label: CommonStockDividendsSharesReceived to ocx_CommonStockDividendsSharesReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockDividendsSharesReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockDividendsSharesReceived_lbl1" xml:lang="en-US" id="ocx_CommonStockDividendsSharesReceived_lbl1">Common Stock Dividends Shares Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsSharesReceived" xlink:to="ocx_CommonStockDividendsSharesReceived_lbl1" xlink:title="label: CommonStockDividendsSharesReceived to ocx_CommonStockDividendsSharesReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockDividendsSharesReceived_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocx_CommonStockDividendsSharesReceived_lbl2" xml:lang="en-US" id="ocx_CommonStockDividendsSharesReceived_lbl2">OncoCyte common stock received as a dividend in kind from BioTime (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockDividendsSharesReceived" xlink:to="ocx_CommonStockDividendsSharesReceived_lbl2" xlink:title="label: CommonStockDividendsSharesReceived to ocx_CommonStockDividendsSharesReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl">This line item represents proceeds from issuance of common stock and warrants, net of discounts and financing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1">Proceeds From Issuance of Common Stock and Warrants, Net of Discounts and Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2">Proceeds from issuance of common stock and warrants, net of discounts and financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl">Number of common stock shares and warrants, net of discounts and financing costs during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1">Proceeds From Issuance Of Common Stock Shares And Warrants Net Of Discounts And Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xml:lang="en-US" id="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2">Proceeds from issuance of common stock and warrants, net of discounts and financing costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:to="ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts to ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SharedFacilitiesAndServiceAgreementAbstract" xlink:label="SharedFacilitiesAndServiceAgreementAbstract" xlink:title="SharedFacilitiesAndServiceAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_SharedFacilitiesAndServiceAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SharedFacilitiesAndServiceAgreementAbstract_lbl1" xml:lang="en-US" id="ocx_SharedFacilitiesAndServiceAgreementAbstract_lbl1">Shared Facilities and Service Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="ocx_SharedFacilitiesAndServiceAgreementAbstract_lbl1" xlink:title="label: SharedFacilitiesAndServiceAgreementAbstract to ocx_SharedFacilitiesAndServiceAgreementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MinimumFixedPaymentDueSharedFacilityAgreement" xlink:label="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:title="MinimumFixedPaymentDueSharedFacilityAgreement" />
    <link:label xlink:type="resource" xlink:label="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl" xml:lang="en-US" id="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl">The periodic minimum payment due under the Shared Facility Agreement for amounts payable for charges to the entity by the parent company for services provided by the parent and for the shared use of a common facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:to="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl" xlink:title="label: MinimumFixedPaymentDueSharedFacilityAgreement to ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl1" xml:lang="en-US" id="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl1">Minimum Fixed Payment Due Shared Facility Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:to="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl1" xlink:title="label: MinimumFixedPaymentDueSharedFacilityAgreement to ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl2" xml:lang="en-US" id="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl2">Minimum fixed payments due under the shared facilities agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:to="ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl2" xlink:title="label: MinimumFixedPaymentDueSharedFacilityAgreement to ocx_MinimumFixedPaymentDueSharedFacilityAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfMarkupFeeAllocatedButNotCharged" xlink:label="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:title="PercentageOfMarkupFeeAllocatedButNotCharged" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl" xml:lang="en-US" id="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl">The percentage markup of the fee for the services and usage of facilities, equipment, and supplies aforementioned which shall be paid by the entity under Shared Facilities Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:to="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl" xlink:title="label: PercentageOfMarkupFeeAllocatedButNotCharged to ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl1" xml:lang="en-US" id="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl1">Percentage of Markup Fee Allocated But Not Charged</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:to="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl1" xlink:title="label: PercentageOfMarkupFeeAllocatedButNotCharged to ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl2" xml:lang="en-US" id="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl2">Markup rate on allocated costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:to="ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl2" xlink:title="label: PercentageOfMarkupFeeAllocatedButNotCharged to ocx_PercentageOfMarkupFeeAllocatedButNotCharged_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeePayable" xlink:label="AllocatedServicesAndFacilityUseFeePayable" xlink:title="AllocatedServicesAndFacilityUseFeePayable" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl">The sum of amounts payable for charges to the entity by the parent company for services provided by the parent and for the shared use of a common facility under a "Shared Facilities and Services Agreement". The fees are allocated proportionally for costs incurred during the period by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeePayable" xlink:to="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl" xlink:title="label: AllocatedServicesAndFacilityUseFeePayable to ocx_AllocatedServicesAndFacilityUseFeePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl1" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl1">Allocated Services and Facility Use Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeePayable" xlink:to="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl1" xlink:title="label: AllocatedServicesAndFacilityUseFeePayable to ocx_AllocatedServicesAndFacilityUseFeePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl2" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl2">Allocated use fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeePayable" xlink:to="ocx_AllocatedServicesAndFacilityUseFeePayable_lbl2" xlink:title="label: AllocatedServicesAndFacilityUseFeePayable to ocx_AllocatedServicesAndFacilityUseFeePayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TermOfPayment" xlink:label="TermOfPayment" xlink:title="TermOfPayment" />
    <link:label xlink:type="resource" xlink:label="ocx_TermOfPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TermOfPayment_lbl" xml:lang="en-US" id="ocx_TermOfPayment_lbl">Represents the maximum number of days upon the receipt of an invoice within which the invoice must be paid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfPayment" xlink:to="ocx_TermOfPayment_lbl" xlink:title="label: TermOfPayment to ocx_TermOfPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TermOfPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TermOfPayment_lbl1" xml:lang="en-US" id="ocx_TermOfPayment_lbl1">Term Of Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfPayment" xlink:to="ocx_TermOfPayment_lbl1" xlink:title="label: TermOfPayment to ocx_TermOfPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TermOfPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TermOfPayment_lbl2" xml:lang="en-US" id="ocx_TermOfPayment_lbl2">Term of payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfPayment" xlink:to="ocx_TermOfPayment_lbl2" xlink:title="label: TermOfPayment to ocx_TermOfPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InterestOnUnpaidOverdueInvoice" xlink:label="InterestOnUnpaidOverdueInvoice" xlink:title="InterestOnUnpaidOverdueInvoice" />
    <link:label xlink:type="resource" xlink:label="ocx_InterestOnUnpaidOverdueInvoice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_InterestOnUnpaidOverdueInvoice_lbl" xml:lang="en-US" id="ocx_InterestOnUnpaidOverdueInvoice_lbl">Represents the percentage of interest charged on invoices not paid when due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestOnUnpaidOverdueInvoice" xlink:to="ocx_InterestOnUnpaidOverdueInvoice_lbl" xlink:title="label: InterestOnUnpaidOverdueInvoice to ocx_InterestOnUnpaidOverdueInvoice_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_InterestOnUnpaidOverdueInvoice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_InterestOnUnpaidOverdueInvoice_lbl1" xml:lang="en-US" id="ocx_InterestOnUnpaidOverdueInvoice_lbl1">Interest on Unpaid Overdue Invoice</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestOnUnpaidOverdueInvoice" xlink:to="ocx_InterestOnUnpaidOverdueInvoice_lbl1" xlink:title="label: InterestOnUnpaidOverdueInvoice to ocx_InterestOnUnpaidOverdueInvoice_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_InterestOnUnpaidOverdueInvoice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_InterestOnUnpaidOverdueInvoice_lbl2" xml:lang="en-US" id="ocx_InterestOnUnpaidOverdueInvoice_lbl2">Interest rate charged on unpaid and overdue invoices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestOnUnpaidOverdueInvoice" xlink:to="ocx_InterestOnUnpaidOverdueInvoice_lbl2" xlink:title="label: InterestOnUnpaidOverdueInvoice to ocx_InterestOnUnpaidOverdueInvoice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeeExpense" xlink:label="AllocatedServicesAndFacilityUseFeeExpense" xlink:title="AllocatedServicesAndFacilityUseFeeExpense" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl">The sum of expenses charged to the entity by the parent company for services provided by the parent and for the shared use of a common facility under a "Shared Facilities and Services Agreement". The fees are allocated proportionally for costs incurred during the period by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeeExpense" xlink:to="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl" xlink:title="label: AllocatedServicesAndFacilityUseFeeExpense to ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl1" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl1">Allocated Services and Facility Use Fee, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeeExpense" xlink:to="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl1" xlink:title="label: AllocatedServicesAndFacilityUseFeeExpense to ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl2" xml:lang="en-US" id="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl2">Allocated use fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedServicesAndFacilityUseFeeExpense" xlink:to="ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl2" xlink:title="label: AllocatedServicesAndFacilityUseFeeExpense to ocx_AllocatedServicesAndFacilityUseFeeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CurrentLiabilitiesMember" xlink:label="CurrentLiabilitiesMember" xlink:title="CurrentLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="ocx_CurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CurrentLiabilitiesMember_lbl" xml:lang="en-US" id="ocx_CurrentLiabilitiesMember_lbl">Primary financial statement caption encompassing current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilitiesMember" xlink:to="ocx_CurrentLiabilitiesMember_lbl" xlink:title="label: CurrentLiabilitiesMember to ocx_CurrentLiabilitiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CurrentLiabilitiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CurrentLiabilitiesMember_lbl1" xml:lang="en-US" id="ocx_CurrentLiabilitiesMember_lbl1">Current Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilitiesMember" xlink:to="ocx_CurrentLiabilitiesMember_lbl1" xlink:title="label: CurrentLiabilitiesMember to ocx_CurrentLiabilitiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CurrentLiabilitiesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CurrentLiabilitiesMember_lbl2" xml:lang="en-US" id="ocx_CurrentLiabilitiesMember_lbl2">Current Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentLiabilitiesMember" xlink:to="ocx_CurrentLiabilitiesMember_lbl2" xlink:title="label: CurrentLiabilitiesMember to ocx_CurrentLiabilitiesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairMarketValueOfCommonStock" xlink:label="PercentageOfFairMarketValueOfCommonStock" xlink:title="PercentageOfFairMarketValueOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PercentageOfFairMarketValueOfCommonStock_lbl" xml:lang="en-US" id="ocx_PercentageOfFairMarketValueOfCommonStock_lbl">Refers to percentage of fair market value of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairMarketValueOfCommonStock" xlink:to="ocx_PercentageOfFairMarketValueOfCommonStock_lbl" xlink:title="label: PercentageOfFairMarketValueOfCommonStock to ocx_PercentageOfFairMarketValueOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairMarketValueOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PercentageOfFairMarketValueOfCommonStock_lbl1" xml:lang="en-US" id="ocx_PercentageOfFairMarketValueOfCommonStock_lbl1">Percentage of Fair Market Value of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairMarketValueOfCommonStock" xlink:to="ocx_PercentageOfFairMarketValueOfCommonStock_lbl1" xlink:title="label: PercentageOfFairMarketValueOfCommonStock to ocx_PercentageOfFairMarketValueOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairMarketValueOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PercentageOfFairMarketValueOfCommonStock_lbl2" xml:lang="en-US" id="ocx_PercentageOfFairMarketValueOfCommonStock_lbl2">Percentage of fair market value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairMarketValueOfCommonStock" xlink:to="ocx_PercentageOfFairMarketValueOfCommonStock_lbl2" xlink:title="label: PercentageOfFairMarketValueOfCommonStock to ocx_PercentageOfFairMarketValueOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl">Refers to the maximum period for options grants in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl1" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period Maximum Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl2" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl2">Maximum period for options grants in period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodOfNontransferableForStockOptionGrants" xlink:label="PeriodOfNontransferableForStockOptionGrants" xlink:title="PeriodOfNontransferableForStockOptionGrants" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodOfNontransferableForStockOptionGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PeriodOfNontransferableForStockOptionGrants_lbl" xml:lang="en-US" id="ocx_PeriodOfNontransferableForStockOptionGrants_lbl">Refers to period of nontransferable for stock option granted.,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfNontransferableForStockOptionGrants" xlink:to="ocx_PeriodOfNontransferableForStockOptionGrants_lbl" xlink:title="label: PeriodOfNontransferableForStockOptionGrants to ocx_PeriodOfNontransferableForStockOptionGrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodOfNontransferableForStockOptionGrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PeriodOfNontransferableForStockOptionGrants_lbl1" xml:lang="en-US" id="ocx_PeriodOfNontransferableForStockOptionGrants_lbl1">Period of nontransferable for stock option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfNontransferableForStockOptionGrants" xlink:to="ocx_PeriodOfNontransferableForStockOptionGrants_lbl1" xlink:title="label: PeriodOfNontransferableForStockOptionGrants to ocx_PeriodOfNontransferableForStockOptionGrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl">Refers to the maximum period for options exercises in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl1" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Exercises In Period Maximum Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl2" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl2">Maximum period for options exercises in period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl1" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Options Available for Grant [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl2" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl2">Shares Available for Grant [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl">Gross number of share options (or share units) granted during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl1" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl1">Share Based Compensation Arrangement By Share Based Payment Award Options Available Grants In Period Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl2" xml:lang="en-US" id="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl2">Options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:to="ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross to ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodForExercisingVestedOption" xlink:label="PeriodForExercisingVestedOption" xlink:title="PeriodForExercisingVestedOption" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodForExercisingVestedOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PeriodForExercisingVestedOption_lbl" xml:lang="en-US" id="ocx_PeriodForExercisingVestedOption_lbl">Refers to period for exercising vested option extended after termination or the expiration date of the option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForExercisingVestedOption" xlink:to="ocx_PeriodForExercisingVestedOption_lbl" xlink:title="label: PeriodForExercisingVestedOption to ocx_PeriodForExercisingVestedOption_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodForExercisingVestedOption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PeriodForExercisingVestedOption_lbl1" xml:lang="en-US" id="ocx_PeriodForExercisingVestedOption_lbl1">Period for exercising vested option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForExercisingVestedOption" xlink:to="ocx_PeriodForExercisingVestedOption_lbl1" xlink:title="label: PeriodForExercisingVestedOption to ocx_PeriodForExercisingVestedOption_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_DocumentAndEntityInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_DocumentAndEntityInformationAbstract_lbl1" xml:lang="en-US" id="ocx_DocumentAndEntityInformationAbstract_lbl1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="ocx_DocumentAndEntityInformationAbstract_lbl1" xlink:title="label: DocumentAndEntityInformationAbstract to ocx_DocumentAndEntityInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockOptionExercisesAbstract" xlink:label="StockOptionExercisesAbstract" xlink:title="StockOptionExercisesAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_StockOptionExercisesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_StockOptionExercisesAbstract_lbl1" xml:lang="en-US" id="ocx_StockOptionExercisesAbstract_lbl1">Stock Option Exercises [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionExercisesAbstract" xlink:to="ocx_StockOptionExercisesAbstract_lbl1" xlink:title="label: StockOptionExercisesAbstract to ocx_StockOptionExercisesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightBankWarrantsAbstract" xlink:label="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:title="ClassOfWarrantOrRightBankWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl1" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl1">Class of Warrant or Right, Bank Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl1" xlink:title="label: ClassOfWarrantOrRightBankWarrantsAbstract to ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl2" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl2">Bank Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl2" xlink:title="label: ClassOfWarrantOrRightBankWarrantsAbstract to ocx_ClassOfWarrantOrRightBankWarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementAbstract" xlink:label="LoanAndSecurityAgreementAbstract" xlink:title="LoanAndSecurityAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_LoanAndSecurityAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_LoanAndSecurityAgreementAbstract_lbl1" xml:lang="en-US" id="ocx_LoanAndSecurityAgreementAbstract_lbl1">Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="ocx_LoanAndSecurityAgreementAbstract_lbl1" xlink:title="label: LoanAndSecurityAgreementAbstract to ocx_LoanAndSecurityAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_LoanAndSecurityAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_LoanAndSecurityAgreementAbstract_lbl2" xml:lang="en-US" id="ocx_LoanAndSecurityAgreementAbstract_lbl2">Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="ocx_LoanAndSecurityAgreementAbstract_lbl2" xlink:title="label: LoanAndSecurityAgreementAbstract to ocx_LoanAndSecurityAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:label="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:title="PrepaymentFeeIfPrepaidTwoYearsOrMore" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl">Refers to percentage of the outstanding principal balance to be paid as prepayment fee if prepaid two years or more after the effective date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:to="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl" xlink:title="label: PrepaymentFeeIfPrepaidTwoYearsOrMore to ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl1" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl1">Prepayment Fee if Prepaid Two Years or More</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:to="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl1" xlink:title="label: PrepaymentFeeIfPrepaidTwoYearsOrMore to ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl2" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl2">Prepayment fee if prepaid two years or more</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:to="ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl2" xlink:title="label: PrepaymentFeeIfPrepaidTwoYearsOrMore to ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:label="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:title="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl">Refers to percentage of the outstanding principal balance to be paid as prepayment fee if prepaid more than one year but less than two years after the effective date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:to="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl" xlink:title="label: PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears to ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl1" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl1">Prepayment Fee if Prepaid More than One Year but Less than Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:to="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl1" xlink:title="label: PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears to ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl2" xml:lang="en-US" id="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl2">Prepayment fee if prepaid more than one year but less than two years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:to="ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl2" xlink:title="label: PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears to ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FutureCashPaymentsOfLoanPayableAbstract" xlink:label="FutureCashPaymentsOfLoanPayableAbstract" xlink:title="FutureCashPaymentsOfLoanPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl1" xml:lang="en-US" id="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl1">Future Cash Payments of Loan Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl1" xlink:title="label: FutureCashPaymentsOfLoanPayableAbstract to ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl2" xml:lang="en-US" id="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl2">Future Cash Payments of Loan Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl2" xlink:title="label: FutureCashPaymentsOfLoanPayableAbstract to ocx_FutureCashPaymentsOfLoanPayableAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentInterest" xlink:label="DebtInstrumentInterest" xlink:title="DebtInstrumentInterest" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_DebtInstrumentInterest_lbl" xml:lang="en-US" id="ocx_DebtInstrumentInterest_lbl">Refers to amount of debt instrument interest as of balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterest" xlink:to="ocx_DebtInstrumentInterest_lbl" xlink:title="label: DebtInstrumentInterest to ocx_DebtInstrumentInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_DebtInstrumentInterest_lbl1" xml:lang="en-US" id="ocx_DebtInstrumentInterest_lbl1">Debt Instrument, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterest" xlink:to="ocx_DebtInstrumentInterest_lbl1" xlink:title="label: DebtInstrumentInterest to ocx_DebtInstrumentInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentInterest_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocx_DebtInstrumentInterest_lbl2" xml:lang="en-US" id="ocx_DebtInstrumentInterest_lbl2">Less: amounts representing interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterest" xlink:to="ocx_DebtInstrumentInterest_lbl2" xlink:title="label: DebtInstrumentInterest to ocx_DebtInstrumentInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementMember" xlink:label="LoanAndSecurityAgreementMember" xlink:title="LoanAndSecurityAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocx_LoanAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" id="ocx_LoanAndSecurityAgreementMember_lbl">Refers to information about a contractual promise to repay a long-term obligation, which includes borrowings under a notes payable contractual obligations for payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndSecurityAgreementMember" xlink:to="ocx_LoanAndSecurityAgreementMember_lbl" xlink:title="label: LoanAndSecurityAgreementMember to ocx_LoanAndSecurityAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_LoanAndSecurityAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_LoanAndSecurityAgreementMember_lbl1" xml:lang="en-US" id="ocx_LoanAndSecurityAgreementMember_lbl1">Loan and Security Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndSecurityAgreementMember" xlink:to="ocx_LoanAndSecurityAgreementMember_lbl1" xlink:title="label: LoanAndSecurityAgreementMember to ocx_LoanAndSecurityAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_LoanAndSecurityAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_LoanAndSecurityAgreementMember_lbl2" xml:lang="en-US" id="ocx_LoanAndSecurityAgreementMember_lbl2">Loan and Security Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAndSecurityAgreementMember" xlink:to="ocx_LoanAndSecurityAgreementMember_lbl2" xlink:title="label: LoanAndSecurityAgreementMember to ocx_LoanAndSecurityAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:label="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl" xml:lang="en-US" id="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl">Refers to amount of debt after interest but before deferred financing costs of long-term debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:to="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl" xlink:title="label: DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts to ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl1" xml:lang="en-US" id="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl1">Debt Instrument, Carrying Amount After Interest but Before Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:to="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl1" xlink:title="label: DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts to ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl2" xml:lang="en-US" id="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl2">Total payments of principal before deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:to="ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl2" xlink:title="label: DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts to ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AdditionalFinalPaymentFeePercentage" xlink:label="AdditionalFinalPaymentFeePercentage" xlink:title="AdditionalFinalPaymentFeePercentage" />
    <link:label xlink:type="resource" xlink:label="ocx_AdditionalFinalPaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_AdditionalFinalPaymentFeePercentage_lbl" xml:lang="en-US" id="ocx_AdditionalFinalPaymentFeePercentage_lbl">Refers to percentage of the original principal borrowed to be paid as additional final payment fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFinalPaymentFeePercentage" xlink:to="ocx_AdditionalFinalPaymentFeePercentage_lbl" xlink:title="label: AdditionalFinalPaymentFeePercentage to ocx_AdditionalFinalPaymentFeePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_AdditionalFinalPaymentFeePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_AdditionalFinalPaymentFeePercentage_lbl1" xml:lang="en-US" id="ocx_AdditionalFinalPaymentFeePercentage_lbl1">Additional Final Payment Fee Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFinalPaymentFeePercentage" xlink:to="ocx_AdditionalFinalPaymentFeePercentage_lbl1" xlink:title="label: AdditionalFinalPaymentFeePercentage to ocx_AdditionalFinalPaymentFeePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_AdditionalFinalPaymentFeePercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_AdditionalFinalPaymentFeePercentage_lbl2" xml:lang="en-US" id="ocx_AdditionalFinalPaymentFeePercentage_lbl2">Additional final payment fee percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFinalPaymentFeePercentage" xlink:to="ocx_AdditionalFinalPaymentFeePercentage_lbl2" xlink:title="label: AdditionalFinalPaymentFeePercentage to ocx_AdditionalFinalPaymentFeePercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtDefaultLegalActionAmount" xlink:label="DebtDefaultLegalActionAmount" xlink:title="DebtDefaultLegalActionAmount" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtDefaultLegalActionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_DebtDefaultLegalActionAmount_lbl" xml:lang="en-US" id="ocx_DebtDefaultLegalActionAmount_lbl">Refers to the amount necessary to trigger a default of the loan agreement caused by legal judgments, or pending or threatened legal actions against the entity per the debt covenant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDefaultLegalActionAmount" xlink:to="ocx_DebtDefaultLegalActionAmount_lbl" xlink:title="label: DebtDefaultLegalActionAmount to ocx_DebtDefaultLegalActionAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtDefaultLegalActionAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_DebtDefaultLegalActionAmount_lbl1" xml:lang="en-US" id="ocx_DebtDefaultLegalActionAmount_lbl1">Debt Default, Legal Action Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDefaultLegalActionAmount" xlink:to="ocx_DebtDefaultLegalActionAmount_lbl1" xlink:title="label: DebtDefaultLegalActionAmount to ocx_DebtDefaultLegalActionAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_DebtDefaultLegalActionAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_DebtDefaultLegalActionAmount_lbl2" xml:lang="en-US" id="ocx_DebtDefaultLegalActionAmount_lbl2">Minimum legal judgments or legal actions amount triggering loan default</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDefaultLegalActionAmount" xlink:to="ocx_DebtDefaultLegalActionAmount_lbl2" xlink:title="label: DebtDefaultLegalActionAmount to ocx_DebtDefaultLegalActionAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AmountAvailableUnderCapitalLeaseAgreement" xlink:label="AmountAvailableUnderCapitalLeaseAgreement" xlink:title="AmountAvailableUnderCapitalLeaseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl" xml:lang="en-US" id="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl">The amount of under capital lease agreement as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountAvailableUnderCapitalLeaseAgreement" xlink:to="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl" xlink:title="label: AmountAvailableUnderCapitalLeaseAgreement to ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl1" xml:lang="en-US" id="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl1">Amount Available under Capital Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountAvailableUnderCapitalLeaseAgreement" xlink:to="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl1" xlink:title="label: AmountAvailableUnderCapitalLeaseAgreement to ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl2" xml:lang="en-US" id="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl2">Available amount under lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountAvailableUnderCapitalLeaseAgreement" xlink:to="ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl2" xlink:title="label: AmountAvailableUnderCapitalLeaseAgreement to ocx_AmountAvailableUnderCapitalLeaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:label="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:title="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl" xml:lang="en-US" id="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl">Refers to the equipment returned financed under the schedule for a restocking fee percentage on original cost of equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:to="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl" xlink:title="label: PercentageOfRestockingFeePaidOnOriginalCostOfEquipment to ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl1" xml:lang="en-US" id="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl1">Percentage of Restocking Fee Paid on Original Cost of Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:to="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl1" xlink:title="label: PercentageOfRestockingFeePaidOnOriginalCostOfEquipment to ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl2" xml:lang="en-US" id="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl2">Percentage of restocking fee paid on original cost of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:to="ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl2" xlink:title="label: PercentageOfRestockingFeePaidOnOriginalCostOfEquipment to ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:title="CapitalLeaseAgreementImputedAnnualInterestRate" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" xml:lang="en-US" id="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl">Refers to annual interest rate on capital lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:to="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" xlink:title="label: CapitalLeaseAgreementImputedAnnualInterestRate to ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl1" xml:lang="en-US" id="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl1">Capital Lease Agreement Imputed Annual Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:to="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl1" xlink:title="label: CapitalLeaseAgreementImputedAnnualInterestRate to ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl2" xml:lang="en-US" id="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl2">Interest rate on lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:to="ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl2" xlink:title="label: CapitalLeaseAgreementImputedAnnualInterestRate to ocx_CapitalLeaseAgreementImputedAnnualInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeasePaymentTerm" xlink:label="CapitalLeasePaymentTerm" xlink:title="CapitalLeasePaymentTerm" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeasePaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CapitalLeasePaymentTerm_lbl" xml:lang="en-US" id="ocx_CapitalLeasePaymentTerm_lbl">Period of time between issuance and maturity of capital lease agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasePaymentTerm" xlink:to="ocx_CapitalLeasePaymentTerm_lbl" xlink:title="label: CapitalLeasePaymentTerm to ocx_CapitalLeasePaymentTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeasePaymentTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CapitalLeasePaymentTerm_lbl1" xml:lang="en-US" id="ocx_CapitalLeasePaymentTerm_lbl1">Capital Lease Payment Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasePaymentTerm" xlink:to="ocx_CapitalLeasePaymentTerm_lbl1" xlink:title="label: CapitalLeasePaymentTerm to ocx_CapitalLeasePaymentTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CapitalLeasePaymentTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CapitalLeasePaymentTerm_lbl2" xml:lang="en-US" id="ocx_CapitalLeasePaymentTerm_lbl2">Capital lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalLeasePaymentTerm" xlink:to="ocx_CapitalLeasePaymentTerm_lbl2" xlink:title="label: CapitalLeasePaymentTerm to ocx_CapitalLeasePaymentTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:label="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:title="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl" xml:lang="en-US" id="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl">Refers to minimum fair value percentage on original cost to purchase an equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:to="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl" xlink:title="label: PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment to ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl1" xml:lang="en-US" id="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl1">Percentage of Fair Value on Original Cost to Purchase an Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:to="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl1" xlink:title="label: PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment to ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl2" xml:lang="en-US" id="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl2">Percentage of fair value on original cost to purchase an equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:to="ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl2" xlink:title="label: PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment to ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MasterLeaseLineAgreementMember" xlink:label="MasterLeaseLineAgreementMember" xlink:title="MasterLeaseLineAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocx_MasterLeaseLineAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_MasterLeaseLineAgreementMember_lbl" xml:lang="en-US" id="ocx_MasterLeaseLineAgreementMember_lbl">Refers to the lease agreement between the parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MasterLeaseLineAgreementMember" xlink:to="ocx_MasterLeaseLineAgreementMember_lbl" xlink:title="label: MasterLeaseLineAgreementMember to ocx_MasterLeaseLineAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_MasterLeaseLineAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_MasterLeaseLineAgreementMember_lbl1" xml:lang="en-US" id="ocx_MasterLeaseLineAgreementMember_lbl1">Master Lease Line Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MasterLeaseLineAgreementMember" xlink:to="ocx_MasterLeaseLineAgreementMember_lbl1" xlink:title="label: MasterLeaseLineAgreementMember to ocx_MasterLeaseLineAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:label="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:title="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl" xml:lang="en-US" id="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl">Represents the period in which change of ownership for a specified percentage should occur.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:to="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl" xlink:title="label: PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur to ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl1" xml:lang="en-US" id="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl1">Period in which change of ownership for a specified percentage should occur</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:to="ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl1" xlink:title="label: PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur to ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:label="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:title="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl">Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:title="label: TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit to ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl1">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl1" xlink:title="label: TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit to ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl2" xml:lang="en-US" id="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl2">Reduction in deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl2" xlink:title="label: TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit to ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl">The portion of the difference between effective income tax rate and domestic federal statutory income tax rate that can be explained by permanent differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentDifferences to ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl1" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl1">Effective Income Tax Rate Reconciliation, Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentDifferences to ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl2" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl2">Permanent differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationPermanentDifferences to ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsTaxableGainLoss" xlink:label="InvestorsTaxableGainLoss" xlink:title="InvestorsTaxableGainLoss" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsTaxableGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_InvestorsTaxableGainLoss_lbl" xml:lang="en-US" id="ocx_InvestorsTaxableGainLoss_lbl">Amount of investor's gain (loss) recognized on the sale of equity instruments subject to taxation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsTaxableGainLoss" xlink:to="ocx_InvestorsTaxableGainLoss_lbl" xlink:title="label: InvestorsTaxableGainLoss to ocx_InvestorsTaxableGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsTaxableGainLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_InvestorsTaxableGainLoss_lbl1" xml:lang="en-US" id="ocx_InvestorsTaxableGainLoss_lbl1">Investors Taxable Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsTaxableGainLoss" xlink:to="ocx_InvestorsTaxableGainLoss_lbl1" xlink:title="label: InvestorsTaxableGainLoss to ocx_InvestorsTaxableGainLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsTaxableGainLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_InvestorsTaxableGainLoss_lbl2" xml:lang="en-US" id="ocx_InvestorsTaxableGainLoss_lbl2">Investors taxable loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsTaxableGainLoss" xlink:to="ocx_InvestorsTaxableGainLoss_lbl2" xlink:title="label: InvestorsTaxableGainLoss to ocx_InvestorsTaxableGainLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfChangeInOwnership" xlink:label="PercentageOfChangeInOwnership" xlink:title="PercentageOfChangeInOwnership" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_PercentageOfChangeInOwnership_lbl" xml:lang="en-US" id="ocx_PercentageOfChangeInOwnership_lbl">Represents the percentage change in ownership necessary under internal revenue code which places limitation on amount of taxable income that can be offset by net operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfChangeInOwnership" xlink:to="ocx_PercentageOfChangeInOwnership_lbl" xlink:title="label: PercentageOfChangeInOwnership to ocx_PercentageOfChangeInOwnership_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_PercentageOfChangeInOwnership_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_PercentageOfChangeInOwnership_lbl1" xml:lang="en-US" id="ocx_PercentageOfChangeInOwnership_lbl1">Percentage of change in ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfChangeInOwnership" xlink:to="ocx_PercentageOfChangeInOwnership_lbl1" xlink:title="label: PercentageOfChangeInOwnership to ocx_PercentageOfChangeInOwnership_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DeferredTaxAssetsPatentsAndFixedAssets" xlink:label="DeferredTaxAssetsPatentsAndFixedAssets" xlink:title="DeferredTaxAssetsPatentsAndFixedAssets" />
    <link:label xlink:type="resource" xlink:label="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl" xml:lang="en-US" id="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPatentsAndFixedAssets" xlink:to="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl" xlink:title="label: DeferredTaxAssetsPatentsAndFixedAssets to ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl1" xml:lang="en-US" id="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl1">Deferred tax Assets, Patents and Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPatentsAndFixedAssets" xlink:to="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl1" xlink:title="label: DeferredTaxAssetsPatentsAndFixedAssets to ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl2" xml:lang="en-US" id="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl2">Patents and fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsPatentsAndFixedAssets" xlink:to="ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl2" xlink:title="label: DeferredTaxAssetsPatentsAndFixedAssets to ocx_DeferredTaxAssetsPatentsAndFixedAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardExpirationDateFederal" xlink:label="TaxCreditCarryforwardExpirationDateFederal" xlink:title="TaxCreditCarryforwardExpirationDateFederal" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl" xml:lang="en-US" id="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl">Expiration date of the tax credit carryforward related to domestic tax authorities, in CCYY-MM-DD format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationDateFederal" xlink:to="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl" xlink:title="label: TaxCreditCarryforwardExpirationDateFederal to ocx_TaxCreditCarryforwardExpirationDateFederal_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl1" xml:lang="en-US" id="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl1">Tax Credit Carryforward, Expiration Date, Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationDateFederal" xlink:to="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl1" xlink:title="label: TaxCreditCarryforwardExpirationDateFederal to ocx_TaxCreditCarryforwardExpirationDateFederal_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl2" xml:lang="en-US" id="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl2">Tax credit carryforwards, expiration date, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationDateFederal" xlink:to="ocx_TaxCreditCarryforwardExpirationDateFederal_lbl2" xlink:title="label: TaxCreditCarryforwardExpirationDateFederal to ocx_TaxCreditCarryforwardExpirationDateFederal_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountState" xlink:label="TaxCreditCarryforwardAmountState" xlink:title="TaxCreditCarryforwardAmountState" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountState_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TaxCreditCarryforwardAmountState_lbl" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountState_lbl">The amount of the tax credit carryforward, before tax effects, related to state tax authorities available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountState" xlink:to="ocx_TaxCreditCarryforwardAmountState_lbl" xlink:title="label: TaxCreditCarryforwardAmountState to ocx_TaxCreditCarryforwardAmountState_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountState_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TaxCreditCarryforwardAmountState_lbl1" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountState_lbl1">Tax Credit Carryforward, Amount, State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountState" xlink:to="ocx_TaxCreditCarryforwardAmountState_lbl1" xlink:title="label: TaxCreditCarryforwardAmountState to ocx_TaxCreditCarryforwardAmountState_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountState_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TaxCreditCarryforwardAmountState_lbl2" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountState_lbl2">Tax credit carryforwards, state</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountState" xlink:to="ocx_TaxCreditCarryforwardAmountState_lbl2" xlink:title="label: TaxCreditCarryforwardAmountState to ocx_TaxCreditCarryforwardAmountState_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountFederal" xlink:label="TaxCreditCarryforwardAmountFederal" xlink:title="TaxCreditCarryforwardAmountFederal" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountFederal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_TaxCreditCarryforwardAmountFederal_lbl" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountFederal_lbl">The amount of the tax credit carryforward, before tax effects, related to domestic tax authorities available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountFederal" xlink:to="ocx_TaxCreditCarryforwardAmountFederal_lbl" xlink:title="label: TaxCreditCarryforwardAmountFederal to ocx_TaxCreditCarryforwardAmountFederal_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountFederal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_TaxCreditCarryforwardAmountFederal_lbl1" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountFederal_lbl1">Tax Credit Carryforward, Amount, Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountFederal" xlink:to="ocx_TaxCreditCarryforwardAmountFederal_lbl1" xlink:title="label: TaxCreditCarryforwardAmountFederal to ocx_TaxCreditCarryforwardAmountFederal_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_TaxCreditCarryforwardAmountFederal_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_TaxCreditCarryforwardAmountFederal_lbl2" xml:lang="en-US" id="ocx_TaxCreditCarryforwardAmountFederal_lbl2">Tax credit carryforwards, federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmountFederal" xlink:to="ocx_TaxCreditCarryforwardAmountFederal_lbl2" xlink:title="label: TaxCreditCarryforwardAmountFederal to ocx_TaxCreditCarryforwardAmountFederal_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the basis for available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent to ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl1" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl1">Effective Income Tax Rate Reconciliation, Change in Basis for Available-for-sale Securities, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent to ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl2" xml:lang="en-US" id="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl2">Adjusted basis for available-for-sale-securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:to="ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent to ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LiquidityPolicyTextBlock" xlink:label="LiquidityPolicyTextBlock" xlink:title="LiquidityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocx_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_LiquidityPolicyTextBlock_lbl" xml:lang="en-US" id="ocx_LiquidityPolicyTextBlock_lbl">Disclosure of accounting policy for liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocx_LiquidityPolicyTextBlock_lbl" xlink:title="label: LiquidityPolicyTextBlock to ocx_LiquidityPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_LiquidityPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US" id="ocx_LiquidityPolicyTextBlock_lbl1">Liquidity [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocx_LiquidityPolicyTextBlock_lbl1" xlink:title="label: LiquidityPolicyTextBlock to ocx_LiquidityPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_LiquidityPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_LiquidityPolicyTextBlock_lbl2" xml:lang="en-US" id="ocx_LiquidityPolicyTextBlock_lbl2">Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocx_LiquidityPolicyTextBlock_lbl2" xlink:title="label: LiquidityPolicyTextBlock to ocx_LiquidityPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorTwoMember" xlink:label="InvestorTwoMember" xlink:title="InvestorTwoMember" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_InvestorTwoMember_lbl" xml:lang="en-US" id="ocx_InvestorTwoMember_lbl">Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorTwoMember" xlink:to="ocx_InvestorTwoMember_lbl" xlink:title="label: InvestorTwoMember to ocx_InvestorTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_InvestorTwoMember_lbl1" xml:lang="en-US" id="ocx_InvestorTwoMember_lbl1">Investor Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorTwoMember" xlink:to="ocx_InvestorTwoMember_lbl1" xlink:title="label: InvestorTwoMember to ocx_InvestorTwoMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl" xml:lang="en-US" id="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl">Number of new shares of stock issued through private placement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1" xml:lang="en-US" id="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1">Stock Issued During Period, Shares, Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl2" xml:lang="en-US" id="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl2">Shares issued through private placement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:to="ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesPrivatePlacement to ocx_StockIssuedDuringPeriodSharesPrivatePlacement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfAccreditedInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NumberOfAccreditedInvestors_lbl" xml:lang="en-US" id="ocx_NumberOfAccreditedInvestors_lbl">The number of accredited investors in the notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocx_NumberOfAccreditedInvestors_lbl" xlink:title="label: NumberOfAccreditedInvestors to ocx_NumberOfAccreditedInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfAccreditedInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NumberOfAccreditedInvestors_lbl1" xml:lang="en-US" id="ocx_NumberOfAccreditedInvestors_lbl1">Number of Accredited Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocx_NumberOfAccreditedInvestors_lbl1" xlink:title="label: NumberOfAccreditedInvestors to ocx_NumberOfAccreditedInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfAccreditedInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NumberOfAccreditedInvestors_lbl2" xml:lang="en-US" id="ocx_NumberOfAccreditedInvestors_lbl2">Number of accredited investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocx_NumberOfAccreditedInvestors_lbl2" xlink:title="label: NumberOfAccreditedInvestors to ocx_NumberOfAccreditedInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_BroadwoodPartnersLPMember" xlink:label="BroadwoodPartnersLPMember" xlink:title="BroadwoodPartnersLPMember" />
    <link:label xlink:type="resource" xlink:label="ocx_BroadwoodPartnersLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_BroadwoodPartnersLPMember_lbl" xml:lang="en-US" id="ocx_BroadwoodPartnersLPMember_lbl">Refers to name of the entity "Broadwood Partners, L.P".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BroadwoodPartnersLPMember" xlink:to="ocx_BroadwoodPartnersLPMember_lbl" xlink:title="label: BroadwoodPartnersLPMember to ocx_BroadwoodPartnersLPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_BroadwoodPartnersLPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_BroadwoodPartnersLPMember_lbl1" xml:lang="en-US" id="ocx_BroadwoodPartnersLPMember_lbl1">Broadwood Partners LP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BroadwoodPartnersLPMember" xlink:to="ocx_BroadwoodPartnersLPMember_lbl1" xlink:title="label: BroadwoodPartnersLPMember to ocx_BroadwoodPartnersLPMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_BroadwoodPartnersLPMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_BroadwoodPartnersLPMember_lbl2" xml:lang="en-US" id="ocx_BroadwoodPartnersLPMember_lbl2">Broadwood Partners, L.P [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BroadwoodPartnersLPMember" xlink:to="ocx_BroadwoodPartnersLPMember_lbl2" xlink:title="label: BroadwoodPartnersLPMember to ocx_BroadwoodPartnersLPMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IssuanceOfCommonStockAndWarrantsAbstract" xlink:label="IssuanceOfCommonStockAndWarrantsAbstract" xlink:title="IssuanceOfCommonStockAndWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_IssuanceOfCommonStockAndWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_IssuanceOfCommonStockAndWarrantsAbstract_lbl1" xml:lang="en-US" id="ocx_IssuanceOfCommonStockAndWarrantsAbstract_lbl1">Issuance of Common Stock and Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="ocx_IssuanceOfCommonStockAndWarrantsAbstract_lbl1" xlink:title="label: IssuanceOfCommonStockAndWarrantsAbstract to ocx_IssuanceOfCommonStockAndWarrantsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:label="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:title="NumberOfCommonStockSharesAvailableInEachSeparableUnit" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl" xml:lang="en-US" id="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl">Refers to the number of common shares included in each immediate separable unit issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl" xlink:title="label: NumberOfCommonStockSharesAvailableInEachSeparableUnit to ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl1" xml:lang="en-US" id="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl1">Number of Common Stock Shares Available in each Separable Unit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl1" xlink:title="label: NumberOfCommonStockSharesAvailableInEachSeparableUnit to ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl2" xml:lang="en-US" id="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl2">Number of common shares available in each separable unit (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl2" xlink:title="label: NumberOfCommonStockSharesAvailableInEachSeparableUnit to ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IssuanceOfSeparableUnits" xlink:label="IssuanceOfSeparableUnits" xlink:title="IssuanceOfSeparableUnits" />
    <link:label xlink:type="resource" xlink:label="ocx_IssuanceOfSeparableUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_IssuanceOfSeparableUnits_lbl" xml:lang="en-US" id="ocx_IssuanceOfSeparableUnits_lbl">Refers to the number of separable units consisting of common stock shares and warrants or rights to purchase common shares issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSeparableUnits" xlink:to="ocx_IssuanceOfSeparableUnits_lbl" xlink:title="label: IssuanceOfSeparableUnits to ocx_IssuanceOfSeparableUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_IssuanceOfSeparableUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_IssuanceOfSeparableUnits_lbl1" xml:lang="en-US" id="ocx_IssuanceOfSeparableUnits_lbl1">Issuance of Separable Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSeparableUnits" xlink:to="ocx_IssuanceOfSeparableUnits_lbl1" xlink:title="label: IssuanceOfSeparableUnits to ocx_IssuanceOfSeparableUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_IssuanceOfSeparableUnits_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_IssuanceOfSeparableUnits_lbl2" xml:lang="en-US" id="ocx_IssuanceOfSeparableUnits_lbl2">Issuance of separable units (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSeparableUnits" xlink:to="ocx_IssuanceOfSeparableUnits_lbl2" xlink:title="label: IssuanceOfSeparableUnits to ocx_IssuanceOfSeparableUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfWarrantsAvailableInEachSeparableUnit" xlink:label="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:title="NumberOfWarrantsAvailableInEachSeparableUnit" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl" xml:lang="en-US" id="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl">Refers to the number of warrants for common shares included in each separable unit issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl" xlink:title="label: NumberOfWarrantsAvailableInEachSeparableUnit to ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl1" xml:lang="en-US" id="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl1">Number of warrants available in each separable unit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl1" xlink:title="label: NumberOfWarrantsAvailableInEachSeparableUnit to ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl2" xml:lang="en-US" id="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl2">Number of warrants to purchase stock in each separable unit (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:to="ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl2" xlink:title="label: NumberOfWarrantsAvailableInEachSeparableUnit to ocx_NumberOfWarrantsAvailableInEachSeparableUnit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SeparableUnitsExercisePrice" xlink:label="SeparableUnitsExercisePrice" xlink:title="SeparableUnitsExercisePrice" />
    <link:label xlink:type="resource" xlink:label="ocx_SeparableUnitsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_SeparableUnitsExercisePrice_lbl" xml:lang="en-US" id="ocx_SeparableUnitsExercisePrice_lbl">Exercise price per share of separable units outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeparableUnitsExercisePrice" xlink:to="ocx_SeparableUnitsExercisePrice_lbl" xlink:title="label: SeparableUnitsExercisePrice to ocx_SeparableUnitsExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_SeparableUnitsExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SeparableUnitsExercisePrice_lbl1" xml:lang="en-US" id="ocx_SeparableUnitsExercisePrice_lbl1">Separable Units, Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeparableUnitsExercisePrice" xlink:to="ocx_SeparableUnitsExercisePrice_lbl1" xlink:title="label: SeparableUnitsExercisePrice to ocx_SeparableUnitsExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_SeparableUnitsExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_SeparableUnitsExercisePrice_lbl2" xml:lang="en-US" id="ocx_SeparableUnitsExercisePrice_lbl2">Separable units, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeparableUnitsExercisePrice" xlink:to="ocx_SeparableUnitsExercisePrice_lbl2" xlink:title="label: SeparableUnitsExercisePrice to ocx_SeparableUnitsExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockVotesPerShare" xlink:label="CommonStockVotesPerShare" xlink:title="CommonStockVotesPerShare" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockVotesPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommonStockVotesPerShare_lbl" xml:lang="en-US" id="ocx_CommonStockVotesPerShare_lbl">Refers to the votes per share entitled to the holders of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotesPerShare" xlink:to="ocx_CommonStockVotesPerShare_lbl" xlink:title="label: CommonStockVotesPerShare to ocx_CommonStockVotesPerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockVotesPerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommonStockVotesPerShare_lbl1" xml:lang="en-US" id="ocx_CommonStockVotesPerShare_lbl1">Common Stock Votes Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotesPerShare" xlink:to="ocx_CommonStockVotesPerShare_lbl1" xlink:title="label: CommonStockVotesPerShare to ocx_CommonStockVotesPerShare_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommonStockVotesPerShare_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommonStockVotesPerShare_lbl2" xml:lang="en-US" id="ocx_CommonStockVotesPerShare_lbl2">Number of votes for each share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockVotesPerShare" xlink:to="ocx_CommonStockVotesPerShare_lbl2" xlink:title="label: CommonStockVotesPerShare to ocx_CommonStockVotesPerShare_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016Member" xlink:label="Warrants2016Member" xlink:title="Warrants2016Member" />
    <link:label xlink:type="resource" xlink:label="ocx_Warrants2016Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_Warrants2016Member_lbl" xml:lang="en-US" id="ocx_Warrants2016Member_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants2016Member" xlink:to="ocx_Warrants2016Member_lbl" xlink:title="label: Warrants2016Member to ocx_Warrants2016Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_Warrants2016Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_Warrants2016Member_lbl1" xml:lang="en-US" id="ocx_Warrants2016Member_lbl1">Warrants 2016 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants2016Member" xlink:to="ocx_Warrants2016Member_lbl1" xlink:title="label: Warrants2016Member to ocx_Warrants2016Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_Warrants2016Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_Warrants2016Member_lbl2" xml:lang="en-US" id="ocx_Warrants2016Member_lbl2">2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants2016Member" xlink:to="ocx_Warrants2016Member_lbl2" xlink:title="label: Warrants2016Member to ocx_Warrants2016Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_July2017WarrantsMember" xlink:label="July2017WarrantsMember" xlink:title="July2017WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_July2017WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_July2017WarrantsMember_lbl" xml:lang="en-US" id="ocx_July2017WarrantsMember_lbl">Refers to security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount issued during July 2017.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July2017WarrantsMember" xlink:to="ocx_July2017WarrantsMember_lbl" xlink:title="label: July2017WarrantsMember to ocx_July2017WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_July2017WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_July2017WarrantsMember_lbl1" xml:lang="en-US" id="ocx_July2017WarrantsMember_lbl1">July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July2017WarrantsMember" xlink:to="ocx_July2017WarrantsMember_lbl1" xlink:title="label: July2017WarrantsMember to ocx_July2017WarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:title="label: SecondFormWarrantExerciseAgreement2016WarrantsMember to ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl1">Second Form, Warrant Exercise Agreement, 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:title="label: SecondFormWarrantExerciseAgreement2016WarrantsMember to ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl2">Second Form - 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:title="label: SecondFormWarrantExerciseAgreement2016WarrantsMember to ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xlink:title="label: SecondFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1">Second Form, Warrant Exercise Agreement, July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xlink:title="label: SecondFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xml:lang="en-US" id="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2">Second Form - July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xlink:title="label: SecondFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl" xml:lang="en-US" id="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl" xlink:title="label: ThirdFormPart2WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl1" xml:lang="en-US" id="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl1">Third Form Part2 Warrant Exercise Agreement July21 2017 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl1" xlink:title="label: ThirdFormPart2WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl2" xml:lang="en-US" id="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl2">Third Form Part 2 - July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl2" xlink:title="label: ThirdFormPart2WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl" xml:lang="en-US" id="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl" xlink:title="label: ThirdFormPart1WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl1" xml:lang="en-US" id="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl1">Third Form Part1 Warrant Exercise Agreement July21 2017 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl1" xlink:title="label: ThirdFormPart1WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl2" xml:lang="en-US" id="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl2">Third Form Part 1 - July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:to="ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl2" xlink:title="label: ThirdFormPart1WarrantExerciseAgreementJuly212017Member to ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" xlink:title="label: FirstFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1">First Form, Warrant Exercise Agreement, July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" xlink:title="label: FirstFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2">First Form - July 2017 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" xlink:title="label: FirstFormWarrantExerciseAgreementJuly2017WarrantsMember to ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="ThirdFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl" xml:lang="en-US" id="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:title="label: ThirdFormWarrantExerciseAgreement2016WarrantsMember to ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xml:lang="en-US" id="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl1">Third Form, Warrant Exercise Agreement, 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:title="label: ThirdFormWarrantExerciseAgreement2016WarrantsMember to ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xml:lang="en-US" id="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl2">Third Form - 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:title="label: ThirdFormWarrantExerciseAgreement2016WarrantsMember to ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl" xlink:title="label: FirstFormWarrantExerciseAgreement2016WarrantsMember to ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl1">First Form, Warrant Exercise Agreement, 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl1" xlink:title="label: FirstFormWarrantExerciseAgreement2016WarrantsMember to ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xml:lang="en-US" id="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl2">First Form - 2016 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:to="ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl2" xlink:title="label: FirstFormWarrantExerciseAgreement2016WarrantsMember to ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NewWarrantsMember" xlink:label="NewWarrantsMember" xlink:title="NewWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocx_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NewWarrantsMember_lbl" xml:lang="en-US" id="ocx_NewWarrantsMember_lbl">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewWarrantsMember" xlink:to="ocx_NewWarrantsMember_lbl" xlink:title="label: NewWarrantsMember to ocx_NewWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NewWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NewWarrantsMember_lbl1" xml:lang="en-US" id="ocx_NewWarrantsMember_lbl1">New Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewWarrantsMember" xlink:to="ocx_NewWarrantsMember_lbl1" xlink:title="label: NewWarrantsMember to ocx_NewWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NewWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NewWarrantsMember_lbl2" xml:lang="en-US" id="ocx_NewWarrantsMember_lbl2">New Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewWarrantsMember" xlink:to="ocx_NewWarrantsMember_lbl2" xlink:title="label: NewWarrantsMember to ocx_NewWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016AndNewWarrantsAbstract" xlink:label="Warrants2016AndNewWarrantsAbstract" xlink:title="Warrants2016AndNewWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_Warrants2016AndNewWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_Warrants2016AndNewWarrantsAbstract_lbl1" xml:lang="en-US" id="ocx_Warrants2016AndNewWarrantsAbstract_lbl1">Warrants 2016 and New Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ocx_Warrants2016AndNewWarrantsAbstract_lbl1" xlink:title="label: Warrants2016AndNewWarrantsAbstract to ocx_Warrants2016AndNewWarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_Warrants2016AndNewWarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_Warrants2016AndNewWarrantsAbstract_lbl2" xml:lang="en-US" id="ocx_Warrants2016AndNewWarrantsAbstract_lbl2">2016 Warrants and New Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ocx_Warrants2016AndNewWarrantsAbstract_lbl2" xlink:title="label: Warrants2016AndNewWarrantsAbstract to ocx_Warrants2016AndNewWarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfWarrantHolders" xlink:label="NumberOfWarrantHolders" xlink:title="NumberOfWarrantHolders" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NumberOfWarrantHolders_lbl" xml:lang="en-US" id="ocx_NumberOfWarrantHolders_lbl">Refers to the number of warrant holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantHolders" xlink:to="ocx_NumberOfWarrantHolders_lbl" xlink:title="label: NumberOfWarrantHolders to ocx_NumberOfWarrantHolders_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantHolders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NumberOfWarrantHolders_lbl1" xml:lang="en-US" id="ocx_NumberOfWarrantHolders_lbl1">Number Of Warrant Holders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantHolders" xlink:to="ocx_NumberOfWarrantHolders_lbl1" xlink:title="label: NumberOfWarrantHolders to ocx_NumberOfWarrantHolders_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfWarrantHolders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NumberOfWarrantHolders_lbl2" xml:lang="en-US" id="ocx_NumberOfWarrantHolders_lbl2">Number of warrant holders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfWarrantHolders" xlink:to="ocx_NumberOfWarrantHolders_lbl2" xlink:title="label: NumberOfWarrantHolders to ocx_NumberOfWarrantHolders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfFormsInWarrantExerciseAgreement" xlink:label="NumberOfFormsInWarrantExerciseAgreement" xlink:title="NumberOfFormsInWarrantExerciseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl" xml:lang="en-US" id="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl">Refers to the number of forms of warrant exercise agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFormsInWarrantExerciseAgreement" xlink:to="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl" xlink:title="label: NumberOfFormsInWarrantExerciseAgreement to ocx_NumberOfFormsInWarrantExerciseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl1" xml:lang="en-US" id="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl1">Number Of Forms In Warrant Exercise Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFormsInWarrantExerciseAgreement" xlink:to="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl1" xlink:title="label: NumberOfFormsInWarrantExerciseAgreement to ocx_NumberOfFormsInWarrantExerciseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl2" xml:lang="en-US" id="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl2">Warrant exercise agreement, number of forms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFormsInWarrantExerciseAgreement" xlink:to="ocx_NumberOfFormsInWarrantExerciseAgreement_lbl2" xlink:title="label: NumberOfFormsInWarrantExerciseAgreement to ocx_NumberOfFormsInWarrantExerciseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl">Weighted average price per share or per unit of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:to="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights to ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl1" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl1">Class of Warrant or Right, Weighted Average Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:to="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights to ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl2" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl2">Weighted average price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:to="ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl2" xlink:title="label: ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights to ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:label="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:title="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" />
    <link:label xlink:type="resource" xlink:label="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl">The fair value of the warrants, determined using the Black-Scholes option pricing model, recognized as noncash charge to shareholder expense included in general and administrative expenses and a corresponding increase to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:to="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl" xlink:title="label: NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses to ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US" id="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl1">Noncash Charge To Shareholder Expense Included In General And Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:to="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl1" xlink:title="label: NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses to ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl2" xml:lang="en-US" id="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl2">Noncash charge to shareholder expense included in general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:to="ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl2" xlink:title="label: NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses to ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightExercisedPeriod" xlink:label="ClassOfWarrantOrRightExercisedPeriod" xlink:title="ClassOfWarrantOrRightExercisedPeriod" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl">Refers to term of warrants to exercise, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisedPeriod" xlink:to="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl" xlink:title="label: ClassOfWarrantOrRightExercisedPeriod to ocx_ClassOfWarrantOrRightExercisedPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl1" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl1">Class of Warrant or Right, Exercised Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisedPeriod" xlink:to="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisedPeriod to ocx_ClassOfWarrantOrRightExercisedPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl2" xml:lang="en-US" id="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl2">Warrant exercise period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisedPeriod" xlink:to="ocx_ClassOfWarrantOrRightExercisedPeriod_lbl2" xlink:title="label: ClassOfWarrantOrRightExercisedPeriod to ocx_ClassOfWarrantOrRightExercisedPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsGroupOneMember" xlink:label="InvestorsGroupOneMember" xlink:title="InvestorsGroupOneMember" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsGroupOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_InvestorsGroupOneMember_lbl" xml:lang="en-US" id="ocx_InvestorsGroupOneMember_lbl">Refers to investors who exercised warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsGroupOneMember" xlink:to="ocx_InvestorsGroupOneMember_lbl" xlink:title="label: InvestorsGroupOneMember to ocx_InvestorsGroupOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsGroupOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_InvestorsGroupOneMember_lbl1" xml:lang="en-US" id="ocx_InvestorsGroupOneMember_lbl1">Investors Group One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsGroupOneMember" xlink:to="ocx_InvestorsGroupOneMember_lbl1" xlink:title="label: InvestorsGroupOneMember to ocx_InvestorsGroupOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_InvestorsGroupOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocx_InvestorsGroupOneMember_lbl2" xml:lang="en-US" id="ocx_InvestorsGroupOneMember_lbl2">Investors Group [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorsGroupOneMember" xlink:to="ocx_InvestorsGroupOneMember_lbl2" xlink:title="label: InvestorsGroupOneMember to ocx_InvestorsGroupOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementMember" xlink:label="WistarLicenseAgreementMember" xlink:title="WistarLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocx_WistarLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_WistarLicenseAgreementMember_lbl" xml:lang="en-US" id="ocx_WistarLicenseAgreementMember_lbl">A License Agreement with The Wistar Institute of Anatomy and Biology ("Wistar") that entitles OncoCyte to use certain patents, know-how and data belonging to Wistar.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WistarLicenseAgreementMember" xlink:to="ocx_WistarLicenseAgreementMember_lbl" xlink:title="label: WistarLicenseAgreementMember to ocx_WistarLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_WistarLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_WistarLicenseAgreementMember_lbl1" xml:lang="en-US" id="ocx_WistarLicenseAgreementMember_lbl1">Wistar License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WistarLicenseAgreementMember" xlink:to="ocx_WistarLicenseAgreementMember_lbl1" xlink:title="label: WistarLicenseAgreementMember to ocx_WistarLicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_WistarLicenseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_WistarLicenseAgreementMember_lbl2" xml:lang="en-US" id="ocx_WistarLicenseAgreementMember_lbl2">Wistar License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WistarLicenseAgreementMember" xlink:to="ocx_WistarLicenseAgreementMember_lbl2" xlink:title="label: WistarLicenseAgreementMember to ocx_WistarLicenseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementAbstract" xlink:label="WistarLicenseAgreementAbstract" xlink:title="WistarLicenseAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocx_WistarLicenseAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_WistarLicenseAgreementAbstract_lbl1" xml:lang="en-US" id="ocx_WistarLicenseAgreementAbstract_lbl1">Wistar License Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WistarLicenseAgreementAbstract" xlink:to="ocx_WistarLicenseAgreementAbstract_lbl1" xlink:title="label: WistarLicenseAgreementAbstract to ocx_WistarLicenseAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_WistarLicenseAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_WistarLicenseAgreementAbstract_lbl2" xml:lang="en-US" id="ocx_WistarLicenseAgreementAbstract_lbl2">Wistar License Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WistarLicenseAgreementAbstract" xlink:to="ocx_WistarLicenseAgreementAbstract_lbl2" xlink:title="label: WistarLicenseAgreementAbstract to ocx_WistarLicenseAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:label xlink:type="resource" xlink:label="ocx_RoyaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_RoyaltyPercentage_lbl" xml:lang="en-US" id="ocx_RoyaltyPercentage_lbl">The percentage of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="ocx_RoyaltyPercentage_lbl" xlink:title="label: RoyaltyPercentage to ocx_RoyaltyPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_RoyaltyPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_RoyaltyPercentage_lbl1" xml:lang="en-US" id="ocx_RoyaltyPercentage_lbl1">Royalty, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="ocx_RoyaltyPercentage_lbl1" xlink:title="label: RoyaltyPercentage to ocx_RoyaltyPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_RoyaltyPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_RoyaltyPercentage_lbl2" xml:lang="en-US" id="ocx_RoyaltyPercentage_lbl2">Royalty rates on amount of cumulative net sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="ocx_RoyaltyPercentage_lbl2" xlink:title="label: RoyaltyPercentage to ocx_RoyaltyPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MaximumReductionInRoyaltyPayments" xlink:label="MaximumReductionInRoyaltyPayments" xlink:title="MaximumReductionInRoyaltyPayments" />
    <link:label xlink:type="resource" xlink:label="ocx_MaximumReductionInRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_MaximumReductionInRoyaltyPayments_lbl" xml:lang="en-US" id="ocx_MaximumReductionInRoyaltyPayments_lbl">The maximum amount of reduction in royalty payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumReductionInRoyaltyPayments" xlink:to="ocx_MaximumReductionInRoyaltyPayments_lbl" xlink:title="label: MaximumReductionInRoyaltyPayments to ocx_MaximumReductionInRoyaltyPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_MaximumReductionInRoyaltyPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_MaximumReductionInRoyaltyPayments_lbl1" xml:lang="en-US" id="ocx_MaximumReductionInRoyaltyPayments_lbl1">Maximum reduction in royalty payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumReductionInRoyaltyPayments" xlink:to="ocx_MaximumReductionInRoyaltyPayments_lbl1" xlink:title="label: MaximumReductionInRoyaltyPayments to ocx_MaximumReductionInRoyaltyPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_MaximumReductionInRoyaltyPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_MaximumReductionInRoyaltyPayments_lbl2" xml:lang="en-US" id="ocx_MaximumReductionInRoyaltyPayments_lbl2">Maximum reduction in royalty payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumReductionInRoyaltyPayments" xlink:to="ocx_MaximumReductionInRoyaltyPayments_lbl2" xlink:title="label: MaximumReductionInRoyaltyPayments to ocx_MaximumReductionInRoyaltyPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:label="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:title="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" />
    <link:label xlink:type="resource" xlink:label="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl" xml:lang="en-US" id="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl">The number of one-year extensions that may be purchased is sales of a licensed product do not commence by the specified date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:to="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl" xlink:title="label: CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions to ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl" />
    <link:label xlink:type="resource" xlink:label="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl1" xml:lang="en-US" id="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl1">Commencement of Commercial Sale Deadline, Number of One Year Extensions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:to="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl1" xlink:title="label: CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions to ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl2" xml:lang="en-US" id="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl2">Number of one-year extensions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:to="ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl2" xlink:title="label: CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions to ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ocx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 4.3.3.1 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesWistarLicenseAgreementDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensationDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensationDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquityStockOptionExercisesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquity2016WarrantsAndNewWarrantsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquityDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBankDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponentsDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetails" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingenciesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBankTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponentsTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidityPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocx-20171231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="ocx-20171231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocx-20171231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://oncocyte.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ocx-20171231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="ocx-20171231.xsd#ShareholdersEquity" />
  <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:type="simple" xlink:href="ocx-20171231.xsd#LoanPayableToSiliconValleyBank" />
  <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ocx-20171231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://oncocyte.com/role/SelectedBalanceSheetComponents" xlink:type="simple" xlink:href="ocx-20171231.xsd#SelectedBalanceSheetComponents" />
  <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocx-20171231.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" xlink:href="ocx-20171231.xsd#OrganizationDescriptionOfBusinessAndLiquidity" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfCashFlows" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfComprehensiveLoss" />
  <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:type="simple" xlink:href="ocx-20171231.xsd#StatementsOfOperations" />
  <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ocx-20171231.xsd#BalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocx-20171231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://oncocyte.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ocx-20171231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityFilerCategory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityPublicFloat" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentAndEntityInformationAbstract to EntityCommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentType" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentType" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentAndEntityInformationAbstract to AmendmentFlag" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentAndEntityInformationAbstract to DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="presentation: AssetsCurrentAbstract to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="AssetsNoncurrentAbstract" xlink:title="AssetsNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: AssetsNoncurrentAbstract to FiniteLivedIntangibleAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsNoncurrentAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="presentation: AssetsNoncurrentAbstract to DepositsAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsNoncurrentAbstract" xlink:to="Assets" xlink:title="presentation: AssetsNoncurrentAbstract to Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsNoncurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="DueToRelatedPartiesCurrent" xlink:title="DueToRelatedPartiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="DueToRelatedPartiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to DueToRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LoansPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LoansPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="CapitalLeaseObligationsCurrent" xlink:title="CapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="CapitalLeaseObligationsCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to CapitalLeaseObligationsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="LongTermLoansPayable" xlink:title="LongTermLoansPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="LongTermLoansPayable" xlink:title="presentation: LiabilitiesNoncurrentAbstract to LongTermLoansPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="CapitalLeaseObligationsNoncurrent" xlink:title="CapitalLeaseObligationsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="CapitalLeaseObligationsNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to CapitalLeaseObligationsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockNoParValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockNoParValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockNoParValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="SellingAndMarketingExpense" xlink:title="presentation: OperatingExpensesAbstract to SellingAndMarketingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNonoperatingNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasicAndDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: StatementEquityComponentsAxis to AccumulatedOtherComprehensiveIncomeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:title="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockGrantedDuringPeriodValueSharebasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockGrantedDuringPeriodValueSharebasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="DebtConversionConvertedInstrumentSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DebtConversionConvertedInstrumentSharesIssued1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DebtConversionConvertedInstrumentSharesIssued1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DebtConversionConvertedInstrumentAmount1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedToInvestorsForCash" xlink:label="CommonStockSharesIssuedToInvestorsForCash" xlink:title="CommonStockSharesIssuedToInvestorsForCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssuedToInvestorsForCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssuedToInvestorsForCash" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedToInvestorsForCash" xlink:label="CommonStockIssuedToInvestorsForCash" xlink:title="CommonStockIssuedToInvestorsForCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockIssuedToInvestorsForCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockIssuedToInvestorsForCash" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesIssuedForCash" xlink:label="CommonStockSharesIssuedForCash" xlink:title="CommonStockSharesIssuedForCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesIssuedForCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesIssuedForCash" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedForCash" xlink:label="CommonStockIssuedForCash" xlink:title="CommonStockIssuedForCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockIssuedForCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockIssuedForCash" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:label="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to FairValueAdjustmentOfWarrants" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockDividendsSharesReceived" xlink:label="CommonStockDividendsSharesReceived" xlink:title="CommonStockDividendsSharesReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockDividendsSharesReceived" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockDividendsSharesReceived" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsCommonStockPaidinkind" xlink:label="DividendsCommonStockPaidinkind" xlink:title="DividendsCommonStockPaidinkind" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendsCommonStockPaidinkind" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DividendsCommonStockPaidinkind" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:label="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:title="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WarrantsIssuedToBanks" xlink:label="WarrantsIssuedToBanks" xlink:title="WarrantsIssuedToBanks" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="WarrantsIssuedToBanks" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to WarrantsIssuedToBanks" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:label="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:title="TransferOfRealizedLossIntoEquityFromSaleOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="TransferOfRealizedLossIntoEquityFromSaleOfShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to TransferOfRealizedLossIntoEquityFromSaleOfShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding_2" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="CommonStockSharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to CommonStockSharesOutstanding" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AllocatedShareBasedCompensationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ContingentlyIssuableWarrantExpenseToInvestors" xlink:label="ContingentlyIssuableWarrantExpenseToInvestors" xlink:title="ContingentlyIssuableWarrantExpenseToInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ContingentlyIssuableWarrantExpenseToInvestors" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ContingentlyIssuableWarrantExpenseToInvestors" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCostsAndDiscounts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="IncreaseDecreaseInDueToRelatedParties" xlink:title="IncreaseDecreaseInDueToRelatedParties" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDueToRelatedParties" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDueToRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="PaymentsForDeposits" xlink:title="PaymentsForDeposits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsForDeposits" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsForDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:label="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:title="ProceedsFromIssuanceOfCommonSharesAndWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonSharesAndWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonSharesAndWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromDebtNetOfIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="RepaymentsOfDebt" xlink:title="RepaymentsOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfDebt" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="RepaymentsOfLongTermCapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermCapitalLeaseObligations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermCapitalLeaseObligations" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: CashAndCashEquivalentsAbstract to CashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashAndCashEquivalentsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashAndCashEquivalentsAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="ContributionOfProperty" xlink:title="ContributionOfProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="ContributionOfProperty" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to ContributionOfProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="DebtConversionConvertedInstrumentAmount1" xlink:title="DebtConversionConvertedInstrumentAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="DebtConversionConvertedInstrumentAmount1" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to DebtConversionConvertedInstrumentAmount1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:label="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="GainLossOnSaleOfEquityInvestments" xlink:title="GainLossOnSaleOfEquityInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="GainLossOnSaleOfEquityInvestments" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to GainLossOnSaleOfEquityInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponents">
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SelectedBalanceSheetComponentsAbstract" xlink:label="SelectedBalanceSheetComponentsAbstract" xlink:title="SelectedBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LiquidityPolicyTextBlock" xlink:label="LiquidityPolicyTextBlock" xlink:title="LiquidityPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="LiquidityPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to LiquidityPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ReverseStockSplitPolicyTextBlock" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:title="ReverseStockSplitPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ReverseStockSplitPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_GoingConcernAssessmentPolicyTextBlock" xlink:label="GoingConcernAssessmentPolicyTextBlock" xlink:title="GoingConcernAssessmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoingConcernAssessmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to GoingConcernAssessmentPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to FairValueMeasurementPolicyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:label="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:title="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="MarketableSecuritiesAvailableForSaleSecuritiesPolicy" xlink:title="presentation: AccountingPoliciesAbstract to MarketableSecuritiesAvailableForSaleSecuritiesPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="IntangibleAssetsFiniteLivedPolicy" xlink:title="IntangibleAssetsFiniteLivedPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IntangibleAssetsFiniteLivedPolicy" xlink:title="presentation: AccountingPoliciesAbstract to IntangibleAssetsFiniteLivedPolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AccountingForWarrantsPolicyTextBlock" xlink:label="AccountingForWarrantsPolicyTextBlock" xlink:title="AccountingForWarrantsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AccountingForWarrantsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to AccountingForWarrantsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SalesAndMarketingCostsPolicyTextBlock" xlink:label="SalesAndMarketingCostsPolicyTextBlock" xlink:title="SalesAndMarketingCostsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SalesAndMarketingCostsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SalesAndMarketingCostsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SegmentReportingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SegmentReportingPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PriorPeriodReclassificationAdjustmentDescription" xlink:title="presentation: AccountingPoliciesAbstract to PriorPeriodReclassificationAdjustmentDescription" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponentsTables">
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SelectedBalanceSheetComponentsAbstract" xlink:label="SelectedBalanceSheetComponentsAbstract" xlink:title="SelectedBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to PropertyPlantAndEquipmentTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:title="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="presentation: ConsolidatedEntitiesDomain to ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorTwoMember" xlink:label="InvestorTwoMember" xlink:title="InvestorTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorTwoMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEquityMethodInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="ScheduleOfEquityMethodInvestmentsTable" xlink:title="ScheduleOfEquityMethodInvestmentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="presentation: ConsolidatedEntitiesDomain to ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="ScheduleOfEquityMethodInvestmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsLineItems to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentsTable" xlink:to="ScheduleOfEquityMethodInvestmentsLineItems" xlink:title="presentation: ScheduleOfEquityMethodInvestmentsTable to ScheduleOfEquityMethodInvestmentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfEquityMethodInvestmentsTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfEquityMethodInvestmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: ReverseStockSplitAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReverseStockSplitAbstract" xlink:title="presentation: AccountingPoliciesAbstract to ReverseStockSplitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="CashAndCashEquivalentsAbstract" xlink:title="CashAndCashEquivalentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAbstract" xlink:to="Cash" xlink:title="presentation: CashAndCashEquivalentsAbstract to Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsAbstract" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: SubsidiarySaleOfStockLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="GainLossOnSaleOfEquityInvestments" xlink:title="GainLossOnSaleOfEquityInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="GainLossOnSaleOfEquityInvestments" xlink:title="presentation: SubsidiarySaleOfStockLineItems to GainLossOnSaleOfEquityInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:title="CommonStockSharesHeldAsAvailableForSaleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:title="presentation: SubsidiarySaleOfStockLineItems to CommonStockSharesHeldAsAvailableForSaleSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesEquitySecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="AvailableForSaleSecuritiesEquitySecuritiesCurrent" xlink:title="presentation: SubsidiarySaleOfStockLineItems to AvailableForSaleSecuritiesEquitySecuritiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockLineItems" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="presentation: AccountingPoliciesAbstract to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="FiniteLivedIntangibleAssetsMember" xlink:title="FiniteLivedIntangibleAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="FiniteLivedIntangibleAssetsMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to FiniteLivedIntangibleAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="presentation: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FairValueByAssetClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FairValueByAssetClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EquipmentAndFurnitureMember" xlink:label="EquipmentAndFurnitureMember" xlink:title="EquipmentAndFurnitureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentAndFurnitureMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentAndFurnitureMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: AssetImpairmentChargesAbstract to AssetImpairmentCharges" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AssetImpairmentChargesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureTable" xlink:label="IncomeTaxDisclosureTable" xlink:title="IncomeTaxDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="ScenarioPlanMember" xlink:title="ScenarioPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioPlanMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioPlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: IncomeTaxDisclosureTable to StatementScenarioAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureLineItems" xlink:label="IncomeTaxDisclosureLineItems" xlink:title="IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxDisclosureLineItems to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureTable" xlink:to="IncomeTaxDisclosureLineItems" xlink:title="presentation: IncomeTaxDisclosureTable to IncomeTaxDisclosureLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="EarningsPerShareBasicAndDilutedAbstract" xlink:title="EarningsPerShareBasicAndDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAndDilutedAbstract" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: EarningsPerShareBasicAndDilutedAbstract to EarningsPerShareBasicAndDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerShareBasicAndDilutedAbstract" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerShareBasicAndDilutedAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SegmentReportingAbstract" xlink:title="presentation: AccountingPoliciesAbstract to SegmentReportingAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails">
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SelectedBalanceSheetComponentsAbstract" xlink:label="SelectedBalanceSheetComponentsAbstract" xlink:title="SelectedBalanceSheetComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: AccountsPayableAndAccruedLiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccountsPayableAndAccruedLiabilitiesCurrentAbstract to AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="presentation: AccountsPayableAndAccruedLiabilitiesCurrentAbstract to AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="presentation: ConsolidatedEntitiesDomain to ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to FiniteLivedIntangibleAssetsNetAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to PropertyPlantAndEquipmentNetAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="Depreciation" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to Depreciation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedBalanceSheetComponentsAbstract" xlink:to="CapitalLeaseObligations" xlink:title="presentation: SelectedBalanceSheetComponentsAbstract to CapitalLeaseObligations" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="presentation: ConsolidatedEntitiesDomain to ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="SellingAndMarketingExpenseMember" xlink:title="SellingAndMarketingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingAndMarketingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingAndMarketingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CurrentLiabilitiesMember" xlink:label="CurrentLiabilitiesMember" xlink:title="CurrentLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationDomain" xlink:to="CurrentLiabilitiesMember" xlink:title="presentation: BalanceSheetLocationDomain to CurrentLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="presentation: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="BalanceSheetLocationAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to BalanceSheetLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SharedFacilitiesAndServiceAgreementAbstract" xlink:label="SharedFacilitiesAndServiceAgreementAbstract" xlink:title="SharedFacilitiesAndServiceAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfMarkupFeeAllocatedButNotCharged" xlink:label="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:title="PercentageOfMarkupFeeAllocatedButNotCharged" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="PercentageOfMarkupFeeAllocatedButNotCharged" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to PercentageOfMarkupFeeAllocatedButNotCharged" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TermOfPayment" xlink:label="TermOfPayment" xlink:title="TermOfPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="TermOfPayment" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to TermOfPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InterestOnUnpaidOverdueInvoice" xlink:label="InterestOnUnpaidOverdueInvoice" xlink:title="InterestOnUnpaidOverdueInvoice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="InterestOnUnpaidOverdueInvoice" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to InterestOnUnpaidOverdueInvoice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeeExpense" xlink:label="AllocatedServicesAndFacilityUseFeeExpense" xlink:title="AllocatedServicesAndFacilityUseFeeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="AllocatedServicesAndFacilityUseFeeExpense" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to AllocatedServicesAndFacilityUseFeeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AllocatedServicesAndFacilityUseFeePayable" xlink:label="AllocatedServicesAndFacilityUseFeePayable" xlink:title="AllocatedServicesAndFacilityUseFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="AllocatedServicesAndFacilityUseFeePayable" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to AllocatedServicesAndFacilityUseFeePayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MinimumFixedPaymentDueSharedFacilityAgreement" xlink:label="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:title="MinimumFixedPaymentDueSharedFacilityAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharedFacilitiesAndServiceAgreementAbstract" xlink:to="MinimumFixedPaymentDueSharedFacilityAgreement" xlink:title="presentation: SharedFacilitiesAndServiceAgreementAbstract to MinimumFixedPaymentDueSharedFacilityAgreement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharedFacilitiesAndServiceAgreementAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to SharedFacilitiesAndServiceAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementMember" xlink:label="LoanAndSecurityAgreementMember" xlink:title="LoanAndSecurityAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="LoanAndSecurityAgreementMember" xlink:title="presentation: DebtInstrumentNameDomain to LoanAndSecurityAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="presentation: VariableRateDomain to PrimeRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: DebtInstrumentTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_LoanAndSecurityAgreementAbstract" xlink:label="LoanAndSecurityAgreementAbstract" xlink:title="LoanAndSecurityAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentFrequencyOfPeriodicPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentPeriodicPayment" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentPeriodicPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentInterestRateStatedPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="DebtInstrumentInterestRateDuringPeriod" xlink:title="DebtInstrumentInterestRateDuringPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtInstrumentInterestRateDuringPeriod" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtInstrumentInterestRateDuringPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AdditionalFinalPaymentFeePercentage" xlink:label="AdditionalFinalPaymentFeePercentage" xlink:title="AdditionalFinalPaymentFeePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="AdditionalFinalPaymentFeePercentage" xlink:title="presentation: LoanAndSecurityAgreementAbstract to AdditionalFinalPaymentFeePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="AmortizationOfFinancingCosts" xlink:title="presentation: LoanAndSecurityAgreementAbstract to AmortizationOfFinancingCosts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:label="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:title="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" xlink:title="presentation: LoanAndSecurityAgreementAbstract to PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:label="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:title="PrepaymentFeeIfPrepaidTwoYearsOrMore" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="PrepaymentFeeIfPrepaidTwoYearsOrMore" xlink:title="presentation: LoanAndSecurityAgreementAbstract to PrepaymentFeeIfPrepaidTwoYearsOrMore" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="LongTermDebtPercentageBearingFixedInterestRate" xlink:title="LongTermDebtPercentageBearingFixedInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="LongTermDebtPercentageBearingFixedInterestRate" xlink:title="presentation: LoanAndSecurityAgreementAbstract to LongTermDebtPercentageBearingFixedInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtDefaultLegalActionAmount" xlink:label="DebtDefaultLegalActionAmount" xlink:title="DebtDefaultLegalActionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LoanAndSecurityAgreementAbstract" xlink:to="DebtDefaultLegalActionAmount" xlink:title="presentation: LoanAndSecurityAgreementAbstract to DebtDefaultLegalActionAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LoanAndSecurityAgreementAbstract" xlink:title="presentation: DebtInstrumentLineItems to LoanAndSecurityAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightBankWarrantsAbstract" xlink:label="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:title="ClassOfWarrantOrRightBankWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: ClassOfWarrantOrRightBankWarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: ClassOfWarrantOrRightBankWarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="DeferredFinanceCostsNet" xlink:title="DeferredFinanceCostsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="DeferredFinanceCostsNet" xlink:title="presentation: ClassOfWarrantOrRightBankWarrantsAbstract to DeferredFinanceCostsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: ClassOfWarrantOrRightBankWarrantsAbstract to PaymentsOfDebtIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightBankWarrantsAbstract" xlink:title="presentation: DebtInstrumentLineItems to ClassOfWarrantOrRightBankWarrantsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FutureCashPaymentsOfLoanPayableAbstract" xlink:label="FutureCashPaymentsOfLoanPayableAbstract" xlink:title="FutureCashPaymentsOfLoanPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to DebtInstrumentCarryingAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentInterest" xlink:label="DebtInstrumentInterest" xlink:title="DebtInstrumentInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="DebtInstrumentInterest" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to DebtInstrumentInterest" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:label="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="UnamortizedDebtIssuanceExpense" xlink:title="UnamortizedDebtIssuanceExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="UnamortizedDebtIssuanceExpense" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to UnamortizedDebtIssuanceExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FutureCashPaymentsOfLoanPayableAbstract" xlink:to="LongTermDebt" xlink:title="presentation: FutureCashPaymentsOfLoanPayableAbstract to LongTermDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FutureCashPaymentsOfLoanPayableAbstract" xlink:title="presentation: DebtInstrumentLineItems to FutureCashPaymentsOfLoanPayableAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="PreferredStockNoParValue" xlink:title="PreferredStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockNoParValue" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockNoParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="CommonStockNoParValue" xlink:title="CommonStockNoParValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockNoParValue" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockNoParValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommonStockVotesPerShare" xlink:label="CommonStockVotesPerShare" xlink:title="CommonStockVotesPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockVotesPerShare" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockVotesPerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IssuanceOfCommonStockAndWarrantsAbstract" xlink:label="IssuanceOfCommonStockAndWarrantsAbstract" xlink:title="IssuanceOfCommonStockAndWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IssuanceOfSeparableUnits" xlink:label="IssuanceOfSeparableUnits" xlink:title="IssuanceOfSeparableUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="IssuanceOfSeparableUnits" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to IssuanceOfSeparableUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:label="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:title="NumberOfCommonStockSharesAvailableInEachSeparableUnit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="NumberOfCommonStockSharesAvailableInEachSeparableUnit" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to NumberOfCommonStockSharesAvailableInEachSeparableUnit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfWarrantsAvailableInEachSeparableUnit" xlink:label="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:title="NumberOfWarrantsAvailableInEachSeparableUnit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="NumberOfWarrantsAvailableInEachSeparableUnit" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to NumberOfWarrantsAvailableInEachSeparableUnit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SeparableUnitsExercisePrice" xlink:label="SeparableUnitsExercisePrice" xlink:title="SeparableUnitsExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="SeparableUnitsExercisePrice" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to SeparableUnitsExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to EquityMethodInvestmentOwnershipPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="SaleOfStockConsiderationReceivedOnTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonStockAndWarrantsAbstract" xlink:to="SaleOfStockConsiderationReceivedOnTransaction" xlink:title="presentation: IssuanceOfCommonStockAndWarrantsAbstract to SaleOfStockConsiderationReceivedOnTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="IssuanceOfCommonStockAndWarrantsAbstract" xlink:title="presentation: EquityAbstract to IssuanceOfCommonStockAndWarrantsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016Member" xlink:label="Warrants2016Member" xlink:title="Warrants2016Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="Warrants2016Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to Warrants2016Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NewWarrantsMember" xlink:label="NewWarrantsMember" xlink:title="NewWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="NewWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to NewWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FirstFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to FirstFormWarrantExerciseAgreement2016WarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to FirstFormWarrantExerciseAgreementJuly2017WarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SecondFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SecondFormWarrantExerciseAgreement2016WarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:label="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SecondFormWarrantExerciseAgreementJuly2017WarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:label="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="ThirdFormWarrantExerciseAgreement2016WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormWarrantExerciseAgreement2016WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to ThirdFormWarrantExerciseAgreement2016WarrantsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormPart1WarrantExerciseAgreementJuly212017Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to ThirdFormPart1WarrantExerciseAgreementJuly212017Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:label="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:title="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="ThirdFormPart2WarrantExerciseAgreementJuly212017Member" xlink:title="presentation: ClassOfWarrantOrRightDomain to ThirdFormPart2WarrantExerciseAgreementJuly212017Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_July2017WarrantsMember" xlink:label="July2017WarrantsMember" xlink:title="July2017WarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="July2017WarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to July2017WarrantsMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsGroupOneMember" xlink:label="InvestorsGroupOneMember" xlink:title="InvestorsGroupOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorsGroupOneMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorsGroupOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfStockByClassTable to TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_Warrants2016AndNewWarrantsAbstract" xlink:label="Warrants2016AndNewWarrantsAbstract" xlink:title="Warrants2016AndNewWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfWarrantHolders" xlink:label="NumberOfWarrantHolders" xlink:title="NumberOfWarrantHolders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="NumberOfWarrantHolders" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to NumberOfWarrantHolders" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightExercisedPeriod" xlink:label="ClassOfWarrantOrRightExercisedPeriod" xlink:title="ClassOfWarrantOrRightExercisedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisedPeriod" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightExercisedPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:label="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:title="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfFormsInWarrantExerciseAgreement" xlink:label="NumberOfFormsInWarrantExerciseAgreement" xlink:title="NumberOfFormsInWarrantExerciseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="NumberOfFormsInWarrantExerciseAgreement" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to NumberOfFormsInWarrantExerciseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="ClassOfWarrantOrRightUnissued" xlink:title="ClassOfWarrantOrRightUnissued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightUnissued" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightUnissued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Warrants2016AndNewWarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: Warrants2016AndNewWarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="Warrants2016AndNewWarrantsAbstract" xlink:title="presentation: ClassOfStockLineItems to Warrants2016AndNewWarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockOptionExercisesAbstract" xlink:label="StockOptionExercisesAbstract" xlink:title="StockOptionExercisesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionExercisesAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: StockOptionExercisesAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionExercisesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: StockOptionExercisesAbstract to ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockOptionExercisesAbstract" xlink:title="presentation: ClassOfStockLineItems to StockOptionExercisesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="SellingAndMarketingExpenseMember" xlink:title="SellingAndMarketingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingAndMarketingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingAndMarketingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EquityMethodInvestmentOwnershipPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairMarketValueOfCommonStock" xlink:label="PercentageOfFairMarketValueOfCommonStock" xlink:title="PercentageOfFairMarketValueOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfFairMarketValueOfCommonStock" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfFairMarketValueOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodOfNontransferableForStockOptionGrants" xlink:label="PeriodOfNontransferableForStockOptionGrants" xlink:title="PeriodOfNontransferableForStockOptionGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodOfNontransferableForStockOptionGrants" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodOfNontransferableForStockOptionGrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodForExercisingVestedOption" xlink:label="PeriodForExercisingVestedOption" xlink:title="PeriodForExercisingVestedOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodForExercisingVestedOption" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodForExercisingVestedOption" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:label="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:title="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="DeferredTaxLiabilitiesInvestments" xlink:title="DeferredTaxLiabilitiesInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesInvestments" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredIncomeTaxLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_DeferredTaxAssetsPatentsAndFixedAssets" xlink:label="DeferredTaxAssetsPatentsAndFixedAssets" xlink:title="DeferredTaxAssetsPatentsAndFixedAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsPatentsAndFixedAssets" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsPatentsAndFixedAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsGrossAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsGrossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureTable" xlink:label="IncomeTaxDisclosureTable" xlink:title="IncomeTaxDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="ScenarioPlanMember" xlink:title="ScenarioPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioPlanMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioPlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: IncomeTaxDisclosureTable to StatementScenarioAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_IncomeTaxDisclosureLineItems" xlink:label="IncomeTaxDisclosureLineItems" xlink:title="IncomeTaxDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureLineItems" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureLineItems to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureTable" xlink:to="IncomeTaxDisclosureLineItems" xlink:title="presentation: IncomeTaxDisclosureTable to IncomeTaxDisclosureLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="presentation: IncomeTaxAuthorityDomain to DomesticCountryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsExpirationDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to ResearchMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="presentation: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="RangeAxis" xlink:title="presentation: TaxCreditCarryforwardTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountFederal" xlink:label="TaxCreditCarryforwardAmountFederal" xlink:title="TaxCreditCarryforwardAmountFederal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmountFederal" xlink:title="presentation: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmountFederal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardAmountState" xlink:label="TaxCreditCarryforwardAmountState" xlink:title="TaxCreditCarryforwardAmountState" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmountState" xlink:title="presentation: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmountState" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_TaxCreditCarryforwardExpirationDateFederal" xlink:label="TaxCreditCarryforwardExpirationDateFederal" xlink:title="TaxCreditCarryforwardExpirationDateFederal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardExpirationDateFederal" xlink:title="presentation: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardExpirationDateFederal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardLineItems" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxCreditCarryforwardTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxCreditCarryforwardTable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="ParentCompanyMember" xlink:title="ParentCompanyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="ParentCompanyMember" xlink:title="presentation: ConsolidatedEntitiesDomain to ParentCompanyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfStockByClassTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="presentation: ClassOfStockLineItems to CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorsTaxableGainLoss" xlink:label="InvestorsTaxableGainLoss" xlink:title="InvestorsTaxableGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="InvestorsTaxableGainLoss" xlink:title="presentation: ClassOfStockLineItems to InvestorsTaxableGainLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfStockByClassTable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="presentation: IncomeTaxDisclosureAbstract to ValuationAllowanceDeferredTaxAssetChangeInAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfChangeInOwnership" xlink:label="PercentageOfChangeInOwnership" xlink:title="PercentageOfChangeInOwnership" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="PercentageOfChangeInOwnership" xlink:title="presentation: IncomeTaxDisclosureAbstract to PercentageOfChangeInOwnership" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:label="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:title="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" xlink:title="presentation: IncomeTaxDisclosureAbstract to PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="presentation: OtherCommitmentsTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="LeaseArrangementTypeAxis" xlink:title="LeaseArrangementTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="LeaseArrangementTypeDomain" xlink:title="LeaseArrangementTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MasterLeaseLineAgreementMember" xlink:label="MasterLeaseLineAgreementMember" xlink:title="MasterLeaseLineAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseArrangementTypeDomain" xlink:to="MasterLeaseLineAgreementMember" xlink:title="presentation: LeaseArrangementTypeDomain to MasterLeaseLineAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseArrangementTypeAxis" xlink:to="LeaseArrangementTypeDomain" xlink:title="presentation: LeaseArrangementTypeAxis to LeaseArrangementTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="LeaseArrangementTypeAxis" xlink:title="presentation: OtherCommitmentsTable to LeaseArrangementTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="CapitalLeaseObligations" xlink:title="CapitalLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="CapitalLeaseObligations" xlink:title="presentation: OtherCommitmentsAbstract to CapitalLeaseObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="CapitalLeaseObligationsIncurred" xlink:title="CapitalLeaseObligationsIncurred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="CapitalLeaseObligationsIncurred" xlink:title="presentation: OtherCommitmentsAbstract to CapitalLeaseObligationsIncurred" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeasePaymentTerm" xlink:label="CapitalLeasePaymentTerm" xlink:title="CapitalLeasePaymentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="CapitalLeasePaymentTerm" xlink:title="presentation: OtherCommitmentsAbstract to CapitalLeasePaymentTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:title="CapitalLeaseAgreementImputedAnnualInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="CapitalLeaseAgreementImputedAnnualInterestRate" xlink:title="presentation: OtherCommitmentsAbstract to CapitalLeaseAgreementImputedAnnualInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:label="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:title="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" xlink:title="presentation: OtherCommitmentsAbstract to PercentageOfRestockingFeePaidOnOriginalCostOfEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:label="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:title="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" xlink:title="presentation: OtherCommitmentsAbstract to PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="presentation: OtherCommitmentsAbstract to CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_AmountAvailableUnderCapitalLeaseAgreement" xlink:label="AmountAvailableUnderCapitalLeaseAgreement" xlink:title="AmountAvailableUnderCapitalLeaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="AmountAvailableUnderCapitalLeaseAgreement" xlink:title="presentation: OtherCommitmentsAbstract to AmountAvailableUnderCapitalLeaseAgreement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="presentation: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsLineItems" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="OtherCommitmentsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to OtherCommitmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:label="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:title="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:title="CapitalLeasesFutureMinimumPaymentsDueCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="CapitalLeasesFutureMinimumPaymentsDue" xlink:title="CapitalLeasesFutureMinimumPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsDue" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:title="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:title="presentation: CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract to CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementMember" xlink:label="WistarLicenseAgreementMember" xlink:title="WistarLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="WistarLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to WistarLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_WistarLicenseAgreementAbstract" xlink:label="WistarLicenseAgreementAbstract" xlink:title="WistarLicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WistarLicenseAgreementAbstract" xlink:to="RoyaltyPercentage" xlink:title="presentation: WistarLicenseAgreementAbstract to RoyaltyPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_MaximumReductionInRoyaltyPayments" xlink:label="MaximumReductionInRoyaltyPayments" xlink:title="MaximumReductionInRoyaltyPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WistarLicenseAgreementAbstract" xlink:to="MaximumReductionInRoyaltyPayments" xlink:title="presentation: WistarLicenseAgreementAbstract to MaximumReductionInRoyaltyPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:label="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:title="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WistarLicenseAgreementAbstract" xlink:to="CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" xlink:title="presentation: WistarLicenseAgreementAbstract to CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="WistarLicenseAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to WistarLicenseAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_InvestorTwoMember" xlink:label="InvestorTwoMember" xlink:title="InvestorTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="InvestorTwoMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to InvestorTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: SubsequentEventTable to TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_BroadwoodPartnersLPMember" xlink:label="BroadwoodPartnersLPMember" xlink:title="BroadwoodPartnersLPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="BroadwoodPartnersLPMember" xlink:title="presentation: RelatedPartyDomain to BroadwoodPartnersLPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: SubsequentEventTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="presentation: SubsequentEventTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfAccreditedInvestors" xlink:title="presentation: SubsequentEventLineItems to NumberOfAccreditedInvestors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocx-20171231.xsd#ocx_StockIssuedDuringPeriodSharesPrivatePlacement" xlink:label="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="StockIssuedDuringPeriodSharesPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="StockIssuedDuringPeriodSharesPrivatePlacement" xlink:title="presentation: SubsequentEventLineItems to StockIssuedDuringPeriodSharesPrivatePlacement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SharePrice" xlink:title="presentation: SubsequentEventLineItems to SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: SubsequentEventLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:title="MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:title="presentation: SubsequentEventLineItems to MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0U!WP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3ZE9VXS+<1K_ ,"H M452M]6L;G_ %5S&?QQ5M9$?[KJWT.: '4444 %%%%
M!1110 45$]S!']^:-?JPJFVNZ:C[&ND#?6@#1HJM'J%I*/DN(S_P(5.'5AE6
M!^AH =10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBD)]J %HJ-KB%#AI8U/H6 I%N(7^[*A^C T 2T444 %%%% !144MQ%"N97"
M?4U$-1LVQBXC.?\ :H M44T$GD$%:=0 4444 %%%% !1110 4444 %%(?7)X
MKE;SX@:/97C6LOF^8IQPM '5T55T^_BU*T6YA!V-TS5J@ HHHH **** "BBN
M<UKQIIFAR^7=>9NSCY10!T=%4=*U2WUBQ6[MB?+;ID5= QWS0 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A(
M523T%+2''>@#AM=\=7-K?/8:;82S3K_%L)%8,]MXMUZUDNKV5;2!02$<%2:]
M3\F%7WB)=Q[XJKJ^?[,GQC[AZ_2@#PS0Y)EUX0M(QPV"=QP>:]ZLO^/*'_=K
MP31_^1J8Y_Y:'C\:]\LO^/*'_=H GJ"[NDM+5YW^Z@R:GKA_B%J$UI:+%&V$
M<?,* .;UOQEJVLWZZ?I+*B.VTD#D"M6R^&0N%$NIZA<F4]0C\5S_ ,,+:"?Q
M)<,0Q*ID9Z5[/0!P-S\+M/\ ))M[V\64#@[ZY"75-?\ !FIK:M.LD.>K<\5[
M9GG&#7GWQ%L('M&NV'SJ./RH ZKP]K<6M6(D4@R ?/BM&[NDM;:29B,(,FO+
MOA3<%)KJ/><.1Q70_$+4VL[#R5./-&* .8UGQ9JVNZF;#3FV1DX# 5JZ?\,1
M<1++JE_=-,>NUZSOA5:QS7-VTOS,G(S7K5 'GM[\+[7RB;._NTD XR_%<HVI
M:_X+U1+5YQ-&6ZOSQ7MA..U>=?$JS4VC76#N7O0!VVCZI%JMBD\9R=HW8]:T
M*\V^&5X5L6@9\Y/0_4UZ30 444R218HR['"CK0!2U75K?2K5III%& < FO,;
MGQOXBUN\>VT@8C)QF-,G%9/C/4+B_P#$DD/F[K4G"J/K7I?@K1K>PT:&01 3
M$<MWH Y6V\ :IJSK/JE],I/) ;!K6_X59I[ !M3OS[;A_A7>D@#)Z"J#ZUID
M9(>^@4CJ"XH XV3X7VT!#V.H7:N/[[\53MM)\9:/J<:BX2>U+=AD@>]=Y_;^
MD?\ 01MO^_@IR:UIDK!([^!F/0!Q0!;@,C0J90 ^.<5)31C&5.35#5M6@TBR
M:>Y8#@XYH T-P(SD8I#(@ZNH_&O)[?7?$GB[4Y(=/G6WLP>"%K>7X?S72@W^
MJ7);K\C 4 =UO4_Q#\Z=7FVJ>%-=TN$S:9J4TBKT1L$_RJ/PIXZOGU5=*U8*
M')P&QC'UH ]-I"Z@X+ ?C2!MP#(05/>O)?'E_<6>MYCGD7G@ T >MY!Z$4A=
M!U91^->1Z9XE\4ZI"MCIR;&'_+9TY-;B^"-9O(O-O]7E^TMU\L@#^5 'H(=3
MT8'\:6O(=:TWQ'X4B-S!?R2P(>=PS74^"O&#ZW ([K FZ=,4 =K103@9K@?%
M?C[^S)/LVGA9)CP>Y% '>EE'5@/J:;YL?_/1?SKS31])\1^)HS>:A?M# _W%
M08-:;?#E%S)%J5WYW;+\4 =UD'H12@@]*\AO-2\2^$;\I<7?FVJGAF'45W?A
M;Q1!X@M-X91(."!WH Z.BBB@ J*X8K"Q'85+4-U_Q[/CTH \)\4RS7/BB6.2
MXD",< (Q'<TB+J7AJZ26&4B/()9V)!%-\3+GQ/G/S!Q_.O2KG08?$'A2,2J0
MR)N'8]* -;PKX@CU[31*N0R !L]S6\3@=*\+\/:G=>&_$R13,R6@<KM(Z\U[
MC!,L\*2(00P!H D'(J&ZN4M+=YI#A5&34I.!DUY;X_\ %KNXT[3V+%OED &3
M0!D^(-7U'Q/K_P!FM)G%HK8!3M6%?6]QI&N1VZW+OAQU;WKT?P)X?73=!:[9
M6$TX^8..E>?>) Q\5@$G(D'\Z /<='+'38=W)VCD?2K]4-&;=I<!/]T?RJ34
M;Z+3K*2YF8*JCN: +=-,B#JZCZFO(Y_&OB77;YK32?*A4L0&*_A6O!X'UC48
MP^K:FY8]HVQ0!Z+YB'HZ_G2Y&.M>=S> =2MT)LM3E##IN;-8,7BKQ%X9U,V>
MI9EA!QO*]: /8\YHK,T;6+?5[)+B)Q\W\.:-<UF#1K%IYB.AVY]: -+(]:8T
M\2_>D0?C7C4WBWQ'XAO38V#Q1*[8"QC)(KH;3X?:@VVZN=2E6YQGY6XH ]%W
MJZ$JP(QV->"Z^H/B&X.Y"=_ !KK;BS\6^&'>>*X^UP'JNW-<%/>2W&J/+-$4
ME=LL,8H ]M\&9_X1Z'/^>!705@>#\_\ "/PY_P \5?U?5K?2+-I[A@!@XR:
M+X92,@BD,B#JZC\:\JC\0Z_XOU9K72YUM[1>K!>M;2_#^:[7-_JER6/78P%
M'=[T/1E_.G5YMJGA/7-)@\W2=1FD5!PC8)_E57P[\0+^/4H]-U5 6+;=VW&/
MK0!ZG7C_ ,20GVELCYL\?G7KP;> R$%3WKR#XD_\?A_WOZT =M\/0?\ A$[?
M)Y_^L*ZNN6^'_P#R*L'&/_U"NIH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI.0<D\4 ! /6J.L _V7/@=$
M/\J@N_$VCV,QBN;^*.0=4+<C\*S-3\6:'/ITR1ZC$6*D  ^U 'DVC$'Q2V$(
M/F'^=>]V?_'G%_NUX!IDL47B)IY9]L1<G?CCK7L=MXOT"*UC5M2BX7!.: .C
MKSWXF6IF@ADWX"#IZ]:[:QU6QU)2UG<),!UVG-5]<TJ/5=.EB,:M(1A21TH
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MG/X^PKJ: .<\;HLGAJ<,,BO-? <C'Q)&N?E!Z#ZUZ9XU('ANXR<5YCX!8?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^0='_P!]4?;_ !%G_D'1_P#?5 '1T5SGV_Q'C_D'1_\ ?5'V_P 19_Y!T?\
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M5A:0',5M$A]54"IR#C XKC+KQ1K=G<QP2Z8FZ3IANE:,>HZ_)&'&G)@]/FH
MZ%00.3DTI&:YQK_Q)GY=.CQ_O4OV_P 18_Y!T?\ WU0!LW.G6=WS/;12'_;0
M&HTT?38_N6-NOTC%97V_Q%G_ )!T?_?5'V_Q%C_D'1_]]4 =!'$L8PH 'H!3
M@#W.:YW[?XBS_P @Z/\ [ZH^W^(O^@='_P!]4 ='3)(HY5Q(BL/0BN?^W^(O
M^@='_P!]4?;_ !%_T#H_^^J -I=.LT;<MK$&]0@J<+@=:Y[[?XBQ_P @Z/\
M[ZH^W^(L_P#(.C_[ZH Z(#N>32/&DB[74,OH17/?;_$6/^0='_WU1]O\19_Y
M!T?_ 'U0!LC3[1'$B6T2N.C!!D4Z2RMIA^\@C<_[2@UB?;_$7_0.C_[ZH^W^
M(O\ H'1_]]4 ;T4"01A(E5%'91@5(1FN=^W^(O\ H'1_]]57O]<UVPM1(^G(
M6_WJ .H9%D^5T#+[U4?1=,E.7L+=C[QBL&QUW7[VU69-,CY[;JL?;_$><?V;
M']=U &[!9VUL,001QCT5<5/@5SGV_P 19_Y!T?\ WU1]O\1?] Z/_OJ@#?>%
M)05E574]F%5?['TT,&^PV^1T/EBLK[?XB_Z!T?\ WU1]O\1?] Z/_OJ@#=-K
M"R;&C0Q]EV\4D5G;0-NB@C0^JKBL/[?XBQ_R#H_^^J/M_B+/_(.C_P"^J .C
MHKG/M_B+'_(.C_[ZH^W^(L_\@Z/_ +ZH Z+G/6EKG/M_B+_H'1_]]4?;_$7_
M $#H_P#OJ@#HB">AJM/IME<G,]K#(?\ :0&L;[?XB_Z!T?\ WU1]O\18_P"0
M='_WU0!L0Z98V_\ J;2&/_=0"K?08%<Y]O\ $6?^0='_ -]4?;_$>/\ D'1_
M]]4 =!)$DJ[9$5E]"*BBL;6%]T5O&C>JJ!6-]O\ $(7/]G1D^FZLN?Q1KEM=
M)!)I:9?I\U ':U!/96MT,3V\<@_VU!K#CU'Q!(FX:<G/3YJ/M_B+_H'1_P#?
M5 &K'HVF1-NCL+=6]1&!5W: NT# ]*YW[?XBQ_R#H_\ OJC[?XBS_P @Z/\
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MCTQ  <?>H Z^BN<^W^(\?\@Z/_OJC[?XBS_R#H_^^J .CHKG/M_B+_H'1_\
M?5'V_P 1?] Z/_OJ@#HZ*YS[?XBS_P @Z/\ [ZH^W^(L?\@Z/_OJ@#HZ*YW[
M?XBS_P @Z/\ [ZI/M_B+'_(.C_[ZH Z.BN<^W^(L_P#(.C_[ZH^W^(O^@='_
M -]4 ='17.?;_$7_ $#H_P#OJC[?XBS_ ,@Z/_OJ@#HZ*YS[?XBQ_P @Z/\
M[ZH^W^(O^@='_P!]4TK@=%2USIO_ !#C_D'1_P#?5(+_ ,18R=.C^FZDU;=@
M='17$WWBK6["XCBETQ"9#@8:M--2\021AUTZ/!_VJ46I; ='17.?;_$7)_LZ
M/_OJA;_Q$1_R#HQ_P*GZ@='17.?;_$>?^0='_P!]4IOO$7;3H_\ OJE<1T5%
M<[]N\18_Y!T?_?5)]O\ $?\ T#H_^^J+A<Z.BN<^W^(_^@='_P!]4OV[Q%C_
M )!T?_?5%P.BHKG1?>(N^G1_]]4GV_Q'G_D'1_\ ?5%QG1T5SIOO$7;3H_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSKN*XGQ)C^V+3_>_QK)W>P]$=C:_\>Z\8XJ:H;;_ (]U^E358!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Q7B$?\5'!V.VNNL_^/6/Z5R'B
M'_D8X,]-M=?9X^RQX]* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "C
MJ**1C@4    P*6D7..:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M3 SFEIA;##F@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =12
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M ]*/[5I_\^(_<')+N>%'Q7\3 ?\ D'7'_?L_X4'Q7\3,_P#(,N?^_9_PKW7
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M8\H@I:3G/6EKSDK(L****8!1110 4444 %%%% !1110 4444 %%%(2!UH
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M* "BBB@ HHHH 0C(Z9H7@=,4'I0IR,YH 6BBB@ HHHH **** "BBB@ HHHH
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M10 4TCYP>:=29 .* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ -BBH;>YANHQ)#(KJ>ZFI=P]: %HI-P]12T %%&<4W>N<;A0 ZBD!!Z&EH
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M%.KY)FX444F1ZT %+2;E]12]: "BBDW#U% "T4FX'O2T %%(6 ."0*-P]10
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M72GQ#I8.#>1 ^FZN/US4+*[UFT$4ZL=W8_6@#OK48MT'M4U0VHQ;H,YXJ:@
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MH'P-T_/_ !_/^M>MT4?VQC/Y_P $'LX]CR3_ (4;8?\ /^_ZT?\ "C=/P/\
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MG.YQFM'2--ATJP2U@#!%Z;CS5Z@""VMXK6(100I%&!@!1@5,!B@#'?-*<]J
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M+TI:0=* %HHHH **** "BBB@ HHHH **** "N8\=X_X1RYS_ '*Z>N8\=?\
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MC278NI=/MWF'1V0$UJI&D:!$4*HZ "@ 7KTQ3J** "D(R.N*6B@! ,"EHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N&\28_MFTQUW?XUW-<-XD.
M=9M,C #=OQH [.US]G3/I4U0VV/LZXZ8J:@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH XGQ#_R,<!Z_+77V?_'K']*Y'Q!G_A(X,?W:ZZT_
MX]8_I0!/1110 4444 %%%% !1110 4444 %%%% !1110 4C#(X-+10 B@@8-
M+110 4444 %%%% !1110 4444 %%%% !1110 4444 %1L!YH-244 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 AZ&D087K3J* "BBB@ HHHH *
M*** "BBB@ HHICLL:EG8*HZDTM>@#ZYCQW_R+EST^[6RVL::IVM>P@^[5RWC
MC4[";0)HX[V)F*]FKLPE*HZT='N3+8\(\!G'BSH?OC^M?5</^HC_ -T?RKY4
M\"#;XMV@J1N'(/UKZJ@(\B,9_A'\J];/])Q1%)61)112 5\[=W-1K*"ZGTI]
M)WZ4M, JK=V<%Y&T5Q DD;#!!%6J* /,K[X'^%;S4S>1BX@);<8HW^6L'XE^
M%=0TOPK+9:"EP;( ;XDRQ; Z_P Z]KK@_'NH>)M-M7GTB,2*O)4#.: /G3PW
MJ>D:/$T>MZ%)<R \LRMD5UD5]\+-;B,4NF7.FRG_ ):JY&/S-:MO\6K':8?$
M_AM]PX9T49K!\4>)/ FN6+QZ-H=X+QNA9<#^= 'J?P_T#P?I[&31-=DN6;JC
MS!B*Y/XW^,[^TF33+5MB#AB.IKE/AIX(URXUZ&^6WDMK>-LD/D9%>A_&#X?W
MWB".&[L2&:,990O)H \P\%Q>#Y(Q/X@$\\AZKOXK;\16_P /+NS;^R8)[:X4
M$A@QY-4?"?BI?!#_ &37-">2->-VT9].]=/??&+1YD\K1/#;2S'LZ@4 <G\,
MO%>JZ5XJBM-TTED6QM*D\9XKW?XB.+CP5+E2-ZYS^!KF/ &M:]K>I)+=Z$EK
M;=RR@$?I75_$@,WA&XC3AL=AGL: /E[POI"ZWXSCTMY94CE;!,9P:^C[3X.^
M#UL%CFTYI)"/F=Y&R?UKP?X<VT\?Q,M':)RH8Y./I7UO&?W0(% 'Q]X_T.T\
M+^,)K;3/-BAC;Y03TKZ"^&EW=7G@)1OW2&,[23\V=M>*_&*"63QO.ZQ.06Z@
M9]:]F^%BO'X%B\I6^T;>-XQSM% '@OC#3M=M?%,\VIV4]R@DR<JVTC/M6UIO
MBCP,ELL6H^&&5P-K%=W^-=EX@\=^+M U!TO]'%Q;AN7 SE<_2J-Q\3O 6HV^
M-6\/W2SD88(@QF@"II^C?"S5[I6BO[G3V8YVM,% KV..RT.V\*- +LW6GA<%
MO,SQ]:^8=<L[7Q'JR_\ ",Z/<PPG^\*][^&/@V\TWP_/;ZP?,CN ,(2>* .!
MU&U^% O9/.2X\S/S8DJH+?X2?-F.ZX]9*]<E^$7A&>=II=/W.QR?F--_X4[X
M-)R=-!_X&: /(_L_PDV?ZN[_ ._@KM_A[#X)CNKD^'%F%QY9SO?/8UTC?!OP
M6Q_Y!F/^!FMC0_ /A_P[,T^FV?E2L,%MQ- 'S-\2F=O%Z>:&'[W^+ZBOI#X=
MI GAR'R,8V+G!KS+XO\ P\O;N\_M:P4R"/DH%Y/3_"LKP?\ %[_A#K Z=JFD
MSF0< @^E &I^T5][3< =#_6H/@#YR/=8/RG/]*Y/Q5KFI?%?6;:+3]/E18C@
M$\C\:]R^&O@N3PIIN;AU,LJ\J!TH [W..M! (P:\_P#B1X\N_!D=L]O8_:?-
M)SM;I]:I^ ?B9>^+;OR9]*-NN/O!\_TH Y+XK_#*^U#5Y=:TR)Y)#SL STK%
M\)>/_$?@^U;3[W1)W4' /DMFO0_B5J'C?2,W>AR;K4](T7<PKBM&^.%SIH^S
M^)-(>:?^]M /Y4 <WX^\6^)_$EJ\EUI3VMGW+1$<8]Z=\#PW_"3#'3/-7/%W
MC/5?'Y^QZ9HTT-N_'(_"N^^$7PYN?#44EYJ#*9)>44#E: /+?C$93K1WN"N[
M@"O7_@EY)\'0A1\^/F_2LCXL_#2\UN/[=IS!FCY9 O)^E<1X&^(=Q\.H9;+5
M](N?10>* /0OCT$'A.)<@?-_45PGP)+_ -NN!TQ_0U1\:>/+[XA*MIIVGSB,
MMP-N>]>H_"3P-+X>TR*^NXRMRX^92.1Q_P#7H ]47[H^E+7)^-_%5SX6TF2]
M@L#=;/X0V*Y3P'\59_%FH"VFM! Q.,;\D<XH I_'33M=O-/@?34D>V4?O5C!
M)[^E>0^%]7T?1/,37= DF8]RK9KZ#^(>J>)]'M4N-&MQ<Q ?O$ Y_+%>;VGQ
M;L6)A\3^'I PX^1!F@#..J?##74$$VFW&GO_ ,]%;&/SKTCX>Z%X2TR03Z+K
MLERS#_5R3 XX]*\M\4>)? >MVSPZ7H-VMZ?NEACG\Z?\*_!&NR:PMX87MK?(
M(+Y% '<?'U6/AN)@5V^8.<_2O(_ASX5'BC6HK>XFD2T)^;RWP>M>L_'=1%X2
MMXW7<ZL 3^5>/^ -1U?1M5CO["T>Z1#S&O?F@#Z%;X+>#/L1A^P-OQS)YAW$
M^M?/GB;39_!'B8RZ=,R+$^8P6KUZZ^/=O!!Y#Z-=I=@892. :\NGT[7/B'KX
M,5C+#%*_WV4D+0![I%XONV^&ZZB[ 79@#;@.]?.UMK/_  DOB(3>(KJ5H=V6
M"'&:^G%\%D>!DT1G1YUA"!^@S7SY+X8UCX>>(UNKK3S=6R/EB@RI&: .U,/P
MH-CY;6$C/C[Y<YS7G=]?1:%XIBG\+/<QVNX9!R>]>I?\+H\)_9 S>'YQ<8^[
MY2[<_6JND?$#6?$6KHFE>&E6U+ %F48Q^5 'J'@WQ%-J_AQ;FX1@Z( <C&:^
M;?&GB#5_$WB^ZLY;C$<<IC1!QQ7U?8V[G3T66)(F=!N5>QQ7S7\0?AWK6C>(
MI]3L8&GBD<R$Q@G% 'IGA/X/>%3HMO=WMFUQ<2+EBSG@U4UKX%Z5<7/GZ3/)
M9L3D@25A>'/C>-$T^.QU73+DO&,#:*S-?^*>O^);Q$T*RN(>?E)% 'K>D>&C
MX>\+7-IJMZ]Q9B(B0%NV/6O)+FT^$@G8%+G.><2<5ZGX'L?$E_HC+XDG#QS)
MM:,C!Z5(_P (/"$K%I-/#,>IW&@#R3[-\),_ZNZ_[^4?9?A)C[EU_P!_!7K0
M^#O@T=--'_?1I/\ A3G@W_H&_P#CYH QOAW'X.B5QX=$NXG_ ):-GFO#/B&9
MY/%=T)R H?C\J^I-!\":'X<+'3[;RR3D'/2O)/BU\-;^:1M1TU/-!^9U YH
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MH **** "BBB@ HHHH **** "BBB@ HHHH :^<<4J_=I:,8Z4 %%%% !1110
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M HHHH *1E5U*LH(/4&EHH RI_#.AW1)GTFSD)ZEH0:CB\)>'H6W1:+8HP[K
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M:0$GJ,5G:+J\>L6"W,:LN1T(K1&>] '%^(1_Q4EOW&VNNM/^/6/Z5R/B%O\
MBI+?.%^7O766DB?94^=>GK0!9HI 01D$&EH **** "BBB@ HHHH **** "BB
MB@ HHHH *1C@4M!QWH :F=O-.I!CM2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !33G>*=2<9S0 M%%% !1110 4444 %%%% !1110 4444 %%)2T)
MW ****0#') X[TJ\+S3N*:<8IZ@&:&=4&68#ZG%-9T1<LV *\N^)LU[?6CQ:
M9.^<?P-CM54O9N:C4FHKN8U:].BKS=CTS[?:\YGC&/\ ;%+]OM/^?B+_ +[%
M?-.B^!M:U0G[5J3VS=O,E/S?E72Q_!O695RFN*?^VK5ZJP> E*RQ*^XRIXN-
M7^'J>X_;;7_GXB_[[%)]NM<9^T18_P!X5XC_ ,*6\0!>-;7_ +^M2CX+>(/^
M@TO_ ']:K6 P6SQ"^XW4I/H>W"^M2.+B+_OL5Q'Q-NH9/"URD<J.Q'0.*X@_
M!37RN#K*_P#?UJ1_@CK<D?ER:M&ZGJ#(QK7#X3!4JJFZZ:7D#;?0Q_A);QS:
MT!-$'^;^+GO7T(-+L,<6D7/^S7!^"?AF?"TJRRSK(P.>#[UZ-TKFS7$PJ5KT
M9:!!66J(H;>*#(BB5!["IJ3-+7D\W-J:!1110 4444 ,;[Z\FGTG&:6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *1C@4M''>@!J9V\TZD&.U+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %-.=PIU)QF@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!KXQS0G2G44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!#*?WB=:E!.>E8>N^+]$\/!1J5XL;-]U0"Q/Y
M5H6&I6^I6,=U;$F)URI(QQ0!ROC'X@P^'0+:TMVN;]SM2/!P#5;PG'XKU2Y_
MM+6)8X(GZ6ZJ>/UKM6L;*=A-);1.X.0Q3FK2XQ\O2@ 484 ]J6BB@ HHHH *
M*** "BBB@ HHHH **** "D8@#FEH^M #4Z4ZD  Z4M !1110 4444 %%%% !
M1110 4444 %%%&: "BBD) &20/K0 M<-XE.=8M..C?XUVWF)_?7\ZXKQ&4_M
MBS.03N]<^M '96N/LZX]*FJ*V_U"\8XJ6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$ C!I-@]33J* $"@4M%% #2@)S2-&K#%/HH 0# QG-07EL+NW,1)&?0U8HH
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M %%%% !1110 4444 %%%% !1110 4C9QQ2T4 -7.WFG4 8HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HV?$@':I*0J"<D4 +1110 4444 %%%% !
M1110 4444 -8_(3TXKYX^,.JW_\ PDL=I%<LD;*. :^AI!E#GTKYP^,1_P"*
MPM\@=!S^5>[D$(RQ.O9F578=X=^%6J>(M/\ M::SLSS@DUK_ /"B];SC^W1C
MZFO0/A?C_A'%P.P_K7<UKBL[QE.M*$6K+R0U!-:G@_\ PHK6?^@]_.F-\!=3
M>0&76$D'N#7O6,4M<W]O8U._,ON'[.)RG@_PG_PBE@L33B1@,<"NI0[AFD*Y
MZTX  <5Y-6O/$3=2IN7:PM(0?6EHJ &XYKF_%O@O3O%-BT5S$OF@?(^.E=-2
M 8I6%8^2/$/PGU[2M8-K;6YN(7.$D4' ^M1W'PR\4>&XHM2:*-@C!MJY)X_"
MOKIHT8@LH)'3-,GMXKA-DJ*Z]PPR*8SQ#PO\=[6!(M/UJPDA=,(9$(/MTKUW
M2/$FFZY LUA<I*K#. >17-^)?A1X:U^.1Q8107# X>,;>?PKR#4OAWXT\%7+
M76@W-U+"C;@(CVZ]* /IJBO O#/QONK*5;/Q-$Z,ORF1EP1^ KU_0_&.B>(5
M4Z=?12L>J[L'\J -ZB@G YIH;//;UH =12=10,XY.: %HI,G/3BA@2/E.#0
MM%(O3!.303B@!:*3G/6EH **:2V>!3J "BD.<<'%'/ Z^] "T444 %%)DYZ<
M4M !1110 444C,J*68@ =2: %HKSCQC\7=)\-W)LK;%Y>#@QIGBN/'QI\2;?
MM!\+77V?^]M.,?7% 'N]%><>$OB]H_B-EAF*VMP>"C'O7HJ.LB*Z$%6&010
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M/X$LI+'P]"LJ[28U- '4TQTCF0HZAE/4$51GUW3+:7RIKR)']"U6X+J&Y7=
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ME5X2.3[4 >,^,?C9?Z9K+Z9I-K [AMH:3)YSBELM5^)^J6PNH8[,*PW!1_\
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MW6=+BD\(LWEO'E-AV5YV-%^,&"K17/L?M _QH M'Q?\ %4PC_B5V^,=<'/\
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MH JV%A!IMJMO;($C7H ,5:HHH **** &L2"*=2$9[TM !1110 4444 %%%%
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M/*C>VH4445SE!1110 'I2 Y%!Y%"C Q0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 TMA@/6G4TKE@?2G4 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"Y_&E!/I2T4 (,XY&*;(S*N5&:?10!$CNPR5Q[4\%L\K3NE% !2$D=!FEHH
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M^[Q2T %%%% !1110 4444 %%%% !1110 4444 %%5KR\BLH&FF)"J,FN!O\
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MN7#SVL,C#HSH": /"5^-%Y_T(R''WN?_ +&D/QFO.H\$+^8_PKW'^P]*&?\
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MO:NOLSFTC/'2@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK$@4
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MH,4M% !1110 4444 %%%% !1110 4444 (RANM   XH) ZTM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (5!.2.E+36?:0,$YIU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 (H('./PI:0'/:EH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N&\2Y&LV>?[W?\:[FN&\2*?[8M,<_-V_
M&@#M+;_4+QCBI:AM1BW0>U34 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!%<R&&VEE R44D"O)+SXTC2M6:TOM/D6,
M.5W!#7K_  1ZBL+6-(\/W6XZE%!DCDM@4 8VF_%/PO?HN+^*)C_#(X!KI;/7
M-*O1FVO[>3/99 :\<\2^&?AHLC$7<<,G/,;9_K7ENJ+I.F7!;0M2NIGSP N
M/UH ^Q5=&'RLI^AIU?*?A[Q#X\BPUD;F51T'EYKL;+XTZUHMVMKXBTF0,QQO
M8[?Z4 >]U'<2&&WDD'\"DUD^'O$EGXBL$N;8XW?PYK6GC,MO)&.K*10!Y.U[
MJ/B_Q@MA/*T6G9(=8N"<>]:7BCPI!X=TE]2TJXGCN(^F7R#Q69-;7GA'Q>FH
M3Q236>26\I?6M'Q/XLB\0:6VF6%C<FXEZ;UP.G_UZ .@\$Z[/J^G*+F1'D0?
M,5KI;B0Q0-*1G:,BN4\'Z0V@:2T\\9#E<LH'-:>GZ]:^(A<VL$4T93AO,7%
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MCM2;QFG44 %&<=:** &?*QW8)(H#Y.,&E)(8 4Z@ I"P'O2T4 -WC.*=110
M9Q3/,'O3Z* $!!Z4M%% "$X[4F\9Q3J* "C.*** &;Q3@0:6B@ II8#CK3J0
M]*  8 XH!SVQ2+G;S3J #.*9Y@I]% #=X/3FG444 (3CM2;QFG44 %&<444
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MX4T@;HM(@&.K2?-_.O,?^$I^* C5$TJ$@C@\_P"-13^)?B?+"ROI<8'?!/\
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M ]:V*3 )SBOE:N,KU5RSFW\S912V#)I:**YTK;C$Q2T4E%M=@%HHHI@%%%%
M!1110 4444 %)CG-+32Q#@4 .HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** $(!'-   P*#TH4Y% "T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% "8!.:6F,^'"^M/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBD8D#@9H 4<44BG(I: "BBB@ HHHH **** "BBB@ HHJ*YN8K2W>>9ML:#
M).* ):8^<#"!J\MU#XBZOK6LR:5X8T\.D9Q)<R9P/PKOM!M-0@L$_M*Y$MQ_
M$5&!0!A^+?#6MZ\XCM-7DM+<GYDCXR.XS4GAOX?:/H#+-]F6>[ZF>3YFSWZU
MU]%    ,#I28YI::20P% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!",CI0N<=,4M(IR.M "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #&7+ XZ>]/IK.JD ]Z=0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %(0#UI:* $ Q2T@(/2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N&\2Y_MBTR/XO\:[FN'\29&LV>?[W'ZT =E:_\>Z?3TJ:HK8DP+D8XJ6@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7&?$+3M?O\ 1@F@S2)<]RC8]*[.
MJM_)+%;/)#$9'4$A0<9H \O^'FA^-[&>=]>N9F1D(17DW8.#6+XE\-_$RYU9
MI--N[A+8L<;9P/TS6AJ?QCU:QNKBRF\*7(905#JYX]^E<!;_ !'UR#Q*FH&>
MXD0$_P"A;R<T ;7_  A_Q7# C4;HM_UV'^-(/!_Q7$@/]HW6>_[X?XUT:_'&
M\^53X8N<XZY/^%,F^-U[-&T2>&;M&/\ 'D\?I0!FZ#X9^)5MKL$FI7\YMPWS
M*;@'(^F:]YA!$2AA@XYYS7S3HNL>,-;\6QS 7R6OF9*'( &*^D[7>+9/,SNQ
MSF@":BBB@ HI,\XI: "BD# G@@T9S0 M%%)GG% "T49&<44 <3XAS_PD<!']
MVNOL_P#CUC^E<AXAS_PDEOC^[77VG_'K']* )Z*** "BBB@ HHHH **** "B
MBB@ HHHH **** /GGXW_ /'[!]?7ZUU_P:P=(4?[/]*Y#XX?\?L'U]/K77_!
MGC2%/;;_ $KZ[$?\BB)SQ^,]65=HQ2T@.1FEKY$Z HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *0CYLTM-+8;% #J*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ [4@SCDYH)P,T*=PS0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 A&2#2TA/(%+0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%-9@HR: %48&*6D4Y&:;(^R-V W,JDA1WH <<XX.*0,#P&R?:O+=
M4U?QQXENWT_3]*?3+3<0;ES\WID=*ZWPMX;O-$A)O-3GO)G^]O/ H K^)O"5
MYXAD17UJ6"W_ (HHR5W#\*T/#W@_2?#MJL=K:Q^;_%*1EF^IK=V@G+ 'TIU
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MA>E #B0!FA1WR>:",C%1^3\V[S&^F: ):*;L&<Y-.H **:5R>II#'G^)OSH
M?11VI",B@!:*9Y?.=S?G3@,=R: %HHII7)ZD4 .HJ/R^,;V_.G@8'7- "TA'
M.:6F%,L/F;\Z 'T4W9_M&E P* %HII7)ZFD,>?XF'XT /HI ,#KF@C(H 6BF
M[/\ :-&S_:- #J*0# I"N3U- #J*;L_VC1L_VC0 ZBF[/]HT[M0 44=J;L_V
MC0 ZD Q2!<=R:7[P[B@!:*:5SW-((\?Q-^= #Z*.U':@ HINS_:-($PV=Q/L
M: 'T44A7)ZD4 +13=G^T:=VH **.U-V?[1H =12!<'J32T %%(5R>I%-$>/X
MF_.@!'SO6I*9PIQDG-/[4 %%-V?[1I F&SN)]C0 ^BBD*Y/4B@!:*;L_VC3N
MU !11VIACS_$WYT /HI N#U)I: "BD*Y/4BFB/'\3?G0 ^BD QW)I>U !2$9
M'6DV?[1I F&SN)^M #@,"EHI"N3U(H 6BF"/'\3?G3^U !11VIACS_$WYT /
MHIGE_-G<WYT^@ HI",BFB/'\3?G0 ^BF[>>IIW:@ HINS_:-)Y?S9W-^= #Z
M**KW-K]I0KYKIG^Z<4 3Y'J*XGQ(I76+0JP.6_QK4;PLS2%CJEX%]!)7+ZMI
M+6FM6F+N>3#?QMGUH ]%ML_9USUQ4U16V?(7/7%2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7OI#%83R+]Y8R1^
M5?-EQ]N\;?$6/3+B\:-!(3A6QT(KZ6EC%Q#)&6^5U*UXOXJ^$NL1:PVL^';V
M-)@2=K#DYH 3XK^)KC0='30[9U*^6%+YRW"__7KEOAM\.;+Q7;75SJ[SD=0P
M.*FB^%/BSQ'J"R:Q*B*#SNSS7J.J>&K_ $?P2VEZ BK>LN/,!- 'CE@TWA/Q
M[#I^F7;M;M+M*NV>,5]/6[F2!&)!)':O$?!7PBU2#53JFOSQM*&W#;DU[A$B
MQQJB?= H ?1VHHH QM6\,Z7K2$7UN&.?O*2I_2LY/A]X>2=9#;NS+T#2L1_.
MNJHH K"Q@%H;3RP(,8V@]JH:1X:T_1)II;-7!F.6#.2/UK8HH YW4O".BZO=
M^;<V;"8'/F*2*@7P%H2R"22WDF8'(WR$UU-% $-M:PVD(B@C"(.@%3444 <3
MX@8-XFMPJ_PUV%I_Q[)]*Y#Q 3_PD<&/[M==:?\ 'JGTH GHHHH **** "BB
MB@ HHHH **** "BBB@ HJG>:I8V!_P!+O(8/:1P*HGQ;X?! .LV63_TU%:1H
MU):J+^X5['B?QPYO(,>O^-=?\&O^0,HX^[_2N&^,>I65_>0FSNHIL'DQMN]:
M[CX,L3I*YS]WT]J^JQ,>7*DFK,QA;F/5E'%.I%S2U\B;A1110 4444 %%%%
M!1110 4444 %%%% !1110 5&R R YP:DI,\XQ0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 AZ&D087K2G@4*01D4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ,9,N&]*?29YQBEH **** "BBB@ HHHH ****
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M %%%% !1110 4'I110 U.G:G444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 U@2.*51@8I: <T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 T@E@?2G4F0#BEH **** "BBB@ HHHH **
M*KW320V\DD$9DD X7/6@"9W"*68X4#)/I4,%[;W:[K:5)!TRIS7E&K6WQ"\2
MZLUKB33].SRRL,D9Y'K7HOASPY;>'].CMH2[,!EF9R<GOUH 37/"VF^(8?+U
M"(R#(/WB*OV6F6NGP)#;1+'&H   JY10 #@4444 %-;..*=10 B_=I:08QQ2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !2$<@XI:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH :^<<4*,#I3J* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 8_WEI]&!10 4444 %%%% !1110 4444
M%%%% !1110 4444 %-;..*=10 U.E.HP!THH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N&\2 '6;3!YW=_P :[FN&\2X.L6F!CYO\: .TM@1 N3GB
MI:AM?^/=/IZU-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% $4L F21&8X=2IKS/7/@]X=O;QKZ\U"YB!)) < 5Z5>2
MF&RFE'5$+?I7S9K>J:IXY\:C1$NWAA9RIRY4<&@#=O? WPSTZ;%UJ\P8=E(/
M]*OVGPF\"W=JU_;ZA<FW7DEB,#]*P/&OPLT_PUX=:_6YEDE4 G+9YQFNK\(:
M*/$G@&XL))6B5TX;=B@"WH/PB\*P7\=_87\\C(<@!QBO5(XQ%&$7H*^7/#]Y
MJ?A#QNNF17ADA>3;C>3VKZAMW,ENCMU(H EHHHH **** "BBB@ HHHH ****
M .)\0_\ (QP9Z;:Z^SQ]ECQZ5R'B$_\ %26_&?EKK[3_ (]8_I0!/1110 44
M44 %%%% !1110 4444 %!Z44'I0!\X_&O_D8HO\ <KTOX5Y_L1/]VO-/C7_R
M,47^[7I?PKS_ &*G3[M?68W_ )%5,PC_ !#T.D;[M+17R9N-3.WFG444D 44
M44P"BBB@ HHHH **** "BBB@ HHHH **** "FG._O3J3(!Q0 M%%% !1110
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M 4444 %%%% !1110 4444 -;.13J3 I: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ IK' ZTZB@!J9QS3J  .E% !1110 4444 %%%% !1110 4444
M%%%% !1110 5PWB4YUFTXX#?XUW-<-XES_;-GG^]_C0!V=MC[.N.F*FJ&UXM
MUZ].]34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@".3.]>M24A )R:6@ HHHH **** "BBB@
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M#K;:YBNH%EA8,C#((J:O/OAM=7,EG)#*[.L8PH)^E=Y+<)!"992%51\Q)Z4
M2,RHI9B !U-<G-\0]%BU@Z6KN]P#@XQBL'6?&T>L:M_8^GW<42*W[V3S ,K7
M$WT&A:9XL5H;N)Y2XS)NSGF@#WZ*02Q+(O1AD4^J6E7$5QIT#12!QL'(^E7:
M .+\0D_\));\Y^6NMM/^/5/I7#^,3<KKD LP/,*\9-:-O_PD_P!D3;MSC_9H
M ZZBJ5BUYY"_:P!)CGD5:^?'I0 ^BFKN_B-.H **9\_7]*%+9Y% #Z1ONTM-
M?.TXH6X,^:/B?_R.OI\_]37N'@#/_"+6X/\ G@5X=\3B?^$SYZ[_ .IKVWX?
M[SX9@STP/Y"OJ<V=\#2]$8Q;YF=;24M,._J*^6L;#Z*9\^>M/HL 4AZ4O:F?
M/GK0 JYQS3J:-W4_E3J "BD.<<"FJ6SR* 'T44'I0 44SYZ4;LY/Y4 .HHIK
M;OX30 ZBF8?/6G]J "B@]*;AL=>: '44T;LY/Y4Z@ IA!\P4XYQP,TT[B1CB
M@!]%(N>XI3TH **9\]*-V<G\J '444UMW\)H =130&V]>:5<]Q0 M%!Z4W#8
MZ\T .HIHW9R?RIU !12'..!3?G^E #Z*1<]Q2T (>E"_=I#NSQ2?/U_2@!]%
M%(V<<=: %HIGSTJ[OXJ '444ASC@XH 6BFKN_B-.H ***80^>#Q0 ^BD&>XI
M: "BFG<3QQ2%F X7/XT /HI <BFRLZQDQKN;L,T 0WEQ%:1&XN)EBB3[S,>!
M5#2?$NF:S-)%97"RM']X@UQFI^$/$WB+6 FJZD_]D$_-;IA<CZBNOT;POI7A
MZ(1Z?:K'G[S#DG\: )]6T/3M7>(WUMYQC/R>U7;2S@LH1%!$L:#H *G P,4A
MW$\<4 .HIF7STXI] !12'..!31OH ?12+GN*6@ HI#G'!Q3/GQUH DHI!G')
MS2T %%-^;/6D ?/)H ?1VHI,G/2@ 7..:6F9?/3BGT %%%-.[UH =13!N)]*
M?0 44ASC@XIGSXZT 244@SCDYI: "BF$/G@\4#<3Z4 /HHIIW$\<4 .HIF7S
MTXI] !3&!WBGTP;MW/2@!]%,._/ XI] !12'..#BF_/]: 'T4@SCDTM !13<
M-SS2#<3Z4 /HHIIW$\<4 .HIGS]<?A1\_3]: 'T4T[NQS3ATH **1L]C33OZ
MC\J ']J:G2A=W1A2@8H 6BFMN_A%)\_7]* 'T4#I2-GL: %HIGSTHW9P?SH
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M4 <5KV%\2P'@G;W%==:G_14)]*Y'Q"#_ ,)'!C^[776G_'K']* )N#S2T44
M%%%% !1110 4C?=-+2-]TT ?,_Q/'_%;?]M/ZFO</ "X\,6_/I_(5X?\4/\
MD=?^VG]37N'@#_D5[?Z#^0KZC-/^1?2^1C#XCJ:***^7-@HHHH *1B0,@4M!
MY&* $4Y&:6D VC I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ II<!
MPN>M.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TH4Y%+10
M 4444 %%%% !1110 4444 %%%% !115:]OK;3K9[BZE6.-!DDF@"S61K_B/3
MO#=B;K4)=B8.T8SDU3T?QII&OW;6^FS&9AWQBM:]TNQU!%6\M(K@ Y D7.*
M/-]-^(?B'Q-K2Q:%I<2Z?NPTTH)/]/>O4HM_E)YN-^!NQZU';V=O:1A+:".)
M1V1<5/0!$S9<+GKZ5+VI"H)!]*6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $4Y%+2 8%+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%(3R!FEI,<YS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UFV
MBE4Y%! /6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!COM8#
MUI](5!(/I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !2,2!P,TM%
M"*<BEI ,=Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCQ)D:M:]
M?O>OUKMZX;Q+QK-H0?XO\: .RM"3;)GTJ>H;4YMU/M4U !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !1110 4444 %(3@=*6B@! <BEHZ=** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU !1110 4444 %%%% !1110 4444 %%%% !1110 444A&1UH %.12TBC I:
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M+7Q!!)/(!A>@-;UMXBTY;9/WHX'K0!N45!!=PW,8>-P0?>IMP]10 M%&<T4
M%%)N'J*-P]: %I&^Z:6D8@#F@#YG^*'_ ".O_;3^IKW#P!_R*]O]!_(5X?\
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MQG-  3CM2TU@2013J "BDW+ZB@$'H: %HHI"0.IH 6BDW+ZBEH ***3<OJ*
M%HI 0>AI: "BD) ZFDWC.* '4444 %(2!UHW+ZBD9EQZT *#FEI%&!02!U-
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MQ#XH8_X37_MI_4U[AX Q_P (O;X]!_(5]1FG_(OI?(QC\1U-%%%?+FP4444
M%-8A1G&?I3J1@2.#0 *=PS@CZTM(HP*6@ HHHH **** "BBB@ HHHH ****
M"C ]*** "BBB@ I,\XQ2TS:=^<T /HHHH **** "BBB@ HHHH **** "BBB@
M HIKR)&N78*/>D5A(N1T/0T 9NL>(M+T*TDGO;J--@SLW#<WT%9?A?QDOBAI
M&ATR[MX5^Y),F X]JHW7PUT^^UM-2NYFE9'W*AZ5V<,,<$:QQ(%51@ "@!&V
M,2'CSCGE:6/!7*\+Z8I[#*D>M(B[%Q0 H '2@\#.,TM% "=1TI:** "BBB@
MHHHH **** "BBB@ HHHH **** $S@XQ2TUE)((.*=VH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBD8$C@XH !R.E+2*,"EH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D)YQBEIFT[LYH ?1110 4444 %%%% !1110 44
M44 %%%% !1110 48HHH :S;1G%*#N'2D9=PI0 HP* %HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &EL$#'6G4TC)'%.H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "D) '-+2,"1P: !6##BEI%&!2T %%%% !1110 444
M4 %%%% !1110 48HHH *:\:2+M=013J* (!:0@?ZI/\ OD5Q>OQI%K-KLC )
M;L/K7=UPWB3']LVF.N[_ !H [2WSY"Y]*EJ&US]G3/I4U !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH *0D#K2TA&1TH  <TM-4$#FG4 %%%% !1110
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M "BBB@ HHHH *1ONFEI&^Z: /F?XH?\ (Z_\#_J:]P^'_P#R*]O]!_(5X?\
M%#_D=?\ MI_4U[AX _Y%>W^@_D*^HS3_ )%]+Y&,?B.IHHHKY<V"BBB@ H)Q
M12$9%  "",BEI%&!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !323
MNQQ3JC96,@84 244=N:* "BBB@ HI-PW;<\T;AG&: %ICS11?ZR1$_WFQ67X
M@NM5MM.=](M/M-S_  J2*\YM/ 'B3Q%J(OO%%])$BMN2"&4\>Q_6@#UAML\9
M"L0#T937(GX;Z5-KYU:[EFNI,Y"3'<H/TKJK&U6RM([=,[(Q@9ZU9H CBMX8
M4"11HBCH%&*DHHH **** "BBB@!#P*%.1F@]*%&!0 M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 A8!@">32TQE)=3Z4^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $!!'%+2+P._P"-+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %-+8<#/6G4T@E@: '4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !2 @]*&SCBD48'.: '4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "$@'!I:8P)8&GT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !112-G'%  "#TI::HP.<TZ@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X;Q+D:S9Y_O=_QKN:X;Q(/^)S:8.?F_QH [2V_U"\8XJ6H;
M8$6ZYQT[5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M49KY<V"BC(-% !112$C'6@!<YZ44U2,<$4Z@ HHI,CUH 6BBB@ HHR!29&:
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MM&1CK0 N0>E%-7I3NE !129'K2T %%%)D>M "T4=:* "BBDR,XS0 M%)D4M
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M .1FG444 (R[NYIOEC'4T^D89'6@ 50.E+35^[3J $(R,4T1@>M/HH ****
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M@!NP>IHV"G44 ,\L9SS3^U%%  >13=@IU% "8&,8I:#TIJ=.U  RANI-)Y8
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3XAS_P ));X_NUU]
MI_QZQ_2N0\0Y_P"$C@ _NUU]G_QZQ_2@">BBB@ I,TM17+F*VED'55)%))M@
M2=1Z4=J^>_&'Q0\16.LM;6=SM4,0 J@T^#6?BI>P1W%M'*T;C*D*O->VLDJ\
MBE.<8W[LS]H?0/X4UOF&.17@O]I?%I>/L\W/^RM)_:7Q: .;:<_0+2>3N/\
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M !1110 4444 %%%% !1110 4444 %%%% !BBF,?G%/H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBD;..#B@!>G2BD7I2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1BBFG[P_QH =1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %& .E(<XX.*!C'!S0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 8%%,;.X<T^@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***1LXX.* %P!THIJ=/_ *].H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "N&\2Y&LV9SGYO\:[FN&\2 ?VS: '.6_QH [2V.8%/M4M0VPQ;J/:
MIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?$.#XC@&?X
M:Z^S_P"/6/Z5R/B''_"10$YQMKKK/'V6/'I0!/1110 5!>_\>,__ %S/\JGJ
M"]_X\9_]P_RJH?$@/E/QAMC\5L5 /SGM[BOI?PD=WAJQ. /W0Z5\T>+_ /D;
M#_OG^8KZ7\)?\BU8\_\ +(5]/GK_ -GIF-/XF;?UI:**^6-@I,<YS2T4 %%%
M% !1110 444C9QQ0 O2BFKG;S3J "BBD) &30 M<_KGBS1O#SHFHW2([_<4#
M)J[J]O>WFF7$%C+Y,SKA)"<8-<;X?^&$%I.;S7)SJ-R3G,IW@'VS0!VVF:G!
MJUFMS"<Q/TXIBZ+IHO3<_P!GP"8]9=O)JY;V\-O&$@14C'15&!4U "    #
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M(O([_C2T %%%% !1110 4444 %%%% !1110 4444 %%%% !28!.:6FL3D8H
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M !1110 4444 %%%% !1110 4444 %%%% !32H)R:=32<-C(H =1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (0",&@# Q0QP*%.1F@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!I7+!LGBG4TL0P%.H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D90PYI:0G Z4  &!BEI%.1FEH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D*YZTM-)^8"@!U%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 C*&'- &!BEI!GO0 M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 UD#$')XIU-8D$4Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *0@'K2TA.!TH  ,"EIJG(IU !1110 4444 %%%
M% !1110 4444 %%%% !1110 5PWB4YUFTXX#?XUW-<-XES_;-GG^]_C0!V=M
MC[.N.F*FJ&UXMUZ].]34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '%>(<_\)'!C^[776>?LL>?2N0\0C_BI+?G'RUU]I_QZQ_2@">J>J_\
M@JY_ZYFKE4]6_P"05<_]<S5T_C7J!\J:E_R/*XS_ *T?SKZA\._\@:W_ .N:
M_P J^7M2P/'"]/\ 6C^=?4'APYT6W./^6:_RKZ//?X<#"G\3->BBF-(J<L<#
MU/2OF3<?17%^)?B1I&@L((6-[=-PL<!W'/O71:-J,NIZ;!=26[P-(N2CC!%
M',^,]>UV%!I_A^P9KF1MIE? 51ZU5\'>#=2LKO\ M'6]2FGO''S1^860?3->
M@-&K9RH)^E"*%7&* % P !VH(R.M+2#/>@!>U%%% !0>112,<#.*  # Q2TB
MG(R:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0KDYI:0D[L<4 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (1D4 8&*1FVBE4Y&30
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A7)!]*6F,6#@#&.]/
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD8X'2@  P*6D4Y&:6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0CG.:6D).1TH 6BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *0#'?-!..U (/2@!:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!",GK2TUF(8#UIU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (J[12TBDD<X_"EH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N&\2<:S:$'^+_&NYKAO$@!UFSQ_>[_ (T
M=G:G-NA]JFJ*V_U"\YXJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH XGQ#_P C'!GIMKK[/'V6/'I7(>(2/^$C@R/X:Z^S_P"/6/Z4 3U3
MU;_D%7/_ %S-7*I:J3_9ESQQL-73^->H,^4]4S_PG"]?]:.W^U7U%X;Q_8EO
MC_GFO\J^8=34R>.A@8Q*._\ M5[%K&M>)8=+M--\.:?*SO&NZY X4$#UKZ/.
M]:<+&%/XCTPW,"2B(RJLAZ*3S536]+76-,>T>1D5OXEZUR'A+P3?P3+J6NW]
MQ<WI^8 R$!>^,9Q7H &!BOF>INSC?#GPXT?0+EKE%\Z9CG<XZ5V8  P!BD&?
M2EH **** "BBB@ HHHH *#THI#TH  "!R:6D!R,TM !1110 4444 %%%% !1
M110 4444 %%%% !1110 4F#G.:6FEP'"^M #J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!" >M+2'I0#D9H 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0@YZTM-+88#UIU !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ( 0.3FEHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "D(.>M+32V& ]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"$ CFA1@=<TM(IR* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&E<D'/2G4UG"D#UIU !1110 4444 %%%% !1110 4444 %%%% !1110 4A (
MYI:* $48'7-+2*<BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&\
M2D?VQ:8&/FY_6NYKAO$F?[9M,CC=_C0!V=KC[.N/2IJBML>0N!VJ6@ HHHH
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MBBB@!I7+ ^E.K.O-7AL[J*!Q\TG2KZ.'0,.AH =1110 4444 %%%% !1110
M4444 %%%% !1110 4=J*KWEVEG"9'Z4 3J-HQ2U5T^]34+43H,*3BK5 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4TJ"X/I3JSKK5HK6YCA8??[YH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P ^MQ_WS0?%=L.MK<?]\UN>5'_SS7\J/*C_ .>:_E0@,/\ X2JVQG[+<?\
M?- \56QZ6MQC_=K<\J/_ )YK^5'E1_\ /-?RI@8?_"5VV<?9;C/^[0?%5L.M
MK<8_W:W/*C_YYK^5'E1_\\U_*@##_P"$JML9^RW'_?- \5VQ.!:W'_?-;GE1
M_P#/-?RH\J/_ )YK^5 &&?%=L#S:W'_?-4-:UV&[TYXQ9W!+# ^45U?E1_\
M/-?RH\J//W%^F!0!QWA[78;'3DMI+2X5E[[:UCXI@!P;2Y_[YK;\J/\ YYI_
MWS1Y4?\ <7\J ,,^*K8=;6XQ_NT?\)5;8S]EN/\ OFMSRH_^>:_E1Y4?_/-?
MRH PQXKMB<"UN/\ OF@^*[8'!M;C_OFMSRH_^>:_E1Y4?_/-?RH P_\ A*K;
M&?LMQ_WS0/%5L>EK<8_W:W/*C_YYK^5'E1_\\U_*@##_ .$KMLX^RW&?]V@^
M*K8=;6XQ_NUN>5'_ ,\U_*CRH_\ GFOY4 8?_"56V,_9;C_OF@>*[8G M;C_
M +YK<\J/_GFOY4>5'_SS7\J ,,^*[8'!M;C_ +YH_P"$JML9^RW'_?-;GE1_
M\\U_*CRH_P#GFOY4 88\56QZ6MQC_=H_X2NVSC[+<9_W:W/*C_YYK^5'E1_\
M\U_*@#%_X2BWVY^RW'_?-<QJ>I+?:[#<K9W C1<$8Y->@^7'_<7\J/*C_P">
M:_\ ?- &!#XFMXXE0VMR,>JT_P#X2NV'6UN/^^:W/*C_ .>:_E1Y4?\ SS7\
MJ ,/_A*K;&?LMQ_WS0/%5L>EK<8_W:W/*C_YYK^5'E1_\\U_*@##_P"$KMLX
M^RW&?]V@^*K8=;6XQ_NUN>5'_P \U_*CRH_^>:_E0!A_\)5;8S]EN/\ OF@>
M*[8G M;C_OFMSRH_^>:_E1Y4?_/-?RH PSXKM@<&UN/^^:/^$JML9^RW'_?-
M;GE1_P#/-?RH\J/_ )YK^5 &&/%5L>EK<8_W:/\ A*[;./LMQG_=K<\J/_GF
MOY4>5'_SS7\J ,,^*K8=;6XQ_NT?\)5;8S]EN/\ OFMSRH_^>:_E1Y4?_/-?
MRH PQXKMB<?9KC_OFE_X2FWW8%K<?7;6WY4?_/-?RH\J/^XOY4 <EKFNPWEB
MT(L[EF(XPHIN@ZVFGZ8D$MG< CO@5U_E1_W%_*CRX_[B_E0!A_\ "5VV<?9;
MC/\ NT'Q5;#K:W&/]VMSRH_^>:_E1Y4?_/-?RH P_P#A*K<C/V6X_P"^:!XK
MMCTM;C_OFMSRH_[B_E1Y4?\ SS7\J ,,^*[8'FUN/^^:/^$JM\9^RW'_ 'S6
MYY4?_/-?RH\J/^XOY4 88\56QZ6MQ_WS1_PE=MG'V6XS_NUN>5'_ ,\U_*CR
MH_\ GFOY4 89\56PZVMQC_=H_P"$JMR,_9;C_OFMSRH_^>:_E1Y4?]Q?RH P
MQXKMCTM;C_OF@^*[8'FUN/\ OFMSRH_^>:_E1Y4?_/-?RH P_P#A*K?&?LMQ
M_P!\T#Q5;'I:W'_?-;GE1_W%_*CRH_\ GFOY4 8O_"40?\^EQG_=II\4V_3[
M)<'_ (#6[Y<?]Q?RI/*C_P">:_E0!PNK:G'=ZI:W$=C<E8^O K<@\30"(#[)
M<#'JM;WE1_W%_*CRX_[B_E0!AGQ7; X^RW'_ 'S2_P#"56^,_9;C_OFMORH_
M^>:_E1Y4?]Q?RH PQXJMCTM;C_OFC_A*[;./LMQG_=K<\J/_ )YK^5'E1_\
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MX_[B_E2>5'_<7\J .!UK4([R_MIHK*X(1LG@5OQ>*+=(U4VER,#^[6_Y4?\
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M^*[8?\NMQ_WS1_PE5OC/V6X_[YK<\J/_ )YK^5'E1_W%_*@##'BJV/2VN/\
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M\$^&1!:_VI?A);JY/F@[<;,]J .SA?S$#@G!Z9J2D''& !2T %%%% !1110
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MA/)KKZ** "BBB@ HHHH **** "BBB@ JIJ-E%J5A-:38,<J[6JW3=F#QWZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[31?$FEZ_;+/I]RLBMT'>@#6HJ*>XCMX6EF<1HHR2:XK4OBWX2TV8PO?EY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 0RVEO.<S0H_^\N:=%!% NV*-4'HHQ4E%
M !1110 4444 5I;"UGYGMXI#ZLH-1_V1IW_/C;_]^Q5VB@".*WAA&(HD0>BC
M%.Y(.13J* /GKXG^"O$&KZJLMAILDR!LDK^->E_#31[[3_"L-IJEJ8]HQY;\
MXKN3GM2T 4UTG3T;<EE I]0@JVJJB[54 >@I:* "H)K.VN/]=!')_O+FIZ*
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M( ;A^5#=5->O44 '08HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0S!W@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_Z;?I1_PNKPQ_TV_2NJ_P"$+\,_] .Q_P"_0H_X0OPS_P! .Q_[]"@#E?\
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MC_A=7AC_ *;?I74_\(9X8/30[+_OT*7_ (0OPS_T [+_ +]"@#E?^%U>&/\
MIM^E'_"ZO#'_ $V_2NJ_X0OPS_T [+_OT*/^$+\,?] .R_[]"@#E/^%U>&/^
MFWZ4O_"ZO#'_ $V_2NJ_X0OPQ_T [+_OT*3_ (0OPQ_T ['_ +]"@#E?^%U>
M&/\ IM^E+_PNKPQ_TV_2NJ_X0OPS_P! .Q_[]"C_ (0OPQ_T ['_ +]"@#E?
M^%U>&/\ IM^E'_"ZO#'_ $V_2NJ_X0OPQ_T [+_OT*/^$+\,_P#0#L?^_0H
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MLO\ OT* .5_X75X8]9?TH_X75X8]9?TKJO\ A"O#'_0#LO\ OT*/^$*\,?\
M0#LO^_0H Y7_ (75X8]9?TH_X75X8_Z;?I75?\(5X8_Z =E_WZ%'_"%^&/\
MH!V7_?H4 <K_ ,+J\,?]-OTH_P"%U>&/^FWZ5U7_  A?AC_H!V7_ 'Z%'_"%
M^&/^@'9?]^A0!RO_  NKPQ_TV_2C_A=7AC_IM^E=5_PA?AC_ * =E_WZ%'_"
M%>&/^@'9?]^A0!RO_"ZO#'_3;]*/^%U>&/\ IM^E=5_PA?AC_H!V7_?H4?\
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M +]"@#E_^%U>&!_SV_2C_A=7AC_IM^E=5_PA?AD_\P.R_P"_0H_X0OPQ_P!
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MT [+_OT*/^$+\,?] .R_[]"@#E?^%U>&/^FWZ4?\+J\,?]-OTKJO^$+\,?\
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M_3;]*ZK_ (0OPQ_T [+_ +]"C_A"_#'_ $ [+_OT* .5_P"%U>&/^FWZ4?\
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MQ_TV_2C_ (75X8_Z;?I75?\ "%>&/^@'9?\ ?H4?\(5X8_Z =E_WZ% '*_\
M"ZO#'_3;]*/^%U>&/^FWZ5U7_"%>&/\ H!V7_?H4?\(5X8_Z =E_WZ% '*_\
M+J\,?]-OTH_X75X8_P"FWZ5U7_"%>&/^@'9?]^A1_P (5X8_Z =E_P!^A0!R
MO_"ZO#'_ $V_2C_A=7AC_IM^E=5_PA7AC_H!V7_?H4?\(5X8_P"@'9?]^A0!
MRO\ PNKPQ_TV_2C_ (75X8]9OTKJO^$*\,?] .R_[]"C_A"O#'_0#LO^_0H
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M]9S?$NTE@G62,*V2/J*V3\#;D;LZI)M[?O37#R>$#H?CJWL7N3+O4G=NSW%
M'T9I6I67]G(#<H/J:MC5]/8A!<H6^M<3:?#^*ZM5D%W,I(Z;SBKEG\/4MIA(
M]W(<'/WS0!V-Q"MY;&,G*,.M8NG^$;'3KT749RX.:VHTCM;=5+X51C)-01:C
M82S>7#=1O)G[H:@"U+<10J6DD"CU-55UBQ8G%TAQ[BH=7T==5MFB,C)D=0<5
MRB_#55+_ .FR_-_MF@#M$U.RD?:MRC'V-7/H:Y#2O L.G3"1KF5B#GEC77A<
M< T &35>6_MH/];*J?4U.2<8QU]*P=;\+IJZX\YTY['% &F-8T_&?M,?YU)#
M?VUP<13*WT-<0/AJF#_ILW_?9K?T3PNFC\B9W/NV: -\$DT$X-*/3%#+E>*
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M1.&'J*D5LBL_2M)72[584=FV]R<U>9D1=SG8HZDT *TBHNYS@55_M:P!P;E
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M^%Y>+?\ G[_\=%<#_8>J?\^$_P#WQ1_8>J?\^$__ 'Q0!WW_  O+Q;_S]_\
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M /?% '??\+R\6_\ /W_XZ*/^%Y>+?^?O_P =%<#_ &'JG_/A/_WQ1_8>J?\
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MB:7_ ,^$'_?%-_L73,_\>$'_ 'Q5YF(' J.:Z@MX6DG=451DDF@"M_8NE_\
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MQF';@'O73>'[62RTF""3[RK@T :G/04X4AH'% #J*** "BBB@ HHHH ****
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M<B,3["KNDZJFJ6:SQ@@,,\US'B_0KW4[O?;;=N!UK:\+V-Q8:9'#/MW  '%
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M .0/+_NF@#YV\(?\CR?^NAKZ=LO^/2/Z5\Q>$/\ D>3_ -=#7T[9?\>D?TH
MLT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!'/_ *AOI7@/B/\ Y*A:?[C?S%>_3_ZAOI7@/B/_ )*A9_[C?S%
M'N6C_P#(.2KQ_"J.C_\ (.2KC8)YH AO+9;N!HF8@,.U<YIW@NWTW4Q>I-(Q
M#9P374,ZHN3PH[U72_MI'\N.56;TS0!;Z^E**0<=:6@ I:2EH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "DS2\4W/- "YI:IWNHVNGQ&6ZE"(.I-<K>?%?P?82;)]4
M ;T"DT =M2&N _X7/X)QD:I_XX:0_&CP3_T%/_'#0!WH^E)G!YK@Q\9_!/\
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M<OPS\'0KF33E4?6@#X\\J3^XU'DR?W&KZ]@^'G@>X)$5BC<XX-6O^%6^$?\
MH&+^= 'QOY,G]QJ/)D_N&OLC_A5OA'_H&+^='_"K/"/_ $#%_.@#XW\F3^X:
M/)D_N'\J^R/^%6>$?^@8OYT?\*L\(_\ 0,7\Z /C?R9/[A_*CR9/[A_*OLC_
M (59X1_Z!B_G1_PJSPC_ - Q?SH ^-_)D_N'\J/)D_N'\J^R/^%6>$?^@8OY
MT?\ "K/"/_0,7\Z /C?R9/[A_*CR9/[AK[(_X59X1_Z!B_G1_P *L\(_] Q?
MSH ^.!%)V1J/*D[HU?8__"K/"/\ T#%_.C_A5GA'_H&+^= 'QN8I/^>9_*CR
MI/[AK[(_X59X1/\ S#%_.C_A5GA'_H&+^= 'R!%IEY, 8K65\^@KVCX0>!KZ
M'54N[Z)XX\$C\J]CMO V@68"P6*J!6_!;1VT82)0JB@!\2^6@0'@5+3 #3AF
M@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IK9IU-()/I0!SVN>%H-9E\R25U/^R:O:/I,>E6:P1N6"C'S5<FNX(#B60*?
M<TJS),FZ%@P/<4 3#-.IJ=.>M.H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***#0 44F31F@!:0TF<\YI"PQQ0 A/-+QC.:0[0N6('U
M-<MXD\=Z'X8MV:]O%,AX5!SDT ='/<Q01EW<*H[MTKSCQ=\7M,T!C!!F>X [
M<BO*_&GQ@O=8?[/IC&. DYP>M<7I?ASQ!XLO2UO;O,YZL>* -KQ+\4M>\2W#
M1HQBB/"K'D$U%X<^&NN>))5F:(QQR')9^IKU/P7\%HK)([C61F8G.S'2O9+*
MPM["V2&WC"JJX% 'G'@[X0Z7H#+/>+Y\^.,\BO2X(8K>,101K&@[*,5)M;'-
M(JL#0!)BEQ1VYI: $I:** "BBB@ HHHH 82.E5-1L(]1M&@<D ]Q5L[<TR25
M85W/@+ZT <[H_A"WTB_>ZCED9F[$UTV:JPW]K/(4BE5F'4 U:Z=J %%8?BO_
M ) \O^Z:W:PO%?\ R!Y?]TT ?.WA#_D>3_UT-?3ME_QZ1_2OF+PA_P CR?\
MKH:^G;+_ (](_I0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@".?_ %#?2O ?$G_)3[/_ '&_F*]^G_U#?2O
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/_J&^E>
M^(_^2GVF?[C?S%>_3_ZAOI7@/B/_ )*?9_[C?S% 'N6C?\@Y*N,VWH*IZ/\
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MB@ HHHH **** "BBB@ HHHH ***0G H .])U_P#KT=N:RM;NY+2U9XQT&>M
M&F !T _"E'WJXGPMXBGU%W#@G#D=?>NVSS0 ^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *:PS3J0XH 9@8Y7-* /3%<?XJUZYTRYVQ*=N!
MWK8\-ZA)J.G1S..2,T ;0I:0=:6@ HHHH **** "BBB@ HHHH **** "BDS2
MT (>E-R!WH8X%-P,9- #L\4QG"+O9L >E4[[5K+3;9YKNYCC11SEA7C/Q ^+
M]J;5K+2)BS$\R+QB@#TOQ%X\T/0(,W-PK2=D5AFO$?%?QOU*_FDM]+41P= >
MAKS22ZU/7;S<_FW#L<=":]-\&?!S4+Y8KV^C\J)CD ]Q0!P-EHGB'QA?>8JS
M2F1L[W!(%>O>&?@,D#1S:O,CMP2J'BO7M%\-V.B64<-O BE5 ) [UJXXR10!
ME:)X<TW08!#96R+C^(+S6P1NZFD7)/2GXH CV#H,TX+MX%.Q2T %%%)0 M%%
M% !1110 4444 %%%% !1110 4444 %%%)0 TKDTTXZ$9I?FS6=KMR]GIK31_
M>!H T  IZ 5)VKA/#/B*YU'4Y()APN.]=UCT.* %%8?BO_D#R_[IK=K"\5_\
M@>7_ '30!\[>$/\ D>3_ -=#7T[9?\>D?TKYB\(?\CR?^NAKZ=LO^/2/Z4 6
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH CG_U#?2O ?$?_)4+/']QOYBO?I_]0WTKP'Q'_P E0L_]QOYB@#W+
M1_\ D')5QE#'DU3T?_D')5[&30!5O;<7-NT!Z,,9KGM,\%V^F:BMXDA+!LXK
MJ7(5,L0,=ZKQW=O(^U9U9_0&@"WVHSFD&>]+0 ?2EI*6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ANO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *0XI::WM0!S^N>%X=:E\R5]
MIJ_H^EKI-FMLARJC&:M2W,,)Q+*JGT)J1)5E3<C!E]10 X?>I]-%.H ****
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M@YSS0 \48%'.** #@4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+(6ED8"1OO?6O3!UK.M=(L;(DP0B,DYXK0&=U $E%%% !1110 4444 %%%%
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MSTK.M-)L+20O;PA'/4UI?C0 M87BO_D#R_[IK=K"\5_\@>7_ '30!\[>$/\
MD>3_ -=#7T[9?\>D?TKYB\(?\CR?^NAKZ=LO^/2/Z4 6:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_U#?2O
M ?$?_)4+/_<;^8KWZ?\ U#?2O ?$?_)4+/\ W&_F* /<M'/_ !+DJ]UJCH^/
M[.2KIXY% $5Q.EO"TKYP*Q[+Q3I]_=BVBW>83BK^KAGTZ0 9.#Q7G7AG3[N/
MQ&DKP%4WYSB@#U3'K2^U(>.:6@ I:2EH **** "BBB@ HHHH **** "BBB@
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MX]:YBX^+W@RUD,<NJ@,.N$)KQ?XN:]?/KDD1<JH..#7E#L7;+,6^IH ^NO\
MA='@;_H+_P#D,TO_  NCP-_T%_\ R&:^0SMQQFFX- 'U]_PNCP+_ -!;_P A
MFD_X71X&S_R%_P#R&:^0L&G# &1UH ^NF^,W@<JP_M?J/^>9KQKXI^+M$\0;
M/[,NO.PV3\I%>5<'K00.U #2>:<I^8?6C'%" EU [F@#WGX+ B-O]ZOH!/\
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M]J<!BCZ4M "8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 8>M(1QROYTI%4-8O6L-/:91D@T 7
M0B9SM4?05)VXKB?#OBN;5-5DMGC(5<<XKML8H 6L+Q7_ ,@>7_=-;M87BO\
MY \O^Z: /G;PA_R/)_ZZ&OIVR_X](_I7S%X0_P"1Y/\ UT-?3ME_QZ1_2@"S
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AIO'<4X
MTWZ4 -+#&XG:HZDUYWXY^*6G^%_W$2B6Z.<=Q74^+;[[#X;O)6X*IQBOCSQ-
MJIU35'<ECM8CDYH ZK7?BQXEUNY(M;B2!>P@)%9B:UXZD7>NHZJ5/H6K<^$7
MAV#5]:D,X#*N, BOI^TTFRL[981;0E0,<H* /D1/&OC/2WW37]\?^NK&O0_
M_P :;OSQ::MAU;^+O7<?%/P;'J>AS7< CB\D;B%0<U\MR&2SO&"M@JW6@#[B
MTK5+?5K);JV^XWK6D,XKQ+X,^,TOK?\ LIHSYD9!+$^M>VT !I.HS2]:#P*
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M]:_:[1H@2,BN6T?P:^G:JMV920&SC-=>9,'D@4GG(QV[U/T84 344PNJ#YF
M'N::9XO^>R?]]"@"4&C-1"9"<+(A^C"G!OFZT 24G--9L=:1I57JZCZF@!^:
M6HO/B'_+6/\ [Z%*)%;[C*?H<T /HS31G/)H)YY.* '9XHS41G13@N@^K"D^
MT1$_ZU!_P(4 3T5$LBMT(^H-.4'NV: '9HS32P7J1^=,,L0/,B?]]"@"7- J
M/SXSTE3_ +Z%.WCJ&!^AH =4-U_Q[/\ 2I"<C@BH;IU%J^6 X]: /E+XO?\
M(PR?6O-J](^+C*WB&3# \]J\[^79C9SZYH 0*<CWKTKP'\-8/%\#.\TB%3C@
MUYLH^9>>]?1OP,P+23']Z@#/_P"&>XAG_2I/^^J3_AGJ/_GYD_[ZKWIF3/)
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MF"#D-BNJI: /&I/@_<B)O]+; _Z:'_&O/7\,OH_CRWM))"^Y3SNSW%?44_\
MJ&^E>!>)/^2GVG^XW\Q0!Z%9>$99[5724J"/[QJU;>#9H9@[SDX/]XUTVC?\
M@Y*ND@F@#*U",V^D,N[E5QG->=^&+F1O$R*TK$;^A->J3PQW$923D&LRU\-:
M=9W8N84Q(#GI0!+JNE?VC"R;BI/3G%<TO@BX^;=.<'I\YKN@2:.M '):=X1>
MTF#O*6P?[U=3M*KA14G/:EH C )&"*Q-8T!M1QL<J0?[V*WZ* .%;P/.PP;@
M_P#?9K;T;06TS[SEO^!9K?HH 85S01E<4^B@#E=4\*-?SM()""3_ 'JH1^")
M]X\Z<E <@!S7<>U)F@#-L-/33(26?Y0.237E'Q)^*<^@Z@UKI5RIQQE><&O7
MM4_Y!LW/\-?'?CWC7KC_ *Z&@#0G^+_BVXR#>\'VK,D\?^(I3EKUL_4URV<G
MBG*-S!>23P* .FC^('B&)@RWK9'N:T8?BWXLA&$ON/<5S$?A_4YDW0V,[CV6
ME_X1K6O^@;<?]\T =6?C%XO_ .?\?E5:X^*_BJY0K)>Y!]*YW_A&M:_Z!MQ_
MWS0/#6M'_F&W'_?- %:_U*ZU*<S7+EW)R357KUK5_P"$9UH?\PZX_P"^:FM/
M">MWDXB2PF5B>I6@#%7 D7ZU]'_ QLVC\@_-7FVE?!WQ)>W";HXXU!R=]?1/
M@[PK!X9TB&%8U%QC]XRCJ: -?5=,.H*0K8S[US9\#S8^6<_]]FNT5JE% ',:
M1X7;3YA(\A;'^U72J,+C'2GT4 -_"N>UCPXVI/O20J?][%='10!PC>";HX N
M.!_M&NCT;2&TRW$;L6/US6Q10 S&.U-*;@<]ZEHH Y/5O"1OY_-21ES_ +54
MF\$3D@>>=O\ OFNYHH SM*T_^SK18,DX&,YS6ABEHH JWMJ+NW:/D$CK7)S^
M#)W<LDY&?]HUVU% '$VO@N:.;?).3_P(UUUM +:W2(9.T58I#0 GO6=J-@+Z
M)E!()]ZT /4TFTYSVH \C\3V$VERJ$G(W'^\:Z3PUX?EELX;J64MN&?O5T^H
M:%8ZF5-PF2O3BK=M;1VMND$(PB# H 4(T:J@Z 8J3&.U.^M** ,35M!_M*(J
M'*D_[6*P1X'N5) N#@_[9KNJ6@#GM(\.G3N6<LW^]FMW! J2B@!AY&,&N8UC
MPJ=3N/-61E/^]BNJHH X0>"+D#:;@[?]XUT>D:2--BV98GUSFMBB@!AY[4R6
M+S(RA[U-10!QMYX-DGNC*DQ&3G[QJ*/P3,DJN9R<'/WC7;T4 4K.V^RQ!.3Q
MBK6/04^B@"G?VANX-F2/QKDI?!$[3M(DY&XY^^:[FB@#CK+PA+;SK)),6V_[
M1KJX8O*C"\FIJ* (SGM6;JNE?VG&%)*D#'7%:U% '"KX(N$#!;@X)_O&M+1O
M"[:=.LKR%F!S][-=110 W!SSTI0*6B@#G=<\.'4Y Z2%6'^UBL;_ (0><J ;
M@\'^^:[NB@#%T;13ID>TL6/US6N-W0]*?10!$Z!D*X/-<UJ?A:2^F\Q)2O\
MP*NJHH X/_A!K@NK&X/'^V:ZO3;$V%NL>22!US6C10!&<FHKFW-Q"T?3(Q5F
MDH XNZ\&2RR[UF(Y_O&EM_!<J3AWF) _VC7:4E %>TMOLMN(ASBICG'2GT4
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MD5RD_@R:25G68@'_ &C7:T4 <1!X+F20,TQX_P!HUUEE:_98%C)S@8JU1VH
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M6PCSGCUJYB@4M "8]:*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $(INVGT4 121++&48?*>HKS+QS\)K7Q%_I%HXBN!G Q7J-0OO9L X%
M'R3K/PI\5Z%.9([5I(NT@/\ 2H;.\\;VBFWA2< #&-IKZZ>+<,$!OJ,TU;:+
M_GA&/?8* /CUO#/B_P 17 #6DDKYS\W%=WX-^".JO=K<ZTGDQ@?<X.:^BUAA
M7[L48/LH%.(P, 4 9>CZ+;:'8?9+9,*!7C'QAL]1DNT-C#(?EYV@U[SAEY)Q
M2M'$X!:)'/NH- 'QWI>G^)A>QEH)L9]#7U)X+2=-"A%R"'V#(-;H@A_Y]XP?
M]P4\1X/3 ]J 'C&>*\H^,)UE[ 0Z>KLCG#!1VKU8J>QI&1'7YT5OJ,T ?$;>
M%]::;<UC*<MR=IKZ.^%7AN*STJ&>:V,=P.<FO21;P'I#%_WP*E540850/H,4
M .QBDQDT[M322* *&KZ;!JUDUI=1AHFKP;QI\$=1:\:[T(>:K?\ ++@8KZ')
MS3=I;CM0!\=W/PV\8:1()9=.9&'(*MFM!-4\=QVOV55F$8&W&TU]:F-3PZ*P
M]Q2?98.H@B_[X% 'QW;^ ?%VNW <6+NSGJQQ7K/@OX&1V$\5WK+B1U.[RL=#
M]:]M6.-1\L2K]!BG8H K6=I%90"&)-BJ,"K*@]S2XP* 30 N*6BB@"*?_4-]
M*\"\1_\ )4+3_<;^8KWZ?_4-]*\!\1_\E0L_]QOYB@#W+1O^0<E7' JGHX_X
MER5>Z4 02RQVL+2R'Y1R:S+/Q+IE[<B&"7=*3C;BK>L*6TV0 9.*\V\,6TZ>
M)49HF"[^M 'J^<<FG=:*!0 M%)2T %%%% !1110 4444 )1BEI* *6J_\@V;
M_=KX[\>_\AZXS_ST-?8NJ_\ (-F_W:^.O'W_ "'KG_KH: .3Z=*LV.#J%OD?
M\M%_G57M5JP_Y"%M_P!=%_G0!]8_#[3K2?35WP@_)79_V+8?\^ZURWPX_P"0
M:O\ N5W5 &=_8MA_S[K1_8MA_P ^ZUHT4 9_]BV!'-NOY41:-8PR;XX%5AWK
M0HH C5-OI^5*4SWQ3Z* (UBQWJ2BB@!,4M%% !1110 4444 %%%% !1110 4
M444 %%%% !2&EI#0 G&.*0<BC  H4Y6@#,U'7K#2MHN9=I;VJW:W<5[;I/ =
MR.,@UP/CNUFEEB,<;-SVKK?#*.FB6RL,$+R* -DG!Y%.ZBD) I1ZT %+BDI:
M "BBB@ HHHH **** "BBB@ HQ110 8HQ110 8HHHH *2EHH **** "BBB@!,
M4M%% !1110 4444 %&*** #%%%% !1110 4E+10 4444 %%%(: #-5;R\@M$
MWSG: ,U:K"\31F2Q8 9.V@">PU[3M0)%O+N(..E:?S9QCBO-/ ]M-!+)Y@(_
M>-C/UKTZ@ '2CFEHH *,444 &*,444 %%%% !1110 48HHH **** "DI:* "
MBBB@ Q1BBB@ HHHH **** "C%%% !BBBB@ HHHH *3B@XHH *3=[4M-8]@:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0^M+29&<4 '45%(JOPZJP]Q4OX5FZK?MI\#2"+
MS,#.,XH M1VMO'S'"B_05-WZUR?A_P 52ZP[!K?RMK%<;L]#75_QT /%+124
M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFK]:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW;R1;^A->FW%LEQ"8GY4UB6/A73M/OA<Q#$@.: .A8>G%+VI.M+0 =:6DI:
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M:<M Z4 \]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6FDD[B<%UXQ7E^M>-]?\4W'D37#LLC86,<5U_@_X,:IK#K<:DYMH",X(SNH
MX"2[UOQ5?;&DEN9"<@'M7IG@OX+W]Z%NM24Q1Y'RGFO8/"_PWT/PVN^&W628
M#[YKK2WE\!0!Z"@#(T'PQ8:#9QPV4*1NH^9E&,FMPCY<9YHC.X9Q4E %8PDC
M)/X5,@(&*=BEH **** "BBB@ HHHH *:>3ZTZFGF@#SWQS>7EM>8M[AHUP.
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M[TUMZ:_IBX_Z:\US5W>ZSX?G\J#6M^.\,F16Y9?#OQKKB^8(Y77OO8UTFE_
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M)'+(949?WC8X]Z]+W#.* 'BBDI: "BBB@ HHHH **** "BBB@ HHHH ****
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M_.@#Z[^''_(-7_<KNJX7X<?\@U?]RNZH **** "BBB@ HHHH **** "BBB@
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MV\(?\CR?^NAKZ=LO^/2/Z5\Q>$/^1Y/_ %T-?3ME_P >D?TH LT444 %%%%
M!1110 4444 --)SWI>O2L#Q;J<VD:/+=09WJI(H T+VUCOH)+>:,.CJ5.17G
M5W\#?#]]<M.TTB,QR0!7F]U\;O$D%XT:DE<XZ5ZG\,/&%_XK65K\DE5R.,4
M>&_$?P.GAO68K;3HYI8V!R=A-;/P]^&]MX@+#4$EC Q_"179?%+XA:CX:UJ*
MWM8496!Y9 :X=/C?XBC^Y$J_[J 4 >F?\*$\.EO^/B:E_P"% >'O^?F:O-?^
M%Z^)_?\ [Y%+_P +U\3_ .U_WS0!Z3_PH#P]_P _,U*OP!\/*0?M$QQ7FO\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@!H![TG
MXS1U-!/.!0!Q?B_P_=:HT;0)NP>:Z/0;5[+28()!AU7!%:)95'S8I<@CVH 6
ME[<4G&*!TXH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *0TM)0 =!Q6+XAN9;:T9XV (7O6UTJG>V,5_&4ES@C'%
M '%>$=;O+]W$S+@.1U]Z[^L73/#5GI99H=W))YK:!SVH <*,4 8I: "BBB@
MHHHH **** $S3=PS0:;N /(H ?\ G433;<Y''>J&JZU9:1;/<7$P 49(W5X3
MXV^-,TZ2VNE_NR>-PZT >RZ]XQT70+9I;F\C#CHF[DUX=X[^,LVLVS6&G*5A
M)Y;H:\R,FK>);Y4=YIW<\;LD"O7_ (>_![?(+[5EWJ /W9'!H \ALM(U?7;H
M+!!-,[GK@FO8O!GP-?SX;S6F"JI#!%ZYKVO3O#NDZ6BBSLH8F7HRK@U>=G_A
MY^M $&GZ?;:?;K!;PA%48R%QFKI!(Q3(6#>N?>I<T 0M!N'!YJ5!M4"EZT4
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TXIU(
M: .&\8ZS<V%WLA8 8'4UL^%[Z2\TR.21U9B!T-3ZIH%IJLF^<$FK6FZ=!IUN
ML4"X &!D4 7A3J0"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX[5(* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%!)ST% %JVU6SO)3%#,&<=0*OCTKRKP3'.GB&;?'(JX'+?C7JO>@!U87BO\
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M7N&DZ/9:'8K:6482-><4 >8>"O@O9Z;$EQJN)92<XZXKUB"VBLH4BMXU5%&
M%%60,CFG!0!P* (5<D\BI^U-VC.>_K2T **6DI: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TU@30!#
M+;0W'^LB1C[BEBA6 ;8U"J.PK$UKQ/;Z/+Y4@R:OZ1JD>J6JS(.&&: -$=:=
M31G-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$5-JCH%%31[3TS0 XCY< 5 T+%JLT9H :@(7!I])Q1F@!<44F:,T +11FB@
MHHS29H 6BBB@ HHHH ***3- "T449H **3-+0 4444 %%%% !1110 4444 %
M%%)F@!:*** "BBB@!,T9I::<4 <+XQT2]U&\WVZ$C [5M^%[.YLM,CBG&& &
M>*W3UZXHZGCI0 \4M(!2T %%%% !1110 4444 %%%&: "BBB@ HHHH ****
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MESQ6-J>M?V<I9H2X%9 \<08/[GGTS0!UP84N3GI6'I6O_P!I' @*CUK; [T
M+FD#9Z4C],US^I^)AIT_EO;DC^]F@#HLG-)D9QFN1_X3:WZ"'<?K6WIFJ_V@
MFX1%10!J?6DS@]*,"FROY<9;&<=J ']>E&:Y2Z\8):W!B:V(P<9)I(O&D4\B
MHD&XD]C0!UO;-,W@GK5>VN#<(&VE/K4YW$?*: 'TF<55O;HVD&\C>:YR3QM!
M%(T;P8Q[T ==D4F>.*Y6U\817,ZQ109W'UKI8F\U ^-M $N30#F@]/6LW5-3
M.FH&\HOD9H TMU .>E<BOC>W8$M!@@^M7M,\2KJ-PJ) 0">N: .BI*.:#]*
M&D@''>C/K6+JWB!=+<*\.[/>LK_A.+<#(M\L>V: .O+$=!FG9%9&D:P=44MY
M)05K8 '6@!V?6DW8J)L*I)%8&H>*%T^;RWAROKF@#H\^@HS7(CQS"654M]V?
M0UT=A??;81($V9&<4 6RP'&:4>M)SFH+J<V\1<+OP,X% $^X9XI2:Y2;QI';
MR;'MMON320^-8IYA&D&XGT- '5YYQ1D>M06MS]HA$C#9GM4Q*@9S0 N:;OPV
M*IWEZ;2!Y2A95K"7QG;_ #;HMBCJ2: .LZC(K&URZ6SM7E$BHP&<DXKC=?\
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MEXD&GSM$\!8 _>H W\TF:Y+_ (3:VX_<\GWK8T[5FU 9\@J/6@#6SZTA/'%
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M=!BG@9I^!Z4#B@ [4M%% $4_^I;Z5X'XC_Y*A9]_D;^8KWV?_4-]*\!\1_\
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M ?$?_)4+3_<;^8KWZ?\ U#?2O ?$?_)4+/\ W&_F* /<M'_Y!R5>YS5'1_\
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MDI1SS0 4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!112$X% "T4W-!(/>@!">:-WL:8QSP*CFFBMX2\DJJ!R=S 4 2$GOBJ&JZQ9
MZ/9R7-U*J(@R03R:\U\<?%VPTEGM=/F62=1AO8UX3K_C76O$<Q22YF9">$#$
M@T >O>+/CI#%&UOH\3,^<;W'%>0ZEX@\0>,;O#R22Y./+3D"MKP;\,=4\3/Y
MTD,B6X^\W(->_>$?AOI7AR '[.CS=V9>: /'_"?P0U+4XH[O47$4;<[<X.*]
MP\->"=(\.6B100AW4<LXYS72!&50J*%4= *< >ZC- #@ 1P/SIV,?_6I0*=0
M S /:@*%/%/HH **** "D-+10 E9&N7LMG;-)$ 2!GFM<^U9FK:>U_ 8P2,C
M'% '-^%O$MYJK.)E4;7*]/0UVF/FS7+Z!X6_LAF.YCEB>3[UU)H =U%+2#I1
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36![4ZFDF@#C_%/B
M2[TFX\N!8SQ_%6IX=U.XU33DFN%4,PR=M5?$'AE=9G\PEA]*T=&TL:58K"&)
MVC'- &HNX''&*?3%I] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4E!I: (SG-4-:O)+#36FB + ]ZT#G-4]4L_M]BT&3D^E ')^&_%5YJFK26T
MRH N.E=U7(:%X3_LK4Y+DY^;UKKS0 M87BO_ ) \O^Z:W!6'XK_Y \O^Z: /
MG;PA_P CR?\ KH:^G;+_ (](_I7S%X0_Y'D_]=#7T[9?\>D?TH LT444 %%%
M% !1110 4444 %(12T4 -Z44$4GXT >)_%#X=^(/$^LQ7&FAS&H.</BN$_X4
M9XI(W-'EO<BOJ5B!\Q( 'K7-:WX\\/Z VVZOXC)WC5QD4 ?/_P#PHGQ/U\OG
MZBC_ (41XF_YY_J*]8N?C=X9@4M&9G;T&*RT^/\ H[2[/L]P 3UP* ///^%$
M>)O^>?ZBD_X41XF_YY_J*^AO#GBRT\1::][ &"+C.:C;QYH$6H&RGOHH9AVD
M<"@#P;3O@CXFM=0BF:'Y5.>HKZ)T*SEL-,@MYQM=$"G\JOP7$=U"LT,JR1MR
MK*<@T_<3P10 H!!P>14@IHX]Z<* %HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG_P!0WTKP'Q'_ ,E0L_\
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MU)R3M[T ;77FE'(I#UI10 M+24M !1110 4444 %%%% !1110 4444 %%%%
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M$T@(P*^N?#-O-;Z+:K,FUA$O'X4 ;*;OX@*?3<^HIPH 6BBB@ HHHH ****
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4C(H NJ?FZ4^FK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCJT;2:=(JC)([5YWX:TR\@\2(\D#A-_4BO4!@C_&D"1@\* ?6@"7BCZTG:E
M_&@ I:3I2T %%%% !1110!D>(O\ D%3?[M?&WBO_ )#=U_UU;^=?9/B+_D%3
M?[M?&WBO_D-W7_75OYT 8/>K^B_\A6V_ZZK_ #JA5_1C_P 36V_ZZK_.@#["
M\$_\@N'_ '175GK7*>"?^07#_NBNK/6@!U)2TE "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:0]* &8;/!HW<
MXH_.E..O% 'GGCK2[J>2)XHV<9["NL\-0R0Z);)(I!"\@UJE5D^\H(]Z-H0
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MS3[FV>0RQ,N9">1[UZ*1FHPJ)PJ ?04\?6@!XS2T@I: "BBB@ HHHH ****
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MD-+36)% '*>)/$\VC7'E1VV\>N[%:F@:H^J6*3O'L+#.,YK,\2^&I=7G\Q&
MX[UI>'],?3+%(7/*C% &R*6FCK3J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT 5-1E:#2[J5/OI$S#Z@5\B>,O&FMZIJ<UO)=ND:/P%8U]<ZS_R!;[_K@_\
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M129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10
MM%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49%
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M6$YFAB"LW6M8<C-8UEK]AJ%PT,$FYUZC-;(Z4 +6#XJ_Y \O^Z:W<UA>*O\
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M@\&N:_X75XN#;A> ?\ % 'UEM.<XQ6#XXRO@[4"IP1'_ %KYL_X7=XR_Y_\
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M':;4%7+D]/>N_P#^%C^%O^@FGY5\U#X1^-QTTUQ_P*G?\*E\;_\ 0.D_[[-
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M[-'_  J7QQ_T#I/^^S0!]*_\+'\+?]!-/RH_X6/X6_Z":?E7S5_PJ7QQ_P!
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M^^S1_P *E\<?] Z3_OLT ?2O_"Q_"W_033\J/^%C^%O^@FGY5\U?\*E\<?\
M0.D_[[-'_"I?''_0.D_[[- 'TK_PL?PM_P!!-/RH_P"%C^%O^@FGY5\U?\*E
M\<?] Z3_ +[-'_"I?''_ $#I/^^S0!]*_P#"Q_"W_033\J/^%C^%O^@FGY5\
MU?\ "I?''_0.D_[[-'_"I?''_0.D_P"^S0!]*_\ "Q_"W_033\J/^%C^%O\
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M!]*_\+'\+?\ 033\J/\ A8_A;_H)I^5?-7_"I?''_0.D_P"^S1_PJ7QQ_P!
MZ3_OLT ?2O\ PL?PM_T$T_*C_A8_A;_H)I^5?-7_  J7QQ_T#I/^^S1_PJ7Q
MQ_T#I/\ OLT ?2O_  L?PM_T$T_*C_A8_A;_ *":?E7S5_PJ7QQ_T#I/^^S1
M_P *E\<?] Z3_OLT ?2O_"Q_"W_033\J/^%C^%O^@FGY5\U?\*E\<?\ 0.D_
M[[-'_"I?''_0.D_[[- 'TK_PL?PM_P!!-/RH_P"%C^%O^@FGY5\U?\*E\<?]
M Z3_ +[-'_"I?''_ $#I/^^S0!]*_P#"Q_"W_033\J/^%C^%O^@FGY5\U?\
M"I?''_0.D_[[-'_"I?''_0.D_P"^S0!]*_\ "Q_"W_033\J/^%C^%O\ H)I^
M5?-7_"I?''_0.D_[[-'_  J7QQ_T#I/^^S0!]*?\+'\+?]!-/RI?^%C^%?\
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M99[>0/&>]6QC% "TT]*4TASB@!..]&/2J-]J5OIUN\]RX54&3FO)O%7QSL;
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MHQ0 GXT?C2XHQ0 GXT?C2XHQ0 GXT?C2XHQ0 GXT'ZTN*,4 )^-';K2XHQ0
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M1_Y'H_\ 70U].V7_ !YQ_2OF'PA_R/7_ &T-?3UE_P >D?TH LT444 %%%%
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M,]?YTX9[T .I,T4G;- "YHW#--S30"#F@"3(HS31GTHXZDT .R**;G-&<>M
M#LBC--S1\WMB@!=XI<TS'I^M(Q'<X^E $M)D#K3 01P:-I(^:@!X.:,BF \X
M/ IW2@!U%)FB@!:*** "BBB@ HHHH ***2@!:3(I".,9J(DH."#0!+O7UI<B
MHE!(W8IV3[4 /S0#FF8!/WJ4J>@H ?13%QG&:?0 444F: %HHI"<=: #(H)
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MS7TCH>K0ZO9+/"X(([&OCCQ%X;O_  I?I#<!@QZ'%>B?"[XA36^HP6$_^JW
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M52'XC^+=%E\JYNKER.OF,:^M&1#\IC0K_NBN,\9_#K1_$-DTS1I#,H)W@=:
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MYKY]M+VXT?4S);2%'1L @T ?= (90R$$'TIK2A2 >M>>?"[Q/<:QH:17*EI
M?OD]:]#;'0\4 2 Y%+3$! YYI] %>^_X\I?]TU\<_$4_\53>_P"_7V+?_P#'
ME+_NFOCGXB?\C3>_[] "?#W/_"36O^^/YU]9>)3C1'_ZY_TKY.^'G_(RVO\
MOC^=?6'B?_D!O_US_I0!\\^$6_XKHX_YZ&OINS&;./GM7S%X0_Y'K_MH:^GK
M+_CTC^E $X!%+2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO^0]!_OBOK[2_P#CPB^E %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBD/2@ YI:CW<>] 8]S0 IIN/[W--EGC@
M0O(X51U)KS7QG\6]+T82V]G,)+@<!D.0#0!Z#>ZE::;"9;J=(T'J:\A\;_&N
MWL6-KHQ#2 <N*\:UOQUK6OW#_:KAV5CT!(K0\*?#K5/$\_F"%UAR/F<<&@#+
MU;Q3X@\67N)KB60L<*BY'\JZ30O@OXDU7RYKF PQ2?-N)SQ7MWA7X6:-H-O&
MTELK7'5FZ\UWR*(8UC5<*HP,4 >>>%OA-HGAT1RS1K/<I@EB.]=_"D<0VQJJ
M@=@,5-MW=3Q3O+7&,4 )DGH.*>.G% %+0 G-)3J* &$X.*4XQ1P32$\XH YC
MQ#XK&B,BB+=N..M;6E7W]HZ?%<@8WC.*Y7QAX?N]2:-K<9P>>*Z/0;.6TTFW
MAEX95P10!J=.M+U'%)BE% "BEHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]**#THH S=
M>_Y EU_NU\@>/_\ D,_B:^O]>_Y EU_NU\@>/_\ D,_B: -KX/\ _(PR?\!_
MK7U?8_\ 'JOTKY0^#_\ R,,G_ ?ZU]76/_'JOTH LF@GTIA:E'K0 [MS61K>
MJII=I)*>"!D5J.P5&8]AFO _C!X[E2;[%83!=J[7% ' >/\ QO>^(-5G"S'R
MU8KCZ<5G>'/!?BG4_+N](L?,!P58D?UK+T/2I]<U=4\MG\ULD@>M?7O@S05\
M/Z%#:; "J =* /%TTKXRPP"%(ML:] "M.%A\9\\*WYK7T6.>U! STH ^<Y-.
M^,Q'SJW_ 'TM07OA_P"+NIV36US;B2%A@@E:^D7Z=,TU<=J /B'5O#^L:).6
MO[<Q.IZ^]>G_  B\?#3[];"^F),PVH#7I'Q2\)#6-%E:*#<ZC=\H]*^8_P#2
M] UA9E1HY(F^4D4 ?<4+^=$LBM\K#-*_*.H^\17F'PL\>/K5B;>]F#3@#;]*
M]0!YS0!\U?&C2[V+4/-DAVHPR#GK7+?#O4;2SU:%;B7:0W3'O7T/\0?!X\56
M>54%XTP!7R_JVAZEX9U6198)(V1SM)7M0!]HV5S%=6R26[[D(&*LU\\^!OC#
M'I]M#:ZDY.  37KUAX_\.ZB@9-1MU)&<%^: .II&Y'-88\7Z$S;?[4MO^_E4
M=5^('AW3(2SZC;R'^ZLG- '2331P0,SG"@'FOD+XC7D5SK=PL;AOF/\ .O0O
M&?QFAN;.6VTIF5B" W:O)]-T75O%.JH5B=W=N6QQ0!V?PATZZEU>.1$RB\DY
MKZABXA13_=KSWX<^ Y/#=N9;G:79>,=J]$4';C(H \?^-'AG[3ID=U:P[I3G
M<17SYI5_=:)JBX8QE&^85]M:AIMOJ5N8;E-RXKPSX@_!YWF:[TB'J,L!S0!Z
M9X!\3QZ]HD#-*I94"GGTKL @ZXKXQM=9\0>"[LP+YMN4;&'!&:]?\,?'>T:W
MCAU8.TV &?H* /<AQ2YKD+#XC^';X KJ-NA/8O6B/%^AY _M2V.?]L4 ;])F
ML&?QCH-O&7?4[; _Z:"L&]^+/AJS@9Q>12X'W4?)H [S-)QBO!M>^.RW<D=O
MHJR1R,X7+#WKT_P9J6H:G9^;?$G<N1D4 =1VR!FJU]+)#:M)&/G .*MXXI"H
MQ@B@#Y]\1_$3QS8ZQ<0VB2>2K87"5D_\+0^(7_/.7_OW7TI]E@8Y:"(_5!1]
MDMO^?>'_ +X% 'S7_P +/^(7_/.7_OW1_P +/^(7_/.7_OW7TI]DMO\ GWA_
M[X%'V2V_Y]X?^^!0!\U_\+/^(?\ SSE_[]T?\+/^(7_/.7_OW7TI]DM_^?>'
M_O@4?9+;_GWA_P"^!0!\U_\ "SOB&/\ EG+_ -^ZC?XF_$&5&C,<V&&#^[KZ
M7-K;?\\(?^^!3&M8/X;>'_O@4 ?&/B.?6KY_-U2%UR<Y*XK6^&NO/I?B&->-
MI'.3[U]*>,O"%IX@T>:)8$$^/D(4#FOESQ)X5U/PGJ/[V-^6)#J.!0!]@Z3?
M#4-/2X&.>.#5TX[UX#\.?BQ::=IZV&H.P"G[S'BO6K'QWX?U"/?'J5NOL7%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (Y_P#4-]*\!\1_\E/M/]QOYBO?I_\ 4-]*
M\!\1_P#)3[3_ '&_F* /<M'_ .0='7&_$_\ Y!W_  "NRT?_ )!T=<;\3_\
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MR:%R* %P?:D">Y_&GTM #0.*44N** "BBB@ I#2TAH ;VXI.HI0<CB@#C)H
M3[HY;%)D YSFN&\9:[>V$D:6S[<GDUTWA^YDO-(MY9FW.R\T :NX8Z4X<TG;
MI0HXZ4 .HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!#THH/2B@#-U[_D"77^[7R!X_\
M^0S^)KZ_U[_D"77^[7R!X_\ ^0S^)H VO@__ ,C#)_P'^M?5]C_QZK]*^4/@
M_P#\C#)_P'^M?5]C_P >J_2@"8KS05/4&G4M %#4;::ZMC'$^UB,$BO+M4^"
M%GJ][+=7-W<&20Y.&XKV"B@#SGPK\+;'PR5,>9"ISN?DUZ)C IU% "9HI:*
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M]/67_'I']* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 1S_ZAOI7@/B/_DI]I_N-_,5[]/\ ZAOI7@/B/_DI
M]I_N-_,4 >Y:/_R#HZXWXG_\@[_@%=EH_P#R#HZXWXG_ /(._P" 4 ?)5[_Q
M_P __70_SJ#O4][_ ,?\_P#UT/\ .H.] ':?#K_D/0?[XKZ^TO\ X\(OI7R#
M\.O^0]!_OBOK[2_^/"+Z4 7**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFEH **:3BC<,4 .HI V:,\4 +129HH 6BDHW#UH 6BDW"C(H 6BDR<TF3VH
M=12 TF\4 .HIGF#.*=F@!:*;NHW@C(.: '44T,"*-_/0T .HII< X]:7- "T
M4A..U&: %HI*,\4 +129S1F@!:*3(%&: %HI,T4 +12$@49H 6BD)I"X'4T
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MH **** (Y_\ 4-]*\!\1_P#)3[3_ '&_F*]^G_U#?2O ?$?_ "4^T_W&_F*
M/<M'_P"0='7&_$__ )!W_ *[+1_^0='7&_$__D'?\ H ^2KW_C_G_P"NA_G4
M'>I[W_C_ )_^NA_G4'>@#M/AU_R'H/\ ?%?7VE_\>$7TKY!^'7_(>@_WQ7U]
MI?\ QX1?2@"Y1110 4444 %%%% !1110 4444 %%%% !1129H 6DS1FF[A0
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M^.I<Z.0>FX?SH M6OQ[L;R%BVFE)P/D0,3DTU?%OCCQ)FXTRP>UMU]6ZU@_
M_P ,:;J<LL][;B5XTW*3V->\W&GPBR:VMT6,8XP* / +KXN^)/#FIM9ZA$9Y
M /N[JVK;QWXV\5QJ^DZ:]NHX)W=:X?X@^']5T_Q:]W]BDD@P"'QP>375>%_C
M-#I%E#876F!/+&"QXH W?,^)I( 1O^^A59O%?C_P]="34=,>Z@4\@/U%=KIO
MQ1\.7T*O+>00,1]TMTK>MM?T'5V$<%Y!.6Z*.: )M#U5]4L([F2,Q,XSY9[5
MIL2!N'2FQP)&/W8 7T J1DRA'K0!QWB+XC:-X<N##>R8<5M^']>M/$>GI>VC
M9B<9%<EXN^%EKXHNS<23;&-=+X2\-KX8TF.P23>J*!F@#>QS2Y]*7%&/2@!I
M'K2$''%.Q1CB@#S[X@_$3_A#/+_T/SRRY^]BN6TWX\V>H0X;3"+GHL0?.:SO
MCZ2#;X/\']35'X,>#+#5[5=2G0-*C'&?8T =0WBCQUK?-AHS6D;?=/F9Q69J
MFJ_$C1HQ-,CR(.2 :]Q\M%4*BJN!V%-EB5X65U5ACN* /%_#WQO=ITL-7L&B
MGSM+,W6O8;2>.\MHKA,$2*&&#GK7S?\ &.VBLM4$MO&(W(SE17H7P.U"[O\
MPV#<3%RN0"?K0!ZOYD2_>D0'W84GG0_\]H_^^A7G7B7P!K^LZG)<VNOFWC9B
M0@7I6-_PJGQ3_P!#2W_?- 'KWG0_\]H_^^A1YT/_ #VC_P"^A7D/_"J?%/\
MT-+?]\T?\*I\4_\ 0TM_WS0!Z]YT/_/6/_OH4&>''^MC_P"^A7D/_"J?%/\
MT-+?]\T?\*I\4C_F:6_[YH ROC'N:YD*R(5P.A'I1\+?$VA:;HT$=Y<(D@49
MR*N-\$]3O;@/J.NF=.ZD=:Z>S^#/A""!4GL3(X')$A% &U_PGWA3('V^+/\
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MG_2@#YW\(?\ (]?]M#7T]9?\>D?TKYA\(?\ (]?]M#7T]9?\>D?TH LT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!'/_J&^E> ^(_^2GVG^XW\Q7OT_P#J&^E> ^(_^2GVG^XW\Q0![EH__(.C
MKC?B?_R#O^ 5V6C_ /(.CKC?B?\ \@[_ (!0!\E7O_'_ #_]=#_.H.]3WO\
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M%% !1110 AZ44'I10!FZ]_R!+K_=KY \?_\ (9_$U]?Z]_R!+K_=KY \?_\
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MB]T7PS!:WR%9E0 C- '9T4@-!H 3-+GBFTA.WK0!X+\?!EH.OW/ZFMGX!?\
M(N'ZM_,U/\7/!^J>)/)-A&7VIC@UH?"+PUJ/AS13!?0F-\G@GWH ],W#.,BF
MO_JV^E(-N_GK2L,HP]10!\V?&XYOEX_AKLO@(,>&NO=OYU3^)W@76?$-V'LH
M"Z@>M=+\)/#6H>&]$^SW\6Q\GC/O0 _Q)H'CN]U*231]1M8K8D[0[D'%8O\
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MNWCC2)0J(JJ.F!BG'ITS2J#0 NTT;33J6@!H!]:=110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2$ TM(U #<^](1QTS1R#TIU #0!C[M SZ
M8KB?%_B.]TN2-;<J,GG-=)H%Y+?:3!-*079<G% &F,&E&<T@&*<.E "T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 (>E%!Z44 9NO?\@2Z_W:^0/'_P#R&?Q-?7^O?\@2
MZ_W:^0/'_P#R&?Q- &U\'_\ D89/^ _UKZOL?^/5?I7RA\'_ /D89/\ @/\
M6OJ^Q_X]5^E %@TM(:6@ HHHH **** "BBB@ HHHH ***3(H 6DH%&10 TJ3
M3=IQBI,T9YH B6$#D@9IVT Y&/RI_:CB@!K*&P::4SP3QZ5)1QF@",1*.@I/
M* .5XJ6C(H 9@;?NC\J9Y9/>ILT=J (_+X['\*7##I3J7- $;*V>#QZ4;%;J
MN*?UZ49_.@!H3MVI<'UIU% #<<<\T@7TX_"GT9YH 84)ZFE*MC&:7G/-+N%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[X;^,+S1M1:QDNF=-^!FOINTD\ZSAE_OH&_.@">BBB@ HHHH **** "BBB@
MHHHH **** *U_P#\>4O^Z:^.?B)_R--[_OU]C7__ !Y2_P"Z:^.?B)_R--[_
M +] !\//^1EM?]\?SKZP\3_\@-_^N?\ 2OD_X>?\C+:_[X_G7UAXG_Y ;_\
M7/\ I0!\[^$/^1Z_[:&OIZR_X](_I7S#X0_Y'K_MH:^GK+_CTC^E %FBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* (Y_P#4-]*\!\1_\E/M/]QOYBO?I_\ 4-]*\!\1_P#)3[3_ '&_F* /<M'_
M .0='7&_$_\ Y!W_  "NRT?_ )!T=<;\3_\ D'?\ H ^2KW_ (_Y_P#KH?YU
M!4][_P ?\_\ UT/\Z@H [3X<_P#(?@_WQ7U]I?\ QX1?2OD'X<_\A^#_ 'Q7
MU]I?_'A%]* +E)TYH/2HPS>G% $F?2HWP?7\*-QS4-W>0V=NTL\JHBCDDT 2
M C&#FLS5O$6EZ)#OOKJ.,>C-@UYKXX^+UII4+0:;.LDY->":[XHU+Q)=F2[G
MD8'HF<B@#W;Q-\==.M-\.E(TC ?>89%>*Z[XVUWQ1>ONG<!SQ&AXQ5CPKX"U
M+Q-*/+MW$0."V"*][\+?"+1M&CADG3S)@ 3O&>: /'O"?PAU376BENU:&!\$
MD\&O>/#/PST;PYLD2/S95[OS78QPQ6ZA(5"*.@%2@9H 8B+&,1C ':E)R?2E
MV_A2[: '#I11BEQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4AI:0T -YQ0,8HQBD!/I0!YSX]ENDEB\IY5&?X:
MZWPP9#HEL9"S,5YW=:T;O3[:\ \Z)6QZBIH8D@B6.-0JKT H DXH%)GGFG=^
M* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 0]**#THH S=>_P"0)=?[M?('C_\ Y#/X
MFOK_ %[_ ) EU_NU\@>/_P#D,_B: -KX/_\ (PR?\!_K7U?8_P#'JOTKY0^#
M_P#R,,G_  '^M?5]C_QZK]* +!I:0TM !1110 4444 %%%% !1110 4TTZD;
MIQ0 PY"MCTKYB^+TURWB/RVF)B[)GWKZ<(."6)]*\5^+_@T3P)J=H'>8YR,4
M :?P;M8DTI6$2J2>H%>L9V\=:^>OA/XQ_LN1K#42(BKX&ZOH"*X2XA26)D96
M ((- $N<]:=TJ D[L_Q5*K9&.AH ?FD8Y%12S16Z%Y9%4#U-16]_;W>?)E5\
M>AS0!P/Q(\6SZ+I,XMP5<*<,*\@\!Z-+X[\0J=1N7= VXJ3UQS7I?Q:TJ\N=
M'N&BBRNTUP_P2FM]/\0[)Y=CX(PQQVH ]XLO"VBZ= B1Z=!N48W;:FET72YQ
MMET^%A[KQ6@'+@,I#*>^:4G ]J /$_BQX*LM/L8]0TU%@E).=O KF_A=XTU*
MSN397,S2J'P,G.*]%^+^K6]MH,:$HS$MP:\?^'FGW5_K#7$,64,F>* /<OB"
M4G\,23,2&:+./PKYN\&>&O\ A(=;CMI)6C1G RI]Z^C_ !YF/PF4*C(A /Y5
MX9\*L_\ "40?,<>8./QH ^CM&\)Z5I5A'$MG"[*,;V7DUHRZ-I4\1BDL8MK=
M<K5^#'E#(J0@$C@&@#P#XG>#M)M"]Q:PF)@,_(.*L_"O5VO]/@TNZM8)H2 I
M+C)K=^*K$6<H"C&TUR'P? ^U0'/.10!@^/[2V@UN..&UBC7SE&%'O7LW@C0-
M,N-+C:XTZV<[.NVO(/B,SG7T!  \]>?QKVWX?#&EI\Q/R4 ;1\,:( 2-+MLX
MZ[*^?_BY"D&H+;01)''V"BOI=B-K#VKYL^+_ /R&EYH T/A9\/+;4K876I-Y
MJYRBYSQ7ML&C:;8P*D=A$$48X6N#^#XQHR?,37I[[FC( R: /FGXG>)IH]<G
MT^QB6$;RH91@UUGPR\ 6KO'J&H1_:"PR1)SVK@/BA97,/BZ>YDCVQB0G/XU[
M5\-=5L[K3H88[@,X7IGVH ["/1M*@&V/3HE'^[45YX9T>]0K)IT!)[E:U&7'
M.XFE63Y"6P,>M 'S+\1?";^'=2FOM.=H$1BPV<5WWPV\>/KVG/ITBN76%LLP
MZX%<U\7]:ADDN;19 6)(P#5GX1>&]2T]9+VXAVP-$V&_ T <3X\7_BH(\\?O
M?\:]F^'L,DOA&9+=V#G'/X&O'/'K_P#%01<=)?\ &O</A6X/A]SC'W: /"/B
M%9:M9^*&EO8+A[;LS+P>:[_P+X[\&0:;#;W5G'#,@PS. ,U[)JFBZ=K,'E7E
MO'*/]H9KA;_X)>'+Z5I!F+/9!@4 ;5OXE\$W:AUN].7V9QFM'['X9U:+=%#:
M7 /39SFO-[WX!Z5L9K.[GWCH,UYQ>-XB^'FL'RKB1HHFX5GXXH ^I[:VBMH5
MC@C6-!T4"I9$\Q".1]*\[\ ^/+WQ*%2YB1>.HKT<^E 'F'B[X:W_ (CO6N(+
M]X%]-V*[#P?H,_A[18K*:;S710"V<UNDJI^:0?B:>&4CY2#]* %!YH[T@ZTO
M>@ [TIZ4AZTO:@#P/X^?*;? !^3^IK!^$O@-/$$::C++\BL<QYX.#6[\?1S;
MX_N?U-;'P"_Y%L_5OYF@#U&+0-(@4+%80+@=EIEWX?TF[@9);*(\?W:U0HSF
MF2+\C?2@#Y=^*.B6GAS65N-/ 1C\V!T%>L_![Q%>ZYX<1KP@E 5&/05YM\;<
M?;EQ_=KL_@)_R+7'/+=?K0!T/B!_'7]I/_8ZV1ML_+Y@.<5E>9\4/^>>F_D:
ME\3ZIXYMM7D32;%'MPQVDGM6-_;WQ._Z!D?Y_P#UJ -3S/BA_P \]-_(T>9\
M4/\ GGIOY&LO^WOB=_T#(_S_ /K4?V]\3O\ H&1_G_\ 6H U/,^*'_//3?R-
M(9/B?M)*Z8H'J#68->^)P/\ R#(_S_\ K5'<ZQ\3;F!HCIL:[AC(/_UJ *6K
M?$3Q?H3-:W/V"2X](\DU3T3PGXH\=7BWVM3/#:2'<8U)%8*^!_'0U0W]Q9>?
M(6W8D.:[6'6?B1;H(XM(A10, #_]5 'J?A[PMI_ARP^SVL2Y')<CDUXI\<1B
M]A_W?ZUNC7/B:^<:7%^?_P!:O,_B%?>);FXC_MJV6)@.,&@#V+X(?\BXO!'7
M^==;X]T*37O#\]K%G<R$#%>&_#_5?&=KI071K))8>>2:]U\+7FMW.GQMJ\"Q
M2D#<!0!\V:/<:E\/?$"S7%@_DA\%Y$XQ7O\ X>^*'AO5;91)?0V\@7D2L!6]
MJWAS3=<A:*[MH9%/<C)KC+OX)^';I]ZEHB#GY!B@#K9O&WAF-<MK-G_W\%>3
M_$KQ]!KL']FZ-%)=-'DEXQN'-=&OP*\/EMS7,S8]:J>)++0/A[I&+-(6F<$$
MD#- '@.CM/'XEA$H:.3>-RGC%?:FC$G1;(G_ )XI_*OEKPGX?D\6>)Y-2",%
M\W/RCCM7U581?9].MX?[D:K^0H LT444 %%%% !1110 4444 %%%% !1110!
M6O\ _CRE_P!TU\<_$3_D:;W_ 'Z^QK__ (\I?]TU\<_$3_D:;W_?H /AY_R,
MMK_OC^=?6'B?_D!O_P!<_P"E?)_P\_Y&6U_WQ_.OK#Q/_P @-_\ KG_2@#YW
M\(?\CU_VT-?3UE_QZ1_2OF'PA_R/7_;0U]/67_'I']* +-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !29I:0\T &:-P-1D<]Z,-^% $F12TQ>E.!
MH 6BBB@ HHHH CG_ -0WTKP'Q'_R5"T_W&_F*]^G_P!0WTKP'Q'_ ,E/M/\
M<;^8H ]RT?\ Y!T=<;\3_P#D'?\  *[+1_\ D'1UQOQ/_P"0=_P"@#Y*O?\
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MJ_2OE#X/_P#(PR?\!_K7U?8_\>J_2@"P:6D-+0 4444 %%%% !1110 4444
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MKVS:.H I: .=\,^$=-\+V206L(\P?>?^\:Z.CM1C/6@ %+110 4444 %%%%
M!1110 4444 %%%% %:__ ./*7_=-?'/Q$_Y&F]_WZ^QK_P#X\I?]TU\<_$3_
M )&F]_WZ #X>?\C+:_[X_G7UAXG_ .0&_P#US_I7R?\ #S_D9;7_ 'Q_.OK#
MQ/\ \@-_^N?]* /G?PA_R/7_ &T-?3UE_P >D?TKYA\(?\CU_P!M#7T]9?\
M'I']* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0!SNMZ;K-U,&L9HD4?WS6,V@>*R!BZMO^^C7=_6C'I0!B:-8ZC:1XOY$=O\
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MK_GW_2NO_P"&?/"_:YO/^^A36_9_\+*,O=W:C_>% ')?\-"77_/O_P".T?\
M#0EU_P ^_P"E=4GP#\)O_J[ZZ;Z.*D_X9\\,_P#/S>?]]"@#D?\ AH2Z_P"?
M?]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_S\WG_?0H Y'_ (:$NO\
MGW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,?\_-Y_WT* .1_P"&A+K_
M )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/#'_/S>?]]"@#D?\ AH2Z
M_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_S\WG_?0H Y'_ (:$
MNO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,?\_-Y_WT* .1_P"&
MA+K_ )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/#'_/S>?]]"@#D?\
MAH2Z_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_S\WG_?0H Y'_
M (:$NO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,?\_-Y_WT* .1
M_P"&A+K_ )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/#'_/S>?]]"@#
MD?\ AH2Z_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_S\WG_?0H
M Y'_ (:$NO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,?\_-Y_WT
M* .1_P"&A+K_ )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/#'_/S>?]
M]"@#D?\ AH2Z_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_S\WG
M_?0H Y'_ (:$NO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,?\_-
MY_WT* .1_P"&A+K_ )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/#'_/
MS>?]]"@#D?\ AH2Z_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AGSPQ_
MS\WG_?0H Y'_ (:$NO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X9\\,
M?\_-Y_WT* .1_P"&A+K_ )]_TH_X:$NO^??]*Z[_ (9\\,?\_-Y_WT*/^&?/
M#'_/S>?]]"@#D?\ AH2Z_P"??]*/^&A+K_GW_2NN_P"&?/#'_/S>?]]"C_AG
MSPQ_S\WG_?0H Y'_ (:$NO\ GW_2C_AH2Z_Y]_TKKO\ AGSPQ_S\WG_?0H_X
M9\\,?\_-Y_WT* .1_P"&A+K_ )]_TH_X:$NO^??_ ,=KK_\ AGSPQ_S\WG_?
M0I/^&?/# _Y>;S_OH4 <C_PT)=?\^_Z4?\-"77_/O^E=6_P$\)IQ)>W*GW<"
ME3X ^%G7*W5TP]0PH Y/_AH2Z_Y]_P!*/^&A+K_GW_2NN_X9\\,?\_-Y_P!]
M"C_AGSPQ_P _-Y_WT* .1_X:$NO^??\ 2C_AH2Z_Y]_TKKO^&?/#'_/S>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD_[[KU[[/!_SQB_[X%'V:#_GC'_WP* /(?\ A;FO_P#0KR?]]TG_  MS7_\
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MKR?]]T?\+<U[_H6)/^^Z]>^S0?\ /&/_ +X%'V:#_GC'_P!\"@#R'_A;FO\
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M\"@#R'_A;FO_ /0L2?\ ?='_  MS7_\ H6)/^^Z]>^S0?\\8_P#O@4?9H/\
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M7D_[[I1\6_$'?PO(1Z[Z]=-O /\ EA'_ -\"@00'_EC'_P!\"@#R/_A;FO\
M_0L2?]]T?\+<U_\ Z%>3_ONO7OLT'_/&+_O@4?9H/^>,?_? H \A_P"%N:__
M -"O)_WW1_PMS7_^A8D_[[KU[[-!_P \8_\ O@4?9H/^>,?_ 'P* /(/^%N:
M_P#]"Q)_WW2_\+<U_P#Z%>3_ +[KU[[-!_SQC_[X%'V:#_GC'_WP* /(?^%N
M:_\ ]"O)_P!]TG_"W-?_ .A7D_[[KU_[-!_SQC_[X%'V:#_GC'_WP* /(?\
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M4?9H/^>,?_? H \A_P"%N:__ -"O)_WW1_PMS7_^A8D_[[KU[[-!_P \8_\
MO@4?9H/^>,?_ 'P* /(?^%N:_P#]"O)_WW1_PMS7_P#H5Y/^^Z]>^S0?\\8_
M^^!1]F@_YXQ_]\"@#R'_ (6YK_\ T*\G_?='_"W-?_Z%>3_ONO7OLT'_ #QC
M_P"^!1]F@_YXQ_\ ? H \@_X6YK_ /T+$G_?=+_PMS7_ /H5Y/\ ONO7OLT'
M_/&/_O@4?9H/^>,?_? H \@_X6YK_P#T+$G_ 'W1_P +=U__ *%>3_ONO7_L
MT'_/&/\ [X%'V:#_ )XQ_P#? H \@_X6YK__ $*\G_?='_"W-?\ ^A7D_P"^
MZ]?^S0?\\8_^^!1]F@_YXQ_]\"@#R'_A;NO_ /0KR?\ ?='_  MS7_\ H5Y/
M^^Z]>^S0?\\8_P#O@4?9H/\ GC'_ -\"@#R'_A;FO_\ 0KR?]]TG_"W=?S_R
M*\G_ 'W7K_V:#_GC'_WP*0VT'_/&+_O@4 >1'XNZ^!G_ (1>3_ONH9OB5K6I
MIY<N@R6ZGC<7KV/[/!_SQC_[X%<WXMTQ[K3W6UA7=M_A6@#SFU\4ZCHV6M[-
MKO<=Q DZ9[5<_P"%N>(/^A7D_P"^Z9\/O#VL65Q*;VW<*96(WKVS7L @@SCR
M8_\ O@4 >1_\+<U__H5Y/^^Z/^%N:_\ ]"O)_P!]UZ]]F@_YX1_]\"C[-!_S
MPC_[X% 'D/\ PMS7_P#H5Y/^^Z/^%N:__P!"O)_WW7KWV:#_ )X1_P#? H^S
M0?\ /&/_ +X% 'D/_"W-?_Z%>3_ONC_A;FO_ /0KR?\ ?=>O?9H/^>,?_? H
M^S0?\\8_^^!0!Y#_ ,+<U_\ Z%>3_ONC_A;FO_\ 0KR?]]UZ]]F@_P">,?\
MWP*/LT'_ #QC_P"^!0!Y#_PMS7_^A7D_[[H_X6YK_P#T*\G_ 'W7KWV:#_GC
M'_WP*/LT'_/&/_O@4 >0_P#"W-?_ .A7D_[[H_X6YK__ $*\G_?=>O?9H/\
MGC'_ -\"C[-!_P \8_\ O@4 >0_\+<U__H5Y/^^Z/^%N:_\ ]"O)_P!]UZ]]
MF@_YXQ_]\"C[-!_SQC_[X% 'D/\ PMS7_P#H5Y/^^Z/^%N:__P!"O)_WW7KW
MV:#_ )XQ_P#? H^S0?\ /&/_ +X% 'D/_"W-?_Z%>3_ONC_A;FO_ /0KR?\
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M+<U__H5Y/^^Z/^%N:_\ ]"O)_P!]UZ]]F@_YXQ_]\"C[-!_SQC_[X% 'D/\
MPMS7_P#H5Y/^^Z/^%N:__P!"O)_WW7KWV:#_ )XQ_P#? H^S0?\ /&/_ +X%
M 'D/_"W-?_Z%>3_OND_X6WX@[>&)#_P.O7_LT'_/&/\ [X%'V>#_ )XQ_P#?
M H \2NO%^IZ\_FSV#V;?W"]3V_Q&US1HA;1:"]RJ\;Q)UJ[\1_#FM7VJ>9ID
M>(\#[BUU7@72KVTT:%-0C4N%&0R\T <</BYX@[^&)/\ ONG?\+<U_P#Z%>3_
M +[KUT06^<>1'_WP*7[-!_SQC_[X% 'D/_"W-?\ ^A7D_P"^Z/\ A;FO_P#0
MKR?]]UZ]]F@_YXQ_]\"C[-!_SQC_ .^!0!Y#_P +<U__ *%>3_ONC_A;FO\
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M /H5Y/\ ONC_ (6YK_\ T*\G_?=>O?9H/^>,?_? H^S0?\\8_P#O@4 >0_\
M"W-?_P"A7D_[[H_X6YK_ /T*\G_?=>O?9H/^>,?_ 'P*/LT'_/&/_O@4 >0_
M\+<U_P#Z%>3_ +[H_P"%N:__ -"O)_WW7KWV:#_GC'_WP*/LT'_/&/\ [X%
M'D/_  MS7_\ H5Y/^^Z/^%N:_P#]"O)_WW7KWV:#_GC'_P!\"C[-!_SQC_[X
M% 'D/_"W-?\ ^A7D_P"^Z/\ A;FO_P#0KR?]]UZ]]F@_YXQ_]\"C[-!_SQC_
M .^!0!Y#_P +<U__ *%>3_ONC_A;FO\ _0KR?]]UZ]]F@_YXQ_\ ? H^S0?\
M\8_^^!0!Y#_PMS7_ /H5Y/\ ONC_ (6YK_\ T*\G_?=>O?9H/^>,?_? H^S0
M?\\8_P#O@4 >0_\ "W-?_P"A7D_[[H_X6YK_ /T*\G_?=>O?9H/^>,?_ 'P*
M/LT'_/&/_O@4 >0_\+<U_P#Z%>3_ +[H_P"%N:__ -"O)_WW7KWV:#_GC'_W
MP*/LT'_/&/\ [X% 'D/_  MS7_\ H5Y/^^Z/^%N:_P#]"O)_WW7KWV:#_GC'
M_P!\"C[-!_SQC_[X% 'D/_"W-?\ ^A7D_P"^Z/\ A;FO_P#0KR?]]UZ]]F@_
MYXQ_]\"C[-!_SQC_ .^!0!Y#_P +=U[_ *%>3_ONC_A;NO\ _0KR?]]UZ]]F
M@_YX1_\ ? H-M!_SQC_[X% 'D/\ PMO7_P#H6)/^^ZBG^)FMZE$;:;P_)"I_
MY:&3I7L!@A!_U,?_ 'P*P/&.GR76@216<*^<3QM49H \QMO$NHZ-,;NWMFNG
M;K$'Z5H?\+=U[I_PB\G_ 'W57X>>&-:L?%%Q/J,+^20,;UX[U[3]G@_YX1_]
M\"@#R+_A;NOCC_A%Y#_P.J6J?$W7]0LVA_X1F1=PQ]^O:OL\'_/"/_O@4OV:
M'_GC'_WP* /G'P'X9UVZ\3B]FL6@0MN.:^BK>';;HK?>45*(T7[B*OT%.&*
M%7I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8I,>YIU% #
M=O/6EY]J6B@!**6B@!*,4M% "44M% "8S3=O/7\Z?24 -*GMQ1M Z4^DZT &
M,CK10** #%+24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444GXT +112"@!:0C-+
M10 S:3U_2@J0.,'ZT^B@!@7(YQFC9BG44 )@T '.:7.** "BBB@ HHHH 6BB
MB@ HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "DI:2@!:0CTZTM% "8)'--*GVI]% $>PYX.*7
M8<YS3Z* "BBB@ I*6DZT %+2=** %HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH *6D_"B@!:2E
MI,4 +2$9I:2@!H3C&32!-O<T^B@! *=249H 6BBB@!*6DHZT +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 )1UI:3B@!AC).<FD,9/TJ6DH 8$(X'2G8]:7(Q1F
M@ I:** $^@HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%(2!0 =J8<YI))5CC9V.% S7DOC3XRVNA7
M,EIIZ^;,G#;N<&@#UP$T%CCI7R+JOQ4\5ZW=,\%Q) ">%A)%5O\ A)O'I3/V
MG4L>NXT ?8!+>AI02?PKY,TCXO>*=&N5$\IG /S+,2>*]@\'?&6PU^=+2Z3R
MKA^%&, F@#U8$&G56CD9@K #:PR,59H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M-)I:8_N?RH
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MV/M(:E_X3CQD.NHWO_?9H ^SL4S.#7QQ;^-O%[W*!M2O<9Z;S7TA\-;Z]O\
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MG[PZ=:\>MO">MW,PC33IBQ]!0!ZK\+Y?!]EH,USKHA$@( ++DUVJ^+?A4[A
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MZWJTJRW5NT,0/?N*^C/"/ABW\,Z9';0 ' ^; QS0!T0;  QGCM3EZYJ/<,X
M_&I5H 6EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 AZ4TC(Y'YT^B@"LUE:L=SV\+'U* TJVELAREO$OT0"IZ,4
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MW@&Q\2ONO+I(U&/D)ZT ;;_M!:\K'9:6[+[U'_PT%X@)S]DMP*]2LO@OX*2
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M%:1H&E@2:9=K*%4G@=L5H:_XXT;3;"?;>JMPH^48[T =)<7=O;1F2:944>K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *&L6[W.ESPQ_?=<"OG7_A1>OZEJMQ<33VZ1/*S ,3G&:^ESUYI"
MH[T >1:+\([#PY:M=7!$LP&,=17B?Q%*KXCDCCC1$"\!1BOKK61_Q+9,5\B?
M$;_D9Y1[?U- $_PY_P"0FO\ OU]>V'_(-M_^N:_RKY"^'/\ R$U_WZ^O+#_D
M&V__ %S7^5 %D=*"<4S/%4=7OWT_3YKA "40MS[4 :/:FY%>#77QZNK6[EA:
M"'Y#@<56_P"&@KK'$$/Y4 ?058/B?0H];L71OO;<"O'5^/\ <L5 @AR3@\5Z
MOX1\3CQ+8)<-@,>H% 'S+XW\%:AH-ZTK0.8V;@@5S%AK%[I5R)8)70CMN(K[
M:O[#3K]/+O(;>4'M)@UR>J?"WPUJH*K:PPY_BB44 >*Z'\:=7TQ LJ!U]3S7
M<:3^T'II^74;:?<3U11BEU#X Z8S$VUQ.?;-<IJ'P,U"#?\ 9U=@.F30!ZS8
M_%WPK?JI,_E;NTA KI[+5](U15>TN+60-TP0:^0-9\$ZWHDKK<VC *>H!-9]
MAKVJZ7(OV>[GBVGH&(H ^Y$C15RJ*/H*%.2=U>2_##Q[)K#QVEU.7;'4G)Z5
MZT#D9 X- '$_%ARO@><H2#O'(^AKY%:YF\XMYCDAL\FOKGXM8_X06?']\?R-
M?(+Y$C?[QH Z_3+KQ'XDCBLK.5U5/D!5C7H&C? [5+Y!+K-X&5AD .2:F^ -
MO#-]I,D:L1)U(]A7T"(E08!X]* /G#Q)\"+ZQB^T:;+&Z#JI)S7F%S'JGAK4
MO*D>2*1>3M)%?;[*K1L",C'>OF?XS00)J99(E#8Z@4 =/\,_BB;FW2QOB24.
MT$]Z]NBE$T*2)]UU!%?#GA^>6'6+?RY&7+#.#7V3HTSGPW;-O.[R5Y_"@#!\
M=^.X?#=A-Y7-PBGCWKYAU3Q#JGB+4B1-*3*V H8XYKIOBC=3R:[<!IG9=QX)
MKB](U$Z9=1W$<0D=&# $9H ],\(_!R^UU1+J+[(\9Y)S73ZG^S_;)9%K"X/G
M#^\>*YBW^.7B*V@6*+2XPJC'"'_"IA\>_$X_YAJ?]\'_  H X'7=%UOPAJ1A
M=ID"\AT) -=]\-OBG-::A#::H[/&QV YR<GI7*>*_'VJ^+8E2ZTY8R/XD0Y_
ME7)6,4\=_;N(9!MD4YV'UH ^Y[29+FV2>,G:XR,UB^+O$</AK1)+QR&8' 4=
M:QOAMJ4M]IRI(TAV)T85Y;\<KZZ34XH%GD$1!R@/% '#>+O'FH>)=08Q221P
M] ,XK2\&_#+5O%JF69RD>>#(3S7GUIDWL6?[]?9'P^BBC\)V)50"4YP* /.'
M_9]M/LWRW'[['=N,UY=XD^'VN^&KN18XY71"</'FOL7CTJM<V=M<J5GMXY >
MH89H ^9?AC>^)],UB-S:7DT9.#O!( KZ4LKI[J!79"C8^8,,5-!96UJ,V]O'
M'_NC%28!YP!0!E^(R?[%DVG!KY)\;S2+KLF9&Z]C7UMXCQ_8LFVOD3QUG^W9
M/K0!J_#:1Y/$$(,CXW^M?0_B?PW?>(= 6WLYD1V7JYQ7SK\,C_Q4$/\ OU]<
MZ?C[#%QVH ^4?%7PPUSPY ]U>WD#H3T5R:\^"YEV=R<5]/?&0?\ $C8^]?,*
M?\?0_P!Z@#OO#/PJU[Q);B>RNX(T/9F(KV#P3\/-7\,6X%]=QN5.3M8T_P"#
MF?[)7)KU*X4&(G&30!\H?%>XD'BBX"R,/G/0UB^!9YCKUMF1S^\'>M3XKG_B
MJ;G/!WFLGP$?^)];?]=!0!]A::0-+A9C@;>2:\O^*OQ CTFR.GVS'SG.0RFO
M1)"5\+,5.#Y?45\I?$B65]; >1FY/4T 8;W^K:Y=[%EFD9S@*&)KU'PK\#KS
M4XUN-5F"Q,,X!.:X7X?A?^$@@/4[Q7U]I1']GQYXXH \.UKX!1V]A+-8R[W4
M9"D]:\GO/#?B+1+WR5@NE.>/+!%?:QQW[U5ETVQF<22VL3L.Y6@#R+X2:IK8
MB-K?VETL8QB24'!KV=&W<XJ.."&-=L<2JH[ 5(H]Z .)^(Y T&X.[!VG^5?(
M+7$OF']Z_P![UKZ[^)0/]A7''\)_E7Q^3^\/'\5 'T3\)4DGC:,,^YXF +'C
MI6=XU^$_B.\\Z^2\MUA0[B"YSBMCX-?ZR/YC]T_RKU7Q+_R+UY_N4 ?%.J:;
M/IEP8IW5F!QE35CPWH%WXAU..SLY%21V !8XJYXQS_:<G^]6Q\)?^1OMO^N@
MH ZW3?@=XLM[Z"=K^V\M'#,-YZ9K8^*7@R_;189;25!]GYDP>M>[1#]T*JZG
MI\%]82V[Q*V\8P10!\165]<Z=J(?S7#*<9W5]3_#'Q1#J?A](&D9IU/)8^U>
M'_%+PR-'U96B@$:').T<57^&_BZ70]4*L1L8@8- 'UNC_,<BO/?B=XIAT[2Y
M[+=AV7M]*ZJ+64E\.+?@J"R;J^6/B)XGEUK7)]LS%4<K@'TH Y%6N9YOEE=B
M6Z U],_"CPO)IL45](&RR]_<5YO\)_"L=_J5M<W-L)(BP)W+D5].6\$5M$(H
M4"*.@ H <5'O0,]J?CVHVB@!1G%+2=J6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>T>&/ ^F>&40PX,BC&2* -S3H(K:W0K (2PY4#I7FGQ:\"'6K ZA;@O.AP%
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MAQW0F@#Z(NO'?AVUA,DFHH%'I7E7BWXXFSOU31&\Z'G<>E<1)\)_&+.L;LS
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 9L%+M'>G44 -V#M2;/<T^B@!,4W8 >!3Z* $Q1BEHH 3%&T4M% "8HQ2T4
M)BDV4ZB@!NP=#2@8Z4M% "$4FW/6G44 -*\4!:=10 @&.E&#ZTM% #2N>O-&
M/2G44 -VT9-.I"* &G)KE_&EQJ5GI,T]@X5D&>3748JM>6,%_ T-S'OC;@C-
M 'RQJWQ1\6P2/;//CGJI.:XF\OM5UZ[\RX:::1N.<FOK2?X6^$+F3?+I@9S_
M +9J>Q^'7AC39-]MI:JWN<T >(_#OX57.I/'>WH*J&RHQBOH^PL8;"SBMXU
M"(%XJ2&VBMHA'#&J*.@ J4# R: $V%3G/%.!!/ HSD<4HZ4 .HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!,4M%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HQ110 8HHHH 3%+110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %_ M # 2(  A$! Q$!_\0
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MKCP1_P!";X;_ /!7!_\ $UU5% '*_P#"N/!'_0F^&_\ P5P?_$T?\*X\$?\
M0F^&_P#P5P?_ !-=510!RO\ PKCP1_T)OAO_ ,%<'_Q-'_"N/!'_ $)OAO\
M\%<'_P 37544 <K_ ,*X\$?]";X;_P#!7!_\31_PKCP1_P!";X;_ /!7!_\
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MKCP1_P!";X;_ /!7!_\ $UU5% '*_P#"N/!'_0F^&_\ P5P?_$T?\*X\$?\
M0F^&_P#P5P?_ !-=510!RO\ PKCP1_T)OAO_ ,%<'_Q-'_"N/!'_ $)OAO\
M\%<'_P 37544 <K_ ,*X\$?]";X;_P#!7!_\31_PKCP1_P!";X;_ /!7!_\
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MKCP1_P!";X;_ /!7!_\ $UU5% '*_P#"N/!'_0F^&_\ P5P?_$T?\*X\$?\
M0F^&_P#P5P?_ !-=510!RO\ PKCP1_T)OAO_ ,%<'_Q-'_"N/!'_ $)OAO\
M\%<'_P 37544 <K_ ,*X\$?]";X;_P#!7!_\31_PKCP1_P!";X;_ /!7!_\
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MKCP1_P!";X;_ /!7!_\ $UU5% '*_P#"N/!'_0F^&_\ P5P?_$T?\*X\$?\
M0F^&_P#P5P?_ !-=510!RO\ PKCP1_T)OAO_ ,%<'_Q-'_"N/!'_ $)OAO\
M\%<'_P 37544 <K_ ,*X\$?]";X;_P#!7!_\31_PKCP1_P!";X;_ /!7!_\
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MKCP1_P!";X;_ /!7!_\ $UU5% '*_P#"N/!'_0F^&_\ P5P?_$T?\*X\$?\
M0F^&_P#P5P?_ !-=510!RO\ PKCP1_T)OAO_ ,%<'_Q-'_"N/!'_ $)OAO\
M\%<'_P 37544 <K_ ,*X\$?]";X;_P#!7!_\31_PKCP1_P!";X;_ /!7!_\
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M$@9R(T.U<!< 8XQ0!SOBKQQJNC:]'!93:=/91W-G:R6Z:==3N!*Z*QDN4Q#
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MM'%Y:6@2R6TN+:)I0H,5R"1<+*SO\K(2@5HV((W9VO'S%->\%,IPRZG,0?\
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M_P#CM']J7?\ T M2_P"_EO\ _': -6BLK^U+O_H!:E_W\M__ ([1_:EW_P!
M+4O^_EO_ /': -6BLK^U+O\ Z 6I?]_+?_X[1_:EW_T M2_[^6__ ,=H U:*
MRO[4N_\ H!:E_P!_+?\ ^.T?VI=_] +4O^_EO_\ ': -6BLK^U+O_H!:E_W\
MM_\ X[1_:EW_ - +4O\ OY;_ /QV@#5HK*_M2[_Z 6I?]_+?_P".T?VI=_\
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M: -6BLK^U+O_ * 6I?\ ?RW_ /CM']J7?_0"U+_OY;__ !V@#5HK*_M2[_Z
M6I?]_+?_ ..T?VI=_P#0"U+_ +^6_P#\=H U:*RO[4N_^@%J7_?RW_\ CM']
MJ7?_ $ M2_[^6_\ \=H U:*RO[4N_P#H!:E_W\M__CM']J7?_0"U+_OY;_\
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M[_Z 6I?]_+?_ ..T?VI=_P#0"U+_ +^6_P#\=H U:*RO[4N_^@%J7_?RW_\
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M4XXJ37O#37?BJ:>R\*+;ZG+?VUROB,312;(T\O>/F82QEDC:/8BE"",GYFP
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MZ1_S^>)/_"CU'_X_0!U5<!\?O^2-^+/^O)OYBM7_ (0/2/\ G\\2?^%'J/\
M\?KBOC3X2T[3/A3XGN[:YUMY8[)]JW.MWEQ&<X',<DK*W7N#@X(Y H [7X3_
M /)+/!O_ &!;/_T0E=57*_"?_DEG@W_L"V?_ *(2NJH **** "BBB@#E?B7_
M ,B[9_\ 8:TG_P!.-O755ROQ+_Y%VS_[#6D_^G&WKJJ "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<Z];IM/NH!)%']L?%^YY@\+>%['H0+K47EQZCY!UH ]3HKRW[-\9[GB:_P#
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MR;^8H U?A/\ \DL\&_\ 8%L__1"5U5<K\)_^26>#?^P+9_\ HA*ZJ@ HHHH
M**** .5^)?\ R+MG_P!AK2?_ $XV]=57*_$O_D7;/_L-:3_Z<;>NJH ****
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M]ZZGP]J/Q)\:VOVG2_&7@:TMCR6T>%[UX_9O,. W8T =_P#\)YI'_/GXD_\
M"<U'_P",4?\ ">:1_P ^?B3_ ,)S4?\ XQ7*_P#"MO%U[_R&OBGKTN>O]GVL
M-E^6W.*7_A2'AZX_Y#6L^*M:]?[0U>1]WUV[: -G4/BOX3TW/]HSZO:8Z^?H
M=]'C\X?<?G6*?V@OAB"0?$V".H_L^Z_^-5HZ?\%?AU88\CPI8/C_ )[EYO\
MT-C73Z?X0\-::0=.\/:/:8Z>1911X_): .('QY\#W'&D7.J:N_\ <L=,G8Y]
M/F0>WYBJ6H_&F]1<Z5\,O'EWQE6ETMHE;W!&XXZ=N]>OJH50J@!0,  8 I:
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M  GFD?\ /GXD_P#"<U'_ .,4?\)YI'_/GXD_\)S4?_C%=510!RO_  GFD?\
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M*(0:?A448 _X]?05V=% &3X=T*#1/#EIHJSSWMM;1>2KW80LR<X4A55< ?*
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MQS\0O#?@F%?[<U!5NY/]390#S;B8GH%C'//J<#WKBC-\2?B(!]E0^ _#K_\
M+24"34IU]EZ0_HP]ZZWP/\-/#?@^5KNPM7N]7DYFU2^?S[J4GJ2YZ9_V<"NT
MH X'PW\)/"6@VLPAL'N]0GYEU.[E,MXSYSO$O5&R <KCD UUVB:3!I%LZ1/+
M/-*WF3W,Y#2SOC&YR !G           K0HH **** "BBB@ HHHH *QO%>@+X
MBT^&U;4+VP\JYCN5DM!$6+1G<H(D1U(# -R.JBMFB@#B]2\#WNIVPM[_ ,:^
M))H1(DH7RK!<,C!U(*VH((90<@]J[2BB@ HHHH **** "BBB@ HHHH ****
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M[\:=_P#(M=510!RO_"+ZO_T/?B3_ +\:=_\ (M'_  B^K_\ 0]^)/^_&G?\
MR+7544 <K_PB^K_]#WXD_P"_&G?_ "+1_P (OJ__ $/?B3_OQIW_ ,BUU5%
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M[\:=_P#(M=510!RO_"+ZO_T/?B3_ +\:=_\ (M'_  B^K_\ 0]^)/^_&G?\
MR+7544 <K_PB^K_]#WXD_P"_&G?_ "+1_P (OJ__ $/?B3_OQIW_ ,BUU5%
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M[\:=_P#(M=510!RO_"+ZO_T/?B3_ +\:=_\ (M'_  B^K_\ 0]^)/^_&G?\
MR+7544 <K_PB^K_]#WXD_P"_&G?_ "+1_P (OJ__ $/?B3_OQIW_ ,BUU5%
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M[\:=_P#(M=510!RO_"+ZO_T/?B3_ +\:=_\ (M'_  B^K_\ 0]^)/^_&G?\
MR+7544 <K_PB^K_]#WXD_P"_&G?_ "+1_P (OJ__ $/?B3_OQIW_ ,BUU5%
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M[\:=_P#(M=510!RO_"+ZO_T/?B3_ +\:=_\ (M'_  B^K_\ 0]^)/^_&G?\
MR+7544 <K_PB^K_]#WXD_P"_&G?_ "+1_P (OJ__ $/?B3_OQIW_ ,BUU5%
M'*_\(OJ__0]^)/\ OQIW_P BUQ7QIT'4;+X4^)[BY\6:WJ$263[K:YBLUC?.
M!R8[=&XSGAAR!G(R*]?K@/C]_P D;\6?]>3?S% &K\)_^26>#?\ L"V?_HA*
MZJN5^$__ "2SP;_V!;/_ -$)754 %%%% !1110!ROQ+_ .1=L_\ L-:3_P"G
M&WKJJY7XE_\ (NV?_8:TG_TXV]=50 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<!\?O^2-^+/^O)OYBN_K@/C]_P D;\6?]>3?S% &K\)_^26>#?\ L"V?
M_HA*ZJN5^$__ "2SP;_V!;/_ -$)754 %%%% !1110!ROQ+_ .1=L_\ L-:3
M_P"G&WKJJY7XE_\ (NV?_8:TG_TXV]=50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<!\?O^2-^+/^O)OYBN_K@/C]_P D;\6?]>3?S% &K\)_^26>#?\
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M (./F;XN\+:Y>WFKG1Y-/EAUK2TTNZDO9&1[?;Y@\U%5&$F1,WR$H,J.>3@
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M_/$G_A1ZC_\ 'ZZJB@#E?^$#TC_G\\2?^%'J/_Q^C_A ](_Y_/$G_A1ZC_\
M'ZZJB@#E?^$#TC_G\\2?^%'J/_Q^C_A ](_Y_/$G_A1ZC_\ 'ZZJB@#E?^$#
MTC_G\\2?^%'J/_Q^C_A ](_Y_/$G_A1ZC_\ 'ZZJB@#E?^$#TC_G\\2?^%'J
M/_Q^C_A ](_Y_/$G_A1ZC_\ 'ZZJB@#E?^$#TC_G\\2?^%'J/_Q^C_A ](_Y
M_/$G_A1ZC_\ 'ZZJB@#E?^$#TC_G\\2?^%'J/_Q^C_A ](_Y_/$G_A1ZC_\
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M  D9TZR.L:1#IBK83//Y13S\OET3.?-! QV(]R +X>T?PKXA6?\ LS4?%9>
MKYD5QK6JV\BAAE6V22JVTC.&Q@X.#P:Q%C\/6.H:U#KE_P")(4M]4&G6:V^M
MZK+),?LL<^W:DS%F^9\8 S@ #/7J/A_X8N]%O+Z]U."&*ZGBBMP5U:[U%F5"
MQR9+@C:,N<(J\<DLV<"'_A#[X^+!J;2VAMQKIU3;N;=Y?V#[.!C;C=OYZXQS
MG/% &<]KX,70;;6!JWBI[*YF-O"(]9U9YI)06!C$(D,F\%6RNW(VG(&#6-H<
M_AB;P^VJ:KJ'B=4DOKNWMTM-7U>:1XH974.8DE9QA5!8D  GG&0*Z2/PCJ]C
MI^F36+6$VIZ;J][J$<,TSQPS1W#S?*7"$JP68'.UN5(Z'-8\OP]UHPV=Z[VL
M^IQ7.H/)!;ZM=:?&4NIQ*")H5\S*[5&PC:<GD$"@#7FTCPC#/912:SXA'VRW
M>ZMY/^$BU(Q2Q( S,)/.V<*=V,YQDXP#5?5=(T*'PC_;6GW7B:;ST06:3^(-
M3A\V21@D2E6F#*"S+U&<'-6=9\!2ZMX=T7PU)):6NBV%L"[P!FD,ZIMC"+)N
MQ&,ECN9BV IRI;-OQA:ZI<^ +>;58;5M4T^:UU"XCLRTD;^1,DC^7N4-RJ'
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M#P?_ !Z@#W^BO /^&J_!'_0*\2?^ \'_ ,>H_P"&J_!'_0*\2?\ @/!_\>H
M]_HKP#_AJOP1_P! KQ)_X#P?_'J/^&J_!'_0*\2?^ \'_P >H ]_HKP#_AJO
MP1_T"O$G_@/!_P#'J/\ AJOP1_T"O$G_ (#P?_'J /?Z*\ _X:K\$?\ 0*\2
M?^ \'_QZC_AJOP1_T"O$G_@/!_\ 'J /?Z*\ _X:K\$?] KQ)_X#P?\ QZC_
M (:K\$?] KQ)_P" \'_QZ@#W^BO /^&J_!'_ $"O$G_@/!_\>H_X:K\$?] K
MQ)_X#P?_ !Z@#W^BO /^&J_!'_0*\2?^ \'_ ,>H_P"&J_!'_0*\2?\ @/!_
M\>H ]_HKP#_AJOP1_P! KQ)_X#P?_'J/^&J_!'_0*\2?^ \'_P >H ]_HKP#
M_AJOP1_T"O$G_@/!_P#'J/\ AJOP1_T"O$G_ (#P?_'J /?Z*\ _X:K\$?\
M0*\2?^ \'_QZC_AJOP1_T"O$G_@/!_\ 'J /?Z*\ _X:K\$?] KQ)_X#P?\
MQZC_ (:K\$?] KQ)_P" \'_QZ@#W^BO /^&J_!'_ $"O$G_@/!_\>H_X:K\$
M?] KQ)_X#P?_ !Z@#W^BO /^&J_!'_0*\2?^ \'_ ,>H_P"&J_!'_0*\2?\
M@/!_\>H ]_HKP#_AJOP1_P! KQ)_X#P?_'J/^&J_!'_0*\2?^ \'_P >H ]5
MU+_DJ?A[_L"ZG_Z/L*/BQ_R2SQE_V!;S_P!$/7C^G_M#>!M7\?:;J5S)J6DV
M5GIEY;M)>VN[?)++:LH40F0](7R3@=/6M;X@_''X=ZQX"\2Z9IWB'SKZ]TRY
5MH(_L5PN^1XF51DQ@#)(Y) H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (9 [ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS:YJ$V+.- R[.3(3]U5]2:\5/QW\8:D9KS1/!RRZ9"?WC^5--L'^TZX5?RH
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M5;==[0JVY9$X&Y3[$\@^HZUD^._C)-H'B8^&O#ND?VKJB85S\S .1G8JKRQ
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MWP9^'7B?PAXPO]0UK3UM[:6R>%'$\;Y8R(0,*2>BF@"K;?LU1_:%:^\4R2Q
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M\0,G]J2H8XH%</Y:G!9F8=6.,<'IGKGCF]6^''CGPC\2+CQ/X/MHM0ADF>9
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M/X@NF1#=HL,:,1RJ'<3CZD#\J]&^&'P]'@GPG-87[Q7%Y?,7NPHR@&,!!GJ
M,\^YKS2\^%/COP+XDGU/P#=>=;R A5$D:N$)SL=9/E8#U_0&@"W^TK:V8BT"
M[ 47S-+&2.K1@*>?H3^IIGQ4EFF_9]\'R7&?.:2T+9ZG_1I.:KV?PL\=^/?$
M<&I>/KDP6D7#*9(RY3.=B+'\JY]3SWYKOOC#X.U/Q-X&T_1_#MDDLEM>QN(O
M,6,)&L<B\%B!QN48H L_!2VBM_A3I!CC56E\V1R!RS>8PR?P 'X5Y3\,HTA_
M:&U6.-0B+->JJ@8 &X\5[9\-M%O_  ]\/]*TK4X1#>6ZN)$#AL9=B.02.A%>
M>^"OA[XFT?XS:CXAOK!8],FFNF283HQ(=B5^4'/.?2@#VVO./'WB7X@Z-KL-
MOX4\.6^I6+6ZN\TD+N1)N8%<JZ]@IZ=Z]'HH \._X3SXT?\ 0CV7_@++_P#'
M:V_"/B[XH:EXHLK3Q!X4M;+2Y"WGW"6\BE,(Q')D(Y8 =.]>K44 %?,WQ4_Y
M+_I?_72R_P#0Q7TS7A_C[X=^)]<^+MAKVGV"RZ;$]L7E,\:D!&!;Y2<\?2@#
M"^-OA2Y\+>*;3QQHFZ%9IU:9E_Y97 Y#8]&Q^8/K7/\ A#7E\3_'_3M:$?E&
M[G#LG]UO)PP'MD'%?3>OZ)9^(]"O-(OTW6]U&4;CE3V8>X."/<5X)X#^$7B[
MPU\2=.U"[L8SIMI</FY6>/YEVL VW=NYR.,=Z */QU=KGXLZ;:7S%;(6\"KS
MP$9VW'^?Y5]'S:=82Z0^FS6T)T]H3"T)&$\O&,8],5P7Q9^&!\>V=O=V$Z0:
MM9J5C\PX25"<[6.,@@Y(/N<]<CSF30/CC/I'_"-2^8=/,?DLYGM^8\8P9,[\
M8[=<4 4_V?IKB'QQK<%H6:V.GR,?0LLBA#]>3^9J/]GI(KCXC7LUP \Z6,CQ
MLW)W%T!/UP3^=>P?"SX;Q^ -(F-Q,D^JWFTW$B?<0#HB]\#)Y[UYWXH^%7B_
MPUXUE\1^ 3N25VE6.)T1H"Q^9-KG:R>GY8XS0!H?M*PP'1="G*K]H%Q(BG'.
MTJ"?U"TNL_\ )J,/_7M;_P#I0E8'B?X<?%+QGI\6IZX\=Q?1R".#3UFB011D
M$NW!"@Y"#@DGOT%>J:=X*N+WX,0^$=446]VUEY3_ #!A'(&W*<C((!"GB@#G
M_P!G4_\ %OKO_L(/_P"@)7$Z@ZR?M5HRG(%["OXB!0?Y4_PMX3^,?@J6ZTO1
M;:!;6X;<TCRPO$K=/,7<<@^V.>X-7="^$WB[2/BMIVM7>+^V2=;B[OS,@+.R
MY<A2=Q 8D=.>N* *7[2G_(Q:'_UZ/_Z'5O\ :%>0>'O!R GRFCE+?[P2+'\V
MK<^-GP_\2>,=9TNXT.Q6YB@MV20F=$P2V?XB*ZWQ_P##X>-_!-KIOF)!J5FJ
MO;2-]T.%P5;'\)]O0&@#B-$O_BH/!=CIECX-T672FL4BB8S+^\B*8W'][U(.
M3QU-6O@CX(\5>#M5U;^V['[+:74";<3H^YU8XX4GLS5SUKHWQLTOPZ_A2VLX
MWL2AB2?SH2R1G@JKEL@8SU&1VQQ7IOPJ\#7_ ()\/R1:IJ$ES>W#!FB$K-%
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M%U\9],MM0.++RK:/YN!Y9D.[]2U>[^.;6TD^'FOP7"(MNNG3'&.%VH2I ]B
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MPUN;ZRC8-T\L^7D?3DUW7PT^$>J:=XD;Q7XPG674P[210"02'S&ZN[#@GDX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M",^_-97C#Q79^#/#\FLWT$\T"2)&4@ +98X'4@4 ;U%(IW*&'<9I: "BBB@
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M44 %%%% $%DXDL+=P7(:)2"YRQX'4]S4]066/L%OMV;?*7&S.WH.F><?6IZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.3_60
M_P"__P"RFI*CD_UD/^__ .RF@"2BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O_JV^AIPZ4U_]
M6WT-.'2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"%?^/R3_ *YI_-JFJ%?^/R3_ *YI
M_-J;->P0\%MS>B\T 6**RSJS9XB&/<U)'JJ$XDC*^X.: -"BHH[B*7&R123V
MSS4M !1110!!9H(K&WC7=A(U4;EP>!W'8U/4%D)!86XE.Z01+N);.3@9Y[U/
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R?Z
MR'_?_P#934E1R?ZR'_?_ /930!)1110 45#-=10#YVY_NCK5)M6.?EB&/<T
M:=%9R:J,_O(B!ZJ:M1W<$HXD4>QX- $]%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 -?_5M]#3ATIK_ .K;Z&G#I0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!"O_'Y)_US3^;5@M]X_6MY?^/R3_KFG\VK!;[Q
M^M "4444 '0Y%78-1ECXD^=?UJE10!O17D$Q 5_F/8\5/7-5:AOYH>,[U]&H
M TM/;?IMJ^U5W0H=JC@<#@59K,LM4@DM("3)S&OS/R3QU/O6@DL<GW'5OH:
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MNH'^[*OXG% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-3UO3KV:[2%XF"^6V#YP!W!1D_7MWKH&=4*AF"[C@9/4T ,2VA3[L2#\*D
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M/YB-H')-*I5D!0@J1P1TQ0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M3QC<Z0UJ/LL<(=90.>BG)R>F21P,Y_'"^&O$)\00W$AM?(\E]N-^[.?P%;E
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MNX9ZCU!]P>* ,[PM82V/AJUM;N$)+AMZ$#NQ//X$5I2-;:;8.^Q(;>!"Q5%
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MM>_#^^L8YKNQO/->%M\2*I$A &<@C^+/0#\^U92^,=<%M+F_)=I58,5&1UR
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M;6;;7+)KJU618UD,9$@ .0 ?7W%:-5=/TZTTNU%M90B&$$MM!)R3W)/)JU0
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MQVUM&(X8QA4':IJ ,?PSJMQK.C)>W,21NSLH" @$#C/-;%%% !1110 4444
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MK(?]_P#]E-25')_K(?\ ?_\ 930!)1110!G:?H=EIE[=7=LC++=-N?+<#G.
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M4 %%%% !1110 4444 %%%% !1110 4444 %1R?ZR'_?_ /934E1R?ZR'_?\
M_930!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #7_ -6WT-.'2FO_ *MOH:<.E !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-=%D
M1D895A@C/:@#F/[>UU]9:U3176"*Y$3LT;8>-F #*_W>$#2$\@?*GWC74UQ7
MG:J?$!2/0BD,5V%9G\P[T+@*RONV\*&D/!'*I][FNUH7PH'\3"BBB@ HHHH
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MQV]JFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HY/]9#_ +__ +*:DJ.3_60_[_\ [*: )**** "BBB@ HHHH **** "BBB@
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M>:X7<WH,]34].SM<+A1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLFSY3C#'D9 P>!SS73C..:TE3481E=.]].WJ2I-R:ML%%%%9E!1110 4444
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MUG7_ (?U'P%<Z1JMLZ75X2ZRJ%+H'.0 .A(*MCZ@\\C"P]*E&'LN92=VX?\
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MI?>*-)\275PL>VS3SH"I#*^SE0/3+$_TK1TWQ7%J/BJ_T,6DD;6H)$Q)P^"
M<C'')X.3G\JS_#NLWD/B63PM+;9@T^RC191@$E54%CR>&W# '(XR.N.KCL[6
M*YEN8[:%+B7 DE6,!GQZGJ:\;$2L^6JK^[[MNBW1W4U=7@^NI/1117GG0%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!"O\
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M8Y\W'L *@>>63[\CM]33HNK3ES7OHU\F*<825O.Y#XF&O'Q%H\FEW*QV2/\
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MTX=*:_\ JV^AIPZ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXH E\^3_ )])OS3_ .*J.6XD!C8VLP ?GE.X('\7J15NB@"#SY/^?2;\T_\
MBJ//D_Y])OS3_P"*J>JM_J-KIEM]HNW98]P4!(V=F)[!5!)/T'8T .%T[%@+
M6;*G!Y3TS_>]Z7SY/^?2;\T_^*J!M1LX)K=-TKM>G?%Y4+R C"C)*@A5Y7DX
M'-7J *LMX887EDM9E1%+,<IP!U_BI_GR?\^DWYI_\54]% $'GR?\^DWYI_\
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M _WO>FZAJ=II<*2WDIC1VV@A&;G!)SM!P  22> !S45WJ=AI=Q&ES,R/=/\
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M:* (//D_Y])OS3_XJCSY/^?2;\T_^*J>B@!J,77+1LA]&QG]":=110 4444
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M3Q5'7=+OKV]TUH;*62.VS$7\Q%P=T3"1OF^:/"ME>23M.W@$=710@>H4444
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MS\/V-C+&\(ES$^Z(-(2(QM90H']T!FP/>M2BB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image12.jpg
<TEXT>
begin 644 image12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (^!!D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHI"0!DD#ZT +141N8%^]-&/JXIAO[4?\ +Q'^!IV8KHL455.I
M68_Y;K^1I/[2L_\ GN/R-%F',BW158:C:$?Z]:<+RU/2XB_[Z%%F%T3T4Q98
MV^[(A^C"GTAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !114<L\4"YED51[F@"2BLJ;6XEXAC9SZG@5GS:I=2\>9L
M'HG'Z]:M0;(=2*.BDECB&9'5!_M'%5)-7M(^C,Y_V1_C7.LQ8Y8DGU)I*I4U
MU,W5?0V)-=/_ "S@ ]V-57U>[?HZI_NK_C5&BJY42YR?4F>[N7^]/(?;<:B)
M+')))]Z2BJ)N%%%% @HHHH **** "GK+(GW'9?H<4RB@9:34;M.D['_>Y_G5
MB/6KA?OJCCZ8-9M%+E0U)KJ;D>N1'_61,OT.:N1:A:R_=F4'T;C^=<O14N"*
M51G8YR,BBN2BN)H3^[D9?8'BK\.M3IQ*BR#UZ&H=-FBJKJ;U%4H-5M9N"_EM
MZ/Q^M7 01D'(-2TT6FGL+1112&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4454NM1
M@M<@MN?^ZO\ 7TH2N)M+<MU4N=1M[;(9]SC^%>36+<ZG<7.1NV)_=7_&J=:*
MGW,I5>QHW&L7$N1'B)?;D_G6>S,[;F8L3U)-)16B26QFVWN%%%%,D**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "IH;J>W.8I&7V[
M?E4-% S:M];!PMPF/]I?\*U(IHYUW1.&'L:Y&G1R/$X:-BK#N#4."Z&BJ-;G
M7T5BVVM$86Y7(_OK_A6O%-',F^-PR^HK)Q:-5)/8?1112*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4'FQGF1  ,J!G/;C&?ITK5T+X;W6G:O#J.J>*]4U-X,>5&7>-<>A^=B1G''
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH;?RV.Y!G)W8VC[IZGM0'F:U%9.G>)=(U;5]1TJQO!+>Z<P6ZB\ME\LG..2
M#T/0FM:@ HHHH **** "BBB@ HHJ*YN8;.UFNKB01P0H9)'/15 R3^5#=@6I
M+16;H6O:9XETJ/4](NA<V<A(60(R\@X(PP!'XBM*AJVX!1110 4444 %%%%
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M],NO[;3R887# Q>6Q!)#-SG(/3IT%6]6\/ZS+X/^&$$>DWS365W$;J,6[EH
M"N2XQE1QWQ72_'/2-1UGP?86^FZ?<WLJZC&[QV\32$+M<$D 'CD<UI9*6G\W
MZH4'=*_\K_)FAIWCC4==\9W%EHL%HWAO2T(U'49E8EI /N1$$#CN2#W]LXZ?
M$+QCK.C7OBG0-&TD^'+,R'R[N63[5<(GWF3;\J_0YZ=ZK:?X<U/P3X\O-)L;
M"[F\)^(HVS]FA9UL9B,<X^ZO.,\<$?W:Y#1/ VDZ# VD^*_AMKVJZFLK".^T
MTR/!,A/RDLLBJGX]N34;[=OQOK_P/(%I_72W]7\S2^+VO:AXD\'>%=9T\6B:
M1=W,4B)(7\];C#\''R[!@CUS7M/A_P#MW^R4_P"$B_L[^T-QW?V=O\K;V^_S
MGUKS7X@^$;RY^%>BV^A:#- VFW,=T=+20S2(N&W*#DEF!;MFO2?#VLMKNDI?
M-I>H::68K]GU"'RI1CN5R<#TJM+22[_Y$ZWBWV_S-6BBBI*"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+6;GS)Q
M I^5.3]:V+B86]N\K?PC\S7*,Q=V=CEF.2:T@M;F566EA****U, HHHH ***
M* "BBB@ HHHH **** "BBB@ HHI0"S!5!)/0"@8E/BADG?9$A9O:KAL[>RMF
MO-4N([:W3D[V _,_TKB]=^*<<"M:>'+954<?:95_55_JWY5-V]AM*.LCL[B"
MQTFV^U:O>Q6\0[%L9]AW)]A7(:M\5;2T#0:!8!^WGSC:OU"]3^)'TKS.^U"\
MU*Y:YO;F6XF;J\C9/T]A[56JU3_F,W6_ET-;5O$VLZXQ^WW\LB$_ZH':@_X"
M.*R:**T22V,6V]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *='(\4BR
M1NR.IRK*<$'V--HH ['1OB5KVE%8YY1?P#C9<?>Q[/U_/-=YI?C3PUXAVQS-
M_9UVW\,Q"J3[-T/XX->)45#II[&D:LEH]3Z$N-+GA&^/]['U!7K^54:\KT#Q
MKK/AYE2WN#-:@\V\WS)CV[K^%>G:+XOT'Q5MBD/V#4&_Y9R$?,?]ENC?H:AJ
M4=S5.,MB:BK5U836ARPW)V<=*JT)W!IK<****8@HHHH **** "BBB@ HHHH
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M$_*3M/T-=/7'5U=K+Y]K')W9>?KWK*HNIM2?0FHHHK,V"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUJ_#X&TR[\<ZO;"&5-,T^-'\B)F9G+*"%!.3SS4NHZ[X1U+Q)IWB.34[A)H
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M2;I3G*E@C8YX'."../:DXR=[=E^12G!6OW9LZ%??8/!7B3Q+91B.[N+IEC;
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MBBB@#JX_$]DGPZE\/&*X^UO-Y@?:/+QN!ZYSV]*TG\8:!J.B:3;ZM87[76F
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M<O%V!^7W%05:COH]>\.V.L1 9D0"0#^$]"/P;(JK62>AT25GH%%%%,D****
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MB]0TJ_TJ;R;^SFMW["1" ?H>A_"DI)["E"4=T4Z***9(4444 %%%% !1110
M4444 %%%% !1110 4444 >I?"?5!/;ZAH4S<$>?"#^3?^RG\ZZ9U*.R,,,IP
M:\@\*:K_ &+XGL+TMMC64+*<X&QN&_('/X5[;J\/EWN\?=D&[\:RDK2]3H@[
MP]#/HHHH **** "BBB@ HHHH V-!_P"7C_@/]:V:QM!_Y>/^ _UK9K"?Q'33
M^$****DL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<UH_AZ[T_P ,:AIDLD#37'F;&1B5&Y HSQGJ/2JOA;PM?:'J<ES<RV[HT)C
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M<W,MNZ-"8P(F8G)93W ]*Z^BFL-37+;[.Q,\PK3=1O[=K_(X?_A#=1_X2?\
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M '?,QQG/^WBK<?>Y?.WX7,K^[S>5_P 3U3P]XX\->*Y9X=$U:&[E@^_&%9&
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MFM427LX;=0HHHKK.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@6^I+I%M=2I8M?;PAMX$0EV4]F(7 /JU3?%R)SX&-RJEDL[VVN9,=D60;C^
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MK?B C7FL>"K%0?.?64GP#T6-&9J(_9?G_P /^;'+[2\G_P  [RBBBD 4444
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MS?P3_P C9<_]<I/_ $(5Z17F_@G_ )&RY_ZY2?\ H0KTBN/ _P +YL]?.O\
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MP#MGO7-7<E.%K;]?EL>A@XPE2JN2E=+2U[==_+U\SN****Z3SPHHHH ****
M"CJ,&BB@#E+N'[/=21=@>/IVJ&MG6X.([@#_ &6_I6-6\7='+)6=@HHHJB0H
MHHH R_B1";CP%9S#_EC<J3],,O\ /%>.U[GXCM_MWP[U2+O$OF#_ ("0W]#7
MAE.GLT16W3"BBBM#(**** "BBB@ KT+QW,/"_P )M+T)2%NM0(:49YP/G?\
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M"^5!RNY90=Q;C.&R#72:/X$U27Q/\0O[2M_L^GZZGE6TXD1BP(8$[0<C&1U
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M-E"$CAGU@WZNDB(1RL0&X$X'7WZ5I:]X&U(>,? ,FE6OFZ7H:F*>4RJI10%
M."<G..P-/3FMTO\ A9_\#<5VH7ZV_'3_ (.QV?A*V\16F@1P^*;VWO=4#L7F
MMU 0KGY1PJ]!QTK<HHI-W*"BBBD 4444 %%%% !1110 4444 %%%% !1110
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MQACTO2[>UCM-;MQ-<($(,;()#E<$ 9(YX-8GB/4[CQA\4+;P;J$-N-,M;SS
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M 4#+^D6OG7/FL/DCY^I[5T-06EN+6V6(=1RQ]34]82=V=,(V04445)04444
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MDCTB)-7#%OM".X^8@@G:#MR<GG&:Z.ET7HOP'U84444 %%%% !1110 4444
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M:^HV,?W[RW7 R<RJ/ZUQ ^',V.=2C!]!$?\ &GCX</GYM44#V@_^RH]MB/\
MGW^(?5, MZ__ )*RGX((;Q7<$$$&*0@C_>%>DUS^@>%+;0IWN%G>>9DV;B,
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MW\_\[O[SR+3/^2:_$C_K_P!2_P#0:M7G_'A\*_\ KXA_])S7J=%"=K?]N_\
MDO\ F$M;_P#;W_DW^1YU:6K7WQ(\>6B-M>?3;6-6ST+(XS^M9OAWXC:1X:\+
M6/AO5;?4(?$-C;"V_LQ;.1Y)F08!0A=I#8R#FO5Z*72W]:7_ ,QMW=_ZZ?Y'
MCMQHUUH/@_X=V%\"MTNNPR2(3G87,C[?PW8_"NI\;?\ (Y^!?^PC+_Z):NYH
MJN;6_G?\O\B?\K?G_F97B8%O"NK@ DFRFP!_N&O%],UOX67G@:TTQ-*M;WQ
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M(N*YHN'<\-HHHKTSB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ='&\LJ1QJ6=V"JHZDGH*]P^((30O
M".@>&8GRT4:M+@]=BXR?JQ8_A7"?"G0O[;\<VKR)NM[$?:9,CC*_='_?1!_
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MINGA\/6M)2;?*N]OYEKY_P#!.AHHHKM/("BBB@ HHHH **** "BBB@ HHHH
M**** "JE]8I>1]ED'W6_H:MT4)V$U?1G(R1O#(T<BE6'44RNGO;&.\CY^60#
MY6KG)H9+>4QR+AA^M;QE<YY0<0AF>"994.&4_G6'\0?"RZW8?V_ID>;N)?\
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M04445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXP5-5Z]'<XM@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[;X=^ YO%VI>?=!H](MF'GR=/,/78I]?4]A^%1^ O -YXPOQ)('@TJ
M)OWUQC[W^RGJ?Y?D#W/C#Q99V>G#POX:5(;"%?+EEB/#>JJ>X]3W_GR5Z]O<
MAO\ D=-*DK<\]OS*GCSQ9%J+1Z)I&(])M,+^[&%E(X&/]D=OS]*X>BNM\*^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00021.jpg
<TEXT>
begin 644 image00021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $> ?T# 2(  A$! Q$!_\0
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M8.1WZUAV&HK'-HK:#K>J7VI3/&+FVE9GC (^;J/7Z\<]J[6#PG]F\*7NF17
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M[\CZUKUQGC3SGT70([D#[?)>V^0HZ28.?ZUV= !1110 4444 %%%% !1110
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M@/\ KD?YU8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWD?5-%%%>L?,!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<Y!QQD,#^/-:M !1110 4444 %%%% #9(TD7;(BNOHPS44=G;1MNCMX5;U5
M#4]%*R&I-*R84444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5B:[HTFI7D$B-:HB[0TC0YF3:V[,;YXSTK;HH YB#PPWDRQ7<
MEO.L<(M[4&(X10Q(9N>6Y'3 X]ZN>']%?2;J[(N6DMY,>7&2<KU.3DXSSCC'
M YYK;HH KG_C_'_7(_SKC+#Q#JM[XE*2?:[33_M/DQQ/IC8=<#[TI;Y6SGC'
MI79G_C_'_7(_SKR_2K&TT_QJD;1VLL_VS>\D>GS[%D;T=I2H/;.#@\4 =SXF
MOK>VGM(;_1KC4K60,^^*U^T>4ZXQE<'&<GGVK;M95GMHI45T5T#!77:PR.A'
M8^U</\38[.>?38;IG,SA_*0Q[XUY3+M\R\=%P.<-VZUU?AORO^$>TS[.YDA^
MS1['*[2R[1@X[?2@#1HHHH **** "BBB@ HHKB_B_P",/^$*\$7FI18-](1;
MV@//[ULX/T !;\*J,7)J*%*2BKLQ/BG\7=,\%NVGV4:ZAK6,F$-A(<]/,([_
M .R.?I7S[KGQ:\;:Q,S-K,MG&>D5D!"J_B/F/XDUPOG2WUY)/=2O+/,Y>21S
MEF8G))/K79Z-H*3V^\XZ=37T&'P=*G'579X-?%U*DM'9%.R^)GC739ED@\1Z
M@Q4YVSR><I_!\BO7_AK^T)%>7<6G>-XH;1W(5-0A&(\_]-%_A_WAQZ@=:\*U
M^Q6VD(4BN6NEX-1B,-3DMB\/B)Q>Y^D2,KHK(P96&00<@BEKY[_9/\?3:MIM
MUX3U28R7.GQB:S=CDM!G!3_@)(Q[-CM7T)7A2CRNS/:C+F5T%%%%24%%%% !
M2%5)!*@D="1TI:* "H;V W-K+"LTL#.,"2(X9#ZBIJ* .4L_!_V5;7R]2FS#
M*T[+Y,?EO*<?/LQ@$ 8&.F2>IS4__")P!MRWER#$VZT^Z?LQW[SMXYYX^;/'
M%=)10!4TJQ33K&.UB9W"Y8N_5F8EF)^I)-6Z** "BBB@ HHHH **** "BBLS
MQ-J3:/H-[J"1K(UO'O"LQ //<@$XH TZ*Y+3O&4+!TU%%5TF,7F6P9HR!&'9
MCN *A1U)';C-2#QUHS:=)>HT[Q1/MD"QY*#;NW'G&,<]<]L9XH ZFBN:NO&%
ME&MY]E@N;M[5XD=8TQG>RKQGTW ^_:NEH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *AFNK>&:**:>*.64XC1G +_0=ZFKG_ !+87-[<
M6ZVMJA(>-_M'F ;=C[MK@C++W '<=NM &L=1L@LI-Y; 1.$D)E7Y&/0'G@^U
M6%=7+!&5BIVM@YP?0UQ<7AFXFMGBNH/+\BV$,9CD&9W#,=QXX!#$<\_,?K6Q
MX9L]2L9KR&^=7MMV8F^7+$DDGCGTZYYSCB@#6/\ R$!_UR/\Z\_,TUQ\0$Q9
M6,L0N0\,ZB,JJ[<,V\-N,AP!C'&!]:] /_'^/^N1_G7':+X7U"R\22:C+8^'
M%BE9,B&!@\07/*''!.>?I0!+\2K)[J"R=((I/+DVAKH1M;*S,JKO5@6))( V
MX]S71Z"=1%CLU>&UBN(V*#[,3Y;J,88 \K]#Z5QGC*:]_MZXMY-;MK6P\H31
MP&\6WE\Q5^4 LN-I;DD$]*[/P]>+?:1;2"ZAO)%0)+/#]QY !N*^V?2@#1HH
MHH **** "BBB@ KYO_;!OG5?#5D/]63/,?<C8!_,_G7TA7AG[5V@/J'A;3-4
MA3<;&=HY".RR 8/_ 'TH'XUMAW:HF8UU>FT?+MI)M8&NHL]?:&$)G@#I7&*Q
MC;:W!JU"V\@"OH85%8\&<'<T-5OC<R$GI6'<MQ6L]L3'NS6)?G82*SJU%8TI
M0=SN_P!G.]DM/C9H BSB?SH7'JIB8_S /X5]V5\6_LGZ#+JGQ0_M0QDVVEV[
MRL_8.X**/KRQ_P" U]I5X-=WF>W1TB%%%%9&H4444 %%%% !1110 4444 %%
M%% !1110 44R:6.&)I)G6.-1EF<X 'N:X;6?BGX>T]VCMWGOY%_Y]T^7_OHD
M _AFKA3G4=HJYA7Q-+#J]627J=Y17DK_ !IM5?\ Y MP4]?.&?RQ6MHWQ>\,
MW\JQ7<D^G2,< W*?)_WTI('XXK26&JQ5W$YZ69X2J[0J+\OS.SEUO3XK\6<E
MQB?>L9PC%5<]%+8VACQ@$YY%2ZK:VNI:=<6EVW^CR#8^U]I'XCH:Q[:QOS-.
MVE7MDVEWL_VHS@%Y%SC<$Q\I!QPW;/0XK+L/!3*T"WRV$D$3('B2,E;C:D@\
MV0'K(2XSUZ=3VP.\T+73=!_M:>U+S75_&")VF=Y#AT(VNQX^[G ]_>G3>$=#
MGMHXIO.D1,X+7+D[6&W;G/W<8%8Q\"3FS,9GM?->)8Y)-AR^+<1<GJ>03]#5
MF\\#0W%Q-(L=D [7! \KL\:J@^BD9]NW- &C?^']#MUN+J]D>,+$J&1[AAY*
MY4C;S\O*J?J*Z/>@!^=?EZY/3ZUY[>>!M0N[RYFGN;&19('B :/_ %F0FW?Q
MDX*=23UR,=*NQ^#9GN6-PUD8?-WN0A+7*F99,2]CM"[5Z\'L.* .V5@V-I!R
M,C!ZTM<[X5TM[.ZU*X='CA:4Q6D3J%,<();  [%V?'^R%KHJ "BJNJ7\&F6$
MMY=$B&( MCKR0!^I%9I\5:.JVA:[0?:1E0>"O!/S>G3'UH W**P+?Q?H<ZJW
MV^&)616!E8+R025^H Y';(]:NW.O:5:R+'<W]O$[!2%=\$[AD?H,T :5%9 \
M3:(54_VI: ,0!F0#).?\#1_PDNBAL?VG:Y&W(\P9&X9&?PYH UZ*RAXATGRH
M)&OH46>-9H]Y*EE;[IP>>>U,;Q+I'FP1I?0R-+)Y8V-G!QGGT'IZY&* -BBL
MN/Q!I4DPCCO8G)C>8%<E=BXW'=TP-P[TC^(M(C.)-0MU.0,,V#D__JH U:*P
M6\7:,%MF6[#).0 VT@)D C=G!7@CK4TGB72(Y5C^VQLQ ;*\@ ]#GI^'6@#8
MHJEI^JV&HNZ6-W#.R ,PC;. >E7: "BBB@ HHHH **** *__ #$!_P!<C_.K
M%5_^8@/^N1_G5B@"*XMH+E0MS#%,H.0)$# '\:E4!5 4  < #M110 4444 %
M%%% !1110 53UC3;;6-+NM/OX_,M;F,QR+['T]ZN44 ?%OQ0^&-_X9U-T*-)
M;N28)P/EE7^C>H_I7FK0W%G+B1",>HK]%+^RMM1M7MKZWBN+=QAHY%# UYQK
MGP7\.:E(7MWN;/)SL4B11_WT,_K7?3Q2M:6APU,,[WCJ?&\FIL(MH7!IF@^'
M]6\5:S#IVD6DMS=3-@*HX [DGL!W)KZSM?V?/#BW >\OKR9,_<15C!^IP:],
M\+^%=$\+6AM]"T^&T1L;V49=_P#>8\G\314Q,;::CIX>770POA!X M?A[X4C
MTZ)EFOICYMY< ?ZR3'0?[(Z#\3WKN***X6VW=G8E9604444AA1110 4444 %
M%%% !1110 4444 %4M:U2TT73)[_ %"416T*[F/<^@'J3T J[7S_ /'CQ,U[
MX@BT*WD_T:R >8 _>E(SS] 1^9K:A2]K-1./'XM82BZG7IZF/XP\9:CXLO&\
MQF@TY6_=6JG@#L6]6_R*QX+0N/E7-5+##,H/2N_\/Z>DT8/&*^BIPC"-HH_,
M\57J5ZCG4=VSB+JS=!\RXK$OHA@\5ZCXAT^&.,[6&<5YSJD85FQ1/8*#LQW@
MKX@:MX&U!6MW:YTMFS/9.WRL.Y7^ZWOW[U](:IJ]CXI\ ?VEI%Q<2V=PJN&@
MC+L,'E70$-@$88#GK7R+J<>5-=_^S-XPDTCQG+X9NI#]AU0%X QX2=1GC_>4
M$?55KQL727Q(^WR;%2:]E)Z'M&FI=?;-&N#9W*RK'%&EO)!(T:Q[VW2"0G*'
M:0VU^?NCGM9UV36M0UFUN=-AN#8F"86LL,@"$M Q#NO!SNP!GICU-=W0!@8'
M K@/H3S&2VFV2E+75O[)*N+:()*)%N?*7#$?> W;L$\;LGOFO2+(2BS@%R<S
MB-1(?5L<_K4U% !1110!GZ\;(::_]I*SV^Y?E7.YFW#:!CG.<5QWVWP,$E?R
M%$1&7;RI FPG!/IMW<>F?>NO\175G9Z3++J,*3V^Y5,;!2&)8 ?>XZD=:XM-
M<\/JPEL]!R(_,+/)&H*[B-_R\L6)ZC&<>QH N0W'A/SE2*PE!;?!+)Y3C83P
MRR$G.>@/7J/6FWNJ>%KR/R8;:>=L>2IMXF#891'\G3(P O'I3SXBTB2UMT7P
M_)Y4A5426&)5 ;:#WQ]T@_D*T1/!+:V=[!H]N-&>T>XFF("RQ;<,JJ@')ZG@
MC! H ;8CPS,+%K.('SW?[/(J/\QQACN^G&2>U9UO>^#HX)8;>T/D@[G58'V\
MC.?3E5W?0$TFF>-;"T@2U.G206Z$QV\<.&_=C(SUP>F>">.34>GZ[X<MK9;:
MWT618"_FKF)&5G!R2&+')&XX]>0* +T4OAF2:2Z$<LK6T<6U71VV!7,:!5/?
M=D>O/-4'N_ _V<$P':V$C BEW2XX4KW;I@,/89JS!XETJ.YC6VT=8TF=(PX1
M%+-DD ^F&P<DXR>.:EN];T6*>[M(='$S6I9"5A38-IW'W&&QQC)/(% #!J?A
M"WAFB*^3$L;Q,K1R*OELPR /0L.W<$U%JU_X;LOL\TVF33F[";05.\M(QVKM
M8@\E23^?>IEUS2+Z>%(=%661O*^>2%-H65PN >3G:22/8@XJY=7R:9-YFIZ,
M@D>Z%M9"W(D+1J"5<YP$Q\W&?2@"!CH%UJUMI<&GM<2J[@MA@J*H8,Q)^\-V
M5[Y-:Z^%]&6+RUL4"9!QN;J.0>O49X/;M7-V_BC34U%[NTT:4,RMF2,*'?*J
M[97.,],D\G;QG%7I/'=HKE4LKMBA/F@[04 Y8XSSQTQU[4 ='8:99:?G[%;1
MPY&T[!CC)/\ ,FKE5=+O!J&GP78AEA$J[A'+C<![X)%6J "BBB@ K)UE+@W^
MDR03S+&+G;)$F K@HW+=\# XZ9K6HH \^B34;NSG$5W>121PK)=F0R<3AFRJ
MXY'&#A>#A>QKH?"]]>SW%];:A R2Q/N9R21DY^7D8Z 8QD8/K7044 5_^8@/
M^N1_G3Y[F&#_ %TJ)[$\U7O)OL\LLV,^7;L^/7'-9/AZ^BN]/6XE8&60;G.>
M2?\ /Y5Q8S%.A:,5J^^R&E<W[>XAN4WV\J2KG&48&J46N:5+<&WCU&T:=3M,
M8F7<#G&,9]:\ZO\ 6WTGXBZ2+)R8KZX%K/$.CJP.#]0<'/IGUQ76:IH5S=W6
ML$*OE7<EF4(DVMMC<%^1R#CI6N%K^WIJ;5@:.JI'8(C,Y 51DD]A7#-I^K1W
MG]GVUQ/M,=Q(Q,SG8JN_V<!SW.\9YSA!FEET'68Y=EJ\PQ& DYO7(5?)VM&5
M/4F3YMWOG/ %= CM?.BWQH9$W2 E%SRP'7'K4E<=H^BZI#XDM[N^4R+$LVZX
M-R6#!@NQ1'VVX()[]><UV- !4=Q<0VT1EN98X8QU>1@H'XFH]1O(M/T^YO;D
MD06\332$=E4$G]!7S8NH3>.M7EO=;N0 <M#"QS' O95'3..IZDUTX;#.O*R=
MD>;F>90R^FI25V]D?2MK=V]Y'YEI/%/'G&Z)PP_,5-7Q]<ZM?>#]:.H>'[GR
M9H6R0O"3*/X77N#^G;!KZCTG5T\3>"(-5L48+?V7FI'GD%D^[]0>*6(H.C*U
M[E9=F$<=3YTK-=#=5@WW2#]*6O/]+\.:CIMEIDMJ8[.>1+>WN([& 1D)P79\
MD@L,8SCC)]:26;Q2;6XPU\C@*9<P(<2;SE8L#.S;_%AB./4USGH'H-%><7K>
M)8H[N6UAU1;NZ\J3&Y'6,B#H/E(^^.< #U(!IL@\50M*;8WD?G3&9V:,28<Q
M1;% [)GS,CL1R10!Z3138]WEKOQOP,X]:=0 4444 %%%% !1110 4444 %%%
M% !1110 5\9>)=0>^\7:O<R'+2W<C?AN./TK[-KXI\6VDFF^+=6@D!7R[J1?
MPW'%=N"=I,\//(N5**-+3Y=I!KL-,UKR8PH.!7GMK/P.:T([DXZU[49:'PU6
MD[G7:OK'GJ1FN1OI-Q.33VD9QZU1NR0":)2"E3=S(U%A@U@Z1?OI?C+0[Z!B
MLEO?0R CV<9_3-:6I38S61X=LI-8\9Z+90J6:>]AC 'NXS7FXEW5CZC+(.,D
MS]"Z***\H^M"BBB@ HHHH S]>N!:::TYM?M3(RE4*D@'( 8X!.!UR 3Q7-Q^
M*[Y+6*XDTLSO=23-#;PDETCCVJ<X4Y8DGT&.]=I2*H7&T 8&!@4 <7>>*-62
M.2&'0)5F5@@.&==P/S+PHR<<@]".I!XJU9^);^]N+9(-(>"*2=(V:XWJ?+(8
MEP-G3Y<#)')':NKHH XRZ\2W[(\4_AN9H9 54%F8,#CA@$X)!QWY'.!S48\5
M7<=S'IUGH1$L4:2&%6)\M" 5!^7 R#CV(/''/;T@4!B0 ">IQUH R/#^ISZF
MMP+K3VLS"50!LD/QDXR!TK5CB2($1(J L6(48R2<D_6GT4 ,:*-F1FC4LARI
M(Z'GD?F?SIY /4 T44   '0 48'H***  # P.!1110 4444 %%%8MWJ4SW.F
M-9,%M);DPS"6%E=OE8X 8# R.OY4 ;5%<*NLZU/:,]K<122/ MVV$0?9QN8%
M.>".!G/. V.<5T'A[61J4EU%()%GB<DJR!0JY( '/^R<Y[^U &BRAK[:P!!B
M((/?FN-O_"6H6DK/H5T%3M$XR,>E=G_S$!_UR/\ .K%85\/"NDI#N><^%/ =
MU%XC37/$,ZRW$!)MX4Y"L1C<?H"<#\:ZGQM-)!X=N'AO/L; K^]R5&,]"P!*
M9Z;NU;M(P#*0P!!&"#WJZ5.-./+$1YW!KVJ3C0?LL.I+;9*F211(+ERDF,N,
M90%5.<#=D'MS7AU6X;R4EU>\&ELB-<7>_#1W!B<F/=C@9"G;V.%[XKTW&.E&
M*T IZ-)/-H]C+> BY>!&E!&"&*C/';FKE%% %#7]/&K:'J&G,VT7=O) 6]-R
MD9_6OCVX%[X>OI;#4HWMYH7,;9]17VC6%XB\)Z+XB'_$VL8YGQM\P$JV/3(Z
MUT8>NZ+/-S'+XXV"3W1\;:Y,]_/%9Z8'NKJ=A&D<8R68\ #WK[%^'FAR>&O
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M224@R,J@%R.F3WJ2B@"O_P Q ?\ 7(_SJQ529"]^N)'3]T>5QSS[BI/L[_\
M/S-_X[_A0!/14'V=_P#GYF_\=_PH^SO_ ,_,W_CO^% $]%0?9W_Y^9O_ !W_
M  H^SO\ \_,W_CO^% $]%0?9W_Y^9O\ QW_"C[.__/S-_P"._P"% $]%0?9W
M_P"?F;_QW_"C[.__ #\S?^._X4 3T5!]G?\ Y^9O_'?\*/L[_P#/S-_X[_A0
M!/14'V=_^?F;_P =_P */L[_ //S-_X[_A0!/14'V=_^?F;_ ,=_PH^SO_S\
MS?\ CO\ A0!/14'V=_\ GYF_\=_PH^SO_P _,W_CO^% $]%0?9W_ .?F;_QW
M_"C[._\ S\S?^._X4 3T5!]G?_GYF_\ '?\ "C[._P#S\S?^._X4 3T5!]G?
M_GYF_P#'?\*/L[_\_,W_ ([_ (4 3T5!]G?_ )^9O_'?\*/L[_\ /S-_X[_A
M0!/14'V=_P#GYF_\=_PH^SO_ ,_,W_CO^% $]%0?9W_Y^9O_ !W_  H^SO\
M\_,W_CO^% $]%0?9W_Y^9O\ QW_"C[.__/S-_P"._P"% $D\,<\+13QI)&PP
MR.,@CZ5R&K?#O1[XDP^9;,3G"G<OY'_&NK^SO_S\S?\ CO\ A1]G?_GYF_\
M'?\ "KA4E#X68UL/2KJU2-SS";X-V4LF3?@+[6_/_H5:>C_"/PW8R"2ZCEO7
M!SB0[4_(?U-=Y]G?_GYF_P#'?\*/L[_\_,W_ ([_ (5;Q%1[LPAEV&@[J/YO
M\Q]M;PVL"06T4<,*#"I&H55'L!4E0?9W_P"?F;_QW_"C[.__ #\S?^._X5B=
MNQ/14'V=_P#GYF_\=_PH^SO_ ,_,W_CO^% $]%0?9W_Y^9O_ !W_  H^SO\
M\_,W_CO^% $]%0?9W_Y^9O\ QW_"C[.__/S-_P"._P"% $]%0?9W_P"?F;_Q
MW_"C[.__ #\S?^._X4 3T5!]G?\ Y^9O_'?\*/L[_P#/S-_X[_A0!/14'V=_
M^?F;_P =_P */L[_ //S-_X[_A0!/14'V=_^?F;_ ,=_PH^SO_S\S?\ CO\
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M>HO'%A/J&DZ+MBU"=8XRS*]NTH=M@P)44JP;KAA]TYS3(9O$<NJ6-I%!>Z?
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MCJT*26%PLH= ^W!# >X/(H L6_\ Q\77^^/_ $$5/4%O_P ?%U_OC_T$5/0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V.-(@PC14#,
M6.T8R3U/UIU% !1110!"MI;K=M=""(7++L,P0;ROINZXJ:BB@ HHHH ****
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MY.W/:NC$>EBRM;0Z?&UO:J$A1E!" #  S]!34MM&1'1-*MU5\;@(E&<=/RH
MQ+B\\+:;OT>>VF@L;=/M1?+F-EE;+L<')7<RYSQEQQ4'D^#[*W0W=I=O-$HC
M/VB.1I<8R W^R <CLO;%=1.=-N)5DGT^&21<89HU)&.E0?9=%_Z!5O\ =*9\
MM?NGJ* '/X0T&Z<7$MF9W?#F1YY&+G;C));DXXJ]H^B6>DS74EFK*UQL#9;.
M%1=J@?04J:E$BA4B*JHP ,  4[^U(_\ GFWYT 6;?_CXNO\ ?'_H(J>JM@_F
..F>4# 9Q@?\! JU0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00022.jpg
<TEXT>
begin 644 image00022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $3 0 # 2(  A$! Q$!_\0
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M8;^_^E B+RY?^>Y_[X%'ER_\]S_WP*?'O9 =W7VH;>!D-W]* &>7+_SW/_?
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MT=]XVAAQCN?\*FJ%?^/Q_P#KFO\ ,U-0 R?_ %$G^Z?Y40_ZE/\ ='\J)_\
M42?[I_E1#_J4_P!T?RH ?0**!0 M%%%,1G:WK-KHT,<EYYI$C8 BC+D #+,0
M.P ))JCJ?BW2=-OS:74LHE";@5B9E+%2P0$=7*@D#N!5O7M&BUF&-);BXMRA
M8;H&"EE8;64Y!X(/U]*RM3\$:;J6JQZA<RW7VB./9&591L/S!6'&<J&.,\4
M:]IJ%OJEC;W=LSJC28VN-C*RL596!Z$$$$>U:.X>H_.LNRTVWTNQM[96:5O.
M+F27!=W=RS$\=R2>*T_+3^ZOY4 (&'G'D?='?ZT[</4?G481/-/RK]T=OK5/
M5M2L]+B1KG!=V5$B0 NY) &!WY-5&+D^6*U$VHJ[*NOZH]A810V<;3:A=;HK
M:-2/O;2=QSQ@=338]%S%OO-0OY9G*EO](*!3QP N!BHO#]@\^H7>J:C8+!-(
M56W61@[QQA<'V7)R<#UK=DC3;]U>H[>];SG[)*$-^K_3T1E&/.^:7R,M?#FE
M&1Y)X?M,CXR\\AD/'N34]II.FVDC_9K.WCW %L(.<5H>6G]U?RIFQ/-/RK]W
MTK)UJDE9R9:IP6J1)N'J*;&PV]1U/>E\M/[J_E38T3;]U>I[5F6+(1@<CJ.]
M.W#U'YTR1$P/E7J.U.\M/[J_E0 W</.ZC[M/W#U'YU'L7SONK]WTI_EI_=7\
MJ $B8;.HZGO[TDS#RSR/SI(D39]U>I[>]$J+Y9^5?RH DW#U'YTH(/2F^6G]
MU?RI54+]T ?04 %%%%(84444 0K_ ,?C_P#7-?YFIJA7_C\?_KFO\S4U #)_
M]1)_NG^5$/\ J4_W1_*B?_42?[I_E1#_ *E/]T?RH ?0**!0 M%%%,1SWC+6
M;G1[6![-K1'<NS-=$[2$0ML&,?,V,#\>#TKGO$7C;4;'Q%]BL[>S-GY*CS96
M)*R,KMDX/W5V<\=SR",5W\L4<RA9HTD4$, RYP1WIK6T#/N:&(MM*Y*#.#U'
MTH QM!U274M'MY[E4:7SWB:2%3Y;[)63<,] VW(Z]>M;>_\ V6_*HI4$<<*1
M(JQJZ@*!@ >PJQ0!B^)[Z6RTBZGMW\J8*BHS*#@EL=#U/-+IFA6&G[7$#3W0
M'S7,XWR,<Y)R??TJHT9UW7CYBV[Z;ITI7:REC++MQWX 4D^O(KI*Z)2=."@G
MJ]7^B_KN8Q2G)R?R(HG_ ':_*W3THD?Y?NMU';WIT/\ JE^E++]W\1_.N<V$
MW_[+?E3=_P"]/RM]WTJ6F?\ +8_[M !O_P!EORIL;_+]UNI[5+38_N_B?YT
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M]EORH 9'&FS[HZG^=$L:>6?E%+$WR?=;J?YTDK?NS\K4 .\I/[H_*G*H7[H
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MN?B?YTDW^K-,C$FS[Z]3_#[T2B3RS\P_[YH FHIF)/[Z_P#?-.4,/O$'Z#%
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M;RS\P_*GQ?<_$_SI)O\ 5F@!</\ WA^5*H(^\<_A2T4 )1112&%%%% $*_\
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M*9_PCVE&W,#6BO&T;1X=V8[&VY&2<_P)]-HH @M/$2W>H/8V]I*UW"S+<)O
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M:_S-34 ,G_U$G^Z?Y40_ZE/]T?RHG_U$G^Z?Y40_ZE/]T?RH ?1110 4444
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00023.jpg
<TEXT>
begin 644 image00023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #U ;T# 2(  A$! Q$!_\0
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M68##X.1(A9CE@8A@C/&KXN\%ZYJ^N?\ $HUB72]-BTZ.WAD6XF:17'G!L*'
M.0\>6;+?*,$$9H ]'I-RX)W#"]3GI7E^L?#K7;C^TDTWQ/<VL,NW[,IFG)4
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MP45Y/XX^)>K>'O&=WIMIIEO<:=9):23S.D_ F<J2TBJ8X@H4G,A //I6K?\
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MB>J6U@T@7Z%SS6$\).H[UZOR3LEZ<OZMFT,7"FK4*7S:NWZ\W^1LGPS>3?\
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M@L2 ,DCN,].]<-I/Q2>#3+S_ (2&SW:E9Q7L\\5K$\)1+>*.4J\<IRCLLHP
M67ONYH KV.L_$:/Q)HUO=60EMY+>*:<&#9&S.LK2(SA2$9#Y:#)'3.UMV0W4
M?%/C@^)=2TBRM+47T.G/JZ6Z,LZI^Z:-+4OA<EI@) V =N1FM:\^*UC8Q7EU
M>:3?Q:=;W$MF+HM&1).D7F",+NSEA\JD]6XJM;?$JWL]5U""_P!*=;Z:^:RM
MQ BAIY%,"B%CN.YQY^<\#:K8Z4 8-QXH^(D6EZ<T>GZA)<-=,WF?8"1+")(1
MME7RPRMAI2#B,$+G)/!]*\!/K,^CS7/B&:9KN6[N D,D"Q>3$LSK&   3E K
M9.<YKE9OBI%<ZQ!I^E6@+_VI:VDDLKAXY()GE3?&R-C<#"WJ/U H:M\1]>M?
MBF_AVVL;-]/&HV]BC/!(I</"DLA\_?Y:NJEF"%26"X')H ]=HKRMOB]!<7=M
M%IVER21_;X[>XE>9"H@>&642QE20_P L+<#CCJ<BNK\ ^-;+QI9W-Q8VUS;^
M24RLZCYE= Z,",@\'D=B"* .IHHHH **** "BBB@ HK/US6=/T*Q^V:M<I;6
MVX)O8$\GMQSV-<Q_PLWP_*2+ :C?GM]ELI&W?3(%:0HU)J\8MHRG6ITW:4DF
M=O17#CQQJ-S_ ,@WP;KTH/W6N$6W!_,\4#6/'-U_Q[^%["S!Z&[OPY'U""K^
MKSZV7S7^9/UF'2[^3_R.XIDTL<,;23.L<:C+,QP!^-<5]D^(5T/WVIZ#89X_
MT>W>4K[_ #'FEA^'EI=R+/XGU&_UV<'(6XE*0J?:-< ?K1[*$?BG]VO^2_$/
M:SE\$/OT_P W^!-J'Q$T.&X:UTQKC6;T<"#3HC,?Q8?+^M5O/\<ZY_Q[VUCX
M<M6_CG/VFX^H4?*/H:['3["STVW6#3[6"UA7HD*!!^0JS1[2$?@C]^OX;?F+
MV4Y?'+Y+3\=_R.*M_AWIT\RW'B*[OM=N0<YO)3Y:G_9C' 'MS7566F6%BJK9
M65M;JO011*F/R%6Z*B=6<_B9I"C"G\*"BBBLS0**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O
M[.VU"RFL[^"*YM9T,<L,J!D=3U!!X(KGO^%?^$_[+BTX>'].%E&SNL0A&,N-
MKD]SD8!SU 'H*ZBB@#);PWHS6KVS:9:M;O<K>-&8P09E((D_W@5'/M2CPYHX
MN%N!IMKYRW;7ZOY8R+AEV&3_ 'BO&:U:* .>M/!/AJSN!/:Z+912B5)PR1XP
MZ,S*1Z8+L1Z;CZU:O/#6C7C7+76FVLK7-Q%=3,R9+RQA0CD_WE"J ?:M>B@#
MG+7P-X8M5VV^AV,:^;'-A8\8>/=L(_W0S >Q(Z<5IZ+HFFZ';O!I%E!9PNV]
MEB7 )P!^@  ]  !6A10 4444 %%<W_PDZM)*L-N&\M\ &3!9<J!@8^\2W3T%
M7]'U;^T)989(O)FB'S+NW9YYP>A'2@#5HHHH ;)&DJ@2HK@'(##/-*H"C"@
M>@I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!C0Q.P9HT9@=P)4$@^OUH2*-&W)&BM@+D+C@=!3Z*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BLF77K:*21)(KA7C;#C8#M'R_-UZ?,O3GG
MI5C3=3@U#>(-ZM'C>KC!4^A'^>M %ZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO>MJWA2W@CAB&V.-0JCT H 2&"*!2(8U0$Y(48J2BB@ HHHH **** "BBB@
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MZXQC'ZTC:S(I<-:'<C;"-QYYQN''W1W-21ZE+-:>:(/))E6(;SG&<9)_/ H
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MQUIW]J-+!;RIY<*2QL^Y\LN00-HQCKR?PZ5JNBR(5=0RGJ"*5$5%"HH50,
M8 H PT\0;Y'5;20A!N)#=L@<#'7GI2R:_L7(M6<[0WROD<@G&<=L<^F:W**
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00024.jpg
<TEXT>
begin 644 image00024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #$ 1L# 2(  A$! Q$!_\0
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MO;1P7<;K<?:#YL@:-/W2Q[(@!PORYQ[U*IIOX-"N;3XC9_X7)XN_YZZ?_P"
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MNZ;"!TP8VR<^W6IM0[#_ 'A;_P"%R>+O^>NG_P#@-_\ 94?\+D\7?\]=/_\
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M";7+J;2)-/D=3'-=&\GD))>:3! +$GMD] .O-?6O_"+>'_\ H!Z5_P" D?\
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M@"2BC-&: "BC-&: "BC-&: "N>\8:M?:4NEMIL*3F6[V31%26>(1.[!.?O\
MRY'KC'>NAS3)(HY&1GC5FC;<A9<E3C&1Z'!(_&@#A= \?QZE<6L0A6>"XG,(
MNXI% RSOY6(R=S J@RPZ'Z'%6\\>76EWDZ:FD(B&H3QV[1+S-!&K[EY.!(K*
M">VUL]CCN8])TZ*ZBN8M/M$N(E98Y5@4.@8DL <9 )))]2:E>QM'QOM8&P[2
M#,8.&8$,WU()!/N: .#O_B#<+'Y4&G+'>0S1)=AKF-TC#2HOR$']X2"?N_=.
M,CM3-1^)D%L89XK=I+?[,DKQH=[-)*(S&N5SC&_YN#[5VR:'I,<=JD>EV*):
MDFW5;9 (23D[./EY&>*6/0])CADA32[%8I0P=%MT"N&^\",<Y[T -\-:M'KN
MAVFI112PI<+N\N0892"01^8-:=1V\,5M!'#;1)##&H5(XU"JH'0 #H*DS0 4
M49HS0 445SOCBZDM=-MV-W/8V3SA+N[@7+P1;6Y!P=N6"@MC@'/'6@#HJ,UY
M?=>-;_34C@T\-J42P,\+WD+I<7B_/B1=JA=B!1DD L#GC(W)?>*O$5MJ1AO$
MM,0?(T=O'(//D$D1W*QS\H23!7O@GZ 'J-%>:/XZU:PCE35;*V%SY1:$P)*4
MED*0NL8SSG$CY_W,\<BK?ACQOJ.IZ9XBNK[2FMVTU6>-%!)R W[M@"3N&T9Z
M?>Z"@#T"BO*=+\?Z_>6!NQIUBT5LW^D%!(?.!E"*8N2!PP/)/0XZY%H>.]7L
MX)/[6L;59C;F6$PI+L>1HDDCB[G=\S@_[O;FBP'IE%>::#XSU/6O& TY[<0V
ML-V1OC5@639."D@.<,&16[=1QZLG\?ZI'>:I;26]E;BUO! +J1)7@B3#XWE>
M=[;0 ,+@N.#QN+ >G45YAJ'CW7K.ZTU?[&CGBO;B5$$892527RP@W$?.0"_0
M\<8ZFJ^F?$#Q%J5G-+#I%K"\'G2R"8.?EC0,8@%8_O.=N3CM\O:@#U>BO,4\
M9:[#'+-'IL<UI'*\7EMYAG9B)64YQC:-@&,$X/'09ZGP'KL^OZ9=3W+VDK07
M3VXEM XCD "G< _(^]^E '2T444 96M:';ZPT)N9[Z(Q @?9KN2#.<==A&>G
M>LW_ (0K3_\ G]UO_P &MQ_\773T4U)K85D<Q_PA6G_\_NM_^#6X_P#BZ/\
MA"M/_P"?W6__  :W'_Q==/7*>+-6FL];TFUM-9M+6>9U/V&54S.F\!V+,<J
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M  (E_P#BJ/=#4['(HR*X[_A6?A'_ *! _P# B7_XJD_X5IX0/321_P"!$O\
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M\V&-\$;E#8/;-<K\3+N^M-$@-C<&TC>?;/<[V3RDVL1\RHY&6"CA>^.];/\
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MM$VYA\CR@G7@%@'(Z9HYGW"R-K_A$8L?\ASQ%_X,GI'\)P(C.VN^(MJC)/\
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M,[1[6P$=_E'S;2<]0"/:NBKDOB+=:G:6NCR:5=3VRMJ,:730V_G$PE7X(P2
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M-%F%S1HK._MW2?\ H*6'_@0G^-']NZ3_ -!2P_\  A/\:+,+FC16=_;ND_\
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M4<S"R#_A&="_Z FE_P#@)'_A1_PC.A?] 32__ 2/_"BBCF860?\ ",Z%_P!
M32__  $C_P */^$9T+_H":7_ . D?^%%%',PL@_X1G0O^@)I?_@)'_A1_P (
MSH7_ $!-+_\  2/_  HHHYF%D'_",Z%_T!-+_P# 2/\ PH_X1G0O^@)I?_@)
M'_A111S,+(/^$9T+_H":7_X"1_X4?\(SH7_0$TO_ ,!(_P#"BBCF860?\(SH
M7_0$TO\ \!(_\*/^$9T+_H":7_X"1_X444<S"R#_ (1G0O\ H":7_P" D?\
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7^ D?^%:\:JB*J *JC  & !112NV!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00025.jpg
<TEXT>
begin 644 image00025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "X 50# 2(  A$! Q$!_\0
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MKJRG<HZ9V\9]<5;T_P#X\+;_ *Y+_*K4(2L[&<ISC=-E_P"W7_\ T$=0_P#
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M'U"^\NX#7MT^)< O,S$?(OJ:*JZ1]VY_ZZ_^R+17F54E-I'J46W!-F]\2/\
MC_TK_KG-_..N1V)N8[%R_#''WOKZUUWQ(_X_]*_ZYS?SCKDZ[L+_  T<&*_B
M,B>V@>)8W@B:-?NH4! ^@ITD,4H42Q1N%.5#*#@^U/HKHLCGNR)K>!E56AB*
MJ<J"@(4^HIRQ1J5*QH"N=N% QGKBGT46079'%!#$S-%%'&S\L54 M]:26W@F
M96FABD9>A= 2*EHHL@N]R.2&*0DR11N2,'<H.0*:+6W",@MX0C_>41C#?45-
M119!=C518XMD:JB 8"J, 5%I_P#QX6W_ %R7^53M]T_2J-C YL;<BZF&8UX
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MO^%+ZRK6Y?Q']5E>_-^!Y,+"$*N+B$N.26 (?[N W/(^7]:1M/A:1F:YC(8
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M!=1-/''%9J7$:\%F!QCZ=?:CZTOY0^J/^8X*SMH;>993- 64$84!0.%''/\
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MLF<'_:-9^J:3)]IFFTRW$+HHF#*1NEE+<[<G VJ7(Z#<X/:NB  &   .@%%
M'.[;J2;0(;G>;I+F2X8N076%5=1N(XR0Z ^^:Z*C SG STS10 4444 %%%%
M%&P_X_\ 5/\ KLG_ **2N<U/1]2U=KIVM197,MH\,[FXWI,X92@3DE5^4G.
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MND7$]@\4;QJ69W&2 /[HZ9^O2@#9_M>Z_P"@:O\ X%#_ .)H_M>Z_P"@:O\
MX%#_ .)JK=1M) ZI.]N>OFH 2H'U!%9_AUKF:P-Q=7$DZ3L7@\Q5#+'_  YV
M@<GK^(H VO[7NO\ H&K_ .!0_P#B:/[7NO\ H&K_ .!0_P#B:BHH E_M>Z_Z
M!J_^!0_^)H_M>Z_Z!J_^!0_^)J*B@"7^U[K_ *!J_P#@4/\ XFC^U[K_ *!J
M_P#@4/\ XFHJ* *%S/)=7EQ)+"(6W*-N_?\ P+SG HILO_'U<?[R_P#H"T4
M=%XK_P"0QI__ %PF_P#0HZR%MHUO)+H ^<\:QDYXV@DCCZDUK^*_^0QI_P#U
MPF_]"CK.Q0!%<P)<VTL$H)CE0HX!P<$8-5+S2;:[8&0S+^[$+B.0J)(Q_"WJ
M/\3ZUH8HQ0!#);1R7%O,P.^#=Y>#@#<,'CZ54.C69MD@*OY:6[6P&\YV,02/
MKP.:T<48H IS:=;3-<&16)G,9DPW7RSE?Y5</-&*,4 %%&*,4 -;[C?0UGVE
MK'>:#9PS;MOE1L"C;65@ 00>Q!K18?(WT-5=(_Y!-E_UP3_T$4 0?V/;A05E
MNEG$AE-PLI$I8C!R>_  QC' I\^F0MH[Z?!^ZCV80YR58'(8^IW<FK^*,4 5
MW@$[6LUP/W\#>8-IX#%2I^HY-5X=)MH;I9E,QV.TD<32$QQLWWBJ]CR?IDXK
M0Q1B@"A<Z5!<"3<TRN\AD,BMAN5V$9QTVG&*=!9^7J#7!VA$@6WA0?PH.3GZ
MG'X"KN*,4 %%&*,4 %%&*,4 4[/_ (_-1ZC]ZO3_ *YK5:UT*TMK=[=9+N2V
M=61H99BR'=U./7WZU:L_^/S4/^NJ?^BUJWB@#.&D6QMKB&5IYA<;?->60L[!
M>@SZ#'\_6I[ZRCO&5GEN(F 9=T,I0E6ZJ?;BK6*,4 4KZQ$VGK;VVV(PE'@X
M^5&0@K^'&/QIK:7;M=_:&,W,HG,/F'RS(.C;?7CZ<9Q5_%&* *%GI=M:7 EB
M\T[598T=RRQ*QR0@[ TRXT>VGCVN902SL[*^"^_[P/L< ?0"M+%&* *EO:E-
M0N[J0@M*%C0#^%%SC\22Q_*K=&*,4 4]6_X\3_UTC_\ 1BU->VT=Y:S6TX)B
ME7:P!P<?6H=6_P"/$_\ 72/_ -&+5PCDT 03VR3B<2-)MFB\IE#X !SD@=CS
MUJ2*-8HDC081%"J/0 8%/Q1B@ HHQ1B@ HHQ1B@ HHQ1B@#.E_X^KC_>7_T!
M:*)?^/NX_P!Y?_0%HH Z?Q':0WFM6"7 <JMO,1M=DYW1^A%4)-,TN.XA@=G6
M>8,8XS<R;G"\D@;NU:VK_P#(>LO^O:;_ -"CK&OK%/\ A*-)O(K?]X1,LTP7
MG;Y>%!/8>E #X=,TN:2:.%GD>!MDJK<R'8V,X/S=<$5!-;Z'!>I:33E+E\ 1
MFZDSST_BXSVSUIFF64]A-K<>DV]O;@W$;0B96$;#RDW'CD\YY]>M5;^Y$^JC
M3KJVF@@\R&6\F@M9&%U*,%55@I 4$+EB<\8'<T 7H;;1)KV2SBG+W4>=T0NI
M,C'7^+MD9].]7/[#L?\ GG/_ .!$G_Q58>E13>?H]DT,RW-C=7$MP[1D(%;S
M,$-T;?O4\>^>E&J65U-J%_,KWZD7UK'%Y4KJHB*H), <8.3D]O:@#<_L.R_Y
MYS_^!$G_ ,52?V'8_P!R?_P(D_\ BJQ8K">6\MK*4WPL([V[7 ED&8M@* OG
M)7)..:?X7M[N";3)+AKUFGT]FNC.[-^]#KMR#PK8)Z8XH U_[$L?[DW_ ($2
M?_%4?V)8_P!R;_P(D_\ BJTJ* ,Q]$L=C?)-T/\ R\2?_%54T;1K)]'L69)L
MF!"?](D'\(_VJW7^XWT-4-*@ANM L8+F-9()+>,.C=&&!P: *?V71#91W8G/
MV61@J2_:I-K$G: #NYR>*E.F:6+L6I9_M)0R"+[3)NV@XW8W=,FL3^R]_@S3
MP]D3=V\R^6IC.Z,?:03@=OE'Y5LM9)%XQ2ZAMPOFVDOG3!?O-OCP"?7 X% $
MC:3IJS1Q-YHED!*+]HDR0.I^]VR/SID6FZ5,UPL3NQMVV38NI/W;8!P?FXX(
M-07GVPZ]J(LC&+PZ=&+0RG"C]XV\]^AVG\JK>&=+=!K%EJ-A$MH\Z, 9#()3
MY:9))4;LD9)[G(H LM#H206TS7!$-SS"_P!ID(<>HYZ<CGIR*G?3M*1;AF,H
M6V_UQ^T2_)QGGGT.:R[?3E/@[36NHKD3P6OE>0GRF3<1^[88X!(7/3 JWHDU
MU!J,]A>(KPKYCSR&,C)^4F0L>"'+/@=@M %\:+8$ A9B",@BYDY_\>H_L2Q_
MN3?^!$G_ ,54?A/?_P (SIGFYSY(QGKMYV_^.XK6H S?[$L?[DW_ ($2?_%4
M?V)8_P!R;_P(D_\ BJTJ* ,&QT:R:^U%2DV%E0#_ $B3_GFO^U388M G:=8K
MH,8%+2_Z7( H'!.=V, ]2*TK D7^J%0"?-3 /_7)*X_2XVM(X9+JUO;V.WL9
MDN;-[8XMR65A%%Q\^2,<EN%!R* .AL[71+V&2:UG:2*/_6,+F0;.,\Y;CCFK
M%OI.FW,,<UOYLD4BAD=;F3# ]"/FK/TF*'5X=1N-2B>:YN0AEADMW2- H.Q%
MW@;\$DD]R>F,5+#'<Q?#]8XE=+M=,VA2,,K>7TQZT 2_8M&$$$QE813N(XF-
MU(!(Q. !\W.:8UOH:Z@+$SD79( B^U29R1D#[V,XYQUIFI65O<6&A7%K;K*T
M,UKY3JN2D65)QZ#&,FH+BYCNM?%DUO<6UG;W:S,5M7/VJ<8PQ8+M" XYSDD=
M@.0"U%!H<T4DL4[/'&X1R+F7AB< =><GICK5G^R=-^T-!^]\Y5#E/M,F=I.,
M_>]16+=67]G71:R\TP6C0AI)E,BQY)"X48++&K,WU89/%7XIY[G5/#L\L7DW
M,EO.T\>,;4VKUSR/FVX!H O?V)8_W)O_  (D_P#BJ/[$L?[DW_@1)_\ %5I4
M4 8&L:-9)8DJDV?-B'_'Q(?^6B_[56;O3-+M())[IGA@CY9WN9 !_P"/58UK
M_D'G_KK%_P"C%JGXSLDOO#UZ#;^?-'&S0KMW$/TR!ZT /DTS2X[B*W=I%GF#
M-'&;F3<P7J0-W05%?VNB:>J&^F: 2$A=]S)SCK_%T'<]!3[RR0>*M+O(K<>8
MR3K-,%SQL4*">PZX%4]<G9;NWO[0W$;M;S6IW63RAAN'R[1@JQ(X)^4CKVH
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M[GT 'KBM6*X(UKRED\R"XMA<1\Y"D$ X]B&4_A0!J#4=0  %M8@ 8 $K\?\
MCM']I:C_ ,^UE_W]?_XFF44 /_M+4?\ GVLO^_K_ /Q-']I:C_S[67_?U_\
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MAY+J+RQN5;>3878\*N?<D"@#5_M+4?\ GVLO^_K_ /Q-']I:C_S[67_?U_\
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M"[@,!MN,9 XSC-/N&TVX,QF!?SHQ#)E'^9 20.GJ373ZEJMIII07UT(C)NV
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M3^= '*_;[;_GHW_?MO\ "C[?;?\ /1O^_;?X5U6YO4_G1N;U/YT <K]OMO\
MGHW_ '[;_"C[?;?\]&_[]M_A75;F]3^=&YO4_G0!Q7G1S7%PT;$C>!RI'\"^
MM%7M9.=4GSS]W_T$44 =)J__ "'K+_KVF_\ 0HZS[G2+>\NO.OWFND5P\4$C
M?NHB.A"#@G/.6S5GQA/:6<FFW%W'<D/*;<R03&,Q(5+,QQU V#/IUK(L;J"[
MT>\OHH-29H(8I5A6^8F0N@<*#^./?]* +VL6UY<JJVPLIH65EE@O$)1B>C9
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M1_85O_S\7_\ X%/_ (T 0T5-_85O_P _%_\ ^!3_ .-']A6__/Q?_P#@4_\
MC0!#14W]A6__ #\7_P#X%/\ XT?V%;_\_%__ .!3_P"- '*:Q_R%)_\ @/\
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M0 W_ (1[2,QG[!!F/&WY>F H'X85?R%21:)IL3$QV4*DEF.%_O##?F.,444
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B$;'<RH."0 !^@ _"BB@"W1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image00026.jpg
<TEXT>
begin 644 image00026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $A @D# 2(  A$! Q$!_\0
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M>_0?2HJVC32W.:55O85F9V+.Q9CR23DFDHHK0R"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#4L-:N+;"RGSH_1C\P^AKI+&^@O4S ^2.JG@C\*X>G1NT
M;AXV*N.A!P142IIFD:KCN=_16%I>N"3;%>X5^@DZ _7TK=Z]*P<7'<Z8R4E=
M!1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO7-*+B=<)J2'4445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH BNYTMK=YI/NJ,_7VKB+J=[FX>:7[S'/T]JU?$MYYMP+9#\D?+>[?\
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MJ1&5T#H0RL,@@Y!K%\1:/<:G'^XO'CP/]2WW&_+_ .O5>ST"[6TA5]6O86"
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M^+[O1]<33;OQ#;V\_P#9;V[^9<3RP/)/MG"R2H"2%^\ -H(XXK<UVQUOP_\
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M!1116I@%%%% !112_NTBEGN9D@M8$,DTSG"QJ.__ -:@!)'@MK6:\OITMK*
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M?!Z6VM?&7AK9H.CZ4=6T^:>*;3]7DN99P%#$7"]&;YL[FS@Y /:@#Z(HHHH
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MF%E;;'(H*Y9&/1AQ2]DN[^]E?6)7O9?<N]_T_0Z:&VU1;NS>2]C:".';.@C
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M6 /[YO6ESXC^1?\ @3_^1!4L#_S]E_X O_DSUGS$_OK^='F)_?7\ZY0?#[0
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MYXL\*7FB66IIIJWB&&>5K;SBT3 AE W#!Y'/M5J/0IDL[6 ZM?,T$_G&0O\
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M./KGTKSBI;F>6ZN9;BYD:2>9VDD=NK,3DG\ZBKU:5-4XJ)RU)\\K@>E>M_\
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MKT/P]\0;?2;SP7.^G2RCP_:W%O(%D \XR;L%>.,;N]>>L<L3ZDFM:;J7?/\
MUN8U53LN02NW^%^M6]O?7.@:S)MT76@L,CG_ )=YP?W4P],'@^Q]JXB@C(Q5
MS@IQ<61";A*Z._U2PN-+U*ZL+U-ES;2&*0>X[CV/7\:K5T6L7/\ PD7A#0_$
MA.Z\0?V7J![F6,?NW/NR8_$5SM>39IV9UM+H%%%% @KV/X)Y_P"$5UKT^W1X
M_P"^#7CE>T?!=-O@K47_ .>FH@#\(Q_C45-C2E\1VM%%%9FX5T_A:';:2RGK
M(^!]!_\ K-<Q7<Z?!]FLH8>ZKS]>_P"M9U7I8UHJ\KEBBBBL#J"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOEBQM%G_ -(G+MMPJ8['&3TYJW/\,=<6ZLX+.;3KYKB].G,UM.2L%P%+%')
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M$\W(B3/4>O%/VJ[/[F+ZO+NOO7G_ )?EW-JBL::[UE8=0,>G1-)%(!:KYO\
MK5SR3Z<<U,+G4_MP0V4?V;[/O\SS.?-_N8]/>CVB[/[F'U>6]U]Z\O\ ,TZ*
MQH;O6&@T]I=/B6220K<J)/\ 5+G@CUXIDFK7UK<,MYIDC1O="&%H#ORA_C;T
M'2E[:.[O]S']6FW9-/YK^O\ @:FY117SN^GWQ\36-CJS?$W28=3O&MH;N76X
M/)#D,P&%R1D*<"M3G/HBBHK.#[-:00>9++Y2*GF2MN=\#&6/<GN:EH ****
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MI7/4G44K01TTX4W"\V<Q_P *XUU]2TZSLWTZ].H22PP36MVLD7FQJ6>-F[,
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MR_XT?\)!I'_03L_^_P O^-<_M8=T=?U>K_(_N9IT5F?\)!I'_03L_P#O\O\
MC1_PD&D?]!.S_P"_R_XT>UAW0?5ZO\C^YE;4Q:_\)-I1E2[-SM?RVC_U0X.=
M];E<[<:Q:3:U8FVUZT2 ;A);AE;S2>G/:NBJ:33<FN_Z&F(C*,8*2Z>?=]U^
M5Q-RA@I(W$9 SR:6O)O&^M:=H7QS\*W6LW]O86G]CWB>;<2!$+%X\#)XS6);
M_$S4W\1V>C-JMO\ V@_C"6PDMO*7?_9^TE#C' /RX?J:U.4]THKY[\.>/?%Z
MV^B:MJ&LPWD&K6>KL+1K-46!K0.8VW+\S$[>1Z=!6G\)?&7BO6]/U+5!<_\
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MM63:JLWL#U-2+:6R737*V\*W+#:TH0!R/0GK7R-']F_X1FWC\:&7R!X4N6T
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MZD]:U.<]RL[>.SLX+: ,(H8UC0,Q8[0,#)/)Z=34U%% !1110 4444 %%%%
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M"=T-S'V=&[CVZCO6)7IQDI*Z.*47%V84444Q 1GKS0!CIQ110 4444 %%%%
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M4WH<U3"*2L? IX)!R"#@@]125]J>)/A3X>\2!CJ\1EN<8%Y&!%<?\"90 _\
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00027.jpg
<TEXT>
begin 644 image00027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %2 >$# 2(  A$! Q$!_\0
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M1117NGB!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !70>
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M?:TW'J>EE6,>$Q"D_A>C]/\ @'U-12(P=%92"K#(([BEKYX_1@HHHH ****
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MN%%%%=AR!1110 4JDJP93@@Y!]#244 7];UC4-=U![[6+N6\O'4*TLF-Q X
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3]):*^\6O'J-Z,,MJG^HC/\ M=W/Y#V->R:7IECI-FEII=I!:6R?=BA0(H_
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M:'ST\VY4O"O=P!G(_"KYX]S+V4]=._X;EJBLNW\0Z3<7WV."_@>YSM"!NI]
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M7P ,X)S7G.B?"[4HM8L[VZ32++9I]U8W+V\\]S-<-,BCS6DD )P5SM[;CR:
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M*<#U->5VNLWEW\6_"6LZYH>OVVIW5S=P)!-9D);6WE%8XT.<-C/F2-ZD]E%
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M8?,RJ2AAP6QQG'.#6'8^!/$4NJ7US<6%SY%QK6DWR?;[]+B<PP,?,,C XW#
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MJVGV%WIE@NH33WL;WL=QILD+>8=]O&V98I69@2!M4$OU!KUV@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "FR(LD;)(H9&&UE(R"*=7C=SXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image00028.jpg
<TEXT>
begin 644 image00028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $_ @4# 2(  A$! Q$!_\0
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MIWVO</Y<8VD[FQG''3@=ZL4KK8;BTDVMPHHHIB"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHILB[XV7.-P(R.U &):^*+&ZO\
M[-:QW<R>;Y/VE(&,._TW_P!>E;8D0LRAU++U /(KC/"DM_I6DPZ%-I=ZEU$S
MQK<H@,)!)(DW9]^G6LC0M*N5N-($>E75K?VRS?VC<R)@3Y4C&[/SY8@CTKAC
MB)V5U=OY6VT_KL>S4P%)RGRRLH[:IWWUZ6O:W75H])\Z/G]XG"[CST'K]*Q=
M'\1KJBV\D-A=K;W$CK%,0I4JHSN.#D ].>:Y30?#C6Z^&V?39%>2TGBO]RGG
M*?*K_CT%2:'HMS:VOA7%A)%(@N7NODP59HR 6]SP*7UBK)I\MOZCY>8W@<-"
M,ESW>MNFRGY]7%?>NYZ")8ST=#TZ'UZ4+-&VW;(AW<+AAS]*\ZMO#;1^#M$A
M&G2K=2W<#WJX(?:"P.[N  <>PJ*Y\,O FIR6>FRI-#JD36913\D64+%/0?>S
MBJ>)J))\G];]OZ9*R_#N3C[7K;9=[7^+Y^AZ7YB>9Y>]?,QG;GG\JKV.H6M]
MY_V699/(D:*3'&UAU'_UZX.\LKV;Q7#.FE&!XM45C+%;<O#TWM-GG/=0.*AD
MT2>&R\0VMGI4R3->"4-&FT3VN]3Y:-GTSQ2>*G=VCIJ$<MHV5ZFKMVTN[.^I
MZ2LL;+N5U*DX!!R,T++&^=CJV!DX.:\TO-'GN;75CIFEW5IIUQ+:".V,?EL6
M5_WCA?X1CO[9JWXQTQM'N+1="A2%-2A.E,B<!=QRK#Z9>F\5-)R<=%_FUIH)
M9;2E-4U4U?DM+)-WU\VO5'H2D,H*D$'D$=Z6H;.WCL[."VA&(H46-1Z # J:
MNQ7MJ>2[7T"BBBF(**** "BBB@ HHK&\92/%X7U%XG9'$7#*<$<B@NG#GFH=
MR'7O%>G:1NC:3S[D?\L8CDCZGH*YS3OB&QNF&HVBK;L?E:$Y9![@]?TK%T+3
M[*X\)ZU=W$(>ZM\^6Y)RN5X_6M?^Q])\[PN/LRXO4)F^8_/^[!]?7TK.[9[:
MPV%I)PG%MZZ^BOH=WINHVFI0":QG29.^T\CZCJ*M5Y1IR)9?$40668H%N3&%
M5CC;MZ'UYKU>KB[GF8S#*A)<KNFKA1113.0**** "BBB@ KG%26^\67LGEC;
MIT"I;"0$(99 26S],#\ZZ.L2/Q/I\FG:?>IYQAOIF@ARF"74.3GT'[MN?I43
MAS6-:57V?-9:M6_KY77S'1)K4[^5J":;]D<%9/*>3?M([<5R=YI3IH?B>UL+
M1A&EW&R0HOWD783CUX!KL+KQ!IMK:O+/=1+(EL;HVXD4R[ I;(4')X!Z>E6=
M+U.SU2S6ZL+F*>$CED<-M.,X..A&>E95,.IJS??\58Z:..E1=XQ733IH[GG^
MHVIUB6^N(X9C87VIVJ(6C9=RA-KM@C(&3U]JK^';:]EUS1[R^@E6:&Y-B"4/
M"10L-WT+&O0AKFFE9I/MML+:%0SW'G)Y0RQ7!;/!R._K26VNZ?<:A<6<<ZB6
M$Q#+$!9#(I90A_BR 3Q6/U)<RDWY_C<ZEF\E3=-0T:MOTM;_ "N8WCC[7?7&
MFZ38VPN/,E^TSK(2L9CC(.UFP<9./RKGK5-1@@M=$N$N+9X-5C/^CNVW[/(&
M; < < DCVXKM?$GB&U\/P)+=P7DRL'=A;0&38B#+NW8*!^)[ U7M_%NF7&M)
MIT7VAB[^4MSY1\AI?+\SRM_]_9\V/PSGBM)X;GFY\W_#=C*CF/LJ2I<BLM?G
MW[;:;?,YFSMKNVGMY8YM1)BUPVB*\KLHM^>"#U'^T?SJMHLFJF^?[3-=+>;+
MDW<9$QR,';U^1<'&TKUKJ-1\:6.GZC>VT]GJ)@L9$BNKQ(-T$)958;CG. '4
MD@'&:VQJFGE[I1?6A:U&;@><N81_M\_+^-1]3LU:1I_:MTTX;_\ !\O._K9G
M%:7;75K8^$Y1+?23W4RR71ED=N?); (/09QQ46AW#10/).NNS:XL$[7<2%@F
MX9P/F^4'IMVUV4>OZ=)??94N8R?(CN1*&'ELDCLB8;H264C'TJ_)<P1LRR31
MHRA2P9@, G S]3P*I86UK/\ K3_+\63+,^9/FAOY^;TVVUV\D>4QS7ZZ?K'V
M22]6.2QBEC"M,V)/, ;#/R6QUQ@>U;.HP75G-K]K;76HI;F"WE63]Y,0Q8[\
M<YP0/FVG@5VO]K:<([J0W]IY=JVVX;SEQ"?1SGY3]:?%J-E+)!'%>6SR3IYD
M2K*I,B_WE&>1[BI6#LOB_K7_ #_ N6;<SNH?C_A\O[OXF!X FFDL;Q)8I%CC
MFQ'(9)'CD! SL\P;@!Z'O74UBZ;XFTS4[$W-C.LNUQ&\091(A,FP;E)XY!Z]
M1TJ2\\2:-9A?/U*T&;E+/ E#%9G.%0XZ'KU]*ZJ4.2*C>YYN(JJM4=1*US6H
MJDVKZ:J7#MJ%F%MWV3,9EQ$WHW/!]C4\-U;S[/(GBD\Q=Z;'!W+TR,=1[U9B
M34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %03V=O<3V\T\*22VY+1,PR4)&"1^%3T4FD]QJ3B[H****8@HHH
MH **** "L_5W:*$2_;#;HO94#%CZ<U/?7D5E#ODR6/"H.K'T%5+.SDGF%WJ.
M#)_RSB[1C_&@"#1+B\>]DBO'8CR@ZJP (R>^*E\5VTUYX=OH+9#),\>%4=3S
M6BMO&MR\X'[UE"D^PJ6@J$W"2DNAXG:W0L=,U.PN1=Q7$VT", *N1_?!Y_*K
M U> /HAWWO\ H0Q)RO'3_5__ %Z]3UC1;#5XME] KD#Y9!PZ_0US^G> =/M[
MII+J:2ZC!RD;#: /]K'7]*SY6>[#,</.+E433_X%CE_#$$^I>,$OK6&>2U6X
M:1Y9 . <]3TS]*]9ID,4<$2QPHL<:C"JHP!^%/JTK'EXO%?6))VLDK!1113.
M0**** "BBB@ KS*T\ :;%INDR6UU9?V@+JX8W0D8K.9$G4JHW8S\^3C^Z:]-
MKS&RTK5C8Z1H3:/-NTR\N+B2XD=5MYD*3A K ELMYJ_PY7YO09 .4721)?RV
M,$^F/86<C/=:NYCQ 6L&M\>:'.%W$ *<-U&,#)[+1-)TBRBO-2M/$=A;:65M
M8B]C/''#OBCV%9&Y&#D<<'%<\WAS6Y](GL;+3+R.*.UM[>,ZC;VQFMV2XA81
MQR1D>;&%5V.X?PK@DDUOZWX3NK0C4I&O=2U![A)'N-.BAA>WV1R(C)"X*2?Z
MQ@VXDX8$?= H R-2T#1;/1["S;7O#L#QZ=8QPK)<B .T+2DS(RL"-WF'#88<
M'(.:M>'="M[?Q=9WL7B?2=0UNWABMI+99$^=$C99"L2GY)/ND, #A2#P36II
MFBZC)IWA<WNF0));ZM+<2A88XR(3'.%=T4E5=BZE@I(W-^6GX)T*_P!.FO;B
M\NI%BDO;R2.S,,0"J]P[*P<#<<J<\G^+VH @\9&;4M)L=,O;OP_:W5]%LN-.
MU)MZR,P&#'R"2K#CCGU!P:BLO"5UIE];O=ZI!)H]I=#4WEF!$[S"#RCO;.W;
MG+D]<G'3FLSQ5I6JQR>)(;311J%SJLRRV]R]O%/$Z")5$$H9U**'4G(R,,2.
M<U#JR>,7EO;.WM]3#*U_(MPDR")E> ^0J?-GASP"!M(^E '2_P#"(Z9+XFU*
M_P!6=;B34+F.>WMS<2*A$<4:_-'NV.04W9*GMZ5R,W@"]AU.>\U/6=)#F.0Q
M1R1[(Y<744X+IP GR[6 S][.3G%1ZUI/BZ?6)[BRAU,ZK"+_ ,NYDG0VH5\"
M 0H6^5O+XZ#YL[CR#2IH_BE[-)U&I2S1QW:VSSX26(/]GPOS2R-R5D(W,3UZ
M#% &[_P@=ZVM:;K+7-A'>V2($MX(2EKDS2.XV=SLDPK_ '@PW=R*GU+PS/+X
MGT2%)K^YMHPTM_=7.UO,16#PQ[@!\RR@,!CIN]:Q]5TKQA#;W,VDW.I-=W0O
MO-66XWJBB[0PB-2P",8?,"X([9(."*<EGXRBLM,DA;6KIH[B4I;R-Y(92T90
M2L)V<8P^"YD&"0RYQ0!/I_PQU+3].:&WU"T:>-8(4ED,CF:.-RV6WEA&QX(*
MJ2#G!YXZ+X?>"9/#$WFW<]M=3+;?9TD2,AE'VB>4\DD@8F QG^&L[QAIWBB7
M4-9NM*GU!83+:I'''*2#;XS-Y:!T^?=C)W*V 0I&>:^D6?BB*\TS^TO[<N<)
M']G9)TA2+]](7^TKO;=^[,>,ER<$9#9- %J#X=20+9>5<6B/"K"5TAP9&-]%
M<@GUXC8<]VS4-A\/M1LS,([G3Q EY!<V]L(W:,&.5G8Y;+)D,0%!8 \CKBJ-
MAIOBV=;>&9]=@5FM5U*26\&9)A,#*\!#'9%LW9 P,%<#(-/;1/%<-@B07>MM
M+.EQ%,S7FYHU6]B$)7)X;R/,^8<D9W9- %JP^&]Q&]@MW-IK06'V>)!%;E3<
MQQ3"3?-DX,AV\=@68Y^; W?!&BR6>KZY?RQ216\EPT-A%*@5HX=Q=\ 'HTKR
M$?[(6N7NM%\96BWAT>[U1[AIKZ"#[5=^8BP^7F X8]=_1C\W."<=([/1O%5W
M:QQS7>O1VP-U(G[XV\H;R4$8)\Z1R/,W$9;KVVX% 'K,DT<31K+(B&1MB!F
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M@LA;W#RFW^SR2)(JPWT5N=Y[[A(#QC&"#D&HU^(.L1Q*]S;:6JWBN;5P[A8
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M(DL$JAXY$.592,@@]Q7P1KWAG5M!6-M3M&CC?Y?,7YT5^\98<!QCE<Y%>G?
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MGV/%>B>%?$EGXDLWFLQ(C1$++'(,%"1Z]#7$_$[Q%9'1ET.WF-Y=?NVDFX(
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MY(AZ#^\Q[+^>!7J-1MS35DCSDY7Y8:MC=!T3Q!\3?%\PME62ZN)#-=7&P)#
M">6( P/H.2?Q-?7'@'P5HWP_T(V]B 96 :ZO)!\\S>I]!Z*.GUYJWX5\.:-X
M%\/+9:9$(;=/FDD;F29_[S'N3_\ JXJY#;RZG(MQ>J4MU.8H#W]VKRL3BG5]
MV.D3TL/AE2]Z6LA$236)!),&CL%.4CZ&7W/M6NJA5"J  !@ =J7ITHKD.HR?
M%EW=V/AV^N-->U2^6/$!NG"1[R0%!)(&23@9(&2*YCP[XGNX=033=5:]FNYK
MJ.$17MJD$\"O'*^\F,F.1"86 *^X/2NWO+6"]M9;:\ACGMIE*212*&5U/4$'
MJ*QE\'^'H]/>T&E6HMVD69@P))=?NMN)SD#('/ )'0T <]9?$A+F>QWZ6]O:
MW5OYR3S385W(<^6A"[6;Y!P6!^88!J-?B(?)LY=1TV>P\R.&]VQS)-NMY(IG
M!)QP1Y+ J/;!(S71-X-\/KY7V?3+6WEA@\B!XT ,:@$# Z97<<'MGBJN@>'?
M#.C&#1;.UMC=V\4=P=T?S-M4Q*Y.,=W&.VX\<T 9U]XZEL+&VO=5TZ2TXDD:
M""YCFWH(#*N3C@GICCD9R5YJS#XW=-1DT[4-+-M?PB4S(EP)$4+")00V!G(.
M.@P1W&";]CH7A>TN)-*M=-LDDBC^TO#Y60$D#19.>""JLN.P&.F*D?P9X;:P
MCL'TBS:V60S+&RYRY7:3GJ<K\ISVP.E &;X?\<C5M;M+&33FLX[JW2:"6:4@
MS%HEE(0;=K !B#AMV5.5 YKLZR+/PUHMEJ$=]::;;174:"-)%7&T!0@P.F=H
M"YZXXZ5KT %%%% !1110!AW133;EY[*6+:3^^MBX&?<#L:L>'YS/#</N8H9F
M* ]@><5>EM;>9]\L,;MTRR@FGQ11PKMB147.<*,4 4]<U Z9ISW*QB1@0H4G
M R37$WUU)JD:R7=Z!QGRQPBGTQUKJ/&G_(!D_P!]/YURT"DZ?&WV(.,8!R/F
M_K0!$EK##,CPW_EL,X8<$>G(-=-H6M32ZDMA,Z7(*;A.!M(('0CH?K6&R,LJ
M?Z""2,YROM^'/]>*G\/_ /(T0_NO*_='CCGCKQQ0!W5%%% !1110 5Q/AWX@
MVNJS6XNK)[""YMY+J&:2XB=?+3&XR!23'P1][CMG-=M7F-K\)X!IYL;O4(/(
M%K+:A[.P6WED#@<RON/F8P#C !(R: .MN/&OANWLXKJ?6+2*"5F1&=L$E0"P
MQU& 03GL<]*?>^+=%TY)I-3U*SM8DF,0=Y@0V(U<GCH K G/0$'N*PK#X>16
MP=FO(Q-)'<I(T-ML5O-C2/."S'*A!U8YSV&!6+XB\#ZM8VK+X<=KFXNK6:RE
MD?RPJ1O!!'@JQZ9@#;@21TVMV .]M/$VBWFK'3+74[66_ .8%?YN%#$?7:P.
M.N#GI6Q7):1X.6PN+"X:\+/;7KWI4)PS-;^05SZ#KG\*ZV@ HHHH **** "B
MBB@ HHHH **** "BBHKJ406TLIZ1H6/X"@#R:\?SM2N';J\S$_F:VK" ;16/
MIEK)J%]'"GWY-S9^@)K8TN;=&OTK0R+XMQ4=Q -AXJT'KGM?\46&GJT0?[1<
M#@QQGA?J>@JDG+1";25V4+U0LY KK_ATQ,%\G\(=2/Q!_P *\MFO=;N&-ZMG
M.+;J-L#&/'UQ^M=G\-_%6G(]Q;WTRVLLQ4IYA^1B,Y&[M^-.=*20H5(MV/3Z
M* <C(Y%%8&X4444 %%%% !1110 4444 %>?_ !M\2ZYX6\%S7WAVS\V4MLEN
M?O?9$/\ RTV]^>/0=373:EXAM[;?':HUW.O!6/E5^IKE;C6]4N&>250ULP*/
M"T68F4\$$'KZ5<)*,DVKDS3E%I.Q\G^%?$/]E>*X]9U)9KUSYAED#CS@SJ5\
MU&;(\Q2=P)[BNY\6>/+>R_L^ZT Z?<ZC<*D]T\L0F*RQ@""X;A56Y^:3=MRO
M3.:R?BOX';P]>G4M,M9(M&N&^X<G[,Y_@R?X?0_A]='X.?":[\:3QZEJPDM?
M#R-][[KW1'\*>B^K?@.>GN2G1E%5F]/ZT/&C&M&3I+?^M3-^%7PUU/Q_J33R
MM);:-')_I-Z1R[=2B>K>IZ#OZ5]<:5IVD^$-!@L--MTMK.$82-!EG;U/<L>Y
M-3QK8>']+M[.QMTA@B41V]M"N/P _K2V5E)),+S4,-/_  )_#$/;WKR<1B95
MWY'IT,/&BO,9:VDMY,MWJ(QCF*#LGN?>M6BBN8Z HHHH *P/%V@)X@.CQ7$,
M$]I;7PN;B*?E7012+C'0_,ZG!XXK?HH \GL/ &M0?8(Y6LGFB6U5-0\YS-8+
M"WS1Q K\RN..H^\VX$ 4S3? >M6$T-S;V6DQW%K'9@^7<N#?20RLSR2'9\K.
M&SSN.>I/!KUNB@#R*Z^'VO7&FA99K02[DDF@CF^28"YNI3&6>-AC$Z$;E()3
M! ZU;T[P)JUAK/A^ZA^RDV:1QRR3W'G^7&LCLR*#$"#M?:K(4']Y2 !7J5%
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M#XAU+Q=>6NJ)%';(9P]ML8-;[9-L?/E@89>>6.[JN!D5Z)110 4444 %%%%
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M1>)9Y6TU[9(-.6UN+IEE0W5P)23(XD5?G(Y.-V,_>(Q7K%%% !1110 4444
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ML<$,DTSJD4:EW9C@* ,DFGUX/^TA\18['3I?">C3![^Z7;>O&<F&,_\ +/\
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M8;!JK!SD["Q&*=*2C%7/H3XF?'R,PS:=X'#%VRK:E*F H_Z9J>I_VF_*N8^
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M!))/3\:U(T2*-4C5411@*HP *=2I4%3UZBHX=4M=V-DC26-HY45XW!5E89#
M]017)>#_  #I7A'7]6O]#!@M]15-]IC*1,I8Y0]@=WW>V./2NOHKI4FDTGN;
M.*;3?0****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\NUV%8?$UQ'QM,X;Z9P?ZUZ?+(D
M,322L$11EF)P *\JOYI-6UJ62W3?)-)^[4#&0.GZ"JB3(]7KS7Q$JW?BV6)>
MCRQQG\@#7I*9V+N #8Y KRW5UN['7999T$<_F^<G<'G((]J(A(]24!5 '  P
M*6L_1=6M]6M?-@.'7AXSU4_X>]:%24%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6;XEU/\ L7P]J>IB+SC9VTDXCSC=M4G&>W3K
M6E39(TEC:.55>-P596&0P/4$4 <3J6H>(M$LO/O=3TJ[,Y@V(D!C9&:>)'VC
M<=R;9#R>0<9SGBO8_$_3[V*]E@L;GRHH_-@ED=8TE7S!'RS$*ARP."<E>1DC
M%;]GX,T"S#B#3D&X1J-\CN45'#JJ[B=JAE!VK@<#BD;P7X?9)T.GC;*P? FD
M C8/Y@,?S?N_G^;Y-O- %#POXXC\1WUK;66FW"B2*62>5I$V0^7*T1'7+99#
M@@=.>.E=C63H_AW2M&D,FF6:0.592P9B2&<NW4GJS$_4FM:@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,/Q?8WE_IJQ6)!P^YX\XWCZ_6L;PKX?O;35A<WD0C
M2($#+ EB1CC%=K13OI85NH5B>*-%.KVL?DLJ7,1RA;H0>H-;=%(9RWASPS-I
MM^MU/<*Q"$;$!ZGU/<5U-%%%P2L%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image00029.jpg
<TEXT>
begin 644 image00029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #V 98# 2(  A$! Q$!_\0
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MS ,!OKCC-3["HW=O^KLOZ]0C'DC#37\E_D_O,#PIX@O]8G1KFS6.UGA,T<B
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MP90RD$'D$=Z6O,M)UBZTV3%N^Z$MS&_(_P#K&O1+B_M+:X@@N+F&*>?B*-W
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MQ4Y_(U/5*UM)([Q[B9XRS($(1=H/.<GGK5VNJFY<OO'/4M?W0HHHJR HHHH
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MSH<21GJI_P *M52O[-I&6XM6$=V@PK'HP_NGVIUI?1SP.[@Q/%GS4;JF/Z4
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M%N2C!:)W9W%%%%=YZ(4444 %%%% !1110 5S/C#5[[2[O25L=I2:4B52FXN
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MQH/3O]?6IZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQUJ/X.%U\/ZF85#2?:/E!X!.P5Q7BFX_X2'7+==(GO\ 4V\H(HFC <')R
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MR<X&>E=C7;"7-%2.Z$N:*D%%%%44%%%% !1110 4444 %%%% !1110 4444
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M(]PS,S#]W+Y;;".H/49J(8J$K=W_ %^J-JF6U8-V::77[_\ )KY%JY\(65S
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'69-WU9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image00030.jpg
<TEXT>
begin 644 image00030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" "- 8 # 2(  A$! Q$!_\0
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M_P#X-)?\:/\ A!]._P"@EK__ (-)?\:/J4NX?78]CZ+HKYT_X0?3O^@EK_\
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MM6HI;>&9XWEBC=HSE"RY*_2O3DKGE1=C&NKZY%POS@&U=]XVXWMM<J#_ ,!
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M##IW_?S_ .M3)_'/A8P2@>(-.)*, /,Z\4<R&HN^QZS\(?\ DF'AC_KPB_\
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M><[)4#C/K@U3_P"$?T;_ *!&G?\ @,G^%:=%%P,S_A'M&_Z!&G?^ R?X4?\
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1ITG=OR''*<1AY*I55DO,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image00031.jpg
<TEXT>
begin 644 image00031.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $A >4# 2(  A$! Q$!_\0
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MV2"Z)EM>GNGT_P *]#M;F*[@6:W</&W0BN.=-P>IZ%.K&HM"6BBBH-0HHHH
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MN.I3<'Y'I4:RJ+S)J***R-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA.#^F:]<KDKJTKG?A97A8****P.H**** "BBB@ HHHH **** "BBB@ HHHH
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M 74;<$D9.14_PX^(.M>(-<TN#6;/3X;/6],DU6P^RE_,A1)%7RY2QPQ*NIW
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MN;B2:7EY&+&FCTLMP_M)\\ME^9%1113/?"BBB@ HHHH **** "BBB@ HHHH
M*Z+PEJ/ES?8IF_=R',>>S>GXUSM*K%6#(2&4Y!'8T&5>BJT'!GIU%5=,NQ>V
M$,XZL/F'HPZU:J3Y647%N+W04444$CHCB1#_ +0KU8]:\KMQNGB7U<#]:]5;
MJ:Y,5NCZ'(]I_+]1****Y#WCHO MMY^N(Y!Q$I?^G\R*]+KDOA[9^78SW+#F
M5@J_0?\ Z_TKK:XJSO(]+#1Y8>H4445D;A1110 4444 %%%% !1110 4444
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ME<VND7,L-]G[,R@$S85F.T9R>%;\JDU+P+XFTNTFN]1T:ZM[2$IYDI"D*&(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM-+HEK%=^;*T2AA-$ZK#'P<?O Z,#Z9]*S-!\*V6H^$XM3N;^XBOKK4QI5I
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MUGLE%>-_\-(_#G_H(WO_ (!2?X5TG@+XN^$O'6M/I7AV[N)KQ(6N"LENT8V
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MB:_JG[.U]9:A/?7OB&[TU[F01L?,:5\R>2,=5&=FWN!B@#UBD9@HRQ '3FO
MK>?Q6WBW2(K34-?M-'6*P.GO=6MU)YZY_P!(6<*A&\GY292NU=I7UK-\1V?B
M'5M&\1P7;>*+Z*RU6TO5O(5N(F>/[4=\:0,@P\2<YCW*=J-U% 'TA15?3RIT
M^VV-,R^4N#.")",#[V>=WKGO5B@ HHHH **** "BBB@ HHHH **** "BBB@
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M3L))#<)OM#)*SVS@]"%4E0%^[NX&*DTKX:^)(?$/AZ?58+J>*UL])CCGM;F
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MZ\8J*L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<"PVT:QQKT J:BBN4]%*VB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>H[:"*VMXH+>-8X8D"(BC 50,  >F*DH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image00032.jpg
<TEXT>
begin 644 image00032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #T ;L# 2(  A$! Q$!_\0
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M=_X3K7O^?F#_ ,!T_P *[6WUJ]?X>OJS/']N$3,'\L8R)-OW>G2O(J]+M?\
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M /Q5<1FC(]11]6I?RA]8J_S,[?\ X6-J'_/C9?\ C_\ \51_PL;4/^?&R_\
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MXV9&-K=0,]LYK9T\.MTC+GK]V0_\+&U#_GQLO_'_ /XJC_A8VH?\^-E_X_\
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MG_H%V'_@.O\ A1_8FD_] NP_\!U_PH_M"'9A]0GW1X517NO]B:3_ - NP_\
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MK9HHNPLC&_X1?1?^@?#^O^-'_"+Z+_T#X?U_QK9HHNPLC&_X1?1?^@?#^O\
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M:@R7^I(5M%.40\&0_P"%>A:WHL.L36?VKF&!BY3^^>,#Z5J(JHH5 %51@ #
M JKZ$VNP1510J *JC  & !2T45)04444 %%%% !1110 4444 %%%% !1110
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MXVN!G]*=:A*B[2,\%CJ>,@Y0NK;IDE%%%8G:<GJD[P:E=R1L,I<(#\Z@@&(
MCEQCU[=!QWKHM+='T^W\LQD*BJ?+;<H('(!K&N[R2TN]5:%D:7S$V1NC2%SY
M8.% ;^@_K6KH]TUW:M(QB8!RJO$"%<#N,U4B47J***DH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH P]>T.?4=2L+^RU*2PNK2.6)6
M6)9 RR;,Y#=_D&*YBW^%FF6]PACNIY+?;'OCF4,2R)M# C&#WZ'!Z8KT.BK5
M2459,EPBW=GGK?#.WD-F;G4&G,%O'9LKVZA9(48LH*J1\W)R>_IQ5J3P?I>G
MPZ=#*[LMK#>D,8T.[S>68\=1GC]:[BF2PQ3;?-C1]IRNY0<?2G[675DNFK>Z
M>;R^$],BU#3Y+&[N8+O388;")Q;1NDC1K(O*D8+%9#SP!C\*R=6\!W5MI>G7
M7AE?MXAMA \%QMC=BC%DD &%RI/3@<>]>LM96S0&$P1"(_PA0!4L$4<$*10H
MJ1H,*JC  JXUY1=T<U;"*O%PJ;>71GC?@?P/JT^HV]QK=B+*&'R_,9Y=SS>6
M0R@*.G*KDD]N!S7L]%%35JRJN[*PF#AA(<L-?-A11161UG):T0+R_P![LF94
MVCY@&/ECT(_0GK[<=-8MNLK=@[2 QJ=[#!;CJ:YO5HW>_OEC#[VE1E5 0S8C
M'.0HZ?4]?PKI;)MUG WF>;F-3OQC=QUQ52)B34445)04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '*ZD&.IWPB5VD,J$+& &;]U@G.T]C^OX5O:.A33H 9#*NT%7)R67''8?RK
MU98Y+[44D5G_ 'D9PA7(/E]\AOY#\:Z/3VW64()!94"L0NT9 YP,#BJD3$L4
M445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '(:M=(NL7]LWV8NQC8?:"-H&PYQEN#QZ#^M=/
MINW^S[7R]Q3REVENN,#&?>JEC\VM:H&Y \K /./E^O\ 05IU4A(****D8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &;8 C6M4.#@^5S@_W3[?U/X5I56@M%AO;JY5B6N-NX;0,
M;1CJ!D_B35FFQ(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKBO
M%'CV+0=8DL'L))RBJV\2!0<C/3%97_"U8?\ H$S?]_A_A7)+'4(2<92U7J>I
M3R;&U8*I"G=/5:K_ #/2J*\T_P"%JP?] F7_ +_#_"C_ (6K!_T"9?\ O\/\
M*G^T,/\ S?@R_P"P<?\ \^_Q7^9Z717FO_"U81UTF;_O\/\ "D_X6K!_T"9?
M^_P_PH_M##_S?@_\@_L+'_\ /O\ %?YGI=%>:?\ "U8/^@3-_P!_A_A1_P +
M5@_Z!,W_ '^'^%']H8;^;\'_ )!_86/_ .??XK_,]+HKSN^^)T-K>3P?V7*W
ME.4W><!G'X5#_P +5AQG^R)L9QGSA_A3>88=.SE^#$LCQ\E=4_Q7^9Z517FG
M_"UH/^@3+_W^'^%'_"U8/^@3+_W^'^%+^T,/_-^#'_86/_Y]_BO\STNBO-1\
M583TTB8_28?X4G_"U8/^@3+_ -_A_A1_:&'_ )OP?^0?V%C_ /GW^*_S/2Z*
M\T_X6K!_T"9O^_P_PH_X6K!_T"9O^_P_PH_M##_S?@P_L+'_ //O\5_F>ET5
MYW:_$Z&<3G^RY5\J(R_ZX<X(&.GO4'_"U8/^@3-_W^'^%/\ M##_ ,WX,2R/
M'MV]G^*_S/2Z*\T_X6K!_P! F;_O\/\ "C_A:L'_ $"9O^_P_P *7]H8?^;\
M&/\ L+'_ //O\5_F>ET5YI_PM6#_ *!,W_?X?X4?\+5@_P"@3-_W^'^%']H8
M?^;\&']A8_\ Y]_BO\STNBO-/^%JP?\ 0)F_[_#_  H_X6K!_P! F;_O\/\
M"C^T,/\ S?@P_L+'_P#/O\5_F>ET5YI_PM6#_H$S?]_A_A1_PM6#_H$S?]_A
M_A1_:&'_ )OP8?V%C_\ GW^*_P STNBO-/\ A:L'_0)F_P"_P_PJ>Q^)T-U>
M0VXTN5/,8+N\X''Z4UF&';LI?@Q/(\?%7=/\5_F>B45YH/BM 1_R"9O^_P /
M\*/^%JP?] F;_O\ #_"E_:.&_F_!C_L''_\ /O\ %?YGI=%>:?\ "U8/^@3-
M_P!_A_A1_P +5@_Z!,W_ '^'^%']H8?^;\&']A8__GW^*_S/2Z*\T_X6K!_T
M"9O^_P /\*/^%JP?] F;_O\ #_"C^T,/_-^##^PL?_S[_%?YGI=%>:?\+5@_
MZ!,W_?X?X4?\+5@_Z!,W_?X?X4?VAA_YOP8?V%C_ /GW^*_S/2Z*\T_X6K!_
MT"9O^_P_PH_X6K!_T"9O^_P_PH_M##_S?@P_L+'_ //O\5_F>ET5YW:_$Z&X
M>1?[+E7;$\G^N!SM4G'3VJ#_ (6K!_T"9O\ O\/\*?\ :&'WYOP8O[#Q][>S
M_%?YGI=%>:?\+5@_Z!,W_?X?X4?\+5@_Z!,W_?X?X4O[0P_\WX,?]A8__GW^
M*_S/2Z*\T_X6K!_T"9O^_P /\*/^%JP?] F;_O\ #_"C^T,/_-^##^PL?_S[
M_%?YGI=%>:?\+5@_Z!,W_?X?X4?\+5@_Z!,W_?X?X4?VAA_YOP8?V%C_ /GW
M^*_S/2Z*\T_X6K!_T"9O^_P_PJ[HOQ'AU35K2Q7398S</L#F4';^&*<<?AY.
MRE^9,\DQT(N4J>B\U_F=]11178>4%%%% !1110 4444 >'?%3_D=+G_KE'_Z
M#6'I%S:Q0:C!>/-&EU"L:O%&'*D.K="1Z>M;GQ4_Y'2Y_P"N4?\ Z#6-X?ET
MV*ZD.KQ"6(A H(8X^==QX(_@W5\I6_WF7J]S]-P?^X4]&_=CMOT-&/5=%BC0
M+IX=UCV@O IP<*.>?FR0S9/3.*=JUWHQTV*33HX$F^T(ZPB,;T0%RVYN^<IP
M?2GV\_A<AGN(B"PC^18WPI!7=@YZ$;O\]%74/#L]O8BZMPDD0=7"QMMP2Y0<
M'.!E<]2<CTQ5W=K.43*R34E">C_2_P#P/^');WQ%I$[2,;+S7)D(:6!#MW&5
ME &>,,\>?]TUF:SJFC7%ELTZQ6"?SM^\J!QDD]^A! V].*9K4VFW,%K)IQCA
M2W_=M"4(=LR,0<_Q87;[\UO?\)+ITVI7LA=;6#SXS%F#S?,A5F++MQ\NX$#%
M'-SWC*2!4U22G3A)VZ7?==+:WO?0RM>U?2K^*\-O:$7,TA=6,2J5);.<@Y^[
M\NWIWKFZZ#5;[1[C1([2R1X[B!Q*C%!A]Y)=<]>,KC/'R\=:Y^N>L[RO=/T.
M_!Q4862:UZE[6_\ D,WW_79OYUJV>M6:6-A#</=^5!M6:S55,,V)"Q<Y/4@^
MG8<XK*UO_D,WW_79OYUMZ7J6C1Z?9)>1_P"DV\3#>L9SN9I,@GH1@K5TW^\E
MK;U]3*LDZ,&XN6VWH1R:MH\<<,=M8JQ6-E9Y+=,NWE!5/4_QY8U,NLZ )(R-
M*7;M17!B4\;AN'7K@-ANO-7)9?#MC$L31VTD=P4WK&&<K&''4@G#[<].I[5E
M:;<Z*=(M[?4O];'(YW")BXRZ$'((!7:&R.O(Q6K<HNW-$Y8QA./,H3WMZ[Z_
M?H/&NV@U"ZG\AVAFLHK8QA%4_*4W#([$*W/N*)M4T5@WE60#94EOLZ8E )^4
M#.$ZKR,YQ3KVZ\.KO^QVJ/F.5AO1^'V+L'4<;M_Z5/>WOAJ65YDMVDE9W;YU
M8 _*VW('\.=G'7@TKO5.2'RQT:IS_P"&[_U_P*]WJ6A-:W44%DRL\9$<GD*K
M!]SD<Y.  RCU^6L"22!H%6.W*2C&Z3S2V[\,<5MI=Z-%J>C7$4*".,@W<?EL
MR]N>>O.>/U-5-8DTI[2 :<F)PWSD*P^7:,YSU._)&.V*SJ>\KW6ATT+0DHJ,
MM==?FM?N_$K:9]V__P"O1_YK5&KVF?=O_P#KT?\ FM.T"[AL-:M+JZ!:")BS
M@#.1@CI^-9))\J9TN3CSR2NUT^1GT5V5IJFC7UG;6LT,-NZ1* )03#&RJP[M
MENO<_P JI>(=1TFY@,%C"H:!U6"18\?())"1GN-K)C-:.C%1YE)&$<7.4^1T
MVOZW.:HKL+K4_#=Q=7<TMLS/*LA!%OM!+%BIQGAAE<GO^%0QZOHB7$V+%5MW
M\Y2(XMK%#LV+G/'1\_44.C%?;0+%S:_A2.6I*ZF74= ^TQ^381F(RYD+1'E-
MF!CGCYNV.U06&H:1"VI0S0E[::=9(-T()"@/C(!X )4X[@$5/LHWMS(KZS/E
MO[-_T_Z9SU)6_;W>AK=ZDTMFS12(HMQMX#;?FP,_+EN1Z5HQ:OX>5I%%DJPN
M0& M\[D#HV.O4@/S]*:I1>\D*>*G'14Y,Y"KVA?\AFR_ZZBKU^VFSZ7:&-;>
MWOG1Y9_+7@;<A$ '0OG)^@JCH7_(9LO^NHJ5'EFM>QHZGM*4G:VY07[H^E+3
M<X3/H*UGT.Y.I3V4#Q2/"(RSE@@R^W:.>Y+ "HC%RV-9U(P?O.W]+_-&716K
M>^'M2LK%KRXA5+=1G?O'/W?_ (H?D?2K-QX6U!+J2&#R9U7=AU? )4 D>S<C
M@U?L:G8R^MT-^=??VW,&BMN+PS?,^UV@#88!5D#,6$>_;CUP1],TC>&-320)
M(D",76-0TP&YCNX'_?+?E]*/8U/Y0^MT/YU]YBT5JVNA7=R]Y'&8A/:ND9C+
M8+%CC@^V"3FFV^A7]Q=200QH[I&LVX.-K*V-I![YSQ2]E/L5]8I*]Y+3^OU,
MRBMV/PMJ#HS,;=/D#*#("68E,+[']XIY]:I7VD7=E;FXF\HP;@@DCD#!FRPP
M/4@HV?3\:'2FE=H4<31F[1DB/2?]?/\ ]>TW_H!JE5W2?]?/_P!>TW_H!JEV
MJ7\*+C\;^7ZAFBNP@\0Z6L)1[9@?(AC,BJ=SE870YYP,,PP1U[U/<7WA^SC$
M"Q6TT,[*95ACW!4#G )S]X CFMU0BU?G1R/&5(NSI/\ K?\ K\CB*6NATR_T
M@:1:6VI1,\L3,25AW$9<'.[/(P""N.]27VHZ%^]^P6$?,<A7S(<X<[-O?H/G
M_,5'LHVOS(T^LSY^7V;ZZ]/Z9S-%=;?ZKX?FDDFBL2\S-(V98\Y)#[2>>1DI
MQVV_G574=)AU;2+JWMPB0C_24$(*YQC(!ZGJ>?P--THI_$A1Q4Y+^&UN<[6W
MX(_Y&_2/^O@?R-0ZQ/IDMK;KIT!CE4_.VS;\NU1@\_,=P8YXX.*F\$?\C?I'
M_7P/Y&BG'EJQ5[ZH=>;GA9R:M[KW]&?0=%%%?7GY2%%%% !1110 4444 >'?
M%3_D=+G_ *Y1_P#H-8_AU=*:ZE_MIRL.SY0 W)SV*]"!ZUL?%3_D=+G_ *Y1
M_P#H-<CFOD\1+EQ$G:^K/U# 0]I@:<;M7BM5OL=;:R>&$N('PH,;*?G\PHP'
ME%BP]?\ 6X'3@9JMI]UI2V\S7#1AXY[EU0PEC*KQ[4 .,##<X.,51\.OIRSW
M0U4(T+PA5W9&&,B9((Y!"[C6A-!X<BM9I(Y_/D$9,49D<%F"GKQW;%5&3DE)
M<J,YTXPDX/G?GO\ UN:4FLZ'!NGC2":40;4BBMP@^^A RR'!P&SG.!T;FJDN
MK:9]AL7@2UAN$G1VB2V!VH6;>&W*<@ @#DYXX&*F7_A%Q:^09(0A;B0;C(1N
M4C)(X/!R!T&<5DZM#HBZ?*VG2G[2LV%5G9BZ>W8 >_7UJYSFE>\3&C2I-J+C
M/?K^OD3:WK%K<Z7]G@BB,TDTK/(D2IM3S/D&-O\ =QT(]ZYRC-&:XYU'4=V>
MM1HQHQY8>IK77V;_ (2F7^T-XM/M1\W9UVYYK7AE\+Q3HWEA@L@<[O,88#1<
M8[J1YO7T%<_K?_(9OO\ KLW\ZI9K3VO))JR>IA]7]K"+<FM%L['42+H<L-[(
MD4?[B%71D=@)96W I@G. 2K<#HI]:BT6?3]/BO[:^:"20R[5E"%\J(Y!\IQP
M-VS\_:F:9;:"^E1/?W(%Z7.4#,N!\V V!P,[.1V)JW=KX;GN2RR)&3*L>U"P
MC"! 2XZ'J-GUYK97TFN5/_,Y)->]2?.UWMVMM^+%M)O#277FM$B+%=C8K"1Q
M)#D=0>G&3W^E5;-O#Z02&X1Y9BSD;]R@<# 7:?NYSUYQZ5>BC\*0WJ$2"6-9
M-V9'<@C?C:1CH%.?PI^FZ5H%W);1QSI-/L!F43,B#YDR<GD8!?'TYJN63LER
MF;J0BFW[1(J8\,;D0M*(WD*&0;RZ [\L1T('[O '/7--:3PW]E$B0N)]DC")
MV? ;#;5)';.S&#ZYJCKT6D116W]D2O(YSYNXD]A^1SNZ=L5CYK&=3E=K([*6
M'52*GSS7J[%[3/NW_P#UZ/\ S6G:!-;6VLVLU\J-;(Q+AUW#H<9'?G%,TP_+
M?_\ 7H_\UJEFLE+EY6=+@I\\'U_R.M>X\.3W=NTZ(1(A\Z3YUV,$0#"C@\[^
M._KZU9)=!>>W9E)2.SV;$1E5Y0&Y?G=DG;T_$USF:,U;KM_97W&,<&HZ*<OO
M.KE_X18S.4#+'EAC,A^7<W(_VR-N,\=<U$I\,&-\I,&-N' RW$ASE![K\N">
M#DUS.:,T>W_NK[@6#_Z>2^\Z*S_L!]>N/M6(],50(L>82YXR<]0>OM5I9O#7
MV.""1<H&,C,@?S,A$X8_[3!UXX&0:Y/-&:%7M]E?<$L'S-/GE]_X^IU4/_",
M+;VS2?O)BJB5?W@ )://XA3)W["I3_PC%PH\Q@K>5'&BQJZMN&,DD\$GGK[<
MUR&:*?M_[J^X3P77VDOO.MU:U\/VD%S&=OVWR<H(9'9 WS8P>>?NY![5@Z%_
MR&;+_KJ*H<#IBKVA'_B<V7_745/M%.::212HNE2DG)RTZ^A07E1GTK4.NZJ2
MI^W2Y5=H. #CC';G&!CTQ66I^4?2ES649..S.F=.$_B29;FU"\FM%M9KJ5[9
M0H$;-D +G'Y;C^=6?[?U;<6_M"?)&#R.?TZ^_6LO-&:I5)+9DNC3>\5]Q=_M
M2_W[OM<N[+'.><LH4_FH _"EEU:_E<-+=R.0P?YL'Y@" <8]S^9JCFC-+GEW
M#V-/^5?<75U6_6XFN%NYA/,5,CYY8KT_*D74[Y+B6=;J42RJ$=@?O*.@],#
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M1_PC6B?] FP_[\+_ (444>RI_P J^X/K5;^=_>P_X1K1/^@38?\ ?A?\*/\
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6UFK.;^]FE1116AB%%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image00033.jpg
<TEXT>
begin 644 image00033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #0 5,# 2(  A$! Q$!_\0
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M?4T9/J:2B@!<GU-&3ZFDHH 7)]31D^II** %R?4T9/J:2B@!<GU-&3ZFDHH
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MX=B\7G44;Q!<V2VBF8LELBG?ROEC/4#&\]CT!KJZ** "BBB@#+U:*_>[M9+
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M[]!@4[_A&;+R]A:8KG)R1R>?;W/'3UJ>YT*TN$B5_,"QQ>2 I RO;/'/TZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<)\WR]6Y_3I0!>HK->#5&  NH1QSA.<YJ:UCOEE!N9HGCV\JJX(- %RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image00034.jpg
<TEXT>
begin 644 image00034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $8 C@# 2(  A$! Q$!_\0
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MR.Z2*R2(2&5A@J1P013P^&PU:/PV:W0JE6K#5/0],_X7'JW_ $#+'_OMJ/\
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M?(Q_U)^E?7.E_P#(.M/^N*?RKV,VBDH6.#!-MRN6A2TE+7C'H!1110 4444
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MG_D<]$_Z_(_YU[F _P!UJ'FXK^-$^I:6DI:\,](**** "BBB@ HHHH ****
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M:\0]$**** "BBB@ HHHH ***1NE '&?&#_DG^I?\ _\ 0A7AO@G_ )'/1/\
MK\C_ )UZY\8O$&GIX>O=&>5UU"549$,; ,-PZ-C%>->&+R&P\2Z7>73;((+E
M))&QG !Y->[@(OZK-'F8J2]K$^KJ6LW0]5M=:L8[W3V=[=\A69"NX>V>U:5>
M$U9V/36P4444 %%%% !1110 4444 !KS[XX?\B,__7S%_6O0&^Z:\H^-7B#3
MY=%FT597&HK+')Y31L,KSR#C!%=&%3E6BEW,J[2@SS[X8_\ (_:-_P!=&_\
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MUXUKK,$=CI_D>6HP-V6?&X\D]\=* /912UXU:^+O$USXMTNSMKR(63^22+B
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MEO$M# EL&FE,8Q,$RI&2^< XR.A% 'LM%>(7NN^(-&A\0_9-3NI9WU90XNH
MHL;=U!$@.QA@].C >E79M>\8S:3%/#J,,4T&FI=,8;/S$N9&FVC[R@@;>2
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MC /S$C.W /K7J_@._O=3\+V5WJ1+W$A;$AB,9E0,0DA0_=+* V/>@#HZ***
M"BBB@"M)_P ?D&=G1NI^;MT_K5FJLA_TN#D#(;C;G/3OVJU0)!0>E%!Z4#,F
MZUW3+35K;3+F^@CU"X_U4!?YW_#^57X)8YXA)"ZR1MG#(00?I7 ^(],OW\<1
M7.BZ;>)-.8HKRY9D-K-;C.[.3O5U' *C/O7/:+H6M>&]'T^'2]&U(K U[!/"
MMR"7:0'RY1N;&WISU'I0!ZUJ5_;:;:FXO9EAA#*I=@>I. ./<U):W,-TK/;N
M'57,;$=F'!%>,ZIX8\0W9L8K[3M2N[A([+R9H[P"&#809A("WS$GGH<^M/\
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M#_L5M3^='^UW1N%*I@@%%4!CW/RY_&MZ@ HHHH **** "BBB@ HHHH ****
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MJ!D#H/H* )**** "BBB@ HHH/2@#B/BEJ4UMHMOIEDVH)>:G+Y*OIT>^XBC
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M+1:98^>WE6<!56GEQ&H.#]YC@9YQR:B@T;2)+2%$TVP:V#>;&HMDV@M_$!C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image00035.jpg
<TEXT>
begin 644 image00035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #2 9H# 2(  A$! Q$!_\0
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M,4=67[RD$?6OT*T]VDT^V=_O-$K'ZD"O,S.*O&1Z.72=I1+%%%%>6>D%%%%
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MC,5N.G+<_A7.0H8XD0N\A48WN<LWN:Z/Q3S%;X..6Y_"N<A5DB17D,C*,%V
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M-\5NT'EZA/!$+9T93<1R/YAW<EBH!))3;Q\N.34<FG^,C X2Z&Y[>-#_ *4
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M@^XKNJY"UL[E;J$FWF #J22AXYKKZSJ/4UI*R"BBBLS4**** "BBB@ HHHH
MP/'MS/9^$]0GM97AF105=#@CYA7BG_"5:]_T%[W_ +^FO9?B1_R)6I_[@_\
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MK^)W_P#PE6O?]!>]_P"_IH_X2K7O^@O>_P#?TUP4VN:BC)MTY"'1W7)8'@L
M.G7@$^S#%$FMZBDLT9L(LQ(27)8!B&QD<?=_KWI>YV_ /WO?\3O?^$JU[_H+
MWO\ W]-=M\)]9U+4M<NH[^^N+B-8-RK(Y(!W#FO&])U*:]NIXIK<Q*B(Z':P
MSD=#GH?;^=>J_!?_ )&"]_Z]O_9A4U8Q]FVD:X>4_;14F>QT445YA[85D>+K
MB6U\-ZA/;R-'*D1*NIP0:UZQ/&__ "*>J?\ 7$U4/B1%7X'Z'B'_  E6O?\
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M@F4KQT !J;X0^#=3\)Q:H=7DM2UQ]GAA6 @[8H8A&I8A5!)'MV_  &]\2/\
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M-*U$P6L<+6&5\HN"O'3GIC@_UIH\0Q/*L*6P:>23RPHE4AN<;@<<KGOWJ/\
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M*ZGX<_\ (Y:?_O'^5*I\#]"J/\2/JCW^BBBO(/H@HHHH \^^,W_( M?^N_\
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M);A0RQ2,&&5.0 &VYVDYP#GBKUE;6$]K%-#90(C*2 8E!&>"/Z5.+*U&S%M
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M%_AGB8[^,Q0<'(JG;Z;96\)BBMH@C!@V5!W9ZY]<U;HKHL<EV4%TBQ6\CN1
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M&U68<$[A65:<73:3-\-3FJL6TSU"BBBO,/<"L3QO_P BGJG_ %Q-;=8GC?\
MY%/5/^N)JZ?Q(SJ_!+T/G:BBBO7/G#%U'2KB:^FN;654:554_O'0\*P!R/0G
M..A[TS^S=3"X6[7)<[W,SY8;E.X#&%. 1M' S6[14\J+]HREH]O<6NGI#>2B
M652?FW%N,\9)ZG\JNT4525M"6[NX4444""BBB@"SIO\ R$;;_KHO\Z^FZ^9=
M,&=2M0/^>J_SKZ:KBQFZ/5R[:7R"BBBN(](**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Q/&__(IZI_UQ-%%73^)&=7X)>A\[4445ZY\X%%%% !1110 4
A444 %%%% %S1_P#D+6?_ %U7^=?3%%%<.,W1ZN7;2/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image00036.jpg
<TEXT>
begin 644 image00036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #N 6D# 2(  A$! Q$!_\0
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M[I6\J/=-Q(=HR_&.?7CBN4^(WB74?#=E8OI-C%=RSRLLF\LQB14+%A&GSN.
M#M!V@Y((%8B?%W26>X6.RO+E(8HR+BV :&69Q$1&K'& ?.3#,%!Y]*DH] ;3
M;%L;K.V.$\L9B7A<$;>G3!(QZ$TU]*T]Y$D>PM&D0EE8PJ2I/)(...@_*N,N
M_B9:65X+:]TF_A>-$%R=\3""5UD9(SM<[B1$W*Y XSCG&1J7Q?2/1;J:RT&]
M_M*&%[@V]Q)$JI&(X9!(S!SD$7$7RKEN3QQ0!Z)#H>GPZRNJ1P8NTMOLD9W'
M;%%D$JB9VKDA<X'.T>E:5>>R?%"S;4);"STR[O+L7<5I$L,D>V4R&8!@Y;
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MUY'\6O$CSWAT6T?$$6#<%3]]NR_05I2INI*R,:]948<S)O%/Q,D,CV_A]55
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M&1DJ1Z]JP;CPAX?N-GG:5;ML1(UY885%*J.#V4X^E=6O0X5;J9S>/]'&JFS
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image00037.jpg
<TEXT>
begin 644 image00037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %6 6H# 2(  A$! Q$!_\0
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M] $U%4)M9TR&5XIM0M(Y$.&5IE!!]QFK<$T5Q&)()$EC/1D8,#^(H DHHHH
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MJ(3C[+(/D#  @@GG:,\_04W1?'6A6OAF"V37);.W31;K3WTA;5RDERV\K,6
MQSD#/7GL,UXV^FWR+(SV5THCB6=R86&V-ONN>.%/8]#6[;>"-9F\-7.KFTN8
M_+GA@BMGMG$EQY@)#1C'(X[4Y8>DEJ_Z_IBC7JMZ+^MSU2;Q[X5'AS2K*/5I
MIQ;7>FSHLZ3O+"L3+YN<_(I !P(P,CU-'A#QA'XJ\3^*QXBGEOM$T^3^VK*1
MD"K"MO*2BXP,!E;&#S7A+VMQ';+</!,MNSF-960A2PZJ#TR.XJ(,0" 2 >"
M>M/ZK"SL]?\ AO\ (2Q4TU=:?\/_ )EK5;^?5=4O-0O&W7%W,\\A_P!IB2?Y
MU4HHKJ225D<K;;NQ&^Z?I7WM\/\ _D0O#?\ V#+;_P!%+7P2WW3]*^]OA_\
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MLOGOY'E-%>JK\%]?GW?9891Y'S7'GJ4RHZ^7Q\YX.!]/6C_A3&N,GVM(;C[
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MQ0)/);J"L;OL5B6"C+8.!SZ&MFL;QCHO_"1>&[W2O,2,7*JI9TWK@,"01W!
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MSV!EDVFW528VWA1@=,@X(_"FR/H>B7_B*S\4V;W,ET42U\RV:=KRV$"*L2$
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M.*(_%R2PW&S1M9^VVY0O8F!5FV-G:XRVUE^4]&.",$4/N):'GZ:MJ,FFWO\
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M.EI*VJ_FU]3TFLGQ;_R+>H?]<C6M63XM_P"1;U#_ *Y&O=/BS6HHHH ****
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M6]0_ZY&M:LGQ;_R+>H?]<C7T!\*:U%%% !1110 4444 %%%% !1110 4444
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M.O"5]>WR?F_Z9RXIRA@JL+73L[Z]XZ:I=W]S.NK)\6_\BWJ'_7(UK5D^+?\
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MM>B@#(_X2/3/^>\G_?B3_P")H_X2/3/^>\G_ 'XD_P#B:UZ* ,C_ (2/3/\
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M;ND_]!2P_P# A/\ &C^W=)_Z"EA_X$)_C5WR8O\ GFG_ 'R*/)B_YYI_WR*
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772450736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 20, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OncoCyte Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001642380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,468,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772788336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 10,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">BioTime shares held as available-for-sale securities, at fair value</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,528<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furniture, net</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">10,216<span></span>
</td>
<td class="nump">14,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due to BioTime and affiliates</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable, current</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease liability, current</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of deferred financing costs, noncurrent</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease liability, noncurrent</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">5,813<span></span>
</td>
<td class="nump">4,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, no par value, 50,000 shares authorized; 31,452 and 28,737 shares issued and outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">59,968<span></span>
</td>
<td class="nump">45,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss on available-for-sale securities</a></td>
<td class="num">(888)<span></span>
</td>
<td class="num">(654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(54,677)<span></span>
</td>
<td class="num">(35,302)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">9,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 10,216<span></span>
</td>
<td class="nump">$ 14,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in equity securities and other forms of securities that provide ownership interests classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772292496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">31,452,000<span></span>
</td>
<td class="nump">28,737,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">31,452,000<span></span>
</td>
<td class="nump">28,737,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772679856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 7,174<span></span>
</td>
<td class="nump">$ 5,677<span></span>
</td>
<td class="nump">$ 4,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,232<span></span>
</td>
<td class="nump">4,265<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,849<span></span>
</td>
<td class="nump">11,140<span></span>
</td>
<td class="nump">8,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,849)<span></span>
</td>
<td class="num">(11,140)<span></span>
</td>
<td class="num">(8,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSES, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Loss on sale of available-for-sale securities and other expenses, net</a></td>
<td class="num">(309)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(217)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="num">(526)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (19,375)<span></span>
</td>
<td class="num">$ (11,168)<span></span>
</td>
<td class="num">$ (8,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding: basic and diluted (in shares)</a></td>
<td class="nump">30,195<span></span>
</td>
<td class="nump">26,529<span></span>
</td>
<td class="nump">21,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759042224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (19,375)<span></span>
</td>
<td class="num">$ (11,168)<span></span>
</td>
<td class="num">$ (8,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Realized loss on sale of available-for-sale securities</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(527)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (19,609)<span></span>
</td>
<td class="num">$ (11,472)<span></span>
</td>
<td class="num">$ (8,263)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773875232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2014</a></td>
<td class="nump">$ 15,147<span></span>
</td>
<td class="num">$ (822)<span></span>
</td>
<td class="num">$ (15,399)<span></span>
</td>
<td class="num">$ (1,074)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2014</a></td>
<td class="nump">18,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,735)<span></span>
</td>
<td class="num">(8,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1', window );">Unrealized gain (loss) on BioTime shares held as available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,815<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock issued to BioTime for extinguishment of debt (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued to BioTime for extinguishment of debt</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockSharesIssuedToInvestorsForCash', window );">Common stock issued to investors for cash (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedToInvestorsForCash', window );">Common stock issued to investors for cash</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest', window );">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest (in shares)</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest', window );">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest</a></td>
<td class="nump">$ 3,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockSharesIssuedForCash', window );">Common stock issued to BioTime for cash (in shares)</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedForCash', window );">Common stock issued to BioTime for cash</a></td>
<td class="nump">$ 8,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of contingently issuable warrant</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockDividendsSharesReceived', window );">OncoCyte common stock received as a dividend in kind from BioTime (in shares)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockPaidinkind', window );">OncoCyte common stock received as a dividend in kind from BioTime</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares', window );">Transfer of realized loss into equity from sale of BioTime shares</a></td>
<td class="num">(397)<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2015</a></td>
<td class="nump">$ 34,901<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="num">(24,134)<span></span>
</td>
<td class="nump">10,417<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2015</a></td>
<td class="nump">25,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,168)<span></span>
</td>
<td class="num">(11,168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1', window );">Unrealized gain (loss) on BioTime shares held as available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 922<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued to BioTime for extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest', window );">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts', window );">Proceeds from issuance of common stock and warrants, net of discounts and financing costs (in shares)</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts', window );">Proceeds from issuance of common stock and warrants, net of discounts and financing costs</a></td>
<td class="nump">$ 9,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2016</a></td>
<td class="nump">$ 45,818<span></span>
</td>
<td class="num">(654)<span></span>
</td>
<td class="num">(35,302)<span></span>
</td>
<td class="nump">$ 9,862<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2016</a></td>
<td class="nump">28,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,375)<span></span>
</td>
<td class="num">$ (19,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1', window );">Unrealized gain (loss) on BioTime shares held as available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued to BioTime for extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest', window );">Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts', window );">Proceeds from issuance of common stock and warrants, net of discounts and financing costs (in shares)</a></td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts', window );">Proceeds from issuance of common stock and warrants, net of discounts and financing costs</a></td>
<td class="nump">$ 7,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants', window );">Issuance of warrants for inducement to exercise 2016 warrants</a></td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_WarrantsIssuedToBanks', window );">Issuance of warrants to Silicon Valley Bank</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares', window );">Transfer of realized loss into equity from sale of BioTime shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">BALANCE at Dec. 31, 2017</a></td>
<td class="nump">$ 59,968<span></span>
</td>
<td class="num">$ (888)<span></span>
</td>
<td class="num">$ (54,677)<span></span>
</td>
<td class="nump">$ 4,403<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">BALANCE (in shares) at Dec. 31, 2017</a></td>
<td class="nump">31,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockDividendsSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends received during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockDividendsSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of common shares issued for conversion of convertible note payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockIssuedToInvestorsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock issued to investors for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockIssuedToInvestorsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares Issued common stock for conversion of convertible note payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockSharesIssuedConversionOfConvertibleNotePayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockSharesIssuedForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for common stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockSharesIssuedForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockSharesIssuedToInvestorsForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period for investors for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockSharesIssuedToInvestorsForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This line item represents proceeds from issuance of common stock and warrants, net of discounts and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfDiscountsAndFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares and warrants, net of discounts and financing costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ProceedsFromIssuanceOfCommonStockSharesAndWarrantsNetOfDiscountsAndFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This line item represents the amount transfer of realized loss into equity from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TransferOfRealizedLossIntoEquityFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_WarrantsIssuedToBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of warrants issued during the period to banks related to financing agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_WarrantsIssuedToBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to warrants issued to certain shareholders as inducement of exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_WarrantsIssuedToCertainShareholdersAsInducementOfExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=95456744&amp;loc=d3e3913-113898<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418191&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773089536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,375)<span></span>
</td>
<td class="num">$ (11,168)<span></span>
</td>
<td class="num">$ (8,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Loss on sale of available-for-sale securities, including selling commissions</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants issued to certain shareholders as inducement to exercise of warrants</a></td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ContingentlyIssuableWarrantExpenseToInvestors', window );">Contingently issuable warrant expense to investors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and interest expense</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Amount due to BioTime and affiliates</a></td>
<td class="num">(753)<span></span>
</td>
<td class="nump">2,007<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,385)<span></span>
</td>
<td class="num">(7,522)<span></span>
</td>
<td class="num">(4,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Net proceeds from sale of available-for-sale securities</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Security deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">843<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">7,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants', window );">Proceeds from sale of common stock and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Financing costs related to sale of common stock and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of loan payable, net of financing costs</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan payable</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayment of capital lease obligation</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,968<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
<td class="nump">11,653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(2,574)<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">7,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>CASH AND CASH EQUIVALENTS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At beginning of the year</a></td>
<td class="nump">10,174<span></span>
</td>
<td class="nump">7,996<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">At end of the year</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">10,174<span></span>
</td>
<td class="nump">7,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Equipment purchased under capital leases</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt issuance costs</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common stock issued to BioTime for extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest', window );">Common stock issued to BioTime upon conversion of convertible note payable and accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Realized loss on sale of BioTime shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of common shares issued for conversion of convertible note payable and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockIssuedConversionOfConvertibleNotePayableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ContingentlyIssuableWarrantExpenseToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingently issuable warrants expense to investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ContingentlyIssuableWarrantExpenseToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution including the issuance of warrant rights to purchase common shares at predetermined price (usually issued together with corporate debt) to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ProceedsFromIssuanceOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763562576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of the Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Description of the Business and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Description of the Business and Liquidity</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">1. Organization, Description of the Business and Liquidity</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte Corporation ("OncoCyte") is a developer of novel, non-invasive blood-based tests for the early detection of cancer. It is focused on developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers that are differentially expressed in certain types of cancers. OncoCyte efforts have focused on developing diagnostic tests for use in detecting lung, bladder, and breast cancers. During 2017, OncoCyte devoted substantially all of its efforts on developing its lung cancer diagnostic test DetermaVu&#8482;.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte was incorporated in 2009 in the state of California and at December 31, 2016 was a majority-owned subsidiary of BioTime, Inc. ("BioTime"), a publicly traded, clinical-stage, biotechnology company targeting degenerative diseases primarily in the fields of ophthalmology, aesthetics and cell/drug delivery. Beginning on February 17, 2017, OncoCyte ceased to be a subsidiary of BioTime for financial reporting purposes when BioTime's percentage ownership of outstanding OncoCyte common stock declined below 50% as a result of the issuance of additional OncoCyte common stock to certain investors who exercised OncoCyte stock purchase warrants (see Note 6).</div></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Liquidity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">For all periods presented, OncoCyte generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants, warrant exercises, a bank loan (see Note 5), and sales of BioTime common shares that OncoCyte holds as available-for-sale securities. BioTime has also provided OncoCyte with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4</font>. OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $54.7 million and $35.3 million as December 31, 2017 and 2016, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017, OncoCyte had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to OncoCyte on or prior to April 30, 2018 (see Note 10), OncoCyte believes it has sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if it determines to devote more resources to the development or initial commercialization efforts for its lung cancer test during that time frame.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div><div>&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929300784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">2. Summary of Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Basis of presentation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Prior to February 17, 2017, BioTime consolidated the results of OncoCyte into BioTime's consolidated results based on BioTime's ability to control OncoCyte's operating and financial decisions and policies through its majority ownership of OncoCyte common stock. BioTime owned 51.1% of the outstanding common stock of OncoCyte at December 31, 2016. Beginning on February 17, 2017, BioTime's percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of "control" of OncoCyte under GAAP and, as a result, BioTime deconsolidated OncoCyte's financial statements from BioTime's consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP with effect from February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime's retained share ownership in OncoCyte, which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte&#8217;s operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Reverse stock split</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Use of estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to the&#160;going concern assessments of OncoCyte financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Going concern assessment</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">With the implementation of FASB&#8217;s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Fair value measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Fair Value Measurements</font> (&#8220;ASC 820&#8221;). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 1</font> &#8211; Quoted prices in active markets for identical assets and liabilities.</div></td></tr></table></div><div style="text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 2</font> &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></td></tr></table></div><div style="text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 3</font> &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating market rate (see Note 5).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Cash and cash equivalents</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2017 and 2016, OncoCyte's cash balances totaled $7.6 million and $10.2 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accounting for BioTime shares</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Investments &#8211; Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte&#8217;s financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Business Combinations</font> ("ASC 805"), transactions between entities under common control. See section <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Recent Accounting Pronouncements</font> included herein.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In 2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes. The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of $0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates or for working capital purposes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Long-lived intangible assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Equipment and furniture</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte&#8217;s results of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Impairment of long-lived assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset&#8217;s carrying value over its fair value is recorded. Through 2017, there have been no such impairment losses.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Accounting for warrants</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font>, then in accordance with ASC 815-40, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</font>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Income taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte activity for 2015, 2016, and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of OncoCyte outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning on February 17, 2017 and thereafter, OncoCyte will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte&#8217;s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte&#8217;s statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2017 and 2016. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2017, 2016&#160;and 2015. OncoCyte is currently unaware of any tax issues under review.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&#8220;2017 Tax Act&#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&#8220;NOLs&#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &#8220;deemed repatriation&#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8).</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 8).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Research and development expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance</font>. Research and development costs are expensed as incurred.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">General and administrative expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">see Note 4</font>) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Sales and marketing expenses</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on OncoCyte&#8217;s headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock-based compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Compensation &#8211; Stock Compensation</font> (&#8220;ASC 718&#8221;).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;&#160; OncoCyte adopted ASU 2016-09 beginning on January 1, 2017.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In connection with the adoption of ASU 2016-09, OncoCyte changed its accounting policies including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable.&#160; All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations.&#160; Prior to the adoption of ASU 2016-09, OncoCyte recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized either as an offset to accumulated excess tax benefits, if any, on OncoCyte&#8217;s statements of operations.&#160; An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.&#160; Because OncoCyte has a full valuation allowance for all periods presented (see Note 8) and an insignificant number of stock option exercises during the current quarter, there was no impact to OncoCyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest.&#160; Based on the nature and timing of OncoCyte&#8217;s grants, straight line expense attribution of stock based compensation for the entire award and the relatively low forfeiture rate on OncoCyte&#8217;s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not significant to OncoCyte&#8217;s financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. OncoCyte uses the Black-Scholes-Merton option pricing model for estimating the fair value of options granted under OncoCyte&#8217;s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Equity-Based Payments to Non-Employees</font>. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee&#8217;s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Valuation of Privately Held Company Equity Securities Issued As Compensation</font>.&#160; OncoCyte common stock began to trade publicly on the NYSE American on December 31, 2015, and since that date the fair value of OncoCyte common stock underlying stock options has been determined with reference to closing prices reported on the NYSE American.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the &#8220;simplified method&#8221; provided under<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14, including, in part, based on its own experience.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Because OncoCyte&#8217;s common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte&#8217;s stock options.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The dividend yield assumption is based on OncoCyte&#8217;s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Net loss per common share</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(19,375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average common shares outstanding &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss per common share &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.64</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,390</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,779</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Segments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte&#8217;s executive management team, as a group, represents the entity&#8217;s chief operating decision makers. To date, OncoCyte&#8217;s executive management team has viewed OncoCyte&#8217;s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte&#8217;s sole operating segment.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Reclassifications</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Certain reclassifications from general and administrative expenses have been made to present sales and marketing expenses shown on the statements of operations for the years ended December 31, 2016 and 2015 to conform and be comparable to the year ended December 31, 2017 presentation. These reclassifications have been made as OncoCyte's sales and marketing expenses have increased in 2017, thus making separate presentation of those category of expenses more meaningful to the readers of this report. The reclassifications had no impact to loss from operations or net loss as reported in the statements of operations and had no impact to the statements of cash flows or to the balance sheets for any period presented.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Recent accounting pronouncements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, <font style="font-style: italic;">Financial Instruments&#8211;Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font> (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte&#8217;s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">In February 2016, the FASB issued ASU 2016-02, <font style="font-style: italic;">Leases (Topic 842)</font>, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope of Modification Accounting</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. OncoCyte currently applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. OncoCyte believes the adoption of ASU 2017-09 will not have a material impact on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763513648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SelectedBalanceSheetComponentsAbstract', window );"><strong>Selected Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected Balance Sheet Components</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">3. Selected Balance Sheet Components</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accrued expenses and other current liabilities</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued bonuses and payroll related expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">636</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">406</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued expenses and other current liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,042</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">797</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Intangible assets, net</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,431</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">746</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Amortization expense amounted to approximately $242,000 annually.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Equipment and furniture, net</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment and furniture</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,479</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,007</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(657</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(319</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment and furniture, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">822</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">688</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Depreciation expense amounted to approximately $338,000, $145,000 and $41,000 for the years ended December 31, 2017, 2016 and 2015, respectively. During the year ended December 31, 2017 and 2016, OncoCyte entered into capital leases for laboratory equipment totaling $381,000 and $626,000, respectively (see Note 9).</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_SelectedBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_SelectedBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929158288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">4. Related Party Transactions</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Shared Facilities and Service Agreement</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On October 8, 2009, OncoCyte and BioTime executed a Shared Facilities and Services Agreement (&#8220;Shared Facilities Agreement&#8221;). Under the terms of the Shared Facilities Agreement, BioTime will allow OncoCyte to use its premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime will also provide accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime will also provide OncoCyte with the services of its laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">BioTime charges OncoCyte a Use Fee for services received and usage of facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates costs incurred, as applicable, to OncoCyte, such costs include services of Bio Time employees, equipment, insurance, lease, professional, software, supplies and utilities. Allocation depends on key cost drivers including actual documented use, square footage of facilities used, time spent, costs incurred by or for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime (collectively &#8220;Use Fees&#8221;). BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime has not elected to charge this markup since the inception of the Shared Facilities Agreement and through the end of 2015. Beginning in 2016, BioTime commenced charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through December 31, 2017 BioTime has not charged OncoCyte any interest.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. Furthermore, BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers thereof to invoice OncoCyte directly.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement otherwise is terminated under another provision of the agreement.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In the aggregate, BioTime allocated and charged such Use Fees to OncoCyte $268,000, $790,000 and $595,000 included in general and administrative expenses, and&#160;Use Fees of $1.1 million, $691,000 and $565,000 included in research and development expenses, during the years ended December 31, 2017, 2016 and 2015 respectively.&#160;Use Fees of $213,000 in sales and marketing expenses are included in OncoCyte&#8217;s statements of operations during the year ended December 31, 2017. There were no Use Fees allocated to sales and marketing expenses during 2016 and 2015.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017 and 2016, OncoCyte had $2.1 million and $2.9 million outstanding and payable to BioTime and affiliates included in current liabilities in connection with the costs incurred under the Shared Facilities Agreement. Since these amounts are due and payable in 30 days of being invoiced, the payables are classified as current liabilities for all periods presented.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The minimum fixed payments due under the Shared Facilities Agreement are approximately $131,000 per month.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763525152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable to Silicon Valley Bank<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loan Payable to Silicon Valley Bank [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Loan Payable to Silicon Valley Bank</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">5. <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">Loan Payable to Silicon Valley Bank</font></div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On February 21, 2017, OncoCyte entered into a Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank (the "Bank") pursuant to which OncoCyte borrowed $2.0 million on March 23, 2017. Payments of interest only on the principal balance were due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017, monthly payments of principal of approximately $67,000 plus interest are due and payable. The outstanding principal balance of the loan bears interest at a stated floating annual interest rate equal to the greater of (i) three-quarters of one percent (0.75%) above the prime rate or (ii) four and one-quarter percent (4.25%). As of December 31, 2017, the latest published prime rate plus 0.75% was 5.25% per annum.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">The outstanding principal amount plus accrued interest will be due and payable to the Bank at maturity on April 1, 2020. At maturity, OncoCyte will also pay the Bank an additional final payment fee of 5.8% of the original principal borrowed. OncoCyte accrued the $116,000 final payment fee included in the loan payable as a deferred financing cost on March 23, 2017 draw date.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">OncoCyte may prepay in full the outstanding principal balance at any time, subject to a prepayment fee equal to&#160; 2.0% of the outstanding principal balance if prepaid after February 21, 2018 but not later than February 21, 2019, or 1.0% of the outstanding principal balance if prepaid after February 21, 2019. Any amounts borrowed and repaid may not be reborrowed.&#160; There are no amounts available to be borrowed on the Loan Agreement.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">The outstanding principal amount of the loan, with interest accrued, the final payment fee, and the prepayment fee may become due and payable prior to the applicable maturity date if an "Event of Default" as defined in the Loan Agreement occurs and is not cured within any applicable cure period. Upon the occurrence and during the continuance of an Event of Default, all obligations due to the Bank will bear interest at a rate per annum which is 5% above the then applicable interest rate. An Event of Default includes, among other events, failure to pay interest and principal when due, material adverse changes, which include a material adverse change in OncoCyte's business, operations, or condition (financial or otherwise), failure to provide the bank with timely financial statements and copies of filings with the Securities and Exchange Commission, as required, legal judgments or pending or threatened legal actions of $50,000 or more, insolvency, and delisting from the NYSE American. OncoCyte's obligations under the Loan Agreement are collateralized by substantially all of its assets other than intellectual property such as patents and trade secrets that OncoCyte owns. Accordingly, if an Event of Default were to occur and not be cured, the Bank could foreclose on its security interest in the collateral. OncoCyte was in compliance with the Loan Agreement as of the filing&#160;date of this Report.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Under the provisions of the Loan Agreement, as consented by the Bank on October 26, 2017, any proceeds received by OncoCyte from sales of BioTime shares may be used by OncoCyte to fund its operations.</div><div style="background-color: #ffffff;"><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Bank Warrants</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On February 21, 2017 and in conjunction with the $2.0 million becoming available under the Loan Agreement, OncoCyte issued common stock purchase warrants to the Bank (the "Bank Warrants") entitling the Bank to purchase shares of OncoCyte common stock in tranches related to the loan tranches under the Loan Agreement. In conjunction with the availability of the loan, the Bank was issued warrants to purchase 8,247 shares of OncoCyte common stock at an exercise price of $4.85 per share, through February 21, 2027. On March 23, 2017, in conjunction with borrowing $2 million, the Bank was issued warrants to purchase an additional 7,321 shares at an exercise price of $5.46 per share, through March 23, 2027. The Bank may elect to exercise the Bank Warrants on a "cashless exercise" basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B) the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national securities exchange, interdealer quotation system, or over-the-counter market.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Bank Warrants are classified as equity since, among other factors, they are not mandatorily redeemable, cannot be settled in cash or other assets and require settlement by issuing a fixed number of shares of common stock of OncoCyte. OncoCyte determined the fair value of the Bank Warrants using the Black-Scholes option pricing model to be approximately $62,000, which was recorded as a deferred financing cost against the loan payable balance. Aggregate deferred financing costs of $196,000, recorded against the loan payable balance, are amortized to interest expense over the term of the loan using the effective interest method. As of December 31, 2017, unamortized deferred financing costs were $113,000.</div><div><br /></div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Future Cash Payments of Loan Payable</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, principal and interest payments due on the loan payable in each of the next three years are as follows (in thousands):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160; <table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">Year Ending</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">December 31,</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Loan</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2018</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">876</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2019</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">835</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2020</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">386</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total payments of principal and interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,097</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less: amounts representing interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(114</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total payments of principal before deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,983</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less: deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(113</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total loan payable, net of deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,870</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr></table></div><div>&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929125264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">6. Shareholders&#8217; Equity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Preferred Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte is authorized to issue up to 5,000,000 shares of no par value preferred stock. As of December 31, 2017, no preferred shares were issued or outstanding.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Common Stock</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has up to 50,000,000 shares of no par value common stock authorized. The holders of OncoCyte&#8217;s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of OncoCyte common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of OncoCyte outstanding preferred shares, if any.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of OncoCyte stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable.</div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Issuance of Common Stock and Warrants</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On August 29, 2016, OncoCyte sold an aggregate of 3,246,153 immediately separable units, with each unit consisting of one share of OncoCyte common stock and one warrant to purchase one share of OncoCyte common stock (the &#8220;2016 Warrants&#8221;), at a price of $3.25 per unit (the &#8220;Offering&#8221;). The sales were made pursuant to the terms and conditions of certain Purchase Agreements between OncoCyte and the purchasers in the Offering. The purchasers included certain OncoCyte existing shareholders other than BioTime. At the close of the Offering, <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">BioTime&#8217;s percentage ownership of the outstanding common stock of OncoCyte declined to 51.2% through which BioTime retained a controlling interest in OncoCyte</font>. OncoCyte received $9.8 million in net proceeds after discounts, commissions and expenses from the Offering. OncoCyte will use the proceeds from the Offering for funding its operations or for working capital or other general corporate purposes.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Pursuant to the terms of the Purchase Agreements, OncoCyte agreed (i) to file a resale registration statement with the Securities and Exchange Commission, or SEC, to register for sale under the Securities Act of 1933, as amended, or the Securities Act, the shares of OncoCyte common stock sold in the Offering and the shares of OncoCyte common stock, or Warrant Shares, that may be issued if the Warrants are exercised, and (ii) to use commercially reasonable efforts to maintain the effectiveness of the resale registration statement under the Securities Act until the earlier of (a) the date that all shares of its common stock covered by the Resale Registration Statement have been sold or can be sold publicly without restriction or limitation under Rule 144 (including, without limitation, the requirement to be in compliance with Rule 144(c)(1)), or (b) August 29, 2018.<br /> &#160;</div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">2016 Warrants and New Warrants</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">The 2016 Warrants have an exercise price of $3.25 per Warrant Share, and may be exercised for five years from October 17, 2016, the date the 2016 Warrants became exercisable. The 2016 Warrants may be exercised on a net &#8220;cashless exercise&#8221; basis, meaning that the value of a portion of Warrant Shares may be used to pay the exercise price (rather than payment in cash), in certain circumstances, including if the Resale Registration Statement is not effective when and as required by the Purchase Agreements. The exercise price and the number of Warrant Shares will be adjusted to account for certain transactions, including stock splits, dividends paid in common stock, combinations or reverse splits of common stock, or reclassifications of common stock.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Under certain provisions of the 2016 Warrants, in the event of a Fundamental Transaction, as defined in the 2016 Warrants, OncoCyte will use reasonable best efforts for the acquirer, or any successor entity other than OncoCyte, to assume the 2016 Warrants. If the acquirer does not assume the OncoCyte Offering Warrant obligations, then the acquirer shall pay the holders of 2016 Warrants an amount equal to the aggregate value equal to the Black Scholes Value, as defined in the 2016 Warrants. The payment of the Black Scholes Value shall be made in cash or such other consideration as the acquirer paid to the other OncoCyte shareholders in the Fundamental Transaction.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">OncoCyte is not required to net cash settle the 2016 Warrants under any circumstance. </font>OncoCyte considered the guidance in ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. Since solely an acquirer, and not OncoCyte itself, may be required to net cash settle the 2016 Warrants in the event of a Fundamental Transaction, the 2016 Warrants are classified as equity.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On February 17, 2017, certain OncoCyte investors exercised 2016 Warrants to acquire 625,000 shares of common stock at an exercise price of $3.25 per warrant for total exercise cash proceeds of $2.0 million (the "Warrant exercise"). In order to induce the investors to complete the Warrant exercise and, in conjunction with the Warrant exercise, OncoCyte issued new warrants to those investors (the "New Warrants"). Certain investors received New Warrants to purchase 200,000 shares of common stock at an exercise price of $5.50 per share and one investor received New Warrants to purchase 212,500 shares of common stock at an exercise of $3.25 per share. The New Warrants are exercisable at any time for five years from February 17, 2017.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The New Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the New Warrants was treated as an inducement offer to certain shareholders to exercise their 2016 Warrants. Accordingly, the fair value of the New Warrants, determined using the </font>Black-Scholes option pricing model,<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> approximating $1.1 million was recognized by OncoCyte as a noncash charge to shareholder expense included in general and administrative expenses and a corresponding increase to equity on February 17, 2017, the issuance date.</font></div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On July 21, 2017, OncoCyte entered into three forms of Warrant Exercise Agreements (each, an "Exercise Agreement") with certain holders of the 2016 Warrants providing for the cash exercise of their 2016 Warrants and the issuance of new warrants (the "July 2017 Warrants") to them.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Pursuant to one form of Exercise Agreement, two investors exercised 2016 Warrants to purchase 226,923 shares of OncoCyte's common stock at the exercise price of $3.25 per share, and OncoCyte issued to them July 2017 Warrants expiring five years from the date of issue, to purchase 226,923 shares of common stock at an exercise price of $5.50 per share.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Pursuant to a second form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 540,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor a July 2017 Warrant, expiring five years from the date of issue, to purchase 270,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;"> commercially reasonable efforts to </font>file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Pursuant to a third form of Exercise Agreement, one investor exercised 2016 Warrants to purchase 1,000,000 shares of common stock at the exercise price of $3.25 per share, and OncoCyte issued to the investor (i) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $5.50 per share, and (ii) a July 2017 Warrant, expiring two years from the date of issue, to purchase 500,000 shares of common stock at an exercise price of $3.25 per share. In this alternative form of Exercise Agreement, OncoCyte also agreed to use commercially reasonable efforts to file with the SEC a registration statement covering the resale of the shares of common stock issuable upon exercise of the July 2017 Warrant and to keep it continuously effective for up to five years, subject to conditions set forth in the Exercise Agreement.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;"><br /> &#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">In the aggregate, upon the exercise of 2016 Warrants under the Exercise Agreements, OncoCyte received gross proceeds of approximately $5.74 million and issued July 2017 Warrants to purchase 1,496,923 shares of common stock at a weighted average price of $4.34 per share.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">The July 2017 Warrants are classified as equity as their terms are consistent with the 2016 Warrants. For financial reporting purposes, the issuance of the July 2017 Warrants is treated as an inducement offer to certain investors to exercise their 2016 Warrants. Accordingly, the fair value of the July 2017 Warrants, determined to be approximately $3.0 million using the </font>Black-Scholes option pricing model, <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">was recorded as a noncash charge to shareholder expense included in general and administrative expenses, and a corresponding increase was recorded to equity on July 21, 2017, the issuance date.</font></div><div><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, OncoCyte has an aggregate of 2,779,221 warrants issued and outstanding at exercise prices ranging from $3.25 and $5.50 per warrant.</div><div><br /></div></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Stock Option Exercises</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">During the years ended December 31, 2017 and 2016, 323,019 and 99,496 shares of common stock were issued upon the exercise of stock options, from which OncoCyte received $610,000 and $218,000 in cash proceeds, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763435072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">7. Stock-based Compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Stock Option Plan</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has adopted a 2010 Stock Option Plan (the &#8220;Plan&#8221;) under which 5,200,000 shares of common stock were made available for the grant of stock options or the sale of restricted stock. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As discussed in Note 4, OncoCyte may grant stock options to employees of BioTime, or employees of other BioTime subsidiaries, who perform services for OncoCyte. OncoCyte records stock-based compensation expense in the accompanying statements of operations for those services performed in the periods presented.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Stock Options</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Options granted under the Plan may be either &#8220;incentive stock options&#8221; within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The options&#8217; exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant&#8217;s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Options Granted</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, 1,384,198 shares were available for future grants under the Plan.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">for Grant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Options</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Outstanding</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at January 1, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,757</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.03</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(962</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">962</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.58</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(100</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">85</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(85</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at December 31, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">880</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Increase in pool</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(896</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">896</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5.17</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(323</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.11</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,384</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,390</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Exercisable at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,835</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.48</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">At December 31, 2017 and 2016, OncoCyte had approximately $1.6 million and $2.7 million, respectively, of total unrecognized compensation expense related to the Plan that will be recognized over a weighted-average period of approximately 2.5 and 2.4 years, respectively.</div><div style="text-align: justify;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">668</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">456</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">841</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">610</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales and marketing</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total stock-based compensation expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">922</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,815</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The assumptions that were used to calculate the grant date fair value of OncoCyte&#8217;s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected life (in years)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.15</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.21</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.83</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Risk-free interest rates</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">2.03</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">1.46</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">1.87</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Volatility</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">66.01</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">64.64</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">74.15</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="background-color: #ffffff;"></font><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Dividend yield</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</div></td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">With the adoption of ASU 2016-09, effectively January 1, 2017, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2017, 2016 and 2015, may have been significantly different.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763463648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">8. Income Taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">U.S. Federal Income Tax Reform</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On December 22, 2017, in response to the enactment of the 2017 Tax Act (see Note 2), the SEC staff issued SAB 118 that allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. OncoCyte is currently analyzing the 2017 Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures, including and changes to OncoCyte&#8217;s existing deferred tax balances, for the year ended December 31, 2017.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte remeasured certain deferred tax assets and liabilities based on the enacted tax rate at which they are expected to reverse in the future. The estimated tax affected amount related to the remeasurement of these balances was a reduction of OncoCyte&#8217;s net deferred tax assets by $6.8 million with a corresponding decrease in the valuation allowance by the same amount, recognized as of December 31, 2017, as discussed below.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2017, the federal portion of the deferred tax assets and liabilities for 2017 were re-rated from 34 percent to 21 percent pursuant to the 2017 Tax Act.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed standalone U.S. federal income tax returns since its inception. For California purposes, OncoCyte&#8217;s activity for 2015 and 2016 was included in BioTime&#8217;s California Combined tax return. As a result of OncoCyte&#8217;s deconsolidation from BioTime on February 17, 2017, (see Note 1), OncoCyte will file a separate California return for tax year 2017.&#160; The provision for state income taxes has been determined as if OncoCyte had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The deferred tax assets, including the operating loss and credit carryforwards, generated by OncoCyte, will remain with OncoCyte.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred liabilities:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total deferred tax liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred tax assets:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net operating loss carryforwards</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,414</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development credit carryforwards</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,141</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,765</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Patents and fixed assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">268</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">179</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Stock-based compensation and accrued payroll</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,260</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,041</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Valuation Allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(15,083</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,954</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net deferred tax asset (liability)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Due to losses incurred for all periods presented, OncoCyte did not record any provision or benefit for income taxes.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Computed tax benefit at federal statutory rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Re-rate of federal net deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">(35)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Permanent differences</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(8)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(1)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(9)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">State tax benefit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">3</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">15</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">1</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">7</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">3</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;">Adjusted basis for available-for-sale-securities</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;11</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;0</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;0</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(6)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(44)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(45)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">As of December 31, 2017, OncoCyte has net operating loss carryforwards of approximately $47<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">.8 million </font>for U.S. federal income tax purposes and <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">$15.6 million </font>for state income tax purposes. Federal net operating loss carryforwards expire in varying amounts from 2030 and 2037, and state carryforwards expire from 2029 and 2037. In addition, as of December 31, 2017, OncoCyte has research and development credit carryforwards for federal and state purposes of $1.0 million and $1.1 million, respectively. The federal credits will expire between 2030 and 2037, while the state credits have no expiration.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">During 2017, OncoCyte sold 266,442 BioTime common shares, in at-the-market transactions which resulted in taxable&#160;loss of approximately $301,000.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">No BioTime common shares were sold in 2016. </font>During 2015, OncoCyte sold 259,712 BioTime common shares in at-the-market transactions which resulted in taxable loss of approximately $397,000.&#160;</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $1.1 million&#160;and $5.1 million for the years ended December 31, 2017 and 2016, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Other Income Tax Matters</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Internal Revenue Code Section 382 places a limitation (&#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these &#8220;change in ownership&#8221; provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.&#160;&#160; </div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. In general, OncoCyte is no longer subject to tax examination by major taxing authorities for years before 2013. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931176208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">9. Commitments and Contingencies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has certain commitments other than those under the Shared Facilities and Services Agreement described in Note 4.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left; background-color: #ffffff;">Master Lease Line Agreement</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On April 7, 2016, OncoCyte entered into a Master Lease Line Agreement ("Lease Agreement&#8221;) with an unrelated financing company for the purchase and financing of certain equipment. OncoCyte may use up to $881,000, as amended, for purchases of equipment financed under the Lease Agreement through April 2017. Each lease schedule OncoCyte enters into under Lease Agreement must be in minimum increments of $50,000 each with a 36-month lease term, collateralized by the equipment financed under the lease schedule. Each lease schedule requires a deposit for the first and last payment under that schedule. Monthly payments will be determined using a lease factor approximating an interest rate of 10% per annum. At the end of each lease schedule under Lease Agreement, assuming no default has occurred, OncoCyte may either return the equipment financed under the schedule for a restocking fee of 7.5% of the original cost of the equipment or purchase the equipment from the financing company at a fair value not less than 12.5% of the original cost of the equipment.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On April 7, 2016, OncoCyte entered into a lease schedule under the Lease Agreement (&#8220;Lease Schedule No. 1&#8221;) for certain equipment costing approximately $435,000 applied against the lease line, requiring payments of $14,442 per month over 36 months. In December 2016, OncoCyte entered into another lease schedule (&#8220;Lease Schedule No. 2&#8221;) for certain equipment costing approximately $161,000, requiring payments of $5,342 per month over 36 months. In April 2017, OncoCyte entered into a third and final lease schedule (&#8220;Lease Schedule No. 3&#8221;) for certain equipment costing approximately $285,000, requiring payments of $9,462 per month over 36 months. After this last tranche, the Lease Agreement was closed and has no remaining financing available.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">OncoCyte has accounted for these leases as a capital lease in accordance with ASC 840,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Leases</font>, due to the net present value of the payments under the lease approximating the fair value of the equipment at inception of the lease. The payments under the lease schedules will be amortized to capital lease obligations and interest expense using the interest method at an imputed rate of approximately 10% per annum.</div><div style="background-color: #ffffff;"><br /></div><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On May 11, 2017, OncoCyte entered into another Master Lease Line Agreement ("Lease Agreement No. 2") with the same finance company above and similar terms. OncoCyte may use up to $900,000 for purchases of equipment financed under Lease Agreement No. 2 through October 28, 2018. As of December 31, 2017, $820,000 under Lease Agreement No. 2 was available to OncoCyte.</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Future minimum annual lease payments under </font>Lease Schedule No.&#8217;s 1, 2, and 3 above <font style="font-size: 10pt; font-family: 'Times New Roman';">for the years ending after December 31, 2017 are as follows (in thousands):</font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><br class="Apple-interchange-newline" /><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">Year Ending</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">December 31,</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Capital Lease</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2018</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">383</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2019</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2020</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">59</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total minimum lease payments</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">690</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less amounts representing interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(63</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Present value of net minimum lease payments</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">627</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Wistar License Agreement</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte has entered into a License Agreement with The Wistar Institute of Anatomy and Biology (&#8220;Wistar&#8221;) that entitles OncoCyte to use certain patents, know-how and data belonging to Wistar.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">Under the License Agreement, OncoCyte has obtained an exclusive, worldwide license under certain patents, and under certain know-how and data ("Technical Information") belonging to Wistar, for use in the field of molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.&#160; OncoCyte has the right to grant sublicenses of the licensed patents and Technical Information subject to certain conditions.<br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte paid Wistar an initial license fee and will pay Wistar royalties on &#8220;net sales&#8221; of &#8220;licensed products,&#8221; as such terms are defined in the License Agreement. The royalty rates will range from 3% to 5% depending upon the amount of cumulative net sales. The amount of royalties payable to Wistar will be reduced by the amount of any royalties that OncoCyte must pay to any third parties on the sale of the licensed products, but subject to a maximum reduction of 50%. The obligation to pay royalties to Wistar will terminate on a licensed product by-licensed product and country-by-country basis until the later of (i) the date a valid claim of a licensed patent covering the licensed product no longer exists, or (ii) the tenth (10th) anniversary of the first commercial sale of the licensed product in each country.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte will pay Wistar a minimum annual royalty each year, which in each case will be credited against total royalties due during the year in which the minimum royalty is paid. OncoCyte will also be obligated to pay Wistar an annual license maintenance fee in the mid-five figures.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte will also pay Wistar a portion of any non-royalty sublicensing income that OncoCyte may receive from any sub-licensee. Non-royalty sublicensing income will include any consideration received from a sub-licensee for granting the sublicense, but excluding royalties, the fair market value of any equity or debt securities sold to a sub-licensee, and any payments received from a sub-licensee for any related research conducted by OncoCyte for the sublicensee.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte also will pay Wistar (a) milestone payments upon the occurrence of certain milestone events in the development and commercialization of a licensed product, and (b) all past or ongoing costs incurred or to be incurred by Wistar, including government fees and attorneys' fees, in the course of prosecuting the licensed patents.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte has agreed to use commercially reasonable diligent efforts, directly or through sub-licensees, to develop and commercialize licensed products. OncoCyte has agreed that it or a sub-licensee will commence commercial sale of a licensed product by a specified date. If sales of a licensed product do not commence by the specified date, OncoCyte may purchase up to three one-year extensions of the deadline by paying Wistar a designated fee for the applicable extension.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte has agreed to indemnify Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel and staff from and against certain claims and liabilities related to the License Agreement and development, manufacture and sale of licensed products, excluding liabilities that result from or arise out of an indemnified party's gross negligence or willful misconduct.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">Wistar has the right to terminate the License Agreement, subject to certain notice and cure periods and <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">force majeure</font> delays in certain cases, if any of the following occur:&#160; (a) OncoCyte fails to pay any amount payable to Wistar; (b) OncoCyte materially breaches any covenant or agreement or any continuing representation or warranty contained in the License Agreement; (c) OncoCyte becomes subject to certain bankruptcy or insolvency events, (d) OncoCyte dissolves or ceases operations, (e) OncoCyte or any of its affiliates or sub-licensees or affiliates of any our sub-licensees challenges the validity, patentability, scope, construction, enforceability, non-infringement, or Wistar's ownership of any issued patent comprising the licensed patents, or assists any third party in any such challenge; or (f) OncoCyte fails to fulfill its product development and commercialization diligence obligations and related performance milestones.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 0.1pt; margin-right: 0.1pt; text-indent: 36pt;">OncoCyte may terminate the License Agreement, with or without cause, upon the passage of a specified period of time after giving Wistar written notice of termination.</div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Litigation &#8211; General</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When OncoCyte is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, OncoCyte will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, OncoCyte discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. OncoCyte is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Tax Filings</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;">OncoCyte tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes OncoCyte has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Employment Contracts</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has entered into employment contracts with certain executive officers. Under the provisions of the contracts, OncoCyte may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Indemnification</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In the normal course of business, OncoCyte may provide indemnification of varying scope under OncoCyte&#8217;s agreements with other companies or consultants, typically OncoCyte&#8217;s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, OncoCyte will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of OncoCyte&#8217;s diagnostic tests. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to OncoCyte&#8217;s diagnostic tests. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments OncoCyte could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts. Historically, OncoCyte has not been subject to any claims or demands for indemnification. OncoCyte also maintains various liability insurance policies that limit OncoCyte&#8217;s financial exposure. As a result, OncoCyte management believes that the fair value of these indemnification agreements is minimal. Accordingly, OncoCyte has not recorded any liabilities for these agreements as of December 31, 2017 and 2016.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763471552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">10. Subsequent Events</div><div>&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On March 28, 2018, OncoCyte entered into a securities purchase agreement with two accredited investors. The agreement provides for the private placement of 7,936,508 shares of OncoCyte's common stock for $1.26 per share, for total gross proceeds of $10.0 million before deducting offering expenses. Of this amount, OncoCyte has received $8.0 million in gross proceeds from the sale of 6,349,206 shares of common stock, and one of the investors irrevocably committed in the agreement to pay to OncoCyte an additional $2.0 million on or prior to April 30, 2018 for the purchase of an additional 1,587,302 shares of common stock. The agreement contains certain registration rights. The investors are existing security holders of OncoCyte, including Broadwood Partners, L.P., which beneficially owns more than 5% of OncoCyte's outstanding common stock.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763447808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of the Business and Liquidity (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Description of the Business and Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Liquidity</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">For all periods presented, OncoCyte generated no revenues. Since inception, OncoCyte has financed its operations through the sale of its common stock and warrants, warrant exercises, a bank loan (see Note 5), and sales of BioTime common shares that OncoCyte holds as available-for-sale securities. BioTime has also provided OncoCyte with the use of BioTime facilities and services under a Shared Facilities and Services Agreement as described in Note 4</font>. OncoCyte has incurred operating losses and negative cash flows since inception, and had an accumulated deficit of $54.7 million and $35.3 million as December 31, 2017 and 2016, respectively.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017, OncoCyte had $7.6 million of cash and cash equivalents and held BioTime common shares as available-for-sale securities valued at $0.8 million. Based on cash, cash equivalents and available-for-sale securities currently on hand, including the $8.0 million in gross proceeds from the private placement completed on March 28, 2018, and the $2.0 million irrevocably committed to OncoCyte on or prior to April 30, 2018 (see Note 10), OncoCyte believes it has sufficient cash, cash equivalents, available-for-sale securities and working capital to carry out its current operations through at least twelve months from the issuance date of the financial statements included herein, but will need to raise additional capital if it determines to devote more resources to the development or initial commercialization efforts for its lung cancer test during that time frame.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte plans to continue to invest significant resources in research and development in the field of molecular cancer diagnostics. OncoCyte expects to continue to incur operating losses and negative cash flows. If results of OncoCyte's research and development efforts, including the results of validation studies of its lung cancer test, DetermaVu&#8482;, are successful to the point where OncoCyte believes that a commercial product can be launched successfully, additional capital will be required to develop a sales and marketing team to market DetermaVu&#8482; and to hire additional administrative personnel for patient billing and reimbursement procedures. OncoCyte will also need to raise additional capital in subsequent years to develop and launch additional diagnostic tests, for working capital, and for other expenses, until such time as it is able to generate sufficient revenues from the commercialization of its diagnostic tests to finance its operations. Delays in the development or commercialization of DetermaVu&#8482; could prevent OncoCyte from raising, when needed, sufficient additional capital to finance the completion of development and commercial launch of DetermaVu&#8482; or the other cancer diagnostic tests that OncoCyte is developing. The unavailability or inadequacy of financing or revenues to meet future capital needs could force OncoCyte to modify, curtail, delay, or suspend some or all aspects of its planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. OncoCyte cannot assure that adequate financing will be available on favorable terms, if at all.</div><div>&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761202256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Basis of presentation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">The financial statements presented herein have been prepared on a separate, stand-alone basis. The financial statements are presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Prior to February 17, 2017, BioTime consolidated the results of OncoCyte into BioTime's consolidated results based on BioTime's ability to control OncoCyte's operating and financial decisions and policies through its majority ownership of OncoCyte common stock. BioTime owned 51.1% of the outstanding common stock of OncoCyte at December 31, 2016. Beginning on February 17, 2017, BioTime's percentage ownership of the outstanding OncoCyte common stock declined below 50%, resulting in a loss of "control" of OncoCyte under GAAP and, as a result, BioTime deconsolidated OncoCyte's financial statements from BioTime's consolidated financial statements. As a result of this deconsolidation, OncoCyte is no longer considered a subsidiary of BioTime under GAAP with effect from February 17, 2017. OncoCyte remains an affiliate of BioTime based on BioTime's retained share ownership in OncoCyte, which is sufficient to allow BioTime to exert significant influence over the operations and management of OncoCyte.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">To the extent OncoCyte does not have its own employees or human resources for its operations, BioTime or BioTime subsidiaries provide certain employees for administrative or operational services, as necessary, for the benefit of OncoCyte (see Note 4). Accordingly, BioTime allocates expenses such as salaries and payroll related expenses incurred and paid on behalf of OncoCyte based on the amount of time that particular employees devote to OncoCyte affairs. Other expenses such as legal, accounting, human resources, marketing, travel, and entertainment expenses are allocated to OncoCyte to the extent that those expenses are incurred by or on behalf of OncoCyte. BioTime also allocates certain overhead expenses such as facilities rent and utilities, property taxes, insurance, internet and telephone expenses based on a percentage determined by management. These allocations are made based upon activity-based allocation drivers such as time spent, percentage of square feet of office or laboratory space used, and percentage of personnel devoted to OncoCyte&#8217;s operations or management. Management evaluates the appropriateness of the percentage allocations on a periodic basis and believes that this basis for allocation is reasonable.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As further discussed in Notes 4 and 7, OncoCyte granted stock options to employees of BioTime, or employees of other BioTime subsidiaries who performed services for OncoCyte, and OncoCyte recorded stock-based compensation expense in the accompanying statements of operations for the services performed in the periods presented.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ReverseStockSplitPolicyTextBlock', window );">Reverse stock split</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Reverse stock split</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On November 18, 2015, OncoCyte effected a one-for-two reverse stock split of its common stock. All share, per-share and related information including the price at which shares of common stock have been sold or may be issued, including shares issuable upon the exercise of stock options or convertible debt, have been retroactively adjusted, in these financial statements and accompanying footnotes, where applicable, to reflect the impact of the reverse stock split.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Use of estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including those related to the&#160;going concern assessments of OncoCyte financial statements, allocation of direct and indirect expenses, useful lives associated with long-lived intangible assets, equipment and furniture, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards, debt or other equity instruments. Actual results could differ materially from those estimates.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_GoingConcernAssessmentPolicyTextBlock', window );">Going concern assessment</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Going concern assessment</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">With the implementation of FASB&#8217;s new standard on going concern, Accounting Standard Update, or ASU No. 2014-15, beginning with year ended December 31, 2016 and all annual and interim periods thereafter, OncoCyte assesses going concern uncertainty in its financial statements to determine if it has sufficient cash on hand and working capital, including any available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the &#8220;look-forward period&#8221; as defined by ASU No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to OncoCyte, it will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, OncoCyte makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent OncoCyte deems probable those implementations can be achieved and it has the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Fair value measurements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for fair value measurements in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Fair Value Measurements</font> (&#8220;ASC 820&#8221;). ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 1</font> &#8211; Quoted prices in active markets for identical assets and liabilities.</div></td></tr></table></div><div style="text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 2</font> &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div></td></tr></table></div><div style="text-align: left;">&#160;</div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td style="width: 36pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; width: 18pt; vertical-align: top; align: right;">&#183;</td><td style="width: auto; vertical-align: top; text-align: left;"><div style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Level 3</font> &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In determining fair value, OncoCyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, OncoCyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for cash and cash equivalents consisting of money market funds and the available-for-sale securities of BioTime common stock held by OncoCyte described below. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amounts of cash equivalents, prepaid expenses and other current assets, amounts due to BioTime and other affiliates, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The carrying amount of the Loan Payable to Silicon Valley Bank approximates fair value because the loan bears interest at a floating market rate (see Note 5).</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Cash and cash equivalents</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Cash equivalents typically consisted of highly liquid investments, with maturities of three months or less when purchased. At December 31, 2017 and 2016, OncoCyte's cash balances totaled $7.6 million and $10.2 million, respectively.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Financial instruments that potentially subject OncoCyte to credit risk consist principally of cash and cash equivalents. OncoCyte maintains cash and cash equivalent balances at financial institutions in excess of amounts insured by United States government agencies. OncoCyte places its cash and cash equivalents with high credit quality financial institutions.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy', window );">Accounting for BioTime shares</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Accounting for BioTime shares</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte accounts for the BioTime shares it holds as available-for-sale equity securities in accordance with ASC 320-10-25,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Investments &#8211; Debt and Equity Securities</font>, as the shares have a readily determinable fair value quoted on the NYSE American and are held principally for future working capital purposes, as necessary. These shares are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses are excluded from the statements of operations and reported in equity as part of other comprehensive income or loss, net of income taxes, until realized. As discussed in Note 1, on February 17, 2017, BioTime deconsolidated OncoCyte&#8217;s financial statements from its consolidated financial statements. Due to this deconsolidation, and based on BioTime no longer having "control" over OncoCyte under GAAP, any realized gains and losses OncoCyte generates from the sale of BioTime shares after February 17, 2017 are included in the statements of operations. Prior to February 17, 2017, any realized gains and losses for shares sold were reclassified out of accumulated other comprehensive income or loss and included in equity, as an increase or decrease to common stock equity consistent with, and pursuant to, ASC 805-50 <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Business Combinations</font> ("ASC 805"), transactions between entities under common control. See section <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Recent Accounting Pronouncements</font> included herein.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In 2017, OncoCyte sold 266,442 shares of BioTime common stock for net proceeds of $934,000 and recognized a $309,000 loss from the sale of the BioTime shares included in other income and expenses, net. The proceeds were used to pay down amounts owed to BioTime and affiliates (see Note 4). No shares of BioTime common stock were sold in 2016. In 2015, OncoCyte sold 259,712 shares of BioTime common stock it held in at-the-market transactions for $815,000 in net cash proceeds to be used for working capital purposes. The sale resulted in a $397,000 realized loss, which is recorded as a decrease to common stock equity on the dates of sale.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, OncoCyte held 353,264 BioTime common shares as available-for-sale securities with a fair market value of $0.8 million. Any proceeds from the sale of BioTime shares may be used by OncoCyte to pay amounts owed to BioTime and its affiliates or for working capital purposes.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Long-lived intangible assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Long-lived intangible assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Long-lived intangible assets, primarily consisting of acquired patents, patent applications, and licenses to use certain patents are stated at acquired cost, less accumulated amortization (see Note 3). Amortization expense is computed using the straight-line method over the estimated useful lives of the assets over a period of 10 years.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Equipment and furniture</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Equipment and furniture</div><div><br /></div><div>Equipment and furniture are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under capital leases, OncoCyte depreciates the equipment based on the lower of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the capital lease. Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in OncoCyte&#8217;s results of operations</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Impairment of long-lived assets</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte assesses the impairment of long-lived assets, which consist primarily of long-lived intangible assets, furniture and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to the excess of the asset&#8217;s carrying value over its fair value is recorded. Through 2017, there have been no such impairment losses.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AccountingForWarrantsPolicyTextBlock', window );">Accounting for warrants</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Accounting for warrants</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</font>, then in accordance with ASC 815-40, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</font>. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate OncoCyte to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing variable number of shares. If warrants do not meet liability classification under ASC 480-10, OncoCyte assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, OncoCyte also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP. After all relevant assessments, OncoCyte concludes whether the warrants are classified as liability or equity. Liability classified warrants require to be accounted for at fair value at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the statements of operations. Equity classified warrants only require fair value at issuance with no changes recognized subsequent to the issuance date. OncoCyte does not have any liability classified warrants as of any period presented. See Note 6.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Income taxes</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte has filed a standalone U.S. federal income tax return since its inception. For California purposes, OncoCyte activity for 2015, 2016, and for the period from January 1, 2017 through February 16, 2017, the date immediately before BioTime owned less than 50% of OncoCyte outstanding common stock, has been or will be included in BioTime's California combined tax return. For periods beginning on February 17, 2017 and thereafter, OncoCyte will file a standalone California income tax return. The provision for state income taxes has been determined as if we had filed separate tax returns for the periods presented. Accordingly, the effective tax rate of OncoCyte in future years could vary from its historical effective tax rates depending on the future legal structure of OncoCyte and related tax elections. The historical deferred tax assets, including the operating losses and credit carryforwards generated by OncoCyte, will remain with OncoCyte. OncoCyte accounts for income taxes in accordance with ASC 740, <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Income Taxes</font>, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. OncoCyte&#8217;s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If OncoCyte&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on OncoCyte&#8217;s statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. OncoCyte will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2017 and 2016. OncoCyte is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation for the years ended December 31, 2017, 2016&#160;and 2015. OncoCyte is currently unaware of any tax issues under review.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">On December 22, 2017, the United States enacted major federal tax reform legislation, Public Law No. 115-97, commonly referred to as the 2017 Tax Cuts and Jobs Act (&#8220;2017 Tax Act&#8221;), which enacted a broad range of changes to the Internal Revenue Code. Changes to taxes on corporations impacted by the 2017 Tax Act include, among others, lowering the U.S. federal tax rates to a 21 percent flat tax rate, eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;), imposing additional limitations on the deductibility of interest and net operating losses, allowing any net operating loss (&#8220;NOLs&#8221;) generated in tax years ending after December 31, 2017 to be carried forward indefinitely and generally repealing carrybacks, reducing the maximum deduction for NOL carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer&#8217;s taxable income, and allowing for the expensing of certain capital expenditures. The 2017 Tax Act also puts into effect a number of changes impacting operations outside of the United States including, but not limited to, the imposition of a one-time tax &#8220;deemed repatriation&#8221; on accumulated offshore earnings not previously subject to U.S. tax, and shifts the U.S taxation of multinational corporations from a worldwide system of taxation to a territorial system. ASC 740 requires the effects of changes in tax rates and laws on deferred tax balances (including the effects of the one-time transition tax) to be recognized in the period in which the legislation is enacted (see Note 8).</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) to provide guidance for companies that are not able to complete their accounting for the income tax effects of the 2017 Tax Act in the period of enactment. SAB 118 allows OncoCyte to record provisional amounts during a measurement period not to extend beyond one year of the enactment date (see Note 8).</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Research and development expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">Research and development expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s research and development functions. Direct research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, outside consultants and suppliers. Indirect research and development expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (see Note 4), are primarily based on headcount or space occupied, as applicable, and include laboratory supplies, laboratory expenses, rent and utilities, common area maintenance, telecommunications, property taxes and insurance</font>. Research and development costs are expensed as incurred.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">General and administrative expenses</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">General and administrative expenses include both direct expenses incurred by OncoCyte and indirect overhead costs allocated by BioTime that benefit or support OncoCyte&#8217;s general and administrative functions. Direct general and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Indirect general and administrative expenses allocated by BioTime to OncoCyte under the Shared Facilities Agreement (<font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">see Note 4</font>) are primarily based on headcount or space occupied, as applicable, and include costs for financial reporting and compliance, rent and utilities, common area maintenance, telecommunications, property taxes and insurance.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SalesAndMarketingCostsPolicyTextBlock', window );">Sales and marketing expenses</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Sales and marketing expenses</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade shows and booths, branding and positioning, and outside consultants. Indirect sales and marketing expenses allocated by BioTime, primarily based on OncoCyte&#8217;s headcount or space occupied, as applicable, include costs for rent and utilities, common area maintenance, telecommunications, property taxes and insurance, incurred by BioTime and allocated to us under the Shared Facilities Agreement.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: justify;">Stock-based compensation</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with FASB ASC 718,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Compensation &#8211; Stock Compensation</font> (&#8220;ASC 718&#8221;).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows.&#160;&#160; OncoCyte adopted ASU 2016-09 beginning on January 1, 2017.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">In connection with the adoption of ASU 2016-09, OncoCyte changed its accounting policies including how it accounts for excess tax benefits and deficiencies, if any, and forfeitures, as applicable.&#160; All excess tax benefits and tax deficiencies from stock based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the statements of operations.&#160; Prior to the adoption of ASU 2016-09, OncoCyte recognized excess tax benefits, if any, in additional paid-in capital only if the tax deduction reduced cash income taxes payable and, excess tax deficiencies were recognized either as an offset to accumulated excess tax benefits, if any, on OncoCyte&#8217;s statements of operations.&#160; An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction.&#160; Because OncoCyte has a full valuation allowance for all periods presented (see Note 8) and an insignificant number of stock option exercises during the current quarter, there was no impact to OncoCyte statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Forfeitures are now accounted for as they occur instead of based on the number of awards that were expected to vest.&#160; Based on the nature and timing of OncoCyte&#8217;s grants, straight line expense attribution of stock based compensation for the entire award and the relatively low forfeiture rate on OncoCyte&#8217;s experience, the impact of adoption of ASU 2016-09 pertaining to forfeitures was not significant to OncoCyte&#8217;s financial statements.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value over the requisite service period. OncoCyte uses the Black-Scholes-Merton option pricing model for estimating the fair value of options granted under OncoCyte&#8217;s Stock Option Plan. The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. OncoCyte has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718 and FASB ASC 505-50,<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Equity-Based Payments to Non-Employees</font>. Stock option awards issued to non-employees, principally consultants and employees of BioTime or employees of BioTime subsidiaries who perform services for OncoCyte, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options can more reliably be measured than the fair value of services received. OncoCyte records compensation expense based on the then-current fair values of the stock options at each financial reporting date. Compensation expense recorded during the service period is adjusted in subsequent periods for changes in the fair value of the stock options until the earlier of the date at which the non-employee&#8217;s performance is complete or a performance commitment is reached, which is generally when the stock option award vests. Compensation expense for non-employee grants is recorded on a straight-line basis in the statements of operations.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The Black-Scholes option pricing model requires OncoCyte to make certain assumptions including the fair value of the underlying common stock, the expected option term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 7).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Prior to December 31, 2015, the Board of Directors determined the fair value of the common stock at the time of the grant of options by considering a number of objective and subjective factors including contemporaneous sales of common stock to investors, valuation of comparable companies, operating and financial performance and general and industry-specific economic outlook, among other factors in accordance with applicable elements of the practice aid issued by the American Institute of Certified Public Accountants titled<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Valuation of Privately Held Company Equity Securities Issued As Compensation</font>.&#160; OncoCyte common stock began to trade publicly on the NYSE American on December 31, 2015, and since that date the fair value of OncoCyte common stock underlying stock options has been determined with reference to closing prices reported on the NYSE American.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. OncoCyte estimates the expected term of options granted based upon the &#8220;simplified method&#8221; provided under<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"> Staff Accounting Bulletin, Topic 14</font>, or SAB Topic 14, including, in part, based on its own experience.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Because OncoCyte&#8217;s common stock had no public trading history prior to December 31, 2015, for the year ended December 31, 2015, OncoCyte estimated the expected volatility of the awards from the historical volatility of selected public companies within the biotechnology industry with comparable characteristics to OncoCyte, including similarity in size, lines of business, market capitalization, revenue and financial leverage. For the years ended December 31, 2017 and 2016, OncoCyte estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of stock of peer companies, for a period equal to the expected term of the options.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of OncoCyte&#8217;s stock options.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The dividend yield assumption is based on OncoCyte&#8217;s history and expectation of dividend payouts. OncoCyte has never declared or paid any cash dividends on its common stock, and OncoCyte does not anticipate paying any cash dividends in the foreseeable future.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per common share</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Net loss per common share</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share reflects the weighted-average number of shares of common stock outstanding plus the potential effect of dilutive securities or contracts which are convertible to common stock, such as stock options (using the treasury stock method) and shares issuable in future periods, except in cases where the effect would be anti-dilutive. Because OncoCyte reported net losses for all periods presented, all potentially dilutive common stock are antidilutive for those periods.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(19,375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average common shares outstanding &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss per common share &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.64</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,390</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,779</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Segments</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte&#8217;s executive management team, as a group, represents the entity&#8217;s chief operating decision makers. To date, OncoCyte&#8217;s executive management team has viewed OncoCyte&#8217;s operations as one segment that includes, the research and development of diagnostic tests for the detection of cancer. As a result, the financial information disclosed materially represents all of the financial information related to OncoCyte&#8217;s sole operating segment.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Reclassifications</div><div><br /></div></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">Certain reclassifications from general and administrative expenses have been made to present sales and marketing expenses shown on the statements of operations for the years ended December 31, 2016 and 2015 to conform and be comparable to the year ended December 31, 2017 presentation. These reclassifications have been made as OncoCyte's sales and marketing expenses have increased in 2017, thus making separate presentation of those category of expenses more meaningful to the readers of this report. The reclassifications had no impact to loss from operations or net loss as reported in the statements of operations and had no impact to the statements of cash flows or to the balance sheets for any period presented.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Recent accounting pronouncements</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following accounting standards, which are not yet effective, are presently being evaluated by OncoCyte to determine the impact that they might have on its financial statements.</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">On January 5, 2016, the FASB issued Accounting Standards Update 2016-01, <font style="font-style: italic;">Financial Instruments&#8211;Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</font> (ASU No. 2016-01). Changes to the current GAAP model primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU No. 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. The classification and measurement guidance will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. ASU No. 2016-01, when adopted, could have a material impact to OncoCyte&#8217;s financial statements based on the current accounting for shares of BioTime common stock OncoCyte holds as available-for-sale securities.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;">In February 2016, the FASB issued ASU 2016-02, <font style="font-style: italic;">Leases (Topic 842)</font>, which requires lessees to recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those annual periods. Early adoption is permitted. OncoCyte is currently evaluating the impact that the adoption of ASU 2016-02 will have on its financial statements.</div><div style="background-color: #ffffff;"><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; background-color: #ffffff; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; background-color: #ffffff;">Compensation &#8211; Stock Compensation (Topic 718) &#8211; Scope of Modification Accounting</font><font style="font-size: 10pt; font-family: 'Times New Roman'; background-color: #ffffff;">, to clarify existing guidance and reduce diversity in practice about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 requires modification accounting to a share-based award unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award, as equity or liability instrument, is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. OncoCyte currently applies the three-step test to all modifications, if any, or as they occur, and if all the conditions are not met, applies modification accounting. OncoCyte believes the adoption of ASU 2017-09 will not have a material impact on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_AccountingForWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounting for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_AccountingForWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_GoingConcernAssessmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for going concern assessment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_GoingConcernAssessmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy of reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_SalesAndMarketingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the recognition of sales and marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_SalesAndMarketingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929138944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computations of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The computations of basic and diluted net loss per common share for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands, except per share amounts):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(19,375</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(11,168</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(8,735</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average common shares outstanding &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">30,195</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">26,529</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">21,009</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net loss per common share &#8211; basic and diluted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.64</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9.17%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(0.42</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.17%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The following common stock equivalents were excluded from the computation of diluted net loss per common share of common stock for the years ended December 31, 2017, 2016 and 2015 because including them would have been antidilutive (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Stock options</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,390</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Warrants</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,779</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,246</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929177376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SelectedBalanceSheetComponentsAbstract', window );"><strong>Selected Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued bonuses and payroll related expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">636</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other accrued expenses</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">406</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accrued expenses and other current liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,042</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">797</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,419</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,673</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(1,431</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Intangible assets, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">746</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Equipment and Furniture, Net</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment and furniture</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,479</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,007</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Accumulated depreciation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(657</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(319</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Equipment and furniture, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">822</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">688</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_SelectedBalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_SelectedBalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929445616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable to Silicon Valley Bank (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Loan Payable to Silicon Valley Bank [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Principal and interest payments due on loan payable</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">As of December 31, 2017, principal and interest payments due on the loan payable in each of the next three years are as follows (in thousands):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160; <table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">Year Ending</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">December 31,</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Loan</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2018</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">876</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2019</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">835</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2020</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">386</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total payments of principal and interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,097</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less: amounts representing interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(114</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td style="width: 94px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total payments of principal before deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,983</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less: deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(113</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td style="width: 94px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total loan payable, net of deferred financing costs</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,870</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr></table></div><div>&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6931183792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Shares</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Available</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">for Grant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Number of</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Options</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Outstanding</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Weighted</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Average</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Exercise Price</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at January 1, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,757</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,240</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.03</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(962</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">962</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.58</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(100</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">85</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(85</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at December 31, 2016</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">880</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.52</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Increase in pool</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options granted</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(896</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">896</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">5.17</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options exercised</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(323</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1.89</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Options forfeited, cancelled or expired</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(200</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.11</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; padding-bottom: 2px; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,384</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3,390</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">3.25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Exercisable at December 31, 2017</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; padding-bottom: 4px; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,835</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2.48</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Categories of Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="10" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">668</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">312</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">456</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">General and administrative</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">841</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">610</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Sales and marketing</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">121</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 64%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total stock-based compensation expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">922</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,815</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Calculate Fair Value of Stock Options</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The assumptions that were used to calculate the grant date fair value of OncoCyte&#8217;s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected life (in years)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.15</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.21</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">6.83</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Risk-free interest rates</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">2.03</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">1.46</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">1.87</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Volatility</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">66.01</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">64.64</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">74.15</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><font style="background-color: #ffffff;"></font><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Dividend yield</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><font style="font-size: 10pt; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</font></td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: right;">-</div></td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; font-weight: normal; font-style: normal;">&#160;</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6659762144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">The primary components of the deferred tax assets and liabilities at December 31, 2017 and 2016 were as follows (in thousands):</div><div><br /></div><table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred liabilities:</div></td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td><td valign="bottom" style="vertical-align: bottom;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom;">&#160;</td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Available-for-sale securities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total deferred tax liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Deferred tax assets:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;">&#160;</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net operating loss carryforwards</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,414</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">11,730</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development credit carryforwards</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">2,141</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,765</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Patents and fixed assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">268</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">179</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Stock-based compensation and accrued payroll</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,260</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">1,041</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Valuation Allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(15,083</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">(13,954</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Total deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">761</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;">&#160;</td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Net deferred tax asset (liability)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Income Tax Reconciliation</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 100%;"><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="13" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Year Ended December 31,</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2017</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2016</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="3" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Computed tax benefit at federal statutory rate</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">34</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Re-rate of federal net deferred tax assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">(35)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Permanent differences</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(8)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(1)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">(9)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">State tax benefit</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">3</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">15</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research and development credits</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">1</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">2</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">0</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">7</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #ffffff;">3</td><td valign="bottom" style="width: 4%; vertical-align: bottom; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; background-color: #cceeff;">Adjusted basis for available-for-sale-securities</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;11</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;0</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; text-align: right; background-color: #cceeff;">&#160;0</td><td style="width: 4%; vertical-align: bottom; text-align: left; background-color: #cceeff;">%</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;">&#160;</td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in valuation allowance</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(6)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(44)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">(45)</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr><tr><td valign="bottom" style="width: 61%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;">&#160;</td><td valign="bottom" style="width: 6%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;">-</td><td valign="bottom" style="width: 4%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">%</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761471856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future Minimum Annual Lease Payments</a></td>
<td class="text"><div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Future minimum annual lease payments under </font>Lease Schedule No.&#8217;s 1, 2, and 3 above <font style="font-size: 10pt; font-family: 'Times New Roman';">for the years ending after December 31, 2017 are as follows (in thousands):</font></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;">&#160;</div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><br class="Apple-interchange-newline" /><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman'; width: 80%; word-spacing: 0px; text-transform: none; orphans: 2; widows: 2; letter-spacing: normal; background-color: rgb(255,255,255); text-indent: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">Year Ending</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">December 31,</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px;">&#160;</td><td colspan="2" nowrap="nowrap" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"></div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Capital Lease</div><div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">Payments</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left;">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2018</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">383</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2019</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">248</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td colspan="2" valign="bottom" style="width: 718px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: center; margin-left: 7.2pt; text-indent: -7.2pt;">2020</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">59</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);">&#160;</td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Total minimum lease payments</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">690</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 16.2pt; text-indent: -7.2pt;">Less amounts representing interest</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 2px; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; background-color: rgb(204,238,255);">&#160;</td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">(63</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: rgb(204,238,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">)</div></td></tr><tr><td valign="bottom" style="width: 94px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td style="width: 624px; vertical-align: middle; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman'; margin-left: 7.2pt; text-indent: -7.2pt;">Present value of net minimum lease payments</div></td><td valign="bottom" style="width: 18px; vertical-align: bottom; padding-bottom: 4px; background-color: rgb(255,255,255);">&#160;</td><td valign="bottom" style="width: 18px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">$</div></td><td valign="bottom" style="width: 170px; vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; background-color: rgb(255,255,255);"><div style="font-size: 10pt; font-family: 'Times New Roman';">627</div></td><td nowrap="nowrap" valign="bottom" style="width: 19px; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: rgb(255,255,255);">&#160;</td></tr></table></div><div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">&#160;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773073728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Description of the Business and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 28, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 17, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 29, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,996<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">BioTime shares held as available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Investor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember', window );">BioTime, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">BioTime shares held as available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in equity securities and other forms of securities that provide ownership interests classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ocx_InvestorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ocx_InvestorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775626144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2015</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 17, 2017</div></th>
<th class="th"><div>Aug. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ReverseStockSplitAbstract', window );"><strong>Reverse Stock Split [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Realized loss on sale of BioTime shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">Shares held as available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of long-lived assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Computations of Basic and Diluted Net Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,375)<span></span>
</td>
<td class="num">$ (11,168)<span></span>
</td>
<td class="num">$ (8,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,195,000<span></span>
</td>
<td class="nump">26,529,000<span></span>
</td>
<td class="nump">21,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocx_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment and furniture, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocx_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment and furniture, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment and furniture, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Equipment and furniture, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember', window );">BioTime, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">259,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Realized loss on sale of BioTime shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockSharesHeldAsAvailableForSaleSecurities', window );">Shares held as available-for-sale securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent', window );">Shares held as available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Long-lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,390,000<span></span>
</td>
<td class="nump">3,017,000<span></span>
</td>
<td class="nump">2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,779,000<span></span>
</td>
<td class="nump">3,246,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockSharesHeldAsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockSharesHeldAsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ReverseStockSplitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ReverseStockSplitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in equity securities and other forms of securities that provide ownership interests classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocx_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ocx_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773729888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other current liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued bonuses and payroll related expenses</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,042<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,673)<span></span>
</td>
<td class="num">(1,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Equipment and furniture, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment and furniture</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(657)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Equipment and furniture, net</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Laboratory equipment value</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759162688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_MinimumFixedPaymentDueSharedFacilityAgreement', window );">Minimum fixed payments due under the shared facilities agreement</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ocx_CurrentLiabilitiesMember', window );">Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AllocatedServicesAndFacilityUseFeePayable', window );">Allocated use fees payable</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AllocatedServicesAndFacilityUseFeeExpense', window );">Allocated use fees</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="nump">$ 595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AllocatedServicesAndFacilityUseFeeExpense', window );">Allocated use fees</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AllocatedServicesAndFacilityUseFeeExpense', window );">Allocated use fees</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember', window );">BioTime, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SharedFacilitiesAndServiceAgreementAbstract', window );"><strong>Shared Facilities and Service Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PercentageOfMarkupFeeAllocatedButNotCharged', window );">Markup rate on allocated costs</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TermOfPayment', window );">Term of payment</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_InterestOnUnpaidOverdueInvoice', window );">Interest rate charged on unpaid and overdue invoices</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_AllocatedServicesAndFacilityUseFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of expenses charged to the entity by the parent company for services provided by the parent and for the shared use of a common facility under a "Shared Facilities and Services Agreement". The fees are allocated proportionally for costs incurred during the period by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_AllocatedServicesAndFacilityUseFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_AllocatedServicesAndFacilityUseFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts payable for charges to the entity by the parent company for services provided by the parent and for the shared use of a common facility under a "Shared Facilities and Services Agreement". The fees are allocated proportionally for costs incurred during the period by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_AllocatedServicesAndFacilityUseFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_InterestOnUnpaidOverdueInvoice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of interest charged on invoices not paid when due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_InterestOnUnpaidOverdueInvoice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_MinimumFixedPaymentDueSharedFacilityAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The periodic minimum payment due under the Shared Facility Agreement for amounts payable for charges to the entity by the parent company for services provided by the parent and for the shared use of a common facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_MinimumFixedPaymentDueSharedFacilityAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PercentageOfMarkupFeeAllocatedButNotCharged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage markup of the fee for the services and usage of facilities, equipment, and supplies aforementioned which shall be paid by the entity under Shared Facilities Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PercentageOfMarkupFeeAllocatedButNotCharged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_SharedFacilitiesAndServiceAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_SharedFacilitiesAndServiceAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TermOfPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of days upon the receipt of an invoice within which the invoice must be paid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TermOfPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ocx_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ocx_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765383312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable to Silicon Valley Bank (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 21, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 23, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_FutureCashPaymentsOfLoanPayableAbstract', window );"><strong>Future Cash Payments of Loan Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total payments of principal and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_DebtInstrumentInterest', window );">Less: amounts representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts', window );">Total payments of principal before deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total loan payable, net of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Bank Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightBankWarrantsAbstract', window );"><strong>Bank Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="nump">8,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Aggregate deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_LoanAndSecurityAgreementAbstract', window );"><strong>Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Periodic payment term</a></td>
<td class="text">Monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payments of principal and interest</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Base rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Prime rate plus variable spread per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AdditionalFinalPaymentFeePercentage', window );">Additional final payment fee percentage</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears', window );">Prepayment fee if prepaid more than one year but less than two years</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore', window );">Prepayment fee if prepaid two years or more</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Interest rate on obligations due to bank</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_LoanAndSecurityAgreementAbstract', window );"><strong>Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_DebtDefaultLegalActionAmount', window );">Minimum legal judgments or legal actions amount triggering loan default</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_LoanAndSecurityAgreementAbstract', window );"><strong>Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_AdditionalFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to percentage of the original principal borrowed to be paid as additional final payment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_AdditionalFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ClassOfWarrantOrRightBankWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ClassOfWarrantOrRightBankWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_DebtDefaultLegalActionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the amount necessary to trigger a default of the loan agreement caused by legal judgments, or pending or threatened legal actions against the entity per the debt covenant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_DebtDefaultLegalActionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to amount of debt after interest but before deferred financing costs of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_DebtInstrumentCarryingAmountAfterInterestButBeforeFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_DebtInstrumentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to amount of debt instrument interest as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_DebtInstrumentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_FutureCashPaymentsOfLoanPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_FutureCashPaymentsOfLoanPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_LoanAndSecurityAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_LoanAndSecurityAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to percentage of the outstanding principal balance to be paid as prepayment fee if prepaid more than one year but less than two years after the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PrepaymentFeeIfPrepaidMoreThanOneYearButLessThanTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to percentage of the outstanding principal balance to be paid as prepayment fee if prepaid two years or more after the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PrepaymentFeeIfPrepaidTwoYearsOrMore</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773606000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 29, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommonStockVotesPerShare', window );">Number of votes for each share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_IssuanceOfCommonStockAndWarrantsAbstract', window );"><strong>Issuance of Common Stock and Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_IssuanceOfSeparableUnits', window );">Issuance of separable units (in shares)</a></td>
<td class="nump">3,246,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit', window );">Number of common shares available in each separable unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfWarrantsAvailableInEachSeparableUnit', window );">Number of warrants to purchase stock in each separable unit (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common shares callable by each warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_SeparableUnitsExercisePrice', window );">Separable units, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="nump">51.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock | $</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommonStockVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the votes per share entitled to the holders of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommonStockVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_IssuanceOfCommonStockAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_IssuanceOfCommonStockAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_IssuanceOfSeparableUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of separable units consisting of common stock shares and warrants or rights to purchase common shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_IssuanceOfSeparableUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of common shares included in each immediate separable unit issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NumberOfCommonStockSharesAvailableInEachSeparableUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NumberOfWarrantsAvailableInEachSeparableUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of warrants for common shares included in each separable unit issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NumberOfWarrantsAvailableInEachSeparableUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_SeparableUnitsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of separable units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_SeparableUnitsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776111104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity, 2016 Warrants and New Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2017 </div>
<div>USD ($) </div>
<div>Investor </div>
<div>Form </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2017 </div>
<div>USD ($) </div>
<div>Investor </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfFormsInWarrantExerciseAgreement', window );">Warrant exercise agreement, number of forms | Form</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,779,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,779,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_Warrants2016Member', window );">2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses', window );">Noncash charge to shareholder expense included in general and administrative expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_NewWarrantsMember', window );">New Warrants [Member] | Investors Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_NewWarrantsMember', window );">New Warrants [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfWarrantHolders', window );">Number of warrant holders | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember', window );">First Form - 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfWarrantHolders', window );">Number of warrant holders | Investor</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">226,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember', window );">First Form - July 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">226,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember', window );">Second Form - 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfWarrantHolders', window );">Number of warrant holders | Investor</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember', window );">Second Form - July 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember', window );">Third Form - 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfWarrantHolders', window );">Number of warrant holders | Investor</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member', window );">Third Form Part 1 - July 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member', window );">Third Form Part 2 - July 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_July2017WarrantsMember', window );">July 2017 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_Warrants2016AndNewWarrantsAbstract', window );"><strong>2016 Warrants and New Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock shares called by warrants (in shares)</a></td>
<td class="nump">1,496,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightExercisedPeriod', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants | $</a></td>
<td class="nump">$ 5,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses', window );">Noncash charge to shareholder expense included in general and administrative expenses | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights', window );">Weighted average price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ClassOfWarrantOrRightExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to term of warrants to exercise, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ClassOfWarrantOrRightExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ClassOfWarrantOrRightWeightedAveragePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of the warrants, determined using the Black-Scholes option pricing model, recognized as noncash charge to shareholder expense included in general and administrative expenses and a corresponding increase to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NoncashChargeToShareholderExpenseIncludedInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NumberOfFormsInWarrantExerciseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of forms of warrant exercise agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NumberOfFormsInWarrantExerciseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NumberOfWarrantHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of warrant holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NumberOfWarrantHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_Warrants2016AndNewWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_Warrants2016AndNewWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_Warrants2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_Warrants2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ocx_InvestorsGroupOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ocx_InvestorsGroupOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreement2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_FirstFormWarrantExerciseAgreementJuly2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreement2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_SecondFormWarrantExerciseAgreementJuly2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormWarrantExerciseAgreement2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart1WarrantExerciseAgreementJuly212017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_ThirdFormPart2WarrantExerciseAgreementJuly212017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocx_July2017WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocx_July2017WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772490352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity, Stock Option Exercises (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_StockOptionExercisesAbstract', window );"><strong>Stock Option Exercises [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_StockOptionExercisesAbstract', window );"><strong>Stock Option Exercises [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">323,019<span></span>
</td>
<td class="nump">99,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_StockOptionExercisesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_StockOptionExercisesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774431952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,630,000<span></span>
</td>
<td class="nump">$ 922,000<span></span>
</td>
<td class="nump">$ 1,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm', window );">Maximum period for options grants in period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm', window );">Maximum period for options exercises in period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PeriodForExercisingVestedOption', window );">Period for exercising vested option</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward', window );"><strong>Shares Available for Grant [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Beginning of the period (in shares)</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">1,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease', window );">Increase in pool (in shares)</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="num">(896,000)<span></span>
</td>
<td class="num">(962,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Options forfeited, cancelled or expired (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">End of the period (in shares)</a></td>
<td class="nump">1,384,000<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">1,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">3,017,000<span></span>
</td>
<td class="nump">2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option granted (in shares)</a></td>
<td class="nump">896,000<span></span>
</td>
<td class="nump">962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(323,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, cancelled or expired (in shares)</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">End of the period (in shares)</a></td>
<td class="nump">3,390,000<span></span>
</td>
<td class="nump">3,017,000<span></span>
</td>
<td class="nump">2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable (in shares)</a></td>
<td class="nump">1,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Option granted (in dollars per share)</a></td>
<td class="nump">5.17<span></span>
</td>
<td class="nump">3.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">1.89<span></span>
</td>
<td class="nump">2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited, cancelled or expired (in dollars per share)</a></td>
<td class="nump">3.11<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">End of the period (in dollars per share)</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average recognition period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,630,000<span></span>
</td>
<td class="nump">$ 922,000<span></span>
</td>
<td class="nump">$ 1,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
<td class="text">6 years 2 months 16 days<span></span>
</td>
<td class="text">6 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">2.03%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">66.01%<span></span>
</td>
<td class="nump">64.64%<span></span>
</td>
<td class="nump">74.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 668,000<span></span>
</td>
<td class="nump">$ 312,000<span></span>
</td>
<td class="nump">$ 456,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member] | General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">841,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="nump">1,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member] | Sales and Marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PercentageOfFairMarketValueOfCommonStock', window );">Percentage of fair market value of common stock</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Term of options</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate fair value of common stock</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PeriodOfNontransferableForStockOptionGrants', window );">Period of nontransferable for stock option grants</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PercentageOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to percentage of fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PercentageOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PeriodForExercisingVestedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to period for exercising vested option extended after termination or the expiration date of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PeriodForExercisingVestedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PeriodOfNontransferableForStockOptionGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to period of nontransferable for stock option granted.,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PeriodOfNontransferableForStockOptionGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the maximum period for options exercises in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the maximum period for options grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) of non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775168464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit', window );">Reduction in deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Available-for-sale securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
<td class="nump">11,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_DeferredTaxAssetsPatentsAndFixedAssets', window );">Patents and fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation and accrued payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,083)<span></span>
</td>
<td class="num">(13,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Computed tax benefit at federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Re-rate of federal net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent', window );">Adjusted basis for available-for-sale-securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(44.00%)<span></span>
</td>
<td class="num">(45.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Company share in market transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,452,000<span></span>
</td>
<td class="nump">28,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PercentageOfChangeInOwnership', window );">Percentage of change in ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur', window );">Period in which change of ownership for a specified percentage should occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TaxCreditCarryforwardAmountFederal', window );">Tax credit carryforwards, federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TaxCreditCarryforwardAmountState', window );">Tax credit carryforwards, state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TaxCreditCarryforwardExpirationDateFederal', window );">Tax credit carryforwards, expiration date, federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_TaxCreditCarryforwardExpirationDateFederal', window );">Tax credit carryforwards, expiration date, federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Computed tax benefit at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember', window );">BioTime, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Company share in market transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">259,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_InvestorsTaxableGainLoss', window );">Investors taxable loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (397)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_DeferredTaxAssetsPatentsAndFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_DeferredTaxAssetsPatentsAndFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the basis for available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_EffectiveIncomeTaxRateReconciliationChangeInBasisForAvailableForSaleSecuritiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between effective income tax rate and domestic federal statutory income tax rate that can be explained by permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_InvestorsTaxableGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investor's gain (loss) recognized on the sale of equity instruments subject to taxation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_InvestorsTaxableGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PercentageOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage change in ownership necessary under internal revenue code which places limitation on amount of taxable income that can be offset by net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PercentageOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period in which change of ownership for a specified percentage should occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PeriodInWhichChangeOfOwnershipForSpecifiedPercentageShouldOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TaxCreditCarryforwardAmountFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, related to domestic tax authorities available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TaxCreditCarryforwardAmountFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TaxCreditCarryforwardAmountState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, related to state tax authorities available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TaxCreditCarryforwardAmountState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TaxCreditCarryforwardExpirationDateFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward related to domestic tax authorities, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TaxCreditCarryforwardExpirationDateFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act of 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774729888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 07, 2016</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 11, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease agreement value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 626,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Monthly payment under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract', window );"><strong>Future Minimum Annual Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amounts representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of net minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=ocx_MasterLeaseLineAgreementMember', window );">Master Lease Line Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease agreement value</a></td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CapitalLeasePaymentTerm', window );">Capital lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CapitalLeaseAgreementImputedAnnualInterestRate', window );">Interest rate on lease agreement</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment', window );">Percentage of restocking fee paid on original cost of equipment</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Monthly payment under capital lease</a></td>
<td class="nump">$ 14,442<span></span>
</td>
<td class="nump">$ 9,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_AmountAvailableUnderCapitalLeaseAgreement', window );">Available amount under lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract', window );"><strong>Future Minimum Annual Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amounts representing interest</a></td>
<td class="num">(14,442)<span></span>
</td>
<td class="num">$ (9,462)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,342)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Master Lease Line Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Increment value of lease agreement</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment', window );">Percentage of fair value on original cost to purchase an equipment</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Master Lease Line Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Lease agreement value</a></td>
<td class="nump">$ 881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_AmountAvailableUnderCapitalLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of under capital lease agreement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_AmountAvailableUnderCapitalLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CapitalLeaseAgreementImputedAnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to annual interest rate on capital lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CapitalLeaseAgreementImputedAnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CapitalLeasePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of capital lease agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CapitalLeasePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum fair value percentage on original cost to purchase an equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PercentageOfFairValueOnOriginalCostToPurchaseAnEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the equipment returned financed under the schedule for a restocking fee percentage on original cost of equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_PercentageOfRestockingFeePaidOnOriginalCostOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=ocx_MasterLeaseLineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=ocx_MasterLeaseLineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762601456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies, Wistar License Agreement (Details) - Wistar License Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>Extension</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_WistarLicenseAgreementAbstract', window );"><strong>Wistar License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_MaximumReductionInRoyaltyPayments', window );">Maximum reduction in royalty payments</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions', window );">Number of one-year extensions</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocx_WistarLicenseAgreementMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_WistarLicenseAgreementAbstract', window );"><strong>Wistar License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_RoyaltyPercentage', window );">Royalty rates on amount of cumulative net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocx_WistarLicenseAgreementMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_WistarLicenseAgreementAbstract', window );"><strong>Wistar License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_RoyaltyPercentage', window );">Royalty rates on amount of cumulative net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of one-year extensions that may be purchased is sales of a licensed product do not commence by the specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_CommencementOfCommercialSaleDeadlineNumberOfOneYearExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_MaximumReductionInRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of reduction in royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_MaximumReductionInRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_WistarLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_WistarLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocx_WistarLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocx_WistarLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762596080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 28, 2018 </div>
<div>USD ($) </div>
<div>Investor </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_NumberOfAccreditedInvestors', window );">Number of accredited investors | Investor</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_StockIssuedDuringPeriodSharesPrivatePlacement', window );">Shares issued through private placement (in shares) | shares</a></td>
<td class="nump">7,936,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement | $</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Broadwood Partners, L.P [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Beneficial ownership percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Investor One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_StockIssuedDuringPeriodSharesPrivatePlacement', window );">Shares issued through private placement (in shares) | shares</a></td>
<td class="nump">6,349,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement | $</a></td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Investor Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ocx_StockIssuedDuringPeriodSharesPrivatePlacement', window );">Shares issued through private placement (in shares) | shares</a></td>
<td class="nump">1,587,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement | $</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_NumberOfAccreditedInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of accredited investors in the notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_NumberOfAccreditedInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocx_StockIssuedDuringPeriodSharesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of stock issued through private placement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocx_StockIssuedDuringPeriodSharesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocx_BroadwoodPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocx_BroadwoodPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=ocx_InvestorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=ocx_InvestorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQZ8W?V'QM?!-L&?MU%^P502P,$%     @ <HJ"3)E<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M1IT_FOHY[1>D7W1^,?5'($V]).TD]8"8"A J%L5)FH)@L4C$/*5Q8Q(WQKB
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M5IL&"#*0UD >PA5$B676!0O#-+,,.V 9@HE;<^+4G"P]9VY^ZN2G2\\KR_,
M268JHY75E]T28Q_N$@%7=TX'.96BA=*556.+%C4>D@A94AT@&,26VB4(W3F6
MS"DV6XH-+;&9ZZ^4!E;W=RY8&"/K\]H[8%F40DLSF$V,AO"+F<;"*]FUE?K+
MFT6G@?\4Z8ECQ;?J(ACF]GN:X1;Y@?FE;H5W9%+-,S-USHQ)HD0&CZJAE;JX
MI@TE9ZF72*WY,+Z'C63=>#.!Z7HL_@-02P,$%     @ <HJ"3+(YY^[H!0
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M7:N)N2E>@"Q"0U,54BFC:!K)0- D#D=N;H7IH@!=:"K:*)[O91PIME!],G=
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M&YH/I"KJ:#Z_U_Q0$[& HFIGD:E<A_\*(%=3N>*>D/0^D@$D<-P$ CKYDY!
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MT?F7C?UO$!UX*;LK/T*=_V"+(:%QX7CKSV8:L\EPV,\_B"W?N'P#4$L#!!0
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M8(NAH';A^,&?S31FD^&PGW\06[YQ\1M02P,$%     @ <HJ"3#5!DB*T 0
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ME0_'&SS;<<Q&PYMN^D%L_L;Y;U!+ P04    " !RBH),H&F"G[0!  #2 P
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M/YMIS";#Z7[^063YQN4_4$L#!!0    ( '**@DSA$CU"M $  -(#   9
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MN/E] HE#3K?TW?$LFM8%!RNRCC?P'=R/[FR\Q6:52BC05J F!NJ<WF^/IWW
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M_:\1'?A4DCL_0JW_8(NAH';A>._/9AJSR7#8SS^(+=^X^ M02P,$%     @
M<HJ"3$$?)Y_3 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M=51M;]L@$/XKB!]0$A*[5F1;:EI5F[1)4:NMGXE]?E'!>(#C[M\7L.NZ&?MB
MN..YY[G#=Z2C5*^Z 3#H3?!.9[@QIC\0HHL&!-,WLH?.GE12"6:LJ6JB>P6L
M]$&"$[K9Q$2PML-YZGTGE:=R,+SMX*20'H1@ZN\1N!PSO,4?CJ>V;HQSD#SM
M60W/8'[U)V4MLK"4K8!.M[)#"JH,WVT/Q]CA/>!W"Z->[9&KY"SEJS.^EQG>
MN(2 0V$< [/+!>Z!<T=DT_@S<^)%T@6N]Q_LC[YV6\N9:;B7_*4M39/A!*,2
M*C9P\R3';S#7$V$T%_\#+L MW&5B-0K)M?^B8M!&BIG%IB+8V[2VG5_'Z21*
MYK!P )T#Z!*0>!TR"?G,'YAA>:KDB-1T]SUSOWA[H/9N"N?T5^'/;/+:>B\Y
MC6A*+HYHQAPG#%UAM@N"6/9%@H8DCO2?<!H.WP4SW/GPW5H]V8<)]D&"O2?8
M?REQ=U5B"/,?D2@H$@4(HBN1$"8.B\1!D3A <'LE$L(D5R)DU1T"5.WG0J-"
M#IV?R95W&;T[ZKOK$S[-[4^FZK;3Z"R-[5'?2964!FPJFQM;<&.?BL7@4!FW
MO;5[-0W,9!C9SV\!61ZD_!U02P,$%     @ <HJ"3(-'[(C$ 0  -P0  !D
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M^NR_BHLH-=PPT3&VLFSMWV![;I6L>B^:2I6_=L^BML]K]X9GO1EN0'H#,A@
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MA).XQ3!M!MY-P,V @&Z0NMU@!(D;"?G2P>V @'Z0>AH*P5HG$I2<]+C 0B9
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M>S-<)(>!T8?QDAQ=;NK+OU!+ P04    " !RBH),TT$!Y+H"  "C"@  &0
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MDHX!G4!.#P/H<B3=\@GH )1*G!7H" ZC !T*Z2A.QZ4A&PY2R4P@ [WH3FE
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MJ83V&=[J"N[TA?6T*,1&M:^Q?J_[6UN_4'(_W$B#T[5X]@]02P,$%     @
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M.YG'@,/!N&UF]ZH?3WU@9#N,7C+._^(?4$L#!!0    ( '**@DS5;Q[.40(
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MO)QRX;&B\HFK;A?8UJ-MB""4' J<]XZ.@7T,@@:  [NZH-&#;// :E1UA%-
MI+P&Q=K->H3\Q<>YH$U&!V<F+G7"[.P \N)>G)R=I+/STV^%Y](-RUA<R6:Z
MD@$A8/<:[/4A=C:>%*0>7MIBJ^4(U>TB.-(9/=&A*;#SC-[L\&WM_#$U&0JA
MMI?-!=VWQF */4G_4(M0S%[V;\Y91X%5H)!7PU#>9!=B1\XQE/,Z,"9XI2Q1
M,U,9)K/9O?ZZG6 4U?[D A+DS%]3P2*O!V(H%VL>'2$X =1&L.D6/F*MUOTB
M=!D*HU'U^G,>^ENFQXP"G"0C12Q'_Q[NP,C"%R9-'-%W)FG\G[7&U"!X!LL]
MP?/T:T9+)=\SLR_(*Y)U2(C.#Q%$I4'=Y_0P,<IXPDO'_/UK(F1)B94?Z:.@
M)R%MH[#&BTFS/^/)HR.5? B,ANFY'>8E;(:W=F7,8$$8<D1=E:&'++S6& FG
MDQ5*7' ^O,2;*42"GL$ [ESE3V Z2I2QPS6X&R(?1%8Z2?Z**J:Q>YJ\HSNC
MON GC ,MBA;O/QY6*GC(MC.1 [E/(R0FXZYJ9 R.EWE=T^LU[,C<&E@/U2]"
M=9@*C+0:^F'9, CD&L26A1W>KG +?;ZPXU*R[J'+5B-+.]Y2 6346V%OX=,1
M3FBN*VH02G ,4,4(5D(P5@ZW^=(!\Z*!#48O../8%TA(@JN08#HM9X57E?RK
MM +Q/W76WA)7#P@'Q,/<<U@6*[91?/EV^?43Z.+F7";$-?(M-S.&T/,EEQ(H
M2"P*5U60/#"U#NSV3:>FH>,P1&3$Z6 ZU=ATW.,H3^P)$WTA+K3TWIBY">S3
M2X[.>OM(#(T<^=X.-7H):C:,V&.5@J(%)FI:U7Q\O>GD0\/ 9909IN>S,AYS
MBXD<,AOW=L')SP(SR@O2:5U]W*1V 2 = YU$E /?M)U<$HJ=/.;T*G[9#4XX
M8S]8;QHC%L?I)5H<:7^]-R+?O25Z:RQ1>OL&5"#014&6<,HMK/,>&%?RIA<^
M%5NE]X$?<\I&0B84_P95I2>UB360]\;PO0.^6M(-QYRX&XY?.QIY]Z0E[FY-
M;*Z?IU<REH_<H027);3K,E]0H4P?U4.^#%P#F+P"Z%WN'PM,D[JJVIJ-10D:
MAQ;--@&[##0]P'NTF$/_1U8Q5%"<#(HY]1C"\]23,T>!BM4*K%WX5XGJ*,8[
M>HA3?STQ,]-&9,?@IREM$]T2)'^!:5N#S.,1S0[,R?K$8W,[Q[NDSL_[G9A5
MY4K#F![- $\M/#3SZ<&1.9OP,V%Y:;<YX=C&;/TZ#? *I3Q<6TXB9%I1C+7Y
M0-L[P #B$L !B:T1  $)GD80=(#!-RO3Y304#O-^QMWARAV8.EY@%BRZO"*C
MM4,-2 8DR!ZJDINY.@0]?1H$#(Z4EQ(?X]TS7W01;WQ,!6H8$HMF7(DGACBW
MA%-:DUQKS*:43YD1L<QD/'XO[HL)3G*$Q5V<'J?*"C[2@[BRATW!STE6J_BE
M&2-,7@N.03S"+^C;817)!FF<2,P='41"L<%H%)LP(]14P#2A@CH< \T^\8US
M8IF->/X[6>7]F\6!,,&GJM'O'2^IO*+?2%:;EI0!S" $3>D3,(TC9 U'J"2T
M\"-LOD<EY5^RE;B3\*A@))+K$D KAHE7[LO#FHB,$JRR4F(9#DRQJ8RC""?K
M5B/U ^1>BQ9.3AFUK<G[HI]R]]'7GAGY>A9W.SB?KEE6P=AE!&QPYCKHR0Y+
MT#^_1S+^PC0::Q^8_!N99"N1 *##U -!%-B!\$E1YG5QS!_BH(D+ YU :1,N
MPZ<2;ZI@.;@(5DS$UFO@J_D3@8K<)V8S*WA"WRWLZYPC,;^A)T.D*),J5=PH
ML5]-*2![:8SR)GNBT.ET>G9T!<.R_"FW,30"'0[<WN1&8WS_4=^WB(UQL4OW
M"/Q1@YAJ*^C\LN2^J8&GHQW)<"Y1LD7WI+K0>#@?&("%45*@MQOS%'$00BZX
M>BBM@.&8G073Q0F*U P"]6W*]K"RSD#[\"P=-R"9317>"KHX:OSR<PK<NN#;
M*:.X2AO U6@A)"$H&KI9T7LNT/OS1[]',/N:]$I#G3ARYU&TI&ODF$U:J++:
MNUM40*HG !C;]:0XF.$C;CYOW[UI7>392P>Y8([D:214#2)7ESD?RIF"60%%
M[L%80HQ*0<H1SM.[0\# 1\<FN=M .-UG\T\MAF)@E;JA%'*&K9.ERRV$R?;D
M&=B?K23#^/EZ78>GK+/,>EAI\G5D7X ?Y(W38N$/$JGF\N,"AN+-=*5SB"&*
M.T\YDKHU+*B"I7E E2SW-IV6#V5\9)94&]I6<S>8N.DK!J\-;V*RA<P_9 =.
M+>!L=V2?1$^BSXN1KQ()F1"!>CE; >8G1(&0CYP=,5W#7%"Q1P1T-]THEDL,
M?%(QH8K@5?A-S$I%-)")E<%*Z:K!5Z1JQF.Q[%J]@[3M.JD5N4(T0R2X[Z22
M9>BN+1=/N WMM@5Y+P)=X MXTG#N("=K8N7\S$25$H]F]>IA&^Q[93@!YR(_
M27$>HXJY.-Q!J(R9 4DW<_N+0011;K(OAP.%(81MXW\Q"V4OG./B*$^4JWH7
M[N7A+IEQ]_H&%:/E4J%I=_0?QC1\M2DQV[<2N7#I^,/=]2O\;\<B.E>)Q&MR
M2TY:!F.PR V<C(2W>"VTX@5.IVBLU:Y7RJH;X0[V>+K=) 0YXUYP[H+,E:]K
M&T0%V#/AC1)$>C@40</UJJR"*./C$@BJU.7D5MS6"!502*#Z3W4&;!2&AS+6
M*<*C#YY_0N08F_D]9&Z0A1-8%P[$ZU)LI'RG2_F!-UP^&AZ:R[7"=.<UXIRC
M#L?X;)>@FFEV.W]WO(B#SCWJ2?09++[<J.JLJI\&H/Z1M(K4L4K\#+"43!VN
MN+BRH+3I6]VDYR<;WS>3-<4:'-VW084=7U3'1CE3R076U3NW/1[7G%UXC23\
MU,!UU^27RMH .LAGS11BTX1XD:CO^#_ZV&TLI4K\$#"GC($([)1/*8<*?]Q4
M/CH5YE_)+"0%*QGO>^+W<Y]G_B=1_L/X?(>TO^/AW=0?) 9].^ES6P $6%*X
M@4HVJ(KJ+ICDCS7U,F^5*=*3E08CEGEN+\D^J_I'79/$WY,DTAS'?W#GC_]D
M#D,5[1#Z]22!IQH(%=Z];\2UQVGL+/9)+2.LV9 OF4V.57G9N;MIC(,,R/=K
M6(I>.]Z>)=75^">RBS2XR@$ZQ*:G;MK]:&>2C#7L")/R2.UJXZEXQDFBF8&2
M$L:YA4HT0/_%W&<:/D@-N8+,^S2*)KZ^>\6:*";;W=B/*]R(G>C!3[>N3A@Y
ML7$':"#1YQ ,C;\<'5_UQCR*C7;PL5X7<YS!X0\8*VPP_T]S,%[K>FF+CQC/
M_EX<.]<F_5BR\A *CA&3%F[L9V8/OBY*+T1#KF :E@]'_4468--W;AK%$"\,
MU0RB;&<8;)FSF95&@C^96(@NWJ-PF #:FT;CU*9*IJ^E[.M6>6FSJ*DRA]G_
MT-/>BRH00FF.O(>-6E?"CP:2B0>'Z2M#D'$B^!53"$1K9/A- VZ$ :_ 7RNQ
MO=#'5VGC/TV^4K*5&(G?W8 _<$[GV(CX!SNJE.(F(HS<2#VEN8N 8NE5NN9R
M2228[@%M@6O22&[74LR".C45<S21UI1*V>\@S%0B>Q#>?>MT+!9'QDE _K;"
M^2",HX/\()K($OC937GEU'X[V&[RR]HY,O%G5.D"S?6<RU$8(W[G,F*R9'PO
MKQWR-')&Z*S)!>,[7#=Y(RQS(-+H11M\"57\3,Z9:"%%$5+#;,"SQ5BY-$JX
MD]O!9(??L#,(EH(58AB3'<0^LP0+O\4R'#7[?1C/"JQ)08N@X#2>;>\WLIG+
MOGRIS5Y5?#N6&: X'T?FGS@+0C*+K;*V,_T<78LQ-D")2):O$/&Y9\V5-?O]
M1,[[^UQI5!RZS/;T$D?VCH(QRJG$[_#4XR?LR]Z2PM,0$AF- @R<6YR4WTAA
M2F0:T'VR42&$!P=I7B.)5D,#0I0#Q98EA"U3C4.#6G(51AFF<T%6'=7THTL2
M ),X%QVKS7@>+G'/R%W&[S=X!+GS#TIZ^0@K1")%?R?15&WEA-!16-0F5GXB
M7B?(EQQP"8(4VPOZ3#EMS"KEJD;(N<FIT'X?D4\FP$2WBL92(\=\0!%^Y"($
MM=W55S#IWFK'*&SJ59G!3.[FCS4H[D<_P^[@GO'686H,I5W4"RFN*(O3&QFN
M3JL.:/T*%H2#_6.5[AU_XGV92<B]MU,9:&=Q#=4(J3:H>V*)V@TDW,_CBG5V
MJ,S5I=T39'-YZ:Y*!Z9!M^ND2/]YH++@B?8I:;%4YD9M('2=RKMZ$B9UE;@J
M^N%+>Q/,28_6W.#Z;0'*DPN1[$$"-S&+@3#Y=744)5!9KD"DO+\W&C9'E0=6
MX0R%L^.SH[/C5  ]H4).&OM;^.QK5[_D8Y\DX[3HG.!! 42;AVN33T.5/"0T
M@I4BH9;;(9HE@+K)1)#>>K]\KI%Q<;-RVORB_72TQ 0A%^MJ]")32$P;N&VI
M<JV7DA>V]ET_5G7&@W/&)H:AR>+&^N;F$L07&!8,9_0?N?7E=[H3]@K?;UT2
M([N7O7BI*22BCAF)D) ?B9.(S6YC=02@J!I&SRF]6NM)]DNVNU+MMH2"^),R
M1AXZ%WTZ6G]/:L@X**YU^& [*K@PVR-4KI&[)UC#K5[!/^I-AUF[T8SH&)E[
M6P*YA5,OR+&/V#8J^X(I9&S=BBIPO<H1$5,17 U3B;B# 99F0<">1K?%1.6.
M:P7AU7ZU._*>RW&#B/P+DHZ@V"*I/;=B6[?AA?]HZ5:ATN&M=T30Y*+)L:1X
MDE[!1]HK6,(,#D\:OIWU- \!Z!CHV*C0'$RP+UE,X2I\7J(]SIA?".9=PWZN
M^CQ+I-'X49JP:V%Z.M"!/98TK-Y#=?ZY1P3YT\B$)?C3UI<SC]QD"\L8064$
M=8P<9G^$\3AW!?-J!]LV4*SPX58EG4S>A\!,-GO8VT+O$%\#>S=[H,ZPV(+W
M1()VB=7KN))&"V(D)2V24:"2BJ9UX#SL7;R54MRF=^?+G(G1)TSO!+I$LB_W
MV%O.K- *A-(V@LH[F8?"K'##)*@XQ]PGV&FEJ9%Q5$B,_.PM)70%YXUEC$$=
MD!XZNG>C&'AG,'NC,LO)T:1H[<7CO'B+U.*0L]S)T2Q-6V[?5V4+P G!3"/V
MNV$S//F>0(W-.>I5EHNJB8%S7\W&C0@Z'[*LGIK(L'\L<9I)]@6E?R,K)L^'
MOLY]@GIEQ7HEUER=2VRN@QFW'4'1%/[2&T]KWM?(FG,B, 9L3I*WM@N\375+
MN&-\-?J[32,">45?P^^[-T2(#42 ,=_C]<TL4CC$O6*T:;1[O>2-C B>K_KJ
MNMQ(&0_%@BMJA8ZYY""3K4K0<-'?#+_O:UW90FJ]7,74E^<,&Q7[E"PT)MH-
M1C;I"99/AX(E">NZ>4RO.%1<40;RP(E?I\D-7L/['Y"&CG15$5>.*QNFFYZW
MX_Z;E/]L,/1NOT*-LN$/NU^7#F$J8TK] *(QA0*1 P/(DCRY,5((2/1;<(P\
M,5P@8RH.Z/*XMO>RJY[J!%1Q^$/R7RB67X_($/H&C>]NW,OD8'J5GER<)8?T
M[VDZ/;_D?U^F%R?XY[\*%2=*Q6$RJB59#:4,]^?D.)U>G26S\_1L=I7,IBFV
MQ1J_]^,#P<2.)^>G/,7CR>DL^!?9X[7BQ@9IN2YQGKU+@NZW30;TF-T=VWFV
M_>O[36>ME20"8V\E-\-G[P1T&A#$_L=^%]SRD_3DZAC^EYY)9Z?'B6N3.TLO
M+J[@I]GI.<:R\H>PJ(]Q8VFPVY8HS+.55+U^:.K-.NTKY'@K.Y_!@M6+EL8X
MTG+D9!<C7.1CG7")M?V_3\(.0;WY8OB6+>_<$K"HY16R22!QV#95CU4<HD(4
M$NE@Q]C12'L_4Y$[[>'G;35.*<!(\&)7[L[LH'2P&Q_ 1%&'.DA=VL0%63<"
MIL)@7.MRHIK!+W1?]@$E>.*EJKU=K1QZ=[0= _O#:.!8)=9==\W<,JZ(3^!L
MSE6U=H HFSMLFHN@B8'6\1GN36_)F;\SW[>[5\W%PBLN*J#%%0A)N,',^T]\
M7)*5$W14(&) F84Q^X>:"[6[<:EUTBK/T'-LFNO 9ZC0DY:K8_DJ*G5D68LP
M5.&+6H1%C1VOS%HOLI^)!=*.#+XP?,.D9_K(H>!!@6CRO/,!$K$E@B*\!"D/
MNCD$Q4%"V6&>TWJ0+A5789;;O/.92:GM,$&9:72\4H9T4##!UUPT[G_U2&PE
MMY9HHAXOWDCH4PUVNUR[ 4PA5@^-JU9*= %H/)J6*&+X'0$,RA]P#X/DGI_#
MY!Y3LLW7BO5_M*F2MR8=[CEPQ2Q-WG#S24%07)[.#AF;L35PV\C+%T-DQ@ZT
MA\%G^,?F0*>XMI]M_3BSHU3/$JVI8HFA-BDWX=.MR#&.H64T3K")+SL1O,/M
M'MNS28IWF)U![6!$JU?7^R!<&[CVU;V,X4H6LA1T!I-^RUUV= &&NF$R;MT3
MNW&F_/#(JP3Y'L:.-Q57@C!RRE\K8D;=#Z!J'H[X?/EK;K2"=88VX^91\7?J
MIG@H"$G'[PPS1&-/M>Y;:7(PX_EH/"3<\\B\,AG43FS\Y=\_0:2D@Q.>9+S
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M?#B@KU200T1=WL'"!>P_JPW#@%EQS2J8*K5'V)\(UG5:N1$]*B!\:O!==G6
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M%1KY+D7Z\H7TGW%=&/J;B\X>3#+!9H&R;TQ\KO75NY R&&YB'68&_T'!@O"
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MRP6B]Z2XI-U=05L7T_?202[87AU.F/.AG"F8%1"2 @L8+3';G>"P,$_OK&E
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M% V1G6(DF![VEE,'T5!3AY$U/-\I.B*=T:CC9EKT& Y"?'8_8VH)SSZ0'$5
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MCV>OO]127[]";IV\F4S\J?]X?GWH.>M<YQ@YG ]IA(/E!?9^'?A9V /0Q>^
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M'NJS[J? [ M02P$"% ,4    " !RBH),'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " !RBH),9O,+8((   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( '**@DRSJ+"&[P   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( '**@DR97)PC$ 8  )PG   3
M      "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ <HJ"
M3!!P\<F9 @  G0D  !@              ( !^ @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( '**@DQ9SQ:.M ,  &X1   8
M      "  <<+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" !RBH),6"&^/#4"  "@!P  &               @ &Q#P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <HJ"3"<14%@B P  P0P  !@
M             ( !'!(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( '**@DR/P+^I50(  "H'   8              "  705  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !RBH),LCGG[N@%   $
M(P  &               @ '_%P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ <HJ"3%N4>]9B!0  =AT  !@              ( !'1X
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( '**@DRB 4QD
MM $  -(#   8              "  ;4C  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " !RBH),8@6_;[8!  #2 P  &
M@ &?)0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ <HJ"
M3!U>YE"T 0  T@,  !D              ( !BR<  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " !RBH),=98E)+4!  #2 P  &0
M        @ %V*0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( '**@DSL9F'#M0$  -(#   9              "  6(K  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ <HJ"3,=]!E&R 0  T@,
M !D              ( !3BT  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " !RBH),39&S:;0!  #2 P  &0              @ $W+P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( '**@DPU09(B
MM $  -(#   9              "  2(Q  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ <HJ"3*!I@I^T 0  T@,  !D
M ( !#3,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !R
MBH),X1(]0K0!  #2 P  &0              @ 'X-   >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '**@DPBM:_*MP$  -(#   9
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M970R,BYX;6Q02P$"% ,4    " !RBH),01\GG],!  "<!   &0
M    @ &T00  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M '**@DR#1^R(Q $  #<$   9              "  ;Y#  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ <HJ"3*>@V]*W 0  T@,  !D
M             ( !N44  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " !RBH),EI!:PLP"  "!"P  &0              @ &G1P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '**@DQU0ODI\00
M /8:   9              "  :I*  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ <HJ"3(]D<$X8 P  -@P  !D              ( !
MTD\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !RBH),
MB8=^@L<"  #_"@  &0              @ $A4P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '**@DRT^,_$8 ,  +4/   9
M      "  1]6  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ <HJ"3--! >2Z @  HPH  !D              ( !MED  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !RBH),\;E5#,H$  #1'
M&0              @ &G7   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( '**@DS,U<!%+@(  ' &   9              "  :AA  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ <HJ"3':>N0:#
M!0  #Q\  !D              ( !#60  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " !RBH),-M\9X&4%  "<'@  &0
M@ '':0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( '**
M@DR42.(\4@,  "(/   9              "  6-O  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ <HJ"3%1'8F8' @  "P8  !D
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M='EL97,N>&UL4$L! A0#%     @ <HJ"3(:(U)AK P  *AD   \
M     ( !Z0@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '**@DRMHL>-
MF $  +<7   :              "  8$, 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( '**@DS)4^7XH@$  !P8   3
M  "  5$. 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ NPP  "00
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>150</ContextCount>
  <ElementCount>290</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>050000 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Organization, Description of the Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Organization, Description of the Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Selected Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SelectedBalanceSheetComponents</Role>
      <ShortName>Selected Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Loan Payable to Silicon Valley Bank</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/LoanPayableToSiliconValleyBank</Role>
      <ShortName>Loan Payable to Silicon Valley Bank</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>070100 - Disclosure - Organization, Description of the Business and Liquidity (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies</Role>
      <ShortName>Organization, Description of the Business and Liquidity (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080300 - Disclosure - Selected Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SelectedBalanceSheetComponentsTables</Role>
      <ShortName>Selected Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SelectedBalanceSheetComponents</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Loan Payable to Silicon Valley Bank (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables</Role>
      <ShortName>Loan Payable to Silicon Valley Bank (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/LoanPayableToSiliconValleyBank</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/StockbasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080800 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Organization, Description of the Business and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetails</Role>
      <ShortName>Organization, Description of the Business and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Selected Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SelectedBalanceSheetComponentsDetails</Role>
      <ShortName>Selected Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SelectedBalanceSheetComponentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Loan Payable to Silicon Valley Bank (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetails</Role>
      <ShortName>Loan Payable to Silicon Valley Bank (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/LoanPayableToSiliconValleyBankTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/ShareholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Shareholders' Equity, 2016 Warrants and New Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquity2016WarrantsAndNewWarrantsDetails</Role>
      <ShortName>Shareholders' Equity, 2016 Warrants and New Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090604 - Disclosure - Shareholders' Equity, Stock Option Exercises (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquityStockOptionExercisesDetails</Role>
      <ShortName>Shareholders' Equity, Stock Option Exercises (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StockbasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/StockbasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090902 - Disclosure - Commitments and Contingencies, Wistar License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingenciesWistarLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies, Wistar License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ocx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SubsequentEvents</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ocx-20171231.xml</File>
    <File>ocx-20171231.xsd</File>
    <File>ocx-20171231_cal.xml</File>
    <File>ocx-20171231_def.xml</File>
    <File>ocx-20171231_lab.xml</File>
    <File>ocx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001140361-18-016477-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-18-016477-xbrl.zip
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M]4ZZR\L:;EL@QBXS@-7O[Y)IHU5X)RMY9>?ZLM:2QZXETTFIB]+RC@6=MR_
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M0*U WY%'8%C<M*<@TC^=-4&O]SO]-OY'!T<;,PO,5WY'91MAS3ZS*5^$)WD
M?U]/FQO7]*[G('K7GC_3@4@/M, XL(@^Z)J/KL4?C?_E.8LD'Z$GX('UH.AN
M^=)A%@"A5KP&E8!J&+=D]8V;*$0'S@(&RX$K:=XK'M>>7@ 20Z',$G;U)?SX
M^</9S[U.?S \/Q^FP%XQRZ*BU#7W!_@RR%.5B<*E1XHIR[2:S RQ%!"IN->
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M"V 6?4VU5<KE8@K,E_!#W@LMXRJ95> .6D2?U,9;00F_!8;K 5[NG:CD&=B
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MT0P',X&_P2;+<V?)XX;E ^/["6;$' $  P9(-XYC(_@SPJ''G!,7>:@[263
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M\H7-B2W>1?RC^VT"<&,!Y^T2_YFKHAM/&J/P*;WX^8FN)?38"O+>L%.$UN4
M6"3?-N@.=@!@(2':ELQ/:O^^)MLX/-\)]H]I[5 F.7:F,/3FN>NVO7;"Q:52
MY4D=N]==2:@Z]A?M\TY9V%^V"UF+0Z[]4R1BW?WLWF8*0OXN$(6 1%@G0_D/
MRCX9[U9K]:56;;OR-Y?+EW#I3)K9[PRW@O4I.V"]S/6#32;,7PQ#6ZZE._-+
MEO=)F/2&13AH[[ 7VHQK=[>!'4:_W-91?/"V=Q.S90@WG'.!]B)44&4BYPW#
M]5QS(^)_CE_8#J'A<L<W=Y;]HE"L<%0A\[$"A36J%,MH4?QH_%V%>'CN(/O8
MYOPHAZ51;\8P9N;W[51QIC[NT\&(Z?4K@#-QYIC-)+,JM@-,G1&>;(;S0?R(
MJ38>A! QT@FZC^YR&I7DS+?!4>D/NIL0=CG4QT72LEQ?(.EYK_\\25J21]D6
MIR8/0=-2A;I09=(-]5X!O*]9,%E$+)AL#N"Y.G.5 C&8;#[56IMX3N=8U\U%
M*5KZ@,=T((:2IH[RG,:_Y+^8\#0HXYDC#P'>_L9_M!%._%Q.3#D3/_ $[ZKN
M&UQGX#3"^<PVZ<P+;?@'5)1V;$SL.Q1PQX9',7^.G6BE]T-;_5,6JGL#M!T#
M"LF8HE:@;1T'MVD>)GAX)_+-"2;X6\;5XH&."Z(=,G%#/_Q Q!PQ!_?5<),"
ME@"@^N&B-3"  HXM:YO^T&FWNNH;.IXQX[@;QIUY9?=M/L3'-.RX+H#<DIIY
MN.]ITUH$T>@//$JA[XV:/K?LT/#MX+M:*W4FB=Z!=3"7L:-V^ */7H1T_&+9
MTPGI\8AB"F [C$1*!/?;'TVY&R<VH .Q&2HV,G\#=80E,4+:Q;O#_5:Q#\SN
MN(L'BS2(9@[#R7#_?RD"@NN0*Q4=_HP8G7+*![# SDXAA;6H([.0%=.#5^$U
M\WW<P!)!PU9G\$%@^@M:?.U<^T*A^#GCJF+0+Q(AGV?CJ0HA4*@%U^5E=@-F
M*PQR? 71#96V0-&1?@'JGCXM'.M?(GKTOGI=O?S4V@V=BVR.IOC<%<)ZP\L<
MP*9%5$7ET=ZPO=Q%+YN_V@)K>=4O2!T3U6\[9A%T6!#<C.5K-_Y7L%+AJF[)
M.2NXV"T9K]UWNQT-ES73+,)O8S-U:Z.+FKF3?([PV9NQ=G0?/ YNO9VKJ>2#
M>>D7P.'WW%$WNE9))!EV^Q=KZ%$<U(J2J]?M[8I<%[VU[+-C<MWBT6+LA^U/
M&X:BW?M'[IMVH.54Q&%N(QYI?]2]6,F, GR$7OZH0(\A1[C5-,46X3QSEWL?
MR_!M8OMB%8POS ^[*Y;"^%ODS+L=$8Q591T(?@2?H%^V%@)R'*[@2F1=SSVL
MQ$<*G#T_P#N/T0QB'JTX*P:0!Y !\(A6T!Z 2C/X[]_LT.%87 DB*-N"J(N>
MBS$CQ "O8HNPD(?:PR)\L'T(E=<K)60H(0B5TTR$PBK%1,( XVRFG+K=P66W
MM]_5J#"5MR-BIW^Y?RK&OY$EK8KR4 ,@4,6(-^B>']H\=H[:/':.V3P6]A<K
MK#36.XU;ZN:+P[DK)^BG%"1Z!_51-=V3:L9,:SV3S4.F0W@EB4TXQD6(+<+N
M%H%.494J"ER1=^;C=3-<#<MS'#R+%Q<9VS(#H_#_@B/'/\:PY/70WCKOTM-)
MUP4[VNH/UE!M'7A5I]76*;TLK?JMX?EA:;6- [T-Q9[D-F?)UFMU#T6V?63X
MMJ!OV7F]"JW 'BS5SA?@R?:I0O3/]X97)OH.HE1VFLA;-'+GZUR#\OF_Q.B]
M/ EX0LQ>H478=:!X<.ZON-+95PI[YWR_D\1UA1A_;QFK SA!VRQ%)1RA$G<Y
MRS4$6^YM5F@1]I"\VK]..J0W2F_CH5I%33"R]$P#S]12XJH0U=3#91X^4G,4
M 5YDBO"W)%=DB&01GA=^S\S)PEM/3*OAF.EG<\X2#KN7:U-A6R?!%B%(2.5-
MIW8HJU/B"3N/JLN(P]'4N\OQ\#2U\:]5=RZ20?"4FSY$,L(Q7KYXX$BLU\;(
M<ZQE=R\N6\9*(E;U"D!\[GW"DH)DIH:)*+843I@KZY^)ZU58P8@J#(/12XJ4
MB7:&LN)18O L'IB^/4J*0AG]<DL5EEB/L-!UG'6E$E=<\5L!Z[KZBX?G)>,*
M[+-CB"*;VC4:47Z/UA\K8!JKKCB^.!-?)Q31ZMF*FQ? BY&KRA6.50,_0];E
MBFMOJ>L^>FU9K-4Z3JHT_AG9,U'P3;N2,L?*<D8TPWLN/PR'G4:[W18U4^%1
M"VO.X0QJ=#(Q\4!R'BR(%\M)!I^XBJT@EBA'2B9'7%</S FW(H=GJ!<(XHEA
MLT-.(W!\1E2C;"JO?MNJ^!<!^,-Y&]$P.,XCB @KUZ1;4G)>+/W7 "(Z2%=?
MEL,':TAE$%?AEP8['Q<?1\!ZY RTP<P+[#!>IC%Y;;A&8,_"S#5.NHR4#)VY
MZXDW<1P'$=<J%T8!U1.6$(R9B:D!*MOW"(94%AL6!1(AVC9\6>^UT_Z1?$GF
MNM&4+H@1XJXE.LXLHI2[$L@G033%25P/H!HSK':+RM4S14&Q1IK5N$T*UN=A
MY+OK:1W/3H4"\9H9EJW#Z<:<T+AHG2>EC7W[SL8*HZ87A.K+9'B-B;,38]'<
M,*E?K0D7+ ?32L53:56Z84<FHM,M//TJ"U 93;=Y4?'B2C"7G?+TA5[@6_QV
MJU[Z[+6,3DI!(E\LJ#=: 6+\6 PX2-$/_=XY:07XVK&Q8.<=WL4+-:G&NM,-
M*;U4=UP)'NJ43K_1[W=):H0BH7+%O8&\?-DR/KK)+<N5Q'"%FY$AR1K$N]LC
MWAE(K;X$L_-&;QUBB?9>OL0A9064^7$VQ*^W/7[=X?E*_"X;_<$J_*[&(3&C
M'0BE'$+4 * U<OGS 5U'<.]EI6!4=J#[1%UMTDRQ$HF;4)RL\&O>M"Q3C"Z*
ML'2!%*I U%]/52C(:P-P=7MM#/OM!F*&T._29R5P97$9HB(^@]\U#"N*JQ]C
M 6%9GS0I(4JNE6*FK!>0MK-D0A);L6"!&-8ZQ^8&LK%;/([HGK!T%B5!B?UG
MHO>NJ/6;IJRG%4]#_HPMORKL*AP&'#W^:<HAV+'(V(&K@-W0L,N!]!32LI;V
M&TKGZP*C[,O9_Q7<ETZGL5H'2LV^D<<OM/N9]/;)[0'76[E#B2LR K5%2QK8
M@!#SR84-EOOREVWA!!=WWW,!BQWX&W MR;0-B0A#:G% 3= SE04:$$=TQ=RK
MQGW0^_3H1:NWJ2"P]_#OJ6I*E"009:Y4$(-"%0MR1AVDU-:B^4P5^L9U$(6?
M>Y)M=@*M"F'F5+2-BPN6C&QG3G4)K#6/E:&Q 41 .6Q0,E$ 4 4O7Z>P.<SZ
M';9_@^1E$Y.:/YU=@4?*FZ2/04S=.]YT^0,ZHV<)MX<D)C3V3V<FJ9TS8X35
MO'TL-@3>DN/,F(6+$O^-E>/5W]NB]&!;X>2U,6S_")]ANJ8<]+71GCU*_-!A
M"K#@]VNL.<??0# T SR"UT:7!@ .H(\.#P'L9 077F%.GN_AWXU>=,_/&_*_
M+S.$I*F;#WSTW8;9\9<@]+WOO"FA34##EBNB3'GL$[@VEOI8_%U.K7Z/URGT
MXT^8TT>JNKCY@':>5F/DA:$WC4DL8;CH#!$*\#5#+/.BV$(\_$8N75/\*1 &
MG=EHOS2ZLT>#FL3L):LK6.D-MI* ^+6)7 NPM[JS+/,VQ9<$$]90--Z3!MAY
MNG''H.JJ:<%JA):VM*N7<_5J2LF+EQ/6,%?/I";4><GU'GPV^^E,_+N4MXZ$
MF\YVK=<WF#952_) ,*CR9:L9KN":*P:\W)0!BVT5)""]TC1=.3HO7\^W^XUN
M;RCT_,[]^JV4!OJWY2F+PF18H3N>,G^1X+^4A:$Q?G@282_:13'S45#WBUIO
MV-N?Q#]A%:NF '1'KS(*X'+O"F"1#(=6 +N$:%>2NVMF$>O=7Z/O#R*YQ<E?
MNN3F^A='9,^[[?TZ_P<W\D4B@C)LR%,5P<9P'\#.GZ^Q#?MW[,NS_:MAO^R7
M;>?2\PVZN1-.;<MR^),TZQ-5U$;JZ!O6U8W3ONE\;^UUE&/AER=\3\>+&5RN
ML7)'ZL4\10>59IPW4DR[UN*[U%:=P1IU]0E//*E*TSZ7>^2B&[O80JY]J]JW
MVI$.>S'88PZE6F))8[Q<@?T^]&-_A8"5Y[CE0G$DWMR7[)DA/$BT;^>NM&4L
M1T\">(;E1:.#.NVEIZ,WQ_\03F/WXG *]ZER7L"3?$4G)W:](;G/6S@5F&L7
M6Z>%VOK\PPY"YAN?;)-.*ZZZ*:0^[N=\;,HDM%N=6?*=+[:$Y9=%3LMF3DXO
M8"O. N*I4$F/C[+!"MF7*Y>!\,SIA-=;&^3C;IXZ72W>29VGIILEZ+2'>(Y4
M[VV#)P;52>L9"T6+@>\@Z\V)]T!36"QDQH@[GGM'1T<]"=3A._T\=4U^2VXA
M9%= .^))]UE&2" Z\XW==YPHL.]Y P]$.18H/KPZ( :0_=BR!$4ZIG]:)/&+
MLV_<G+BH-F&]\3@5G4LZ>YE'?'$M*Q)GJ<7E%>[0[9VIYW SP@.BELWN7#PR
M;P;TM!/AU18\\0FOV]1K#<9L&*,H%#=;["FU#L)#Q9X[MA$ SY\WY!E4U?S)
MYZ)]I\D79L"#JN%\1ERJS2;8&6\MF73X61TI?9@ K,;(\3R\9N8S^I7NN<GO
M9@X+IJQA!-RG\Y'6*YA$G+$=$>,3L0+@=&#K5J(1TXN'Y"%^0,SNZ)YS *97
MK%@0'\46?UMJT0C7W!6)>T0AH>);I*YE)_V/CH/_DSY0S+:4JJ'K8G0$+F9J
MO&V%U*#SY^#+JD=];\X<T8G,-30%A YPP&!)-!V$9-8>2:CM>U9D@HSHS\*B
M!9$Y$4><Z2RIQ<<D?Y+;%^15G*$7 ,WI\+H\+N_C>4IQQZOW(Z[8^8]X*4\>
M7XUFGAA0I#?HNF0T!>G!9F9&C(<8/7DF01RHH<XO2Z*H0_J@WR,SN528O(Q"
MD@Q FCDYPQV)2X$&G2:?RSLU,^8K*HOSX0Y?Y%I%1Q)GC4,9L,0CQ2($D;I]
M<-[^46"5W!C IW%N#;@T5N+6(5T,</%.5V9N0+6Y\!VU7$+4_7D3?I<?P<,+
M;#S;'-J.P .O82)<+^R7](6%TS!R-BT\)VM/B799,86QP==45QH69G<] U4G
M#,T? 1&@#BB0%[:< P>8&"\Z[7#R$D]?PYK[ ?/GBKCBLB9>$,<2$J1IEE.>
M&K/AS4F)XO&;QY@KLW+/LD?6E=P1_G@^'$SCQ(;/,4TP"E:2(=K(Z3?P:#\D
M83N\E&-%\:KB@#B2&!*_4=.K>>V 5)AV&8+F8D[@X822Q85IT_%PXS/W4I]0
MBSXN;EZ@UI/J9FI;S3%JA+%]%_E\L<?=D:\M$2JUP#.\820T!>HAUX-Q);%C
MVRDRP" >/*O%4(EPDQ/%4//B$/":T@Z\97Q>,R"!)7P43J]3WT5PH(2FDJ-;
M<OC4X.2)D)E7#)18>Z$=R8,C_1_S7".YO@5D_,ZU= [.CG=F %(8V.(C4*])
M(97 <RRA9G48A,>';\;W.-:"3'9!WO/'E!+S29FXJ%R$'8D)K*YB)(AM=6NF
MHBQ)W)C5.2_82VPXBE? 7?UVC#+@\L8Y"JY6\R!Y@]_3\U*@+?C3\>2]/+)0
M2L?;_V8QXR_H>+&L+T9@+0BZ@.Z5@X'QQ*WQ@&805]_QE] 3=0KD-Z-Y[+W'
M[K?>H1,TCG [60B.M\OGP5_HNX8"&TR+'Q"" ! R8;AH^83W>D+L0-=+T<^S
MXG@U7BT'188%$#6@$V;9   2DH]!0M#:6S:(7>B0Y*JH0Q<\E'M/<<,")^2X
M5RTC%RY4?S8Q0T:PB8UI3'F9+^M*Y+I1.,J,F_88[ZFC)]0R/HZ%*[KD'<NC
M$"Z>27J=Z5$RU1CB>@CBQJ!H)0RRTB2#"ZN"*ADODDJ/Q^+,PEM).#@((+)>
M;"\L'L#:BQHE/%%0=-?>I,6)QSM9UL0'IZX]UOP+BWKKACZX]<1L !$#;Q3]
MT/$8UA _85]>Y%4.4:PWI\?&#"+X$")O!D\Y-I%5=()&/\;#MV;PKN>ZW!%W
M0D-X4MG:Q+&*HU/TGX5J@=%&JH*1LC;R O1B&HIR$XFJ)/@C+#*"UQ9I7LG%
M.6%(8F3U*4E2P+IAH1 "%T7&QY)U7B2CHYB.-A>AS_PO =AS+P@@(+LC"4<E
M+V*2<80':0)I)H^?M23G+*0MDM!K2;HJ)R<!"@'K!Y)6PP6;4?--P0:(>2G7
M[$'R350O?W"8DFBM[GD")SEL3B8XYDN\DPS633A9*NJB.Z-4O AM^FLMK8-.
M0.($,=L)E$=/5Z1%B+T0DK\ABZVI/B"FL!TC'Z,3,KISBB1=602/Q2(@'3.3
MZIM%Y#.J$Q#240!&%(7FQ%-L99X"8#$U6$8<O=T@;_5&S/WN1[/0).,%XNPY
M !_\)3R9AO'"T@:R[( >H";PIBB\X,VDNXP/<^UAB1/0&[53K&/HW91UI">U
MG^4Z1=G'P(PX#H<X6W M!>TVZB_AC0CQAS]!3F>\0;X\Z$3*18"B<(EGXH<P
MUK#=,89_DK<!"K&2H B\!Q<TW\2>*6ADL<4X'3"=@3I9YA;16"S #NY!)L$R
MIZH4%*B@WZTP>D,9@W$>WX'N&5.8 F/%=GBM8RF=%'.Q5H-2Q[!LE&O$9V('
M]I0\.G0^UBHTRAE[(G>,ML%D$<9OL<,/WG< IE/X0XF?(Y0<Z1) 2=Y/O[/O
M-6_E 4(WX :E'_%1"4R>=W*,NWC%]]L^V:'*_L4U!#IOC%^XBU71#LYRA;(7
M(Z[KSWMP)[PHT'T>H;Q5A4^IFCT?G!-,]B5!%0KR" ND\"#00S11"U+SEIR8
M:HWX!2H;%(@]#,V;:ZK7P.R$PM_#*FNXAP'!Q#\FP(<Q-C: ^X#9;N)IF?3T
MC9F'N@N#!OJJ@9$&,#_'_Y=:[CMW[(DG^!YUF(/>DH=._(PJD5+\ *_9I*E&
MPCY.J+P9/2I2Y<(M0_C2&6N: Q\SP3NCU+8,N< 8@4N*!E6O]"8'P_H^%*I(
MS1X'!3@4 12/:P<4O<2@J>@A%P)\<CT0EJC"*BDD:&F/\\BET5<!HXT-] ML
M*KV0)@NXXVAO*;GM6 B0\BM:J05%:)-%14]"\"4!07G^"</"+O'K!K,P#<TQ
MB$66!LE$OI1UI:C G-QJ0C*)-2/3G)C[?9N*XNKF&WLT/@ WN'>'+!+[!X1C
M$*:M5R\A@#L6X-(NE+ZM JJ!0G5XA@JA1* E9$X0-,P?$7@AEBVT@?$ TLY1
M_F2<DJ@9VH/!4E(X7" SIR2&Z(V0D,>%S/#L#.V0.CBI"J8D7 '_,X('*2$2
M",Z,"PKIL.GZ!/E/)D54=@DS'+]2D$HNS @$A=_K1P8HY+5@,E$0"D3VWK9D
MV2]D;P"=9#$^,!P#F7"\'O^%&OIOC(GW -/A[C:5D-,(H**$1B)PF'$ HP\J
M =&V;) 77Y0<9?JF7B!U4>*5)[($_D HZH:65J-7,=L!S7T*A/=DF&AUL6@S
M[KH?1\'FU*$9GF!A*BP$P\=E Q\I/WK/XU1+RT@.?!#?IK);\3"9+-DHKN<J
MDSPFAC_(I2SKQ*,,2#,OO 5Y9$,4]1&1+\[B.51A5^YI-V2A-K GP*WHD6CN
M:(5U^4>5IC$)TJKRT$<A\Z+6D.;L)8Y>.BDJ%%J2A#+C_0#P+"GI25&L/,ZC
MWDT5X(JS!Y(EQ8D5>8I&ANBPM* #&6FV<#[#,R;./'\X$PP0G4&)=X4\_PY&
M^K<*[C.IP?CYP XQO1)$5/'4#U*NYQ<@1(3I#I']0R4<@YUUYNY$.   TC.I
M9&<#E+:#A3#]J4/D%*&L/1T1I46EP71"#VE !Y(\<F'Q!5F>$#,AI,8MD?1(
M-DZ6C<-DM$_&1/I6)-'ZP0DA>*X\?A3;1=Q+0%>3B[*B\%HN_9-33O0H541-
M,X>F381UHBTL.IJ0R3 D:0T%+$$#*SN3CH5,9%!$C8OIS>;J<WSX"3>I'0=>
MP+UKF!P\/QA])C2?5#H%4?DV$<6PI1H,%CD_Q<TI9I!),=HFE]XJD[54N:[$
M9"1B^[$HB0 >SPC3237%V(UTMCF0U?4)<[5%GZ3F ,GX2(#:.I6U-&./?BQ*
M[,7[A3%?QUZ$KMRG[+M6FW@C6LBH1/<0,9<4YR74(1SID[2,_\?&[E="[C.G
M#<58W,V.IM@;=Z&G6$F/I"@#HQ9^$!?2D0;<#H@CXR0B@V\C8<9F'M W3M#3
M2<!\#DI\IR2VO I$=6Y0:"EMNNA&TNBYA5)7$QL"*3KS@='5%56.!2[/I5OL
MZU$8K.T\)'5IM7%9?@E+4DE8PWEI-DAK3+)1)Y"E74C2.8H7U#CB\N4&;4>*
MM)N!/Q\#^[5K.S^=A7Z$]07W"-!@<X \U2<:4\F*898T1,J!S'-OL6+\9^\+
M\_].[Q8@4F^A#4T[O=H+H^X7Y!PR[@!D_+DA(5<!X[\SK;J7@TO=48*KY+5-
M>Q\U>V<_G[<7.E\OGV'?".10O4P$<AJEKP/^8W[7J2* =X<7O8O5@'_,])LJ
M%^@B[-+K],^[I0#]UO8PX&B GV>VEK=,VP27WT$UT@5;3%.^QXL8H"&I)QI(
M)&C/:U'FN5B'^.Y@T.]WJX[W^>[Q/K\$8E8=[\'.\=Z:Q5TOL4$-0W;%65"1
M;]#O 5D27L^P ;H@0RR*&Z,P@'A55'T.5_A,#17-V.#*SU=0L;!%[BPHVLO+
MP7"9Z*^R;\=(D'RW*4V0_OFPLQ5!)%HZ+INH[QOMO9(,CS;%_G'8D1UZ,@[R
M81JRN():A5F?M-2MRG^_IP/.J)4\EYQY5%7:@&L5%5*B,^RN\W\J2(GS$BC1
M/>]==HZ.$H,R*+$'"=\])2Y*H,3V>F+F\PF>G;WGZ*'@]8@7G[P@>-DP/G/:
M'O_&'AO&51CZ]B@*U>$WX6CDD"$93HP&@]R,<6=VL4>KZE):Q 8U.YW^Q0*"
MRR:K G[9+JSK\+L<M"^/";_S&+_S(O@-NX/>QNB]C[O)J./D\4UGO3%1L(B'
M*]"U/?=F_$7EL)^&0@KVO/'W!?9FG-4;9FW%(6'?3.H'W<$FL+^E>Y\!L!6S
M*"%-W([W=9N?/.;*IKITNVJN'42/E?H7'T_U?<4#!LL4_3L^"C_2 5-\E2:\
MI?ENW+_+"?']O.[EW:Y<-/ST>WH@TOD(XY5K*0AC  4HO^OCBV /P<6_\BQ$
M?S'0:[7;%UI#\Z*HQ.3%%W!;'T\0T>DT\1G/GR7C@*JA38CFE2DO.\//-[2Q
ME%96J*16DCF9*9Y'(QA-LDCFC$BOL;(:C 1BCD[*H^TJU5 4\BVI6A*=UNF0
M7L;U+AG+0C[7GGADC2=V<%KI<O:.CVW3#@]-LJ]<7%1XSWS<, Y.5(8VLV7'
MA]]F?L8>\!-QC"&RDCM2$GJBLV15L9C2.-]45:2@C<GWR7/OFG3. @=H&+_@
M?;;5GLLU\^F\D5B)K?*DW?;EQ0+TRV:(814^%C4 G3E1D+AITFV+&X 6<]E6
M(OE15I!%-^8=E7SX(BYPK.'TS9VS K[7>7>I[[4,3MVQW<2/+4P48F<+)L/&
M!WC?)==K+84<_6+DR$*85AFZ<OC 3*XTX-.IA*,MDXUVK]M[*DW2TG2.TI2C
M"_+@222)>,0VU?DC.A2U"]1].NUMSB'"DE/(EF.[#VK.?OX5AIPX\Z5X+P4F
MS0FX=2);V@9AONZ33USC Q_EX3\A;9\]UV3!Y,;_@J?&F"/__I;<N=E=ZN#)
MH!P6[\U\ DQJ+?#T\2+_)(=O-WAGA3X0]3ILU[1GS$EUY=Z!*BA?_M?D?U8Y
M&,OUP9C3P5[,6GY*#NGA#CP>92:R+>(M7H)WM%>T%[9RD5*PKYE@W_ 78>&+
M02>S !LC(8]TJ@HVS7^(Z^PK&%"\^$&T#R=IP43VDH,OV./X9BP'O?&_XF%F
MXCOY53$VZ^9BF0&AP (M<;S%XR*?E";=KK@J;^R]P/L4+EH)-&U>B$N'6.5#
M7,^$B&+L^0_,MU8)P%40\#"X42]CHO%:?W4KHG<Z_4Y_F3"LF_$@6!59FD[G
MHI=U.S?'*L5@XBW:?5J+C;;P>3*^L95=.7SIX&YO$;8"%RT_GKX1Y]FOL*X)
MJJNU6&Q+Z17&(!YXKT _E=YKX=T&T/B=^)7MU,UY>]A;3>[%F0Z"32$UT[L\
M7Z,\-\4&/\<_O!<7O!JTQ02?Y!4/+&'.73ZV\05*G35'M*&9>@SM^UI"P ?U
MG9Q,'P,<7#4138/Y&DM_ .?8C@]H!W05X78 V<E3NA"/MOMK]-LN*?U5W;;,
M5$&3]6LW] K@PS6]E[+/7[4ZGYMG=SL%R+%BTFI@6FCA+P;G.\'T'9]Y@9T7
MFXGOI=7Q1.R_9=:]T\WJ@_S!=P=5(=\@2\'U0/DP@% +\GIN#H#),T\\ ],;
M9N&+A]X=3)OE!!?$JPR0-LM8=?H+RY@#4WSO$'VYE'[_*JL14<2<M@-?5+KJ
M7WA;T:#KBHNQ?SSTS5@?6(Y+PR:Z50T97W]<RR0_Y]4%6%NN(*D;L+MV-0]<
MU#0;>4Y>-S^:Z*(E]C9S+&EERS:(S=B;&;'#%X=5MG!#IN2,-Z.2\7BCHFTL
M(&&\P%O%6H,)PDQO@2-.R(D+X^<-4-'ZW0\L&:V=.#8>L%[/E&'M\7MF.[3[
MJ<I7B0XB\(9XU)N)XA^J)+>LB(KI7=^FRMWTG+B83J"*:NMX/3Y,]^*ARR6B
M_J"XYZ_5&0<:X.-O/;!K=&>9*AM[?CQQQHW#:[DA]NVP\.)T$"9-$@@&+'6!
M#5GPCGX%:H<O88'/7DQ>68J%B!^?=TS0\7PNZ_YPEQH&!%HI NHE084#DQ8"
M]-J#QEFRQL0B@45%"S<!91D, D+^B/4>41TD &2*'\0@J@I( D+XB8;6Z]3@
MR(UX9BP/H8HVI_@U0YVX0 Y5$[9B5J%[W4G'&E6!!*\O*;!QI\+DXBZ]0V7M
M5#6EW.+X*2A@F!0BN55I59<A_FCR65(W)TM<FZH?B*Y7DFY")N2#+2G],6>,
M(RS#(-$@@;6G4_ (J4X559!(+Q ]PE0M 5G"WYQP*Q(%Z,RXHX]6Q6$IDZR6
MPI8JJ)@J69#6'U0&3E:\B&L-WLO2)!HPPM1XJB"\J,"1+AJ*NDF6SB#:JAF+
MZ""L56<M:"\:)AX3_$1+U6B!5P(N:YS'C*#S7ZHVHT1'JY<BA&AA/JU& ]6,
M4&5Y$ [X[YC;H71O(MK:P!>%*E_2$2!90U$_MY4I^T.DT*#.UNA13;)4,2FJ
MPI&HB(>))IH"A268Q4_IY79D%6-I8FQ?(3-"+>W8LL4-0S),L=*O3P5'9 U'
M/%"-AD+P)SSD<.M.U=6(QX+%]V05>,\%2<GA/JHY(F\XII5;92W$54"5'J,@
M$#J#RE3T,S6=9,^O%,(I%@52Q7> L5:-_H/0.O)GTDDV*!6?-F=HU87@+9.X
M&!!1F"008$B'T=2UA0P>5)$Z5$UT1YA*3L5UZM*5'B7'8'G2>'X)4%+N3M7]
MEF6KN57=FF*Z7U?=JG3%_ ";&$=S26T73TCAP?H4*^J-S[ 8E.HYQ)DKJU+=
MRL)5_6X7*YG+^DET!@NK)'Y%C1:A[;%(ZCN7PP$5F&-35-36@F^,#^J^,3$]
MEMW^,P+\24FF(,2"5[F@9_T.4BQ:[2E-DJC(ERY7:'C2TB0*/ HCE79'%KWM
M9;3'_FE(?,1$]37(=5RT0E":X9*FPU)UJ<5TJ&'EA$@*87E9($NZRH>PV<?$
M:QBRP!%5GTX<(>\!J15[J9WVCTG=P>F(2L;?>\(V>@^B$QJVF#$=*H&9 EC>
MB0QSJ405T7,7*Z8-UG?BV+JFHT&12R,)W@)YA#X5MD25Q=5JB,43"N9(>K 1
MZM1'B]Q?V57O#NP@=N?:9)U>Q+&+)6LXI>%*0_)RH<B:ZDZ6S]6B*G_*453!
MGV@)1XN+ME9;?%D]WH3XS[68+[J6(0G0:T!G%T#]H2/"SM**C>Z]/? R'?DM
M)GZ@E0_+,JSD$-6Q072$F(C2?^D%!_]$>$"+3)*2]?0$#3D4DU(6AV TC:K/
MG]PSC@OL.<"13J;GF&*!^$A;K)1DLX[\J&!)7(ZHLQFZM=4-OY=I_27*%XO\
MNE1%U0W&0#71]0>C/)05JI>G*H"S!Q):BP<X@]AWL(/XXB!]L1!/DW61?0&U
M^J^R1P"932Q..<7CJG'XKU<A'(O<2O)N;H"J!:;2%%/$H'5!$HT)+%0-HHY>
M2MM4H1?;&L]%,#FIXV4Z,%E;<BMP;2EFW,T"-]1[L=A2T<NX/.!249+2HR)7
MG>HTE@0MT<PBL!?$ Y\*CYJ!T1(MF40TJ?^D%]D4'98"):5K@O\$-EL4;,>P
MQ.>Y+26JP@Y:4D(MNVJHH-L^DCNPF Y/T]OG4ZHKB3VQI6>7))O2 32158IN
MW*W#5,TZD-Q<R"O;F-XB-+?37ME" =)Q/I2--)BI2I=Q0(7M2*E+W(+@-[3X
MBIA)DDV@*?,2D@\#["@C2!L*MUSQ/O.Q.B]Y[MT5VFLAE;CHZ%26T] =<",J
MCX1:.#_I3O5RDW47J4_E7ZY]6SV8<3'B:HOX O6BU:N("+(UDL7!8KJB]:FH
M;\\L+)ZNU;<'?8G=(;BHPBH_2^Y+8%Q2)FH)Z*)T:ES%F%H(PK)0ADPQJ*@E
MILR8'$?6,I='OT4G'!H1WX8UL!IQKR=9-WCWP(O"O[+= #;JH4:G,]%+.^5
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M[R4RJX0U!L;U0BG(;_!M ;<TZSD04_-LAAX(F%C?]T:>SV13<>TA"2?X'4Q
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M(5P.A^D-JI53E MOSN'-!7@O^H-MX!6/->DY0P/^2@*O[Q5=34%L['^3/=P
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M1L=/[)>AGN4^'KQ'E<; 7."FUI19J#A9 ""CZ@.'62;#U>1T4YH.2I(6BG?
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M, %! X&'[Z8>D-^QOR..X82YU%\5/@ CH/:;>3Z-(YN#YA24%T*,;XTXT!,
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M_A_RBJKR!*&N68#K2!/R#5.5 @V!'4<!Y[J/@;YHS@T?G8O.+UQS@X.QU%F
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MN/Z!4DAI:DA!W%[7)2CY_H)04C=*A$B6@33O6*+3,#'ENICFH"F>&Z;?(QW
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M1L24A[(,/J] D!.\TQX]GN1@^13U";.JIE9.PV8-FVT1T'AU>6IA6Q6L>E5
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M](ZH #2\V/!BPXL-+VYD"]X\=GFKN&$=N_PA &U94'_Y;V(<!F//]RCV=D6
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M'Q[,CK_$213^(<XEM :TB1B'$0E&);&Q5J:G3SCK=SFU^EWO4\8,;7>=6E,
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MYR:.TYG1EN=BC++VK??@303<;+^Y2>4BMFSM"!4!9<&D(%( (3SK#-2[[>G
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M+3Z';=0;!N>H.IA44"+R%=[Q2Z8_'X.F@E3'3B&)S+3"1PE*[I22E<S5ES:
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M+;>_;^3-P'@_/UC>3P+K3:ZH,]9HAJ/7^9BK'< ^F9PC)L'CNV2MP^[%^>"
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MBI83D-G9!,[Z=>H?.-EEBD+<-"21S1<T%R+2:SM/!2;JU\\6^9RW> @T)D5
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MGGJE4)*_DM)7[$=PTS"S<>:<E>0K2P_\E&=+WB?H#!T)=#2_F=DC!V,L)N2
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M#(<=;9]6ZGE/QKN:._2"!_HD;?"T@=J>F*]&]9\BPC0"[_P^""-:X9@F>!W
MAVLQ*E+:';9T-5&L"+K,3G'+V/!YIIO]E*38J&FS.G\-/+&8SNS1V'P$SY^2
MLM (75%AT_=<B;3*W#@QM!>_? (O;=CO'0_FE$$S^C3;O@I4&D)ZL->S"!VH
M*Z!Q]%@7$RM?X=[P!7[\A86\KH2SJ[C$-B7#0>]KBMAE[/V2W'.$;O?4ERFX
M)H66TK@PA-P#'Z@%RZ&5/R24+U4:(!K*D-:T,:=MS-O@4'(?$Z=:])',I@K0
M"BGMC),\[)PG3%P+0?-@C5W*FE*QZQ.G!^\N (?Q1H@8;[?&F- S#1ZQ@BU;
M<CN12K:@]_D%N'74D_@NTE'(.7W<:B+3B* YV_ACSI!O=9F*/$T"E0P<C%$(
MN$]L-UN0B 9> R]>)&R2)#GZ%9D/8\489UG]%[KT\?0A%9-()=.%\-8H5['/
M%?.P(/6HR6K4*_WGFL2R9<N=WGO/KYWKMU[EFC=!F77,VM=5_P_,VI/B)!/2
M51K@I_/K=WSF>MKKGOPU\V+H@!(J@A365^PY&8<^YD]@FA)^=ZV>^G6&)LO'
MY7-^_2LHF#;JE4$+5<N-N UCW-!RZN""G'[&!,#:W(S8+E,3,?%N*M,PJ<YW
M*H()?&EI+9X 8(Z;'5G$LF@V9?J1MJI<H)1F""U.8?OMA:C68,UG7E9,\,0
MU\ HR.Z0%W=$(?SWD*2_4U>,,F"K':P5'FB'XB9)4\I6R/#]* FPOC=TF,"
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MGIRMHI+7YF=5QNSS">2UB"*@P,ZJ6TD6N_U=\FY'^G$5!JZI'\$GZ*[F.KT
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MN%:*Q]N<.32;#^;#F^$M8&&.#/-N.!W,Q^9M-YL*D;ARUV#NBG*//=")Z^4
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M[_*_ASCMM&A6WAB'SMM=BVU^]Z.E6/]1NB<76N&Y.QV@.<$?G^+TX OD%GZ
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M#*TJ]^P/IJ46_4NN[2UYHJW1N1/AC$TAXC4BL^&:/>-2M.=A16-G"1^URH/
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M?/.Q X&]S1]FY2?K^LK)B@?LI)3';S]<1NDKEN*=-GM4*?AM_%/E[_,^61L
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M_\M9@*8!3,5,- #*8W($T%2VC6U0\BJLX>CV(3V(\/-BA;)9]']E7E3Y= W
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MF=8V,$I$B:NK(,[HF1!JR_" ;\LL7%'PIQ!DF;#A8$N/S530-:!QC/"E5]_
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MHHFW=QO ;6C!Z3; Z3: [=GM=!O@=!M 'FU>_YW^\QCDZ+_^'U!+ P04
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M6CBSS88EMSE;_G'[&'*,76USL>U#;+^18QN@T :Z5F$\ZC7FD2E@]F3@@\G
MCAR%("DDCT@I2QK"7G %@@,VI*>D+-+H=BAE]#+Q8M%^R>H]_Z0[Q6*0ZBP8
M]:00EHPZ-K$7C>3F3<M&,JW]PE%S8;1X[L?2D:H/&?@'ER\?=12Z"TA2>[.
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M+#=Z-&P>D=HJ_TO8/2I$=J:_$=@*?8?%8,^'./*7J&SUX,,:K!>GH)XF'LK
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M^UF7_($=/7NREPZ!I$,>I"&._9#&>!T-> -78Z/6W=7=XH+X$V'4B#-%E#[
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M$>?L/(=Q,:30'C]@I=,("@ =!'@:O3@)*U"O)HS#[!0<*$X%7HH_Z%YZ?F+
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M9CRC!Y03=N'6!'YG@=5Y-!T:0LUQ4^QX$#<JA\7NFD4<L\]B%ONP\0(-G$#
M>!4B=YVUZRM3Q%1KJ *H3 .;,WT?;C<U&+Q:T4IA)?"?2!HLZ'BE[RP#R_K*
M6M*I?$T#0'<Q7.T/ 7NJ"/^5(1(:^%$@Z55:X'_4GYU]>:))1L6]>OR_9;N3
MU3N:T'649\5)=N*$C%530*Q:F_((H@M5XD%Q@1TH$!KEX#5?9XVTBD98;H/B
MHN\W]\4U3LN&1+$)-UPN4W$*[%/XPG^>V+,(ALD+7<A#QJ$A1")XT\94M&_C
M*=W=%1*(#9R#ZZI21?R]>U Y."(GW5A0.ZD.P:U"1DM,>/H6(U# ^SJ"A&^5
MV@G_=Y2W5M9N:$8YL!X!11A 6U-?:;4=Q%*-/Z>+TR#7MO'/9#&H_U6$JA5]
MIC$K+ZE<%II>KU@#H64(/\#^-@<6C2%3S#"VP8=HT%B*,>_WT@AKWTIRL=]+
M8MX1D]6>[-\&4>SW:FS&]7'#EZ[?C2^ 6&WXDNB9W_SP9L/7$\MX%5#-VK/R
M/6#)2[1ZL1V35&*C.20WC,L>K0\];S2J0?UT;FH8NI#9_=Q=.L@UVD3069V3
M BE=1J'T_(K^HSW4&X_&PWMGS!;2H-LE>^8-:&Z+!\U/""V'$[.CN=\SS/R+
M]E"[_UYMI':TD3L8<8JC;]BF;X]?0^<JQ]RPWIUUC+N[+^YJW1Q_W]!8K- 6
MK\05(_1BLJ8Z)4!9]:(8JP/<2&-C&3/*/6I=@-$2+2?'.V@M K1F]+RIS'&P
MR5P@I!,V1MEM!1J$%OH?F=XU&W]'O^3O>*O^&!J:]-9L8Y/*VE3!2>X??TT3
MI3TH,4KC01FD#B0R&: Y)#29\3$P-LD-#PI.NC;.SR.\2AJG+8Y)).KUG16Q
M [65["M#Q3)>9YFOMD8^"7ND,'@H)<&DQ%,-)KQBWKQ#EN=H19-55MXV7 3U
MZS!:<3]1TKN;#22\2^MZX='11F<>=\@ \*2/%$8#P56R9"<ON3A-LW'K,Q_9
MTNB9$S[,2$A6E1T2)41H$L&\^C[HN=D/0@8;TG]=ZNKTVLPT>YB/=VQ#LSQ:
MGH@C[].7#W1S3],NW70R-<OD,F/));.*RBF- RV5E'K!>[JB:1B33^6'<Z=#
M;=\QBY^Z W^9> OU:GOS@7U+[UB5$(M3:&EV(E^9,@K6L-<(CL6^TC0J 4Q>
MM"S0*]=WU*RVQ7;N*D&4.TC7ZRB.N-[<ZU?FCF:V7=(ABE*GQ1:#Y=DH<Q:F
M290\9-<TK:O':+E(5J=1O.5M5<P96VI5OQA8:R2S@'XP:6;G4L<Y&TN!& AL
M\V(<4)RE7 @7!*S$BU<.Q;$2A-LC98%2CO"\F>.UQ1(;U=%M\@(--)ELY=-7
M6MO1V8[&KND[(6W'T[6DZ9Z6JXJ6":=E<:2.N.,Z*_CX/1]MK5@<AVGCTYE/
M\X " \[)P5RTX"#*+"/ A]4L(F#'!=#E2#@>EX?([-!73P04('Q#[GM8_7J
MJ9C%PT7FG+-PW>9=LSA:OJB6WX#2BK30DT8F9,<^^O(8S)\-&646U%STBV"J
MOM<03--!>GYU%'7\DOIP#S2T]2.@KY$HXR&_EBK& 87<$2DER:?JO]XL\;C!
M'C"XCP/?K,%]O:;+/'JFNX-W;\*<WE#Q2Q>3,9&8G.8?\7QTP9L1[^1Z1Y1C
MF*K3PBA38ZD\PCGJ.&-\.[0A8*SYH'A:G%]U7[[A-W,$P, ?P\=!)W2,L-J*
M*Z-;YW7,.7GDN.4"9TFXS(LW6H3,@(BC-V01;U2&)H@V<M?XQ>O8IHP--QKC
MP0U]DXIPP]9D72VF)=)C36=>/$# I&4,,J/#/@+);=K&'UW+9J4-7BD^NAGN
M.",*^-H *2T4YS<4/=DV<D1*,V+S1F5H)WHDJO\E30X@NT_%*]6HP -B^3Z6
M6.355@A1FVQY0UY:P@,2/-"B1:8W6IP@=AG:,$ONA[5I;$"#>-GMIUFR](FE
M]3!$_.%_E(("UC)<62#&/FP9C-O&+U!;_6#9I*4"L#T34.RXWB=0E=;5")^$
M^:[\SFKE;[R#8N@0B.=[!;$[.D9U'-,X(Q9U@LS(!$&K[W;J64=E"\8&)H5A
MTXE-!S#DUP#.,M[HN]\^PO3MV08558N\#B/U$,K^['9'U@=,14YQ)CQR>Z8.
M5?9-PYJ0 1](OY]Z>=X=!![Z<1"X*Z@/G(D9=>0]LJ.A4S9#C]+W*WI>Y8\T
M7:S^>]NY\-XB1*I,6,3!OHD)@EW7Z=013>%_;-B2F@V*3_V/04HL608:7=_:
M1Y.N-=N0(6^-9W'AA"5YE&RCY*&ZD9(EF7SHJ7@K!->J-GH,L.HDH%BWPWV,
M&=HD^[ SS%/07,!JB?GS3@HRDHVQ:Q2,(.',VH$YP@UL\P$$O<%Q;7#HFC Z
M6:\WF6Y5M':-$VC*6%+<P'@HP6)</,"@_#!6.US$4;ESO%:C<XL'3ZMM&QYO
MS7"#9:NE%%PPS[HPLGF*V0NEMS1]CI94?I/&)4N>:2;>)RU.TR^B7/.Y..[G
MDN5_H[F T4,2_8.NBH-'KIZD&6Q*GW7RF\;GV*@T12M1:_X)&ZR-A).UH[IE
M>9ND.YGVE65+<?;5S'%S4H*Q&?';"=93N&_%^>F^[_P98M\DZ;E-1KEN).[+
M847/KF4'Y]&;?(&"E52W/&*4U&CSXV G<^?*HH"N'Q3,[:I(V2:WZQ(]5@,
M\YY(DZO!Z#ENPX=<<S.O#D*J4GTTAOJ%."J(WJ)772HO@_'SEH\1J^>D!:37
MAJ&WKC#TUH=4C5V.7-,T8JOW+*T^$G+'JOP_J7/7PSN%<U_'>=+F'L2 3]?R
M649^Z@8%O]/HX5%L8 YYI1@^4)+N1<3)&5S/DS@Y+1>G& D:$3[1D%#:CDG&
MAII?8+[,\_=M5&R<E0\-Y4_KV-U].C:XMNVA1C^I:6UXDF@$NP]]*:L4_<-
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M^4_UR6V?A#:IU.=?MAF$,VW$ '>^*5)H#>E#!* -,X:&]GFDC:-*RZ6K7C
MRN_H;Y0?37B#!UR*PYSI20VQT;R>-/+KC&<X!MC ;NJ2T:#:IA_(SYR$HQS1
M>;E"7)4+ERS939'TKW&W4=G3#J RGGE&)PZ62\!.#22$F0EJR7ITZL$UW%:
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MTV'*$L9 E!&I9';GBF-@SU#R 0WN7YM*^4>$TY'=Q]%#<7M,5I]_>.\5-2T
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M50<,,S$RK QQBEG+CO"O"RJ#S=9W48IR5QSD5U]/ESV&Z=RO!8W"&,/K\W;
M&&*M&3"&MV;&>/$EVFPWTA,&I<]V#&\]&TW=AC5<3O8-Z\G6E0^JCSPY:D[>
M)PSP4W:AWA!K8[BG/Q\XHT0-3MFS&ISM9V/!V;2&"DZ)82TX>_)!]9$OX)3V
M"0/\E!UP-L5:X.SKSPE.Q@/Y2[T;Y^IS0M/L,7IJ;-IY$6^(L"3G/QSW_U"*
M]($\SLX>]$/MC"?(,,_HRW!C6V)@WPC;P3N:T'6TC/BXC=6:Y&FG.CMQ1V*0
M(<.A%Q"&F>P$CS'MFI,D:#,?HUOAC"''WP7M1[MCNH_(SA#96R+W+Z2C4(I]
M8U*J6W*;GTIS3H]<TER<;G^=LN=H15?O7CYF8C_M^WI=:+',H^?6>4D5C>T5
MJY_=1G%DB(&[0G]US=JU+HY8&@O$&?[+XLZ"2D/$AOU27[@3GS<T#( 0&]NY
M;>[#;33);NMY4A2C949[MW@0/BXQ7-R[<=W \/="BT3)#V2G2!9?(9H5J6P*
M.!]&LE(<DC'<@'7R0CM.P]XEYI3,8.\XP:!S@LWB]J_D_<75[[?D_<W5!_+^
M_')Q>7)^^2M9G-R=_U8<SO'G0XD"NB,[QO7YT* @.]QC:$M\BQ'E92$C8@3
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M@E"##L,?K E3!3ZKU@P->19.JJ)HV314Q+WB"+9BA2;\,O/MC8B(!48U>\S
MXQG,-C22V;34NQCV,4FK5/M7%J^BY.'7,$K$M[I*&A$YC3+^Z)3_,WDHOZ9E
MD8?EQA#OQKMQ% 7'-FR*V(C4QB$1$\5UL+="'K@^^3XN[C$0ZV"'5S6B,080
M;S'1"8O"8SU"8C/.MYHW8D,/PH4)-Z.GNR-Q]>;=S/N/.1P78* JT:+B@0<G
MXP*[NTO] 6?DZO5Z-'1[6J[9!>Y2P*AS<R$6*EQY?(2N"Z3I5@J0H#;GJL%U
M&FWH39C3#U0<E-?!LN)I]5/TGHYD3,<>9ADI-ZUCA$PC*#XDXE/RJ?Q\YK4
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M]@M!0(B0DDS?<RJ2];7D+%-9=PP\!Y%;[6@,YCJQNQ#R-'CC ,L8OL<ARX<
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MI,71G&0=1BEY%H^*XY399L.S429([F,&064+XJP2#)>X\TAJGYA31Z9OYG5
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M0_5KP[BJRIX,Y+-.5^X;V\ZUYUFVI:MS6$8#J_83&D 5+P08G;E,9U#GP!@
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M!K<"IR#I!9-. 7(D1BB^1!)[> TJ0ZSB!MC8L,+$U9*&E5\':QC6_AW _7A
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M!%2.C#3L*]6+:AZ02MY=7<XH?V ))5JR/<1++#E!P( ;)4PWQ"C]V"/@^!5
M0%<V66( X>8"J5VKJP=REH>Q/0",%P@HM(([X:\<BU:/_XG00N!P,:$Z/G\
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MV(3/?[.Z?VAUZ3#@3<-IKQ=ZW2D<ODC87&"/LKX6M>(.P6#XE-?U:J#9%97
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M40M6GAOF_<L!J,;+"PM01 _OEN:[Z[4,_W70W/M,?L_.,P]]:7'"]KCZF.N
M?SSVXNOALB?X";OH.X]4IW6>=!P]%:+'$SSG=\_W/"LJ2J'/:P:)#(])N4E2
M&:Z"8>K!KBI*%;DZ@QOJ/]RDOZ=?T@^WZ=_9/]]^ "=F%Y5GW)FAWZ/=?DO/
MV*BWO__MR]N?/_S0O(PJY(,'),+D?!992LD3C7+&(7E@ K.TW!0BJL;FQ(;2
ME'^%F5V??J!E(_AH:UQKF-*J'EI,I**X&[U<C3'*W ;X#!)PY:?/Z55JEG>S
M=^FW3!^QPUN*>UD;O]%S^4:9^NZ?WQO5K(=F;Q1Q75/MU*[3?Z1@7Z\?:!Y7
M]$J8W@X>S ;+;S0VV .3PZRQUT8C:3K8&A!W5\]]*[I=-S9<R6!75J^8!;1#
M%.<YCQM8H2HZ\P)E")#,]C6VE6283FF-"?>@&$19]<S$N*./K8MUDT:&+#&,
MR'%$#CPM4&D64RQ4^2VWX_SQUE\S6>[8.F]@BQ]R-$Q8)8 &'G8FP::LVFFA
M3;/08Z%MTD.,C]_W-"WL#S$Z=,:'&#5=T#"3E#+](49;L'N<J<FG>8A!Q>=%
MK7>O)Q<+C[1U%<4XTM:#8=M FV1A'FAKR9Q*0R<ZN>A(1-%-\Y.+,R+)7@)>
MG8\N?  ;^NBB(6K*HXN.6!38]AY=O 1@.A]9^  3LV YK(EI^3F)[N2*^X5"
M/+X#Z+%AJCBY=IA/W5T-4VQ?;$2.ML3N$-G%39[LHOQ)7>6.MJ1@$Q"IXZMH
M#U-A?@?WJXJ"W_06[,CVP&_N2N-C[SXS?T^=TKD:BKI@[B#'0)#"J1L^(L %
M3% C7(*C\9S\(4;,?)T7 R2Z*N >*/&L^#W &;&#R(@4%ZR<GSI6=,6X/; 2
MZ$;.IRC)(=&4EK]!O\=6 8@.YFS)>N[B#),A95\/"0EY"\= KDGB]2B;1GOY
M]CG+FE'RVSBT[._>N: [,$8 ZLG&-GVY^DSL(0Y]:=CC$B?"+?JE%Q.!&(@]
MNNX"!$10D-\44)O%QTX?IP:W7+"!BG>_94Q2F,LM)E(QX'K>A>NH73U]N!K<
M<,&&*W8IJ7=106,F ^(4?#F_A*I6]WRS^^[I,$0FJ5P^1GG\"Z][=97>\$C\
M%Y$3"+DL'04))Z!9F I9@&_]*M3I8#MFP68X6!,+7V##V6NFI<JC(3@_RGB8
MIB#WHD1GDBZC_FY E<BF &%/.2Y46:VJ70&^Q>*T&Z^(79"I3:O7JB3>FSL@
M(TW6I,$;SGZ;XU16)1=P1GZI55X((5(*S\%\57\OE#YO_??S]</,"6]7$&Y^
MTUH!?H'>>$%_56@OU#UOA<8-_S+^U^M?L[1D(@OF7\)MLT]9SO=>UQQ^8C+'
M$6!;RD,0V)S2+TIA*B= *-A2]$"PPHI3.R ,9B1;D[1-+)+B^%Y<V!=A7FC\
MU[/9HQ?6F,J\7O91",.422.*82=W.D!CQ8AM92)!642*K1 \?Y&9B>"KCQ@'
MQB]BH6CGM?'C=YJODH*&C,69R/ -QPW+F,-E'YK18H)R!I-$]]Q'99J'YJAB
M]?RC<T9*XNO0FV(2R:4?$N?MU8]_ER5J_;S!.I/93:[O*F1'W@V'[-[)D)T<
MUPK9D5H(N3JEH-TBK )VZ&Y6LS!3 &]L6@N(X9E,<7+C,!S)ZUG_7Q4= 82G
MH.A+2',0.[[B\B%*MG(GR+=_7[/MEOT_#,':9%F(\MUK&8F:P\@:3&PQ.R_S
MN:+;7%/1%Y>$_09;L+C<QTH*$D%]+F;^DFTB'#1YKY<;1-'Y$+9L=_0^25.X
MU\*?2\M=7S&.FQ\_UPV;C<+Y&FY+8".9;P.IWE;<^)LMV)[,NZ>SF.1<E@1E
MAR=ED5H8]P2Y./('""12XA(Z')Z(0<'>^2W(HLRT#S2<G=5V\('F=UF #:'%
M7.>R+.?2LKR:A2G- O8^<4%F88F[QG;^RB]Y5G3S1Z80A;UK[!6U!)/<,['%
M[AKU<PUND76B+_C_-NH[%]RE4R&['R'9@']2I4E9_*3298[K,YW*QG!(I[ -
M]@AV ]GK'JGH]EK[S19L,I:U,1R8Y%S&(M#&4&;E'$X"N<!7<X*.Z].S)PO9
M%FIF9[8M_!]A4%)Z#Y6E@F\+!^8ZEUUAVT)E%91[\6.2"K^C^.G5$*#C\?0,
M ?J] +;)E$>6S,W]C18,E&(JO7<!1D>W\O\'1GNG2&MYA\GS'Q,WG! ]3'V<
MSR^:PB@"\L I5!HT_5[2%"K<1NL2:@G1?)>D\MA+%+BEW_=)+CZ)>:=.T:I9
MT,]?%,8(1YGUR^[+D]82MG.C1_B'!2MB#O^H' ^8'G+UA]!Y:N :S,+'0!=B
MMOT':<DNT_@C+QY]E8HN4[ "W15E'JVZ?<!L2.0O8$;BH3(F M#TQD:83GG,
M>5RHH;R&LAA,&J/)'VK\S,<"5KC('-];6Z5,R)5>68A""YL?KLK4*5X:I3(9
MJL+6@T-]MGP#C/%B0 9"M'NM4=H+44I(6M1#)O52=,3H-6>6KZ.S8QD@JW<<
MXZS1RC-OHZ*X7O\S@NU,>9U_3>XWY;LH_5-^HE,(:SI5P-F<SJ>NJJD4O'J\
MMA*U15?M&%WP\; =D,]AP\!IS@A0J8^7HV/VR,E\7FJG?*LIC[J>JZ70J4"+
M6!W85BP*<L__<O&2X:FK+AP4GHB!IL]9E#)/[1M=53GSU>JV.9K5PG2X_#7&
MAWNHV1ASM"7!5)!.G\SH+V"8;&(D!AZ:&"U&J8S??^;PCMHJ-$:J-,=01&"@
MX9EQ4VD^:#M_N6C3&&Q,M&&> ^14=B/^1.G5FO^9Q+>/V>\TRHOK_$N6=Q%K
M0Z).!(Q(?"*M!@+0SP;,96HCKZ8LM&7@>6B_*HN2:1K$8_=YDJZ2?;0E=Q$3
M*5HSRE[T)((.>4HB]$4BR5I\PAZ6CQGO*5_ OF"702<[<<0 9PKK-5V5T&H>
MCA3F/D2PP5_FAH].P-> NH[Z&DN: .XXIPL6PGR!#N<,!X1^$@B5HPD;3GY7
M" 6*T\6A[N0A ! ]*\4;2D&L$F\AT1>.YRTXCAG,TX6CKB)\ #@&]VU T.TF
M2J]3"J+?5>5G6A3PB9J,D;]CSF;0!S)A@ZZ>XT*G\96,YV&GQX9L)_"IN!M5
M,L$D2RDW%N2N*LF60LX0?'RP(<_*V;( _Z"EL0.BB?$9YSALD$QG-)-.!G3H
MS"<00AL'';\OM1HQ)MP%Y&KTN5:CVC-\518KSW$:;0GA89I)#NUUFL\BA,X,
M>J?F2\^KSEBYM]/H#*(;_*DJJYR^CXJ-3#DNKM<0961_0:ZQYB#&DDK^<L94
M'@;!4 ;:<FDI3Z?I5FPNQ&@"P]75(GYVSZ/JDF0Q871;K&3N+[*MH88<E$+:
M"9P&HGA+E*50!)R>O^)4]S:GPBGB.O&!WI57*6/-=_)7*0,;+8YRA@<'J2QA
MS2"?O.!>EMAABD$IV@Q@/5$CQ!#ML@IRKM8D9N-)4A.P_Q44$$I@CU6,H=A0
M6BXA!##RRC/3%]3)^.T=7^?X#G +@B*<?/)!]O;X@9QQ ,OAZ1E1SY\W)G1I
MX(Z@\%NM]7PQ[[8.2[$'!Z18L(W#_TK+4A"VO6#/V"B(628G 1/-<NH*DPG2
MVKY0*#%BF-36'CR2TJ8&!\@S$JRQ%U,C:;9)1@WBQN*:-&[11'=958H"H-Q+
MJJ(MV3,T)@6/V_,].7N\S=+[-W!]DF1WV^2>TYZ1QTVRVC!VJVT5TX+<97F>
M/3)]*DB5QC1G=&E6L@=[Z=DVA1SX%/R6G-S[S[QZ&V)O),'I&"%FV4V";BRW
MJ<D]*+R#9FNVQ;@#>RQ34XQ<:.:<*ZPL<S1M<14F/_/ /WQV9EN6.[K&,C-/
M$EV6.9FVZ JV"7\?Y?D36WXNN8MW"4?$RI]Y5Y7O*%MFZ*<D9?M%-NA]5APU
M<<1BU[NQ=V&'YJ;;"P\;+'">CYGG[\A>'X 0^09U[ '.ANXX%_:8D>0T)FO%
MC[DYA0CK';PF8+*HP(0'N'OW(7X &]JPV'/NW]JXSG!F'0P0:G&?2$CMZPO?
M*$Y$L"*<5QW4X6HHV)&:'^$,7U5-BZ/EZAIF7,IM!G:.:59&6[/XE?ML0FH<
M<VYOX3NHO3=?LQKI>\,+W*N*:=&S7!5#]+TOXS@!7R_:@ICM39V[<5.GAW:T
MU()"_H)&%!XVPX _MA]L+E*G^J8<AC-V\^0>J)OZSL-W-.[DZT:U.&X!:FL!
M*50SN[0V@,J<WGA;DPV(E;(:RPF/7A0/TD*6)VZ9'W@8R?VZ;5TN&#)=#Z-/
M%7P:5PT??7X.EZ$0O&"?A4!/#)ZW,'AD]AKV]%0QJ/%E\#&(' W\0-=1M2T_
MT_MH>[GB1<ZX@]03Z1L;VHCBZ8=Z;EATC$-$WT9D#>TT!DD[S=YEY"RE*UH4
M4?[$/V?>QCT_$(P%)^6&;'EPO8ZGKZ(*JL/?/9$MB"+_JN)[OC,Y@UN#>RIN
M&/'2K3F-2IJRP6)DM!)'B=%]!,E"LDTA+QJXES>%>"!OE3U0YA0O(1@WBK_,
M#B?'NPX=57-',<PY(+S1 EMC0ER!K0)2<LP9X:.(&"8C4J>#HH'XD"^,_.,Z
M0]SQ_ L32:Y@@B[82<J[8'=,&YBSC@V3OZXPFF#QN)F4IO-T(#<0+_&%'&:<
M0P185+'Y?T!FR_MHGT#PCT8%K4\XN]$.6SH5\S"G\W'>3:6@QS\L!6L]>2L^
M%[<'SX2Y'B(]:26&,^UCXQM>B,@LYEV0EY9=; ^JS.-]=WQ_4Q;U#L!.YE1H
MQHF'V$I$P3'$1N1)6-TJ26!9DA!.<\A0>0EHU85+@L+5,W1B(PHQ@&(K%@6T
M$$RIT2IML !MQ_"^!+#JXBI!P8K;"4<&;Z[77VD!!;69@PI1G2B)K]-K>:P
M!T[7ZX__KI)]CVODQ^30-\>)B5^'$@>1Z-5A?&8QT-7$E6DG_D/50Y+3LLK3
M^N28_8]0>QA5K#8TKF2OYXCDM<A.?)7P5CWRK K.G<$UJT7,7>[%#\<9%JJ.
M&JXX\&OT87&>S2RJA=43R$,\OE*)#D*-,]L#N3@$@\-9IAJ*!<]Z@G$UEY>M
M&?I>1+.HAF=-%V>YB!5=O.: KR#G707IKB!20?1KQ\M6$%T1EYD4!-%#[?6"
MKW;[JJ3Q99I6T5;E27V-RJZZN1&K'BR6Q#X]+:Q$87N@3M*U[2WLF37S]/F(
M0V9^SILXIKK8WLP.HR.\,M^7WNF&8<6G;HGA('U2A./T&W(2BX=MZ#S4'\HC
MDHX(PD,6/)"^+%CKFA!-A&O/=D36\A![$CG)QD,W\]JNNI9Z44' J9&LZU<T
M$9(#N5TRU^N6YKL!_ZIG5(\CU1J%I'8-GB%=HV,Q)IK4I5*MA.%(,ME1<D?+
M1TI3DA1%Q0\GX6[R+BK%W60V2N/ZG#$GB=RDOZ=?T@^WZ=_9/]]^(*(0Q)GL
M4QSM]EMZ1GZX>?O[W[Z\_?G##X<J*06/VK$_LQS6H#74WV*R5+5,Q@%*,.^R
MM-P49WQ*Y29A0RGTU7XJ%N1W]<&N1W\U&-'K:8.@3R&/^(7!,KH3U,/? <5'
M;HW*Z(8!SQT;!NZ('3CP'(P.XS">1(\0!XB<'R B+%=Y M P6-_MH!'H*.]3
ME.2_1=N*MJ,TM]D- ]D&_(G4Y##/A4W/<9X=&Z3(JHW0D$=Z#O,P":]:LVT$
M678R<W'->) '8#)X0@<7SB13Y@DL\K3.":@]05=7T.BCKC8<^^*N]C.:27_0
MS^U<)A!"<X[.[H !X1R.C^S8&[QIZ,H"C^_F4A6#([RI=07O&,]6<IB#/)=9
MA-"8H\.\QD)CO+J\:HS!F=[4&H/HKGZ)"@9L[A-_3M)#@*NWAJC98/D[C0WV
MT/EAUMANI)$TG0(;$'<RO;IY\RHR!<_V45XF=.ZXCR$,,MN7U5:P83JE1B;<
M@R(-Q>$R$^..,>8\B4$R3@3#%E=P$1M6&E<'"U?';HM/S"#)XJOTGU#Y]_V&
MO6.V*%P_ILPJ;)+]IRS_MJ>K9)W0^+!J?-MDU3:^7JVJKI5&XG:((/AQ\_/M
M?&0'B"<@3&? U?/FSI:2ULG"7AQR)*DL*KWB;/D1@V(L4X4+Q;P9@R@X>Z8/
MC/_\80844&?HR#IR"WT8-[Q#__G-JWE8D0B,>034N;?U42*&EKTJF09$2]4R
M1"_@-OK^OBJ+RS3^O^RNN%R5UVL8(^9UE;+'D&!PE:ZR'65_?/R^IVE!W]&4
MKI/N\0$*+_F;>_+RL$)>DK%7?XS)Z.R0/V]U@Y49G80/(V7TG5 QD/QX)X;^
MQ.U0SCS9J*ARX?SS8LRR&"70@"E0)HR9-/B()Q7MJQQ2(W@ @\V!P(1Y2@),
M&>IW ">8]<R> @[T,V0$MNV7%UMEO1#F-J=NHO@'*+,(II7,-QC4E#/ROM8S
M& CLH+L6UU_XX*/27\GTIU?5Z@'0$G7+[U##6SS>R0;*5()IV#EL>>-*%(]*
MTO9*%A4%G?D 8UD:HSG*6(;&(!YJ?%RO*8/$PT$<R/Y*X44EVX1[>,RCWT4I
M<X ^)&QT3MDK[#8N\64C?V5W-AX6Q%4HMM?L.0^=X?!BR\L60<HM& U9DRBN
MQ]0'+E3):'K4W!6&M3QFGQ1ELB)K&M,\VI*"_085P^?3T?!R$T$1QA3J/S./
M?!LEJ2C'N%<S;(B?^W#'&_09'@#;9LJ5H[)0?C.:21=1O&3?"8300N8;U^1-
MEY=?O6BS.",W?8KRJB<:#WA.1?'S>WTDX[F\OK,(H2XBF>=5"0;>^W*4 -&5
MO4H?X,I_7K )0$FJ7YCS\#DKNJ[JV##YV^B'>2BMCBFV*SDB1Z=U@V2ML*D8
M]T-!H-HU^7'+!OU$<O;&[]/D/Y07ON!%EJ(M534O2O#V5/.8@A35W;\8:G@J
M#Y,&7V1F=VX4&)GY2VPKF(Y"*= PQT!X0W&7Q@2X(.TMW-&5CXE\3G[A.(,A
M,P?V,%"B<49\8.+G3 QQQG,6QJ2X@.6\"992@@7,T?-'B6:U]D%)H,M;*G)5
MGP<?IUF-C^VYAM4S%BG]_8ASR M5.F$FF>S]M#W)2RI%XG <><BH.+3"$/4/
M>;$:R&?/Z0--*T:4Q51F9.RW$;AVVV27B"\':_FA<+52,16X:<1KLO6ZH"4$
M:U+V3\;FQ.AY[7@&SA5TBUMG^6.4QW/';<S@V),//X@:?<[[$5E?8KN&=TB\
MHU^ TDIQ1OK15:8>>)\2F SN'+FC"3$!YX,\/&)KS"4<'14WT R'GVE\2K[3
M6'S8 :4=4=W]R(S(J\&'B0CL%<)*JK[KAS$3M7^3756C+7_;,JX/5YW$'_#Y
M8\2W]]UT%WY(2**RS).[JN3+ (->+ X5^5]TM\]R6&<:81>1);,7\^+G 6N8
MF> V]U)@"<G,%3#=!B,F](=6(^;2)M$"I,9)-N+\\<^;*37 +)Z<D9L&,#F)
M?'+:N-0V6PH#3-\&3*9R,%LQV<CTAR<$K34F\K21J.W!% :)B#M@2.-@,A/1
M"5ON;3Y^WR<Y7TD_L"E\$@?>/1G'=H2-]&)30L^4*C,Q(1*'K20/94M9,+HX
M/.)-EE2J RP4*\ZGM8%E^^9M5(I&U75R _>0JG*3Y0E</.75SMZ___WW-U^^
MO/GP018Z6T#"KR7R,A],'"=/F?%H9DK92)T,]&@9N78B<>"N<FT%L)LD9Z2A
M"!]XBJVD>QFX'<B3#0E<_PQ8<UFXZ:YV<G'@>R[@VV.7F=&E;4-^IG+.7@9^
M![)60^(WM%,E(A??RNBH7+[I\"$'JC4<6P\;S"=QEH[E62E=E[S3MG+ )SI3
M@25X+O)!F3HV'"5(^J1=+XE$=6,V-B2'4!(EZZJL!*/F48,XNJ!IM"KE%GX;
M/<X=/S+&WY Z:S!BH,,-RD'-/9(0&.;AW*,>03X 'W*%Q- SP@>?'LQL?!U'
MG 7P:SH2 GLS/=)\T#;HN12G"3,;E\019M.X'Q:QG%Z"<1<D6.RFQ7Y"-\0C
M5G/, -$5T<5L3M@;L=E>:.%BK,(FNXD>*<%Q']HO\0G7]' 8]TV6&YU!@)V]
MA^*$NV!>RG11EUYY?N@;]%66&U1!@)V]Q^($NXDO\:J,H'=1D12?LKSNW VU
M>Z(M_497E5@%91Y1!^M!95A<_W60$?B6E?6,YK@X[#I)GPM:;C(["7^:&\=U
M(Z#!$CYPE Z?KD9'LD>BN=W=$XGV^^T39*YRV<:7E_EI]#ZG\+=\)"_&B#I!
M65HF:05\96YLEA9'V50BO['@Y828]#OXZ41%-/7CO6%_O>$7:XKZ]WL&%Z'=
M;8/%Q3<O5;2_%&<MSN;&G.-W6:*QF^QFMO/L)C=S5G>Z#Z6/WM7VX/+8'AP$
MG:F,X5>[@(#:4S ,X2^;.TUKVIOHSE.<W#RPW==E_*^JX![)@ _PYN #O*HZ
M @Q/0=41-Y:?DW]7"=O(/MUDVV3U=$N_E^\8]9\=$S$V3/ZJ^F$>IDG'%'N3
M-2)'9R$&R2X^),6*;1$@OLRV.M%J!3$"V"'L^6BN]%O%868G?_0E9^8OI*UF
M.@JE*<,< V$'Q6<=$^""&N8YUH_)'V( @1&$#YFY,P4&2C2.EP],_-R?(<YX
M'LR8%!>PG#? \OR!H5FF?8 1H/[,[6/6VQ)*^[Q3<:;Q'*&D0\TM5(V9KH"Q
M*@[M\1?OJB)):5$0)HKW#X?KZ7'RD,051-3A?OD>B@+OLI0^G?%2@*KY&F\9
MOJ=L-)S0\H3[@GE2Y8;'V"!D*)92N J2,&;[/%LG(M*64T:20M9%M=J0J!!7
MXMG\5.0.O.W]/J<KX8@!;]X.;B$U:HXQE!F\]OY"$O70;@6)#@]L,*(6H#GB
M; 7#1LD9PAXLI,N3V\L>*2YC]K81KXI_*YFIO2J*BL8?*M!(T4KBVR9B@+G)
MDP>VZ[F!HA,]K9V=:.7WMJ3U0+>5)&PS[")<IQOVO"Y^K3B6V.XEI8^DX"/A
MKP)8D83S8E8\SZK[#3/ G(6H,<([*L1<3*,!T\SVU0UPF2<.VIIJQ49IL8/L
M*1&/8NN=I*)AG:T1G(8((B*H9'^=,R((SX@D)37M2P*T9NV9!M%^>SQK<7@;
M/R?1:+AF6T3Q<-Q:_P@>-A\[<Q&^:5&MV79.@VK$#:I8JZ_7ERN1U47CNE9<
M1R$,1LK?8G"DASH.\,7VH,9%Z71MC)*G+*>UAQ35P^H*JG6B1\IVJ7.G<9B\
M]<SJ];059H!(J<<HWW"00G%1#&0X@NEMT]<^C#F4@SP5[&A\"'_P^/D'(\SQ
MO $#08X0.F]"J,\8G0J$- NV/X00%^-W>1;%CUD6WT1Y"47Z/M_T1HU'Q\GO
M.##. _5:KMB+\)@@'>2'Z2Z^0F$@_G;3:%?GD\I0\^$W(XKZC'S^Z\U?9EZ'
MQU]Y9O%VVCJ@)5$:,,(S%)905M]1"4XH8BOO,5#(YYN%1(EQT*)9=?W@XK?B
M#K*V6F\?:'Z7Z5?<44%.L#GO@PVW+R<%',U:ZP<<S%/9 EKQKJ F;K;;92G?
M@%^F\3^C/(^@1-Q=4>;1JGOR8$NFSG"-R7Q.TPR%X!VR60K4GKU9\;E0PV'9
M%@0BYL*O=2@:\H>BFONTSA8QF<?;[)SM&;*HC_SL1&+'GQI"1=RK3FN\2C]&
MJ\TWNH]R^/,?Z5&W=B\>G9B5)0^$S:.5Q%!Q+I=)C.TX[7DV7/.R%25;"4V7
M1XE)NMI6,=^D$LH8D62W8QLSB$L7BB>I&%,9O5Y(",T-GAD26OJWO5;LNAMB
MA[G,H2^H03PGZ>B:T@K\M99!>6Q3,ZAUI.9!@,E+UHB18.*T*H$3@+06B[E5
M\IH$NFJT IKM=2,Z4HK.<K&8L\QY%60D5#JM@@39]K6D'#6#'!EVM*WK#D/9
MQK69HB?J#LL9WZSUD&F]M[:6%7#KO4B*4F3DUCK*ER^EJ6PS]Z@V<UE.\N1^
M(RJ[UXF^'9=P"8[>*'".=G?ZEZS;S+4ICC=O?1P#X1$YC- OP 6)G3!!V_.9
MNPD@ D9&=_SV(/%L%3G &=/3&)/C I;S-EBZMFHQ+@$&<'3=(SV $R 5J8XX
MV4> ;$@[@1\S4@1?W410J#"/A>PQQ]R8E=8MJ!=XN-$Z$N%9<ES'"G29'QCZ
M/7(3+EU'W%SRA)A'#=78",5">RLP4P-\;./Y<G \$GL)"62<2(NI-/S<+QO)
M6' ^[X5S<QLF[_0\DWC*%! ?B9Z$A#BB,];V]#Y^I_DJ*>A-GAQIA\%(=?MN
M:*3/-0T]7_2;=:.BM'<P1B@OU$=PQV+%K[X)W>G;E6156911&B?I_=R7XPS>
M?F;UFCH7*O1$]?6),;[AH(5SA6U<AB.HX'I:._@!S;PDS/BH4P&/[I*9-WH\
M+Y -,\>,C1B(<D31>1-%E4 1;1LK6.CC;+N-V#ZO-EQSWP=# Y?NKI<WN!#7
MZ\:YRF]P;>B&YOQ\I0/*L6'R&^J'>2B#CBGV&CTB1Z<%@V2=(,8##&@LT3QY
M?"L:2<#S3;:-87CG>&/FM7KTY6?F+ZJM"CH*I0?#' -A"F5Q'A/@@B:V++=R
M-O@ N#0NLC>>/T@TJ[$/2OS6X2'.>#OU,2DN6&GMP(79@7"IV&V?!EHTRZL/
M6A 75K7W9@_^J_<REGZ _#Y] SRP?,P.>P'52M !6$-P\6OC?M5J&Q7\+!^^
M8".<5!_OMS:UAU1N2 60Q_\YW;/?A9>(H?Q6/-3)/A2[%87![N'#PQK,_U?P
M;X6M#E0_5D45;;=/A/Z[2LHG69D?R/@I0TX8TX@4>[I*ULE*.KR/"5048Y^O
M:%Y&<%\[85]UG;,O//,B/P#'S 1 ;24\'JO43\<%'=DHR[B>M1VFV=)=(Q.>
M+.3:CNM+URS4MF_=;W'NYXFW+.OYV[U[MA3S5WZX9?*LW[UFV;5]]XA+[?]5
MVR?X4 GJ76Z'!\GOHAOD@=)^EMA+[Z 4'5P'B!K[5KGD/1V6R<)@G>P6;TMY
M1>H\YODRL J*IHLTWQ5JI4_2HLSYMSPC:FVM]FRWLX^>>-D;J#2@%E2V9Y;]
M&V6E(5G]#;X36-C_GGDY'8%;9@J.MI+UCU>*-L0M"()1EMAA]O;894MM#8*E
MV5Q?5&C675=88%;FA%X#\:<LWTDQ*FAY>9]37H *S/^@A?9A49\4NK#P"M3;
M"\0_6W2>@SZR[\CR=>LVRXF%A^)D.$#N'G'8<SN<?;C.9 8]1CK(=1>.K<'\
MZ!=("=">*:4\'/_6]&=DB;N:.75!>Y@\O3+X'C^[244L8^HQ VR5.&^I!'GS
MBGO=:Y\?]ZB9;&-3,(H[^+(Q]FP#Q"Y<A4[OX3K%/[S8OGJZB[1R9CML#&#;
M&KOA3;K?C&;2\8F\7[<(D1]?<R]XL<&F)2B+LTL<3EM"N\9ZR5.ZQ\.S"*$S
M1V[RJV*88&$YBH'H.]]NDIS/ @HRG@].Y2T0]WK.?DSD[^K*Q,-$N(G$]IF]
M9J&S#QY,7_WE&2R=IPIE6(!N&SDW?LK$^<QF%JU&\9+]Q./K\UMH2,*(Q6+/
MR0>\9'%"^59X \MP N96#8UG/)=N^'G%[G+Q?&*_.>!KR/F1AI#S)7O%<RN$
MQB.>2R%"><-O,;QA:R9]WK %$RS38"PRJ#=L.PLCVV#']-4;GMO"V:M0GX5S
M O2 @3/FUVO@+&<SBU;C>\/6XO'U^=@;?ON,O>$95,/$&YY0-Q"]82NY@;QA
MZSG@:TB/-_SVV7C#,RB$B3<\H4(@>L.?DKPHO=,J/+G(7]69BX=U<)2)[1'[
M34-G('RXOOK$,]@Y7SW*T$#=-G2.#)6E\YK//,J-XAA[R@^@ULPUYM3/.9-B
M?B71^,?S:8F?A^PA&,]%]IQ$ %TY;^K*DKWC^15"XQ_/IQ AXL6Z6>A3N;O!
M8GL.W4BQ#0>,/;.YO& Q8NLIC&Z7+3F^>L)S[O@==*:[W7<#L6:K;\[L:)]O
M.X_I%1@W'&PO&UEU6X'@YW=[;CX=& L 3Z8$2*%?.Z$!XK[V$T!6A7;$=YFW
MYN;#^UA\=S*\3QG9'?5;/3B81G21_58'>9-'<JW]5E>.KW[K$O?BXS;,$\26
M6W"]"7.>Q_0*/$VTUMYO=69I'*5=XCH^GPZX!F;1E2!P0#:TW^HQ 615Z 9A
M7_&.$7=%QSMF TGZ..B5:I^K5I#'SWTZAG6Y8?N+.@':YE^]XU]]O3GZD6F1
MF!F I]-8K#NT[A[6SP,;TC@]&W6<K< ,W1?IX]*,O-O+UG5*M'K;GCT/^U@B
M-C;4L;=ZY^<G],YUK0.MWGF@W@>7:=P0=WE7E'FTZO9A-B?HZ8V@(T J+=[/
M'LV"F8LRJ3H^Q*%3@1[6WK8&J.$+*DP^ H:>0N4&KTM?N+R?N*^0^:"8X,@+
M4^1^6)X?_(Z*X+\X^!G4S<> '^:^J-U&]N^B.5EW<S0X2.V0-(/P&BM+ENA[
MI2$IAMV2FT1C3>U5![BY]QG#+[6_PW'/*QAL92S':YH6M[@%P4F(IO$=]O8(
M.32"OU[785CY_'ECPJR%NS$H4-NR-_@&:\#>D6$/C;ZFZLI>/&]HF+4^-X9&
M@"40XI/%5:H+46K61$.JSB(Y2H6 ^Q$9H991,[%CJF'"1;O0KC/9<D9I$%5G
M7)%BL)35UQ0^F?.[[=>W$09=!322-PUF49=T0WD(:&TM^GP\N4H'#F%/'9XC
MK@(^/G&<"0-!^-Z%H5 $E)[7$:0>FWG6-;&GCM$1GP4?HYA-W^&XKO:<KO.O
M<(3V3PK_I?'E \VC>]%LOAY3R$'=W3\")]4ZWH>33XMG=[G87I+_5+2=HCTY
M7ZBQ)!*#Y4GIH9-]EO,_JC0I&\Y541\ %ZT3X)F;3R. -D-%3Z>#M3O3NLFU
M[[SFTR@4'PYA#H%TB?EZ[T6VQ"&^PY2$#S@CM9Y)1H1S:HPMZL$SK[#+42*-
MMSB_%OEYE9["\3Q-A(D$TJ5S[<+T8Y*2.-MNH[PX+%(_O6I,.11OFU]C,"-W
M[$5$Q>8]>_'W]#;[!@ 0P=*/W_<T+>A5NMI6,8VOTE]HRB:VO4SCRWB7I D<
MID'ZF1QX=.*%SUE% #$Y^VQH\>:!'DE$GYIV9XPLZ>)V0\DZ2G+R$&VK.G52
M><IG)*;0#CM)F3&K"NAE#8_?;:/5GV^^K9ADZ*>]AY^%VS@8L,MBNCTC.5UE
M]VGR'[""!4G%O,F*3YQW\#Y,G>W<^91((B</G;GOQ?3YD7S4^@)JN#BNC\@J
MRQEL]AGWXH%'3B'ADLD0^95S!TX#:&865"4ZP0,\(76  7O>RS$K.,%>_#E-
M9% @:"Q57; DMQEI,"5R,%%L(:8L&1/&F;19J^%S!^Z>C0KK@M2+UV'/8#?N
M9! #XO@3FTB3SP^:C+IHOVJR)0:?FR:'/A)0YQ#Q#<V3+#:)_6M(AH+\1R38
M09..@$G"]OTRK>(@?2R::0ULL] *M8,7+DG.P$+<I+^G7](/M^G?V3_??N#'
M<E%Y!O^R@=%NOV7C?KAY^_O?OKS]^<,/AQM8A;A71?=9#I&5->2@,D%92LD3
MC7+& :S,+DO+#=NV@ $J-PD;2E,21T]S9T]8P7(HGC( &X.X28=Z,$#2*VD"
M+0@7:M<(\\7_</"\)B""XG1Q:!/R]@1B@"!VCY3 T6J-1%\X]F5$[$\<>C:Q
M8T_H(;HW5^D#+=C0XI<\J_;7*>V]Z#TR2GYC[2@//='PQ'95AL7HU&&(JN&0
M)&H8>=P<7)&X=E!F]@O&7FYF_";:R-<0*+ /\@N#&)1E?82_ U;8XET_)?PQ
M8<\7<O'6'QV:-=D='GXK[P!CJ\7V@>9WF7ZY'1'C )/S8YB<"D0T:Z<[1##O
M;"=%&>6?DQ5$%^K$P]YETF2HNJ<].-3GGNP 8^Q5TT"6]G+L&.G%)9%/&_W!
MH  )@>-"0<X 4K#I5"4_-+Q,V1O=/?%]][LDVV;W3^1'^4/_Y2=1)X4Q@>D7
MS,"NLO=/)8\H5DR&JFBRCTK*#QW_3+/'-YOLD;.+HS(B["?.TGM^_IC)"<R\
M<AOA+;/#1><2[@!5??UVE'- ...4&C 0X@ID*"\@P'H,YV68;TP4Z4H)(,#(
MLWS "'?$P@$&DES!=/ZBP*0K#(  IN#^@:Z>B]'@01\!IX[+(.O AM6X?HL!
M]8 ^+*5LAMDK']0)DVHM@X3#>H%8I664?VA#:UR=Q8#ZY8'+RN3:@PO1['[-
MGJ)M^71#&1#9#N6^BT;M<_G->IY[X/Z(&_962R= !^_^\3S5<E]_!KNF7 QD
M&Y\G?L6;5"ED5D!*8\K?6P6Y%!"HO!?0+ZK5!M(I)0$_-87D3)5S$>?)=@N[
M)'F]"3Z#'1:D==+5)A4;,T:4I"7=;JF0L,\S-J_9$R7UJ,D,7G1;:8Z&*CW1
M\,"&'\H*KN5L!3RV3LO/S\CAR7-\U9K5U^Y=^ZVQO2SQEE4M>ZLW?EZ_<9)'
M)61HIR3:957*,R:8K:NV(B<KI<RD1-NYD[+<T*!9+NW0@+@H?HF^)[MJ]Y7&
MU0H6DJM42936O0,GX_'R^QF,]P#V*'?L1=54H [Y9O1\T=V)H0T=R!45I"1U
M5^&9ET%S7&0.KZZM+*.D2GD,980&(,JR:BS)"WILV97CAM%VBF#3+-2X:/-;
MR(U$X"WLQN*\,'?^@C&G<0=P,8>9VYSM&-L5W]==K_E?^2J)MM^8/_:!1C&C
MIZH0RW5*?Z=1_O%[R7;W;&Y'!4\P>*EL:#]>/FEY/I+1\Z<1)J/-Y//FS=V:
M0VVC+*5O( F:T'J8.'+=14_DCM9-*&*2%,+A!ZJ(;$6X*(8( ,">Q!E)LY*L
MY 3)W1//NI:M*"@_C)V[W00.V#-DS'42#WW8UAF)_G.;4QMQ\K@Q9A%,#R'S
MN\$#E.K A0 ;HOB<D4.95$@P V;DP.U5I7J LT2=\LP\]Q6/F)*.,95@FM4J
M*]RSO+WJ2P\FEJ@OM<?<?&.?V?^Q#]5'[#]WS#NY^']02P,$%     @ <HJ"
M3 P*@_J25P  P 0& !0   !O8W@M,C Q-S$R,S%?<')E+GAM;.U]67,DN9'F
M^YKM?^CM>>XN54LKJ672C/'LX0RKDD:RNE=/LF DF(RIR$ J(I+%U*]?(*Z,
M X?CB 203&NSZJH,AP/N^. XW.'XZW^\K=/O7E%>)#C[V_<??_S=]]^A+,;+
M)%O][?MM\4-4Q$GR_7_\^__^7W_]/S_\\ O*4!Z5:/G=T^Z[J\M?SNZ?DY20
M%M_=W2_(7]%W?_CQ]^2_C]^=YSA:YLERA7[X@18F5%__0O]XB@KT':DT*_[R
M5B1_^_ZE+#=_^?#AV[=O/W[[_8\X7WWXZ7>_^_CA_WVZ?8A?T#KZ(<F*,LIB
M]/UWA/XO1?7C+8ZCLFIQK_C;4YZV#'[_H:N+2T'_]4-+]@/]Z8>//_WP^X\_
MOA7+[YLFTL^ 2EKRMPE](]/'GW_^^4/UM2,EC!(!ZTYLHKWOOJOUE^,4W:/G
M[^C_O]S?<$O__(%2?,A0>1L]H914614O=QOTM^^+9+U)4?O;2XZ>V7S2/._8
M4.W\3+7S\8]4._^VY_S!I'DK"J5'7$:IG796_*9MG51CWNC/ME0K:O)GFUHF
M0QP=0,N]:LP;?8?R!"^OLN7\#1]79:OQ#V64'P JT\K,!9B_U0I-Q612BG<E
M^C'&ZYKUP_:I0/_<HJR\>B5_%)>HC)*TD#<8QV^D/1__]/&GVM;_&Y>37L,N
M\'J=E&O*Z2Q;7N"L)#,DF5035/R6$*.>WR8QR@ITMLH1HF3Z+=>ORKIHLPAA
MV-P;\LL:/49O)LUC,=%$;(GC:KE A%QO2+]4:Q@#W(KY:3;R)<K1"TZ7Q))?
M_7.;E+NJFL6&\KYZ0WF<%";J5.1O2PC2AC_^%N5Y5*/L,_K6_LNF*(!:; ED
ML]F&C;O%4787[:*G%#WB![(AB''V:Y2F:'<>95_U&PKDJ]?H>Y16$R>9,7>/
MI(N***8(-("#E*-FUZ,4Q83O>932_<##"T(E'>\X,YSU8'QU)^?U.LIWB^>'
M9)4ESTE,QL!9'.-M9=SO,.E+HSE#D;^>$(M\%67)OQJK6L1Y4AFIQ?/YMD@R
M5- A?IN0$;0T&H]ZU5B?P!_I.+,\?[<\C:=O[<8Q>-B<O+7;)68WAQW6;BJ,
M[1S&35^[(+9SFC;]IBNQGU.$]O^S";&OX #VV4 :S7KL;&LM[&=GF"SL3A,6
M)@BSJ<'NI&!M.K"W6["R39AG7K(^(]G>$5C<"LPS35J?(.>=5V:;3PXRC\P]
M?^B;(H*XRKHNGB^BXN4ZQ=_T%J9,/N:-JDS<Z-B!]&12&C92P->")LF8(%:0
M&.3D%=WBPEBC4W[FC5QLJ%-6TU3Q&.DUJV]/"F+^"-\75)+Q"G D3)HF8F:A
M>:8MTFW$)8ZW5.%DU%\1^U7N;K)GG*]UEPYB=OTF$N05A+#Z<DM^&-2%WDJ4
M+=&RK8TV55>(JLZVUA3'@XI2ZKO'N40J\L,_1'6</15E3F;5EDU*74E_^UZE
M"/E,1805^: N4Z.[RBE6H/C'%7[]L$3)!R+G'^A?J,!_^.%W'YN0@W\C/_VC
M;L$]6B6TXJS\'*W12$0122,2FV0H0A\,9_E0G"B/6X[DKP,D3 ,5&HH/FVJ
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M#FS+;1(])6EU>D3FUNGM9,[B7[58HW)X,1\4(G8UR FG0OOC=+C<HD?<2_S
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MH!.,[.30#?DK=S$\(1BO@'L$#@/-AT<Q-]ET0W6/T_0:Y]^B?!REH5EZGUU
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M\T35J@V[22<$&$O#D;8^K#6(404P$$]%0@9>..CJ>VQ\/R7S-I@^ X8C#\K
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M*-[F=9[TURA)Z4_7.*>Y O9?:NE'$#1AT?2+'@O/ 6I!+RIXU:O.4NH!-ZE
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MYEW'"IHN[MAAP7#7!%,[B$5FAJ&4=AX?%'I?\S5O,M&?E7L<P[U&RA63YS&
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MK2%+=O \U*M.8@6;:@)?\ @$/(OC[7J;TFU6?T*&@U#"0 Y++H/C "I,/S-
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M')D07Y*AYA6=@-*V@[Q/ZFWVZ]5@;0%_J2Z[WF1UC&YS4OF(\K6M\2:MP'3
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M^===91YH&NPH8\<T"R@:P9@4#E._2_L#0Z0:9W7G<:76C,EMCMV 8SV.C\3
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M4$L! A0#%     @ <HJ"3(!,U[P>*P$ W% , !               ( !
M &]C>"TR,#$W,3(S,2YX;6Q02P$"% ,4    " !RBH),<"6(#C@1  !4M0
M$               @ %,*P$ ;V-X+3(P,3<Q,C,Q+GAS9%!+ 0(4 Q0    (
M '**@DP:Z%!.YQ   $;M   4              "  ;(\ 0!O8W@M,C Q-S$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( '**@DQ1[U]]LS0  !%K P 4
M      "  <M- 0!O8W@M,C Q-S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( '**
M@DQM2E8%0K,  #N]"@ 4              "  ;"" 0!O8W@M,C Q-S$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( '**@DP,"H/ZDE<  , $!@ 4
M  "  20V @!O8W@M,C Q-S$R,S%?<')E+GAM;%!+!08     !@ & (0!  #H
%C0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
